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INTRODUCTION  
 
Presently, a large number of drugs are used to treat and prevent 
different diseases. Doctor of any speciality should be able to know 
them well for correct prescribing pharmacotherapy to patients. In this 
regard, there is a need for quality training of students of higher 
medical educational institutions in pharmacology, knowledge of 
which is basic and integrates theoretical and clinical disciplines. 
Pharmacology finishes theoretical training of future doctors and is 
a logical continuation of courses of normal and pathological 
physiology, biochemistry, microbiology, and anatomy. Therefore, the 
authors, when presenting the material, considered it necessary to 
briefly recall physiological, biochemical, immunological, and 
anatomical knowledge that is necessary for understanding of 
pharmacodynamics of drugs and their mechanisms of action.  
Suggested textbook contains main rules of drug prescription, 
data of general and special pharmacology. With the aim to form 
stable skills in students to work with drug nomenclature, the unified 
nomenclature system of drugs, based on International Nonproprietary 
Names (INN), is given in the textbook. This system is used in 
modern educational literature of different countries. In most cases, 
the authors indicate both INN and most commonly used trade names 
of drugs. 
All chapters of the textbook are given in volume that is 
necessary for clear understanding of principles of action and 
effective and safe use of drugs. Each pharmacological group is 
constructed in a unified and logical sequence which facilitates the 
perception, assimilation and use of information.  
Due to large volume of information which should be mastered 
by students, the authors focus on group properties of drugs and 
describe the main representatives of groups. At the same time, the 
same drugs, used for different indications, are described in different 
chapters (e. g., -adrenergic antagonists are given in chapters 
“Antiadrenergic drugs”, “Drugs for treatment of hypertension”, 
4 
 
“Drugs for treatment of ischemic heart disease”, and “Antiarrhythmic 
drugs”). 
Main data about drugs are given in one main chapter, and 
additional information is given in other chapters. Data about 
pharmacodynamics, pharmacokinetics, clinical applications, and side 
effects are given for each group of drugs; and, if it is necessary, 
corresponding data about individual drugs are additionally given.  
Suggested textbook contains data about new drugs and modern 
scientific data. Mechanisms of action and therapeutic indications for 
drugs are given considering modern data of biochemistry, 
pathological physiology and fundamental pharmacology. This 
textbook contains some elements of clinical pharmacology. 
A separate chapter of the textbook describes general principles 
of treatment of acute poisoning by drugs and other toxic substances. 
Measures to prevent the ingress of poison into the body, inactivation 
of poisons by antidotes, restriction of poisons action by physiological 
antagonists, acceleration of poison elimination from the body, and 
resuscitation measures are given in this chapter. Besides, 
resuscitation measures at cases of inhibited respiration, collapse, 
acute heart failure, and bronchoconstriction are considered, 
especially in acute period of poisoning.    
The textbook is recommended for third year students of higher 
medical educational institutions. Its structure and content correspond 
to the curriculum of pharmacology, approved at an interdepartmental 
meeting of heads of pharmacological departments of higher medical 
educational institutions.  
We will be grateful for any comments and suggestions that may 
arise from the readers of this textbook. 
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DRUGS INFLUENCING INNER ORGANS 
 
DRUGS INFLUENCING RESPIRATORY SYSTEM 
 
Drugs used in different acute and chronic diseases of respiratory 
organs are classified into the following groups:  
1. Drugs which are used in bronchial obstruction syndrome. 
2. Expectorant drugs.  
3. Antitussive drugs. 
4. Breathing stimulators.  
5. Drugs which are used in acute respiratory insufficiency.  
 
 
Drugs Used in Bronchial Obstruction Syndrome 
 
Bronchial obstruction syndrome is condition which is 
accompanied by recurrent attacks of expiratory dyspnea (difficult 
exhale) owing to spasm of bronchial smooth muscles, oedema of 
bronchi, and increased bronchial secretion.  
In 2/3 cases, the cause of bronchial obstruction syndrome is 
bronchial asthma.  
There are two forms of asthma: 
– atopic (allergic);  
– nonatopic (infectious). 
Drugs used in bronchial obstruction syndrome are classified into 
three groups: 
1. Bronchial spasmolytics. 
2. Drugs eliminating the oedema of bronchial mucous 
membrane:  
– stabilizers of tissue basophil membranes;  
– glucocorticoids; 
– drugs influencing leukotrienes system:  
   a) leukotriene receptor antagonists; 
   b) inhibitors of leukotriene synthesis.  
3. Expectorants and mucolytics.  
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Bronchial Spasmolytics  
 
The smooth muscles tone of bronchi is under control of 
parasympathetic nervous system, excitation of which results in spasm 
of bronchi. Sympathetic innervation of bronchi is absent. However, 
both α- and β2-adrenergic receptors are located in bronchial smooth 
muscles. These receptors are excited by catecholamines of blood or 
by administered adrenoceptor agonists. Excitation of α-adrenoceptors 
results in spasm of bronchi, while excitation of β2-adrenoceptors 
causes the bronchodilation.  
Besides vegetative innervation, bronchial tone is under control 
of the ratio of concentration cAMP/cGMP in the smooth muscle’s 
cells. An increase of cAMP concentration and a decrease of cGMP 
leads to bronchodilation.   
Bronchial spasmolytics are classified as follows.  
1. Adrenoceptor agonists.  
1.1. Adrenoceptor agonists with direct action: 
– α, β-adrenoceptor agonist: adrenaline (epinephrine) ; 
– nonselective β1,2-adrenoceptor agonists: isadrinum 
(isoprenaline), orciprenaline; 
– selective β2-adrenoceptor agonists: salbutamol (Ventolin) , 
fenoterol (Berotec) , terbutaline (Bricanyl),  salmeterol,  
formoterol .  
1.2. Adrenoceptor agonists with indirect action 
(sympathomimetics): ephedrine  and ephedrine-containing drugs 
(Theophedrin,  Antasthman, Solutan,  etc.).   
2. M-cholinergic antagonists: atropine, platyphyllin,  
ipratropium bromide  (Atrovent), metacinium (metocinium 
iodide), troventol,  oxytropium bromide, tiotropium 
bromide (Spiriva®), bamipine (Soventol).  
3. Myotropic antispasmodics: theophyline, euphyllinum  
(aminophylline).  
4. α-Adrenoceptor antagonists: phentolamine, pyrroxane, 
prazosin.  
5. Calcium channel blocker: nifedipine (fenigidin, Adalat).  
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Adrenoceptor Agonists 
 
Adrenaline (epinephrine)  is nonselective α- and  
β-adrenoceptor agonists. It should be noted that β-adrenoceptors are 
more sensitive to adrenaline than α-adrenoceptors. Therefore, certain 
doses of adrenaline do not influence α-adrenoceptors and do not 
cause vascular spasm and elevation of the blood pressure. 
Owing to stimulation of β1-adrenoceptors, epinephrine increases 
the cardiac contraction and heart rate that leads to the increase of 
myocardial oxygen demand. Simultaneously, adrenaline increases 
renin secretion by juxtaglomerular apparatus that activates the renin-
angiotensin-aldosterone system and increases the vascular tone 
(influence of angiotensin II) and circulating blood volume.     
Excitation of β2-adrenoceptors of smooth muscles and tissue 
basophils results in activation of adenylate cyclase and increase of 
cAMP level. Owing to this, level of free calcium ions in the cells 
decreases and relaxation of bronchial smooth muscles develops. The 
release of histamine, serotonin, slow-reacting substance of 
anaphylaxis, that includes leukotrienes LTC4, LTD4 and LTE4, and 
other bronchoconstrictors also decreases.   
Adrenaline is administered parenterally because in case of 
peroral intake epinephrine is inactivated by COMT  
(catechol-O-methyltransferase) in gastrointestinal tract. Optimal 
mode is intramuscular because the excitation of β2-adrenergic 
receptors in vessels of skeletal muscles results in vasodilatation and 
increase of adrenaline absorption speed. In case of subcutaneous 
administration, α-adrenergic receptors are mainly excited, that results 
in vasoconstriction and slows down the drug absorption. Intravenous 
and intra-arterial routes of epinephrine administration are no used 
due to danger of tachyarrhythmias and gangrene.   
In case of intramuscular administration, bronchodilation 
develops in 3–7 minutes and lasts up to 30–40 minutes. 
Epinephrine’s biotransformation occurs in all tissues of body by 
means of methylation and desamination. Metabolites of adrenaline 
exhibit β-adrenoblocking activity that is a cause fast tolerance to 
the drug.     
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Side effects are increase of blood pressure, tachycardia, 
elevation of minute blood volume, hyperglycemia, tremor, etc.  
Adrenaline is used to interrupt an asthma attacks when other 
adrenomimetics are ineffective.  
Ephedrine  is indirect α- and β-adrenoceptor agonist 
(sympathomimetic). The drug stimulates noradrenaline release by 
sympathetic nervous terminals, inhibits mediator reuptake, and 
sensitizes adrenergic receptors to catecholamines.  
In frequent ephedrine use, tachyphylaxis develops owing to 
exhaustion of noradrenaline storage in presynaptic adrenergic fibers. 
In comparison with adrenaline, broncholytic activity of 
ephedrine is less, but duration of action is longer. Drug is 
administered parenterally, in inhalations, and perorally after a meal. 
In case of peroral intake, the effect develops in 40–60 minutes. 
Duration of action is up to 6 hours. At intramuscular administration, 
effect develops in 10–15 minutes and lasts up to 4 hours.  
Ephedrine is used both to interrupt and to prevent 
bronchospasms.  
Side effects of ephedrine are excitation of central nervous 
system, insomnia, increase of blood pressure, tachycardia, elevation 
of minute blood volume, hyperglycemia, tremor, etc. Adrenaline can 
cause paradoxical drowsiness in child under 5-year-old. 
Isadrinum (isoprenaline)  is direct β1- and β2-adrenoceptor 
agonist. Drug is administered in inhalations, sublingually, and 
parenterally. For interruption of bronchospasm, it is administered in 
inhalations. In this case, effect develops in 1–3 minutes and lasts up 
to 1–1.5 hours. At peroral intake, isadrinum undergoes fast 
degradation. Sublingual and intravenous modes of administration are 
used to treat atrioventricular blockage and other disturbances of heart 
rhythm. 
Even inhalation administration of isadrinum can increase heart 
rate and cardiac output due to stimulation of β1-adrenoceptors of the 
heart. Blood pressure is not practically changed at inhalation 
administration of the drug.     
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   Salbutamol (Ventolin), fenoterol (Berotec), terbutaline 
(Bricanyl), salmeterol, and formoterol are selective  
β2-adrenoceptor agonists. These drugs have no pronounced effects  
of β1-adrenergic receptors stimulation, such as tachycardia, 
disturbances of cardiac rhythm, hypertension, and tremor. 
Selective β2-adrenoceptor agonists are administered parenterally 
(subcutaneously, intramuscularly, or intravenously), in inhalations, 
and perorally. In case of peroral intake, bioavailability of these drugs 
is about 50 %. At inhalations, a patient does 1–2 inspirations of the 
drug. At 1st inspiration, the drug reaches proximal bronchus and, 
through jugular vein, carried in the right ventricle and after – in 
pulmonary circulation. At 2nd inspiration, the drug reaches distal 
part of bronchus and enters the left ventricle, after that – in systemic 
circulation. Most of the inhaled drug “settles” in the upper sections 
of respiratory tract, from which it is gradually removed into the 
stomach, that can lead to side systemic effects as in case of peroral 
intake.  
At parenteral administration, β-adrenomimetics reach to all part 
of respiratory system, where exhibit their broncholytic effect. The 
degree of β-adrenomimetics binding with plasma proteins  
is 10–25 %.   
Bronchodilatation develops in 3–5 minutes after inhalations and 
in 20–30 minutes in case of parenteral administration. At peroral 
intake, the effect develops in 1 hour.  
Salbutamol  (Ventolin)  is prescribed in aerosol for  
1–2 inspiration up to 6 times a day. Powder-like form of salbutamol 
is administered by means of spinhaler no more than 4 times a day. In 
comparison with aerosol, powder-like form has some advantage. 
Thus, about 15 % patients can not coordinate the inhaled drug 
administration with act of inspiration, whereas the use of spinhaler 
does not require this. Insufficient efficacy of therapy with 
salbutamol, short period of half-life, significant prevalence of 
nocturnal asthma attacks were the reasons for creating of prolonged 
drug form salbutamol SR. Twice-daily tablet formulation of 
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salbutamol SR provides the stable plasma concentration of drug 
during a day.   
Fenoterol (Berotec)  has higher broncholytic activity and 
longer action than salbutamol. The drug is administered by  
1–2 inhalations 2–3 times a day.  
Terbutaline (Bricanyl)  is administered by 1–2 inhalations  
3–4 times a day to treat bronchial asthma. 
Prolonged forms of β2-adrenomimetics (formoterol , 
salmoterol , etc.) act about 12 hours. These drugs are prescribed 
2 times a day that allows to use them for prevention of asthma 
attacks at morning.  
Biotransformation of β2-adrenomimetics occurs in different 
organs by COMT and MAO (monoamine oxidase). Some drugs 
undergo conjugation with glucuronic or sulfuric acids. The 
unchanged drugs and their metabolites are excreted by kidneys. At 
inhalations, the excretion through the lungs has an important 
meaning. 
It should be noticed that high doses of selective β2-adrenoceptor 
agonists can excite also β1-adrenoceptors with development of 
tachycardia, disturbances of coronary blood circulation, heart failure, 
hyperglycemia, tremor, etc. Long-term use of β2-adrenoceptor 
agonists is accompanied by decrease of β2-receptors sensitivity with 
reduction of broncholytic effect. Such cases need to cancel  
β2-adrenoceptor agonist and to prescribe of M-cholinergic 
antagonists, glucocorticoids and other drugs to restore  
β2-adrenoceptors sensitivity. 
Selective β2-adrenoceptor agonists are used both for cessation 
and for prevention of asthma attacks. At acute bronchospasm,  
β2-adrenomimetics are administered parenterally. Inhalant or peroral 
β2-adrenomimetics are prescribed at moderate bronchospasm, for 
prevention of asthma attacks, and for potentiation of broncholytic 
action of aminophylline, chromoglycate sodium or glucocorticoids. 
Prolonged drugs (salmeterol, formoterol ) are used to prevent the 
nocturnal asthma attacks and exercise-induced bronchoconstriction. 
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Presently, inhalant powder-like drug Seretide Multidisk  is 
implemented to treat asthma. The drug contains salbutamol and 
fluticasone propionate.    
 
M-Cholinergic Antagonists  
 
Belladonna-containing drugs,  a tropine , platyphyllin , 
and metacinium  were first effective drugs for treatment of asthma. 
These drugs are prescribed in aerosols, taken orally or administered 
parenterally. But short duration of action (about 1.5–2 hours), 
predominant influence upon the upper sections of the bronchi, 
increase of the sputum viscosity, and numerous side effects have 
become an occasion for restrict of its use in treatment of asthma. It 
should be noticed that atropine keeps its meaning at bronchospasm 
due to intoxication by cholinesterase inhibitors or  
M-cholinomimetics, inspiration of irritative agents, etc.    
Nowadays, M-cholinergic antagonists for inhalation are used in 
medical practice. These drugs are ipratropium bromide  
(atrovent ) and troventol . Both drugs are quaternary compounds 
with low solubility in lipids. Therefore, these drugs have selective 
influence upon M-cholinoceptors of bronchi. Also, these drugs 
decrease the release of allergy mediators from the basophils. 
Atrovent is used for inhalations in aerosol and in capsules for 
inhalations. Troventol is used in aerosol. Its effect develops in 20– 
40 minutes after inhalation and lasts up to 8 hours. At inhalation, part 
of the drug enters the gastrointestinal tract, but its absorption is about 
6 %. The drug is metabolized in the liver and excreted with urine 
and, partly, – with feces. Troventol does not penetrate central 
nervous system.  
Atrovent and troventol are used to prevent and treat 
bronchospasms in chronic obstructive bronchitis, acute and chronic 
pneumonia, and in bronchial asthma as additional drugs at therapy by 
β-adrenomimetics. These drugs are used to prepare respiratory tract 
for inhalation of antibiotics, mucolytics, glucocorticoids, and 
cromolyn sodium.  It should be noticed that efficacy of drugs is 
higher in elderly patients (independently on form of bronchial 
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asthma). Sometimes, high efficacy of atrovent and troventol is 
observed at so-called “psychogenic” asthma.   
These drugs are well tolerated by patients. Side effects of 
atrovent and troventol are dry mouth, disturbances of accomodation, 
increase of viscosity of sputum, etc.  
Tiotropium bromide  blocks simultaneously M1-cholinergic 
receptors in ganglia and M3-cholinoceptors in smooth muscles of 
bronchi and bronchial glands. The drug’s effect develops in 1.5– 
2 hours and lasts up a day.  
Nowadays, pharmaceutical industry produces co-formulated 
drugs Berodual  (containing atrovent and fenoterol) and Ditec  
(containing cromoglycate sodium and fenoterol). The efficacy of 
such co-formulated drugs is higher than at the use of each 
components itself.      
 
Myotropic Antispasmodic Drugs 
 
Theophylline  and euphyllinum  (aminophylline) are 
methylxanthines which are used to treat bronchial asthma.  
Despite of medicine is using these drugs more than 70 years, 
their mechanism of action is not clear enough. It is known that these 
drugs block the activity of phosphodiesterase – enzyme which 
catalyzes the transformation of cAMP to inactive 5-AMP. On the 
molecular level, stabilization of cAMP level causes the decrease of 
calcium entrance into the cells and reduction of bronchial tone.   
Simultaneously, drugs also block adenosine receptors. 
Adenosine is agonist of purinergic receptors A1 and A2. 
Bronchospasm develops if the activity of A1-receptors is more than 
activity of A2-receptors. In patient with bronchial asthma the quantity 
of A2-receptors is reduced. Methylxanthines restore quantity of  
A2-receptors and reduce quantity of A1-purinergic receptors, that 
results in bronchodilation.  
Also, methylxanthines stabilize the membranes of basophils and 
reduce the release of allergy mediators promoting bronchospasm. But 
this the effect is of secondary importance at the prescribing of usual 
therapeutic doses of drugs.    
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Methylxanthines inhibit the release of cytokines stimulating 
inflamation (interleukins 1β, 4, and 5) and increase synthesis of 
interleukin 10 exhibiting anti-inflammatory action.  
Besides, an influence of drugs upon the mucociliary transport 
and mucosal oedema is not excluded.   
Methylxanthines stimulate respiratory centre, increase heart 
activity, decrease the blood pressure in pulmonary artery, stimulate 
synthesis and release of endogenous catecholamines by adrenal 
medulla, and improve contractability of the emaciated diaphragmatic 
muscle. Methylxanthines have weak diuretic activity owing to 
increase of kidney blood flow. These drugs stimulate central nervous 
system and irritate stomach mucosa.  
Drugs are administered intravenously slowly or drop-by-drop, 
intramuscularly, orally (prior a meal) and rectally. Bioavailability of 
methylxanthines from gastrointestinal tract is about 90 %. The 
degree of binding with plasma proteins is about 50 %. These drugs 
easily penetrate through blood-brain and placental barriers and are 
excreted in mather’s milk. The blood therapeutic concentrations are 
maintained during 4–5 hours. Drugs are administered 4–6 times  
per day.  
Methylxanthines undergo hepatic biotransformation by means of 
oxidation and demethylation. It should be noticed that only 10–20 % 
administered dose of methylxanthine is metabolized in newborns, 
premature baby, and elderly patients. Metabolism of methylxanthines 
increases in child aged 1–10 years. Some drugs (glucocorticoids, 
barbiturates, rifampicin, etc.), smoking, and protein-rich meals 
accelerate metabolism of methylxanthines. Methylxanthine 
metabolites are excreted with bile. About 10 % administered dose of 
xanthine is excreted in unchanged form by kidneys. Clearance of 
methylxanthines is higher in men than in women, so, the latter have 
higher possibility of xanthine overdose and intoxication.   
Methylxanthines are administered parenterally for interruption 
of asthmatic status. Wherein, ampule’s content is diluted by isotonic 
sodium chloride solution and is heated to body temperature. It is 
impossible to dilute aminophylline by glucose solution because it 
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slows doun the hepatic metabolism of the drug and promotes its 
accumulation.  
Also, methylxanthines are used to prevent bronchial asthma 
attacks.  
There are prolonged forms of theophylline which are classified 
into two generations:  
– 1st generation drugs: Theopec, Theo-Dur, Ventax, 
Durofillin, Retafyllin, Theotard ;  
– 2nd generation drugs: Theo-24, Uniphyl, Phyllocontin,  
Euphylong .             
The 1st generation drugs are prescribed two times a day:  
1/3 dose is taken at morning and 2/3 – at evening. The 2nd 
generation drugs are taken once a day at evening.  
Methylxanthines side effects are nausea, tachycardia, tremor, 
headache, insomnia, etc. Due to stimulation of gastric secretion, 
methylxanthines can provoke exacerbation of ulcer disease in some 
patients. 
The overdose of methylxanthines leads to intoxication. Riboxin 
(inosine) intravenously slowly, anticonvulsants, and diuretics are 
used to reduce the symptoms of intoxication. In severe cases, 
hempsorption or hemodialysis are preformed and sympthomatic 
therapy is prescribed.    
 
α-Adrenoceptor Antagonists  
 
Prazosin, phentolamine,  and pyrroxane  block  
α1-adrenergic receptors of prealveolar sphincters and improve 
bronchial patency. Broncholytic activity of these drugs is 
significantly less than activity of β-adrenomimetics. But  
α-adrenoceptor antagonists can be useful in patients with 
tachyphylaxis to β-adrenoceptor agonists or in patients with 
accompanied hypertension or chronic heart failure.  
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Calcium channel blockers  
 
Calcium antagonists are increasingly used in a treatment of 
bronchial asthma. These drugs reduce calcium entrance into smooth 
muscle cells of bronchi. Calcium ions participate secretion of mediators 
by basophiles, in processes of cellular adhesion and epithelial 
permeability. Calcium ions are essential for normal function of enzymes 
(e. g., adenylyl cyclase and guanylyl cyclase), nervous impulse 
transmission, and muscular contraction and relaxation. But, the role of 
drugs in therapy of bronchospasms is not clear enough. There is 
evidence about the effective use of calcium antagonists (nifedipine) to 
prevent bronchoconstriction in patients suffering by exercise-induced 
asthma.       
 
Drugs Eliminating Oedema of Bronchial Mucous 
Membrane  
 
Glucocorticoids 
 
Glucocorticoids (beclomethasone , budesonide, flunisolid , 
triamcinolone , etc.) play an important role in a therapy of 
bronchial asthma. These drugs influence upon different links of 
asthma pathogenesis and are indispensable in severe forms of the 
disease.  
Mechanism of glucocorticoids action at syndrome of bronchial 
obstruction is not clear enough. It is proved that glucocorticoids 
suppress exudation and limit oedema of bronchi mucous membrane. 
These effects arise due to the reduction of synthesis of inflammation 
mediators (e. g., prostaglandins), potentiation of catecholamines 
action owing to the increase of cAMP activity, inhibition of  
M-cholinergic activity owing to the decrease of cGMP activity, 
direct drugs influence upon smooth muscles of the bronchi, and 
antiallergic action of glucocorticoids. It should be noticed that 
glucocorticoids, first of all, inhibit hyperactivity of delayed type, and 
only in prolonged use – hyperactivity of immediate type.     
Drugs are administered in inhalations, perorally, 
intramuscularly, and intravenously. Administration of drugs by 
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means of all routes, except inhalational, can leads to many side 
effects. A use of special inhalation forms (dosed aerosols) allows to 
avoid majority of side effects. Aerosols exhibit anti-oedema effect, 
prevent bronchoconstriction, and improve evacuation of thick and 
viscous sputum.    
At inspiration of aerosol, only 10–20 % dose enters to the lungs, 
main amount of the drug is swallowed into the stomach. But 
significant systemic effects do not develop in this case. Drugs 
undergo hepatic biotransformation. About 70 % metabolites are 
excreted with the bile, and about 20 % – with urine.   
A use of inhaled glucocorticoids restors the reaction of bronchi 
to bronchodilators and decrease the frequency of administration of 
the latter.  
Inhaled glucocorticoids do not cause a fast effect. Therefore, 
these drugs used to treat chronic bronchial asthma only. Inhaled 
glucocorticoids are ineffective and are no used to treat acute asthma 
attacks. At bronchoconstriction in patients with hormonal-dependent 
asthma and at asthmatic status, glucocorticoids are administered 
parenterally or taken orally (in milder cases). Administered doses are 
individual and drugs are administered 2–4 times a day. Both when 
systemic glucocorticoids are prescribed and when inhaled forms are 
administered, the step approach is used. That is, high dose of drug is 
prescribed initially and is decreased after reach of the therapeutic 
effect. Considering circadian rhythm of corticosteroid release by an 
adrenal cortex, inhaled glucocorticoids are usually prescribed in first 
part of a day. 
Cough and hoarseness can be observed at the used of inhaled 
glucocorticoids. Sometimes, paradoxical bronchoconstriction 
develops that can be easily prevented by prior administration of 
bronchodilators. Gastritis and ulcer disease are also possible. 
Sometimes, a rosacea appears. It is necessary to remember about 
possibility of candidiasis. To prevent this complication, is necessary 
to rinse mouth and throat. At initial symptoms of candidiasis, 
antifungal drugs are prescribed.  
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Stabilizers of Tissue Basophiles Membranes 
 
This group includes such drugs as sodium cromoglycate , 
nedocromil  sodium , and ketotifen . Drugs are used only to 
prevent bronchoconstriction and for systematic treatment of 
bronchial asthma (mainly of allergic origin). Stabilizers of tissue 
basophiles membranes are ineffective in case of acute bronchospasm. 
These drugs inhibit phosphodiesterase and prevent the calcium 
ions entrance owing to blockade of opening calcium channels. Thus, 
drugs suppress the release of histamine and leukotrienes. Besides, 
these drugs increase activity of β-adrenergic receptors owing to 
restoration of their sensitivity to catecholamines.   
There is evidence, that these drugs also block chloride channels 
of basophils. It is known, that transport of chloride ions into the 
basophiles results in hyperpolarization of membrane, which is 
necessary for penetration of calcium ions into the cells. The chlorine 
outflow from neurons leads to depolarization of nervous endings that 
increases the activity of vagus nerve with the following increase of 
bronchial tone. Therefore, blockage of chloride channels is the base 
of anti-inflammatory and antiallergic effects of stabilizers of tissue 
basophiles membranes. Drugs predominantly influence upon 
pathochemical stage of allergic reactions of immediate type. Besides, 
these drugs exhibit efficacy at allergic reactions of delayed type. 
Stabilizers of membranes of tissue basophiles decrease the oedema of 
bronchi mucous membrane and prevent (but not eliminate) 
bronchospasm.  
Sodium cromoglycate  and nedocromil sodium  are used as 
solutions or powders for inhalations. Only 10 % of administered dose 
reaches to distal part of respiratory tract. Most of the dose “settles” 
on the mucous membranes of mouth and pharynx and enters the 
stomach during swallowing. But these drugs are not absorbed from 
gastrointestinal tract and are excreted with feces. Maximal effect of 
the inhaled drug develops in 2 hours and lasts about 4–6 hours. 
Drugs are administered 2–4 times a day.   
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Sometimes, an inhalation of powder-like forms of the drugs is 
accompanied by bronchoconstriction. In such case, bronchodilators 
are administered previously to prevent it.    
Stabilizers of tissue basophiles membranes are used for 
treatment of atopic bronchial asthma. Pronounced effect develops in 
2–8 weeks after the treatment initiation. The large advantage of 
therapy by these drugs is possibility to decrease or even discontinue 
glucocorticoids intake. These drugs are commonly prescribed 
together with bronchodilators and expectorants.  
Anti-inflammatory activity of nedocromil sodium is in 10 times 
more than activity of sodium cromoglycate. Nedocromil sodium is 
effective in both allergic and non-allergic asthma. Maximum 
therapeutic activity of drugs develops in 5–7 days after initiation of 
treatment. Drug is prescribed 2 times a day.  
There are the special forms of nedocromil-sodium and sodium 
cromoglycate which used to treat allergic rhinitis (Lomusol , 
Rynacrom) and conjunctivitis (Opticryl , Tilavist). Also, 
Nalcrom  (effective medicinal form of sodium cromoglycate) is used 
in the treatment for alimentary allergy.  
Mechanism of ketotifen  action is similar to nedocromil 
sodium. Bisedes, ketotifen is able to block H1-histaminergic 
receptors. Drug is administered perorally after a meal. About 90 % of 
administered dose of ketotifen is absorbed from gastrointestinal tract. 
Its degree of binding with plasma proteins is about 75 %. 
Therapeutic concentration in the blood is observed in 2 hours after 
drug intake and keeped up to 12 hours. Drug is prescribed 1–2 times 
a day. Ketotifen undergoes biotransformation in liver. Its metabolites 
are excreted with urine and bile.  
Side effects are dry mouth, decrease of bronchial secretion, 
hoarseness, drowsiness, and increase of appetite.  
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Drugs Influencing Leukotriene System 
 
Inhibitors of Leukotriene Synthesis 
 
Leukotrienes play an important role in pathogenesis of atopic 
bronchial asthma. Leukotrienes are synthesized from arachidonic 
acid by means of enzymes, one of which is 5-lipoxygenase. This key 
enzyme of leukotriene synthesis is contained in tissue basophils, 
eosinophils, monocytes, and neutrophils.  
Zileuton  selectively blocks 5-lipoxygenase and affects 
synthesis of leukotrienes А4, В4, С4, D4 and Е4. It leads to  
anti-inflammatory and broncholytic effects. The drug does not 
influence activity of cyclooxygenase.  
Zileuton is easily absorbed from gastrointestinal tract. Maximal 
drug concentration in the blood is observed 2–2.5 hours after oral 
intake. The degree of its binding with plasma proteins is 93 %.  
The drug is taken 4 times a day.  
Zileuton is used to treat bronchial asthma. Besides, its  
anti-inflammatory effect may be useful at rheumatoid arthritis and 
ulcerative colitis. Side effects of zileuton are fever, headache, 
dizziness, muscular pain, dispepsy, and fatigue.              
 
Blockers of Leukotriene Receptors 
 
Zafirlukast  (Accolate) blocks cysteinyl leukotriene (CysLT) 
receptors C4, D4, and E4 and, thus, prevents effects of leukotrienes. 
Accolate eliminates bronchoconstriction, decreases vascular 
permeability, and inhibits bronchial secretion. 
The drug is taken orally 2 times a day in 1.5–2 hours prior 
a meal. Its degree of binding with plasma proteins reaches 99 %. 
Stable therapeutic effect is observed in a week from the treatment 
initiation. About 90 % of taken dose is excreted by the liver. 
Accolate easily penetrate placenta and is excreted with mother milk. 
Patients who treated by zafirlukast should avoid intake of 
theophylline.  
Zafirlukast is used in the basic treatment for atopic bronchial 
asthma and aspirin-, cold- and exercise-induced asthma. 
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Zafirlukast may be combined with glucocorticoids,  
β-adrenomimetics, and stabilizers of membrane of tissue basophils.  
Zafirlukast should be taken regullary, even in periods which are 
free from asthmatic symptoms. It is aspecially necessary to adhere to 
the mode of administration of the drug in periods of asthma 
exacerbation. Even regular drug intake during a year does not result 
in tolerance. Discontinuation of zafirlukast does not leads to 
aggrevation of patient’s condition. 
Pranlukast  and montelukast  (Singulair)  are drugs which 
are also reffered to the group of blockers of leukotriene receptors. 
Montelukast is taken 1 time a day.   
 
 
Expectorant Drugs 
 
This group includes a lot of drugs decreasing a sputum viscosity 
and facilitating its discharge. These drugs are used in symptomatic 
therapy for serious cough with little amount of viscous sputum (e. g., 
acute respiratory diseases, pleuritis, whooping cough). Expectorants 
decrease a number of infectious agents in the bronchi, improve the 
bronchial drainage and gaseous exchange, decrease the inflammation 
and irritation of nervous ending in bronchial mucosa. 
Expectorant drugs are classified as follows.    
1. Expectorant drugs of direct action: root of  Althaea 
officinalis  (marsh-mallow), leaves of  plantain , mucaltin,  
pertussinum, potassium iodide, terpin hydrate, sodium 
benzoate, sodium hydrocarbonate . 
2. Expectorants of reflex type of action: grass of 
Thermopsis,  grass of Labrador tea, root of  milkwort ,  
ipecacuanha, etc. 
3. Mucolytics: acetylcysteine, bromhexinum, ambroxol,  
desoxyribonuclease, crystalline trypsin , etc.     
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Expectorant Drugs of Direct Action 
 
Most representatives of this group are agents of plant origin. It is 
thought that after absorption into blood, these drugs are partly 
secreted by bronchial glands and have the covering and  
anti-inflammatory action. Also, these agents increase the production 
of bronchial secretion.    
Because the plant agents have the insufficient action upon the 
viscosity of sputum, these drugs are commonly combined with 
iodides, bromides, terpin hydrate, sodium benzoate, sodium 
hydrocarbonate, etc.  Iodine ions, secreted by bronchial glands, 
increase the secretion of water and decrease the viscosity of sputum.  
Mucaltin  contains mix of polysaccharides obtained from grass 
of Althaea officinalis. The drug is prescribed in tablets for oral 
intake.  
At peroral intake of small doses (about 0.25 g) of sodium 
hydrocarbonate , its expectorant effect is doubtful because the 
agent is neutralized by hydrochloric acid of stomach. Therefore, 
intake of 35 g of sodium hydrocarbonate with hot milk, honey, and 
2–3 drops of iodine is more effective.  
A large amount of drunk water also increases bronchial 
secretion.     
The combination of peroral administration of expectorants with 
inhalation therapy is more effective. The sodium hydrocarbonate is 
the main component of common solution for inhalations. This agent 
has neutralized and loosening effects concerning acidic 
mucopolysaccharides and decreases its viscosity. Bromides or 
iodides can be also added to inhalation solutions. At steam 
inhalations, vegetable essential oils (e. g., anise, eucalyptus) are 
effective. These oils exhibit emollient and anti-inflammatory effects.   
 
Expectorant Drugs of Reflex Action 
 
This group includes the drugs of plant origin which contain 
saponins. For expectorant effect, these drugs are taken orally. 
Saponins irritate the mucous membrane of stomach and reflexively 
cause the weak stable activation of vomiting centre. The expectorant 
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doses of these agents are less than the threshold vomitive doses; 
therefore, vomiting and significant nausea do not arise. But mild 
nausea reflexively activates the parasympathetic nervous system that 
is accompanied by increasing of secretion of salivary, gastric, and 
bronchial glands; decreasing of viscosity of sputum, and facilitating 
of sputum discharge. The activity of bronchi ciliary epithelium is 
increased. Lysosomal enzymes, released by goblet cells of 
epithelium, promote the proteolysis of sputum proteins. Expectorants 
of reflex action improve the release of viscous slippery sputum. 
These drugs are used in the treatment for acute respiratory diseases 
with poor slippery secretion.  
The high doses of these agents significantly excite the vomiting 
centre and cause the nausea and vomiting.        
 
Mucolyt ics  
 
Acetylcysteine (ACC), bromhexine, ambroxol  
(Mucosolvan, Lasolvan),  Mesna, crystalline trypsin,  
desoxyribonuclease,  crystalline chymotrypsin  and other 
drugs are reffered to this group.   
Molecules of acetylcysteine  contain free HS-group. Due to 
this, the drug reduces the disulfide groups of glycoproteins. The 
breakage of disulfide bonds is accompanied by depolymerization of 
protein components of sputum that improves its discharge. 
Simultaneously, amount of liquid component of bronchial secretion 
is increased.  
Unlike proteolytic enzymes (trypsin, chymotrypsin), 
acetylcysteine does not aggressively influence upon the epithelium 
and does not increase the size of defects in mucous membrane. 
Nowadays, acetylcysteine is one of the basic agents in the treatment 
for chronic bronchitis, pneumonia, and bronchiectatic disease. About 
4–8 ml of 10 % acetylcysteine is used in inhalations 3–6 times a day. 
Inhalation, lasting 15–20 minutes, is accompanied by active 
coughing. After liquidation of acute symptoms, the maintenance 
therapy (1–2 inhalations of acetylcysteine a week) is used. Also, 
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acetylcysteine is administered intramuscularly or intravenously. The 
drug is contraindicated at bronchial asthma.  
Pharmacological properties of Mesna are similar to 
acetylcysteine. The drug is administered in inhalations.   
Bromhexinum  and ambroxol  increase the activity of 
lysosomes of epithelial goblet cells, secretion of proteolytic enzymes, 
and synthesis of surfactant by pulmonary tissue.  Surfactant 
synthesized in the alveols and consists of phospholipids, proteins and 
polysaccharides. Surfactant provides elasticity of pulmonary tissue 
and promotes the discharge of sputum from pulmonary tract. Also, 
bromhexinum and ambroxol increase the synthesis of lysozyme and 
immunoglobulins G and A. Both drugs show the mild antitussive 
activity. 
Bromhexinum is used in aerosol for inhalations and in tablets for 
oral intake 3–4 times a day. Its effect develops in a day, but 
maximum effect is observed in 5–10 days after the therapy initiation. 
The drug is well tolerated by patients. Ambroxol is taken orally  
2–3 times a day. The drug is low toxic. Sometimes, ambroxol may be 
the cause of nausea and vomiting.  
 
 
Antitussive Drugs 
 
Antitussive drugs suppress cough reflex due to either inhibition 
of cough centre or decrease of sensitivity of nervous endings in 
respiratory tract.   
The excessive, exhausting cough promotes irritation of mucous 
membranes, its hyperemia, impairs the condition of patient. In such 
cases, the cough attacks are not productive and are not accompanied 
by discharge of sputum.  
The excessive inhibition of cough centre by antitussive agents is 
also inadmissible, because in this case the discharge of sputum is 
broken. Therefore, the doses of antitussive drugs should be correctly 
chosen. These agents are used in bronchitis, pneumonias, 
bronchiectatic disease.  
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Classification of antitussive drugs is as follows. 
1. Drugs with central action, which suppress the cough centre:   
– opioid analgesics: codeine and ethylmorphine ; 
– non-opioid antitussive drugs: glaucine,  oxeladine 
(Tusuprex), and butamirate . 
2. Drugs with peripheral action, which block the sensitive 
nervous endings in respiratory tract: Libexin (prenoxdiazine).  
Codeine  is alkaloid of opium. Drug exhibit moderate analgetic 
and expressed antitussive effects.  Its duration of action is 3–4 hours. 
The therapeutic doses of codeine do not suppress the respiratory 
centre. Long-time use of codeine can cause constipations and urinary 
retention. Codeine is contraindicated to children under 2 years. 
Prolonged use of codeine can cause the development of addiction.  
Ethylmorphine  is obtained by chemical modification of 
morphine. Its antitussive activity is 1.5–2 times higher than codeine’s 
activity.   
The creation of the drugs that selectively inhibit the cough centre 
and do not cause addiction was an important achievement in 
antitussive therapy. These agents are called non-opioid antitussive 
drugs. Therapeutic efficacy of these drugs is about equal to codeine. 
But these drugs also exhibit antispasmodic action upon smooth 
muscles of the hollow organs. Non-opiod antitussive drugs do not 
cause tolerance and drug dependence.      
Glaucine  exhibits the moderate antitussive effect and decreases 
the oedema of bronchi mucous membranes. The drug is well 
tolerated by adults and children (over 2 years old).  Sometimes, 
glaucine can cause the drowsiness, dizziness, and weakness. 
Libexin  (prenoxdiazine)  is antitussive agent with peripheral 
action. The base of its antitussive effect is local anaesthetic action. 
Besides, Libexin has the bronchial antispasmodic action which is 
higer than antispasmodic effect of papaverine. It is supposed, that 
Libexin has mild inhibitory influence upon the cough centre. Libexin 
is taken orally 3–4 times a day. The drug is well tolerated by adults 
and children. Libexin does not cause drug dependence.  
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Chemical structure of butamirate (Sinecod)  is similar to the 
structure of oxeladine (Tusuprex) . Besides central antitussive 
action, the drug exhibits expectorant, anti-inflammatory, and 
bronchodilating effects. Tablets, drops or sirup of Sinecod are taken 
orally to treat acute and chronic cough. Butamirate is component of 
co-formulated drug Stoptussin.    
 
 
Analeptics 
 
Analeptics (so-called “reviving” drugs) are drugs which directly 
or reflectory stimulate activity of respiratory and vasomotor centres. 
According to mechanism of action, analeptics are classified as 
follows.  
 1. Analeptics with central action: caffeine , bemegride , 
etimizol, and corazole .  
2. Analeptics with reflex action: lobeline  and cytitonum .  
3. Analeptics with mixed mechanism of action: cordiamine  
(nikethamide), camphor , sulfocamphocaine , and carbogen .  
Analeptics with reflex action cytitonum and lobeline stimulate 
respiratory centre due to excitation of Nn-cholinergic receptors of 
carotid bodies. These drugs are reffered to the group of  
N-cholinomimetics and their characteristics are given in the 
appropriate chapter. It should be noticed that these drugs practically 
are not used nowadays.  
Depending on predominant influence upon certain parts of 
central nervous system, the drugs of 2nd and 3rd groups are divided 
into 3 groups:  
– analeptics with predominant influence upon the brain cortex: 
caffeine ; 
– analeptics with predominant influence upon medulla 
oblongata: cordiamine , etimizol , camphor , bemegride , 
sulfocamphocaine , and carbogen ; 
– analeptics with predominant influence upon spinal cord: 
strychnine .   
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Stimulation of respiratory centre by analeptics is manifested by 
the increase of minute volume and frequency of respiration. This 
effect is most pronounced at respiratory depression. It should be 
noticed that analeptic effect is unstable and short-term. But 
analeptics give time gain which is aspecially important for 
liquidation of the cause of the disruption of vital functions.  
The analeptics with moderate but prolonged effect are most 
valuable. Such analeptics are etimizol, cordiamine, camphor, and 
sulfocamphocain. Practical implementation of etimizol led to 
discontinuation of bemegride’s use.   
At repeated respiratory depression (that is after administration of 
analeptic), repeated administration of analeptics is dangerous, 
because it can provoke either exhaustion of respiratory centre or 
convulsions. Clonic convulsions are associated with predominant 
excitation of the brain. Administration of corazol, bemegride, 
cordiamine, and camphor can provoke clonic convulsions. Tetanic 
seizures can occur after strychnine administration which excites 
mainly spinal cord. High doses of the drugs predominantly 
influencing brain can provoke clonic-tonic convulsions. 
Stimulation by analeptics of vasomotor centre and sympathetic 
innervation of the heart results in certain increase of vascular tone 
and blood pressure. In generally, Blood supply is improving. This 
effect is marked againt the background of the lowered blood 
pressure. Except camphor and caffeine, analeptics have no direct 
influence upon the heart.   
Pharmacological characteristic of caffeine  is given in the 
appropriate chapter (“Psychostimulants”).  
Cordiamine  (nikethamide) is 25 % solution of diethylamide 
of nicotinic acid. The drug is readily absorbed after oral intake, 
undergoes hepatic metabolism with partial formation of nicotinamide 
that does not influence pharmacological properties of the drug. 
Inactive metabolits of cordiamine are excreted by kidneys. 
Cordiamine excites respiratory and vasomotor centres by means of 
both direct stimulation of centres and reflex action (influence upon 
carotid artery chemoreceptors). Cordiamine increases peripheral 
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vascular resistance and blood pressure, stimulates frequency and 
depth of respiration. The drug inhibits GABAA-receptors in the 
medulla oblongata. Cordiamine insiglificantly influences heart rate 
and oxygen demand of myocardium and does not have 
arrhythmogenic properties. It should be noticed that cordiamine 
exhibits convulsive activity and increases oxygen demand of brain. 
At central genesis collapse, сordiamine’s action is more reliable than 
action of caffeine. Cordiamine is also used to treat moderate 
hypotension in elderly persons and infectious patients. The drug is 
used to eliminate asphyxia during surgery and in postsurgical period. 
The ability of cordiamine to increase general tone of central nervous 
system and to reduce asthenic phenomena is useful in asthenic 
patients.  
Etimizol  exhibits stable stimulative effect upon respiratory 
centre. Its stimulative influence upon vasomotor centre is weak. 
Besides analeptic properties, etimizol stimulates pituitary-adrenal 
system; due to this the drug is able to reduce steroid drugs 
withdrawal symptoms. Etimizol exhibits moderate antiallergic effect 
that is used in the treatment for bronchial asthma. The drug inhibits 
the brain cortex and may be used as sedative agent at alarm states. 
Simultaneously, etimizol exhibits certain nootropic properties 
(activates protein synthesis in the brain, increases energy exchange, 
and improves long-term memory.  
Camphor  is terpenoid which obtained from camphor laurel 
(Cinnamomum camphora) or great basil (Ocimum basilicum). 
Synthetic camphor produced by processing of turpentine. 
Administered subcutaneously, camphor reflectory stimulates 
respiration and increases vascular tone. In high doses, camphor 
directly stimulates vital centres of medulla oblongata. The drug has 
broad therapeutic window. Camphor increases the contractability of 
the heart, improves coronary blood flow and microcirculation, 
increases the resistance of heart to arrhythmogenic factors and toxic 
doses of cardiac glucosides. The drug stimulates inrerferon synthesis 
and exhibits expectorant effect. At topical application, camphor 
exhibits irritative and antiseptic effects. Camphor is used to treat 
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acute and chronic heart failure and collapse. Also, the drug is used to 
reduce respiratory depression at pneumonia, infectious diseases, 
intoxication by opioid analgesics and hypnotics. Toxic doses of 
camphor provoke convulsions. 
Sulfocamphocaine  is complex drug of camphorsulfonic acid 
and novocaine. The drug is water-soluble; therefore, it is 
administered both subcutaneously and intravenously. Indications for 
use of sulfocamphocaine are identical to camphor indications. 
Both camphor and sulfocamphocaine can cause allergic 
reactions.  
Bemegride  (Megimide)  is analeptic for intravenous 
administration. The drug is characterized by low degree of binding 
with plasma proteins and excreted with urine in unchanged form. 
Due to stimulation of GABAA-receptors, bemegride stimulates the 
central nervous system, activates vital centres of medulla oblongata 
(first of all – respiratory centre).  
Bemegride is used in the treatment for acute poisoning by 
hypnotics, opioid analgesics, general anaesthetics, ethyl alcohol, etc. 
Overdose of bemegride can provoke muscle twitching and 
convulsions. Bemegride is contraindicated at epilepsy and 
psychomotor excitement.  
Carbogen  is mixture of carbon dioxide and oxygen in ratio 
5 : 95 volume percents. Inspiration of carbogen increases the volume 
of respiration in 5–8 times. Accumulation of hydrogen ions and 
reduction of pH in the respiratory centre irritates the chemoreceptors 
located in the medulla oblongate near respiratory centre. It leads to 
stimulation of respiration. Reflex stimulation of respiratory centre 
from carotid bodies is also important. Effect of carbogen develops 
during 5–6 minutes. Also, carbogen inspiration improves general and 
cerebral blood circulation.  
Strychnine  is alkaloid of the seeds of strychnine tree 
(Strychnos nux-vomica). The drug is readily absorbed from the 
gastrointestinal tract, undergoes hepatic biotransformation, and 
excreted with the urine. Strychnine is accumulated in the human 
body. The drug selectively activates the neurons of spinal cord, 
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facilitates the transmission in the synapses, increases the reflex 
activity of central nervous system, suppresses the postsynaptic 
inhibition mediated by glycine. Strychnine stimulates vasomotor and 
respiratory centres, littly activates the cortex, improves visual 
functions. The drug increases blood pressure, coronary circulation, 
and tone of both smooth and skeletal muscles and activates taste and 
scent. Strychnine is used to treat arterial hypotension, fast 
fatigability, paralysis, paresis, gastrointestinal atoly, and functional 
visual impairment.  
 
 
Drugs Used to Treat Pulmonary Oedema  
 
Pulmonary oedema is one of the reasons of acute respiratory 
insufficiency and develops at different diseases of cardiovascular 
system, damage of the lungs by chemicals, renal and hepatic failure. 
A choice of the drugs depends on the degree of pulmonary 
oedema and level of blood pressure.  
The drugs decreasing blood pressure are used to reduce the 
oedema against the background of the hypertension. With this end in 
view, ganglionic blockers (hygronium , pentaminum , 
benzohexonium ), vasodilators of myotropic action (sodium 
nitroprusside , nitroglycerin ), and α-adrenoblockering drugs 
(phentolamine  or small doses of aminazine) are used. The 
mentioned drugs decrease the blood pressure and reduce venous 
return to the heart, that promotes cardiac unloading and improves its 
work. In result, blood pressure in pulmonary circulation is decreased 
and output of transudate into the alveoli is reduced.  
Potent diuretics (furosemide , etacrynic acid ) decrease the 
blood volume and blood pressure that also promotes the reduction of 
pulmonary oedema. 
Sometimes, opioid analgesics (morphine , fentanyl  or its 
combination with droperidol  – Thalamonal ) are used in the 
treatment for pulmonary oedema. The drugs relax peripheral arteries 
and veins and reduce cardiac preload and afterload. The use of opioid 
analgesics is accompanied by the decrease of blood pressure in 
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pulmonary circulation, reduction of dyspnea and elimination of 
cough. 
At pulmonary oedema against the background of the arterial 
hypotension, the drugs for normalization of blood pressure are used 
(phenylephrine , ephedrine). Dehydrating drugs and diuretics are 
also used with caution in this case.  
At pulmonary oedema, foam accumulates in the lumen of alveoli 
and violates the gas exchange. The antifoam agents (ethyl alcohol , 
anti-fomosilane) are used to inhibit the foaming. The antifoam 
agents decrease the superficial tension of foam bubbles; therefore, 
foam is transformed to liquid which takes up significantly less 
volume in the alveoli. Alcohol vapors with oxygen are inhaled by 
means of nasal cateter or mask. Alcoholic solution of anti-fomosilane 
with oxygen is used in aerosol for inhalation. Unlike ethyl alcohol, 
anti-fomosilane does not irritate mucous membranes of respiratory 
tract. Its effect develops faster. 
Glucocorticoids (prednisolone , dexamethasone) are used to 
treat pulmonary oedema owing to their prominent anti-inflammatory 
and anti-oedema effect.  
Oxygen  is inhaled in all cases of the pulmonary oedema.  
Sometimes, cardiac glycosides with fast onset of action 
(strophanthin , corglycon ) are used to treat pulmonary oedema 
against background of the heart failure. 
Interstitial pulmonary oedema with multiple atelectasis and 
severe respiratory failure develops at infant respiratory distress 
syndrome developing due to the insufficiency of pulmonary 
surfactant production. Artificial pulmonary ventilation and 
administration of colfosceri l palmitate  (Exosurf) is used in such 
cases. Colfosceril is administered intratracheally no more than two 
times. The drug reduces superficial tension of pulmonary fluid and 
maintains elasticity of alveoli. Sometimes, Alveofakt  is also used 
with this end in view. It is highly purified surfactant obtained from 
the lungs of cattle.    
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Table 1 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product  
Codeini phosphas Orally 0.01–0.03 g  
1–3 times a day 
Powders  
Libexinum Orally 0.1–0.2 g 3–4 times 
a day 
Tablets 0.1 g 
 
Acetylcysteinum Orally 0.2 g 3 times a day; 
intramuscularly 0.1–0.2 g 
2–3 times a day 
Tablets 0.2 g; 
ampoules 2 ml  
of 10 % solution 
Bromhexinum  Orally 0.008 g 3–4 times 
a daily 
Tablets 0.008 g 
Euphyllinum Orally 0.25 g 2–3 times 
a day; 
intramuscularly 0.24–0.36 g 
1–3 times a day; 
intravenously slowly  
or drop-by-drop (in 200– 
400 ml of 0.9 % solution  
of NaCl) 0.12–0.24 g  
Tablets 0.25 g; 
 
ampoules 5 ml  
of 2 % solution 
 
Cromolynum-
natrium 
For inhalation: 1 capsule  
4 times a day 
Capsules 0.02 g 
Adrenalini 
hydrochloridum  
Subcutaneously or 
intramuscularly (sometimes 
intravenously) 0.000 3–
0.000 7 g  
Ampoules 1 ml  
of 0.1 % solution 
Salbutamolum 1–2 inhalations of aerosol 
2–3 times a day to prevent 
bronchospasm  
or 2 inhalations to interrupt 
acute bronchospasm 
Aerosol 10 ml 
Furosemidum Intramuscularly or 
intravenously 0.02 g 
Ampoules 2 ml  
of 1 % solution 
Hygronium Intravenously drop-by-drop 
0.04–0.1 g (as 0.1 % 
solution in isotonic sodium 
chloride solution) 
Ampoules 0.1 g  
of powder for injection 
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Step 1. Tasks for Self -Control  
Drugs Influencing Respiratory System 
 
1. Spasm of smooth muscle of bronchi developed in the patient. 
Usage of activators of what membrane cytoreceptors is 
physiologically valid to decrease attack? 
A. -Adrenoreceptors. 
B. - and -adrenoreceptors. 
C. -adrenoreceptors. 
D. H-cholinoreceptors. 
E.  M-cholinoreceptors. 
2. A 13-year-old girl with history of asthma complained of 
cough, dyspnea, and wheezing. Her symptoms became so severe that 
her parents brought her to the emergency room. Physical 
examination revealed diaphoresis, dyspnea, tachycardia, and 
tachypnea. Her respiratory rate was 42/min, pulse rate was 110 beats 
per minute, and blood pressure was 130/70 mm Hg. Choose from the 
following list the most appropriate drug to reverse the 
bronchoconstriction rapidly. 
A. Salbutamol. 
B. Ipratropium. 
C. Methylprednisolone. 
D. Beclomethasone. 
E. Cromolyn sodium. 
3. A 45-year-old woman suffers from allergic seasonal coryza 
caused by the ambrosia blossoming. What drug from the stabilizer of 
the adipose cells group can be used for prevention of this disease? 
A. Dimedrol. 
B. Tavegyl. 
C. Diazolinum. 
D. Ketotifen.  
E. Phencarol. 
4. Which of the following β-adrenoceptor agonists has such 
a slow onset of action that it is not indicated for the relief of acute 
asthma symptoms? 
A. Isoproterenol. 
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B.  Albuterol. 
C. Epinephrine. 
D. Terbutaline. 
E. Salmeterol. 
5. A patient with bronchial asthma was treated by euphyllinum, 
after that the condition of patient was improved. What mechanism of 
action has this drug? 
A. Prevention of histamine discharge from basophils. 
B. Blockade of phosphodiesterase.  
C. Activation of Na, K-ATPase. 
D. Blockade of M-cholinoreceptors. 
E. Activation of adenylyl cyclase (adenyl cyclase). 
6. A 12-year-old girl with a childhood history of asthma 
complained of cough, dyspnea, and wheezing after visiting a riding 
stable. Her symptoms became so severe that her parents brought her 
to the emergency room. Physical examination revealed diaphoresis, 
dyspnea, tachycardia, and tachypnea. Her respiratory rate was 
42/min, pulse rate was 110 beats per minute, and blood pressure was 
132/65 mm Hg. What drug is contraindicated in this patient? 
A. Inhaled cromolyn sodium. 
B. Inhaled beclomethasone. 
C. Inhaled ipratropium. 
D. Inhaled albuterol. 
E. Intravenous propranolol.  
7. A 12-year-old girl with a childhood history of asthma 
complained of cough, dyspnea, and wheezing after visiting a riding 
stable. Her symptoms became so severe that her parent brought her 
to the emergency room. Physical examination revealed diaphoresis, 
dyspnea, tachycardia, and tachypnea. Her respiratory rate was 
42/min, pulse rate was 110 beats per minute, and blood pressure was 
132/65 mm Hg. What is the most appropriate drug to rapidly reverse 
bronchoconstriction? 
A. Intravenous propranolol. 
B. Inhaled albuterol.  
C. Inhaled ipratropium. 
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D. Inhaled cromolyn sodium. 
E. Inhaled beclomethasone. 
8. A 12-year-old girl with a childhood history of asthma 
complained of cough, dyspnea, and wheezing after visiting a riding 
stable. Her symptoms became so severe that her parent brought her 
to the emergency room. Physical examination revealed diaphoresis, 
dyspnea, tachycardia, and tachypnea. Her respiratory rate was 
42/min, pulse rate was 110 beats per minute, and blood pressure was 
132/65 mm Hg. Indicate the drug, which is likely to be ineffective in 
this patient.  
A. Intravenously prednisolone. 
B. Inhaled beclomethasone. 
C. Inhaled ipratropium. 
D. Inhaled albuterol. 
E. Inhaled cromolyn sodium. 
9. Ethyl alcohol was introduced to patient with acute pulmonary 
oedema. What action of ethyl alcohol was used in this case? 
A. Ethyl alcohol decreases the permeability of lung’s vessels.  
B. Ethyl alcohol decreases the superficial tension of foam and 
transforms it to the fluid.  
C. Analgesic action. 
D. Ethyl alcohol increases the rate of metabolism into the body. 
E. Hypnotic action. 
10. A patient with bronchial asthma attack has a concomitant 
disease – angina pectoris. What bronchodilator should be prescribed 
in this case? 
A. Noradrenaline hydrotartrate. 
B. Adrenaline.  
C. Salbutamol. 
D. Atropine sulfate. 
E. Isadrinum. 
11. Chronic bronchitis is diagnosed. A patient is treated with 
mucolytic – a drug, which stimulates formation of surfactant, 
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improves rheological properties of sputum, reduces its viscosity. 
What is this drug? 
A. Panadol. 
B. Papaverine hydrochloride. 
C. Libexinum (prenoxdiazine). 
D. Ambroxol.  
E. Codeine. 
12. Bronchospasm has developed in patient using  
-adrenoblockers during long time. Choose the most rational drug 
group for interruption of bronchospasm in this patient. 
A. Cholinesterase inhibitors. 
B. -adrenomimetics. 
C. Adrenomimetics with indirect action. 
D. M-cholinomimetics. 
E. Myotropic spasmolytics. 
13. A patient with asthmatic status is delivered to urgent unit. 
The patient has been suffering from bronchial asthma for 12 years. 
Earlier attacks were reduced by salbutamol but now this drug is 
ineffective.  What drug should be administered to patient first? 
A. Prednisolone. 
B. Acyclovir. 
C. Oxytocin. 
D. Famotidine. 
E. Bisacodyl. 
14. A patient with purulent bronchitis is delivered to the 
pulmonary department. For depression of sputum and simplification 
of its release the doctor prescribes to him drug A. Indicate this drug. 
A. Morphine. 
B. Tincture of valerian. 
C. Cholosasum. 
D. Acetylcysteine. 
E. Prednisolone. 
15. A patient with acute laryngotracheitis suffers from dry 
cough. Prescribe antitussive drug for this patient. 
A. Morphine.  
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B. Glaucine. 
C. Acetylcysteine. 
D. Mucaltin. 
E. Ambroxol. 
16. A patient suffering from chronic bronchitis takes synthetic 
mucolytic drug that facilitates the sputum thinning. What drug is it? 
A. Acetylcysteine. 
B. Enalapril. 
C. Heparin. 
D. Diazepam. 
E. Furosemide. 
 
37 
 
DRUGS INFLUENCING CARDIOVASCULAR 
SYSTEM 
 
There are many drugs influencing cardiovascular system. 
Depending on their clinical use, these drugs are classified as follows.  
1. Cardiotonic drugs. 
2. Antihypertensive drugs. 
3. Hypertensive drugs. 
4. Antiarrhythmic drugs.  
5. Drugs which used to treat ischaemic heart disease.  
6. Hypolipidemic (lipid-lowering) drugs.  
7. Drugs improving cerebral circulation.  
8. Venotropic drugs.    
 
 
CARDIOTONIC DRUGS 
 
Cardiotonic drugs are drugs which increase contraction of 
myocardium and normalize the functions of heart. Cardiotonics are 
divided into cardiac glycosides and non-glycoside cardiotonics.  
 
Cardiac Glycosides 
 
Cardiac glycosides are nitrogen-free compounds with 
cardiotonic activity. Cardiac glycosides are contained in such plants 
as foxglove, lily of the valley, spring adonis, strophanthus, etc. It is 
known 15 species containing cardiac glycosides and used in 
medicine.  
Presently, the main and most studied cardiac glycosides are:  
– digitoxin –  main glycoside of leaves of foxglove (Digitalis 
purpurea); 
– digoxin  and celanidum –  glycosides of leaves of woolly 
foxglove (Digitalis lanata);  
–  strophanthin –  glycoside of seeds of Strophanthus kombe; 
–  corglycon – novogalenic drug derived from the leaves of lily 
of the valley (Convallaria majalis); 
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–  infusion of Adonis herb (pheasant’s eye, Adonis 
vernalis) . 
The glycoside content of plants varies greatly and depends on 
conditions of growth, drying methods, and other factors. Сonsidering 
this, drugs of cardiac glycosides undergo biological standardization. 
The main object of study are frogs; sometimes, cats are used. The 
base for standardization of glycosides is their ability to cause cardiac 
arrest in systole (in frogs) or in diastole (in cats). The activity of 
investigated drug is compared to activity of standard and expressed 
in “frog” action units or “feline” action units. Thus, 1 g of digitoxin 
contains 8 000–10 000 “frog” action units (or 1 911–2 271 “feline” 
action units); 1 g of sthrophanthin – 43 000–58 000 “frog” action 
units (or 5 800–7 100 “feline” action units).       
Cardiac glycosides influence cardiovascular, urinary, and 
nervous systems. Respectively, effects of cardiac glycosides are 
divided into cardiac and extracardial ones.  
There are the following cardiac effects of cardiac glycosides:  
1. Positive inotropic effect. Cardiac glycosides increase and 
shorten systole, increase stroke volume and cardiac output, and 
decrease the amount of residual blood in the cavity of the heart.  
2. Positive tonotropic effect. Cardiac glycosides increase the 
tone of myocardium and decrease the size of enlarged heart. It 
promotes more complete expulsion of blood from the ventricles.  
3. Negative chronotropic effect. Cardiac glycosides decrease 
heart rate and prolong diastole. As a result, blood supply to the heart 
improves. 
4. Negative dromotropic effect. Cardiac glycosides decrease the 
impulse conduction through conductive heart system, especially 
through atrioventricular node.  
5. Positive bathmotropic effect. Cardiac glycosides increase the 
excitability of myocardium and may promote the ventricular 
tachyarrhythmias.  
The first three effects are the base of therapeutic action of 
cardiac glycosides. The fourth and the fifth effects are undesirable 
effects, which develop predominantly in case of glycosides overdose.  
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Cardiac glycosides interact with membrane Na+, K+-ATPase of 
cardiac histiocytes. Owing to this interaction, the partial blockage of 
ATPase activity develops. It results in increase of intracellular Na+ 
ions concentration and simultaneous reduction of K+ concentration. 
This change in intracellular ions balance causes the increase of Ca2+ 
ions concentration in cardiac histiocytes. The increase of free 
calcium concentration in the cardiac histiocytes causes the reduction 
of inhibitory influence of troponin upon the contractile proteins of 
myocardium that leads to increase of cardiac contractility. This 
phenomenon is called positive inotropic effect .  
Cardiac glycosides form the complexes with phospholipids, 
proteins, and carbohydrates of the membranes of cardiac histiocytes 
and endothelial cells, that leads to the increase of permeability of 
membranes for calcium and elevation of intracellular calcium 
concentration.    
Positive inotropic effect develops if inhibition of  
Na+, K+-ATPase equals approximately 35 %. If enzyme inhibition is 
less, cardiotonic effect does not develop. Toxic effects develop if 
enzyme inhibition equals or is more than 60 %.  
Positive inotropic effect of cardiac glycosides is manifested by 
the increase of rate of tension development in myocardium and speed 
of cardiac muscle contraction, elevation of stroke volume. All systole 
phases are shortened. Amount of residual blood in the ventricles 
cavities is decreased. The following changes are observed on ECG: 
the increased wave R, narrowed complex QRS, decreased ST 
segment below the isoelectric line, and flattened or inverted T wave.  
The energy of ATP is more productively used at the therapy with 
cardiac glycosides. An elevation of Ca2+ ions in diastole promotes 
the maintaining of myocardium tone, that is positive tonotripic effect 
is observed.  
Prolongation of diastole and decrease of heart rate (negative 
chronotropic effect ) is the result of increased vagal influence 
upon heart. Increase of cardiac contraction force is accompanied by 
enhance of stroke volume and excitation of baroreceptors of aortic 
arch and carotid glomeruli.  Excitation carries out to vagus centre. 
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Increase of vagal tone results in decrease of excitability and 
automatism of sinus node and decrease of heart rate. On ECG, 
prolongation of interval PP is registered. Negative chronotropic 
effect is accompanied by the reduction of myocardium oxygen 
demand and improvement of metabolism in the heart during diastole 
that promotes the restoration of the heart energy resources, 
normalizes the activity of ionic channels which participate in 
transport of Ca2+ ions from the cytoplasm into extracellular space, 
mytochondies, and sarcoplasmic reticulum.   
During treatment by cardiac glycosides, the conductibility 
through atrioventricular node slows down (negative dromotropic 
effect). Mainly, it is the result of increased vagal tone. Negative 
dromotropic effect is most typical for digitalis drugs.  At long-time 
therapy by cardiac glycosides, the changes of electrolyte balance 
become the main cause of slowdown of impulces conduction. On 
ECG, prolongation of interval P–Q is observed.  
Positive bathmotropic effect  is ability of toxic doses of 
cardiac glycosides to increase excitability of myocardium which 
results in geterotopic focus of excitation. It is the result of significant 
electrolyte change in cells which develop in toxic doses (elevation of 
Ca2+ ions concentration and reduction of K+ ions concentration into 
cardiac histiocytes). Wherein, on ECG, extrasystoles are registered.  
Besides cardiac effects, cardiac glycosides also have several 
extracardial effects. At heart failure, myocardium doesn’t fulfil pump 
function that leads to the decrease of cardiac output and phlebostasis. 
Administration of cardiac glycosides increases cardiac output and 
decreases venous blood pressure. Blood volume in veins and hepatic 
portal system is decreased. Blood pressure is normalized. Owing to 
the increase of stroke volume and cardiac output, some elevation of 
blood pressure is obcerved in patients with hypotension. General 
blood flow and cerebral blood circulation are improved. The oxygen 
deficiency, blood concentration of carbon dioxide, excitability of 
respiratory and vasomotor centres, and dyspnea are decreased.  
Diuresis increases owing to rise of blood flow and enhancement 
of glomerular filtration. Additionally, cardiac glycosides have direct 
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influence upon renal tubules: drugs block K+, Na+-ATPase and 
decrease reabsorbtion of sodium and water. Administration of 
cardiac glycosides results in reduction of oedemas. Cardiac 
glycosides have sedative effect in central nervous system.  
Cardiac glycosides stimulate smooth muscles of inner organs 
and that leads to increase of intestinal peristalsis, increase of tone of 
bladder, bronchi, and uterus.  
There are the following therapeutic indications for cardiac 
glycosides.   
1. Treatment of chronic systolic heart failure.  
2. Supraventricular tachyarrhythmias (digitalis drugs are 
preferable).  
3. Prevention of heart failure.  
4. Acute heart failure (strophanthin, corglycon). But in recent 
years, their use in acute heart failure is almost stopped owing to the 
introduction in medicine the safer drugs (dobutamine, dopamine, 
amrinone, etc.).  
5. In ophthalmology, cardiac glycosides (e. g., Digophton ) are 
used to treat asthenopia, presbyopia, eye pain at the migraine attack, 
and eye fatigue in cases of violation of blood circulation, long stay in 
front of the TV or sewing.    
Molecule of cardiac glycosides consists of two parts: sugary part 
(glycone) and nonsugary one (aglycone). Glycone influence drugs 
pharmacokinetics: solubility, ability to penetrate through biological 
membranes, binding with plasma proteins, cumulation, etc. Aglycone 
influence cardiotropic properties of drugs. Aglycone consists of 
steroid part and lactone ring. Dependently of quantity of ketone and 
alcogol groups in glycone structure, cardiac glycoside may be polar 
or nonpolar. Polar glycosides are strophanthin and corglycon; 
relatively polar drugs are digoxin and celanidum; nonpolar glycoside 
is digitoxin. Polar glycosides are poorly absorbed in gastrointestinal 
tract, don’t undergo biotransformation, and are excreted with urine. 
Nonpolar glycosides are well absorbed in intestine, bind with plasma 
proteins, undergo hepatic biotransformation, and are excreted 
42 
 
predominantly through intestine. Nonpolar glycosides have high 
ability to cumulation.  
According to pharmacokinetics, cardiac glycosides are divided 
into three groups: 
– drugs with fast onset of effect and short duration of action 
which are characterized by low ability to cumulation: strophanthin  
and corglycon ; 
– agents with moderate speed of effect development and 
intermediate duration which are characterized by reasonable degree 
of cumulation: digoxin  and celanidum ; 
– glycosides with slow onset of effect and long duration of 
action which are characterized by high degree of cumulation: 
digitoxin . 
Drugs of the first group (strophanthin  and corglycon) 
predominantly are used in acute heart failure. These drugs are 
administered intravenously slowly. Prior administration, solution of 
glycosides is diluted in 10–20 ml of isotonic sodium chloride 
solution or isotonic glucose solution. Fast intravenous administration 
can lead to vascular spasm and increase of preload and afterload on 
the heart. Strophanthin effect develops in 5–10 minutes after 
administration and reaches maximum in 30–90 minutes. 
Approximately 85–90 % of administered dose is eliminated during 
the first day.  
Drugs of the second group (digoxin  and celanidum) occupy 
an intermediate position. These drugs are administered both 
intravenously and perorally in acute and chronic heart failure. Drugs 
effects develop in 0.5–2 hours after intravenous administration. 
Maximum effect develops in 1–5 hours. Drugs are completely 
excreted in 2–7 days.  
Digitoxin  is used perorally or rectally in chronic heart failure. 
In case of peroral use, onset of drug action is in 2 hours and 
maximum effect develops in 12 hours. Only 7–10 % of administered 
dose is excreted during the first day after administration. Digitoxin is 
completely excreted from the body in 2–3 weeks.  
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Infusion of Adonis herb is preparation of perennial herb 
pheasant’s eye (Adonis vernalis). Properties of Adonis glycosides are 
similar to properties of digitalis glycosides but are less effective. 
Also, Adonis glycosides exhibit weak diuretic effect. In comparison 
with digitalis glycosides, duration of action of Adonis glycosides is 
less; therefore, danger of cumulation is practically excluded. At oral 
intake, the degree of glycosides absorption is enough for therapeutic 
effect. Infusion of Adonis herb is used in the treatment for slight 
forms of chronic heart failure, neurosis, and vegetative-vascular 
dystonia. Adonis herb is component of Bechterew’s mixture, 
Cardiovalen, and Adonis-bromine.  
Cardiac glycosides are dosed according to certain rules. First of 
all, it is necessary to take into account the degree of drug’s daily 
excretion. The coefficient of daily excretion characterizes the daily 
excretion of cardiac glycosides from the patient’s body. This is 
percentage ratio of dose which was introduced into the body during 
the day to quantity of glycoside, which was excreted from the body 
during day. For example, coefficient of daily excretion of digitoxin 
equals 7–10 %, for strophanthin – 40–50 %.  
The treatment of chronic heart failure is carried out in two 
phases: phase of initial digitalization and supporting phase. During 
the initial digitalization the full effective dose of glycoside is 
received in organism. The realization of phase of saturation is crucial 
task, as the sensitivity of the patients to glycosides is individual, and 
the effective dozes of drugs are close to toxic. This phase may be 
carried out with different velocity. The moderate (for 3 days) and 
slow (for 8 days) types of initial digitalization are most commonly 
used in practice. Fast type of digitalization (during 1 day in organism 
of patient the full effective dose is taken) creates the biggest threat of 
intoxication. Fast digitalization is fulfilled only for inpatients and 
under ECG control.   
The scheme of moderate digitalization:  
– first day: 1/2 of full effective dose (divided in 3–4 intakes) is 
taken by patient; 
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– second day: patient takes 1/4 of full effective dose (divided in 
2 intakes) and amount of the drug which eliminated during 1st day 
(that is, coefficient of elimination for dose which patient took in 1st 
day;  
– third day: patient takes 1/4 part of full effective dose (divided 
in 2 intakes) and amount of the drug which was eliminated for two 
days.     
In the second stage (supporting phase), patient takes the 
supportive dose. The calculation of supportive dose is performed 
according to ratio: supportive dose = dose of saturation (full effective 
dose) · coefficient of daily excretion. 
Daily supportive dose is not divided in several intakes. 
 
Symptoms and treatment of glycosides overdose  
 
In glycoside overdose, disturbances of heart rate observed in  
90–95 % of patients. Ventricular arrhythmias (extrasystoles, 
paroxysmal ventricular tachycardia, and ventricular fibrillation) are 
most common among them. The cause of ventricular arrhythmias is 
decrease of potassium concentration and simultaneous increase of 
calcium ions concentration in cardiac histiocytes. Also, complete or 
partial atrioventricular blocks can develop.  
Less dangerous complications include nausea, vomiting, 
epigastric pain, xanthopsia (seeing of objects in yellow or green 
colour), “rings” and “balls” before eyes, psychical disturbances 
(excitement and hallucinations), allergic reactions, and headache.  
At appearance of overdose symptoms, the cardiac glycosides 
therapy is stopped. Non-glycoside cardiotonic (dopamine  or 
dobutamine) should be prescribed.  
Drugs binding glycosides and reducing their blood circulation 
should be prescribed. They are agents decreasing glycoside 
absorption in gastrointestinal tract: tannin , cholestyramine , 
charcoal , laxative  drugs. These drugs are prescribed 
independently of glycoside administration mode because cardiac 
glycosides undergo enterohepatic circulation. Drugs binding 
glycosides in the blood are unithiol  and antibodies or  digoxin 
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immune Fab (Digibind) . Unithiol contains sulfhydryl groups in 
molecules, therefore binds with cardiac glycosides and restores the 
activity of myocardial ATPase. 
Potassium- and magnesium-containing drugs, such as 
potassium chloride,  Asparkamum, Panangin , polarized 
mixture (potassium chloride,  insulin,  and glucose),  
magnesium sulfate,  and  Trilon B  are used for treatment of 
glycoside intoxication. Potassium and magnesium slow down the 
impulse conduction, therefore they are not prescribed to patients with 
bradycardia and atrioventricular blockage. Intravenous 
administration of potassium-containing drugs should be fulfilled 
under control of ECG.  
For treatment of ventricular tachyarrhythmias, l idocaine  and 
dipheninum  are used. In some cases, atrioventricular blockage may 
be reduced by administration of atropine .  
 
Non-Glycoside Cardiotonics 
 
Cardiac glycosides are highly effective drugs to treat heart 
failure. But their use is restricted by narrow therapeutic index, 
significant amount of side effects and contraindications. Therefore, 
synthetic non-steroid drugs with cardiotonic activity were introduced 
in medicine.       
According to mechanism of action, non-glycoside cardiotonics 
are classified as follows: 
1. Drugs stimulating β1-adrenoceptors: dopamine and 
dobutamine .  
2. Phosphodiesterase inhibitors: amrinone, milrinone, and 
sulmazol .  
3. Drugs with different mechanisms of action: levosimendan 
and vesnarinone .  
Dopamine  is noradrenaline precursor. In average therapeutic 
doses, dopamine stimulates dopaminergic receptors and  
β1-adrenergic receptors of heart. It results in increase of cardiac 
contraction force. Owing to excitation of dopaminergic receptors of 
smooth muscles of vessels, drug dilates renal and mesenteric vessels. 
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In high doses, dopamine can also excite α-adrenoceptors. Dopamine 
is used in severe cardiovascular insufficiency, shock, severe arterial 
hypotension.  
Dobutamine  selectively excites β1-adrenoceptors. Drug 
stimulates heart work without influence upon the vessels. 
Dobutamine is used in acute heart failure.  
Both dopamine and dobutamine are administered intravenously 
drop-by-drop.  
Recently, cardiotonic drugs with favourable influence upon 
coronary circulation were approved in medical practice. Amrinone  
and milrinone  are among them. Drugs inhibit phosphodiesterase 
activity and promote accumulation of cAMP in myocardium. It leads 
to the increase of intracellular calcium concentration, inactivation of 
adenosine (A1) receptors, and cardiotonic effect.  
Amrinone is administered perorally or intravenously. The drug is 
used in the treatment for heart failure resistant to therapy with 
cardiac glycosides. Duration of action is 4–7 hours. Amrinone side 
effects are thrombocytopenia, dyspepsia, hypotension, arrhythmias, 
disturbances of renal function, etc.  
Cardiotonic activity of milrinone is 20 times more than 
amrinone. Drug is administered intravenously. Duration of action is 
48–72 hours. Milrinone is used for short-term therapy of acute heart 
failure.  
Sulmazol  inhibits phosphodiesterase activity and blocks  
A1 adenosine receptors of heart. It results in cardiotonic effect. 
Furthermore, drug increases activity of microfibrillar ATPase.  
Levosimendan  binds with troponin C that leads to the increase 
of sensitivity of the cardiac myofibrils to calcium ions. The drug 
increases the force of cardiac contractions without elevation of 
myocardial oxygen demand. Besides, levosimendan causes 
vasodilation, increases coronary circulation, and reduces peripheral 
vascular resistance; therefore, the drug has positive effect on the 
heart at acute heart failure. The drug is administered intravenously 
drop-by-drop. Duration of levosimendan’s action is 6–24 hours.    
 
47 
 
Table 2 – Drugs for prescription 
  
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product 
Digitoxinum Orally 0.000 1 g once a day; 
for rectal use 0.000 15 g once 
a day  
Tablets 0.000 1 g; 
suppositories 0.000 15 g 
Digoxinum Orally 0.000 125–0.000 25 g 
once a day; 
intravenously slowly 0.000 125–
0.000 25 g with 10–20 ml  
of isotonic sodium chloride 
solution once daily 
Tablets 0.000 25 g; 
 
ampoules 1 ml of 0.025 % 
solution 
Celanidum Orally 0.000 25 g 3 times a day; 
intravenously slowly 0.000 2 g 
with 10–20 ml of isotonic 
sodium chloride solution once 
a day 
Tablets 0.000 25 g; 
ampoules 1 ml of 0.02 % 
solution 
Strophantinum Intravenously slowly 0.000 25 g 
with 10–20 ml of isotonic 
sodium chloride solution once 
a day 
Ampoules 1 ml  
of 0.05 % solution  
Unithiolum Intramuscularly 0.25 g Ampoules 5 ml of 5 % 
solution  
“Asparcamum” 
or 
“Pananginum” 
Orally 1–2 tablets 3 times a day Tablets containing 
magnesium asparaginate 
and potassium 
asparaginate  
Lidocainum  Intravenously slowly 0.05–0.1 g; 
intravenously drop-by-drop 
0.05–0.1 g with 100 ml of 
isotonic sodium chloride solution 
Ampoules 2 ml  
of 10 % solution;  
2 or 10 ml  
of 2 % solution 
Dipheninum Orally 0.117 g 1–3 times a day Tablets 0.117 g 
 
Step 1. Tasks for Self -Control  
Cardiotonic Drugs  
 
1. A patient with chronic heart failure being treated by digitalis 
drugs developed the symptoms, which confirmed the beginning of 
cardiac glycosides toxic activity. What drug should be administered 
to reduce the negative effect of cardiac glycosides? 
A. Atropine sulfate. 
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B. Sodium chloride. 
C. Potassium chloride. 
D. Dipiroxime. 
E. Caffeine sodium benzoate. 
2. Patient complains of weakness, dyspnea, and low extremities 
oedema. Diagnosis: chronic cardiac insufficiency. What medicine 
should be prescribed first? 
A. Digoxin. 
B. Raunatine. 
C. Propranolol. 
D. Caffeine. 
E. Papaverine. 
3. Point out a statement which most directly describes the 
mechanism of action of digitalis drugs? 
A. Decrease of calcium release from the sarcoplasmic reticulum. 
B. Decrease intracellular concentration of sodium ions. 
C. Increase intracellular level of ATP. 
D. Stimulation of production of cAMP. 
E. Inhibition of Na+, K+-ATPase. 
4. Point out a drug which is not used to treat overdose of cardiac 
glycosides: 
A. Preparations of anti-digoxin FAB fragments. 
B. Polarased mixture. 
C. Quinidine. 
D. Dipheninum (phenytoin). 
E. Lidocaine. 
5. Which of the following aggravates a digitalis-induced 
arrhythmia? 
A. Decrease of concentration of serum angiotensin II. 
B. Decrease level of sodium in the blood. 
C. Slowdown of heart rate by propranolol (anaprilinum). 
D. Decrease of serum calcium. 
E. Decrease of potassium concentration in the blood.  
6. A patient with chronic cardiovascular insufficiency during 
digitalization demonstrated the following symptoms: headache, 
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fatigue, nausea, colour vision impairment (surrounding objects are 
perceived in green colour). On ECG the sinus bradycardia and signs 
of impairment of atrioventricular conductivity were detected. What 
drug can be prescribed to relieve the symptoms of intoxication? 
A. Atropine.  
B. Naloxone. 
C. Bemegride. 
D. Dipiroxime. 
E. Unithiol.  
7. A patient complains of oedemas, rapid pulse, short breath, 
cyanosis of mucous tunics. The diagnosis is chronic cardiac 
insufficiency. What drug should be prescribed for this patient? 
A. Nitroglycerin. 
B. Digoxin.  
C. Mesatonum. 
D. Cordiaminum. 
E. Papaverine. 
8. A patient with signs of acute cardiac insufficiency is delivered 
to a hospital. What drug should be prescribed for urgent aid to this 
patient? 
A. Corglycon. 
B. Etimizol (Aethimizolum). 
C. Dithylinum. 
D. Pyridostigmine bromide. 
E. Digitoxin. 
9. A patient with cardiac insufficiency took a medicine. 
Consequently, his heartbeats increased, pulse became stronger, 
oedema decreased, diuresis increased. What drug did the patient 
take? 
A. Reserpine. 
B. Propranolol. 
C. Verapamil. 
D. Digoxin.  
E. Diltiazem. 
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10. Acute cardiovascular insufficiency is accompanied by edema 
of lungs. What cardiac glycoside should be prescribed to the patient? 
A. Triamterene. 
B. Spironolactone. 
C. Dichlothiazidum. 
D. Acetazolamide (Diacarb). 
E. Corglycon.  
11. A patient with cardiogenic shock, hypotension, asthma, and 
oedemas was prescribed a nonglycosidic cardiotonic. Which drug 
was injected to the patient? 
A. Bemegride. 
B. Dobutamine. 
C. Cordiaminum. 
D. Etimizol (Aethimizolum). 
E. Caffeine sodium benzoate. 
12. A 68-year-old patient with cardiac insufficiency, who had 
been taking digitalis medicines for a long time, had symptoms of 
intoxication, which were quickly eliminated by the application of the 
donator of sulfhydryl groups – unithiol. What is the mechanism of 
the therapeutic effect of this drug? 
A. Increase of energy supply to the myocardium. 
B. Reduction of ionized calcium accumulation. 
C. Inhibition of potassium release from cardiac histiocytes. 
D. Slowing-down of sodium coming into cardiac histiocytes. 
E. Reactivation of Na+, K+-ATPese of cardiac histiocyte’s 
membranes.  
13. Cardiotonic drug was prescribed to a 50-year-old patient 
with chronic cardiac insufficiency and tachyarrhythmia. What drug 
was prescribed to patient? 
A. Digoxin.  
B. Dopamine. 
C. Dobutamine. 
D. Amiodarone. 
E. Mildronate. 
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14. A patient with complains of frequent pulse, dyspnea, 
cyanosis of mucous tunics was hospitalized to a cardiological 
department. Examination revealed oedemas on the lower extremities 
and ascites. Chronic cardiac insufficiency was diagnosed. What 
drugs should be prescribed to this patient?  
A. Drotaverine hydrochloride. 
B. Cordiaminum. 
C. Corglycon.  
D. Digitoxin. 
E. Adrenaline hydrochloride. 
15. Extrasystoles, vomiting, disturbances of vision and sleep, 
alarm, decreasing of diuresis have developed in patient with heart 
insufficiency in the result of uncontrolled digitoxin using. What 
group of drugs should be administered to this patient? 
A. Donators of NO. 
B. Agonists of 1-adrenergic receptors. 
C. Blockers of angiotensin II receptors. 
D. Blockers of K+ channels. 
E. Donators of SH-group. 
16. A 60-year-old female suffering from ischaemic heart disease 
for 20 years is delivered to cardiologic department. What drug should 
be administered to this female for interruption of ciliary arrhythmia 
attack? 
A. Digoxin. 
B. Adrenaline. 
C. Bicillin V. 
D. Laevomycetin (chloramphenicol). 
E. Ascorbic acid. 
17. Acute heart insufficiency has developed in 60-year-old 
patient. What drug should be administered to patient? 
A. Caffeine sodium benzoate. 
B. Adrenaline hydrochloride. 
C. Corglycon. 
D. Noradrenaline hydrotartrate. 
E. Atropine sulfate. 
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18. A patient suffers from left ventricular insufficiency. Indicate 
the drug which should be prescribed to him.  
A. Piracetam. 
B. Digoxin. 
C. Etimizol (Aethimizolum). 
D. Vinpocetine. 
E. Bemegride. 
 
 
ANTIHYPERTENSIVE DRUGS 
 
Antihypertensive drugs are agents of different chemical structure 
which able to reduce increased blood pressure.  
Hypertensive disease is the most prevalent disease of 
cardiovascular system. Nearly 25–30 % of word population suffers 
from hypertensive disease. The frequency of disease is higher in 
Japan and in highly developed countries of Europe and America.  
Approximately 80 % of all cases of the increased blood pressure are 
accounted for essential hypertension. Another 20 % of cases are 
symptomatic hypertension (renal, endocrinal, etc.). 
Different viewpoints exist about primary mechanisms of 
hypertensive disease. Most common etiotropic factors are psycho-
emotional overload and age-related changes in diencephalon-
hypothalamus structures of brain. Heredity also plays an important 
role. In the initial stages of disease, excessive sympathoadrenal 
system activation is observed. That results in increase of cardiac 
output, increase of vessels tonus, activation of renin-angiotensin-
aldosterone system. Renal changes cause the decrease of sodium and 
water excretion that results in increase of blood volume. Sodium ions 
are accumulated in vessels wall that causes the vessels oedema. 
Simultaneously, ionized calcium level increases in cells of smooth 
muscles of vessels. Owing to described change, muscular cells 
sensitivity to vasopressors (catecholamines, angiotensin II, etc.) 
increases. Hypertrophy of vessels muscular layer develops gradually. 
These processes are predominantly expressed in small arterioles.  
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According to their efficacy and meaning in the treatment of 
hypertensive disease, antihypertensive drugs are classified as 
follows. 
I. Basic antihypertensive drugs: 
1) β-adrenoceptor antagonists;  
2) inhibitors of angiotensin-converting enzyme and blockers of 
angiotensin II receptors;  
3) diuretics;  
4) blockers of calcium channels.  
II. Ancillary drugs: 
1) α-adrenoceptor antagonists;  
2) α, β-adrenoceptor antagonists; 
3) central α2-adrenoceptor agonists; 
4) ganglionic blockers;  
5) sympatholytic drugs; 
6) myotropic antispasmodic drugs; 
7) agonists of imidazoline receptors; 
8) vasopeptidase inhibitors.  
 
Basic Antihypertensive Drugs 
 
β-Adrenoceptor Antagonists  
 
Owing to likeness of chemical structure of β-adrenoceptor 
antagonists with catecholamines, these drugs interact with  
β-adrenoceptors and prevent or eliminate catecholamine influence 
upon the heart and vessels.  
β1-adrenoceptors are located in myocardium cells, in 
cardionector, in cells of juxtaglomerular apparatus of kidney, and in 
fatty tissue. β2-Adrenergic receptors are located in cells of smooth 
muscles of bronchi, vessels of skeletal muscles, uterus, liver, 
pancreas, and membranes of presynaptic ending of sympathetic 
fibers. In central nervous system, both β1- and β2-adrenergic 
receptors are located.  
According to selectivity to types of β-adrenoceptors, drugs are 
divided into selective β1-adrenoceptor antagonists and nonselective  
β1,2-adrenoceptor antagonists. But if β1-blockers are used in high 
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doses, selectivity is worsened. Therefore, correct drug dosage is 
important.  
β-blockers have intrinsic sympathomimetic activity or haven’t it. 
Along with adrenergic blocking activity, β-blockers with intrinsic 
sympathomimetic activity can stimulate β-adrenoceptors within 
physiological limits. Due to this, heart rate doesn’t significantly 
decrease at rest. Drugs influence upon activity of sinus node is 
manifested only during increased physical and emotional stress (that 
is in case of high catecholamine activity). 
On the base of these typical properties, β-adrenoceptor 
antagonists are classified into several groups: 
1) nonselective β-adrenoceptor antagonists or β1,2-adrenoceptor 
antagonists: 
 a) nonselective β-adrenoceptor antagonists without intrinsic 
sympathomimetic activity: propranolol  (anaprilinum) and 
nadolol (Corgard).  
b) nonselective β-adrenoceptor antagonists with intrinsic 
sympathomimetic activity: pindolol (Visken),  oxprenolol  
(Trasicor), and sotalol  (Sotalex).  
2) cardioselective β-adrenoceptor antagonists or β1-adrenoceptor 
antagonists: 
a) drugs without intrinsic sympathomimetic activity: 
metoprolol  (Vasocardin), atenolol  (Tenormin),  nebivolol  
(Nebilet), betaxolol  (Lokren),  and bisoprolol. 
b) drugs with intrinsic sympathomimetic activity: acebutolol  
(Secrtal),  talinolol  (Cordanum), celiprolol (Celiprol ).  
Some β-adrenoceptor antagonists have membrane stabilizing 
activity. This activity is associated with the ability of drugs to 
decrease membrane permeability for Na+ and K+ ions in cardiac 
conductive system. It promotes antiarrhythmic effect of  
β-adrenoceptor antagonists. Membrane stabilizing activity is 
expressed in propranolol, oxprenolol, acebutolol; in less degree – in 
nadolol, pindolol, metoprolol, and alprenolol. 
β-blockers also differ in degree of molecules lipophilicity and 
ability to penetrate through membranes including blood-brain barrier. 
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Atenolol is an example of drug with expressive hydrophilic 
properties which can not penetrate through hematoencephalic barrier. 
Atenolol lacks sedative effect, has low speed of gastrointestinal 
absorption and long duration of action. Atenolol is administered once 
a day. Such drug as propranolol penetrates through blood-brain 
barrier and exhibits anxiolytic activity.  
In recent years, nebivolol (Nebilet)  is widely used in 
medicine. Besides β-adrenoblocking activity, the drug stimulates 
synthesis of nitric oxide that improves coronary circulation and 
reduces peripheral vascular resistance.  
Antihypertensive effect of β-adrenoceptor antagonists is 
associated with the following mechanisms.  
Drugs block β1-adrenoceptors in the heart, that slows down heart 
rate, decrease the force of cardiac contraction, cardiac output, and 
adrenergic reaction to physical exercise. In case of single drug 
administration, there is 10–25 % decrease of cardiac output level. 
But in case of regular use, this value is 5–15 %. Drugs with intrinsic 
sympathomimetic activity decrease the cardiac output in less degree; 
but it doesn’t influence upon their hypotensive activity. 
Drugs block β1-adrenoceptors of juxtaglomerular apparatus cells 
that results in the decrease of renin secretion, reduces of angiotensin 
II synthesis and aldosterone release. These changes also promote the 
reduction of blood pressure.  
Lipophilic β-adrenoceptor antagonists penetrate through blood-
brain barrier and cause sedation. Prolonged use of these agents 
results in inhibition of central links of sympathetic nervous system 
tone regulation.  
Nonselective β1,2-adrenoceptor antagonists block presynaptic  
β2-adrenergic receptors, that reduces noradrenaline secretion and 
decreases excitation of postsynaptic α-adrenoceptors in the vessels 
and in the heart.   
β-adrenoceptor antagonists are administered perorally or 
parenterally. Lipophilic drugs (anaprilinum, oxprenolol , etc.)  
are readily absorbed in gastrointestinal tract. These drugs bind with 
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plasma proteins, undergo hepatic biotransformation, and are excreted 
with bile. These drugs are taken 3 times a day.  
Hydrophilic β-blockers (pindolol , atenolol , nadolol , etc.) 
are slowly absorbed in gastrointestinal tract. Degree of their binding 
with plasma proteins is low. These drugs are excreted in unchanged 
form through the kidneys. Hydrophilic β-adrenoceptor antagonists 
are taken 1–2 times a day.  
β-adrenoceptor antagonists are prescribed to treat essential and 
symptomatic hypertension. Initial hypotensive effect develops in 
several hours after drug intake. Stable decrease of blood pressure is 
developed gradually; therefore, efficacy of β-blockers should be 
assessed in 3–4 weeks after initiation of therapy. It is advisable to 
prescribe β-blockers to patients with hyperkinetic syndrome 
developing due to physical exercise. Commonly, β-blockers are 
prescribed in combination with other hypotensive agents.  
For example, a combination of β-adrenoceptor antagonists with 
diuretics (e. g., “Tenoric”) is widely used in medicine to treat 
hypertensive disease.  
Besides, β-adrenoceptor antagonists are used in the treatment for 
tachyarrhythmias (mainly of supraventricular localization), effort 
angina resistant to nitrates, hypertrophic cardiomyopathy, and 
thyrotoxicosis. Drugs also are used to stimulate labor in women with 
hypertension and to treat parkinsonism of vascular origin.  
Therapy with β-adrenoblocker is initiated with its minimal dose 
which is increased every 2–4 weeks up to optimal therapeutic dose. 
This dose does not cause hypotension, bradycardia, and water 
retention in the body.    
Clinical use of nonselective β-adrenoblockers is restricted by 
their most common side effects – bronchospasm and disorders of 
peripheral blood circulation (intermittent claudication).  
Besides, bradycardia and disorders of atrioventricular 
conduction are observed during therapy with β-adrenoblockers. Heart 
failure due to use of β-adrenoblockers does not develop as often as 
expected, because the decrease of blood pressure facilitates the heart 
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work; and heart work is not worsened even against background of the 
reduction of cardiac output.  
Lipophilic β-adrenoblockers penetrate the central nervous 
system and can cause insomnia, disturbed sleep, and hallucinations. 
Hypoglycemia may be observed in patients with diabetes 
mellitus who treated by nonselective β-adrenoceptor antagonists, 
because these drugs inhibit glycolysis. Besides, therapy with  
β-adrenoblockers is accompanied by worsening of lipid metabolism 
and increased level of lipoproteins of low- and very low density, that 
promotes atherosclerosis.  
β-adrenoceptor antagonists are not recommended to pregnant 
women, because drugs increase uterine tone.   
Abrupt discontinuation of long-time intake of β-adrenoblockers 
can lead to “rebound” syndrome. The main manifestations of this 
phenomenon include hypertensive crisis, angina attacks, and 
tachyarrhythmias. Phasing out of the drug with the use of another 
scheme of treatment is most reliable way of prevention of “rebound” 
syndrome.  
 
Calcium Channel Blockers (Calcium Antagonists)  
 
Calcium channel blockers are classified as follows. 
1. First-generation calcium channel blockers: verapamil  
(Isoptin), nifedipine (phenigidine),  and diltiazem.  
2. Second-generation calcium antagonists: 
a) verapamil group (phenyl alkyl amine derivatives):  
gallopamil , anipamil,  and falipamil;  
 b) nifedipine group (dihydropyridine derivatives): 
amlodipine, felodipine, isradipine,  nimodipine,  
nitrendipine,  lacidipine, and nicardipine;  
c) diltiazem group (benzothiazepine derivatives): clentiazem. 
3. Third-generation calcium antagonists: naftopidil ,  
emopamil. 
In comparison with the 1st generation calcium antagonists,  
2nd generation drugs are characterized by longer duration of action, 
higher tissue specificity, and less side effects.  
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The 3rd generation drugs are characterised by aditional types of 
activity: naftopidil exhibits α-adrenoblocking activity; emopamil has 
sympatholytic activity.  
Calcium channel blockers block potential-dependent calcium 
channels in membranes of cardiac histiocytes and smooth muscles of 
vessels. It results in decrease of total peripheral vascular resistance 
and decrease of cardiac contraction. Also, calcium channel blockers 
decrease platelets aggregation, suppress automatism of sinus node 
and ectopic foci of rhythm in atrium, and slow down conduction 
through atrioventricular node.  
There are the following types of calcium channels: T, N, P, and 
L. Blockers of calcium channels inhibit the slow L-channels. Intake 
of these drugs leads to significant reduction of cytoplasmic calcium 
concentration and relaxation of smooth muscles of arteries. It is 
proved that intracellular calcium concentration is increased in 
hypertensive patients, that is considered as the one of the causes of 
tendency to generalized vasoconstriction. Blockers of calcium 
channels insignificantly influence venous vessels. 
Calcium channel antagonists decrease of myocardial contractile 
function, that promotes the regression of left ventricle hypertrophy. 
Unlike other groups of antihypertensive drugs, as a rule therapy by 
calcium channel antagonists is not accompanied by postural 
hypotension. Therapeutic doses of calcium channel blockers do not 
influence normal blood pressure, carbohydrate and lipid metabolism. 
Therefore, these drugs may be prescribed to patients with diabetes 
melites. Calcium channel antagonists do not reduce blood circulation 
in extremities and do not influence physical endurance. The drugs are 
able to increase the water and sodium excretion from the body.  
Calcium channel blockers are administered parenterally, orally, 
and sublingually. These drugs are readily absorbed in gastroinestinal 
tract, bind with plasma proteins, penetrate in different tissues and 
organs including central nervous system. Duration of action of the 
first-generation drugs is 4–6 hours. Second-generation drugs act up 
to 12 hours. Calcium channel antagonists undergo high degree of 
liver biotransformation and excreted mainly by kidneys.  
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The main indications for use of calcium channel blockers are 
hypertensive disease, hypertensive crisis, nephrogenic hypertension, 
hypertension in patients with disorders of cerebral circulation, 
ischaemic heart disease, and supraventricular tachyarrhythmias, 
migraine, Raynaud’s disease, thrombosis, hypertrophic 
cardiomyopathy, and cold-induced bronchoconstriction.  
Such drugs as nifedipine, felodipine, and diltiazem are effective 
at monotherapy of hypertensive disease of mild and moderate 
severity. Stable effect developed in 1–2 weeks after initiation of 
therapy. Tachycardia may be observed at the initiation of the 
treatment, aspecially in the young patients. At severe hypertensive 
disease, calcium channel antagonists are combined with  
β-adrenoblockers and angiotensin-converting enzyme inhibitors.  
At the last time, there is tendency when short-acting calcium 
antagonists are replaced by drugs with long-lasting effect  
(e. g., nitrendipine, felodipine, amlodipine). Nitrendipine’s activity is 
three times higher than activity of nifedipine. The drug causes 
systemic vasodilation with the decrease of peripheral vascular 
resistance. Besides, nitrendipine dilates renal vessels, increases 
excretion of sodium ions and water, and increases the blood level of 
natriuretic hormone. Most pronounced effect is observed in elderly 
patients with hypertension against the background of the low renin 
level. Long-time use of nitrendipine causes the regression of 
myocardial hypertrophy. The drug is taken once a day. At 
hypertensive crisis, nitrendipine may be used sublingually.  
Felodipine exhibits marked influence upon the vessels. The drug 
does not cause negative inotropic effect and does not influence 
conductibility of the heart. Felodipine is effective at hypertensive 
disease of any degree of severity, including elderly patients with 
renovascular hypertension. In comparison with nifedipine, the drug 
exhibits higher efficacy in case of its combination with diuretics and 
β-adrenergic antagonists.            
Side effects of calcium antagonists include headache, dizziness, 
flushing, constipation, oedema of feet, shins, and elbows owing to 
vascular stasis, and disturbances of microcirculation. Also, both 
bradycardia (for verapamil) and tachycardia (for nifedipine) are 
possible.  
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Angiotensin-Converting Enzyme Inhibitors  
 
Angiotensin-converting enzyme (ACE) inhibitors are divided 
into three generations: 
– I-generation drugs: captopril  (Capoten), methiapril ; 
– II-generation drugs: enalapril , lisinopril , ramipril ,  
benazepril ,  fosinopril , perindopril ,  trandolapril ; 
– III-generation drugs: zofenopril . 
The I-generation drugs contain HS-group in their molecular 
structure.   
The II-generation drugs contain carboxyl or phenolic groups in 
their molecules. These drugs are characterized by higher activity, 
lack of sulfhydryl groups in molecules, longer duration of action, less 
frequency of side effects.  
Renin is synthesized in juxtaglomerular cells in the result of 
sympathetic stimuli, reduction of renal blood flow, decrease of blood 
pressure, and increase of sodium concentration in distal convoluted 
tubules. Renin influence angiotensinogen and cleaves from it 
angiotensin I. Angiotensin-converting enzyme (kinase II) transforms 
angiotensin I to angiotensin II. Synthesis of angiotensin II occurs in 
the heart, brain, lungs, and other organs. High concentration of ACE 
is found in vascular endothelium. In the adrenal glands, angiotensin 
II is metabolized into angiotensin III. Angiotensins II and III 
stimulate the aldosterone release, that increases of the renal 
reabsorption of sodium and water and stimulates the potassium 
excretion. Also, angiotensins II and III increase vascular rigidity and 
stimulate collagen synthesis, that promotes myocardial fibrosis.    
There are 4 types of angiotensin II receptors. The main 
cardiovascular effects are due to excitation of angiotensin receptors 
of the first type (AT1). Angiotensin II causes significant 
vasoconstriction and stimulates cardiac contractions. Besides, 
angiotensin II acts as growth factor of cardiac histiocytes and 
vascular smooth muscle cells, increases secretion of vasopressin, 
prolactin, and adrenocorticotropin.  
It should be noticed that ACE also catalyzes inactivation of 
bradykinin and enkephalins. Bradykinin and enkephalins relax 
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vessels, decrease blood pressure, increase sodium and water 
excretion, retards potassium in the body, and suppress platelets 
aggregation.  
ACE inhibitors decrease angiotensin II synthesis and, therefore, 
prevent its effects. Besides, these drugs promote bradykinin and 
enkephalin protection that results in the increase of their effects. 
Owing to this mechanism, ACE inhibitors cause the following 
effects: 
– both venous and arterial tone is decreased; 
– blood pressure is lowered; 
– both preload and afterload upon the heart is diminished;  
– blood circulation in heart, kidneys, and other inner organs is 
improved; 
– secretion and activity of atrial natriuretic peptide is increased; 
– diuresis is increased.  
Also, ACE inhibitors suppress lipid peroxidation and improve 
carbohydrate metabolism.    
It should be noted that the application of ACE inhibitors is 
accompanied by decrease of hypertrophy of myocardium and 
vascular wall. ACE inhibitors decrease the possibility of ventricular 
arrhythmias.   
ACE inhibitors are prescribed orally. Enalapril (Vasotec) and 
lisinopril are also administered intravenously. Taken orally drugs are 
readily absorbed from gastrointestinal tract. Absorption of ACE 
inhibitors is independent from food, except captopril which should 
be taken in 2–3 hours before a meal. Most drugs bind with plasma 
proteins in high degree. Only captopril and lisinopril are 
characterized by low degree of binding with proteins which is  
20–30 %. ACE inhibitors easily penetrate in different tissues of the 
body.    
Therapeutic effect of captopril develops in 1 hour after intake. 
Onset of effect of other drugs is 2 hours after oral intake. Duration of 
captopril action is 6 hours; other drugs act up to 24 hours. In this 
regard, captopril is taken 4 times a day; other drugs are prescribed 
once a day. The main route of drugs elimination is kidneys. But such 
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drugs as ramipril, benazepril, and perindopril are predominantly 
excreted by liver (approximately 60 % of the administered dose).   
Trandolapril is one the most effective and long-acting ACE 
inhibitors. Its ability to inhibit ACE is in 6–10 times more than those 
of enalapril. Trandolapril acts up to 48 hours.  
ACE inhibitors increase blood circulation in myocardium, liver, 
brain, and kidneys. The drugs efficacy is proportional to blood renin 
concentration. And while drugs reduce blood pressure in patients 
with normal renin activity, drugs efficacy in this case is less.  
ACE inhibitors are effective at mild, moderately severe, and 
refractory to other drugs hypertensive disease. These drugs are 
combined with centrally acting hypotensive agents, calcium channel 
blockers, β-adrenoceptor antagonists, and diuretics. To prevent 
marked hypotension, ACE inhibitors initially should be taken in low 
doses. Captopril may be used sublingually to cessate hypertensive 
crisis. 
Nowadays, ACE inhibitors are used in the treatment for chronic 
heart failure. Owing to reduction of arterial and venous tone, these 
drugs decrease preload and afterload upon the heart, and blood 
pressure in ventricles. In three months after the initiation of treatment 
with ACE inhibitors, hypertrophy of the left ventricle is significantly 
reduced.  
ACE inhibitors are also used in postinfarction cardiosclerosis 
and diabetic nephropathy. At the last patology, these drugs dilate an 
efferent artery and decrease intraglomerular hypertension which is 
the main cause of glomerulosclerosis.  
Intake of ACE inhibitors can lead to excessive hypotension. This 
complication is more likely in patients which were treated by high 
doses of diuretics prior therapy by ACE inhibitors.  
Therapy by ACE inhibitors is often accompanied by dry cough 
which is refractory to action of antitussive drugs. This cough is due 
to inhibition of bradykinin inactivation and increase of prostaglandin 
E2 synthesis in the bronchi. These phenomena can also lead to 
development of anhioedema.  
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ACE inhibitors can cause skin allergic reactions, neutropenia, 
metallic taste in mouth, headache, dizziness, and hyperkalemia. 
Dispite of significant number of side effects, therapy by ACE 
inhibitors has no age limit. Discontinuation of ACE inhibitors intake 
does not lead to rebound effect. But long-time therapy by ACE 
inhibitors is accompanied by slow developing tolerance.   
It should be noticed that some patients are resistant to ACE 
inhibitors, because angiotensin II synthesis is regulated, except ACE, 
by other enzymes (chymases, cathepsins, etc.). In this case, blockers 
of angiotensin receptors more completely inhibit renin-angiotensin 
system.        
 
Blockers of Angiotensin Receptors 
 
Angiotensin receptor blockers include such drugs as losartan 
(Cozaar) , valsartan (Diovan), candesartan, irbesartan, 
telmisartan,  etc.  
The first approved for clinical use drug of this group saralasin is 
not used nowadays. Losartan was approved in 1992; later, other 
angiotensin receptor blockers was created.   
Drugs block AT1 angiotensin receptors in vessels, adrenal gland 
and other organs, decrease concentrations of aldosterone and 
norepinephrine in the blood. Besides, angiotensin receptor blockers 
increase renal excretion of sodium and exhibit diuretic action.  
Consequently, total peripheral vascular resistance, systemic 
blood pressure, and pressure in the pulmonary circulation are 
reduced. Blockage of AT1 receptors leads to the increase of blood 
level of renin, angiotensin I, and angiotensin II. The increase of 
angiotensin II concentration results in stimulation of AT2 receptors 
that is accompanied by activation of natriuresis and relaxation of 
vessels due to NO release. Also, activation of AT2 receptors leads to 
inhibition of endothelial proliferation. It should be noticed that 
natriuretic and diuretic effects also promote the vasodilation. 
Angiotensin receptor blockers do not influence bradykinin 
metabolism. Hypotensive activity of angiotensin receptor blockers is 
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identical to the activity of ACE inhibitors, but these drugs are 
tolerated by patients better.   
Angiotensin receptors blockers are taken orally once a day. 
Their bioavailability is approximately 30 %. Antihypertensive effect 
develops for 6 hours and lasts up to 24 hours. Unchanged drugs and 
their metabolites are excreted by liver. Maximum effect is obcerved 
in 3–6 weeks of permanent therapy and kept long time after phasing 
out of the drug.  
Angiotensin receptor blockers are used to treat hypertensive 
disease, renovascular hypertension, for diagnostics of increased 
activity of renin-angiotensin system, and chronic cardiovascular 
insufficiency.  
Side effects of angiotensin receptor blockers include headache, 
vertigo, postural hypotension, hypokalemia, cough, and allergic 
reactions. Besides, angiotensin receptor blockers exhibit teratogenic 
action, therefore these drugs are contraindicated in pregnancy.  
 
Diuretics  
 
Hydrochlorothiazide  (dichlothiazidum), chlortalidone 
(Oxodolinum, Hygroton), furosemide, clopamide 
(Brinaldix), indapamide, spironolactone, triamterene  and 
other diuretics are used to treat hypertensive disease.  
Diuretics reduce sodium and water reabsorption and decrease the 
volume of extracellular fluid. These drugs exhibit own hypotensive 
effect and significantly potentiate effect of other antihypertensive 
drugs. Drugs are widely used for monotherapy of initial stage of 
hypertensive disease. Different diuretics are often used together for 
potentiation of their action and for diminish of side effects. Thiazides 
(hydrochlorothiazide), non-thiazide sulfonamides (chlortalidone, 
clopamide, indapamide), and potassium-sparring diuretics 
(triamterene, amiloride, spironolactone) are most widely used 
diuretics for treatment of hypertensive disease. Strongly acting loop 
diuretics (furosemide, etacrynic acid, torasemide) are used to treat 
aggravation of II and III stages of hypertensive disease and to arrest 
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hypertensive crisis. It should be noticed that diuretics with low and 
moderate efficacy do not influence blood pressure in healthy people.  
Initially, diuretics decrease blood pressure due to the increase of 
sodium and water excretion and reduction of circulating volume. In 
6–8 weeks after therapy initiation, diuretic effect is gradually 
decreased, and cardiac output is normalized. It is due to the increase 
of renin activity in result of the reduction of plasma volume and 
blood pressure. Under the circumstances, hypotensive effect of 
diuretics is associated with the decrease of peripheral vascular 
resistance. Likely, reduction of vascular tone is the result of gradual 
decrease of intracellular sodium and increase of intracellular 
potassium in cells of vascular wall. Despite of increased activity of 
renin-angiotensin system, resistance of peripheral and renal vessels is 
reduced. Diuretics decrease both systolic and diastolic blood pressure 
and maintain or even increase cardiac output. Diuretic drug therapy 
is not accompanied by postural hypotension.  
Hydrochlorothiazide (hypothiazid, dichlothiazidum) is most 
widely used diuretic in the treatment for hypertensive disease. 
Usually, the drug is taken two times a day in individual doses.  
Recently, the new group of diuretics with vasodilating effect was 
approved in medicine. Indapamide and its prolonged form 
Indapamide retard  are representatives of this group. At treatment 
of hypertension, long-acting drugs (Indapamide retard, chlortalidone, 
and clopamide) are preferable. These drugs are taken once a day or 
once in 1–2 days.  
Excessive diuretic effect leads to muscular weakness (due to 
potassium loss), dry mouth, paresthesia, and thirst. For prevention of 
hypokalemia, potassium-contaning drugs are prescribed  
(e. g., potassium chloride, Asparcam, Panangin); or thiazide diuretics 
are combined with potassium-sparing agents. Besides, diuretics 
(e. g., thiazides) decrease calcium level in the blood, cause 
hyperglycemia, hyperuricemia, and increase cholesterol 
concentration in the blood.     
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Supporting Antihypertensive Drugs  
 
Vasopeptidase Inhibitors  
 
Recently, new group of hypotensive drugs – vasopeptidase 
inhibitors – was approved in medicine. The representatives of this 
group are omapatrilat  and aladotrilat .  
Vasopeptidases are presented by two enzymes of cellular 
membrane – angiotensin-converting enzyme (ACE) and neutral 
endopeptidase (NEP, neprilysin). The last enzyme catalyzes 
inactivation of vasodilator peptides (natriuretic peptide, bradykinin, 
and adrenomedullin).     
Omapatrilat inhibits the activity of ACE and neprilysin that leads 
to the decrease of angiotensin II concentration and the increase of 
concentration of vasodilator peptides. Due to such mechanism, 
omapatrilad decreases peripheral vascular resistance, circulating 
blood volume, blood pressure, and afterload. Besides, omapatrilat 
exhibits cardioprotective action.  
Omapatrilat is taken orally one time a day. The drug is readily 
absorbed in gastrointestinal tract. Its bioavailability is about 30 %. 
Omapatrilat binds with plasma proteins, undergoes nepatic 
metabolism, and is excreted mainly by kidneys. Duration of 
omapatrilat’s action is about 24 hours.  
Omapatrilat is used to treat hypertensive disease and chronic 
heart failure.  
Side effects of omapatrilat are headache, cough, dyspeptic 
disorders, and skin rash.          
 
α-Adrenoceptor Antagonists  
 
α-Adrenoceptor antagonists are divided into: 
– α1-adrenoceptor antagonists: prazosin, doxazosin, 
terazosin ; 
– α1,2-adrenoceptor antagonists: phentolamine,  
tropaphenum, pyrroxane . 
Nonselective α-adrenoceptor antagonists relax vessels owing to 
blockage of both α1 and α2-adrenoceptors. But these drugs aren’t 
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used for systemic treatment of hypertensive disease because they 
don’t promote stable hypotensive effect. Shortness of effect is the 
result of blockage of presynaptic α2-adrenoceptors which regulate 
negative feedback. Blockage of these receptors results in excessive 
noradrenaline release and restoration of adrenergic transmission in 
vessels. Nonselective α-adrenoceptor antagonists are used in the 
treatment for pheochromocytoma (tumor of adrenal gland medulla), 
hypertensive crisis, and pulmonary oedema.  
Stable and prolonged blockage of postsynaptic α-adrenergic 
receptors is observed in prescribing of selective α1-adrenoceptor 
antagonists (prazosin, doxazosin, etc.) because these agents don’t 
affect negative feedback in adrenergic synapses. Blockage of  
α1-adrenoceptors in vessels leads to the decrease of general 
peripheral resistance, venous return, and left ventricular preload. 
Hypotensive effect of α1-adrenoceptor antagonists isn’t accompanied 
by tachycardia and elevation of cardiac output. Prazosin and 
doxazosin additionally exhibit moderate antispasmodic influence 
upon vascular smooth muscles. Also, both drugs decrease 
concentration of low-density lipoproteins and of very low-density 
lipoproteins. This effect is very useful in case when arterial 
hypertension is accompanied by hyperlipidemia. 
At oral intake, selective α1-adrenoceptor antagonists are readily 
absorbed in gastrointestinal tract. These drugs are xcreted from the 
body mainly with feces; only insignificant amount of administered 
dose is excreted by kidneys. Prazosin is prescribed two times per 
day, doxazosin – once a day.  
Indications for use of selective α1-adrenoceptor antagonists are 
the following: hypertensive disease, chronic heart failure, chronic 
renal failure, and pulmonary hypertension. It should be noticed that 
the absence of influence upon carbohydrate metabolism allows to use 
these drugs in patients with accompanied diabetes mellitus. Prazosin 
and doxazosin are also used to treat benign prostatic hyperplasia and 
hypertension of pregnancy.   
Side effects of selective α1-adrenoceptor antagonists include 
headache, excessive hypotension, drowsiness, diarrhoea, nasal 
congestion, dry mouth, polyarthritis, frequent urination, and female 
urinary incontinence.  
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α-, β-Adrenoceptor Antagonists  
 
Labetalol  (Trandate) and carvedilol  (Dilatrend ) are 
drugs blocking both α- and β-adrenergic receptors.   
Labetalol blocks β1, β2, and α1-adrenergic receptors. Wherein, its  
β-adrenoblocking activity is 3 times more than ability to block  
α-adrenoceptors. The drug is taken orally to treat arterial 
hypertension of administered intravenously to treat hypertensive 
crisis. Labetalol is readily absorbed in gastrointestinal tract, 
metabolized by liver, and excreted by kidneys in form of metabolites. 
The drug dilates vessels and decrases blood pressure without 
significant influence upon cardiac output. Its duration of action is  
8–10 hours. At regular long-time intake, labetalol decreases heart 
rate and prevents the increase of force of cardiac contraction at 
physical activity. Side effects of labetalol are dizziness and postural 
hypotension.  
Carvedilol (Dilatrend) is 10–100 times more potent blocker of  
β-adrenoceptors than labetalol. Also, its α-adrenoblockering activity 
is 1.5–3 times more. Simultaneously, carvedilol exhibits 
antioxidative activity. The drug decreases peripheral vascular 
resistance, renin blood concentration, cardiac preload and afterload. 
Carvedilol is taken orally. Its hypotensive effect lasts up to 15 hours. 
The drug is used to treat hypertensive disease, ischaemic heart 
disease, and chronic heart failure. Its possible side effects are 
headache, bronchoconstriction, skin rash, and fatigability.      
      
Central α2-Adrenoceptor Agonists  
 
Clonidine (clopheline,  Catapresan) and methyldopa  
(Dopegyt, Aldomet ) excite α2-adrenoceptors in neuronal 
membranes of vasomotor centre that is accompanied by inhibitory 
effect. Antihypertensive effect is due to the inhibition of pressor part 
of vasomotor centre and general decrease of sympathetic innervation 
tone. It is accompanied by the decrease of peripheral vascular 
resistance and heart rate, reduction of catecholamines secretion by 
adrenal glands, and temporally decrease of renin production.  
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Clonidine (clopheline) is one of the most potent and fast-
acting hypotensive agents. The drug is an agonist of α2-adrenergic 
and I1-imidazoline receptors. Stable hypotension may be preceded by 
the short-time (before penetration of the drug in central nervous 
system) increase of blood pressure due to excitation of vascular  
α2-adrenergic receptors. This phase lasts 5–10 minutes. Hypotensive 
effect of clopheline lasts 10–12 hours. As a rule, clonidine therapy is 
started with small doses which are taken 2–4 times a day. Clonidine 
dose is gradually increased.  
So-called rebound syndrome develops due to disinhibition of 
sympathetic centres at sudden phasing out of clopheline intake. It 
starts in 18–36 hours after cessation of the drug intake and lasts from 
1 to 5 days. Rebound syndrome symptoms are the increase of blood 
pressure up to hypertensive crisis, tachycardia, encephalopathy, heart 
rhythm disorders, and abdominal pain. Small doses of clopheline in 
combination with β-adrenergic antagonists are used to arrest rebound 
syndrome. Slow decrease of clonidine dose allows to avoid return 
syndrome. Gradual phasing out of clopheline intake lasts at least  
7 days.  
Clopheline is taken orally and administered parenterally. The 
drug is readily absorbed in gastrointestinal tract and excreted from 
the body by kidneys. Clopheline is used to treat hypertensive disease 
and to arrest hypertensive crisis.  
Clonidine easily penetrates central nervous system and exhibits 
hypnotic and sedative effects, decreases the body temperature. The 
drug potentiates effects of ethyl alcohol and other central nervous 
system depressants. Clopheline increases appetite, decreases 
secretion of salivary glands. Clopheline therapy is accompanied by 
such side effects as postural hypotension, dry mouth, constipation, 
urinary retention, visual disordes, sodium and water retention, etc. 
Long-time clopheline intake leads to tolerance that needs to increase 
drug dose in 2–5 times. Clonidine reduces renal circulation due to 
renin hyperproduction. Slowdown of blood circulation in brain, 
retina, and lower extremities promotes thrombosis.  
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Methyldopa  is transformed to α-methyl-norepinephrine which 
stimulates postsynaptic α2-adrenoceptors in neuronal membranes of 
vasomotor centre. It leads to the vasodilation and reduction of total 
peripheral vascular resistance. Also, decreased cardiac output is 
observed at initialization of therapy. Drug relaxes renal vessels and 
increases diuresis. Besides, methyldopa exhibits sedative and 
hypnotic effects. The drug is taken orally or administered 
parenterally once a day.  
Therapy by methyldopa is accompanied by such side effects as 
weakness, fatigue, disorder of attention, drowsiness, dry mouth, nasal 
stuffiness, dizziness, dyspepsia, and skin rash. Sometimes, 
methyldopa intake is aggravated by agranulocytosis, hemolytic 
anemia, and thrombocytopenia. In comparison with clopheline, 
postural hypotension is less common. The described side effects be 
found more often in aged patients. Long-time intake of methyldopa 
leads to tolerance. Small doses of methyldopa may be prescribed 
with diuretics and β-adrenergic antagonists. It should be noticed that 
combination of methyldopa with central nervous system depressants 
increases hypotensive action, but combination with MAO inhibitors 
provokes hypertensive crisis.  
 
Ganglionic Blockers 
 
Ganglionic blockers include such drugs as benzohexonium 
(hexamethonium), pentamine (azamethonium bromide),  
pirilenum (pempidine), hygronium (trepirium iodide),  and 
arfonad . Drugs block Nn-cholinergic receptors in sympathetic 
ganglia and prevent propagation of sympathetic vasoconstrictive 
impulses to vessels. Administration of ganglionic blockers is 
accompanied by significant dilation of arterioles, venules, and 
capillaries that leads to the decrease of blood pressure. Due to 
inhibition of reflexes which maintain stable level of blood pressure at 
change of body posture, ganglionic blockers can provoke postural 
hypotension. Cardiac output and stroke volume are decreased mainly 
owing to reduction of venous return to the heart. Dilation of veins is 
accompanied by reduction of cardiac preload. Blood is deposited in 
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vessels of mesentery and lower extremities. The reduction of blood 
pressure is observed in pulmonary circulation and in right ventricle. 
Circulating blood volume is decreased. Peripheral vascular resistance 
and left ventricle afterload are reduced due to dilation of small 
arteries, arterioles, and metarterioles.  
Ganglionic blockers with short action (hygronium, arfonad) are 
used for controlled hypotension during surgical operation. Besides, 
ganglionic blockers are used in the treatment for pulmonary and 
brain oedema and to arrest hypertensive crisis. Nowadays, ganglionic 
blockers are scarcely used to treat hypertensive disease, because their 
administration results in significant number of side effects: decrease 
of tone and motility of gastrointestinal tract and bladder, 
constipation, accomodation disorder, and dry mouth. The most 
serious complication of ganglionic blocker administration is postural 
hypotension. Regular intake of ganglionic blockers leads to 
tolerance.   
 
Sympatholytics  
 
Sympatholytics reserpine  and octadine  inhibit adrenergic 
transmission due to influence upon presynaptic membranes of 
adrenergic nerves. These drugs exhaust noradrenaline storage.  
Reserpine  is alkaloid of Rauwolfia. The drug violates the 
deposition of noradrenaline in vesicles and promotes its inactivation 
by MAO. Hypotensive action of reserpine is mainly due to its 
peripheral effects: vasodilation, decrease of total peripheral 
resistance, bradycardia, and decrease of cardiac output. But reserpine 
also reduces noradrenaline storage in central nervous system that 
leads to the decrease of vasomotor centre tone and reduces the 
activity of limbic system and reticular formation. Therefore, 
reserpine exhibits psychosedative and hypnotic effects and provokes 
depression. Reserpine is taken orally once a day. Its hypotensive 
effect develops in 1–5 days after therapy initiation. After phasing out 
of the drug intake, hypotensive effect persists during 3–4 weeks. 
Rebound syndrome is not characteristic of reserpine intake 
discontinuation. Reserpine does not cause postural hypotension. 
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Reserpine is weak hypotensive agent and, as a rule, is a component 
of the co-formulated drugs (“Normatens” , etc.).   
Side effects of reserpine are determined by its mechanism of 
action. Thus, long-time intake of reserpine in usual hypotensive 
doses (1 mg a day), especially by aged patients, may be accompanied 
by depression and parkinsonism due to exhaustion of dopamine 
storage in the brainstem nuclei. Increased parasympathetic influence 
upon inner organs is accompanied by elevation of secretion and 
motility of gastrointestinal tract (hypersalivation, exacerbation of 
ulcer disease and gastritis, and diarrhea), increase of bronchial tone, 
bradycardia, nasal congestion, etc. Reserpine potentiates hypotensive 
action of diuretics, ganglionic blockers, and peripheral vasodilators. 
Combination of reserpine with antiarrhythmic drugs and cardiac 
glycosides should be used carefully.    
Octadine  violates noradrenaline release and prevents its 
neuronal reuptake. The drug is poorly soluble in lipids and does not 
penetrate central nervous system. At initiation of the treatment, 
octadine decreases cardiac output. Long-time intake of octadine is 
accompanied by reduction of total peripheral resistance and venous 
blood return to the heart. Drug is taken orally once a day. 
Hypotensive effect develops in 4–7 days after initiation of treatment. 
After phasing out of the drug, its hypotensive effect persists  
1–2 weeks. Octadine can cause postural hypotension. Other side 
effects include bradycardia, atrioventricular conduction disorders, 
increased bronchial tone, diarrhoea, nasal stuffiness, etc.  
 
Potassium Channel Activators  
 
Potassium channel activators are diazoxide  and minoxidil .  
These drugs activate (open) potassium channels in membranes and 
promote K+ output from the cells that is accompanied by membrane 
hyperpolarization and inactivation of calcium channels. Under these 
circumstances, the sensitivity of smooth muscles to vasoconstrictive 
agents (catecholamines, angiotensin II, etc.) is sharply decreased. 
Potassium channel activators dilate only arterioles. Their hypotensive 
effect is due to reduction of total peripheral vascular resistance.  
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Minoxidil  is one of the most potent drugs of this group. Drug is 
used to treat most severe and malignant forms of hypertension, which 
are resistant to other hypotensive agents and their combinations. 
Minoxidil significantly decreases blood pressure and reduce cardiac 
afterload. The drug is taken orally. Minoxidil is readily absorbed in 
gastrointestinal tract and excreted from the body mainly by kidneys. 
Its hypotensive effect lasts 24 hours. Side effects of minoxidil are 
hirsutism, pericardium lesion, skin rash, thrombocytopenia, 
leukopenia, headache, sodium and water retention in the body.  
Diazoxide  is more potent hypotensive agent than minoxidil. 
The drug is administered intravenously to arrest hypertensive crises. 
Effect develops in 2–5 minutes and lasts 6–18 hours. Besides 
reduction of arterioles tone, diazoxide suppresses the heart activity. 
Drug inhibits secretion of insulin and causes hyperglycemia. Side 
effects include sodium and water retention and increased blood 
concentration of uric acid. The drug is potent relaxant of uterus. Oral 
diazoxide (Proglycem) is used to treat hypoglycemia associated 
with hyperinsulinism (e. g., in patients with inoperable islet 
cell carcinoma).    
 
Nitric Oxide Donators 
 
Sodium nitroprusside  is hypotensive agent influencing 
resistance and capacitance vessels. Hypotensive effect of drug is not 
accompanied by the increase of cardiac output. Mechanism of action 
of nitroprusside is similar to nitroglycerin’s mechanism. In the body, 
sodium nitroprusside releases nitrous oxide which stimulates 
cytosolic guanylate cyclase. Due to this, the level of cGMP is 
increased, and intracellular calcium concentration is reduced. 
Hereby, tone of smooth muscles of vessels is decreased.  
Sodium nitroprusside is administered intravenously  
drop-by-drop to arrest hypertensive crises, for controlled 
hypotension, and to treat pulmonary oedema and acute left 
ventricular failure. Hypotensive effect develops in 2–3 minutes. Drug 
administration is accompanied by tachycardia, headache, dyspeptic 
disorders, and muscular twitching.  
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Miscellaneous Drugs 
 
Apressinum  (hydralazine) moderately relaxes resistance 
vessels, decreases total peripheral resistance and blood pressure. 
Drug is taken orally. Apressinum is readily absorbed in 
gastrointestinal tract, bind with plasma proteins. For dosage of drug, 
it is necessary to remember that speed of its metabolism is dissimilar 
in different patients. As a rule, the drug effect lasts 6–8 hours. Side 
effects of hydralazine include tachycardia, heart pain, arrhythmias, 
myocardial infarction, headache, water-salt balance disorder, 
autoimmune disorders (rheumatoid arthritis, systemic lupus 
erythematosus, etc.), dyspepsia, etc. Hydralazine is contraindicated at 
stenocardia, myocardial infarction, ulcer disease of stomach, and 
systemic lupus erythematosus.   
Dibazolum  (bendazol ) exhibits antispasmodic action upon all 
inner organs containing smooth muscles. The drug decreases blood 
pressure due to vascular relaxation, reduction of total peripheral 
resistance and cardiac output. Hypotensive effect of dibazolum is 
moderate and short-lasting. As a rule, dibazolum is combined with 
other hypotensive agents to treat hypertensive disease. Also, the drug 
is administered intramuscularly or intravenously to arrest 
hypertensive crisis, aspecially with phenomena of encephalopathy. 
Side effects appear seldom.  
Magnesium sulfate  is administered intravenously or 
intramuscularly to arrest hypertensive crises. Besides myotropic 
spasmolytic action, drug also suppresses neurotransmission in 
vegetative ganglia. High doses of magnesium sulfate inhibit 
vasomotor centre. Also, the drug exhibits sedative effect and inhibits 
convulsions. Magnesium sulfate is characterized by narrow margins 
of safety. The drug overdose leads to respiratory depression. Calcium 
ions are antagonists of magnesium ions; therefore, calcium chloride 
is administered at overdose of magnesium sulfate.  
Papaverine  is alkaloid of opium which is obtained by means 
of synthetic way. It is myotropic antispasmodic agent. The drug 
inhibits phosphodiesterase activity that leads to accumulation of 
intracellular cAMP with the following relaxation of smooth muscles. 
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The drug exhibits vasodilating and spasmolytic effects. High doses 
of papaverine suppress the excitability of myocardium and slows 
down intracardiac conduction. Papaverine has weak sedative action 
upon central nervous system. The drug is used in the treatment for 
vascular spasms (including cerebral vessels) and spasms of smooth 
muscles of bronchi and organs of abdominal cavity. Side effects 
appear seldom.   
No-Spa  (drotaverine) has properties similar to papaverine but 
exhibits more expressed and longer spasmolytic action. The drug is 
used alone or in combination with nicotinic acid (Nicospan).   
Pentoxifylline (Trental) improves microcirculation and 
rheological properties of blood. The drug dilates vessels and 
increases oxygen delivery to the tissues. Its mechanism of action is 
associated with blockage of adenosine receptors and inhibition of 
phosphodiesterase that leads to cAMP accumulation in vascular 
smooth muscles and thrombocytes. Besides, pentoxifylline decreases 
platelet aggregation, increases erythrocyte elasticity, and decreases 
blood viscosity. The drug is taken orally and administered 
intravenously or intramuscularly.    
 
Imidazoline Receptor Agonists  
 
Moxonidine  (Physiotens ) and rilmenidine  stimulate  
I1-imidazoline receptors of vasomotor centre in medulla oblongata 
that results in reduction of sympathetic nervous system activity. 
Moxonidine exhibits high hypotensive activity. The drug is taken 
once a day. In comparison with clopheline amount of side effect of 
moxonidine is significantly less. Hypotensive activity of rilmenidine 
is superior of moxonidine. Both drugs do not cause rebound 
syndrome.  
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Principles of Hypotensive Drugs Combination 
 
Treatment of hypertensive disease is a difficult problem 
requiring perseverance and attention of both doctor and patient. 
There is initial transitory stage in development of hypertensive 
disease, when blood pressure increases episodically due to influence 
of stress. Gradually, periods with normal blood pressure become 
shorten, but periods with insignificantly increased blood pressure are 
drown out. At this stage, patients visit a doctor seldom, whereas 
arterial hypertension is successfully treated namely at this stage.  
At this period, patients should restrict consuming of sodium chloride, 
fluids, to avoid stress, to refuse from bad habits, and streamline work 
and rest. Medicinal herbs fees with hypotensive and sedative 
properties and small doses of tranquilizers are used to treat this stage 
of hypertensive disease. But, intake of hypotensive drug is also 
possible. These patients need medical supervision during several 
years even in case of full normalization of blood pressure.  
But patients visit a doctor only at stage when patology became 
stable. In case of I (“mild”) stage of hypertension when diastolic 
blood pressure is within 95–104 mm Hg, intake of drugs is obligate, 
and treatment lasts long time. At II (“moderate”) stage of 
hypertension when diastolic blood pressure is 105–115 mm Hg, 
lifelong pharmacotherapy is necessary. The aim of treatment is to 
stop disease progress and to prevent hypertensive crises.  
At III (“severe”) stage of hypertensive disease when diastolic 
blood pressure is 115 mm Hg and higher, pharmacotherapy is 
difficult and is carried out with aim to delay maximally the 
development of severe complications (insult, infarction, heart and 
renal failure).  
Antihypertensive drugs are prescribed according to so-called 
step scheme of hypertensive disease treatment. There are four steps 
of hypertensive disease therapy. Monotherapy is used during first 
step of treatment (at I–II stages of hypertensive disease). It should be 
noticed that there is no universal drug to treat all patients. Treatment 
is initiated by minimal effective doses of chosen drug. Its dose is 
gradually increased but the dose, when side effects appear, no 
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achieved. Wherein, blood pressure is decreased gradually, and  
long-time periods of high blood pressure are not observed. If effect is 
absence in 2–4 weeks after therapy initiation, it is necessary to 
replace the drug by another. The hypotensive drugs of basic group 
are used for monotherapy.  
When monotherapy is ineffective, two drugs are prescribed to 
treat hypertensive disease. The effect of potentiation allows to 
prescribe both drugs in minimal doses. Chosen drugs should to 
defuse the side effects one of another. As a rule, the drugs of basic 
group are combined, but supporting hypotensive drugs are also used.  
At the third level of hypertensive disease treatment, the third 
agent of basic or supporting group is added to scheme of therapy. It 
is forced step because the less quantity of taken drugs, the more 
easily is control of the result.  
At progress of hypertension, patient needs the fourth stage of 
treatment when strongly acting drugs (octadine, minoxidil, etc.) or 
some drug of basic group, which are not used previously, are 
included in scheme of the treatment. The task of this stage is not only 
to control blood pressure, but also to restore regional circulation and 
cardiac and renal functions. Prevention of hypertensive crises is the 
most important task of this stage because crises become more 
dangerous due to further progress of hypertensive disease.  
Commonly, co-formulated drugs are used to treat hypertension: 
“Tenoric”  (contains atenolol and hydrochlorothiazide), 
“Capozide”  (captopril and hydrochlorothiazide), “Enap-H”  
(enalapril and hydrochlorothiazide), “Logimax”  (metoprolol and 
felodipine), “Hyzaar”  (losartan and hydrochlorothiazide), etc. 
These co-formulated drugs provide long-time and stable hypotensive 
effect.          
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Drugs Used to Arrest Hypertensive Crisis  
 
Hypertensive crisis is a sharp eleveation of blood pressure which 
accompanied by headache, “gray tog”, “seeing spots”, irritability, 
tachycardia, chest pain, nausea, vomiting, etc. Hypertensive crisis 
can cause insult, acute left ventricular failure with pulmonary 
oedema, myocardial infarction, fast progression of renal failure. The 
treatment of hypertensive crisis is an emergency care task.  
According to classification of Ukrainian association of 
cardiologists (1999), hypertensive crises are divided into two types: 
– complicated crisis – states with progressive damage of 
different organs (insult, myocardial infarction, bleeding, acute renal 
failure, etc.) which are dangerous for patient life and need immediate 
(within 1 hour) reduction of blood pressure; 
– noncomplicated crisis – states without acute or progressive 
damage of different organs which are potensially dangerous for 
patient life and need to reduce blood pressure during several hours 
(up to 24 hours).   
The patient should be in a sitting or half-sitting position. The 
treatment of hypertensive crisis begins with intravenous 
administration of hypotensive drugs with fast onset of action. For 
long-time hypotensive effect, the drugs are also administered 
intramuscularly. Blood pressure is monitored.   
Sodium nitroprusside, nitroglycerin, diazoxide, labetalol, 
esmolol, propranolol, furosemide, torasemide, magnesium 
sulfate, verapamil, clopheline, phentolamine, enalaprilat, 
nimodipine, and other drugs are administered to arrest hypertensive 
crisis. For first hours, blood pressure should be decreased 20–25 %. 
Fast reduction of blood pressure can provoke dangerous 
complications (coma, angina pectoris attack, arrhythmias, etc.). 
Therapy of noncomplicated crises does not require intravenous 
drug administration. Clopheline, nifedipine, captopril,  
prazosin, propranolol,  and labetalol  are taken orally of 
sublingually. Also, such drugs as bendazole, pyrroxane, 
diazepam, furosemide, torasemide,  and clopheline  may be 
administered intramuscularly.  
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Aminazine  (intramuscularly, 50–100 mg) or droperidol  
(intramuscularly or intravenously, 5 mg) are administered to patients 
with high tone of sympathoadrenal system, vomiting, anxiety, and 
other symptoms of encephalopathy.  
 
 
HYPERTENSIVE DRUGS 
 
Drugs which increase blood pressure are used to treat shock of 
different genesis, collapse, arterial hypotension, and allergic 
reactions which accompanied by reduction of blood pressure. The 
cause of hypotension should be identified before drug administration. 
Pathogenetic therapy in any cases includes administration of drugs 
increasing blood pressure.  
Hypertensive drugs are classified according mechanism of action 
as follows.  
1. Drugs stimulating vasomotor centre – analeptics: caffeine, 
cordiaminum, camphor, sulfocamphocaine .  
2. Drugs which tone central nervous system and cardiovascular 
system: pantocrinum, tinctures of Ginseng, Schizandra; 
extracts of Eleutherococcus,  Rhodiola . 
3. Drugs with peripheral vasoconstrictor and cardiotonic activity.  
3.1. Drugs which stimulate both α- and β-adrenergic receptors in 
vessels and heart: norepinephrine, epinephrine,  ephedrine .  
3.2. Drugs which stimulate α-adrenergic receptors: mesatonum 
(phenylephrine) .  
3.3. Gormonal drugs: vasopressin,  pituitrin . 
3.4. Agonists of dopaminergic receptors: dopamine . 
3.5. Drugs with peripheral action: angiotensinamide .  
3.6. Drugs selectively stimulating β1-adrenergic receptors: 
dobutamine .  
4. Drugs increasing blood volume: polyglucinum, 
rheopolyglucin,  Neohaemodes.  
Dopamine  exhibits dose-dependent effects. Small doses of 
dopamine (1–5 mg/kg in 1 minute) stimulate peripheral dopaminergic 
receptors, relax renal and mesenteric vessels without influence on 
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cardiac function. Moderate doses of dopamine (5–20 mg/kg in  
1 minute) stimulate β1-adrenergic receptors of the heart that leads to 
the increase of cardiac output and heart rate. Renal blood flow is also 
increased. Blood pressure does not change significantly. 
Administration of high doses of drug (more than 20 mg/kg in 
1 minute) results in excitation of α-adrenergic receptors. Resistance 
of renal vessels, peripheral vascular resistance, and blood pressure 
are incresed. Heart rate and force of cardiac contraction are increased 
too. Dopamine can provoke cardiac arrhythmia. Dopamine does not 
penetrate central nervous system. The drug is administered 
intravenously drop-by-drop to treat shock of different genesis.  
Angiotensinamide  is amide of natural angioconstrictor 
angiotensin II. Vasoconstrictive effect of angiotensinamide is  
40 times greater than those of noradrenaline. Hypertensive effect of 
angiotensinamide is due to excitation of angiotensin receptors of 
arterioles. Wherein, venous tone is increased insignificantly. Vessels 
of internal organs (especially kidneys) and skin are the most sensitive 
to angiotensinamide. The drug practically does not directly influence 
heart and its circulation. 
Angiotensinamide stimulates aldosterone synthesis that leads to 
sodium and water retention in the body. Owing to this, extracellular 
fluid volume and blood pressure are increased. Besides, 
angiotensinamide increases adrenaline release, stimulates vasomotor 
centre, improves transmission through sympathetic ganglia, and 
increases peripheral effects of noradrenaline.  
The drug is administered intravenously drop by drop to treat 
acute arterial hypotension. Tachyphylaxis does not develop to 
angitensinamide. Its possible side effects are headache, allergic 
reactions, renal vasoconstriction, etc.  
At hypotension with hypovolemia, therapeutic effect is achieved 
by means of administration of blood, plasma, or plasma expanders. 
These agents are especially effective at hemorrhage and body 
dehydration. Simultaneously, antiaggregants and anticoagulants are 
administered.  
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Frontline treatment of shock includes administration of drugs 
stimulating α-adrenergic receptors (norepinephrine, mesatonum, 
etilefrine), dopamine, or angiotensinamide . The 
administration of epinephrine with this aim is possible but 
inadvisable, because stimulation of β-adrenoceptors is accompanied 
by vasodilation of some vascular regions and hypertensive effect is 
less expressive. Also, it should be noticed that marked 
cardiostimulatory effect of adrenaline is dangerous in patients with 
coexisting ischaemic heart disease.  
To treat different forms of arterial hypotension, the drugs of 
choice are midodrine  and eti lefrine (phethanolum). In 
comparison with other drugs (mesatonum , caffeine , etc.) these 
drugs have longer effect.  
Pharmacology of groups 1, 2, 3.1, 3.2, 3.3, 3.6, and 4 is given in 
corresponding chapters.               
 
Table 3 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and mode of 
administration 
Drug product 
Hygronium Intravenously drop-by-drop 
0.04–0.08 g (as 0.1 % 
solution in isotonic NaCl 
solution) 
Ampoules 0.1 g of powder 
for injection 
Pentaminum Intramuscularly 0.05–0.1 g; 
intravenously slowly 0.01–
0.025 g (in 10–20 ml  
of isotonic solution of NaCl 
solution) 
Ampoules 1 or 2 ml  
of 5 % solution 
Benzohexonium Orally 0.1–0.2 g 3–6 times 
a day; 
subcutaneously or 
intramuscularly 0.025 g  
1–2 times a day 
Tablets 0.1 g; 
 
ampoules 1 ml  
of 2.5 % solution 
Tropaphenum Subcutaneously  
or intramuscularly 0.01–0.02 g;  
intravenously slowly 0.01 g 
in 10–20 ml of isotonic NaCl 
solution 
Ampoules 0.02 g  
of powder for injection 
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Continuation of the table 3 
Drug name 
(Latin) 
Single dose and mode of 
administration 
Drug product 
Anaprilinum Orally 0.01–0.04 g; 
intravenously slowly 0.001 g  
Tablets 0.01 or 0.04 g; 
ampoules 1 or 5 ml  
of 0.1 % solution  
Metoprololum Orally 0.05–0.1 g Tablets 0.05 or 0.1 g 
Prazosinum Orally 0.000 5–0.002 g Tablets 0.001, 0.002 or 0.005 g 
Octadinum  Orally 0.025–0.05 g Tablets 0.025 g 
Reserpinum Orally 0.000 05–0.000 1 g Tablets 0.000 1  
or 0.000 25 g 
Clophelinum Orally 0.000 75–0.000 15 g; 
subcutaneously  
or intramuscularly 0.000 05–
0.000 1 g; 
intravenously 0.000 05–
0.000 1 g in 10–20 ml  
of isotonic NaCl solution 
Tablets 0.000 075  
or 0.000 15 g; 
ampoules 1 ml  
of 0.01 % solution  
Methyldophum Orally 0.25 g Tablets 0.25 g 
Phenigidinum Orally 0.01–0.02 g Tablets 0.01 g 
Diazoxidum Intravenously 0.075–0.3 g Ampoules 20 ml (0.3 g) 
Magnesii sulfas Intramuscularly  
or intravenously slowly 1–5 g 
Ampoules 5, 10 or 20 ml  
of 20 % or 25 % solution 
Captoprilum Orally 0.025–0.05 g Tablets 0.025 g 
Losartanum Orally 0.1 g Tablets 0.1 g 
Dichlothiazidum Orally 0.025–0.05 g Tablets 0.025 or 0.1 g 
Furosemidum Orally 0.04 g; 
intramuscularly  
or intravenously 0.02 g 
Tablets 0.04 g; 
ampoules 2 ml  
of 1 % solution  
Spironolactonum Orally 0.025–0.05 g Tablets 0.025 g 
Noradrenalini 
hydrotartras 
Intravenously        
drop-by-drop 0.004–0.008 g  
in 1 l of isotonic NaCl 
solution 
Ampoules 1 ml  
of 0.2 % solution  
Mesatonum Orally 0.01–0.025 g; 
subcutaneously  
or intramuscularly 0.003–
0.005 g; 
intravenously 0.001–0.003 g 
in 10–20 ml of isotonic 
sodium chloride solution, or  
intravenously drop-by-drop  
Powders;  
ampoules 1 ml  
of 1 % solution  
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Step 1. Tasks for Self -Control  
Antihypertensive and Hypertensive Drugs  
 
1. A 58-year-old female has undergone surgery for bowel 
necrosis. Despite having been treated with antibiotics, on 
postoperative day 5, she develops symptoms (fever, hypotension, 
tachycardia, decreased urine output, and confusion) consistent with 
septic shock. What haemodynamic support would be helpful? 
A. Antibiotic administration. 
B. Fluid and dobutamine infusion. 
C. Atropine administration. 
D. Fluid administration. 
E. Dobutamine infusion. 
2. In a hypertensive patient who is taking insulin to treat 
diabetes, which of the following drugs is to be used with extra 
caution and advice to the patient? 
A. Methyldopa. 
B. Prazosin. 
C. Octadine (guanethidine). 
D. Anaprilinum. 
E. Hydralazine. 
3. Drugs that block catecholamine uptake process (e. g., cocaine, 
tricyclic antidepressants) are apt to block the antihypertensive action 
of which of the following drugs? 
A. Diazoxide. 
B. Propranolol. 
C. Prazosin. 
D. Hydralazine. 
E. Guanethidine.  
4. Point out nonselective β-adrenergic blocking agent that is also  
a competitive antagonist at α1-adrenoceptors. 
A. Labetalol.  
B. Nadolol. 
C. Pindolol. 
D. Acebutolol. 
E. Timolol. 
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5. A 35-year-old female with pheochromocytoma is treated with 
labetalol. Select the mechanism of labetalol action.  
A. Mixed α- and β-antagonist.  
B. α-Adrenergic antagonist. 
C. β-Adrenergic agonist. 
D. β-Adrenergic antagonist. 
E. α-Adrenergic agonist. 
6. A 65-year-old male has a blood pressure of 170/105 mmHg. 
Which of the following would be effective in lowering this patient’s 
blood pressure? 
A. Scopolamine. 
B. Prazosin.  
C. Dobutamine. 
D. Proserinum. 
E. Terbutaline. 
7. A 66-year-old male with a one-year history of essential 
hypertension has minimal response to diet and diuretic. His blood 
pressure is now 160/105 mmHg. The diuretic is discontinued, and 
propranolol is given. Select the mechanism of action that is associated 
with propranolol.  
A. β-Adrenergic agonist. 
B. α-Adrenergic antagonist. 
C. M-cholinergic agonist. 
D. Sodium channel antagonist. 
E. β-Adrenergic antagonist.  
8. A patient has a hypertensive emergency with blood pressure  
of 210/140 mm Hg. Which of the following drugs would be most 
effective intravenously? 
A. Atropine. 
B. Pirilenum (pempidine). 
C. Pachycarpine. 
D. Arfonad (trimethaphan). 
E. Scopolamine. 
9. ACE inhibitors are associated with a high incidence of which 
of the following adverse reactions? 
A. Hirsutism. 
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B. Proteinuria. 
C. Agranulocytosis. 
D. Hepatitis. 
E. Hypokalaemia. 
10. Point out antihypertensive drug producing marked relaxation 
of smooth muscle of both venules and arterioles. 
A. Sodium nitroprusside.  
B. Anaprilinum. 
C. Octadine. 
D. Reserpine. 
E. Verapamil. 
11. A 50-year-old male with a two-year history of essential 
hypertension well controlled on dichlothiazide is found on a recent 
physical examination to have a blood pressure of 160/105 mm Hg. 
Dichlothiazide is substituted with another agent. Two weeks later, he 
returs for follow-up complaining of a taste loss. Select the drug 
which is most likely to have caused this adverse effect. 
A. Propranolol. 
B. Adenosine. 
C. Captopril. 
D. Nifedipine. 
E. Furosemide. 
12. A 54-year-old female is treated for essential hypertension 
with an antihypertensive drug that controls her blood pressure. One 
day, she comes to the emergency department with chest pain, 
tachycardia, anxiety, and blood pressure of 240/140 mm Hg. She has 
not taken her medication for two days. Which antihypertensive drug 
can account for her findings? 
A. Prazosin. 
B. Propranolol. 
C. Doxazosin. 
D. Minoxidil. 
E. Clonidine. 
13. A 48-year old salesman with known hypertension complains 
of a decreasing annual income, a loss of “drive”, and a depressed 
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outlook on life. His blood pressure is normal on medication.  
What is the antihypertensive drug being most likely to be the cause 
of his new complaints? 
A. Reserpine.  
B. Methyldopa. 
C. Hydralazine. 
D. Hydrochlorothiazide. 
E. Guanethidine. 
14. Clonidine hydrochloride lowers blood pressure by reducing 
sympathetic tone. It is believed to act by inhibiting sympathetic 
outflow from the vasomotor centre in the medulla. What is a 
potentially serious adverse reaction that has been reported? 
A. Systemic lupus erythematosus. 
B. Anaphylaxis. 
C. Irreversible nephrotoxicity. 
D. Ventricular fibrillation. 
E. Withdrawal syndrome resembling hypertensive crisis.  
15. Diuretic drug was prescribed to the patient with hypertension 
in the course of complex treatment. In a few days blood pressure 
decreased but signs of hypokalaemia developed. What drug could 
cause such complications? 
A. Triamterene. 
B. Lasix. 
C. Spironolactone. 
D. Enalapril. 
E. Clophelinum. 
16. A patient with hypertensive disease with accompanying 
obstructive bronchitis receives anaprilinim (propranolol) in complex 
therapy. After a while, the attacks of asthma become more frequent. 
What is the cause of this side effect? 
A. Stimulation of bronchial 1-adrenoceptors.  
B. Blockade of bronchial 1-adrenoceptors. 
C. Blockade of bronchial 2-adrenoceptors. 
D. Blockade of bronchial 2-adrenoceptors.  
E. Stimulation of bronchial 2-adrenoceptors. 
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17. For the correction of arterial pressure in collaptoid state 
mesatonum has been injected to the patient. What is the mechanism 
of this drug action? 
A. Stimulation of - and -adrenoceptors. 
B. Stimulation of -adrenoceptors. 
C. Blockade of -adrenoceptors. 
D. Blockade of -adrenoceptors. 
E. Stimulation of 1-adrenoceptors.  
18. A patient suffers from hypertensive crisis. What is it 
necessary to prescribe to the patient for normalization of the arterial 
pressure? 
A. Propranolol. 
B. Magnesium sulfate. 
C. Prazosin. 
D. Atropine. 
E. Reserpine. 
19. High renin level is developed in blood of 55-year-old patient 
with hypertensive disease. What hypotensive drug should be 
prescribed for the treatment of the patient? 
A. Prazosin. 
B. Clophelinum. 
C. Enalapril. 
D. Papaverine.  
E. Magnesium sulfate. 
20. Antihypertensive agent has decreased the blood pressure 
during first several days of treatment owing to diminish of minute 
heart volume. In four weeks of using, minute heart volume restored 
to initial level, but blood pressure had remained low. Indicate drug 
which is used in this case.  
A. Losartan. 
B. Prazosin. 
C. Methyldopa.  
D. Octadine. 
E. Anaprilinum. 
21. A 65-year-old patient received the injection of drug A. for 
interruption of hypertensive crisis. It is known, that drug A. has 
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anticonvulsive and analgesic actions; and in case of peroral 
administration it also shows the laxative and bile-expelling actions. 
Identify drug A.  
A. Magnesium sulfate. 
B. Sodium nitroprusside. 
C. Clophelinum. 
D. Pentaminum. 
E. Dibazole. 
22. A patient with hypertensive crisis was admitted to the 
cardiological department. He was given an intravenous injection of 
an antihypertensive drug – alkali-earth metal salt. What drug was 
injected? 
A. Potassium chloride. 
B. Sodium hydrocarbonate. 
C. Calcium lactate. 
D. Benzohexonium. 
E. Magnesium sulfate. 
 
 
DRUGS TO TREAT ISCHAEMIC HEART 
DISEASE (ANTIANGINAL DRUGS)  
 
Antianginal drugs eliminate the imbalance between myocardial 
oxygen demand and oxygen delivery to the heart. Due to this, drugs 
arrest angina attacks and relief progression of ischaemic heart 
disease. According to data of WHO, frequence of ischaemic heart 
disease elevated more than 10 times during last 40 years. Tendency 
to increase is mainly kept at the expense of 35–40-year-old people. 
There are several clinical forms of ischaemic heart disease: angina 
pectoris, myocardial infarction, atherosclerotic cardiosclerosis, etc.   
Antianginal drugs are classified as follows.  
1. Drugs decreasing myocardial oxygen demand and improving 
supply of oxygen to a heart.   
1.1. Organic nitrates: nitroglycerin, nitrosorbidum 
(isosorbide dinitrate ), isosorbide mononitrate , erynitum, 
sustac mite,  sustac forte, trinitrolong, nitrong .  
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1.2. Calcium channel antagonists: verapamil,  gallopamil ,  
nifedipine, nicardipine,  amlodipine, dil tiazem, 
nisoldipine .  
1.3. Potassium channel activators: nicorandil , pinacidil .  
1.4. Different drugs: amiodarone, molsidomine .  
2. Drugs decreasing myocardial oxygen demand.  
2.1. β-adrenoceptor antagonists: anaprilinum, nadolol ,  
oxprenolol , metoprolol , talinolol ,  nebivolol , acebutolol .  
2.2. Bradicardiac drugs (sinus node inhibitors): ivabradine, 
alinidine, falipamil .  
3. Drugs increasing oxygen delivery to myocardium.  
3.1. Myotropic coronary vasodilating drugs: carbocromen, 
dipyridamole, papaverine,  No-spa .  
3.2. Coronary vasodilating drug with reflex action: validolum .  
4. Cardioprotective drugs: trimetazidine (Preductal),  
ATP-long,  antioxidants and antihypoxants (emoxypine 
(Mexidol), Oliphen, Ubinonum) .    
It should be noticed that treatment of ischaemic heart disease is 
complex and necessarily includes, besides antianginal agents, drugs 
of other groups: tranquilizers, antiaggregants, anticoagulants, 
vitamins, anabolics, hypolipidemic drugs, etc.  
The main antianginal drugs are organic nitrates, calcium channel 
antagonists, and β-adrenergic antagonists.     
 
Drugs Decreasing the Myocardial Oxygen Demand 
and Improving the Myocardial Blood Supply  
 
Organic Nitrates  
 
Nitroglycerin was implemented in medicine in 1876. Take into 
account its efficacy and frequency of clinical use, nitroglycerin is the 
main antianginal drug down to here. Different nitroglycerin-
containing drugs and some other organic nitrates are used nowadays 
to treat ischaemic heart disease. Organic nitrates are effective at all 
forms of angina pectoris – effort angina, Prinzmetal’s (variant) 
angina, postinfarction angina, progressive angina pectoris.  
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It is known that myocardial oxygen demand is determined by 
heart work. In turn, heart work depends from heart rate, force 
of cardiac contraction, preload, and afterload. Preload is determined 
by the degree of pressure in ventricles at the end of diastole (depends 
on venous return). Afterload is determined by blood pressure level in 
the aorta (depends on peripheral resistance).  
Vasodilation, caused by nitrates, is occurred by means  
of NO-groups acting analogically endothelial relaxing factor. It is 
known that in patients suffering from ischaemic heart disease the 
production of endothelial relaxing factor is reduced due to lesions of 
arterial wall endothelium. 
Organic nitrates interact with sulfhydryl groups of cysteine 
which is a part of nitrate receptors located in membranes  
of endotheliocytes. An interaction of nitrates with HS-groups  
of cysteine leads to the S-nitrosocysteine synthesis and the release  
of NO2 which is transformed in NO. Nitric oxide diffuses into the 
cells of vascular smooth muscles where stimulates guanylyl cyclase 
that leads to the increase of cGMP level. cGMP by means  
of cGMP-dependent protein kinase influence smooth muscles 
contraction, reducing calcium intracellular concentration. It results in 
dephosphorylation of myosin light chains and smooth muscle 
relaxation. Besides, nitrates stimulate synthesis of prostaglandins and 
suppress thromboxane A2 synthesis, that leads to the decrease  
of adhesion and aggregation of platelets and improves 
microcirculation. Low doses of nitrates dilate veins, whereas high 
nitrate doses also relax arteries.    
Besides peripheral action, nitrates also exhibit expressive central 
action. Drugs decrease adrenergic influence upon heart and vessels 
that also promotes vasodilatation.  
The main factor of anti-ischaemic effect of nitrates is their 
ability to decrease venous blood return to heart due to the dilation  
of capacitive vessels and blood deposition in them that is 
accompanised by the reduction of cardiac preload. Reduction  
of arterioles tone is less expressive but also useful because results in 
the decrease of cardiac afterload.   
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Decrease of both preload and afterload leads to the reduction  
of heart work and reduction of myocardial oxygen demand.  
Improvement of coronary blood flow is a secondary 
consideration. But unlike other coronarolytics, nitrates dilate large 
coronary arteries that promotes to increase of perfusion pressure at 
the entrance to sclerous segments of vessels. Therefore, nitrates 
increase blood velocity in the ischaemic area. Steal phenomenon is 
uncharacteristic of nitrates.  
It is necessary to note, that redistribution of intracardial blood 
flow is in favor of the most vulnerable subendocardial sections.  
Also, nitrates dilate vessels of brain, internal organs, and retina. 
Because nitrates are myotropic antispasmodics, they relax smooth 
muscles of internal organs (gastrointestinal tract, bronchi, etc.).      
The used medicinal forms of nitrates determine the routes of 
drugs administration, speed of effect development, and duration  
of antianginal action. If a drug is used to prevent angina attacks, 
speed of its effect development is not critical. But it is determinative 
factor in case when a drug is used to arrest angina attacks. A number 
of medicinal forms of nitroglycerin  for sublingual administration 
are used to arrest stenocardia attacks: tablets, alcoholic and oil 
solutions (dosed by drops), spray for irrigation of mouth, and 
capsules. These medicinal forms are used only sublingually because 
nitroglycerin is destroyed at first passage through the liver. Also, 
there is medicinal form of nitroglycerin for intravenous 
administration.   
At sublingual administration, nitroglycerin avoids the first 
passage through the liver. Drug is readily absorbed into superior vena 
cava system and enters systemic blood circulation. The 
bioavailability of sublingual nitroglycerin is more than 90 %. It 
should be notised that nitroglycerin absorption significantly depends 
on intensity of salivation. At dry mouth, bioavailability of 
nitroglycerin is significantly reduced. Therefore, nitroglycerin spray 
is preferable to use in patients with disorders of salivation.  
At sublingual administration, maximum concentration of 
nitroglycerin in the blood is observed in 2–3 minutes. Nitroglycerin 
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effect lasts 15–20 minutes and is determined by active metabolit of 
nitroglycerin – dinitroglycerin. In 20–30 minutes, only trace of drug 
is observed in the blood. Nitroglycerin undergoes hepatic 
biotransformation by conjugation with glutathione. Its metabolites 
are excrated through the liver and lungs.  
Medicinal forms with slowly release nitroglycerin are used to 
prevent angina attacks. These drugs are special microcapsulated 
forms containing granules of nitroglycerin with different velocity of 
absorbtion. These drugs are prescribed from 1 to 3–4 times a day. 
Nitroglycerin sustained-release forms include tablets “Sustac mite” 
and “Sustac forte”, polymer plates “Trinitrolong”. There are 
transdermal forms of nitroglycerin: ointment and plaster discs with 
nitroglycerin. Therapeutic effect of transdermal nitroglycerin 
develops slowly and lasts 8–24 hours.  
Group of nitrates with prolonged action includes 
nitrosorbidum, isosorbide mononitrate ,  and isosorbide 
dinitrate . The efficacy of these drugs is less than those of 
nitroglycerin.  
Nitrates are used to arrest and to prevent angina attacks. Also, 
drugs are administered intravenously drop-by-drop to treat 
myocardial infarction in acute period. 
Postural hypotension is the most dangerous complication of 
nitrate therapy. Other side effects of nitrates include reflex 
tachycardia, increased intracranial and intraoccular pressure, 
headache, feeling the heat, and hyperemia of the face. Cases of 
hemorrhagic stroke also are described. Tolerance develops 
approximately in 58 % of patients who regularly take nitroglycerin 
during 1.5–2 months. To prevent tolerance, nitrate-free period  
of 10–12 hours duration (overnight) is needed.  
Sudden phasing out of long-time nitrate intake leads to rebound 
phenomenon. It is characterized by increased intensively of chest 
pain and increased frequency of angina attacks. Rebound 
phenomenon can result in myocardial infarction and sudden death. 
Therefore, phasing out of nitrate intake should be done by gradually 
reducing the drug dose and the frequency of its intake. 
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It is necessary to notice that long-time intake of nitrates can 
provoke methemoglobinemia.  
 
Calcium Channel Blockers (Calsium Antagonists) 
 
Calcium channel blockers are classified as follows: 
– calcium channel blockers, 1st generation: verapamil , 
nifedipine, diltiazem ; 
– calcium channel blockers, 2nd generation: gallopamil ,  
amlodipine, felodipine,  nicardipine, nisoldipine ; 
– calcium channel blockers, 3rd generation: naftopidil ,  
emopamil .  
According to chemical structure, calcium channel blockers are 
divided into 3 subgroups:  
– phenylalkylamine derivatives: verapamil , gallopamil ; 
– dihydropyridine derivatives: nifedipine,  nicardipine,  
nisoldipine,  isradipine,  felodipine ,  amlodipine ; 
– benzothiazepine derivatives: diltiazem, clentiazem . 
In comparison with the first-generation, the second-generation 
drugs are characterized by longer duration of action and higher 
selectivity to calcium channels of certain localization.  
Third-generation calcium antagonists are drugs with additional 
properties: naftopidil  exhibits α-adrenoblocking activity, 
emopamil  – sympatholytic activity. All three generations exhibit 
antianginal, antiarrhythmic, and antihypertensive activity.  
Calcium channel blockers inhibit calcium entrance through  
L-type slow calcium channels into the muscular cells of vessels and 
heart. A decrease of free calcium ions concentration in the cardiac 
histiocytes leads to reduction of energy consumption of ATP for 
mechanical work of myocardium. A force of the heart contractions 
decreases that results in reduction of myocardial oxygen 
consumption. Decreased heart work is also a result of relaxation of 
peripheral arteries and reduction of afterload. Dilation of coronary 
vessels also promotes the antianginal effect, because it improves 
myocardial oxygen delivery. Besides, calcium antagonists improve 
the subendocardial blood flow and collateral circulation.  
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Also, calcium antagonists inhibit platelet aggregation and release 
of thrombocytic biologically active substances which induce 
vasospasm and increase blood clotting. 
Calcium channel blockers are taken orally or sublingually and 
administered parenterally. Drugs are completely (more than 90 %) 
and rapidly absorbed from the gastrointestinal tract. But drugs 
undergo first-pass elimination in the first passage through the liver. 
Bioavailability of calcium channel blockers is about 35 % (for 
nifedipine, nitrendipine, and amlodipine  it varies from 65 to 
90 %). About 90 % dose reaching systemic circulation binds with 
plasma proteins. Calcium antagonists readily penetrate various 
tissues and organs including central nervous system. Duration of 
action of first-generation drugs is 4–6 hours. Second-generation 
calcium channel blockers act 12 hours. Almost 100 %  
of administered dose of calcium antagonists are metabolized by liver 
with the formation of inactive metabolites. Only metabolites of 
verapamil  and diltiazem  exhibit some pharmacological activity. 
Metabolites of calcium channel blockers are excreted mainly by 
kidneys (80–90 %) and partly – by liver.  
Calcium channel blockers are used to treat all types of angina 
(variant angina and effort angina). Derivatives of phenylalkylamine 
and benzothiazepine are predominantly used in the treatment for 
angina with coexisting supraventricular tachycardia. Dihydropyridine 
derivatives are used to treat angina which is accompanied by 
bradycardia, disorders of atrioventricular conduction, or arterial 
hypertension.      
Besides, calcium antagonists are used in the treatment for 
hypertensive disease, supraventricular tachyarrhythmias, atrial 
flutter, atrial fibrillation, and to prevent cold-induced 
bronchospasms.  
Side effects of calcium channel blockers are headache, dizziness, 
arterial hypotension, flushing (as a rule at nifedipine intake), 
constipations, bradycardia (for phenylalkylamine derivatives) or 
tachycardia (for dihydropyridine derivatives).  
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Potassium Channel Activators 
 
This group includes nicorandil  and pinacidil . Potassium 
channel activators open ATP-sensitive potassium channels and 
promote potassium ions outflow from the smooth muscle cells that 
leads to membrane hyperpolarization and reduces vascular tone.  
Pinacidil  dilates both peripheral and coronary vessels and 
decreases afterload. The drug’s administration is accompanied by 
reflex tachycardia. Besides, pinacidil decreases the blood level of 
cholesterol and triglycerides. Its side effects are headache, 
tachycardia, hypertrichosis, etc. Pinacidil is used to treat angina 
pectoris and heart failure.  
Nicorandil  activates potassium channels and increases the 
synthesis of NO (nitrate-like action). Its administration leads to 
relaxation of coronary, resistance, and capacitance vessels, thereby 
both preload and afterload are reduced. Nicorandil’s action is 
accompanied by reflex tachycardia. Drug is used in the treatment for 
effort angina, vasospastic angina, acute myocardial infarction, 
chronic heart failure, and hypertensive disease. Side effects are 
headeche, tachycardia, and dyspepsia.  
 
Different Antianginal Drugs Which Both Decrease  
the Myocardial  Oxygen Demand and Improve  
the Blood Supply 
 
This group includes amiodarone  and molsidomine .  
Amiodarone  exhibits antianginal and antiarrhythmic effects. 
Its mechanism of action is associated with blockage of potassium, 
calcium, and sodium channels. Besides, amiodarone exhibits β- and 
α-adrenergic blocking activity. Also, amiodarone is antagonist of 
glucagon. Therefore, amiodarone slows down heart rate and 
decreases blood pressure. Consequently, myocardial oxygen demand 
is decreased. Also, amiodarone improves coronary circulation.  
Amiodarone is taken orally or administered intravenously 
slowly. Degree of its absorption from gastrointestinal tract is 
approximately 50 %. Amiodarone undergoes hepatic 
biotransformation. Its metabolites are excreted mainly by intestine. 
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Drug is used to prevent angina pectoris attacks, to prevent and to 
treat both supraventricular and ventricular tachyarrhythmias. Marked 
therapeutic effect of amiodarone develops in several weeks after 
treatment initiation.  
Long-time amiodarone therapy may be accompanied by 
deposition of microcrystals of the drug in the cornea, skin 
pigmentation, photodermatoses, thyroid dysfunction, bradycardia, 
and hypotension. 
Molsidomine (Corvaton) undergoes hepatic metabolism 
with formation of active metabolite releasing NO. Nitric oxide is 
strong vasodilator and, therefore, is also called “endothelium-derived 
relaxing factor”. Molsidomine selectively relaxes peripheral veins, 
decreases adhesion and aggregation of thrombocytes, and increases 
the elasticity of large arteries. Molsidomine decreases both cardiac 
preload and afterload, reduces myocardial oxygen demand, and 
increases coronary circulation. Unlike nitrates, long-time 
molsidomine intake does not lead to tolerance, because the drug does 
not interact with HS-groups of proteins.  
Molsidomine is administered parenterally, sublingually, and 
taken orally. Gastrointestinal absorption of molsidomine is about 
60 %. Drug does not bind with plasma proteins. At oral intake, the 
drug effect develops in 20–30 minutes. Sublingually taken 
molsidomine begins to act in 5 minutes. Duration of molsidomine 
action is 6–8 hours. Biotransformation of molsidomine occurs in 
liver. Metabolites of molsidomine undergo renal and hepatic 
excretion.  
Molsidomine is used both to treat and to prevent angina pectoris 
attacks. Besides, the drug is used in the tretment for chronic and 
acute heart failure, myocardial infarction, and hypertension. Its side 
effects are headache, hyperemia of the face, nausea, muscular 
spasms, etc.  
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Drugs Decreasing Myocardial Oxygen Demand 
 
β-Adrenoceptor Antagonists  
 
β-adrenoceptor antagonists are the main drugs in therapy of 
majority of cases of ischaemic heart disease.  
Depending on selectivity to certain types of -adrenergic 
receptors, -adrenergic antagonists are classified as follows:  
1) β1 and 2-adrenoceptor antagonists (nonselective  
-adrenoceptor antagonists): anaprilinum (propranolol ),  
nadolol,  sotalol , oxprenolol , and pindolol ; 
2) β1-adrenoceptor antagonists (cardioselective -adrenoceptor 
antagonists): metoprolol , talinolol , atenolol,  nebivolol ,  
acebutalol , etc.  
 The drugs decrease excessive influence of stress and negative 
emotions upon cardiovascular system due to blockage  
of β1-adrenergic receptors in the heart. Under the influence  
of β-adrenoceptor antagonists, the force of cardiac contractions and 
heart rate are decreased that leads to reduction of myocardial oxygen 
demand.  
It should be noticed that β-adrenoceptor antagonists negatively 
influence coronary circulation due to blockage of β2-adrenergic 
receptors of coronary vessels (for nonselective drugs) and reduction 
of stroke volume and cardiac output. Therefore, high efficacy  
of β-adrenoceptor antagonists in ischaemic heart disease is the result 
of pronounced reduction of myocardial oxygen demand.  
Long-time (during months and years) therapy by individually 
selected doses of β-adrenoblockers decreases in 2 (and more) times 
frequancy of sudden death of patients with ischaemic heart disease 
and postinfarction patients, improves patients’ state, increases 
exercise tolerance, significantly decreases frequancy and severity of 
angina attacks.      
Generally, cardioselective β-adrenoceptor antagonists are 
preferable in the treatment for ischaemic heart disease because these 
drugs do not block vascular β2-adrenergic receptors and, thus, reduce 
of coronary and peripheral circulation in less degree. Besides, unlike 
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β1,2-adrenergic antagonists, these drugs insignificantly increase risk 
of bronchoconstriction at concomitant pathology of respiratory 
organs. 
β-Adrenergic antagonists with intrinsic sympathomimetic 
activity (pindolol, etc.) reduce myoacardial contractile activity in less 
degree, therefore these drugs are preferable in the treatment for 
ischaemic heart disease for patients with symptoms of heart failure 
and for posinfarction patients.   
β-adrenoceptor antagonists are taken orally and administered 
pareneterally. Most drugs are readily (70–90 %) absorbed from 
gastrointestinal tract.  Bioavailability of β-adrenoceptor antagonists 
is nearly 50 %. Biotransformation of drugs occurs in the liver. 
Degree of binding with plasma proteins for different drugs varies 
from 5 to 90 %. Duration of action for majority of drugs is 
approximately 8 hours; for metoprolol – 12 hours; for atenolol and 
pindolol – 24 hours. Lipophilic β-adrenoceptor antagonists are 
excreted mainly by the liver; hydrophilic ones – by the kidneys.  
Most commonly, β-adrenoceptor antagonists are used to treat 
effort angina in patients with tendency to increase blood pressure and 
heart rate. Usually, cardioselective β-adrenoceptor antagonists are 
used together with drugs of other groups. β-adrenoceptor antagonists 
with intrinsic sympathomimetic activity (e. g., pindolol) are 
preferable for treatment of patients with concomitant bradycardia and 
with hidden symptoms of heart failure. 
Also, β-adrenoceptor antagonists are used in the for treatment 
for hypertensive disease, supraventricular tachyarrhythmisas, 
extrasystoles, thyrotoxicosis, and to prevent repeated myocardial 
infarction.   
Side effects of β-adrenoceptor antagonists are bradycardia, 
conduction disorders, arterial hypotension, heart failure, 
bronchoconstriction, worsening of lipid spectrum (drugs increase the 
level of atherogenic lipoproteins), central nervous system 
suppression, hypoglycemia, vasospasm of limbs, and dyspeptic 
disorders.  
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It should be noticed that therapy by β-adrenergic antagonists is 
not accompanied by tolerance. These drugs keep their efficacy at 
longstanding intake. But sudden cessation of β-adrenoceptor 
antagonist intake can result in serious aggravation of ischaemic heart 
disease up to myocardial infarction. Therefore, discontinuation of the 
drug intake should be gradual.  
 
Bradicardic Drugs 
 
Bradicardic drugs are alinidine,  ivabradine, and 
falipamil . These drugs significantly decrease heart rate and 
myocardial oxygen demand. Bradycardia is due to direct suppressive 
influence of drugs upon automatism of sinus node (drugs slow down 
phase of diastolic depolarization). Besides antianginal action, 
bradicardic drugs also exhibit antiarrhythmic effect. Drugs don’t 
influence circulatory dynamics.  
Ivabradine is the most studied representative of this group. The 
drug blocks If-channels that leads to reduction of Na
+ and K+ inward 
current into the cells of sinus node. Therefore, ivabradine slows 
down diastolic depolarization and decreases automatism of sinus 
node. Simultaneously, blood supply of endocardium is improved. 
The drug does not influence myocardial contractility and conduction. 
Ivabradine is used to treat ischaemic heart disease and chronic heart 
failure. The drug is taken two times a day. Ivabradine does not cause 
rebound syndrome.      
 
Drugs Increasing Oxygen Delivery to Myocardium 
 
Coronary Vasodilating Drugs with Myotropic Action 
 
This group includes drugs which dilate coronary vessels and 
eliminate coronary spasm (e. g., dipyridamole,  papaverine).  
Dipyridamole (Curantyl)  influences myocardial 
microcirculation, because it decreases the tone of small resistance 
vessels owing to inhibition of reuptake of adenosine by cardiac 
histiocytes and erythrocytes. Drug also inhibits the activity of 
adenosine deaminase. It is known, that adenosine is released in 
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hypoxia of myocardium and causes marked dilation of coronary 
arteries. Also, dipyridamole suppresses the platelets aggregation and 
improves microcirculation. The drug does not change the systemic 
peripheral resistance. Dipyridamole is used to prevent angina attacks 
for patients without atherosclerotic lesions. It is necessary to note, 
that in patient with coronary atherosclerosis, dipyridamole does not 
improve oxygen delivery to ischaemic area. Moreover, the drug can 
worsen blood circulation in ischaemic region. It is explained by the 
fact that in ischaemic area small coronary vessels are relaxed in 
maximum degree (compensatory reaction). After dipyridamole 
administration, small vessels are relaxed also in non-ischaemic 
regions of myocardium. It promotes the reduction of blood 
circulation in ischaemic area. This phenomenon is called steal 
syndrome. This effect of dipyridamole is sometimes used to 
determine latent coronary insufficiency. 
Dipyridamole is taken orally and administered parenterally. Side 
effects are headache, dyspepsia, hypotension, etc.  
Papaverine  is alkaloid of opium. Drug exhibits low coronary 
vasodilating activity and has short duration of action. Mechanism of 
action is associated with inhibition of phosphodiesterase that leads to 
increase of intracellular cAMP concentration. Increase of cAMP 
concentration results in reduction of calcium concentration in 
vascular smooth muscles and elevation of calcium level in cardiac 
histiocytes. Therefore, relaxation of coronary vessels is accompanied 
by increase of cardiac contraction force. Simultaneously, papaverine 
insignificantly inhibits reuptake of adenosine by cardiac histiocytes. 
Besides, papaverine decreases systemic arterial pressure, reduces the 
cerebrovascular tone, and relaxes the smooth muscles of inner 
organs. Papaverine has a limited use to prevent angina attacks.  
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Antianginal Drugs with Reflex Action 
 
Validolum  is 25–30 % menthol solution in menthol ether of 
isovaleric (3-methylbutanoic) acid. Drug is taken sublingually to 
interrupt slight angina attacks. Menthol irritates the cold receptors in 
oral cavity that leads to reflex relaxation of coronary vessels. The 
antianginal activity of validolum is low. If in 2–3 minutes after the 
drug intake pain is not arrested, validolum should be replaced by 
nitroglycerin.  
 
 
Cardioprotective Drugs 
 
Trimetazidine (Preductal,  Vastarel)  directly influences 
cardiac histiocytes in ischaemic area and normalizes their energy 
balance. It is not accompanied by changes of total hemodynamics. It 
is expected that trimetazidine’s mechanism of action is associated 
with inhibition of 3-ketoacyl-CoA thiolase that leads to reduction of 
fatty acid oxidation. Against this background, glucose oxidation is 
activated that favourably influences myocardial function. 
Trimetazidine is taken 3 times a day. Preductal MB is prolonged 
medical form which is taken 2 times a day. Trimetazidine is readily 
absorbed from gastrointestinal tract, undergoes hepatic 
biotransformation, and excreted by kidneys. The drug is well 
tolerated by patients.  
 Adenosine triphosphate (ATP)  participates in different 
metabolic processes. At interaction with actomyosin, it degrades to 
ADP and inorganic phosphate. This process is accompanied by 
release of energy which is used for the cardiac work and anabolic 
processes. Besides, ATP is considered as one of the mediators of 
adenosine receptors. In patients with ischaemic heart disease, ATP 
concentration in myocardium is decreased. Administration of ATP 
increases cerebral and coronary blood circulation. Value of 
exogenous ATP is questionable, because significant amount of 
energy is necessary for penetration of ATP across the cell 
membranes. Therefore, special medical form – ATP-long – was 
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approved. It plays the role of coordinating drug: ATP together with 
potassium, magnesium, and histidine penetrate inside of cardiac 
histiocytes. Intracellular ATP provides anti-ischaemic and 
antiarrhythmic affects. 
Special drugs to reduce cardiac hypoxia – antihypoxants – are 
used in medicine. Antioxidants hold a high positin between 
antihypoxants. These drugs exhibit antiradical effect and inhibit lipid 
peroxidation. These drugs include such agents as emoxypine  
(Mexidol ), ubinone  (ubiquinone), oliphen , etc.  
 
 
Principles of  Complex Therapy of Myocardial 
Infarction  
 
Myocardial infarction is acute disease developing due to 
occurrence of one or more foci of heart muscle necrosis in result of 
absolute or relative coronary circulation deficiency. In most cases, 
the main cause of myocardial infarction is atherosclerosis of 
coronary vessels (it is registered in 90 % of died from infarction). 
Usually, myocardial infarction is accompanied by severe pain, fear of 
death, excitement, sharp activation of the sympathoadrenal system, 
spasm of the coronary and peripheral arteries. It creates additional 
load upon the heart and increases the conflict between oxygen 
delivery to myocardium and its oxygen demand. In 90 % cases, 
myocardial infarction is accompanied by cardiac arrhythmias and 
acute heart failure, which can lead to ventricular fibrillation and 
cardiogenic shock. All medical measures in myocardial infarction 
should be held whithin short timeframes. A patient needs bed regime.  
Opioid analgesics (phentanyl, morphine, promedol, 
tramadol, etc.), tranquilizers (diazepam), and neuroleptics 
(droperidol , on the condition that blood pressure is not decreased) 
are administered to relief pain and to eliminate death anxiety and 
excitement. If painful syndrome is not reduced, opioid analgesic is 
administered again in 20–30 minutes. If it is necessary, inhalation 
nitrous oxide with oxygen is given to patient. It should be noticed 
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that analgesia by metamizole (analgin) and diphenhydramine 
(dimedrol) is, as a rule, ineffective. 
Nitroglycerin  or isosorbide dinitrate  are administered 
intravenously drop-by-drop to unload the heart. The earlier these 
drugs are administered the higher is their effectiveness. It is 
necessary to notice, that nitrates’ administration is contraindicated at 
collapse and shock.   
β-adrenoceptor antagonists are administered to decrease the 
heart work and to reduce tachycardia. Selective β1-adrenoceptor 
antagonists (metoprolol  or talinolol ) are preferable. These drugs 
are prescribed for initial intravenous administration with the further 
their oral intake.  
To prevent or eliminate ventricular tachyarrhythmias, 
l idocaine  or amiodarone  are administered. 
To support cardiac contractile function, cardiac glycosides are 
used seldom, because they can provoke dangerous arrhythmias 
against the background of ischaemia. Dopamine  or dobutamine  
are preferable cardiotonics for this aim. These drugs are administered 
intravenously drop-by-drop.  At danger of pulmonary oedema, 
dopamine is administered together with nitroglycerin. Also, infusion 
of glucose with insulin is used to maintenance of the heart trophism.    
Fibrinolytics (streptokinase, urokinase, alteplase , etc.) 
are used to eliminate coronary thrombosis. These drugs lyse thrombi 
and restore coronary circulation. To prevent further thrombosis, 
anticoagulants (heparin, fraxiparine,  etc.) are administered. 
Antiaggregants (aspirin, clopidogrel, t iclopidine ) are 
prescribed as early as possible.  
Inhaled oxygen is used during all period of acute myocardial 
infarction therapy. Hyaluronidase is used to increase vascular 
permeability in ischaemic area. Antioxidants (α-tocopherol,  
emoxypine, etc.) and glucocorticoids are prescribed to suppress 
inflammation.      
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Table 4 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product 
Nitroglycerinum Sublingually 0.000 5 g  
at an attack of angina 
pectoris (it is necessary 
previously to get to the core 
of a capsule by teeth); 
intravenously drop-by-drop 
0.000 5–0.00 1 g 
(concentration  
of administered solution is 
0.01 % or 100 mcg / ml)  
Tablets 0.000 5 g; 
capsules 0.000 5 g  
of 1 % oil solution; 
 
 
ampoules 10 ml  
of 0.1 % solution,  
2 ml of 0.5 % solution,  
and 2 ml of 1 % solution  
Isosorbide 
mononitrate 
Orally 0.02–0.04 g 2–4 times 
a day 
Tablets 0.02 or 0.04 g  
Sustac mite Orally 1 tablet 2 times a day Tablets containing 2.6 mg 
nitroglycerin  
Sustac forte Orally 1 tablet once a day Tablets containing 6.4 mg 
nitroglycerin 
Validolum Sublingually 0.05–0.06 g  
at an attack of angina 
pectoris 
Tablets 0.06 g; 
capsules 0.05 g 
Anaprilinum Orally 0.01–0.04 g 3 times 
a day; 
intravenously slowly 
0.001 g in 10–20 ml  
of 0.9 % NaCl solution  
Tablets 0.01 or 0.04 g; 
 
ampoules 1 or 5 ml  
of 0.1 % solution  
Amiodaronum Orally 0.2 g 1–2 times 
a day; 
intravenously slowly 
0.005 g/kg in 10–20 ml  
of 0.9 % NaCl solution  
1–3 times a day 
Tablets 0.2 g; 
 
ampoules 3 ml  
of 5 % solution 
Verapamilum Orally 0.04–0.08 g 3 times 
a day; 
intravenously slowly 0.005–
0.01 g in 10–20 ml  
of 0.9 % NaCl solution 
Tablets 0.04 or 0.08 g; 
ampoules 2 ml  
of 0.25 % solution  
Amlodipinum Orally 0.005–0.01 g 1 time 
a day 
Tablets 0.005 or 0.01 g  
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Step 1. Tasks for Self -Control  
Drugs to Treat Ischaemic Heart Disease  
(Antianginal Drugs)  
 
1. Therapy with anaprilinum (propranolol) has positively 
affected the course of the disease of a 44-year-old woman with 
angina pectoris. What is the mechanism of antianginal action of this 
drug? 
A. Decrease of the need for oxygen and increase of the coming 
of oxygen into the myocardium. 
B. Decrease of the oxidative exchange in the myocardium due to 
the inhibition of Krebs cycle enzymes. 
C. Decrease of myocardium energy consumption due to the 
decrease of load. 
D. Increase of oxygen coming into the myocardium.  
E. Inhibition of 1-adrenoceptors and decrease of the 
myocardium need for oxygen. 
2. Bronchlospasm was developed in patient with angina pectoris 
after taking of antianginal drug. What drug could provoke this effect? 
A. Nifedipine. 
B. Propranolol.  
C. Sustac forte. 
D. Dipyridamole. 
E. Nitroglycerin. 
3. Anaprilinum (propranolol) therapy caused positive effect in 
the dynamics of the disease of 44-year-old woman suffering from 
stenocardia. What is the main mechanism of this drug effect? 
A. Decrease of oxidative exchange in myocardium due to 
enzyme blockade of Krebs cycle. 
B. Increased oxygen supply to the myocardium. 
C. Decreased power inputs of myocardium due to reduced 
loading. 
D. Decreased need in increasing of oxygen supply to the 
myocardium. 
E. Blockade of -adrenoceptors and decrease of myocardial 
requirements to the oxygen.  
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4. A 48-year-old patient after severe psychoemotional exertion 
suddenly began feeling sharp pain in the heart region, irradiating into 
left arm. Nitroglycerin relieved pain 10 minutes later. What 
pathogenetic mechanism is responsible for the development of pain 
in this case? 
A. Occlusion of coronary vessels. 
B. Compression of coronary vessels. 
C. Dilation of peripheral vessels. 
D. Spasm of coronary vessels.  
E. Increase of myocardial needs in oxygen. 
5. A patient after tooth extraction developed persistent substernal 
pain. Sublingual antianginal substance relieved the pain, but the 
patient complained of headache and dizziness. What medicine did 
the patient use? 
A. Metoprolol. 
B. Validol. 
C. Nytroglycerin.  
D. Verapamil. 
E. Anapriline. 
6. A patient with acute myocardial infarction was given 
intravenously different solutions during 8 hours with medical 
dropper 1 500 ml and intranasall oxygen. He died because  
of pulmonary oedema. What caused pulmonary oedema? 
A. Neurogenic reaction. 
B. Inhalation of the oxygen. 
C. Volume overload of the left ventricular.  
D. Decreased oncotic pressure due to haemodilution. 
E. Allergic reaction. 
7. Therapeutic action of β-adrenergic receptor blockers such as 
anaprilinum (propranolol) in angina pectoris is believed to be 
primarily the result of: 
A. Increased sensitivity to catecholamines. 
B. Dilation of the coronary vasculature. 
C. Reduced production of catecholamines. 
D. Increased peripheral resistance. 
E. Decreased requirement for myocardial oxygen.  
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8. Which of the following drugs is considered to be most 
effective in relieving and preventing ischaemic episodes in patients 
with variant angina? 
A. Isosorbide dinitrate. 
B. Nifedipine.  
C. Sustac-mite. 
D. Propranolol. 
E. Nitroglycerin. 
9. A 69-year-old male with angina develops severe constipation 
following treatment with: 
A. Nitroglycerin. 
B. Captopril. 
C. Propranolol. 
D. Verapamil.  
E. Dobutamine. 
10. Administration of which of the following antianginal agents 
results in antianginal effects for only 10 hours, despite detectable 
therapeutic plasma levels for 24 hours? 
A. Transdermal nitroglycerin.  
B. Atenolol. 
C. Amlodipine.  
D. Validolum. 
E. Verapamil. 
11. A 70-year-old female is used nitroglycerin for for sublingual 
intake to interrupt angina pectoris attacks. Point out process which is 
involved in the mechanism of nitroglycerin action. 
A. Excitation of β-adrenergic receptors. 
B. Inhibition of phosphodiesterase. 
C. Excitation of α-adrenergic receptors. 
D. Inhibition of norepinephrine release. 
E. Increase of cGMP concentration.  
12. Which of the following is unlikely to occur with low 
concentrations of nitroglycerin? 
A. Increased coronary blood flow. 
B. Decreased end-diastolic blood pressure. 
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C. Decreased myocardial oxygen demand. 
D. Decreased preload and afterload. 
E. Decreased heart rate. 
13. A 61-year-old female has intermittent bouts of chest pain on 
exertion of two months’ duration, associated with numbness and 
tingling in the fourth and fifth fingers of her left hand. ECG is 
normal. She is placed on anaprilinum (propranolol), which relieves 
her symptoms. What cardiovascular effect has this drug? 
A. It increases sensitivity to catecholamines. 
B. It dilates the coronary vasculature. 
C. It decreases production of catecholamines. 
D. It decreases the requirement for myocardial oxygen.  
E. It increases peripheral vascular resistance. 
14. A patient comes to your office with effort-induced angina 
and resting tachycardia. You choose the following drug to treat the 
patient because it slows heart rate by blocking L-type calcium 
channels in SA node. 
A. Metoprolol. 
B. Verapamil. 
C. Nitroglycerin. 
D. Isosorbide dinitrate. 
E. Propranolol. 
15. Which of the following haemodynamic effects of 
nitroglycerin are primarily responsible for the beneficial results 
observed in patients with angina? 
A. Increased blood flow to the subepicardial layer. 
B. Reduction in systemic vascular resistance (afterload). 
C. Reduction in preload.  
D. Reduction in the force of myocardial contraction. 
E. Increased heart rate. 
16. A combination of drugs, consisting of nitroglycerin patch 
and β-blocker, such as propranolol, is prescribed to woman to treat 
her attacks of angina. Which effect of propranolol would counteract 
adverse effect of nitroglycerin? 
A. Reduction in coronary vasospasm. 
B. Decrease in afterload. 
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C. Decrease in preload. 
D. Increase in myocardial contractile force. 
E. Decrease in heart rate.  
17. Metoprolol would produce the following beneficial effect in 
a patient with angina: 
A. Increase in diastolic filling time.  
B. Increase in collateral blood flow. 
C. Increase in afterload. 
D. Decrease in preload. 
E. Increase in blood flow through concentric stenosis. 
18. A doctor recommended to patient, who had an acute 
myocardial infarction, to take acidum acetylsalicylicum in the dose 
0.25 g once per 2–3 days during 3–4 months. What effect did the 
doctor count on?  
A. Antiaggregant. 
B. Anti-inflammatory. 
C. Antipyretic. 
D. Analgesic. 
E. Vasodilative. 
19. A patient with ischaemic heart disease has not informed the 
doctor that he had attacks of bronchospasm. The doctor prescribed a 
drug, which has made the attacks of angina pectoris less frequent, but 
the attacks of bronchospasm have become more frequent. What drug 
has been prescribed? 
A. Nitrosorbidum (isosorbide dinitrate). 
B. Atenolol. 
C. Propranolol (anaprilinum). 
D. Diltiazem. 
E. Verapamil. 
20. A patient has been suffering from bronchial asthma for a 
long time. Recently he had attacks of angina pectoris. What drug is 
contraindicated to him? 
A. Dipyridamole. 
B. Nitroglycerin. 
C. Sustac forte. 
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D. Propranolol. 
E. Nifedipine. 
21. A 53-year-old woman suffers from attacks of angina 
pectoris. The patient suffers from severe chest pain, arrhythmia, and 
short breath. What drug is the most expedient for prescription in this 
case to provide first aid? 
A. Amiodarone. 
B. Nitrosorbidum. 
C. Nitroglycerin.  
D. Sustac forte. 
E. Propranolol. 
22. A doctor has prescribed hypolipidemic drug to patient with 
ischaemic heart disease. It is known, that this drug predominantly 
decreases the level of triglycerides in the blood. What drug was 
prescribed to the patient? 
A. Nicotinic acid. 
B. Fenofibrate. 
C. Glybenclamide. 
D. Insulin. 
E. Prednisolone. 
23. A patient with acute stenocardia attack is delivered to 
hospital. What drug should be administered to patient for interruption 
of angina pectoris attack? 
A. Calcium chloride. 
B. Vicasolum. 
C. Heparin. 
D. Nitroglycerin. 
E. Furosemide. 
24. A doctor has diagnosed acute attack of stenocardia which is 
accompanied by tachyarrhythmia and hypertension in 60-year-old 
patient. It is known, that this patient also suffers from diabetes 
mellitus and bronchial asthma. The doctor administered 
intravenously some antiadrenergic drug to patient. Identify this drug. 
A. Octadinum. 
B. Anaprilinum. 
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C. Phentolamine. 
D. Reserpine. 
E. Metoprolol. 
25. A patient suffering from bronchial asthma began to feel chest 
pain. Indicate the antianginal drug which is contraindicated to this 
patient.  
A. Isoptin (verapamil).  
B. Corinfar (nifedipine). 
C. Nitrosorbide. 
D. Anaprilinum. 
E. Sustac forte. 
26. A patient suffering from coronary artery disease had taken a 
certain drug many times a day in order to arrest stenocardia attacks. 
Overdose of this drug finally caused intoxication. Objectively: 
cyanotic skin and mucous membranes, dramatic fall in the arterial 
pressure, tachycardia, and respiration inhibition. Blood has increased 
concentration of methemoglobin. The drug that was taken by patient 
relates to the following group: 
A. α-Adrenoceptor blockers. 
B. Organic nitrates. 
C. Myotropic spasmolytics. 
D. Adenosine drugs. 
E. Calcium channel blockers. 
 
 
ANTIARRHYTHMIC DRUGS 
 
Cardiac arrhythmias are disorders of frequency, rhythmicity, or 
sequence of excitation and contraction of heart’s compartments. 
Depending on localization of pathological focus, arrhythmias are 
divided into supraventricular, atrioventricular, and ventricular ones. 
There are tachyarrhythmias (extrasystoles, paroxysmal tachycardia, 
flutter and fibrillation of atriums or ventricules) and 
bradyarrhythmias (different types of blockades, sick sinus 
syndrome). Ventricular arrhythmias are most dangerous and require 
urgent care.  
112 
 
Direct reasons of rhythm disorders are quite varied. But, 
obviously, local disorders of electrolyte balance are most common 
causes of arrhythmias. Deficite of K+ and Mg2+ or excessive 
concentration of Na+ and Ca2+ develop in myocardium due to 
hypoxia, inflammation, toxic or autoimmune lessions, increased 
sympathetic tone, excessive concentration of thyroid hormones, etc. 
Graphically, process of formation of action potential is as 
follows.  
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Figure 1 – Action potential of cardiac histiocytes and sinus node: 
 
4 – phase of spontaneous (slow) diastolic depolarization; 
0 – phase of rapid depolarization;  
1 – phase of initial (early) repolarization;  
2 – plateau; 
3 – rapid repolarization; 
RP – resting potential; 
ERP – effective refractory period 
 
This action potential is the result of activation and inactivation 
of multiple ion channels, which allows the flow of charged ions 
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across the membrane. The ions flow through open channels 
according to the electrochemical driving forces at any given moment.  
Physiological pacemaker is sinus node located in the wall of 
right atrium. From it, impulses carried out to atrioventricular node, 
then – bundle of His and its left and right branches, and then – 
Purkinje fibers. The mentioned structures form cardiac conductive 
system, through which impulses come to muscular fibeds of 
ventricles. 
Cells of sinus node are able to spontaneous slow depolarization 
(phenomenon of automatism) during diastole (phase 4). At normal 
physiological state, automatism of other parts of conduction system 
is inhibited by sinus node and is less expressive. In sinus node, phase 
4 is associated with penetration of Ca2+ (and insignificant amount of 
Na+) through slow Ca2+ channels in pacemaker cells during diastole. 
When critical level of membrane potential is achived, fast ionic 
channels opened and permeability of cellular membrane for Na+ and 
Ca2+ is sharply increased. Excitation wave spreads to adjacent 
membrane sections. It is phase of rapid depolarization (phase 0). 
After phase 0, repolarization begins. Early repolarization (phase 1) is 
due to transient outward current of K+ ions. During plateau (phase 2), 
ions of Ca2+ and Na+ enter the cell, but, simultaneously, K+ ions 
come out of the cell. Phase 3 (rapid repolarization) is result of 
Na+, K+-ATPase activity which restores initial ratio of ions’ 
concentration inside and outside of the cell (pumps Na+ out of the 
cell and K+ - into the cell). Alongside, calcium ATPase pumps 
excessive Ca2+ ions out of the cell. 
During phases 0, 1, and 2, cardiac cells are transiently 
unresponsive to any activation stimuli. This time is called absolute 
refractory period. Only at the end of phase 3, stimule of increased 
force can cause cellular excitation. Time from the start of action 
potential to moment, when new cellular excitation become possible, 
is called effective refractory period. Refractoriness is protective 
mechanism from excessively-fast repeated excitation which can 
affect cardiac contractile function. 
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Speed of diastolic depolarization of cardiac histiocytes and 
conduction system depends on activity of vegetative nervous system. 
Activation of sympathetic nervous system and stimulation of 
adrenergic receptors increase cellular membrane permeability for 
calcium and sodium ions that accelerates spontaneous diastolic 
depolarization. Increased parasympathetic tone, activation  
of M-cholinergic and purinergic receptors is accompanied by outflow 
of potassium ions and membrane hyperpolarization that deccelerates 
spontaneous diastolic depolarization and decreases heart rate.   
Antiarrhythmic drugs are classified as follows:     
1) drugs which are used to treat tachyarrhythmias:  
a) membrane stabilizing drugs (sodium channel blockers,  
or class I according to classification of Vaughan–Williams – one of 
the most widely used classification scheme of antiarrhythmic drugs): 
– subgroup IA: quinidine sulfate, novocainamidum 
(procainamide), disopyramide, and ajmaline;  
– subgroup IB: lidocaine, trimecaine,  and dipheninum 
(phenytoin);  
– subgroup IC: flecainide, propafenone, aetmozinum 
(moracizine), and ethacizine.  
b) β-adrenoceptor antagonists (class II): anaprilinum 
(propranolol) , pindolol, talinolol , metoprolol ,  atenolol.  
c) drugs increasing the duration of action potential (class III): 
amiodarone, ornidum (bretylium),  and sotalol .  
d) calcium channel blockers (class IV): verapamil  and 
diltiazem .  
e) drugs which selectively inhibit Na+ and K+ iflux in sinus node 
cells (bradycardiac drugs): falipamil , alinidine , and ivabradine .   
f) miscellaneous antiarrhythmic agents: 
– potassium- and magnesium-containing drugs: potassium 
chloride,  Asparcamum, Panangin;  
– adenosine;  
– cardiac glycosides: digoxin .  
2) drugs which are used to treat bradyarrhythmias:  
a) adrenergic agonists: epinephrine (adrenaline),  
isadrinum (isoprenaline),  and ephedrine . 
b) M-cholinoceptor antagonists: atropine,  etc. 
c) hormonal drugs: glucagon .  
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Drugs Used to Treat Tachyarrhythmias  
 
Membrane Stabilizing Drugs  
(Blockers of Sodium Channels , Class I)  
 
Drugs of Class IA  
Membrane stabilizing drugs reduce permeability of cellular 
membrane for sodium ions through “slow” sodium channels of 
ectopic focuses of automatism, therefore these drugs inhibit speed of 
spontaneous depolarization of sodium type (phase 4). Besides, these 
drugs inhibit sodium permeation through “fast” channels (phase 0) 
and outward potassium current during repolarization (phase 2) that 
leads to prolongation of effective refractory period. Due to this, 
duration of refractory period in ectopic focus are aligned with those 
in unchanged myocardial regions. Quinidine-like drugs prolong the 
duration of P–Q interval, QRS complex, and QT interval of ECG. 
Membrane stabilizing drugs inhibit contractile function of left 
ventricle and decrease blood pressure. Against the background of 
administered quinidine and disopyramide, heart rate is accelerated 
due to blockage of M-cholinergic receptors. Mentioned drugs 
promote atrioventricular conduction.   
Quinidine is alkaloid of Cinchona bark. Initially, it was used as 
antimalarial agent. The drug is taken mainly orally, sometimes – 
administered intravenously. The last route of administration is used 
seldom owing to danger of significant hypotension and development 
of heart failure. At oral intake, quinidine’s bioavailability is  
44–89 %, that is determined by different velocity of its 
biotransformation at first passage through the liver. The degree of 
binding with plasma proteins is about 70–80 %. At oral intake, onset 
of the drug action is 1–2 hours, duration – 8 hours. Quinidine is taken 
3–5 times a day. The main route of drug excretion is kidneys. 
Quinidine is used to treat supraventricular and ventricular 
tachyarrhythmias. The drug exhibits maximum efficacy at 
supraventricular arrhythmias, especially paroxysmal atrial 
tachycardia and auricular flutter and fibrillation. Side effects of 
quinidine are dyspepsia, exacerbation of heart failure, hypotension, 
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visual disorders, headache, tinnitus, thrombocytopenia, diminished 
hearing, hepatotoxicity, photosensitization, and lupus-like syndrome.               
Novocainamidum (procainamide)  is a derivative of the 
local anaesthetic agent novocainum (procaine). The drug is 
administered parenterally (intramuscularly or intravenously) and 
taken orally. Procainamide is readily absorbed from gastrointestinal 
tract. Its bioavailability is about 85 %. A degree of binding with 
plasma proteins is 15–20 %. About 70 % administered dose is 
metabolized in the liver. Unchanged procainamide and its acetylated 
metabolites are excreted mainly by kidneys. The drug is taken  
4–6 times a day. Procainamide inhibit myocardial contractility in less 
degree than quinidine. The drug is most effective at ventricular 
tachyarrhythmias (extrasystoles, paroxysmal ventricular 
tachycardia). Procainamide is not used to treat chronic forms of 
arrhythmias. Its side effects are dyspepsia, hypotension, (less than at 
quinidine’s use), systemic lupus erythematosus, agranulocytosis, 
myalgia, arthralgia, etc. Fast intravenous administration can provoke 
collapse and convulsions.       
Disopyramide  (Rytmilen)  is taken orally or administered 
parenterally (intramuscularly and intravenously). The drug is readily 
absorbed from gastrointestinal tract. Its bioavailability is 70–85 %; 
the degree of binding with plasma proteins is 20–30 %. 
Disopyramide acts 4–5 hours, therefore the drug is taken 3–4 times  
a day. About 50 % administered dose undergoes hepatic 
biotransformation. The drug and its metabolites are excreted by 
kidneys. Disopyramide is used to treat ventricular extrasystoles, 
paroxysmal supraventricular and ventricular tachycardia; to prevent 
arrhythmias during surgical operations on the heart and large vessels. 
Side effects of disopyramide are mainly due to its M-cholinoblocking 
activity: dry mouth, accommodation disorders, increased intraocular 
pressure, tachycardia, and dyspepsia. Sometimes, the drug can cause 
agranulocytosis and photosensitization. Disopyramide significantly 
suppressed cardiac contractility. 
Ajmaline (Arytmal)  is alkaloid of Rauvolfia serpentina. The 
drug is administered parenterally and taken orally. Ajmaline is badly 
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absorbed from gastrointestinal tract; its binding with plasma proteins 
is insignificant. The drug is almost completely metabolized in the 
liver; its metabolites are excreted by kidneys. Ajmaline is prescribed 
3–6 times a day. The drug is used to treat ventricular 
tachyarrhythmias only. The following side effects are observed at the 
drug intake: dyspepsia, hypotension, asystolia, cirrhosis-like changes 
of liver, cholestasis, and disorders of cardiac conduction.      
 
Drugs of Class IB 
Members of class IB block Na+ channels (mainly in phase 4) and 
increase membrane permeability for K+ ions facilitating their ouflax 
from the cells. These drugs influence Purkinje fibers and cardiac 
histiocytes in ventricles. The drugs of IB class shorten phase 2  
of membrane repolarization. These agents decrease the duration  
of effective refractory period and action potencial. An increase of 
duration of P–Q interval and QRS complex is observed on ECG. 
Drugs of IB class decrease duration of QT interval. These drugs do 
not affect practically left ventricle contractility and blood pressure.   
Lidocaine is administered intramuscularly, intravenously  
drop-by-drop, or taken orally. But its gastrointestinal bioavailability 
is less than 30 % due to significant biotransformation at first passage 
through the liver. About 10–40 % administered dose of lidocaine 
binds with plasma proteins and acid glycoproteins. Long-time 
infusion of lidocaine is often accompanied by complications, because 
toxic metabolites are synthesized due to its biotransformation. 
Lidocaine is drug of choice to treat and to prevent ventricular 
arrhythmias at myocardial infarction, in postoperative period, at 
implantation of electric cardiac pacemaker, and glycoside 
intoxication. As a rule, the drug is well tolerated by patients. Side 
effects of lidocaine are hypotension, drowsiness, vertigo, weakness, 
nervousness, numbness of tongue and lips. Chemical structure and 
pharmacological properties of trimecaine  are similar to lidocaine.   
Dipheninum (phenytoin) is taken orally and, sometimes, 
administered intravenously. Its gastrointestinal absorption is slow, 
but bioavailability is high – 98 %. About 87–93 % administered dose 
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binds with plasma proteins. The drug is metabolized in the liver 
practicly completely (about 90 % administered dose). Metabolites are 
excreted mainly by kidneys and partly – by liver. Dipheninum is 
effective only at ventricular arrhythmias (especially due to 
glycosides overdose). The drug is able to improve atrioventricular 
conduction. Dipheninum exhibits antiarrhythmic action against the 
background of hypokalemia and does not suppress cardiac contractile 
function. Its side effects include neurological disorders (ataxia, 
disartria, increased nervousness or lethargy), fever, and difficulty in 
breathing. Large doses of dipheninum can provoke bradycardia, 
hypotension, and gum hypertrophy.  
 
Drugs of class IC 
Mechanism of action of IC class drugs is similar to those of of 
class IA. These drugs influence all compartments of the heart 
decreasing membrane permeability for Na+ ions and slowing down 
diastolic depolarization (phase 4). It should be noticed that these 
drugs do not influence membrane permeability for K+ ions (phase 2). 
On ECG, drugs of IC class prolong duration of P–Q interval and 
QRS complex. Duration of QT interval is not changed. These drugs 
decrease myocardial contractile function and blood pressure.  
Aetmozinum (moracizine) is taken orally and administered 
intravenously drop-by-drop. Its gastrointestinal bioavailability is 
about 38 %. Less than 10 % administered dose binds with plasma 
proteins. The drug effect develops is 10–20 min. after intravenous 
administration and in 2–3 days in case of oral intake. Aetmozinum is 
practicly completely metabolized in liver; its metabolites are 
excreted by kidneys. Aetmozinum is used to treat severe ventricular 
tachyarrhythmias arising against background of angina pectoris. 
Also, the drug is used in the treatment for atrial fibrillation and atrial 
flutter. Typical side effects of aetmozinum is associated with its 
ability to block M-cholinergic receptors and include dry mouth, 
tachycardia, and difficulty urinating. Besides, the drug can cause 
dizziness, stomach pain, skin itch, and numbness of tongue.  
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Ethacizine  is administered intravenously and taken orally. The 
drug is readily absorbed from gastrointestinal tract, but its 
bioavailability is only about 40 % because significant amound of the 
drug is inactivated at first passage through the liver. Little amount of 
administered dose is bonds with plasma proteins. At intravenous 
administration, the drug effect develops in 10–15 min., at oral intake 
– in 1–2 days. Inactive metabolites of ethacizine are excreted by 
kidneys. The drug is used to treat ventricular and supraventricular 
tachyarrhythmias. Its side effects are nausea, numbness of tongue, 
dizziness, disorders of accommodation. Intravenous drug 
administration can cause tinnitus, numbness of different body parts, 
and mesh before eyes. It should be noticed that ethacizine exerts  
M-choliblocking activity and increases heart rate.      
Besides mentioned above antiarrhythmic mechanism, 
propafenone  exhibits weak β-adrenoblocking activity and inhibits 
calcium channels. Unlike ethacizine, propafenone slows down heart 
rate. The drug is administered intravenously or taken orally. At oral 
intake, tablet cannot be chewed because the medicinal remedy causes 
superficial anaesthesia and has marked bitter taste. The drug 
bioavailability is 50 %. At oral intake, effect develops in 1 hour and 
lasts 6–7 hours. Propafenone degree of binding with plasma proteins 
is about 95 %. The drug is excreted brom the body by the kidneys 
and liver. The drug is taken 4 times a day to treat ventricular and 
supraventricular tachyarrhythmias against myocardiodystrophy, 
valvular heart disease, etc. Side effects of propafenone include 
decreased contractile myocardial function, atrioventricular blockage, 
sinus dysfunction, and dyspepsia.     
 
 -Adrenoceptor Antagonists  
 
Group of β-adrenoceptor antagonists is represented by such 
drugs as anaprilinum (propranolol ), oxprenolol, pindolol,  
metoprolol, talinolol , atenolol, etc. Their mechanism of action 
is associated with blockage of cardiac β1-adrenoceptors that 
eliminates arrhythmogenic influence of of catecholamines. Besides, 
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some drugs (e. g., propranolol) influence calcium and sodium inward 
current in phases 4 and 0 (quinidine-like membrane stabilizing 
effect). But, this effect is appreciable only if drugs are administered 
in large doses and has secondary importance in diapason of usual 
therapeutic doses. β-Adrenoblockers decreased oxygen myocardial 
demand and, therefore, eliminate hypoxia and associated with it 
metabolic and electrolyte disorders and dysfunction of cellular 
membranes. These drugs somewhat accelerate exit of K+ ions and 
shorten phase 2 decreasing effective refractory period. Owing to the 
decrease of catecholamines influence upon diastolic depolarization, 
β-adrenergic antagonists inhibit sinus node automatism and activity 
of ectopic pacemakers. β-Adrenoblockers slow down conduction 
through atrioventricular node. Prolongation of P–Q interval is 
observed on ECG. Sedative influence of these drugs upon central 
nervous system is also important. 
β-Adrenergic antagonists are used to treat supraventricular and 
ventricular tachyarrhythmias which caused by high sympathoadrenal 
tone (neurogenic or hormonal disorders of rhythm, initial period of 
myocardial infarction, etc.). Intravenously administered propranolol 
is rescue medication at paroxysmal rhythm disorders. 
Inhibition of contractile myocardial function (up to heart failure) 
is one of the most serious side effects of β-adrenoblockers. 
Therefore, administration of β-adrenergic antagonists is dangerous in 
acute period of myocardial infarction with symptoms of heart failure. 
Besides, these drugs can cause atrioventricular blockage. Due to 
blocking of β2-adrenoceptors, nonselective β-adrenergic antagonists 
(propranolol, oxprenolol, nadolol, etc.) can provoke bronchospasm, 
disorders of blood circulation in extremities, headache, etc. As a rule, 
selective β1-adrenoblockers (metoprolol, talinolol, atenolol, etc.) do 
not cause such side effects.           
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Drugs Slowing Down Repolarization  
 
Amiodarone (Cordarone)  is most interest drug of this group. 
The drug exhibits broad spectrum of antiarrhythmic activity. 
Amiodarone blocks K+ channels and slows down repolarization in 
phase 3, prolongs action potential, and significantly increases 
duration of effective refractory period. Besides, amiodarone exerts 
moderate blocking activity concerning Na+ channels, α- and  
β-adrenergic receptors. Also, the drug weak inhibitor of Ca2+ 
channels. By means of blockage of glucagon receptors, amiodarone 
eliminates its stimulating influence upon the heart. Duration of QT 
and P–Q intervals is increased.    
Amiodarone is taken orally or administered intravenously. The 
drug is poorly absorbed from gastrointestinal tract and undergoes 
biotransformation in the liver and in intestinal wall. Its 
gastrointestinal bioavailability is 20 %. The degree of binding with 
plasma proteins is more than 90 %. Amiodarone and its metabolites 
are excreted by liver. The drug is prescribed one time a day. At oral 
intake, amiodarone effect develops is 1–2 weeks and lasts  
15–20 days after phasing out of the drug.  
Amiodarone is used to treat supraventricular and ventricular 
tachyarrhythmias and effort angina. 
Long-time amiodarone therapy leads to sedimentation of yellow 
brown micro-crystals in the cornea which disappeared after cessation 
of the drug intake. Other side effects of amiodarone include 
dyspepsia, headache, athaxia, paresthesia, thyroid dysfunction 
(molecules of amiodarone contain iodine), diffuse interstitial 
pneumonia, pulmonary fibrosis, gray-blue skin coloration, and 
hepatocellular necrosis.    
Bretylium (ornidum)  slows the inward current of Ca2+ in 
phase 2 of action potential. Besides, the drug exerts sympatholytic 
properties by reducing of catecholamine release from presynaptic 
nervous endings. Bretylium is administered intramuscularly and 
intravenously. The drug is not absorbed from gastrointestinal tract. 
At intramuscular administration, antiarrhythmic effect develops  
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in 30 minutes and lasts 12 hours. Bretylium is excreted by kidneys in 
unchanged form. 
Bretylium is used in the treatment for ventricular 
tachyarrhythmias, especially during acute period of myocardial 
infarction and in cases refractory to lidocaine. Its side effects include 
hypotension, hot feeling, nausea, oedema of nasal mucosa, temporary 
visual disorders, etc. Sometimes, necrosis develops in the site of 
intramuscular injection.        
Medical drug sotalol  consists of l- and d-isomers. l-Sotalol is 
nonselective blocker of β-adrenergic receptors; d-sotalol inhibits 
potassium channels. Due to this mechanism, sotalol prolongs 
repolarization. Also, sotalol inhibits sinus automatism, slows dows 
conduction, and causes bradycardia. The drug is easily absorbed 
from gastrointestinal tract. Its bioavailability is 90–100 %. The main 
route of its excretion is kidneys. Sotalol is used to treat ventricular 
and supraventricular tachyarrhythmias. The drug is taken 2 times  
a day. Its side effects are bradycardia, decrease of contractile 
myocardial function, fatigue, etc.  
Nowadays, number of new drugs, inhibiting potassium, channels 
and prolonging effective refractory period, are used in medicine. 
Dofetilide  (Tikosyn)  is one of them. The drug inhibits potassium 
channels and prolongs repolarization. Also, dofetilide causes mild 
bradycardia. The drug is easily absorbed from gastrointestinal tract; 
its bioavailability is about 90 %. Dofetilide is partly heptic 
metabolized by liver and excreted by kidneys. The drug is used to 
treat supraventricular tachyarrhythmias. It should be noticed that 
dofetilide exerts proarrhythmogenic action and can cause ventricular 
tachyarrhythmias and conduction disorders. Besides, the drug can 
cause such side effects as chest pain and dizziness.       
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Calcium Channel Blockers (Class IV) 
 
Verapamil  and diltiazem  block slow calcium channels  
of L-type. These drugs affect inward calcium current and slow down 
Ca2+-dependent depolarization (phase 4, and partly – phase 0) in 
sinoatrial and atrioventricular nodes. Thus, the drugs inhibit 
automatism and slow down atrioventricular conduction. Practically, 
calcium channel blockers do not influence Purkinje fibers. Duration 
of P–Q interval is increased. Calcium antagonists reduce contractile 
myocardial function, heart rate, and blood pressure. 
Verapamil is most commonly used calcium channel blocker to 
treat arrhythmias. The drug is administered intravenously or taken 
orally. Oral bioavailability of verapamil is about 20 %. Its degree of 
binding with plasma proteins is 90 %. Verapamil and its metabolites 
are excreted with urine (about 80 %) and bile. The drug is taken  
3–4 times a day. Verapamil is used to treat supraventricular 
tachyarrhythmias (paroxysmal tachycardial and atrial fibrillation) 
and angina pectoris. Its side effects are hypotension, exacerbation of 
heart failure, atrioventricular blockage, dyspepsia, constipation, 
headache, fatigue, and swelling in the legs.  
Diltiazem exerts less expressive antiarrhythmic activity. At oral 
intake, its effect develops in 30 minutes and lasts 6 hours. Diltiazem 
is metabolized by liver and excreted by intestine. Its side effects are 
identical to those of verapamil.           
 
Miscellaneous Antiarrhythmic Agents  
 
This group includes potassium chloride,  Asparcamum, 
Panangin , adenosine, and digitalis glycosides.  
Adenosine  is nucleotide synthesized due to degradation of 
ATP. Adenosine acts as mediator of purinergic synapses and as local 
hormone. Adenosine interacts with adenosinergic receptors of A1–A4 
types which, through G-proteins, stimulate or inhibit adenylyl 
cyclase. The drug slows down atrioventricular conduction and 
inhibits contractile myocardial function (influence upon  
A1-receptors), dilates coronary vessels and decreases platelets 
aggregation (influence upon A2-receptors). Besides, adenosine 
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increases bronchial tone (through A1-receptors), stimulates the 
release of biologically active substances from basophils (interaction 
with A3-receptors), and inhibits central nervous system.  
Adenosine is administered intravenously. Its duration of action is 
about 30 seconds. The drug is used to terminate supraventricular 
tachyarrhythmias. Wherein, its effect is associated with inhibition of 
atrioventricular conduction. Side effects of adenosine are breathing 
disorders, short-time atrioventricular blockage, face redness, etc. it 
should be noticed that antagonists of adenosine are methylxantines 
(caffeine, theophylline).   
Potassium-containing drugs (potassium chloride,  
Asparcamum, Panangin, polarizing mixture ) are used at 
arrhythmias accompanied by reduction of potassium concentration in 
plasma and in myocardium: glycoside intoxication, atrial fibrillation, 
ventricular extrasystolia, myocardial infarction, etc.). Potassium ions 
influence myocardium like acetylcholine: decrease heart rate, inhibit 
conduction, automatism, and excitability. Low concentrations of K+ 
ions dilate coronary vessels, but high concentrations cause coronary 
vasoconstriction. Potassium drugs are taken orally and administered 
intravenously. Overdose of potassium leads to paresthesies, 
dyspepsia, atrioventricular blockage, and renal dysfunction. 
Magnesium drugs (magnesium sulfate,  magnesium 
orotate, magnesium aspartate ) also exert antiarrhythmic 
activity. These drugs are aspecially effective at hypomagnesaemia. 
Magnesium drugs are used in the treatment for ventricular 
tachycardia and fibrillation.  
Digoxin  is cardiac glycoside which used to treat 
supraventricular tachyarrhythmias. The drug activity is associated 
with the increase of vagal tone that leads to slowing of conduction 
through atrioventricular node. Therefore, conduction of extremely 
frequance impulci to ventricles is worcened.     
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Drugs Used to Treat Bradyarrhythmias 
 
Atrioventricular and sinoatrial blockages, atrial asystole, and 
blockage of conduction through bundle of His results in 
bradyarrhythmias. This pathology can develop at myocardial 
infarction, acute inflammation and dystrophia of myocardium, 
intoxications by cardiac glycosides, cholinomimetics, potassium 
salts, etc. Extreme case of bradyarrhythmia is attack of temporary 
asystole with loss of consciousness up to 5 seconds or more  
(Stokes–Adams attacks).  
 
M-cholinergic Antagonists  
 
M-cholinergic antagonist atropine  improves automatism and 
conduction by means of the decrease of inhibitory vagal influence 
upon the heart. The drug is administered parenterally and taken 
orally. Atropine is easily absorbed from gastrointestinal tract. Its 
degree of binding with plasma proteins is about 50 %. Atropine is 
used to treat sinus bradycardia, sinoatrial and atrioventricular 
blockages, intoxications by cardiac glycosides. Its side effects are 
dryness of mucous membranes, constipation, tachycardia, increased 
intraocular pressure, disorders of accommodation, decrease of 
bladder tone, disorders of hit emission, etc.     
 
Adrenomimetics  
 
Epinephrine (adrenaline), isoprenaline (isadrinum),  
and ephedrine  excite cardiac β1-adrenoceptors that increases of 
automatism and facilitates conduction. Generally, these drugs are 
more effective than M-cholinoblockers. Isoprenaline is taken 
sublingually 4–6 times a day. Ephedrine is usually taken orally. At 
severe cases of bradyarrhythmias, isoprenaline or adrenaline are 
administered intravenously. It should be noticed that epinephrine is 
used only in crucial cases to treat bradyarrhythmias, because the drug 
significantly increases oxygen demand of the heart.     
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Glucagon 
 
Glucagon  stimulates glucagone receptors in myocardium and 
conductive system of the heart that increases calcium release from 
intracellular depot with the following increase of sinus node 
automatism, facilitation of conduction through atrioventricular node, 
and increase of myocardial contractile function. The drug is 
administered intravenously, sometimes – intramuscularly or 
subcutaneously. At intravenous administration, its effect develops in 
1–4 minutes and lasts 20–30 minites.  
Glucagon is used in the treatment for congestive heart failure 
with severe bradycardia, heart failure at full atrioventricular blockage 
and ventricular fibrillation, acute heart failure, cardiogenic shock, 
severe hypoglycemia, and poisoning by β-adrenergic antagonists, 
calcium antagonists, and cardiac glucosides. Therapy by glucagon 
may be accompanied by dyspepsia, worsening of coronary 
circulation, hypertensive crises, allergic reactions, decreased tone of 
esophageal sphincter, etc.  
Severe and long-lasting bradysystole requires emergency care 
with the use of artificial pacemaker.     
 
Table 5 – Drugs for prescription 
 
 
Drug name 
(Latin) 
Single dose and mode  
of administration 
Drug product 
Chinidini sulfas Orally 0.1–0.3 g 2–3 times 
a day 
Tablets 0.1 or 0.2 g 
 
Novocainamidum Orally, intramuscularly,  
or intravenously 0.25–0.5 g 
1–3 times a day 
Tablets 0.25 or 0.5 g; 
ampoules 5 ml  
of 10 % solution 
Kalii chloridum Intravenously drop-by-drop 
2 g in 450 ml of water for 
injection  
Ampoules 50 ml  
of 4 % solution 
“Asparcamum”  
or “Pananginum” 
Orally 1–2 tablets 3 times 
a day 
Tablets containing 
magnesium asparaginate 
and potassium asparaginate 
Dipheninum Orally 0.117 g 1–3 times 
a day 
Tablets 0.117 g 
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Continuation of the table 5 
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product 
Lidocainum  Intramuscularly 0.2–0.4 g; 
intravenously drop-by-drop 
0.05–0.1 g, in the following – 
drop-by-drop 2 mg/min. 
Ampoules 2 ml  
of 10 % solution  
and 2 or 10 ml  
of 2 % solution 
Anaprilinum Orally 0.01–0.04 g 3 times 
a day; 
intravenously slowly 0.001 g 
in 10–20 ml of 0.9 % solution 
of NaCl once a day 
Tablets 0.01 or 0.04 g; 
 
ampoules 1 or 5 ml  
of 0.1 % solution  
Amiodaronum Orally 0.2 g 1–2 times a day; 
intravenously         slowly  
0.005 g/kg in 10–20 ml  
of 0.9 % NaCl solution 
1 time a day 
Tablets 0.2 g; 
 
ampoules 3 ml  
of 5 % solution 
Verapamilum Orally 0.04–0.08 g 3 times 
a day; 
intravenously slowly 0.005–
0.01 g in 10–20 ml  
of 0.9 % NaCl solution 
Tablets 0.04 or 0.08 g; 
 
ampoules 2 ml  
of 0.25 % solution 
 
 
Step 1.  Tasks for Self-Control  
Antiarrhythmic Drugs  
 
1. Ventricular arrhythmia followed myocardial infarction  
of a patient. Cardiac rhythm was normalized by the introduction of 
antiarrhythmic drug with local anesthesia effect. What drug was 
introduced? 
A. Propranolol. 
B. Lidocaine.  
C. Verapamil. 
D. Panangin. 
E. Anaesthesinum. 
2. A 45-year-old patient has diagnosis of ciliary arrhythmia and 
essential hypertension. What drug is it necessary to prescribe to this 
patient for prevention of arrhythmia attacks? 
A. Lidocaine. 
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B. Sustac-forte. 
C. Potassium chloride. 
D. Propranolol.  
E. Strophanthin. 
3. A 55-year-old patient with continuing ventricular arrhythmias 
was admitted to the hospital. The patient is taking timolol drops for 
glaucoma, daily insulin injections for diabetes mellitus, and 
angiotensin converting enzyme inhibitor for hypertension. You 
decide to use phenytoin instead of procainamide. What is the reason? 
A. Cholinergic effect of procainamide would aggravate diabetes. 
B. Local anaesthetic effect of procainamide would aggravate the 
hypertension. 
C. Local anaesthetic effect of procainamide would potentiate 
diabetes. 
D. Hypertensive effect of procainamide would aggravate 
hypertension. 
E. Anticholinergic effect of procainamide would aggravate 
glaucoma.  
4. In patient with attacks of paroxysmal atrial tachycardia, 
an ideal prophylactic drug is: 
A. Verapamil.  
B. Procainamide. 
C. Lidocaine. 
D. Nifedipine. 
E. Adenosine. 
5. Which of the following is an antiarrhythmic agent that has 
relatively few electrophysiologic effects on normal myocardial tissue 
but suppresses the arrhythmogenic tendencies of ischemic 
myocardial tissues? 
A. Disopyramide. 
B. Lidocaine.  
C. Quinidine. 
D. Propranolol. 
E. Procainamide. 
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6. A 59-year-old man with a history of rheumatic heart disease is 
found to have atrial fibrillation, for which he is treated with digoxin. 
Treatment with digoxin converts his atrial fibrillation to a normal 
sinus rhythm. In which of the following decrease does this treatment 
most likely result? 
A. Sinus node automatism.  
B. Speed of the cardiac muscle shortening. 
C. Conduction speed in the atrioventricular node.  
D. Atrial maximum diastolic resting potential. 
E. Duration of the refractory period. 
7. A 62-year-old patient with chronic heart failure and atrial 
tachyarrhythmia takes simultaneously quinidine and digoxin. If these 
drugs are administered concurrently, which of the following 
influence does quinidine have on digoxin? 
A. Ability of digoxin to inhibit the Na+, K+-stimulated ATPase is 
reduced. 
B. Metabolism of digoxin is prevented. 
C. Absorption of digoxin from the gastrointestinal tract is 
decreased. 
D. Effect of digoxin on the atrioventricular node is antagonized. 
E. Concentration of digoxin in the plasma is increased.  
8. Patients with genetically low levels of N-acetyltransferase are 
more prone to develop a lupus erythematosus-like syndrome with 
which of the following drug? 
A. Lidocaine. 
B. Procainamide.  
C. Digoxin. 
D. Captopril. 
E. Propranolol. 
9. The first-line drug for treating an acute attack of reentrant 
supraventricular tachycardia is: 
A. Edrophonium. 
B. Adenosine. 
C. Propranilol. 
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D. Mesatonum. 
E. Digoxin. 
10. A 36-year-old male was admitted to the hospital with 
tachycardia, respiratory rate of 26 breaths per minute, and ECG 
evidence of arrhythmia. Intravenous bolus dose of antiarrhythmic 
agent is administered, and within 30 sec he has a respiratory rate of 
45 breaths per minute and complains of a burning sensation in his 
chest. Select the drug most likely to have caused these adverse 
effects. 
A. Nifedipine. 
B. Digoxin. 
C. Adenosine. 
D. Lidocaine. 
E. Dobutamine. 
11. A 68-year-old female has atrial fibrillation, which is treated 
with antiarrhythmic agent that blocks Na+ channels. On the recent 
office visit, she complained of recurrent attacks of feeling faint and 
of experiencing an episode of loss of consciousness. ECG should 
mark prolongation of the QT interval. Plasma concentration of the 
drug was in the therapeutic range. Select the drug most likely to have 
caused these adverse effects. 
A. Verapamil. 
B. Quinidine. 
C. Bretylium. 
D. Adenosine. 
E. Amiodarone. 
12. A 55-year-old male has recurrent ventricular arrhythmias 
after myocardial infarction, for which he is given an antiarrhythmic 
agent that blocks Na+ channels and prolongs the action potential. One 
year later, a blood test is positive for circulating antinuclear antibo-
dies. Select the drug which most likely to have caused this 
phenomenon.  
A. Verapamil. 
B. Amiodarone. 
C. Adenosine. 
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D. Procainamide.  
E. Sotalol. 
13. 24 hours after an acute myocardial infarction, a 46-year-old 
male is being treated with a continuous intravenous drip of 
antiarrhythmic drug to suppress frequent multifocal premature 
ventricular contractions. He develops generalized seizure activity. 
The seizure activity can be most readily explained by: 
A. Lidocaine toxicity.  
B. Systemic embolization. 
C. Systemic hypotension. 
D. Ventricular tachycardia. 
E. Ventricular asystole. 
14. False statement concerning the use of calcium antagonists as 
antiarrhythmics: 
A. They slow inward calcium current thereby decreasing the rate 
of spontaneous phase 4 depolarization in Purkinje fibers. 
B. They slow conduction speed through the atrioventricular node 
and increases functional refractory period. 
C. They are useful for slowing ventricular rate in atrial 
fibrillation. 
D. Hypotension may be a limiting side effect. 
E. Verapamil, diltiazem, and nifedipine exert equally effective 
antiarrhythmic actions.  
15. Although most antiarrhythmic drugs (and indeed most drugs) 
are chemically synthesized, some compounds that occur 
endogenously in humans are useful. Indicate which of the following 
agents occurs endogenously and is a useful antiarrhythmic agent. 
A. Lidocaine. 
B. Digoxin. 
C. Adenosine. 
D. Quinidine. 
E. Dipheninum (phenytoin). 
16. Which of the following calcium channel blockers would 
most likely suppress atrial tachyarrhythmias involving the AV node? 
A. Diltiazem. 
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B. Nifedipine. 
C. Nicardipine. 
D. Verapamil.  
E. Amlodipine. 
17. Point out the incorrect statements. 
A. Lidocaine is used mainly for atrial arrhythmias.  
B. Lidocaine must be given parenterally. 
C. Procainamide is associated with a reversible lupus 
phenomenon. 
D. Quinidine is active orally. 
E. All antiarrhythmic drugs can suppress cardiac contractions. 
18. Bronchoobstructive syndrome appeared in a patient during 
the treatment of ciliary arrhythmia. What antiarrhythmic drug can 
cause such complication? 
A. Novocainamidum. 
B. Ajmalin. 
C. Nifedipine. 
D. Propranolol.  
E. Verapamil. 
19. A patient with myocardial infarction and cardiac 
insufficiency has ventricular arrhythmia. What antiarrhythmic agent 
is a drug of choice in this case? 
A. Disopyramide. 
B. Quinidine. 
C. Lidocaine. 
D. Novocainamidum. 
E. Verapamil. 
20. A drug was prescribed to a 56-year-old patient who suffers 
from ischaemic heart disease with atrial extrasystoles. It is known, 
that drug blocks K+ channels, decreases the adrenergical influence 
upon the heart, significantly increases the duration of action 
potential, and dilates the coronary vessels. What drug was 
prescribed?  
A. Lisinopril. 
B. Corglycon. 
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C. Nitroglycerin. 
D. Dobutamine. 
E Amiodarone. 
21. In experiment on the heart muscle antiarrhythmic agent 
lowered excitability of cardiomyocytes, not influencing the action 
potential form. Identify this agent.   
A. Amiodarone.   
B. Lidocaine.  
C. Verapamil.   
D. Quinidine.  
E. Novocainamidum.   
 
 
VENOTROPIC DRUGS  
 
Like arteries, veins are mainly innervated by sympathetic 
nervous system. There are α1-, α2- and β2-adrenergic receptors in the 
smooth muscles of veins. Stimulation of α-adrenoceptors leads to 
constriction of veins, whereas activation of β2-adrenoceptors results 
in their relaxation. Unlike regulation of arterial tone, humoral 
regulation of venous tone is significantly less important. Humoral 
regulation is realized by means of such biologically active substances 
as epinephrine, serotonin, histamine, kinins, angiotensin II, 
vasopressin, etc. Their influence may be multidirectional and 
depends on regulator concentration, type and initial tone of vessels, 
and density of corresponding receptors in membranes of smooth 
muscle cells. Specific mechanisms of humoral regulation upon 
venous tone are not understudied. 
According to pharmacological effect, drugs influencing venous 
tone are divided into venodilators and venoconstrictors.  
Venodilators are drugs which reduce venous tone. As a rule, 
these drugs are capable to dilate not only veins but also arteries. But 
influence of these drugs upon resistance and capacitance vessels is 
not identical. The drugs influencing mainly veins or drugs dilating 
veins and arteries in identical degree are used as venodilators. Such 
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drugs decrease cardiac preload and are used to treat ischemic heart 
disease, acute and chronic heart failure.  
Drugs relaxing mainly veins are classified as follows.  
1. Nitrous oxide donators: nitroglycerin,  nitrosorbide 
(isosorbide dinitrate) , isosorbide mononitrate,  and 
molsidomine . 
2. α-Adrenoblocking drugs: prazosin  and doxazosin .  
3. Sympatholytics: octadinum (guanethidine) .   
4. Diuretics: furosemide . 
These drugs are mainly used to treat ischemic heart disease and 
hypertension.  
There are drugs dilating in identical degree both resistance and 
capacitance vessels. Their classification is follows.  
1. Nitrous oxide donators: sodium nitroprusside . 
2. Angiotensin-converting enzyme inhibitors: captopril ,  
enalapril,  and lisinopril . 
3. Angiotensin receptor blockers: losartan  and valsartan .  
4. α2-Adrenomimetics of central action: clofellinum 
(clonidine)  and guanfacine . 
5. Ganglionic blockers: pentaminum (azamethonium) , 
benzohexonium (hexamethonium) .  
6. α1,2-Adrenoblocking drugs: phentolamine (regitine) .   
7. α, β-Adrenoblocking drugs: labetalol . 
8. Phosphodiesterase inhibitors: milrinone .  
These drugs are mainly used to treat hypertensive disease, as 
well as acute and chronic heart failure (angiotensin-converting 
enzyme inhibitors, sodium nitroprusside, milrinone, etc.).  
Drugs constricting veins are classified as follows.  
1. α-Adrenomimetics: phetanol (et ilefrine) and midodrine 
(Gutrone) . 
2. Alkaloids of Claviceps purpurea: dihydroergotoxine , 
dihydroergotamine, dihydroergocryptine,  and Vasobral   
(α-dihydroergocryptine  with caffeine).  
These drugs are used in the treatment for hypotension and 
orthostatic collapse. 
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α-Adrenomimetics are drugs of synthetic origin. Phetanol 
provides long-lasting activation of vascular α-adrenoceptors.  
The drug is taken orally and administered parenterally to treat 
hypotensive states.  
Midodrine is prodrug which is administered intravenously or 
taken orally. In the body, midodrine is converted into highly active 
metabolite desglymedodrine which exhibits α1-adrenomimetic 
activity. Midodrine is used to treat hypotension and orthostatic 
collapse.  
Alkaloids of Claviceps purpurea (ergot alkaloids) are agonists-
antagonists of α-adrenergic receptors. Concerning arteries, these 
drugs exert antagonistic properties and relax them. Concerning veins, 
ergot alkaloids are agonists and increase their tone. 
Dihydroergotamine maleate and other ergot alkaloids are used to 
treat migraine, and disorders of blood circulation (Raynaud’s disease, 
etc.). these drugs are administered parenterally or taken orally.  
 
Drugs Exerting Venoprotective Properties 
 
Chronic venous insufficiency of lower extremities is widely-
spreeded circulation disorder affecting 10–40 % of population. Drugs 
exerting venoprotective properties and drugs exerting simultaneouly 
both venotonic and venoprotective properties are used to treat this 
pathological state. 
Venoprotectors are classified as follows.  
1. Drugs containing rutin and its derivatives (flavonoids): rutin, 
troxerutin (Troxevasin) . 
2. Drugs containing extract of Ginkgo biloba: Ginkyo, 
Bilobil, Memoplant, Gincor fort .  
3. Synthetic drugs: calcium dobesilate (Doxium) .  
Rutin  decreases permeability of small vessels, eliminates 
angiasthenia, improves microcirculation, and recuces oedemas. Its 
semisynthetic analogue troxerutin is taken orally, administered 
parenterally, or applied topically. The drug has long duration of 
action, its half-life is 24 hours. Troxerutin exerts higher toxicity than 
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rutin. Its side effects are gastrointestinal erosies, allergic reactions, 
and headache.  
Drugs of Ginkgo biloba extract contain flavone glycosides 
exerting antioxidant, antioedema, and antiaggregant properties. 
These drugs are taken orally and easily absorbed from 
gastrointestinal tract.   
Calcium dobesilate  decreases vascular permeability and 
thrombocyte aggregation. At oral intake, the drug is readily absorbed 
from gastrointestinal tract. Its half-life is 1 hour. Side effects of 
calcium dobesilate are allergic reactions and dyspepsia.   
 
Drugs Exerting both Venotonic and Venoprotective 
Properties 
 
This group is classified as follows.  
1. Bioflavonoids: Detralex . 
2. Drugs obtained from horse chestnut (Aesculus 
hippocastanum) fruits: Aescin, Reparil, Aescusan, Aesflazidum, 
Venoplant, Anavenol (contains dihydroergocryptine, aesculin, and 
rutin).  
3. Drugs obtained from Ruscus aculeatus: Cyclo 3 Fort  
(containing extract of Ruscus aculeatus , hesperidin methyl 
chalcone , and ascorbic acid).  
4. Grape seed extract: Endotelon . 
5. Synthetic drugs: tribenoside (Glyvenol) .  
Detralex  is most effective agent of this group. The drug 
contains two flavonoids (diosmin and hesperidin) obtained from 
fruits of Kumquat. The drug is taken orally 2 times a day. Detralex is 
metabolized by intestinal microflora to its active metabolite 
diosmetin. The drug increases venous tone, decreases capillary 
permeability, exerts anti-inflammatory effect, decreases formation of 
free oxygen radicals, affects platelets adhesion, improves 
microcirculation and lymphatic drainage, and restores tissue 
trophicity. Detralex is excreted from the body mainly by kidneys, 
partly – with bile. The drug is well tolerated by patients. Its side 
effects are dyspepsia, insomnia, and headache. Detralex is used to 
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treat chronic venous insufficiency of lower extremities and 
hemorrhoids. 
Drugs obtained from horse chestnut fruits (Aescin , Reparil , 
Aescusan , etc.) contain triterpenoid glycosides (saponins) which 
exert venotonic, anti-edematous, and anti-inflammatory effects. 
These drugs are taken orally or applied topically. Aescusan is taken 
orally 3 times a day in tablets or orall drops.   
Drugs of Ruscus aculeatus contain saponins and flavonoids. 
Cyclo 3 Fort  is the most widely spreaded drug of this group. The 
drug is taken orally. Its typical side effect is dyspepsia.  
Endotelon  is drug of grape seed extract. The drug contains 
oligosaccharides which bind with mucopolysaccharides of venous 
wall. Endotelon stimulates collagen synthesis, increases venous tone, 
decreases venous permeability and fragility. The drug is taken orally 
in the treatment for first manifestations of lymphatic and venous 
insufficiency. Its side effects are dyspepsia, headache, skin allergies.   
Synthetic drug tribenoside increases venous tone, exhibits 
venoprotective and capillary protective effects, inhibits 
inflammation, and improves microcirculation. The drug is taken 
orally (1 capsule 2–3 times a day), administered rectally, or applied 
topically. Its side effects are dyspepsia and skin rach. 
Besides phlebectomy, phlebosclerosants (e. g., decilat, 
polidocanol) are also used to treat varicose veins. Their intravenous 
administration leads to vascular obliterating. 
Ointments and gels containing venoprotectors are used topically 
to treat varicose veins. There are Cyclo 3 crem, Ginkgo biloba 
gel, troxerutin ointment, Venitan gel,  etc. Besides,  
anti-inflammatory and antiallergic drugs (e. g., glucocorticoids), 
antibacterial drugs (local antibiotics and antiseptics), and drugs 
providing wounds healing (methyluracil ointment) are used. At 
varicose veins, anticoagulants, antiaggregants, fibrinolytics, and 
drugs improving rheological properties of blood (pentoxifylline, 
rheopolyglucin, etc.) are used to prevent thrombosis.      
 
       
138 
 
DRUGS INFLUENCING DIGESTIVE SYSTEM 
 
Drugs Influencing Appetite  
 
Appetite is an emotional feeling about human desire to eat 
certain foods. Appetite is realized by neurohumoral way. Nervous 
system has the predominant role in this regulation. Appetite is under 
control of hunger centre (lateral nuclei of the hypothalamus) and 
saturation centre (ventromedial nuclei of the hypothalamus). These 
centres receive impulses from the gustatory, visual, and olfactory 
systems. An appetite largely depends on the state of cortex and 
limbic system. 
The primary importance in the regulation of appetite belongs to 
such mediators as noradrenaline, serotonin, and dopamine influecing 
the appropriate receptors (β1- and β2-adrenergic receptors,  
α1-adrenergic receptors, 5-HT1B and 5-HT2C-serotoninergic receptors, 
D1-dopaminergic receptors). Besides, specific neuropeptides 
regulating appetite and energetic balance are in hypothalamus. 
Appetite-increasing substances (orexigens) are neuropeptide Y, 
orexigens A and B, ghrelin (stomach peptide which after absorption 
in the blood stimulates growth hormone production by 
hypothalamus), hormone stimulating the growth hormone secretion, 
GABA, etc.  
There are substances which reduce appetite (anorexigenic 
substances). They are leptin (hormone of fatty cells which penetrates 
into the brain and stimulates production of anorectic substances by 
hypothalamus and simultaneously inhibits the secretion of orexigenic 
substances), α-melanocyte-stimulating hormone, hormones 
stimulating release of thyrotropin, neurotensin, serotonin, 
cholecystokinin, glucagon-like compounds, etc. 
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Drugs Increasing Appetite 
 
Appetite is stimulated by means of taste and extractive 
substances of pepper, cinnamon, cloves, bay leaf, garlic, onion, 
horseradish, dill, mustard, etc. Broth, vegetable broths, juices, 
mineral water, dry wine, and beer also have stimulating influence 
upon appetite.  
Medicines which are used to stimulate appetite and gastric juice 
secretion include bitters: tinctures of wormwood, centaury ordinary, 
water shamrock, rhizome of calamus, etc. These drugs are taken  
15–20 minutes before a meal.  
Mechanism of their action is associated with stimulation of 
receptors in oral cavity that results in increase of reflex excitability of 
hunger centre. Owing to this, first (complex-reflex) phase of gastric 
secretion is enhanced at meal. 
Drugs increasing appetite also include insulin, aminazine, 
amitriptyline, lithium carbonate, clonidine, and anabolic steroids. 
 
Drugs Decreasing Appetite 
(Anorexic or Anorexigenic Drugs) 
 
Drugs decreasing an appetite are called anorexigenic drugs or 
appetite suppressants. Anorexigenic drugs are used in the treatment 
for alimentary obesity. This disease is accompanied by metabolic 
disordes which increase the hazard of diabetes mellitus, 
cardiovascular diseases, etc. 
The main mode of obesity treatment is to decrease amount of 
high energy value food and increase of physical activity.  
According to mechanism of action, anorexigenic drugs are 
classified as follows:  
1. Drugs stimulating catecholaminergic system of brain: 
amphetamine, chlorphentermine (Desopimon), mazindol,  
and amfepramone (phepranone).  
2. Drugs stimulating serotoninergic system of brain: 
fenfluramine, dexfenfluramine .  
3. Drug stimulating both catecholaminergic and serotoninergic 
systems of brain: sibutramine .   
4. Inhibitor of gastrointestinal lipases: orlistat .  
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  Active anorexigenic drug amphetamine  (phenaminum) is 
a derivative of phenylalkylamine. The drug exhibits both central and 
peripheral adrenomimetic action. Amphtamine increases the release 
of norepinephrine and dopamine by nerve terminals and supresses 
their reuptake. It is accompanied by excitation of central adrenergic 
and dopaminergic receptors and reduction of hunger feeling. Owing 
to excitation of corresponding receptors, the drug causes a lot of side 
effects: insomnia, agitation, tachycardia, increased blood pressure, 
etc. Besides, phenaminum intake can result in both physical and 
psychical dependence. With reference to above mentioned, 
phenaminum is not used presently as anorexigenic drug. 
Amfepramone (phepranone) is a derivative of 
phenylalkylamine. Its mechanism of action is identical to those  
of phenaminum. But phepranone stimulates central and peripheral 
nervous systems in less degree. Phepranone is taken orally  
30–60 minutes before a meal. Because the drug can cause insomnia, 
it should be taken in the first half of a day. Its possible side effects 
are agitation, insomnia, tachycardia, increase of blood pressure, etc. 
Long-lasting phepranone intake leads to tolerance and drug 
dependence. 
Fenfluramine  selectively acts in serotoninergic synapses and 
inhibits neuronal reuptake of serotonin. The drug inhibits central 
nervous system and increases blood pressure.  
Sibutramine  simultaneously inhibits neuronal reuptake of 
norepinephrine, serotonin, and dopamine. The drug decreases blood 
concentration of uric acid and lipids. The following side effects are 
observed at sibutramine therapy: tachycardia, sleep disorders, 
headache, and increased excitability of central nervous system. 
A decrease of intestinal lipid absorption is one of the ways of 
treating obesity. It is achieved by inhibition of lipase activity 
(enzyme which is necessary for lipid absorption). This mechanism of 
action is typical for orlistat . The drug inhibits lipase in stomach and 
intestine that reduces hydrolysis of dietary triglycerides. Lipid 
absorption is decreased by 30 %. Also, orlistat inhibits absorption of 
lipid-soluble vitamins. About 83 % absorbed drug dose is excreted 
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through intestine in unchanged form. Full elimination of orlistat 
occurs during 3–5 days. Side effects depend on triglycerides level in 
food and include urging to stool, abdominal pain, diarrhoea, nausea, 
and vomiting. 
Restriction use of sugar or use of sweeteners (saccharin, etc.) is 
also recomemded for decrease of calorie food. Sweeteners have 
a low calorie and are badly absorbed from intestine.  
Recently, hormon of fat cells leptin  is recommended for 
reduction of appetite. Its administration promotes the lowering of 
body weight in patient with obesity. But, the drug is effective only in 
patients with deficiency of endogenous leptin. 
Melanocortins  inhibit an appetite owing to interaction with 
specific MC4-receptors. Other agonists of these receptors also have 
anorexigenic effect. 
Cholecystokinin  is also noteworthy. Besides the regulation of 
functions of digestive system, this hormon also acts as saturation 
factor. Series of compounds activating the cholecystokinin system 
are now being studied. 
It should be borne in mind that pharmacotherapy of obesity has 
auxiliary character and the base of obesity treatment is combination 
of low-calorie diet with additional physical activity.  
 
Drugs Influencing Function of Salivary Glands  
 
Salivary glands secretion is under control of both 
parasympathetic and sympathetic nervous systems. The tone of 
parasympathetic nervous system is predominante; therefore, 
stimulation of M-cholinoceptors, located in salivary glands, 
determines the degree of salivation. 
Drugs with M-cholinomimetic activity (proserinum , 
carbacholine , pilocarpine , aceclidine , etc.) increase 
salivation. Cholinoblocking drugs (atropine , scopolamine , etc.) 
inhibit salivation. Drugs with blocking activity are used to reduce 
hypersalivation at Parkinson disease, helminth infestation, and 
poisoning by heavy metals.  
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Drugs Used in Hyposecretion of Digestive Glands 
 
Hypofunction of digestive glands (stomach, pancreas, liver) is 
accompanied by malnutrition of the body and disorders of 
gastrointestinal motility. Wherein, disorders of function of one organ 
can leads to secretory disorders of other organs.   
 
Drugs Used in Hyposecretion of Stomach  
 
Mucosa of stomach secretes several enzymes, the main of which 
is pepsinogen. Its transformation to active pepsin occurs in the acidic 
environment. Necessary acidity is achieved owing to secretory 
activity of parietal cells producing hydrochloric acid (precisely, ions 
of hydrogen). 
Hypofunction of gastric glands occurs in 10–15 % practically 
healthy people. Sometimes, it is only insufficient secretion of 
hydrochloric acid, but quite often it combines with hyposecretion  
of pepsinogen. Hyposecretion can cause inflammation with 
development of hypoacid gastritis. 
Vagus nerve and several gastrointestinal hormones regulate the 
stomach secretion. It is known, that the increase of vagal tone and the 
release of gastrin and histamine result in the elevation of gastric 
secretion. In turn, reduction of cholinergic influence and suppression 
of gastrin or histamine release cause the decrease of gastric juice 
secretion. Endogenous substances supressing gastric secretion are 
secretin, cholecystokinin, prostaglandins, vasoactive intestinal 
peptide, peptide inhibiting gastric secretion, etc.   
Administration of gastrin, histamine or extractive substances can 
significantly increase gastric secretion in patients with hypoacid 
gastritis which is caused by functional disorders. But administration 
of these substances does not increase secretion in patients with 
organic lesions of the gastric mucosa. Thereby, these substances may 
be used for diagnostics of gastric pathology. 
Pentagastrin  is a synthetic histamine analogue. The drug 
stimulates gastric secretion. Pharmaceutical industry produces 
0.025 % ampoule solution of pentagastrin. The drug is administered 
subcutaneously to diagnose stomach pathology. Sampling of gastric 
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juice is carried out every 15 minutes after pentagastrin injection. Its 
administration allows to estimate the secretory ability of stomach and 
to determine the character of stomach damages. At functional 
insufficiency of gastric mucosa, pentagastrin increases the secretion. 
But secretion is not increased in patietns with organic diseases of the 
stomach. 
Attempts to increase secretion have low efficiency or are 
completely ineffective in patients with hypoacid gastritis which is 
accompanied by atrophic process. Therefore, treatment of patients 
with such pathological states needs the drugs of substitutive therapy. 
With this end in view, such drugs as natural gastric juice , 
pepsin , diluted hydrochloric acid , acidin-pepsin , abomin,  
and carbonated mineral water  are used.  
The most physiological drug is natural gastric juice , which 
is obtained from animals. The drug is taken with meals in dose 
1 tablespoon. Artificial gastric juice  (obtained by insisting of 
stomach mucosa of pigs in 0.2–0.5 % hydrochloric acid solution) is 
less active. It is taken also with meals in dose 1–2 tablespoons. 
Abomin  is tableted drug obtained from gastric mucosa of calves 
and lambs. It is taken with meals in dose 1–2 tablets. Course of 
treatment is 1–3 months. Abomin contains several proteolytic gastric 
enzymes. The treatment with this drug needs simultaneous intake  
of hydrochloric acid. 
Pepsin  is obtained from gastric mucosa of pigs. Mixture of 
pepsin and hydrochloric acid is used with meals in dose 
1 tablespoon.  
Acidin-pepsin  is used in patients with hypoacid gastritis. One 
tablet of drug is dissolved in 1/2 glass of water and is taken during or 
immediately after eating. 
Hydrochloric acid  is used to treat hypoacid gastritis without 
pepsin deficiency. Diluted standard solution of hydrochloric acid is 
taken with meals in dose 10–15 drops with 1/2 glass of water. This 
solution in recommended to take through tubule to prevent tooth 
enamel destruction. Organic acids (malic, citric, or acetic) are also 
used in hypoacid gastritis. These acids realease hydrogen ions in 
stomach and undergo absorption and energy metabolism in body. 
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An eating of acidic foods, such as sauerkraut, fruits, etc. also is 
recommended.  
 
Drugs Used in Hypersecretion of Gastric Glands 
and in Disorders of Trophism and  
Regeneration of Gastric Mucosa 
 
These drugs are used in patients with hyperacid gastritis, ulcer 
disease of stomach and duodenum. According to studies, 
approximately 10 % of 30–55-year-old males and 6 % of females 
under 55 years suffer from ulcer disease. Ulcer disease lasts for years 
and is characterized by periods of exacerbation and remission. 
According to modern ideas, ulcer disease is a result of imbalance 
between protective and agressive factors influecing upon the stomach 
mucus. 
Acid-peptide (predominant role of hydrochloric acid) influence 
and Helicobacter pylori have leading part between aggressive 
factors. Other agressive factors are bile components, certain drugs 
(e. g., nonsteroidal anti-inflammatory agents and glucocorticoids), 
thermal and mechanical lesions of the mucous membrane, frequent 
stressful situations, etc. 
Protective factors include mucosal barrier, microcirculation, 
regenerative ability of mucous membrane of stomach and duodenum, 
bicarbonate secretion, etc. 
Considering the above-mentioned factors, the main aims of ulcer 
disease therapy are: 
– decrease of acid-peptide aggression; 
– antibacterial therapy against Helicobacter pylori; 
– increase of protective ability of mucous membrane of stomach 
and duodenum; 
– stimulation of regeneration on the ulcer surface. 
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Drugs Decreasing Secretory Activity of Gastric Glands 
 
This group occupies the central position in treatment of ulcer 
disease of stomach and duodenum, hyperacid gastritis, esophagitis, 
and Zollinger-Ellison syndrome. To understand the mechanisms of 
drugs action, it is necessary to consider the mechanisms of secretion 
regulation at the cellular level. 
Secretion of gastric juice occurs continuously throughout the day 
(nearly 2–3 l a day) and sharply increases during digestion. Mucous 
membrane of stomach contains 3 types of cells: сhief cells secreting 
pepsinogen, parietal cells secreting hydrogen ions, and surface 
mucous cells (foveolar cells) secreting mucin and bicarbonate.  
M3-cholinergic, H2-histaminergic, and gastrinergic receptors are 
located in parietal cell membranes. Stimulation of these receptors 
leads to an increase of proton pump activity. In turn, proton pump 
secretes hydrogen ions in the stomach cavity. An increase of gastric 
juice acidity promotes transformation of pepsinogen to pepsin. Also, 
acetylcholine, gastrin, and histamine increase the secretion of 
pepsinogen by сhief cells. M-cholinolytics, H2-histamine receptor 
antagonists, and proton pump inhibitors are used to decrease parietal 
cell secretion. Especially pronounced therapeutic effect of these 
drugs is observed in patients with ulcer disease of duodenum, in 
which acid-peptic factor is greater.  
Drugs decreasing the gastric secretion are classified as follows.  
1. M-cholinoceptor antagonists: 
– nonselective M-cholinergic antagonists: atropine , 
platyphyllin , and metacinium; 
– drugs blocking predominantly M1-cholinoceptors: 
pirenzepine  and telenzepine .  
2. H2-histaminergic receptor antagonists: cimetidine , 
ranitidine , famotidine , nizatidine , and roxatidine .  
3. Proton pump inhibitors: omeprazole , pantoprazole , 
lansoprazole , rabeprazole , and esomeprazole .  
4. Prostaglandins and their synthetic analogues: misoprostol . 
5. Gastrin receptor antagonists: proglumide .  
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M-Cholinoceptor Antagonists  
 
This group includes atropine, platyphyllin, metacinium, 
pirenzepine (Gastrozepin),  and telenzepine . Depending on 
their affinity to the different types of M-cholinoceptors, these drugs 
are devided into selective (blocking only M1-cholinoceptors) and 
nonselective (blocking all types of M-cholinoceptors) M-cholinergic 
antagonists. Nonselective drugs (atropine, platyphyllin,  
metacinium) are the first agents which were used to treat ulcer 
disease and hyperacid gastritis. Mechanism of their action is 
associated with blockage of M3-cholinergic receptors which are 
located in membranes of the cells of mucous membrane of stomach 
and in the cells of smooth muscles of gastrointestinal tract. Drugs 
eliminate vagal influence predominantly upon basal and nocturnal 
secretion. These drugs exert less influence upon stimulated secretion. 
These drugs decrease gastric juice volume as well as hydrochloric 
acid concentration in it. Simultaneously, nonselective  
M-cholinoblockers reduce the tone of stomach and intestine and 
prolong gastric emptying time that leads to activation of gastric 
secretion owing to gastric distension.  
It should be noticed that clinically significant antisecretory effect 
of M-cholinergic antagonists develops in case of high degree of 
blockage of M-cholinergic receptors. As a rule, such degree  
of blockage is accompanied by lot of side effects (constipation, dry 
mouth, accommodation disorders, tachycardia, etc.). Therapeutic 
effect of M-cholinergic antagonists quickly reduces owing to 
tolerance.  
Practically, such nonselective drugs are used as tincture  and 
extract  of Belladonna ; tablets and injections of atropine , 
platyphyllin , metacinium , etc. Co-formulated drugs are used: 
“Bekarbon”, “Bellastezin”, “Bellalgin”, etc.  Nonselective 
drugs are used to reduce hypertonus of pyloric section with delayed 
food evacuation and to relieve cramping (spasmodic pains).  
Pirenzepine  and telenzepine , selective M1-cholinergic 
antagonists, are mainly used presently. These drugs exhibit high 
affinity to M1-cholinergic receptors of parasympathetic ganglia of 
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stomach. It results in low probability of side effects. Besides, there is 
evidence that these drugs increase the mucosal resistance to 
damaging factors.  
Pirenzepine  is administered parenterally and taken orally. Its 
gastrointestinal bioavailability is 20–30 %. Maximal concentration in 
blood is achived in 2 hours after drug intake. Absorbed pirenzepine 
binds with plasma proteins in insignificant degree. The drug is 
excreted predominantly with bile in unmodified form. Pirenzepine is 
prescribed 2 times a day for 15–20 minutes prior a meal. Therapeutic 
course lasts 3–4 weeks. Long-time intake of high doses of 
pirenzepine can cause side effects which is typical for nonselective 
M-cholinergic antagonists: dry mouth, tachycardia, etc.  
Telenzepine  is 25 times more active M1-cholinergic antagonist 
than pirenzepine. Besides marked inhibition of gastric secretion, the 
drug significantly suppresses secretion of salivary glands that 
restricts its clinical use.  
 
H2-Histaminergic Antagonists  
 
H2-histaminergic antagonists are classified as follows: 
– I-generation drug: cimetidine ;  
– II–generation drug: ranitidine  (Zantac); 
– III-generation drug: famotidine  (Quamatel); 
– IV-generation drug: nizatidine  (Axid); 
– V-generation drug: roxatidine  (Roxane). 
 This classification is based on different pharmacological 
activity of the drugs and differences in their pharmacokinetics and 
side effects.  
H2-histaminergic antagonists block corresponding receptors at 
competitive type. The drugs of II–V generations exert significantly 
higher degree of affinity to H2-receptors. Therefore, it is possible to 
prescribe these drugs in significantly less doses. H2-histaminergic 
antagonists inhibit basal and nocturnal secretion, as well as secretion 
stimulated by food, gastric distension, histamine, etc. Drugs increase 
the production of prostaglandin E2 by the mucosal membrane of 
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stomach and duodenum. It results in gastroprotective effect, owing to 
which drugs promote the ulcer healing.  
It should be noticed that sharp discontinuation of drug intake 
(except nizatidine and roxatidine) can result in rebound syndrome. 
This phenomenon is caused by hypergastrinemia which is developed 
owing to decrease of gastric juice acidity and increase of density of 
H2-histaminergic receptors and its affinity to histamine. Therefore, 
discontinuation of therapy with these drugs should be gradual with 
simultaneous use of other antisecretory agents.  
H2-histaminergic antagonists are administered intravenously and 
taken orally. Their gastrointestinal bioavailability varies from 50 to 
90 %. Degree of binding with plasma proteins is 15–20 %. Drugs 
easily penetrate placenta and may be secreted with breast milk. 
Cimetidine easily penetrates through blood-brain barrier. Duration of 
cimetidine effect is 6 hours, ranitidine – 8–12 hours, famotidine – 
12–24 hours, nizatidine and roxatidine – more than 24 hours. 
Ranitidine is prescribed 2 times a day (at the morning 30 minutes 
before a meal and at night), famotidine and other drugs – once a day 
at night. Course of treatment lasts from 4 to 6 weeks.  
Cimetidine is low-active, short-acting, and rather toxic drug. It 
blocks androgenic receptors that leads to gynecomasty and sexual 
disorders in males; inhibits microsomal hepatic enzymes, therefore, 
potentiates effects of some medicines (e. g., diazepam, propranolol, 
theophylline). Long-time use of cimetidine can provoke leukopenia. 
Therefore, cimetidine is not used in medicine nowadays.   
Less than 50 % dose of ranitidine is metabolized in the body. 
Famotidine and other drugs are not metabolized practically. The 
main route of their excretion is kidneys.  
Mechanism of action of ranitidine bismuth citrate  
(Pylorid) is associated with blockage of H2-histaminergic receptors.  
Besides, the drug exerts high bactericidal activity against 
Helicobacter pylori.  
Indications for clinical use of H2-histamenergic antagonists are 
the following: 
– ulcer disease of stomach and duodenum;  
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– hyperacid gastritis; 
– duodenitis, esophagitis, and other diseases which are 
accompanied by increasing secretion of hydrochloric acid;  
– prevention of ulcers and erosions in patients with 
craniocerebral traumas, sepsis significant burns, etc; 
– emergency in bleeding ulcers of stomach, duodenum, and 
esophagus (0.05 g ranitidine is administered intravenously every  
6–8 hours). 
Side effects of H2-histaminergic drugs are diarrhoea, 
constipation, skin rash, headache, myalgia, and dizziness.  
Due to binding with H2-histaminergic receptors of blood cells, 
drugs can provoke leukopenia, thrombocytopenia, and haemolytic 
anaemia. Blockage of H2-histaminergic receptors in the membranes 
of tissue basophils cal cause the aggravation of bronchial asthma, 
cutaneous manifestations of systemic lupus erythematosus, etc. 
It should be noticed that long-lasting artificial inhibition of 
gastric acidity promotes cancerogenesis.  
 
Proton Pump Inhibitors  
 
Proton pump inhibitors include omeprazole, pantoprazole , 
lansoprazole, rabeprazole, etc.   
Single way of hydrochloric acid secretion exists independently 
on mode of stimulation (acetylcholine, histamine, gastrin, etc.). It is 
reliased on the level of membranes of parietal cells by means of 
energy-dependent exchange of potassium ions and hydrogen ions. 
There is specific H+, K+-ATPase in parietal cell membranes which 
provides secretion of hydrogen ions into stomach cavity and entry of 
potassium ions into the blood.  
Based on these data, drugs blocking H+, K+-ATPase activity 
were established. All proton pump inhibitors are prodrugs. In acidic 
environment near parietal cells, these drugs are transformed to active 
metabolites – sulfenamides, which interact with sulfhydryl groups of 
H+, K+-ATPase. Proton pump inhibitors markedly decrease basal, 
nocturnal, and stimulated secretion of hydrochloric acid. These drugs 
are also effective in cases which are resistive to M-cholinergic and 
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H2-histaminergic antagonists. It should be noticed that these drugs 
also suppress the activity of H+, K+-ATPase of Helicobacter pylori 
that results in bacteriostatic effect.  
Therapy with proton pump inhibitors is accompanied by an 
increase of gastrin concentration in the blood. Therefore, sudden 
discontinuation of the drug intake can cause the rebound syndrome. 
In this regard, cessation of proton pump inhibitor intake should be 
under the shelter of antacids.   
Proton pump inhibitors are administered intravenously or taken 
orally before a breakfast. Drugs are poorly absorbed in acidic 
enviroment; therefore, proton pump inhibitors should be taken 
together with sodium hydrocarbonate solurion. Enteric-soluble 
granules of drugs are protected by means of gelatin capsules from 
hydrochloric acid. Therefore, it is impossible to chew them. Their 
gastrointestinal bioavailability is 35–50 %. The degree of binding 
with plasma proteins is about 95 %. Proton pump inhibitors undergo 
the hepatic biotransformation. Maximum effect develops in  
1–2 hours after drugs intake. Proton pump inhibitors are accumulated 
in acidic environment of parietal cells where they exert their effect. 
Proton pump inhibitors are taken once a day. Their effect persists for 
24 hours (sometimes up to 3–4 days). Such long-lasting effect is due 
to irreversible inhibition of proton pump. Thereby, a new synthesized 
enzyme is needed for restoration of secretion. It should be noticed 
that about 1/2 of human H+, K+-ATPase is restored during  
30–48 hours.    
Indications for clinical use of proton pump inhibitors are 
identical with indications of H2-histaminergic antagonists. 
The following side effects are observed during treatment with 
proton pump inhibitors: headache, drowsiness, dizziness, diarrhoea 
or constipation, and abdominal pain. These phenomena arise after 
first drug intake and, as a rule, disappear in 1–2 days. Visual and 
hearing disorders are described in case of intravenous drug 
administration. Long-time administration of proton pump inhibitors 
is accompanied by risk of mucous membrane hyperplasia with 
formation of carcinoids in submucosal layer of stomach.  
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Prostaglandins and Their Synthetic Analogues 
 
Representative of this group is misoprostol  (synthetic 
analogue of prostaglandin E1). The drug exhibits two dose-dependent 
effects. Low doses of the drug exert gastroprotective effect owing to 
the increase of secretion of bicarbonates and mucus and 
microcirculation improving. Large doses of the drug cause blockage 
of hydrochloric acid secretion. Misoprostol blocks both basal and 
stimulated secretion of hydrochloric acid. Misoprostol is used to treat 
erosions and ulcer disease of stomach and duodenum. The drug is 
taken in tablets 3–4 times a day (with meals and at night). Course of 
treatment lasts 3–8 weeks. Side effects of misoprostol are abdominal 
pain, meteorism, diarrhoea, allergic reactions, decrease of blood 
pressure, etc.  
 
Gastrin Receptor Antagonists  
 
Representative of this group is proglumide . The drug inhibits 
gastrointestinal motility and reduces gastric secretion. Its mechanism 
of action is associated with blockage of both CCKA and CCKB 
subtypes of gastrin receptors. Antisecretory activity of proglumide is 
equivalent to the first generation of H2-histaminergic antagonists.  
 
Gastroprotective Drugs  
 
This group includes drugs with different chemical structure and 
mechanisms of action, which provide protection of gastric mucosa 
from aggressive influence and/or create conditions for ulcers healing 
or stimulate this process. Basically, gastroprotectors are used to treat 
ulcer disease of stomach and duodenum.  
Gastroprotectors are classified as follows: 
1) drugs creating mechanical protection of gastric mucosa: 
sucralfate  (Venter),  bismuth subcitrate (De-nol). 
2) drugs increasing protective function of mucous barrier: 
carbenoxolone, misoprostol.  
Sucralfate  (Venter) is sulfated disaccharide in complex with 
aluminum hydroxide. Sucralfate is polymerized in acid enviroment 
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of stomach. Polymerized molecules exert significant negative charge, 
owing to which drug binds with positively charged protein radicals 
of the damaged surface. The sucralfate concentration on the ulcer 
surface is 5–7 times more than on the healthy mucosa. Protective 
pellicle is held on the ulcer surface of stomach up to 8 hours and on 
the duodenal ulcer – up to 4 hours. Sucralfate is taken 4 times a day: 
3 times in 30 minutes prior a meal and once at night. Duration of 
treatment is 4–6 weeks.  
Sucralfate does not decrease secretion of hydrochloric acid and 
pepsin, but these substances can be absorbed on the surface of drug 
molecules.  
Sucralfate is well tolerated by patients. Its intake can result in 
the following side effects: epigastric discomfort, dry mouth, itching 
and redness of the skin. Sucralfate is able to decrease intestinal 
absorption of phosphate and fluoride. The drug is contraindicated in 
pregnant women, children up to 4 years of age, and nursing mothers. 
De-nol  is colloidal bismuth subcitrate, which forms complex 
with proteins in acidic environment. Most of the drug is concentrated 
in erosive surface and protect it from damage. Besides, the 
gastroprotective activity of De-nol relates to its ability to increase the 
local synthesis of prostaglandin E2 by mucosa of gastric antrum and 
duodenum. Due to this, De-nol improves the microcirculation and 
stimulates the secretion of hydrocarbonate. The drug exerts 
bactericidal effect against Helicobacter pylori. Bacteria disappear 
from the mucosal surface in 30–90 minutes after De-nol intake. 
Pathogen is not completely detected after 3 weeks of treatment, but 
discontinuation of De-nol intake can be accompanied by 
recolonization of Helicobacter pylori. Therefore, combination  
of De-nol with antibacterial drugs is most appropriate.  
De-nol is taken in 30 minutes before a meal and at night. Course 
of treatment lasts 4–6 weeks.  
The drug is well tolerated by patients. Its side effects are nausea, 
vomiting, diarrhoea, headache, and dizziness. Bismuth sulfide 
(formed in the intestines) stains tongue and feces black.   
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Carbenoxolone (Biogastron)  is glycyrrhizic acid of licorice 
root. The drug stimulates mucus secretion and increases its viscosity. 
Besides, carbenoxolone inhibits enzymes participating in 
prostaglandin inactivation. Carbenoxolone exerts some 
mineralocorticoid and anti-inflammatory activity. The drug inhibits 
the transformation of pepsinogen to pepsin.  
Orally taken carbenoxolone is absorbed from the stomach. The 
degree of binding with plasma proteins is 80–90 %. Carbenoxolone 
is excreted from the body by kidneys (60 %) and partly – by liver. It 
should be noted, that drug undergoes enterohepatic recycling.  
Carbenoxolone is taken 30 minutes before a meal and at night. 
The drug is mainly used to treat ulcer disease in patient with high 
secretory rate. Sometimes, the drug is used to treat duodenal ulcers.  
Side effects of carbenoxolone are the result of its 
mineralocorticoid activity and include oedemas, body weight gain, 
hypertension, muscular weakness, etc.   
Misoprostol  is a synthetic analogue of prostaglandin E1. It is 
known that gastric mucosa synthesizes prostaglandins, which 
stimulate secretion of mucus and bicarbonate, inhibit secretion of 
hydrogen ions by parietal cells, expand the vessels of deep layers of 
mucosa, increase the resistance of vascular wall to aggressive factors, 
and promote healing of erosions and ulcers. 
Especially pronounced gastroprotective effect of misoprostol is 
observed at treatment of ulcers, which are developed owing to  
the use of steroidal and nonsteroidal anti-inflammatory drugs (these 
drugs inhibit prostaglandin synthesis). Misoprostol is taken with 
meals 3–4 times a day. Its effect develops in 30 minutes and lasts up 
to 3 hours. Duration of treatment is 4–8 weeks. Misoprostol is not 
used as drug for monotherapy due to frequent side effects which 
include abdominal pain, nausea, vomiting, rash, uterine bleeding 
during menstruation, etc. Drug is predominantly recommended to 
prevent ulcers in patient treated by anti-inflammatory drugs.    
Somatostatin  is also can be referred as gastroprotector. This 
drug is used to interrupt bleeding from peptic ulcer.   
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Antacids 
 
This group includes the following drugs: sodium 
hydrocarbonate , calcium carbonate, magnesium oxide ,  
aluminium hydroxide, Almagel, Phosphalugel , Maalox,  
Gastal , etc.  
These drugs are weak bases which inactivate hydrochloric acid 
by means of direct chemical interaction with it.  
Depending on their ability to be absorbed from gastrointestinal 
tract, antacids are divided into drugs of resorptive action and drugs of 
pre-resorptive action. Drugs of resorptive action are sodium 
hydrocarbonate  and calcium carbonate .  
Sodium hydrocarbonate  is highly soluble in water. After 
intake, drug is readily distributed in stomach. The drug exerts almost 
lightning, but short antacid effect. Duration of its effect is  
15–20 minutes. Interaction of sodium hydrocarbonate with 
hydrochloric acid is accompanied by carbon dioxide release which 
expands the stomach. It results in belching gas and the feeling of 
heaviness in epigastrium. Rebound syndrome is typical for sodium 
hydrocarbonate, because gastric distension leads to secondary 
increase of secretion of hydrochloric acid and pepsin that is the cause 
of fast resumption of pain.   
Long-time intake of sodium hydrocarbonate can result in the 
systemic alkalosis owing to absorption of bicarbonate ions. A risk of 
this complication increases in patients with impaired renal function. 
Symptoms of systemic alkalosis include poor appetite, nausea, 
vomiting, weakness, abdominal pain, muscular spasms, and 
convulsions. Also, long-lasting intake of sodium hydrocarbonate is 
accompanied by accumulation of sodium ions, increased blood 
pressure, and oedemas.  
Calcium carbonate  is poorly soluble in gastric contents. Its 
action is slow, and absorption is less than absorption of sodium 
hydrocaronate. Drug neutralizes hydrochloric acid with the release of 
carbon dioxide. Calcium carbonate causes most pronounced rebound 
syndrome. Regular drug intake together with milk diet (typical diet 
for patients with ulcer disease) is accompanied by calcium retention 
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in the body and development of “milk alkali syndrome”. Symptoms 
of this syndrome include nausea, vomiting, polyuria, hypercalcemia, 
calcification of vessels and kidneys, formation of renal stones, 
azotemia, and psychical disorders.   
Pre-resorptive antacids are magnesium oxide, aluminium 
hydroxide, Almagel and other drugs.  
Magnesium oxide  interacts with hydrochloric acid without 
carbon dioxide release. Therefore, rebound syndrome is 
uncharacteristic of magnesium oxide intake. Magnesium chloride, 
synthesized in reaction of neutralization, is poorly absorbed from 
intestine and exerts weak laxative effect. Its laxative effect is 
associated with increased osmotic pressure into the intestine and 
stimulation of secretion of cholecystokinin that stimulates peristalsis. 
Magnesium oxide does not influence systemic acid-base balance. Its 
antacid effect develops slowly.   
Aluminium hydroxide  exerts both antacid and absorptive 
effects. The drug interacts with hydrochloric acid without carbon 
dioxide release. Systemic alkalosis is uncharacteristic of regular 
intake of aluminium hyroxide. But, regular drug intake can lead to 
slowdown of intestinal motility that promotes constipation. A part of 
administered dose, which does not interact with hydrochloric acid, 
turns into phosphate and carbonate. These aluminium salts is poorly 
absorbable in the intestine. Therefore, regular aluminium hydroxide 
intake reduces absorption of phosphates and can cause 
hypophosphatemia and hypophosphaturia. Deficiency of phosphates 
is manifested by fatigability, muscular weakness, thinking 
disturbances, anorexia, etc. Prolonged phosphate deficiency is 
accompanied by bone lesions (osteoporosis, osteomalacia), impaired 
healing of wound, and increased risk of infections. Besides, 
aluminium binds fluoride ions into intestine that results in damage to 
dental enamel.  
Co-formulated antacid drugs are widely used in medicine to 
decrease risk of side effects and to increase drug efficacy. These 
drugs include Almagel ,  Posphalugel,  Maalox, Gastal , etc. 
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Almagel  consists of aluminium hydroxide gel, magnesium 
oxide, and sorbitol. Magnesium oxide exerts laxative effect and 
sorbitol – cholagogic effect. Gel-like form promotes uniform drug 
distribution over the gastric surface.  
Almagel A  contains additionally anaesthesine which causes 
local anaesthesia and inhibits gastrin secretion.  
Phosphalugel  contains aluminium phosphate in form of 
hydrophilic colloidal micelles, pectin gel, and agar-agar. The drug 
exerts antacid and absorptive effects. Micelles of aluminium 
hydroxide bind bacteria, viruses, toxines, and gases and eliminate 
them from intestine. Drug does not influence upon systemic  
acid-base balance and phosphate absorption. Pectin and agar-agar 
promote the formation of mucoid protective layer in gastrointestinal 
tract.  
As a rule, all antacids are prescribed in 1 hour after a meal (in 
connection with decrease of buffering effect of food in period of maximal 
secretion) or in 3 hours after a meal (for restoration of antacid action after 
food evacuation). Also, antacids are taken before bedtime to protect 
mucous membrane during nocturnal secretion. In acute period of 
disease, the course of treatment with antacids lasts 2–4 weeks. In 
cases when pain arises during a meal, antacids are prescribed in  
30–40 minutes before the meal. 
Antacids are used to treat ulcer disease of stomach and 
duodenum with hyperacid syndrome, hyperacid gastritis, hiatal 
hernia, esophagitis, and reflux esophagitis.   
 
Drugs Used to Treat Hypofunction of Pancreas  
 
During a day, pancreas produces 1.5–2 l of juice containing 
more than 10 enzymes. Pancreatic juice also contains significant 
amount of bicarbonate and, therefore, has alkaline reaction. It 
promotes neutralization of hydrochloric acid and the normal activity 
of pancreatic enzymes involving in the digestion of peptides, lipids, 
and carbohydrates.   
Trypsin, chymotrypsin, carboxypeptidases A and B, and elastase 
complete proteolysis of proteins which are initiated by pepsin. 
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Amylase provides the hydrolysis of polysaccharides. Lipase and 
phospholipase hydrolyze fatty acids and phospholipids. Bile is also 
necessary for hydrolysis of lipids because it promotes their 
emulsification. Besides, bile participates in absorption of amino 
acids. 
Pancreatic insufficiency develops due to past acute and chronic 
pancreatitis and in patients suffering from chronic gastritis, ulcer 
disease, cholangitis, etc.  
Drugs of pancreatic enzymes often contain also pepsin or bile 
components. Such combination increases functional integration of 
digestive system and is the most effective in patients with chronic 
digestive disordes and in elderly and senile age patients. Pancreatic 
enzymes are obtained from pancreas of butcher livestock, some 
enzymes – from microorganisms and, even, plants.   
Pancreatin  (powder of the dry pancreas of butcher livestock) 
contains predominantly two enzymes – trypsin and amylase. It is 
used in patients with pancreatic insufficiency. Pancreatic 
insufficiency is commonly laced with insufficiency of digestive 
function of stomach and intestine. Therefore, co-formulated drugs 
are commonly used in medicine: Mezym Forte  (pancreatin 
contaning amylase, lipase, and protease), Panzinorm  (drug contains 
pancreatin, extract of gastric mucosa, bile ecstract, amino acids), 
Digestal  (consists of pancreatin, bile extract, hemicellulose), 
Festal , Enzystal , Licrease , Kreon , etc. All drugs act in alkaline 
environment and are inactivated in acidic. Therefore, drugs are 
manufactured in intestinal-soluble dragee or capsules. Course of 
treatment with pancreatic enzymes lasts from 2 up to 4–6 weeks. 
Regular drug intake decreases bloating and diarrhoea and improves 
performance status of the patient.  
Drugs of pancreatic enzymes are used to treat chronic 
pancreatitis, achylia, chronic hypoacid gastritis, hepatitis, 
cholecystitis, etc.  
These drugs are well tolerated by patients. It should be noticed 
that these drugs contain significant amounts of purines and can cause 
exacerbation of gout and formation of urate kidney stones. 
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Drugs Inhibiting Pancreatic Secretion  
 
Drugs inhibiting pancreatic secretion are used to treat acute 
pancreatitis.  
Normally, inactive trypsinogen is synthesized in pancreas. In 
duodenum, it is activated to trypsin by means of enterokinase. At 
acute pancreatitis, trypsinogen is converted to trypsin directly within 
pancreas owing to action of enteropeptidase (enterokinase). In turn, 
trypsin activates other proteolytic enzymes of pancreas. These 
processes result in autolysis and necrosis of pancreas. 
Simultaneously sinthesized bradykinin causes vasodilation and 
hypotension.   
An aim of acute pancreatitis treatment is to suppress both 
secretion and activation of proteolytic enzymes – trypsin and 
kallikrein. The following drugs are used for this aim: 
1. M-cholinoceptor antagonists: atropine , etc.; 
2. Inhibitors of proteolytic enzymes: aprotinin (Contrycal , 
Trasylol , Gordox), aminocaproic acid , etc.  
Contrycal is used most commonly. The drug is obtained from 
pulmonary tissues of livestock for slaughter. Contrycal inhibits the 
proteolytic enzymes and prevents or reduces the autolysis and 
necrosis of pancreas. Contrycal is dosed with international units (IU) 
and administered intravenously drop by drop.  
Treatment of acute pancreatitis also includes administration of 
analgesics, antibiotics, antacids, plasma expanders, electrolytes, and 
other drugs. 
 
Drugs Improving Hepatic Functions  
(Hepatotropic Drugs)  
 
Hepatotropic drugs are devided into bile-expelling drugs, 
hepatoprotectors, and drugs for dissolution of gallstones.  
Hepatocytes produce bile continuously. In periods between 
digestion, bile is deposited in large bile-ducts and in gallbladder, in 
which bile is concentrated. Sphincters are located in choledochous 
duct, gallbladder, and in major duodenal papilla (sphincter of Oddi). 
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Parasympathetic nervous system plays an important role in the 
process of bile evacuation. Increase of its tone is accompanied by 
relaxation of sphincters and gallbladder contraction.  
Massive bile ejection occurs during digestion. It is stimulated by 
cholecystokinin, which is synthesized by duodenal epithelium owing 
to food intake. Daily volume of produced bile is about 1 L.  
Process of digestion requires the bile acids which emulsify fats 
and activate lipase. Bile acids also promote absorption of fat-soluble 
vitamins (A, D, E, K, F). Besides, bile increases activity of 
pancreatic proteases and amylase, exerts bacteriostatic action against 
putrefactive intestinal microflora.        
Bile-expelling drugs are devided into two groups:  
1) drugs stimulating bile production (choleretics, or 
cholesecretics); 
2) drugs promoting bile excretion (cholekinetics).  
 
Drugs Stimulating Bile Secretion  
 
These drugs are classified as follows. 
1. Drugs containing bile and bile acids: Allochol , 
Cholenzymum , l іobіlum , chenodeoxycholic acid . After 
absorption, these drugs stimulate bile formation in hepatocytes and 
simultaneously exhibit function of substitutive therapy.  
2. Drugs of plant origin: Cholaflux , Cholagol , Flaminum, 
berberine sulfate,  Cholosas, syrup of wild rose ,  
decoctions from flowers of  Helichr ysum arenarium, oats 
seeds, Stigmatum maydis .  
3. Synthetic drugs: oxaphenamіdum ,  cycvalonum, 
nіkod inum, Odeston . 
Bile-contaning drugs stimulate bile formation in hepatocytes and 
simultaneously perform the function of drugs for substitutive 
therapy.  
Tablets “Allochol” consists of bile, garlic and nettle extracts, 
and activated carbon. Drug is taken orally 3 times a day after a meal. 
Dose is 1–2 tablets. Course of treatment is 3–4 weeks.      
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Tablets “Cholenzymum” consist of dry bile, chopped dried 
pancreas, and dried mucous membrane of the small intestines of 
slaughter cattle. Drug is taken orally, in dose 1 tablet three times 
a day after a meal. 
Liobilum  is manufactured in tablets containing 0,2 g of freeze-
dried bovine bile. Drug is taken orally, in dose 1–3 tablets at the end 
of a meal 3 times a day. The course of treatment is 1–2 months. 
Drugs of plant origin are widely used in the form of infusions, 
decoctions, and extracts. Cholesecretory activity is typical for 
flavonoids and essential oils of everlasting flower, corn silk, 
barberry, dandelion root, fruits of mountain ash and wild rose, etc. 
Pharmaceutical industry produces extracts of these plants in different 
medicinal forms: drops for oral intake “Cholagol”, tablets 
“Flaminum”, tablets of berberine sulfate , sirup “Cholosas”.  
“Cholagol” consists of pigments of turmeric root, frangula 
emodin, magnesium salicylate, peppermint oil, and eucalyptus oil. 
Drug has choleretic, moderate antispasmodic, anti-inflammatory, 
disinfectant, and laxative effects. “Cholagol” is taken 30 minutes 
prior a meal in dose 5–10 drops on a piece of sugar 3 times a day.  
“Flaminum” contains dry extract Helichrysum arenarium. Drug 
is taken in dose 1 tablet 3 times a day 20 minutes before a meal 
(tablet is dissolved in 1/2 cup warm water).  
Sirup “Cholosas” contains extractum of wild rose. “Cholosas” 
has choleretic and hepatoprotective effects. Drug restores and 
maintains normal function of hepatocytes, restore the flow of bile, 
normalizes the immune system. Besides, “Cholosas” has  
anti-inflammatory and diuretic effects, increases intestinal motility. 
Due to content of vitamin C and other bioactive natural products, 
drug improves immunity. “Cholosas” is taken 30 minutes prior 
a meal in dose 1 teaspoon 2–3 times a day.  
Synthetic drugs (oxaphenamіdum , cycvalonum , 
nіkodinum , Odeston) increase bile production and promote its 
excretion. These drugs exert more prominent choleretic effect than 
bile-containing drugs and drugs of plant origin.  
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Synthetic drugs (except nikodinum) increase the tone of 
gallbladder and relax the smooth muscles of bile ducts. Besides, 
some of them (for example, nikodinum) have antimicrobial effect 
that is clinicaly useful in treatment of inflammatory diseases of liver, 
bile ducts, and gallbladder. These drugs are taken prior a meal  
3 times a day.   
 
Drugs Stimulating Bile Discharge  
 
Cholokinetics causes the contraction of gallbladder and 
relaxation of Oddi sphincter that leads to bile release into the 
duodenum. Mechanism of action of most of them is due to irritation 
of duodenal mucosa owing to that cholecystokinin is released into 
the blood. Cholecystokinin itself causes the release of bile. 
Cholecystokinin  is a duodenal hormone, molecules of which 
consist of 33 residues of aminoacids. The drug is obtained from 
duodenal mucosa of pigs. Cholecystokinin promotes the gallbladder 
contraction, activates pancreatic secretion, and inhibits hydrochloric 
acid secretion by parietal cells of stomach. Cholecystokinin is used 
for diagnostics of gallbladder contractility and its content.  
Magnesium sulfate is administered in a warm solution (25–10 % 
of 50–200 ml respectively) by means of duodenal probe one time in 
several days or taken orally (25 % solution in dose 1 tablespoon)  
3–4 times a day during 2–3 weeks. The drug also may be used for 
tubage. In this case, patient, lying on his right side, drinks for  
30 minutes 100 ml of 10–20 % magnesium sulfate solution. After this, 
patient should lie during 1.5–2 hours with hotty over the liver area. 
Also, the following drugs are used as cholokinetics: sorbitol  
(50–70 ml of 10 % solution, 2–3 times a day before meals), 
sunflower  or olive oil  (1–2 tablespoons 2–3 times a day, it is 
possible to mix with lemon juice), plants containing bitters 
(dandelion, yarrow, wormwood , etc.), essential oils   
of  coriander  and cumin , extracts  and fruit juice  of  
cranberries, cowberry , etc.    
Cholokinetics are used in the treatment for dyskinesia, chronic 
hepatitis, hypoacidic and anacidic gastritis. Drugs are contraindicated 
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in acute period of hepatic diseases, at cholelithiasis, at exacerbation 
of hyperacid gastritis and ulcer disease.  
 Myotropic antispasmodics (No-spa, papaverine, 
Nicoverin, atropine, platyphyllin), are used to reduce 
spasticity of bile ducts. These drugs reduce pain occurred in 
pathology of bile ducts. Myotropic spasmolytics are effective in 
moderate pain and well combined with other hepatotropic drugs. At 
intensive pain due to cholelithiasis attack, these drugs are 
administered parenterally together with analgesics.  
 
 
Hepatoprotectors 
 
As hepatoprotectors are reffered drugs increasing the resistance 
of liver to unfavourable factors and decreasing the damage and 
destruction of hepatocytes.  
Hepatoprotective effect is due to the normalization of hepatocyte 
metabolism, the increase of microsomal enzymes activity, and 
restoration of damaged cell membranes. Drugs are used to treat acute 
and chronic hepatitis, hepatic dystrophy, cirrhosis, and toxic liver 
damages (including alcoholism and hepatic coma).   
Hepatoprotectors obtained from thistle (Silybum marianum) and 
other plants richest on flavonoids are used most widely in medicine: 
Legalon, Carsil ,  Siliborum, Silibinin,  Rosanol, Catergen, 
Hepabene, Hepatofalk Planta, LIV-52 , etc. 
Flavonoids are phenolic compounds – derivative of chromone. 
Together with ascorbic acid, flavonoids participate in redox 
processes and are the part of cellular antioxidant system. Flavonoids 
exert anti-inflammatory, bile-expelling, antiviral, analgesic, and 
immunomodulatory effects. These agents stabilize the vascular wall, 
improve the hemophoresis, reduce vascular spasm, increase level of 
calcium and glucocorticoids in the blood, and decrease cholesterol 
level. Flavonoids are widely used to prevent gastric, hepatic, and 
cardiovascular diseases. Their antioxidative activity is higher than 
activity of vitamin E. Flavonoids are easily absorbed in 
gastrointestinal tract and accumulated in the liver and kidneys. 
163 
 
Flavonoids of Silybum marianum exert high hepatotropism so that 
these drugs are highly effective at hepatic diseases. Besides, these 
drugs stimulate protein synthesis, normalize phospholipids 
metabolism, and increase the glutathione reserve in a liver.  
Legalon  is an extract of Silybum marianum fruits. The drug 
contains mixture of flavonoids with hepatoprotective activity – 
silibinin, silimarin, etc. Mechanism of Legalon action is associated 
with stabilization of hepatocyte membranes and antioxidative 
properties. The drug stimulates protein synthesis, normalizes 
phospholipids metabolism, and increases the glutathione reserve in 
the liver. Legalon is taken orally in capsules, dragee, and emulsion. 
The drug is low toxic and well tolerated by patients.  
 Presently, monopreparation of flavonoid silibinin is approved in 
medicine – silibinin dihydrosuccinate sodium (Legalon 
SIL) . The drug is administered intravenously to treat poisoning by 
death cup (Amanita phalloides). 
Another group of hepatoprotectors is presented by drugs which 
are involved in the building of cellular membranes (unsaturated fatty 
acids, choline, phospholipids, essential amino acids, etc). As a rule, 
these drugs also contain vitamins which participate in detoxifying 
function of liver and in restoration of cellular membranes. This group 
includes such drugs as Essentiale,  thiotriazoline,  
ademetionine, lipoic (thioctic) acid , etc.  
Essentiale  contains unsaturated fatty acids as part of 
phospholipids, vitamins of group B, and tocopherol. The drug is 
administered intravenously in crucial cases (hepatic coma, acute 
poisoning with hepatic dysfunction, etc.). Also, Essentiale is taken 
orally to treat chronic hepatitis, liver cirrhosis, hepatic dysfunction in 
patients with diabetes mellitus, to prevent cholelithiasis reccurence, 
in pre- and postoperative periods, etc. Dose for oral intake is  
2–3 capsules 3 times a day before a meal.  
Thiotriazoline  is synthetic agent with anti-ischaemic, 
antioxidative, membrane stabilizing, and immunomodulatory 
activity. Drug prevents hepatocytes destruction, inhibits fatty 
infiltration and necrosis of liver. Thiotriazoline normalizes peptide, 
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carbohydrate, and pigmentary metabolism in the liver. Thiotriazoline 
stimulates both synthesis and discharge of bile. Besides, 
thiotriazoline reduces the ischemia of myocardium, decreases the 
necrotic zones after myocardial infarction, and activates fibrinolytic 
properties of blood. Drug is administered intravenously and 
intramuscularly in hepatitis, hepatic cirrhosis, ischaemic heart 
disease, myocardial infarction, cardiosclerosis, and arrhythmias.   
Ademetionine  (Heptral) contains the methyl groups which 
are essential to synthesis of membrane phospholipids, cysteine, 
glutathione, and taurine. These substances are essential for 
detoxifying function of liver.  Besides, ademetionine exerts 
antidepressive, analgesic, and anti-inflammatory effects. The drug is 
taken orally and administered intravenously or intramuscularly to 
treat intrahepatic cholestasis; toxic, viral, drug-induced, and 
alcoholic liver damage; cirrhosis, encephalopathy, including those in 
hepatic failure; depressive and abstinence syndrome. 
Lipoic acid  stimulates detoxifying function of liver, exhibits 
an antioxidant activity, participates in lipid and carbohydrate 
metabolism. The drug is prescribed to treat infectious hepatitis, 
chronic hepatitis, cirrhosis, intoxications, coronary atherosclerosis, 
and diabetic polyneuropathy. 
 
Drugs Used to Dissolve Gallstones   
(Cholelitholytic Drugs)  
 
It is proved, that certain derivatives of deoxycholic acid, such as 
ursodeoxycholic acid  (Ursofalk) and chenodeoxycholic 
acid  (Chenofalk) are able to dissolve cholesterol stones in 
gallbladder containing less than 4 % calcium. Intake of these drugs is 
accompanied by reduction of cholesterol concentration in bile. 
Chenodeoxycholic acid inhibits the synthesis of cholesterol in 
hepatocytes. Ursodeoxycholic acid decreases the intestinal 
absorption of cholesterol and suppresses its synthesis. Reduction of 
cholesterol concentration in bile decreases probability of stones 
formation in gallbladder. The change in ratio of cholesterol and bile 
acids in favor of the latter promotes gradual dissolution of 
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cholesterol-containing gallstones. These drugs are effective in case  
of long-time their intake (more than 1 year). Side effects of 
cholelitholytic drugs are increase of aminotransferase activity, 
diarrhea, and itching. Ursofalk is also used to treat biliary cirrhosis.  
 
Drugs Influencing Gastric Motility  
 
These drugs are divided into agents which increase gastric 
motility (prokinetics) and those which inhibit gastric motility.  
Prokinetics include such drugs as metoclopramide , 
cisapride , domperidone (Motilium), etc. Prokinetics are used at 
delayed gastric emptying and at gastroesophageal reflux. 
Metoclopramide blocks peripheral and central D2-dopaminergic 
receptors and activates 5HT4-serotoninergic receptors. Cisapride acts 
as 5HT4-serotoninergic receptor agonist and indirectly excites 
cholinergic receptors of intramural ganglia. Domperidone blocks 
peripheral D2-dopaminergic receptors that improves peristaltics.  
M-cholinoblocking drugs (atropine , platyphyllin , 
metacinium), ganglion blocking drugs (benzohexonium , 
pirilene), drugs blocking both M- and N-cholinoceptors of ganglia 
(Buscopan , Pro-Banthine), and myotropic spasmolytics 
(papaverine , No-Spa , etc.) are used to reduce gastric motility.   
 
Emetic Drugs 
 
Emetic drugs are apomorphine , herb of  thermopsis , root 
of ipecacuanha , copper sulfate, and zinc sulfate. 
Vomiting is complex reflex act with protective value which 
develops due to activation of vomiting (emetic) centre. Stimulants of 
vomiting centre convey impulses from the mucous membrane of 
stomach, intestine, and other internal organs; impulses from 
vestibular apparatus and the cortex (psychogenic vomiting), from 
visual, scents and taste analyzers, etc. But chemoreceptors of trigger 
zone are of principal importance in stimulation of vomiting. Trigger 
zone is located on the base of the fourth ventricle of cerebrum. 
Neuronal membranes of its chemoreceptors contain  
D2-dopaminergic, 5-HT3-serotoninergic, and M1-cholinergic 
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receptors. Excitation of these receptors results in stimulation of 
vomiting centre.  
Certain chemical substances which are synthesized in disturbed 
metabolism in renal and hepatic failure or in toxemia of pregnancy, 
as well as number of drugs (opioid analgesics, digitalis, antitumoral 
agents) also are stimulants of chemoreceptors of trigger zone.   
Apomorphine  is an emetic drug with central action. The drug 
is a specific agonist of D2-receptors. Apomorphine is used for 
elimination of poison from the stomach in cases when gastric lavage 
is impossible (for example, poisoning by mushrooms or by other 
foods, which do not pass through a tube, etc). Apomorphine is 
administered subcutaneously or intramuscularly. Emetic effect 
develops in 2–15 minutes. 
Inducing vomiting is contraindicated to unconscious patients, 
pregnants, in childhood and advanced age, as well as in poisoning by 
gasoline, kerosene, turpentine, acids, alkalis, and other substances, 
affecting mucous membranes. In such cases, the gastric lavage with 
absorbents and the following saline laxatives is preferable. 
Thermopsis herb  and ipecacuanha root  are agents which 
excite emetic centre reflexively. These drugs, taken orally in high 
doses, excite stomach receptors and stimulate vomiting by reflex 
mechanism. It should be noticed that alkaloids of thermopsis and 
ipecacuanha after absorption into the blood can directly stimulate the 
chemoreceptors of trigger zone.  
Copper sulfate  and zinc sulfate  also have the peripheral 
mechanism of emetic action which is associated with irritation of 
mucous membrane of stomach. 
It should be noted, that the use of emetic drugs in medical 
practice is significantly restricted.   
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Antiemetic Drugs 
 
Antiemetic drugs are classified as follows. 
1. Agents which are used to treat vomiting of central origin:  
– antagonists of D2-dopaminergic receptors: metoclopramide, 
thiethylperazine, perphenazine (aethaperazinum), aminazine  
(chlorpromazine), triftazinum, etc.; 
– antagonists of 5-HT3-serotoninergic receptors: ondansetron, 
tropisetron, granisetron . 
2. Agents which are effective at vomiting due to violation of 
vestibular apparatus: 
– M-cholinoblockering drugs: scopolamine, “Aeron”; 
– antagonists of H1-histaminergic receptors: dimedrolum, 
diprazinum.  
At kinetosis (seasickness and airsickness), vomiting occurs due 
to overexcitation of vestibular apparatus. Vestibular apparatus carries 
out impulses to the cerebellum, which, in turn, transmits impulses to 
the vomiting centre. Because M-cholinergic and H1-histaminergic 
receptors of cerebellum participate in this transduction of impulses, 
the following drugs are used to prevent vomiting of vestibular origin: 
tablets “Aeron” (contain M-cholinoblocking agents scopolamine 
and hyoscyamine), tablets or patch of scopolamine  (Scopoderm 
TTS), and H1-histaminergic antagonists – dimedrolum  and 
diprazinum . These drugs are effective at kinetosis due to blockage 
of M-cholinergic and H1-histaminergic receptors in cerebellum. But 
it is possible, that a direct inhibitory influence upon vomiting centre 
also participates in antiemetic effect of these agents. Their side 
effects include drowsiness, dry mouth, and blurred vision.    
Metoclopramide  (Cerucal, Reglan) is one of the most 
often used antiemetic drugs. Mechanism of its action is associated 
with the blockage of D2-receptors in neurones of trigger zone. High 
doses of the drug block also 5-HT3-serotoninergic receptors. 
Metoclapramide is used in the treatment for stomach and duodenum 
ulcer, meteorism, dyskinesia, oncological diseases of gastrointestinal 
tract, radiation sickness, uraemia, delayed gastric emptying, and 
reflux esophagitis. The drug is taken orally or administered 
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parenterally (intramuscularly or intravenously). Its effect develops 
quickly and lasts 6–8 hours. Side effects of metoclopramide include 
drowsiness, tinnitus, dry mouth, and extrapyramidal disorders typical 
for parkinsonism. 
Certain neuroleptics – phenothiazine derivatives, such as 
thiethylperazine, perphenazine (aethaperazinum), 
chlorpromazine (aminazine), and triftazinum  are also used as 
antiemetic agents. Their mechanism of action is associated with 
blockage of D2-receptors of trigger zone. Thiethylpirazine also 
directly oppresses vomiting centre. Besides, these drugs exert 
marked sedative and antipsychotic effects. Neurileptics are effective 
in vomiting of central origin. 
Ondansetron  (Zofran), tropisetron, and granisetron  are 
antagonists of 5-HT3-serotoninergic receptors. Drugs are 
characterized by high efficacy in vomiting following cancer 
chemotherapy, in postoperative period, and in radiation sickness. 
Drugs are taken once a day orally or administered parenterally. Their 
antiemetic effect lasts to 24 hours. Side effects are headache, 
dizziness, and constipation.  
  
Drugs Influencing Intestinal Motility  
 
Drugs stimulating intestinal motility (Prokinetics)  
 
This group includes drugs which elimanate intestinal atony. 
According to mechanism of action, these drugs are classified as 
follows:  
1) drugs stimulating M-cholinergic receptors: aceclidine ; 
2) cholinesterase inhibitors: proserinum, pyridostigmine, 
distigmine ;   
3) agonists of 5-HT4-serotoninergic receptors: cisapride ;   
4) agonists of motilin receptors: erythromycin , 
oleandomycin .  
Aceclidine  interacts with M-cholinergic receptors of smooth 
muscles of gastrointestinal tract and excites them. 
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Cholinesterase inhibitors (proserinum , etc.) suppress the 
activity of cholinesterase and increase the level of acetylcholine in 
cholinergic synapses.  
Motilin receptors are located in antrum and in duodenum. These 
receptors are excited by motilin. It is gastrointestinal polypeptide 
hormone which stimulates gastrointestinal motility. Antibiotics 
erythromycin  and oleandomycin  excite motilin receptors and 
stimulate intestinal motility.  
Besides, such drugs as hormonal agent vasopressin and laxative 
drugs also stimulate intestinal smooth muscles.  
 
Drugs Inhibiting Intestinal  Motility and  
Reducing Intestinal Spasms 
 
Following groups of drugs are used to eliminate intestinal 
spasticity:  
1) M-cholinoblockers: atropine, platyphyllin, metacinium;   
2) ganglion blockering drugs: pirilenum, benzohexonium 
(hexamethonium);   
3) myotropic spasmolytics: papaverine, drotaverine (No-spa).  
Pharmacology of M-cholinoblockering and ganglion blockering 
drugs is presented in relevant sections. Myotropic spasmolytics or 
myotropic antispasmodic agents inhibit the enzyme 
phosphodiesterase that leads to accumulation of cAMP and decrease 
of smooth muscles’ tone and motility. 
 
Antidiarrheal Drugs 
 
Antidiarrheal drugs are used in the treatment for diarrhea. These 
drugs eliminate diarrhea by means of slowdown of intestinal 
peristalsis and contraction of its sphincters or by means of reduction 
of irritants influence upon intestinal mucosa. For pathogenetic 
therapy, drugs eliminating intestinal dysbiosis are used.  
Diarrhea is due to different diseases and intoxications 
(psychogenic diarrhea, cholera, dysentery, poisoning by heavy metal 
salts and arsenicum, sharp change of feeding habits, insufficiency of 
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gastric or pancreatic secretion, etc.). Long-lasting diarrhea is 
dangerous by dehydration and loss of electrolytes that is 
accompanied by hypotension, disorders of conscious, convulsions, 
and other disorders.  
Each disease, accompanied by diarrhea, needs specific therapy. 
Thus, chemotherapy is used to treat infectious enterocolitis. 
Substitutive therapy by pepsin, gastric juice, or pancreatic enzymes 
are used in the treatment for diarrhea due to insufficiency of gastric 
or pancreatic secretion. At dysbiosis, pathogenic microflora is 
eliminated by antibacterial drugs and patient receives probiotics and 
prebiotics.  
Besides mentioned above drugs, nonspecific anti-inflammatory 
agents are used to treat diarrhea: enveloping, astringent, and 
absorbing drugs.  
Astringent drugs are able to form protective film on the surface 
gastrointestinal mucosa. Due to this, astringents protect mucosa from 
irritation, reduce inflammation, accelerate epithelization of erosions 
and ulcers, and slow down peristalsis. The following astringent drugs 
are used to treat diarrhea: albumin tannate (albutannin,  
tannalbin),  infusions or decoctions of oak bark, Hypericum 
grass, blueberry fruits ,  bismuth subnitrate, etc. 
Albumin tannate  is compound of tannin with casein. The drug 
exerts astringent action only in the intestine, because protein is 
degisted and tannin is released. Tannin itself exhibits astringent 
effect. Albutannin is taken orally 1–2 tablets 3–4 times a day.  
Bismuth subnitrate  exerts astringent and antibacterial effects.  
Astringent drugs are used to treat inflammatory intestinal 
diseases. The drugs are prescribed alone or combined with 
antibacterial, spasmolytic, and enveloping drugs.  
Enveloping drugs are high molecular weight substances which 
form colloids with water mechanically protecting gastrointestinal 
mucosa from irritants. It leads to decrease of intestinal peristalsis and 
reduces inflammation. Starch slime,  slime of f lax seeds, slime 
of gum arabic, etc. are used as enveloping drugs.   
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Activated carbon, diosmectite (Smecta)  and other 
absorbing drug are used in the treatment for gastritis, meteorism, 
infectious gastrointestinal diseases, food toxicoinfection, and 
poisoning.  Activated carbon is taken 1–2 g 3–4 times a day to treat 
meteorism. At acute poisoning, 20–30 g activated carbon is taken 
orally with the following intake of saline laxatives.     
     Loperamide (Imodium)  is a phenylpiperidine derivative 
which stimulates μ-opioid receptors in the intestine and inhibits 
peristalsis. Besides, the drug increases tone of pyloric sphincter and 
exerts weak analgesic action. Antidiarrheal effect of loperamide lasts 
4–6 hours. 
 
Antiflatulent Drugs 
 
Antiflatulent drugs are used in the treatment for meteorism. 
Antiflatulent drugs include preparations obtained from Peppermint 
leaves and Chamomile flowers.  
Peppermint leaves contain etheric oils, carotene, flavonoids, 
polyphenols, sterols, microelements, and menthol. At application on 
mucous membranes or skin, menthol irritates cold-sensitive receptors 
and causes feeling of coldness. Excitation of cold receptors leads to 
contraction of superficial vessels and reflex relaxation of vessels of 
inner organs. This property of menthol is used to eliminate angina 
pectoris attacks. Also, menthol exerts mild local anaesthetic and 
antiseptic effects. In gastrointestinal tract, menthol irritates receptors 
of gastric and intestinal mucosa and activates their peristalsis and 
secretion. Besides, peppermint preparations stimulate bile secretion. 
Galenical preparations of peppermint exhibit antispasmodic action 
and inhibit putrefying in intestine.  
Chamomile flowers contain flavonoids, dioxycumarins, choline, 
ascorbic acid, carotene, etheric oil, and other bioactive substances. 
Etheric oil of Chamomile exerts mild stimulating effect upon centres 
of medulla oblongata, activates contractile activity of myocardium, 
and dilates cerebral vessels. Besides, etheric oil of Chamomile 
stimulates bile secretion, reduce inflammation, and activate 
regeneration of epithelium. In high doses, etheric oil inhibits central 
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nervous system and decreases skeletal muscle tone. Galenical 
preparations of Chamomile are used as antiseptic, bile-expeling, 
diaphoretic, and antiflatulent drugs. Also, these drugs are used to 
treat gastric and intestinal pain, ulcers and different inflammatory 
diseases of gastrointestinal tract.      
 
Laxative Drugs 
 
Laxative agents are classified as follows:  
1. Saline laxatives: magnesium sulfate, sodium sulfate . 
2. Organic laxatives.  
2.1. Drugs of plant origin:  
– vegetable oils: castor oil ; 
– drugs contaning anthraquinone glycosides: extract of  
buckthorn (Rhamnus cathartica) cortex , rhubarb (Rheum) 
root,  senna leaves .  
2.2. Synthetic drugs: isaphenine, phenolphthalein, 
sodium picosulfate  (Guttalax), bisacodyl ,  Duphalac . 
3. Combined drugs: Саfiоlum  and Regulax .   
 
Saline Laxatives  
 
Magnesium sulfate and sodium sulfate  are used to 
purificate both small and large intestines. These drugs create high 
osmotic pressure in intestine that causes the retention of water in the 
intestinal lumen. An increase of intestinal content volume results in 
distension of bowel and irritation of intestinal mechanoreceptors that 
increases peristalsis. Drugs act throughout small and large intestines. 
Saline laxatives are taken orally in dose 15–30 g with 1–2 glasses of 
water. Their effect develops in 2–3 hours and lasts up to 6 hours. 
These drugs are used at acute constipation and in the treatment for 
acute poisoning to prevent the absorption of toxins into the blood. 
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Vegetable Oils  
 
Castor oil  is extracted from castor seeds. In duodenum, castor 
oil is hydrolysed by pancreatic lipases to glycerin and ricinic acid. 
Ricinic acid irritates receptors and stimulates the peristalsis 
throughout small and large intestines. Besides, ricinic acid affects 
intestinal absorption of ions and water.  
Castor oil is taken orally in dose 15–30 g for 30 minutes. 
Laxative effect develops in 2–6 hours. Castor oil is used at acute 
constipation, for preparation of a patient to roentgenologic 
examinations or to surgery on the abdominal organs. Also, castor oil 
may be used in the treatment for poisoning caused by lipid-insoluble 
toxins. It should be noticed that castor oil stimulates the uterine 
contractions.  
 
Drugs Containing Anthraquinone Glycosides  
 
 These drugs increase the peristalsis and facilitate feces 
excretion. Extracts of buckthorn cortex, rhubarb root, and 
senna leaves  are most commonly used drugs of this group. Natural 
vegetable anthraquinone glycosides lack laxative effect. But, under 
the influence of intestinal bacteries, these substances are hydrolyzed 
into anthraquinone derivatives, which irritate the intestinal receptors 
and stimulate peristalsis. These drugs act only in large intestine.  
Drugs are taken orally once in 2–3 days, as a rule at the bedtime 
or in the morning before breakfast. Laxative effect develops  
in 8–10 hours.  
Anthraquinone glycosides accumulate in the mucous membrane 
and smooth muscles of the bowels and can cause the atrophy of its 
smooth muscle layer. In this case constipation becomes chronic and 
resistant to laxative drugs. Long-lasting intake of these laxatives can 
cause hepatic dysfunction.  
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Synthetic Laxative Drugs  
 
Phenolphthalein  is absorbed into the small intestine and 
secreted into the large one, where it irritates receptors and decreases 
the absorption of electrolytes and water. Laxative effect develops in 
6–8 hours after the drug intake. Phenolphthalein can cumulate in the 
body and affect the kidneys. Side effects of phenolphthalein include 
allergic reactions, intestinal colics, tachycardia, and collapse.  
Mechanism of action of isaphenine  is similar to 
phenolphthalein, but this drug is less toxic.    
 Sodium picosulfate (Guttalax) and bisacodyl under the 
influence of intestinal bacteries release the active radicals stimulating 
intestinal receptors and increasing peristalsis. The drugs are used to 
treat chronic constipations. Onset of their laxative effect is observed 
in 6–10 hours after drugs intake. 
There are combined laxative drugs – Саfiоlum  and Regulax. 
These drugs are used in the treatment for chronic constipations.  
Vaseline oil and other oils also exert laxative effect. 
Disaccharides (lactulose and sorbitol) soften contents of large 
intestine and increase its volume that stimulate peristalsis. Lactulose 
is an active component of Duphalac. Glycerin suppositories are 
also used for fast defecation. Glycerin irritates intestinal mucosa and 
stimulates contraction of rectum. Its effect develops in  
15–20 minutes.    
 
Table 6 – Drugs for prescription 
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product 
Desopimonum  Orally 0.025 g 2 times a day  Tablets 0.025 g 
Succus gastricus 
naturalis 
Orally 15–30 ml with meal  Vials 100 ml  
Pepsinum  Orally 0.2–0.5 g with meal  Powder 
Acidum 
chidrochloricum 
dilutum 
Orally 10–15 drops with 
meal  
Vials 50 ml 
Ranitidinum  Orally 0.15 g 2–3 times 
a day  
Tablets 0.15 g 
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Continuation of the table 6 
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product 
Pirenzepinum  Orally 0.05 g 2 times a day; 
intravenously  
or intramuscularly 0.01 g  
2 times a day  
Tablets 0.025 or 0.05 g; 
ampoules 2 ml  
of 0.5 % solution 
Omeprazolum  Orally 0.02 g once a day  Capsules 0.02 g 
Magnesii oxydum  Orally 0.25–1.0 g 4 times 
a day  
Powder; 
tablets 0.5 g 
Almagelum  Orally 1 teaspoon 4 times 
a day  
Vials 150 ml 
De-nolum  Orally 0.12 g 4 times a day  Capsules 0.12 g 
Sucralfatum  Orally 0.5–1 g 4 times a day Tablets 0.5 or 1.0 g 
Apomorphini 
hydrochloridum  
Subcutaneously  
0.002–0.005 g  
Ampoules 1 ml  
of 1 % solution 
Metoclopramidum  Orally 0.01–0.02 g 2–3 times 
a day; 
intramuscularly  
or intravenously 0.01 g  
1–3 times a day  
Tablets 0.01 g; 
ampoules 2 ml  
of 0.5 % solution  
Aethaperazinum  Orally 0.004–0.006 g  
3–4 times a day  
Tablets 0.004 or 0.006 g 
Cholenzymum Orally 1 tablet 1–3 times 
a day after a meal  
Combined tablets 
containing 0,1 g dry bile, 
0,1 g dried pancreatic 
gland, and 0,1 g dried 
mucous membrane of the 
small intestines 
Cholosasum Orally 1 teaspoon 2–3 times 
a day after a meal  
Vials 50 or 300 ml  
Papaverini 
hydrochloridum  
Orally 0.04–0.06 g 3–4 times 
a day; 
subcutaneously, 
intramuscularly  
or intravenously 0.02–0.04 g  
Tablets 0.04 g; 
 
ampoules 2 ml  
of 2 % solution  
Nospanum  Orally 0.04–0.08 g 2–3 times 
a day; 
subcutaneously, 
intramuscularly  
or intravenously 0.04–0.08 g  
Tablets 0.04 g; 
 
ampoules 2 ml of 2 % 
solution 
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Continuation of the table 6 
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product 
Oxaphenamidum  Orally 0.25–0.5 g 3 times 
a day after a meal  
Tablets 0.25 g 
Pancreatinum  Orally 0.25–0.5 g 3 times 
a day during or after a meal  
 
Tablets 0.25 or 0.5 g 
Magnesii sulfas  Orally 10–30 g in 1 glass  
of water  
Powder  
Oleum Ricini  Orally 15–30 g  Capsules 1.0 g 
Isapheninum  Orally 0.005–0.01 g  
1–2 times a day  
Tablets 0.01 g 
Contrical Intravenously drop-by-drop 
10 000–50 000 IU  
Vials 10 000, 30 000 or 
50 000 IU of powder for 
injection 
 
 
Step 1.  Tasks for Self -Control  
Drugs Influencing Digestive System  
 
1. A 37-year-old man was admitted to the surgical department 
with symptoms of acute pancreatitis: vomiting, diarrhoea, 
bradycardia, hypotension, weakness, dehydration of the organism. 
What medicine should be used first? 
A. No-spa. 
B. Contrical.  
C. Etaperazine. 
D. Ephedrine. 
E. Platyphyllin. 
2. Cimetidine slows metabolism of many drugs because it 
inhibits the activity of: 
A. Phase II glucuronidation reactions. 
B. Monoamine oxidase (MAO). 
C. Cytochrome P-450.  
D. H+, K+-ATPase. 
E. Tyrosine kinase. 
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3. The absorption of phosphate reduces when large and 
prolonged doses of which of the following antacids are given? 
A. Calcium carbonate.  
B. Magnesium hydroxide. 
C. Magnesium trisilicate. 
D. Sodium bicarbonate. 
E. Sucralfate. 
4. Omeprazole, an agent for the promotion of peptic ulcers 
tretment, has a mechanism of action that is based on: 
A. Anticholinergic action. 
B. Gastric secretion. 
C. Pepsin secretion. 
D. Prostaglandins. 
E. H+, K+-ATpase.  
5. The approved indication for misoprostol is: 
A. Pathologic hypersecretory conditions such as Zollinger-
Ellison syndrome. 
B. Regional ileitis. 
C. Ulcerative colitis. 
D. Reflux esophagitis. 
E. Prevention of gastric ulceration in patients using large doses 
of aspirin-like drugs.  
6. Bismuth salts are thought to be effective in peptic ulcer 
disease because they have bactericidal properties against: 
A. Staphylococcus aureus. 
B. Helicobacter pylori.  
C. Clostridium difficile. 
D. Escherichia coli. 
E. Bacteroides fragilis. 
7. Misoprostol has a cytoprotective action on the gastrointestinal 
mucosa because it: 
A. Coats the mucosa. 
B. Neutralizes acid secretion. 
C. Antagonizes nonsteroidal anti-inflammatory drugs. 
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D. Enhances secretion of mucus and bicarbonate ion. 
E. Relieves ulcer symptoms. 
8. Point out the primary pharmacological effect of omeprazole: 
A. Reduction of secretion of intrinsic factor. 
B. Reduction of gastric motility. 
C. Stimulation of secretion of pepsin. 
D. Elevation of volume of gastric juice. 
E. Reduction of secretion of hydrochloric acid.  
9. Which of the following is not associated with sucralfate? 
A. It has moderate acid-neutralizing properties.  
B. It maintains gel-like qualities even at acid pH. 
C. It binds to ulcer craters more than to normal mucosa. 
D. It contains polyaluminium hydroxide. 
E. It reacts little with mucin. 
10. Point out the preferred drug for therapy of Zollinger-Ellison 
syndrome: 
A. Metronidazole. 
B. Sucralfate. 
C. Omeprazole. 
D. Ranitidine. 
E. Misoprostol. 
11. A 36-year-old woman with severe erosive esophagitis is 
prescribed pantoprazole. Which of the following side effects of such 
therapy is one of the most common? 
A. Headache. 
B. Constipation. 
C. Vomiting. 
D. Heartburn. 
E. Paresthesias. 
12. While taking non-steroidal anti-inflammatory drug for 
arthritis, a 65-year-old man developed gastric ulcer. He was 
prescribed ranitidine for 8 weeks. This drug binds a receptor located 
in the: 
A. Cell wall. 
B. Nucleolus. 
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C. Cytoplasm. 
D. Cell membrane.  
E. Nucleus. 
13. Gastric acid secretion is stimulated by the presence of: 
A. Acetylcholine and pepsin. 
B. Histamine and motilin. 
C. Norepinephrine and gastrin. 
D. Norepinephrine and histamine. 
E. Gastrin and acetylcholine. 
14. A physician must always be aware of possible drug 
interactions.  Aluminum hydroxide antacids tend to interfere with the 
gastrointestinal absorption of: 
A. Cephalexin. 
B. Tetracycline.  
C. Erythromycin. 
D. Chloramphenicol. 
E. Penicillin G. 
15. One mechanism to reduce gastric acid secretion is by 
blocking the H+, Na+-ATPase pump in the parietal cell. One drug that 
has this pharmacologic action is: 
A. Omeprazole. 
B. Pirenzepine. 
C. Misoprostol. 
D. Serotonin. 
E. Isoniazid. 
16. Concomitant administration of calcium and/or magnesium 
antacids to patients receiving one of the tetracycline drugs may have 
the following effects upon the action of the tetracycline: 
A. Suppresses hypersensitivity reactions. 
B. Decreases the action.  
C. Enhances the action. 
D. Increases toxicity. 
E. Causes no significant change. 
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17. Famotidine is prescribed to a patient with gastric ulcer. The 
acidity of gastric juice has considerably decreased. What mechanism 
underlies the action of the drug? 
A. Blockade of N-cholinoceptors. 
B. Blockade of H1-histaminic receptors. 
C. Blockade of M1-cholinoceptors. 
D. Suppression of Na+, K+-ATPase activity. 
E. Blockade of H2-histaminic receptors.  
18. A 40-year-old patient suffers from gastric ulcer at the stage 
of exacerbation accompanied by a substantial increase of the acidity 
of gastric juice, pain, and dyspeptic syndrome. Choose the drug for 
treatment of this patient. 
A. Festal. 
B. Allocholum. 
C. Famotidine.  
D. No-spa. 
E. Papaverine hydrochloride. 
19. A patient complains of stomachache and heartburn. Tests 
revealed the increase of gastric juice acidity. What drug should be 
prescribed to the patient for neutralization of the excessive acidity  
of gastric juice? 
A. Benzohexonium. 
B. Almagel. 
C. Papaverine hydrochloride. 
D. Ranitidine. 
E. Atropine. 
20. In a patient with stomach ulcer Helicobacter pylori were 
detected. What drug, which influences Helicobacter pylori, should be 
prescribed in this case? 
A. Maalox. 
B. Almagel. 
C. Famotidine.  
D. Metronidazole. 
E. Atropine sulfate. 
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21. To a patient with ulcer disease of stomach was prescribed 
drug, the mechanism of which action is based on the blockade  
of H2-hystamine receptors. Call this drug. 
A. Dithylinum. 
B. Bisacodyl.  
C. Omeprazole. 
D. Atropine sulfate. 
E. Famotidine. 
22. A patient suffering from chronic hyperacidic gastritis takes 
an antacid drug for heartburn elimination. After its ingestion the 
patient feels better but at the same time, he has a sensation  
of stomach swelling. Which of the following drugs might be the 
cause of such side effect? 
A. Aluminium hydroxide. 
B. Sodium hydrocarbonate. 
C. Magnesium oxide. 
D. Magnesium trisilicate. 
E. Pepsin. 
23. Metoclopramide has antiemetic properties because it: 
A. Decreases gastric secretion. 
B. Lowers esophageal sphincter pressure. 
C. Accelerates gastric emptying time. 
D. Has sedative properties. 
E. Is a central nervous system dopamine-receptor antagonist.  
24. Point out the drug to treat steatorrhea of pancreatic 
insufficiency: 
A. Secretin. 
B. Misoprostol. 
C. Pancrelipase.  
D. Cimetidine. 
E. Bile salts. 
25. A 20-year-old woman goes to the emergency department, 
stating that within the past hour she ingested “a handful of sleeping 
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pills”. She is still awake. Which of the following drugs can be given 
to induce vomiting? 
A. Apomorphine hydrochloride.  
B. Metoclopramide. 
C. Morphine. 
D. Promethazine. 
E. Ondansetron. 
26. A 62-year-old woman on haemodialysis is scheduled for a 
screening colonoscopy. Which drug should be prescribed for her 
colonic preparation? 
A. Cholosasum. 
B. Omeprazole. 
C. Magnesium oxyde. 
D. Magnesium sulfate.  
E. Ranitidine. 
27. A 37-year-old man was admitted to the surgical department 
with symptoms of acute pancreatitis: vomiting, diarrhoea, 
bradycardia, hypotension, weakness, dehydration of the organism. 
What medicine should be used first of all? 
A. Contrical.  
B. Platyphyllin. 
C. Etaperazine. 
D. Ephedrine. 
E. No-spa. 
28. A 48-year-old woman receives epidural anaesthesia for 
vaginal hysterectomy. In recovery room, a fentanyl infusion was 
begun epidurally for relief of postoperative pain.  About six hours 
later, she began to complain of nausea and had two episodes of 
vomiting. How could nausea and vomiting best be relieved?  
A. Administer apomorphine.  
B. Sedate the patient with midazolam (versed).  
C. Withhold oral administration of fluids.  
D. Discontinue the fentanyl (sublimaze) infusion. 
E. Administer ondansetron.  
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29. In esophagitis, elevation of the head of the bed, abstinence 
from ethanol and tobacco, and small frequent meals are all useful 
adjunctive therapeutic measures. Other useful therapy may include 
all of the following except: 
A. Amitriptyline.  
B. Metoclopramide. 
C. Bethanechol. 
D. Cimetidine. 
E. Omeprazole. 
30. An ambulance took a patient to a hospital in serious 
condition (nausea, vomiting). It is established that the day before he 
celebrated a wedding with the family. The initial diagnosis is food 
toxicoinfection. What drug is it necessary to use first of all? 
A. Adrenaline hydrochloride. 
B. Butamide. 
C. Clophelinum. 
D. Dimedrol. 
E. Magnesium sulfate. 
31. Intestine colic has developed in hypertensive patient. Choose 
the drugs group which is most rational for interruption of colic in this 
patient.  
A. Adrenomimetics. 
B. Miotropic spasmolytics. 
C. Sympathomimetics. 
D. M-cholinoblockers. 
E. Cholinesterase inhibitors. 
32. Laxative drug having osmotic activity was prescribed to 
patient. What is this drug? 
A. Sustac. 
B. Bisacodyl. 
C. Vaseline. 
D. Isaphenine. 
E. Magnesium sulfate. 
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33. Laxative drug was prescribed to patient with brain edema. 
Indicate this drug. 
A. Liquid paraffin. 
B. Cortex of buckthorn. 
C. Magnesium sulfate. 
D. Castor oil. 
E. Bisacodyl. 
 
 
DIURETIC DRUGS 
 
Diuretics are drugs which increase the excretion of salts and 
water from the body. These drugs are also referred as “saluretics” 
because their mechanism of action is associated with the ability to 
increase excretion of sodium and chlorine ions. Diuretics are widely 
used in medicine, including the emergency treatment. Various renal, 
cardiovascular, and hepatic diseases and some other pathological 
states are accompanied by retention of salts and water that leads to 
the increase of tissues hydratation, development of edemas, and 
accumulation of fluids in body cavities.    
Mechanism of diuretics action can be understood based on the 
modern ideas about process of diuresis. About 150–200 l of fluid and 
25 000 milliequivalents of sodium are filtrated in human kidneys for 
24 hours. But up to 99 % of initial urine undergoes reabsorption and 
only 2 l of fluid and 100 milliequivalents of sodium are excreted with 
urine. Initially, sodium reabsorption from the renal tubules occurs 
through apical membrane. Sodium is transported through apical 
membrane by means of special carrier protein which is synthesized 
under control of aldosterone. After entering in the cells of renal 
tubules, sodium ions are absorbed through basal membrane in the 
interstitium and capillaries. Sodium transport through basal 
membrane is an active process that occurs by means of special 
pumps. These pumps transport sodium ions against concentration 
gradient with energy consumption. There are pump transporting 
sodium ions in exchange for potassium ions and pump transporting 
sodium ions together with chlorine or hydrocarbonate ions 
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independently of potassium. Reabsorption of water is a passive 
process dependent on sodium reabsorption. Resynthesis of ATP is 
provided due to oxidative phosphorylation in renal cortex and due to 
glycolysis – in renal medulla. Sodium transport through intercellular 
spaces is also important part of reabsorption. Sodium is pumped by 
lateral cellular surfaces into channels, which are cloused from the 
direction of apical membrane but are opened from the direction of 
basal membrane. Increased sodium concentration in these 
intercellular spaces leads to water flow from channel in the 
peritubular capillaries. Intercellular spaces create the necessary 
conditions for flow of water and sodium ions from peritubular space 
into channel that is very important. 
In different segments of nephron, a degree of resistance of 
channel wall for water reabsorption is different. Descending part of 
Henle’s loop is easily permeable for water, whereas ascending 
segment is permeable for sodium and chlorine ions and poorly 
permeable for water. Urine becomes hyposmotic due to passing 
through ascending segment. But interstitial fluid in renal medulla 
becomes hyperosmotic that promotes the reabsorption of water in 
descending part of Henle’s loop. Final urine formation is occurred in 
distal convoluted tubules and collecting ducts. 
Transport of sodium ions and water is under hormonal control. 
Vasopressin (antidiuretic hormone) controls water retention in the 
body. Mineralocorticoid aldosterone stimulates sodium reabsorption 
and simultaneous secretion of potassium through apical membrane of 
nephron by electrochemical gradient. Renal sodium transport is also 
regulated by natriuretic peptide which secreted by atriums, 
hypothalamus, and liver. Such hormones as estrogens, somatotropin, 
and insulin increase sodium reabsorption. Progesterone, 
parathyroidin, and glucagon inhibit sodium reabsorption. Some 
biologically active local agents synthesized in kidneys also are 
important (e. g., kinins, prostaglandins, dopamine). 
Based on the characteristics of the process of urine formation, it 
is evident that diuretics can either directly influence uropoiesis or 
change hormonal regulation of this process. 
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There are numerous classifications of diuretics. Classification 
based on the action mechanism of diuretics and localization of their 
action is given below.  
1. Diuretics acting on the level of epithelial cells of renal tubules 
and inhibiting sodium and water reabsorption.   
 1.1. Diuretics acting on the level of basal membrane:  
a) derivatives of anthranilic and benzoic acids: furosemide,  
torasemide (torsemide), and bumetanide (Bufenox); 
b) benzamide derivatives: clopamide and indapamide ;  
c) benzothiadiazine derivatives  (thiazides): dichlothiazidum 
(hydrochlorothiazide), cyclomethiazide, and polythiazide ;    
d) derivatives of dichlorophenoxyacetic acid: etacrynic acid 
(ethacrynic acid) ; 
e) carbonic anhydrase inhibitors: acetazolamide (diacarb) . 
1.2. Diuretics acting on the level of apical membrane – drugs 
inhibiting transporters of sodium: triamterene, amiloride .  
2. Aldosterone antagonists: spironolactone .  
3. Osmotic diuretics: mannitol .   
4. Drugs increasing renal circulation: euphyllinum 
(aminophylline) . 
5. Diuretics of plant origin: horsetail herb, bearberry 
leaves,  birch buds , etc.  
Depending on the efficacy of diuretic activity, all drugs are 
classified as follows:  
1. Most effective diuretics: furosemide (Lasix), etacrynic 
acid (Uregyt),  clopamide (Brinaldix),  mannitol.  
2. Diuretics with moderate activity: dichlothiazidum, 
cyclomethiazide, polythiazide, hlortalidone  (oxodolinum, 
Hygroton) . 
3. Diuretics with weak activity: diacarb, spironolactone 
(Verospiron, Aldactone) ,  triamterene, amiloride,  
euphyllinum, drugs of plant or igin .  
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Depending on speed of effect development, diuretics are 
classified as follows:  
1. Diuretics with fast development of the effect (within  
30–40 minutes): furosemide, etacrynic acid,  mannitol,  
bumetanide, torasemide .  
2. Drugs with a moderate speed of the effect development (onset 
of action is in 1–4 hours after drug administration, and duration of 
the action is 9–24 hours): dichlothiazidum, diacarb, 
euphyllinum, cyclomethiazide,  clopamide, chlortalidone  ,  
triamterene, indopamide .  
3. Diuretics with slow development of the effect (onset of action 
is in 2–5 days after drug intake, and duration of action is  
5–7 days): spironolactone, potassium canrenoate .       
  
Diuretics Acting on the Level of Epitelial Cells  
of Renal Tubules 
 
Derivatives of Antranilic and Benzoic Acids  
(Loop Diuretics) 
 
Furosemide (Lasix),  torasemide (Trifas), bumetanide 
(Bufenox) inhibit hexokinase, malate dehydrogenase, succinate 
dehydrogenase, and Na+, K+-ATPase. Besides, these drugs dissociate 
energy production and its supply to the ionic pumps. These changes 
cause the reduction of sodium current through basal membrane in 
intersticium. Also, loop diuretics increase the synthesis of 
prostaglandins and kinins which dilate renal vessels and increase 
sodium excretion. 
A main segment of these drugs action is a thick ascending limb 
of the Henle’s loop; therefore, these drugs are referred as “loop 
diuretics”. In certain degree, anthranilic acid derivatives inhibit 
sodium reabsorption in proximal tubules. 
All agents of this group increase potassium excretion that is 
undesirable. It is due to the increase of luminal membrane 
permeability for sodium ions in distal convoluted tubules that is 
accompanied by the increase of intratubular potencial and elevation 
of passive potassium secretion into the tubular lumen.   
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Furosemide (Lasix)  was introduced in medical practice in 
1963. The drug exerts marked diuretic effect both at parenteral and 
enteral administration. At oral intake, its effect develops in 30– 
60 minutes and lasts 6–8 hours. At intravenous administration, 
furosemide’s effect develops in 5–10 minutes and lasts 2–4 hours.  
Furosemide is readily absorbed from gastrointestinal tract and 
binds with plasma proteins. Furosemide undergoes hepatic 
metabolism through hydrolysis and conjugation with glucuronic acid. 
Metabolites are excreted by kidneys.  
Furosemide is a low toxic agent with therapeutic dosage range 
from 0.002 g to 2.0 g. It is one of the most potent diuretics. 
Furosemide is used in the treatment for chronic oedemas of cardiac, 
renal, and hepatic origin; acute heart failure, pulmonary oedema, 
brain oedema, acute and chronic renal failure, forced diuresis, 
hypertensive disease, and hypertensive crisis.   
At hypertensive disease, therapeutic effect of furosemide is 
mainly result of the decrease of sodium concentration in the arteriole 
walls, and only partially is a result of circulatory volume decrease. 
Reduction of sodium concentration in vascular wall leads to the 
decrease of vascular sensitivity to vasoconstrictors. 
Side effects of furosemide are hypokalemia, hypochloraemic 
alkalosis, hyperglycemia (due to reduction of pancreatic insulin 
secretion), hyperuricemia (furosemide competes with uric acid for 
binding with special carrier protein in proximal convoluted tubules), 
hypocalcemia, hypomagnesemia, hyperreninemia, ototoxicity (due to 
intravenous administration of high doses of furosemide).  
Torasemide  acts longer than furosemide and is presribed once 
a day.   
Bumetanide (Bufenox)  acts faster than furosemide. Its 
diuretic effect is 20–50 times higher than furosemide. Duration of 
bumetanide action is 4–6 hours. The drug is administered 
parenterally or taken orally. Indications for use and side effects are 
like furosemide. Its therapeutic indications and side effects are same 
with those of furosemide. But bumetanide causes less hypokalemia 
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than furosemide. Long-lasting therapy with bumetanide can cause 
muscular pain.   
 
Benzamide Derivatives  
 
Pharmacological properties of clopamide  are like to those of 
furosemide. Clopamide exerts high natriuretic activity. The drug is 
taken orally. Onset of its diuretic effect is 1–3 hours. Duration  
of action is 8–20 hours.  
Indapamide (Arifon)  exerts diuretic and hypotensive effects. 
Its chemical structure is similar to those of clopamide. The drug is 
taken orally once a day in the morning. Indopamide is used 
predominantly to treat hypertensive disease.  
 
Benzothiadiazine  Derivatives  (Thiazides) 
 
 Hydrochlorothiazide (dichlothiazidum ) exerts moderate 
diuretic activity. The drug inhibits sodium and chlorine reabsorption 
mainly in initial part of distal convoluted tubules. Partly, its effect 
appears in proximal convoluted tubules. Hydrochlorothiazide is 
effective both in orall and parenteral administration; but practically, 
it is used mainly for orall intake. Its diuretic effect develops  
in 30–60 minutes after intake and lasts 8–12 hours. About 60 % 
taken dose binds to plasma proteins. Hydrochlorothiazide is excreted 
through kidneys. Development of tolerance is uncharacteristic of 
dichlothiazidum. Hydrochlorothiazide is used to treat oedemas due to 
chronic cardiac, hepatic and renal diseases; hypertensive disease, 
diabetes insipidus, and nephrolithiasis.  
Mechanism of dichlothiazidum action in diabetes insipidus is the 
following. The drug inhibits phosphodiesterase in cells of renal 
medulla that that leads to accumulation of intracellular cAMP. 
Owing to this, the water reabsorption through epithelium of 
collecting ducts is increased. Volume of urina is reduced. That is, 
dichlothiazidum potentiates or restores the effect of vasopressin in 
patients with diabetes insipidus.   
Most common side effects of hydrochlorothiazide are 
hypokalemia and hypochloraemic alkalosis. Hypomagnesemia, 
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hypercalcemia (due to increase of parathyroid hormone activity in 
kidneys), hyperuricemia, and hyperglycemia are also possible.  
Pharmacological properties and therapeutic indications of 
polythiazide  and cyclomethiazide  are similar to those  
of dichlothiazidum. But, their diuretic activity is higher than activity 
of dichlothiazidum (polythiazide – 50 times, cyclomethiazide –  
100 times).   
Chlortalidone  (oxodolinum) is like to thiazides. The drug is 
characterized by long duration of action. After oral intake onset of its 
action is in 2–4 hours, duration of effect is about 3 days.    
     
Derivatives of Dichlorophenoxyacetic Acid  
 
Etacrynic acid  (Uregyt) is dichlorophenoxyacetic acid 
derivative. According to mechanism of action, this drug is a loop 
diuretic. The agent suppresses the reabsorption of sodium and 
chlorine ions on the level of basal membrane of epithelial cells in the 
thick ascending limb of the Henle’s loop. Diuretic effect of etacrynic 
acid is high. Etacrynic acid is administered parenterally and orally. 
At oral intake, its effect develops in 30–60 minutes and lasts up to  
8 hours. At intravenous administration, the effect develops  
in 5–15 minutes and lasts 3–4 hours. 
Therapeutic indications for etacrynic acid are chronic oedemas 
of cardiac, renal, and hepatic origin, acute heart failure, pulmonary 
oedema, brain oedema, acute and chronic renal failure, forced 
diuresis, treatment of hypertensive disease, and interruption  
of hypertensive crisis. 
Etacrynic acid exerts higher toxicity than furosemide. Its side 
effects are hypokalemia, hyponatremia, hypomagnesemia, 
hypochloremic alkalosis, hypocalcemia, hearing impairment, 
weakness, dizziness, diarrhea, etc. Intravenous administration  
of etacrynic acid is painful and can cause phlebitis.   
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Carbonic Anhydrase Inhibitors  
 
Diacarb (acetazolamide) is a weak diuretic which inhibits 
carbonic anhydrase of epithelial cells in proximal convoluted tubules. 
This enzyme catalizes the synthesis of carbonic acid from water and 
carbon dioxide: Н2О + СО2  Н2СО3. Carbonic acid dissociates to 
hydrogen and hydrocarbonate ions. Kidneys secrete the hydrogen 
ions into urine with reabsorption of the hydrocarbonate ions. This 
process provides support of an acid-based balance in the body. 
Diacarb decreases reabsorption of the hydrocarbonate ions that leads 
to the increase of urine pH and reduces alkaline reserve of the blood. 
Retention of hydrogen ions is accompanied by compensatory 
secretion of potassium ions. Therapy with diacarb quickly leads to 
acidosis due to hyperchloremia.  
Diacarb inhibits activity of ciliary body of the eye that decreases 
secretion of aqueous humor. Inhibition of carbonic anhydrase also 
leads to the decrease production of cerebrospinal fluid and reduction 
of intracranial pressure.  
Effect of orally taken diacarb develops in 1–1.5 hours and lasts 
6–12 hours. The drug is used in the treatment for alkalosis, 
exacerbation of glaucoma, glaucomatous crisis, intracranial 
hypertension, epilepsy, and poisoning by barbituric acid derivatives 
(increase of urine pH promotes renal excretion of barbiturates).  
Main side effects of diacarb are acidosis and hypokalemia.  
      
Diuretics Acting on the Level of Apical Membrane  
 
Drugs Inhibit ing Proteins Which Transport Sodium 
 
Triamterene  and amiloride  are weak diuretics. These drugs 
inhibit the passive transport of sodium ions through apical membrane 
of epithelial cells into the distal convoluted tubules and collecting 
ducts. The agents interact both with sodium transport proteins and 
sodium channels. Triamterene and amiloride inhibit renal potassium 
secretion and, therefore, are referred as “potassium-sparing 
diuretics”. Both drugs are taken orally. Effect develops  
in 15–20 minutes after drug intake and lasts up to 12 hours.  
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These drugs are used in long-lasting maintenance therapy of 
chronic cardiovascular failure of various genesis, in the treatment for 
hypertensive disease and cirrhosis. Besides, potassium-sparing 
diuretics are widely used in combination with thiazides or loop 
diuretics to prevent hypokalaemia.  
Side effects of potassium-sparing diuretics are hyperkalaemia, 
nausea, vomiting, headache, muscular convulsions of muscles of the 
lower extremities. 
 
Aldosterone Antagonists  
 
Chemical structure of potassium-sparing diuretic 
spironolactone (Aldactone, Verospiron) is similar to 
aldosterone. Spironolactone binds with intracellular cytoplasmic 
receptors of aldosterone and prevents its transport to the nucleus and 
following interaction with nuclear chromatin. It results in the 
decrease of synthesis of sodium transporting proteins – permease. 
Owing to such mechanism spironolactone decreases the aldosterone-
dependent sodium reabsorption and potassium secretion in collecting 
ducts of nephron.  
Diuretic effect of spironolactone develops in 2–5 days after 
therapy initiation and lasts several days after cessation of the drug 
intake.  
Spironolactone is used in the treatment for chronic heart failure, 
liver cirrhosis, nephrotic syndrome, essential hypertension in adults, 
ascites, and hyperaldosteronism. Also, the drug is used in 
combination with other diuretics to prevent hypokalaemia.  
Side effects of spironolactone include dizziness, drowsiness, 
headache, ataxia, nausea, vomiting, diarrhea, hepatic disfunction, 
gynecomastia, menstrual disorders, urticaria, hyperkalemia, etc.    
 
Osmotic Diuretics  
 
Mannitol  exerts pronounced diuretic action and weak saluretic 
effect. The drug is readily filtered in renal glomerulus but is not 
reabsorbed from the primery urine. Thereby mannitol creates high 
osmotic pressure in tubular lumen and significantly decreases the 
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water reabsorption. Reduction of sodium concentration in the tubular 
lumen creates concentration gradient of sodium between the 
intersticium and tubular lumen. According to this concentration 
gradient, sodium ions move through intercellular spaces into the 
tubular lumen.  
Mannitol increases the osmotic pressure of the blood that 
promotes water entering the blood vessels and the increase of 
circulatory volume. Hypervolemia activates secretion of atrial 
natriuretic peptide which stimulates natriuresis.  
The drug is administered slowly intravenously. Diuretic effect 
develops in 10–15 minutes and lasts 4–6 hours.  
Mannitol is used as to treat acute oedemas of brain and lungs, 
glaucoma, acute poisonings (for forced diuresis), acute renal failure, 
and shocks with decrease of blood pressure. It should be noticed that 
dehydrating therapy is dangerous in patients with heart failure. 
Elevation of blood osmotic pressure results in hypervolemia, 
particularly in patients with concomitant renal failure. The increase 
of pulmonary circulation pressure and systemic blood pressure can 
cause the overload of the left ventricle and development of 
pulmonary oedema.   
Therapy with mannitol can be aggravated by dehydration, 
hyponatremia, impaired consciousness, nausea, vomiting, dizziness, 
and chest pain. The drug is not recommended to prescribe children 
under 1 year. 
 
Drugs Increasing the Renal Blood Supply  
 
Aminophyll ine (euphyllinum), theophyl line, and 
theobromine increase diuresis due to improving of renal perfusion 
and glomerular filtration. Besides, drugs mildly reduce sodium 
reabsorbtion in proximal convoluted tubules. These effects are based 
on the ability of methylxanthines to stimulate purinergic (adenosine) 
receptors and to inhibit the phosphodiesterase activity that leads to 
accumulation of cAMP and reduction of vasopressin activity. 
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Methylxanthines are weak diuretics. These drugs are used to 
treat chronic cardiac, hepatic and renal diseases with insignificant 
oedemas in elderly patients. 
It should be noticed that children are especially sensitive to 
methylxanthines. Intravenous administration of these drugs to them 
can provoke severe poisoning. Due to this, methylxanthines are 
contraindicated to children under 2 years. 
 
Diuretics of Plant Origin 
 
Herbal diuretics occupy a special position among diuretics. 
These agents are used in the form of infusions and broths. The 
following herbal agents are used as diuretics: leaves of  
bearberry,  leaves of  orthosiphon stamineus, leaves and 
buds of birch, horsetail herb , flowers of  cornflower , etc. 
These drugs exert mild diuretic activity. Herbal diuretics are 
prescribed to children and elderly patients with oedemas caused by 
cardiovascular, hepatic, and inflammatory renal diseases. These 
drugs are taken 3–4 times a day. Therapy with herbal diuretics does 
not result in disorders of electrolyte balance. 
Lespenephryl  is a drug which is derived from leaves and 
stems of Lespedeza capitata and Pimpinella anisum (anise) fruit. The 
drug increases diuresis, excretion of nitrogenous compounds, and 
excretion of sodium and potassium ions. Lespenephryl is used to 
reduce azotemia at renal failure, acute and chronic nephritis. The drug 
is also used to reduce extrarenal azotemia. Lespenephryl is taken 
orally in a dose of 1–2 teaspoons a day. In severe cases, a daily dose 
may be increased up to 6 teaspoons. For long-lasting maintenance 
therapy, Lespenephryl is taken in dose 0.5–1 teaspoon alternate day.  
Lespeflan (extract of Lespedezae bicoloris) is a similar drug 
with Lespenephryl. The drug is taken in a dose of 1 teaspoon or  
1 tablespoon 3–4 times a day. A course of treatment lasts 3–4 weeks. 
Lespeflan is contraindicated in pregnancy.  
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Principles of Combined Diuretics  Treatment 
 
Diuretics are often combined among themselves as well as with 
agents of other groups to treat chronic heart failure, renal failure, 
hypertensive disease, etc.  
Diuretics with different mechanisms of action are commonly 
combined to increase sodium and water excretion from the body. 
Thus, osmotic diuretic mannitol is combined with loop diuretics 
(furosemide, etacrynic acid). This combination is used in urgent 
therapty (forced diuresis at poisoning, acute brain oedema, etc.). 
Combination of diuretics acting on the level of basal membrane 
(furosemide, hydrochlorothiazide, etc.) with diuretics which affect 
apical membrane (spironolactone, triamterene, etc.) is often used in 
medicine. Such combination increases the efficacy of diuretics and 
prevents the hypokalemia. Phrmaceutical industry manufactures such 
co-formulated drugs as “Triampur Compositum” (triamterene 
and hydrochlorothiazide), “Moduretic” (amiloride and 
hydrochlorothiazide), etc.  
Diuretics are commonly combined with hypotensive agents to 
treat hypertensive disease. There are the following co-formulated 
drugs: “Tenoric” (β-adrenergic antagonist atenolol and diuretic 
chlorthalidone), “Enap-H” (angiotensin-converting enzyme 
inhibitor enalapril and hydrochlorothiazide), “Crystepin” 
(sympatholytic reserpine, clopamide, and α-adrenoblocker 
dihydroergocristine), etc.   
Potassium-sparing diuretics (spironolactone, triamterene) are 
used together with cardiac glycosides to prevent hypokalemia. 
It should be noticed that some diuretics can enhance toxicity of 
other drugs. Thus, furosemide and etacrynic acid increase ototoxicity 
of some antibiotics (gentamicin, etc.). 
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DRUGS INFLUENCING MYOMETRIUM 
 
Uterus is a smooth muscle organ which is under control of 
certain hymoral and nervous factors. There are M-cholinergic, α- and 
β-adrenergic receptors in myometrium. M-cholinergic and  
α-adrenergic receptors stimulate contractile activity of uterus, while 
β2-adrenergic receptors inhibit it. Expressed stimulating influence 
upon uterus is characteristic of estrogens, posterior pituitary hormone 
oxytocin, and prostaglandins E2 and F2α. Progestins (progesterone, 
etc.) inhibit the uterine contractile activity. 
Drugs influencing myometrium are classified as follows. 
1. Drugs stimulating uterine contractile activity. 
1.1. Drugs of oxytocin group: oxytocin,  demoxytocin 
(desaminooxytocin, Sandopart), methyloxytocin 
(mesotocin), and pituitrinum.  
1.2. Drugs of prostaglandin group: dinoprost  
(prostaglandin F2 α), methyldinoprost, and dinoprostone 
(prostaglandin E2). 
1.3. Estrogens: estron, estradiol, and sinestrol. 
1.4. β-adrenoblockers: propranolol  (anaprilinum).  
1.5. Miscellaneous drugs: proserinum, pachycarpine, 
castor oil, calcium chloride, quinine, vi tamins C and B1.  
2. Drugs inhibiting uterine tone and contractile activity 
(tocolytics).  
2.1. Drugs stimulating β2-adrenergic receptors: fenoterol  
(Partusisten), salbutamol  (Salbupart), and terbutaline 
(Bricanyl).  
2.2. General anaesthetics: oxybutyrate sodium.  
2.3. Hormonal drugs: progesterone.  
2.4. Miscellaneous drugs: magnesium sulfate.  
3. Drugs increasing uterine tone and accelerating uterine 
involution in postpartum period.  
3.1. Ergot alkaloids: ergotal, ergotamine, ergometrine, 
methylergometrine, and ergot extract. 
3.2. Synthetic drugs: cotarnine.  
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4. Drugs decreasing tone of uterine neck: atropine, dinoprost, 
and dinoprostone .  
 
Drugs Stimulating Contracti le Activity of Uterus  
 
Oxytocin and prostaglandins are physiological stimulants of 
uterine contractions. The membranes of uterine smooth muscle cells 
contain receptors which are sensitive to these substances. Their 
excitation activates entrance of sodium and calcium ions into the 
cells that leads to depolarization and contraction of smooth muscle 
cells. Oxytocin and prostaglandins are allowed for in-patients only. 
 
 
Drugs of Oxytocin Group 
 
Oxytocin  is a polypeptide hormone of posterior pituitary which 
consists of 8 amino acids. The drug in doses 3–5 units causes the 
rhythmic contraction of myometrium that promotes labor. Sensitivity 
of pregnant uterus to oxytocin is higher than that of non-pregnant 
uterus. High doses of hormone (up to 10 units) cause more frequent 
and stronger uterine contractions and promote the increase of 
intrauterine pressure that can result in disorders of blood supply  
to placenta.  
Oxytocin is destroyed when taken orally; therefore, drug is 
administered intravenously drop-by-drop. The drug effect develops 
in 0.5–2 minutes. Oxytocin undergoes fast biotransformation in the 
liver and kidneys. To arrest postpartum uterine hemorrhage, oxytocin 
may be administered intramuscularly.   
Demoxytocin is a synthetic analogue of oxytocin with higher 
activity. Buccal tablets of the drug are taken sublingually. 
Desaminooxytocin is used to accelerate postpartum uterine 
involution and to stimulate lactation.  
Pituitrinum  contains two hormones of posterior pituitary – 
oxytocin and vasopressin. Therefore, this drug not only stimulates 
the uterine contraction, but also increases the blood pressure. The 
drug is administered subcutaneously or intramuscularly. Therapeutic 
indications are the same as for oxytocin.  
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Prostaglandins Preparations  
 
Small amount of prostaglandins is permanently synthesized in 
the uterus. Prostaglandins dilate the uterine vessels and exert 
cytoprotective effect due to improving of placental blood supply. 
Concentration of prostaglandins significantly increases during labor. 
Prostaglandins E2 and F2α are used as medications.  
Dinoprost  (prostaglandin F2 α) inhibits the function of 
corpus luteum, blocks progesteron synthesis, and increases the level 
of estrogens. The drug sensitizes myometrium to oxytocin. Dinoprost 
causes rhythmical contraction, increases the tone of both pregnancy 
and non-pregnancy uterus, and relaxes uterine neck.  
Prostaglandin F2α increases bronchial tone, stimulates cardiac 
rhithm and force of cardiac contraction, increases gastrointestinal 
motility, constricts pulmonary vessels, and increases the vascular 
permeability.  
Methyldinoprost  is more active and long-acting dinoprost 
analogue.  
Dinoproston  (prostaglandin E2) causes the rhythmic 
uterine contraction and relaxes uterine neck. The drug decreases 
peripheral vascular resistance, dilated pulmonary vessels and 
bronchi, increases capillary permeability, stimulates gastrointestinal 
motility, and inhibits gastric secretion. 
Dinoprost and dinoproston cause degeneration of corpus luteum 
(luteolysis). As partus stimulants, these drugs differ from oxytocin by 
their ability to relax uterine neck.  
Prostaglandins administration can cause excessive uterine 
contraction with disorders of uterine and placental circulation. 
Duration of prostaglandins action is longer than that of oxytocin. 
Most common side effects of prostaglandins include nausea, 
diarrhea, headache, and elevation of body temperature. Intravenous 
administration of prostaglandins can cause phlebitis. Due to lot of 
side effects, prostaglandins are seldom used for stimulation of labor. 
Drugs may be used for abortions.  
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Estrogens 
 
Such estrogens as estron (folliculin) , estradiol , and 
synestrol  are commonly used to stimulate labor. These drugs 
increase oxytocin level by means of inhibition of oxycitonase. 
Besides, estrogens sensitize oxytocin receptors. Estrogens 
preparations are administered parenterally. 
 
β-Adrenergic Antagonists  
 
Propranolol (anaprilinum) decreases tocolytic effect of 
catecholamines, which are released through β2-adrenergic receptors. 
To stimulate labor, propranolol is administered intravenously  
drop-by-drop. The drug is contraindicated in parturient women 
suffering from heart failure, hypotension, bronchial asthma, and 
conduction blocks.  
 
Miscellaneous Drugs 
 
The following drugs may be used to stimulate labor: 
proserinum, serotonin, pachycarpine, quinine, castor oil, 
calcium chloride, ascorbic acid, and vitamin B1.  
Proserinum  inhibits acetylcholinesterase activity and provides 
accumulation of acetylcholine in M-cholinergic synapses of uterus 
that increases the uterine contraction.  
Serotonin  stimulates the intensivity of mitochondrial 
respiratory function in myofibrils, influence ATP, actomyosin, and 
calcium. The drug improves membrane permeability for calcium ions 
that leads to the increase of uterine contraction.  
Serotonin is administered intravenously drop-by-drop.  
Pachycarpine  is a ganglionic blocker. The drug blocks  
Nn-cholinergic receptors of mesenteric ganglion and sympathetic 
ganglions. Besides, pachycarpine stimulates the release of oxytocin 
by posterior pituitary and sensitizes myometrium to action of estron 
and oxytocin. 
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Quinine  inhibits oxytocinase and increases oxytocin 
concentration. It should be noticed that quinine causes bradycardia 
both in mather and in fetus that restricts its use.  
Castor oil  increases the cholinergic influence upon the uterus 
and, therefore, stimulates uterine contraction.  
It should be noticed that proserinum, serotonin, pachycarpine, 
quinine, and castor oil are not used to stimulate labor nowadays.   
Such vitamins as ascorbic acid  and thiamin  induce labor. 
Vitamin C stimulates synthesis of estrogens, which stimulate the 
uterine contraction. Thiamin stimulates synthesis of acetylcholine 
and inhibits the activity of acetylcholinesterase. These effects result 
in stimulation of labor.  
 
Drugs Decreasing Uterine Tone and  
Contractile Activity (Tocolytics)  
 
Stimulation of β2-adrenergic receptors leads to the decrease  
of uterine contractile activity and its relaxation. Density  
of β2-adrenergic receptors in the uterus depends on periods of 
pregnancy. The highest density of β2-adrenergic receptors in the 
uterus is observed during the last trimester of pregnancy that 
provides the rest of the uterine muscle and childbearing. Before and 
during labor the density of β2-adrenergic receptors decreases that is 
accompanied by the increase of uterus sencitivity to oxytocin and 
estrogens.  
β2-Adrenergic agonists are reliable drugs to reduce uterine tone 
and its contractile activity. These drugs are widely used in obstetric 
practice. β2-Adrenergic agonists exert few side effects, are well 
tolerated by pregnant women, and do not negatively influence upon 
the fetus and newborn. The following β2-adrenergic agonists are used 
as tocolytics: fenoterol (Partusisten), salbutamol  
(Salbupart), and terbutaline  (Bricanyl). These drugs are taken 
orally or administered intramuscularly and intravenously drop-by-
drop. Their maximal tocolytic effect develops in 2 hours after oral 
intake, in 30 minutes after intramuscular administration, and in  
5–10 minutes after intravenous administration. Administration  
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of β2-adrenominetics can cause tachycardia (both in mother and 
fetus), constipations, nausea, anxiety, decrease of diastolic blood 
pressure, and hyperglycemia.   
Therapeutic indicatons for β2-adrenomimetics are the folliwng: 
– to prevent premature labors; 
– high tone of the uterine neck at onset of labor;  
– excessive fast labor with strong and fast uterine contraction 
which create a threat of uterine rupture; 
– fetus hypoxia caused by labor’s abnormalities; 
– the need for intrauterine fetal resuscitation; 
– performance of intrauterine fetal rotation, especially in case of 
twins; 
– preparation to operation during delivery (cesarean section).   
Therapy by progesterone  or synthetic progestin turinal  is 
provided in cases of threat of abortion in early period of pregnancy 
(under 4 months) and in recurrent abortions owing to insufficient 
production of progesterone. In these instances, vitamin E  
(tocopherol) is also used.  
Magnesium sulfate  is an antagonist of calcium. The drug is 
administered intravenously in dose 5–10 ml of 25% solution to relax 
uterus. Recently, calcium channel antagonist nifedipine  is used as 
tocolytic. Sometimes, general anaesthetic oxybutyrate  sodium 
(oxybate sodium) is used to decrease excessive uterine at labor.  
 
Drugs Increasing Uterine Tone and  
Its Involution in Postpartum Period  
 
Postpartum uterine atony and delayed involution are 
accompanied by bleeding which can cause the hemorrhagic anemia. 
The drugs containing ergot alkaloids are most effective agents to 
eliminate uterine atony: ergotamine, ergometrine, 
methylergometrine,  ergotal , and ergot extract . Besides, 
a synthetic drug cotarnine  is used with this end in view. Oral intake 
or intramuscular administration of these drugs is accompanied by 
stable contraction of myometrium that results in mechanical 
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compression of blood vessels and cessation of hemorrhage. It should 
be noticed that oxytocin  exerts similar effect in postpartum period.  
There are the following therapeutic indications for the drugs 
increasing myometrium tone:   
– postpartum hemorrhage, uterine atony, delayed involution  
of uterus, bleeding after manual placental separation; 
– dysfunctional uterine bleeding in woman with uterine fibroids;  
– hemorrhage associated with inflammation; 
Ergot alkaloid ergometrine is also used in the treatment for 
migraine.  
Therapy with ergot alkaloids is accompanied by the following 
side effects: nausea, vomiting, diarrhea, and headache. Overdose  
of ergot alkaloids causes the acute poisoning with the following 
symptoms: motor excitement, convulsions, nausea, vomiting, 
epigastric pain, tachycardia, and sensation disordes. Long-lasting 
drug intake leads to chronic poisoning – ergotism which exists in two 
clinical forms: gangrenous and convulsive. Gangrenous form 
develops owing to spasm of peripheral vessels and following 
necrosis of the extremities. Convulsive form is caused by the drug 
influence upon central nervous system.  
 
Drugs Decreasing the Uterine Neck Tone  
 
The group includes atropine, No-spa, dinoprost ,  and 
dinoprostone . Theese drugs relax uterine neck and promote labor. 
Besides, lidase  is used to reduce cervix rigidity. The drug contains 
enzyme hyaluronidase which catalyse the degradation of hyaluronic 
acid.  
 
Table 7 – Drugs for prescription 
Drug name 
(Latin) 
Single dose and route 
of administration 
Drug product  
Dichlothiazidum  Orally 0.025–0.05 g  
1–2 times a day  
Tablets 0.025 or 0.1 g 
Oxodolinum  Orally 0.025–0.1 g once  
in 2–3 days  
Tablets 0.05 g 
Triamterenum Orally 0.05–0.1 g 2 times  
a day  
Capsules 0.05 g 
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Continuation of the table 7 
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product 
Furosemidum  Orally 0.04 g once a day  
at the morning; 
intramuscularly or 
intravenously 0.02 g  
1–2 times a day  
Tablets 0.04 g; 
 
ampoules 2 ml  
of 1 % solution  
Acidum 
etacrinicum  
Orally 0.05–0.1 g 1 time 
a day or 1 time in 2 days; 
intravenously 0.05 g once 
a day  
Tablets 0.05 g; 
ampoules 0.05 g  
of powder for injection 
(dissolved before 
administration) 
Spironolactonum  Orally 0.025-0.05 g once 
a day  
Tablets 0.025 g 
Mannitum  Intravenously 0.5–1,5 g/kg  Vials 30.0 g of powder  
for injection (dissolved and 
used as 10–15 % solution); 
ampoules 200, 400  
or 500 ml of 15 % solution  
Ergometrini 
maleas  
Orally 0.000 2–0.000 4 g  
2–3 times a day; 
intramuscularly  
or intravenously  
0.000 1–0.000 2 g  
2–3 times a day  
Tablets 0.0002 g; 
 
ampoules 1 ml  
of 0.02 % solution  
Oxytocinum  Intravenously drop-by-drop 
5 IU in 500 ml  
of 5 % glucose solution; 
intramuscularly 0.2–2 IU  
Ampoules 1 ml (5 IU) 
Fenoterolum Orally 0.005 g 4–6 times 
a day; 
intravenously drop-by-drop 
0.0005 g in isotonic solution 
of sodium chloride  
or glucose  
Tablets 0.005 g; 
 
ampoules 10 ml  
of 0.005 % solution 
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Step 1. Tasks for Self -Control 
Diuretic Drugs. Drugs Influencing Myometrium 
  
1. The brain oedema was developed in patient with brain trauma 
in postoperative period. What drug should be prescribed to this 
patient? 
A. Urea. 
B. Furosemide.  
C. Amiloride. 
D. Dichlothiazidum. 
E. Spironolactone. 
2. Brain oedema was developed in patient with brain trauma in 
postoperative period. What drug should be prescribed to this patient? 
A. Mannitol.  
B. Spironolactone. 
C. Amiloride. 
D. Dichlothiazidum. 
E. Urea. 
3. A 46-year-old patient with ciliary arrhythmia had pulmonary 
oedema. What diuretic is it necessary to use for the treatment of this 
patient? 
A. Dichlothiazidum. 
B. Triamterene. 
C. Spironolactone. 
D. Amiloride. 
E. Furocemide.  
4. The alternate usage of dichlothiazidum, etacrin acid and lasix 
did not cause marked diuretic effect in the patient with marked peri-
pheral oedema. The aldosterone level in the blood is increased. 
Indicate which drug should be prescribed? 
A. Spironolactone.  
B. Amiloride. 
C. Mannitol. 
D. Urea. 
E. Clopamide. 
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5. Diuretic drug was prescribed to the patient with hypertension 
in the course of complex treatment. In a few days blood pressure 
decreased but signs of hypokalaemia developed. What drug could 
cause such complications? 
A. Triamterene. 
B. Clophelinum. 
C. Spironolactone. 
D. Lasix. 
E. Enalapril. 
6. Of the following agents, which is best avoided in a patient 
with a history of chronic congestive heart failure? 
A. Spironolactone. 
B. Mannitol. 
C. Hydrochlorthiazide. 
D. Ethacrynic acid. 
E. Amiloride. 
7. Furosemide inhibits the sodium-potassium dichloride (Na+, 
K+, 2Cl–) co-transporters that are located in the: 
A. Distal convoluted tubule. 
B. Collecting duct. 
C. Descending limb of Henle’s loop. 
D. Proximal tubule. 
E. Ascending limb of Henle’s loop. 
8. Hyperkalemia is a contraindication to the use of which of the 
following drugs? 
A. Hydrochlorothiazide. 
B. Etacrynic acid. 
C. Spironolactone. 
D. Furosemide. 
E. Chlorthalidone. 
9. A reduction in insulin release from the pancreas may be 
caused by which of the following diuretics? 
A. Amiloride. 
B. Triamterene. 
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C. Spironolactone. 
D. Hydrochlorthiazide.  
E. Etacrynic acid. 
10. A patient with nephrotic diabetes insipidus is best treated 
with which of the following? 
A. Etacrynic acid. 
B. Triamterene. 
C. Furosemide. 
D. Spironolactone. 
E. Hydrochlorthiazide. 
11. A 50-year-old male with pitting oedema of the ankles 
develops gynecomastia and erectile dysfunction while being treated 
with which of the following agents? 
A. Amiloride. 
B. Furosemide. 
C. Spironolactone.  
D. Triamterene. 
E. Hydrochlorthiazide. 
12. From the list of diuretic drugs choose the agent that is most 
useful for the treatment of acute pulmonary oedema. 
A. Triamterene. 
B. Hydrochlorthiazide. 
C. Furosemide.  
D. Spironolactone. 
E. Amiloride. 
13. From the list of diuretic drugs choose the agent that is most 
useful for the treatment of acute hypercalcemia. 
A. Hydrochlorthiazide. 
B. Amiloride. 
C. Furosemide. 
D. Spironolactone. 
E. Triamterene. 
14. From the list of diuretic drugs choose the agent that is most 
useful for the treatment of essential hypertension. 
A. Triamterene. 
B. Hydrochlorthiazide.  
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C. Furosemide. 
D. Spironolactone. 
E. Amiloride. 
15. The solution of some drug was introduced to pregnant 
woman for prevention of premature delivery. This drug is also 
known as anticonvulsant, hypotensive, cholagogic, and laxative drug. 
Contraction of uterus and pain stopped, soothing effect occurred. 
What drug has been prescribed to woman? 
A. Salbutamol. 
B. Oxytocin. 
C. Fenoterol. 
D. Magnesium sulfate.  
E. Ergometrine maleate. 
16. A patient with chronic cardiovascular insufficiency had signs 
of lungs oedema. What diuretic should be prescribed to the patient 
for the fast elimination of this condition? 
A. Furosemide.  
B. Spironactone. 
C. Clopamide. 
D. Diacarb (acetazolamide). 
E. Triamterene. 
17. The significant decrease of blood pressure has developed in 
patient in the result of diuretic overdose. Choose the group of 
hypertensive drugs which is preferable for using to this patient. 
A. N-cholinomimetics. 
B. Cardiac glycosides. 
C. Analeptics. 
D. Plasma substitutes. 
E. Adrenomimetics. 
18. A patient with pulmonary edema is delivered to resuscitation 
unit. What drug should be administered to patient for decreasing of 
blood pressure in small circle of circulation and for decreasing of 
circulating blood volume?  
A. Acetylcysteine.   
B. Unithiol. 
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C. Sulfacyl sodium. 
D. Metronidazole. 
E. Furosemide. 
19. Ascites has developed in patient with cirrhosis. Indicate the 
drug which should be administered to him for excretion of humor 
from body. 
A. Aminazine. 
B. Potassium chloride. 
C. Furosemide. 
D. Atropine sulfate. 
E. Heparin. 
20. Identify laxative drug which can be used for reflex 
increasing of uterus contractions in cases of insufficient labor 
activity.  
A. Sustac. 
B. Bisacodyl. 
C. Magnesium sulfate. 
D. Castor oil. 
E. Vaseline. 
21. Despite treatment with cardiotonics and thiazide diuretic a 
patient suffering from chronic cardiac failure still presents with 
edemata and faces a risk of ascites. What medication should be 
administered in order to increase the diuretic effect of the  
above-mentioned drugs? 
A. Mannitol. 
B. Amiloride. 
C. Furosemide. 
D. Spironolactone. 
E. Clopamide. 
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DRUGS INFLUENCING HEMOPOIESIS  
 
Drugs influencing hemopoiesis are classified as follows.  
I. Drugs which influence erythropoiesis.  
1. Drugs stimulating erythropoiesis. 
1.1. Drugs which are used to treat hypochromic (iron-deficiency) 
anemias: 
– iron-containing mono-drugs: ferrous sulfate , ferrous 
lactate, and Ferrum-Lek;   
– iron-containing co-formulated drugs: Fercoven  (iron and 
cobalt salts with carbohydrate solution), Ferroplex  (iron lactate 
with ascorbic acid), Ferramid  (complex compound of iron with 
nicotinamide), Tardyferon  (iron lactate, ascorbic acid, and 
mucoprotease), Haemostimulinum  (contains dry cattle blood, iron 
lactate, and copper sulfate), etc.; 
– cobalt-containing drugs: Coamidum ; 
– recombinant human erythropoietins: epoetin alfa (Eprex) 
and epoetin beta (Recormon) .  
1.2. Drugs which are used in the treatment for hyperchromic 
anemias: cyanocobalamin and folic acid .  
2. Drugs inhibiting erythropoiesis: sodium phosphate 
labelled by radioactive isotope 3 2P .  
II. Drugs which influence leukopoiesis.  
1. Drugs stimulating leukopoiesis:  
– non-specific drugs stimulating nucleic acid synthesis: sodium 
nucleinate,  pentoxyl,  methyluracil , and Leucogen; 
– myeloid growth factors: lenograstim (Granocyte),  
molgramostim (Leukomax),  and f ilgrastim (Neupogen).  
2. Drugs which inhibit leukopoiesis. 
2.1. Drugs inhibiting leukocytes in interphase:  
– alkylating drugs: cyclophosphan (cyclophosphamide),  
thiophosphamide (ThioTEPA), and myelosanum;  
– antimetabolites: methotrexate and mercaptopurine ;  
– cytotoxic antibiotics: rubomycin ;  
– glucocorticoids: prednisolone and dexamethasone; 
– enzyme agents: L-asparaginase ; 
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– cytokines: interferon α .  
2.2. Drugs which inhibit mitosis of leukocytes: 
– cytotoxic drugs of plant origin: vinblastine and 
vincristine .  
 
Drugs Influencing Erythropoiesis  
 
Iron ions, cyanocobalamin, and folic acid are primarily 
necessary for normal erythropoiesis. Their deficiency is accompanied 
by development of anemia. Erythropoietin stimulates erythropoiesis. 
This hormone is synthesized by peritubular intersticial renal cells 
(about 90 %) and in the liver (10 %). Erythropoietin stimulates 
proliferation and differentiation of erythrocytes.    
 
Drugs Stimulating Erythropoiesis  
 
Drugs which are Used to Treat Hypochromic Anemias  
 
Main cause of hypochromic anemia is insufficient hemoglobin 
production by bone marrow erythroblasts due to iron deficiency. Iron 
deficiency most commonly develops owing to iron deficit in food, 
absorption disorders, hemorrhages, during pregnancy, lactation, etc.  
Therefore, iron-containing drugs are the main agents which are 
used in the treatment for hypochromic anemias. Daily demand of 
iron for adults is about 0.2 mg/kg (considering that only 10 % taken 
iron is absorbed from gastrointestinal tract). Distribution of iron in 
organism is the following: about 70 % of iron (3–4 g) is included in 
hemoglobin, 10–20 % is deposited in the forms of ferritin and 
hemosiderin, 10 % is included in muscular protein myoglobin, and 
about 10 % is in structure of respiratory and other enzymes.  
Only ionized iron (better in form of divalent ion) is absorbed in 
gastrointestinal tract. Hydrochloric acid converts molecular iron to 
ionized form. Ascorbic acid restores trivalent iron to divalent one. 
Therefore, hydrochloric acid and ascorbic acid are necessary for 
normal absorption of iron in gastrointestinal tract. Iron absorption 
occurs mainly in small intestine by means of active transport. 
Apoferritin of intestinal mucosa binds with iron ions with formation 
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of ferritin. After entering blood circulation, iron ions interact with  
β1-globulin transferrin which delivers iron to various tissues, 
including bone marrow, where iron is included in hemoglobin. The 
excess of iron is deposited in forms of ferritin or hemosiderin. Iron is 
eliminated from the body through intestine (due to epithelial 
desquamation and with bile), kidneys, and sweat glands. 
At hypochromic anemias, iron-containing drugs are prescribed 
mainly orally. To prevent contact of iron with mucous membrane of 
oral cavity, iron-containing drugs are used in form of tablets with 
special coating or in capsules. It is associated with iron ability to bind 
with hydrogen sulfide and forms iron sulfide coloring teeth black. 
Therapy with iron preparations commonly causes constipation due to 
binding of hydrogen sulfide which is physiological stimulant of 
intestinal peristalsis.  
Iron-containing drugs are taken 1.5 hours prior a meal or 2 hours 
after a meal.  
Recently, co-formulated drugs, containing iron, microelements, 
and vitamins (ascorbic acid and vitamins of group B) are used in 
medicine for treatment of hypochromic anemias: Ferroplex,  
Sorbifer , Ascofer,  Globiron , etc. Ferrogradumet  is 
a representative of co-formulated drugs with prolonged action.  
Treatment of hypochromic anemia lasts 3–6 months. First 
improvement of hemopoiesis is observed in 5–7 days after initiation 
of therapy. If oral therapy by iron-containing drugs is failing,  
iron-containing drugs are administered parenterally. Parenteral 
administration of iron-containing drugs is admitted only for  
in-patients, because it is commonly accompanied by serious side 
effects: redness of the face and neck, lower back pain and joint pain, 
tightness in the chest, tachycardia, nausea, vomiting, allergic 
reactions, etc. These side effects are eliminated by administration of 
analgesics and atropine.  
Coamidum  is a cobalt-containing drug which is used in the 
treatment for hypochromic anemia. It is complex of cobalt and amide 
of nicotinic acid. Cobalt stimulates erythropoiesis and promotes 
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absorption of iron from gastrointestinal tract. Coamidum is 
administered subcutaneously.  
Recently, recombinant human erythropoietins are used in 
medicine: epoetin alfa (Eprex, Epogen)  and epoetin beta  
(Recormon). These drugs are used to treat aplastic anemia, anemias 
occurring due to chronic renal diseases, rheumatoid arthritis, 
malignant diseases of bone marrow, AIDS, etc. Recombinant human 
erythropoietins are administered subcutaneously or intramuscularly  
3 times a week. Their side effects are headache, hyperkalemia, 
arthralgias, etc. Initial therapeutic effect of recombinant human 
erythropoietins develops in 2 weeks; normalization on hemopoiesis 
is observed in 8–12 weeks.    
 
Drugs Used to Treat Hyperchromic Anemias  
 
Megaloblastic anemia occurs due to deficiency of vitamin B12 
(cyanocobalamin). Lack of vitamin B12 results in disorders of DNA 
synthesis and specific pathological changes of erythropoiesis. 
Erythroblast transforms to hyperchromic megaloblast which 
converted into megalocyte. Megalocytes are characterized by high 
RNA/DNA ratio, high iron content, and sharply lowered ability to 
transport oxygen. Because these cells are oversaturated by 
hemoglobin, color index is usually more than 1.1–1.3. However, the 
total hemoglobin in the blood is reduced considerably due to the 
significant decrease erythrocytes amount. Megaloblastic anemia 
occurs due to the loss of Castle’s intrinsic factor – glycoprotein of 
gastric mucosa which is essential for absorption of vitamin B12. 
Deficiency of Castle’s intrinsic factor develops at Addison Biermer 
anemia (primary loss of Castle’s intrinsic factor), total gastrectomy, 
atrophy of mucous membrane of stomach and duodenum, exclusively 
vegetable diet, and invasion by broad tapeworm. Reducrion of 
vitamin B12 absorption leads to disorders of neucleic acid synthesis. 
Beside erythropoiesis, peripheral nervous system is also affected at 
megaloblastic anemia. It is due to reduction of myelin synthesis, 
which needs cyanocobalamin as a cofactor.  
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At megaloblastic anemia, cyanocobalamin  is administered 
intramuscularly once a day or every other day. Normalization of 
erythropoiesis, functions of gastrointestinal tract and nervous system 
is observed in 1–2 month.   
Folic acid (vitamin Bc)  is essential for synthesis of proteins, 
nucleic acids, and macroergs.  Folic acid deficiency leads to disorders 
of erythropoiesis with development of macrocytic anemia, at which 
erythroblast turns into hyperchromic macronormoblast with 
following transformation into macrocyte.  
Folic acid is used to treat drug-induced and alimentary 
macrocytic anemia, celiac sprue, and anemia of pregnancy.  
Drug-induced macrocytic anemia is developed owing to therapy with 
dipheninum, phenobarbital, isoniazid, some hormonal drugs, etc.  
It should be noticed that alone use of folic acid in patients with 
megaloblastic anemia normalizes erythropoiesis but does not reduce 
pathological changes of nervous system and gastrointestinal tract. 
Therefore, folic acid is used in the treatment for megaloblastic 
anemia together with cyanocobalamin.  
Folic acid is taken orally. Sometimes, the drug causes allergic 
reactions.  
      
Herbal Drugs Which Used to Treat Anemias  
 
Herbal drugs, containing a variety of microelements, vitamins, 
antioxidants, and other bioactive substances stimulating 
erythropoiesis, are widely used to treat anemias. These drugs 
increase the body resistance to different unfavarable factors, imrove 
general well-being, stimulate immunity and hemopoiesis.  
The following herbal drugs are used in the treatment for anemia: 
European wood strawberry fruits,  seeds and fruits of  
black currant ,  rowan fruits, rose fruits , etc. 
European wood strawberry fruits contain ascorbic and folic 
acids, pectin, carbohydrates, salts of iron, cobalt, manganese, 
calcium, magnesium, phosphorus, etc.  
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Seeds and fruits of black currant contain ascorbic acid, rutin, 
thiamine, carotene, pectins, carbohydrates, organic acids, potassium 
and iron salts, etc. 
Rose fruits contain ascorbic acid, rutin, riboflavin, 
phylloquinone, tocopherol, organic acids, pectins, carbohydrates, 
flavone glycosides, salts of iron, magnesium, manganese, etc. Rose 
fruits are used as infusion 1 : 20 or as sirup. 
 
Drugs Inhibiting Erythropoiesis  
 
 Drugs inhibiting erythropoiesis are used to treat polycythemia 
(hyperglobulia). Solution of sodium phosphate labeled by  
radioactive isotope 3 2P  is one of these drugs. Therapy by this 
drug leads to reduction of number of erythrocytes and platelets. The 
drug is dosed in millicurie and administered intravenously or taken 
orally.   
Drugs Influencing Leukopoiesis  
 
Drugs Stimulating Leukopoiesis  
 
Various poisons, radioactive radiation, certain medicines, etc. 
can damage leukopoiesis and provoke leukopenia and 
agranulocytosis. Drugs stimulating leukopoiesis are classified as 
follows:  
– non-specific drugs stimulating nucleic acid synthesis: sodium 
nucleinate,  pentoxyl ,  methyluracil , and Leukogen ; 
– myeloid growth factors: lenograstim (Granocyte),  
molgramostim (Leucomax),  and f ilgrastim (Neupogen).  
Sodium nucleinate  is sodium sult of nucleic acid which 
obtained from yeast. The drug is administered intramuscularly or 
taken orally to stimulate leukopoiesis and immunity.   
Pentoxyl  is a synthetic agent – pyrimidine derivative. Pentoxyl 
stimulates leukopoiesis, accelerates wounds healing, and exerts  
anti-inflammatory effect. The drug is taken orally 3–4 times a day.  
Methyluracil  is a synthetic agent stimulating synthesis of 
pyrimidine nucleotides, increasing leukopoiesis, accelerating wound 
healing, and stimulating immunity (antibody synthesis and interferon 
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production). Also, the drug exerts anti-inflammatory action. 
Methyluracil is taken orally and applied topically in ointments. Its 
therapeutic indications are leukopenia, agranulocytosis, 
gastroduodenal ulcers, wounds, burns, bone fractures, chronic 
pancreatitis, etc.      
Leucogen  is prescribed to treat leukopenia and agranulocytosis. 
The drug potentiates the effects of other leukopoiesis stimulants. 
Leukogen is taken orally.  
Recently, growth factors regulating leukopoiesis have been 
approved in medical practice: molgramostim,  lenograstim, and 
filgrastim .  
Human recombinant granulocyte-macrophage colony 
stimulating factor is obtained by means of genetic engineering. 
Appropriate drug is called molgramostim (Leucomax). It is 
glycoprotein stimulating proliferation, differentiation, and activity of 
granulocytes and monocytes. These cells realize phagocytosis, 
stimulate immunity, and produce biologically active substances 
regulating cytokines production. Molgramostim increases the body’s 
resiatnce to bacteria, fungi, and tumors. The drug is administered 
intravenously at inhibition of leukopoiesis due to cancer 
chemotherapy, after bone marrow transplantation, at aplastic anemia 
and AIDS. Side effects of molgramostim are nausea, vomiting, 
diarrhea, hyperthermia, muscular pain, skin rash, and allergic 
reactions. 
Filgrastim  (Neupogen) is a recombinant human granulocyte 
colony stimulating factor. This glycoprotein stimulates proliferation 
and differentiation of granulocytic progenitor cells and increases the 
activity of mature granulocytes. Therapeutic indications for 
filgrastim are the same as for molgramostim. Filgrastim is 
administered intravenously or subcutaneously. Side effects are 
seldom and include arthralgias, allergic reactions, hepatic 
dysfunction, etc.    
Pharmacokinetics and pharmacodynamics of leukopoiesis 
inhibitors are considered at the chapter “Antitumoral drugs”.  
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Table 8 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product 
Ferri lactas  Orally 1.0 g 3–5 times a day  Capsules 1.0 g 
Fercovenum Intravenously 2–5 ml once 
a day  
Ampoules 5 ml 
Coamidum Subcutaneously 0.01 g once 
a day  
Ampoules 1 ml  
of 1 % solution 
Ferrum Lek Intramuscularly 2 ml  
1–2 times a day; 
intravenously 2–5 ml 1 time 
a day  
Ampoules 2  
(for intramuscular 
introduction) or 5 ml 
(for intravenous 
introduction) 
Cyanocobalaminum Subcutaneously,  
intramuscularly  
or intravenously  
0.000 1–0.000 5 g 1 time a day  
Ampoules 1 ml  
of 0.003 %, 0.01 %, 
0.02 % or 0.05 % 
solution  
Acidum folicum  Orally 0.005 g 1 time a day  Tablets 0.001 g  
Penthoxylum Orally 0.2–0.3 g 3 times a day  Coated tablets 0.2 g 
Filgrastimum  Intravenously  
or subcutaneously 
0.000 005 g/1 kg 1 time a day  
Vials 0.000 3 g  
or 0.000 48 g of powder 
for injections 
Cyclophosphanum  Orally, intravenously  
or intramuscularly 0.2–0.4 g 1 
 time a day  
Coated tablets 0.05 g; 
ampoules 0.1 g or 0.2 g 
powder for injection 
Chlorbutinum Orally 0.002–0.01 g 1 time 
a day  
Tablets 0.002 g  
or 0.005 g 
Myelosanum Orally 0.002–0.006 g 1 time 
a day  
Tablets 0.002 g 
Mercaptopurinum  Orally 0.001–0.001 25 g/kg 
1 time a day  
Tablets 0.05 g 
Methotrexatum  Orally, intramuscularly  
or intravenously 0.03 g  
2 times per week or 0.05 g  
1 time per 5 days  
Coated tablets 0.002 5 g; 
ampoules 0.005, 0.05  
or 0.1 g powder  
for injection 
Vinblastinum 
(Rosevinum) 
Intravenously 0.000 15–
0.000 3 g/kg 1 time a week  
Ampoules 0.005g  
or 0.01 g powder  
for injection 
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Step 1. Tasks for Self -Control  
Drugs Influencing Erythro- and Leucopoesis  
 
1. Methotrexate (structural analogue of the folic acid which is 
competitive inhibitor of the dihydrofolate reductase) is prescribed for 
treatment of the malignant tumour. On which level does 
methotrexate hinder synthesis of the nucleic acid? 
A. Transcription. 
B. Reparation. 
C. Mononucleotide synthesis.  
D. Processing. 
E. Replication. 
2. A nucleophilic attack on deoxyribonucleic acid that causes 
disruption of base pairing occurs as a result of the administration of: 
A. Cyclophosphamide. 
B. Methotrexate. 
C. Prednisolone. 
D. Filgrastim. 
E. Mercaptopurine. 
3. Which of the following is a chemotherapeutic drug that 
possesses a mechanism of action involving alkylation? 
A. Vincristine. 
B. Fercoven. 
C. Methotrexate. 
D. Myelosan. 
E. Pentoxyl. 
4. Binding to the enzyme dihydrofolate reductase is the 
mechanism of action for: 
A. Vincristine. 
B. Cyclophosphamide. 
C. Molgramostim. 
D. Sodium phosphate with radioactive isotope of 32P. 
E. Methotrexate.  
5. Which of the following is considered to be the effective 
mechanism of action of the vinca alkaloids? 
A. Inhibition of purine synthesis. 
B. Inhibition of the microtubules function.  
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C. Inhibition of DNA synthesis. 
D. Inhibition of protein synthesis. 
E. Damage and prevention of DNA repair. 
6. A 34-year-old male with Hodgkin’s disease is treated with 
combined chemotherapy with the use of vinblastine. What is the 
mechanism of this drug action? 
A. Scission of DNA strands. 
B. Inhibition of dihydrofolate reductase. 
C. Inhibition of enzymes involved in purine metabolism. 
D. Inhibiotion of topoisomerase. 
E. Prevention of assembly of tubulin dimers onto microtubules.  
7. A 45-year-old male on combination therapy for remission-
maintenance acute lymphocytic leukemia develops suprapubic pain, 
dysuria, and haematuria. Evidence of haemorrhage and inflammation 
is apparent on cystoscopy of the urinary bladder. Which of the  
following agents most likely caused these findings? 
A. Vincristine. 
B. Cyclophosphamide.  
C. Mercaptopurine. 
D. Doxorubicin. 
E. Methotrexate. 
8. Which vitamin can mask the symptoms of pernicious anaemia 
by alleviating the anemia but not preventing the neurological 
damage? 
A. Vitamin D. 
B. Niacin. 
C. Vitamin B12. 
D. Folic acid.  
E. Vitamin C. 
9. Neurotoxicity is rarely dose limiting in cancer chemotherapy. 
The only antineoplastic agent that has a dose-limiting neurotoxicity is: 
A. Methotrexate. 
B. Cisplatin. 
C. Bleomycin. 
D. Vincristine. 
E. Doxorubicin. 
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10. Which class of drugs binds avidly to tubulin and cause arrest 
of cells in metaphase? 
A. Antimetabolites. 
B. Vinca alkaloids. 
C. Alkylating agents. 
D. Antiestrogens. 
E. Nitrogen mustards. 
11. After the examination of a 40-year-old man the diagnosis of 
hypochromic anemia was made. What drug should be prescribed for 
this patient? 
A. Fercoven.  
B. Cyanocobalamin. 
C. Pentoxyl. 
D. Heparin. 
E. Vikasolum. 
12. A pregnant woman’s blood analysis revealed megaloblasts 
and a high colour index. The diagnosis is megaloblastic anemia. 
What drug should be prescribed to the patient? 
A. Cyanocobalamin.  
B. Pyridoxine hydrochloride. 
C. Nicotinic acid. 
D. Ascorbic acid. 
E. Coamidum. 
 
 
DRUGS INFLUENCING BLOOD COAGULATION  
  
Two systems exsist in a body in dynamic equilibrium: one of 
them promotes blood clotting and another system prevents it. The 
system promoting blood coagulation include platelets and plastic 
clotting factors which are contained in them, as well as plasma 
proteins sinthesized in liver (prothrombin, kappa factor, fibrinogen, 
etc.). The system preventing blood clotting is presented by 
proteolytic enzyme fibrinolysin (plasmin), its predecessor 
profibrinolysin (plasminogen), plasma proteins inhibiting thrombin 
formation (antithrombin III, etc.), as well as substances which are 
produced or fixed on the vascular endothelium (prostacyclin, 
heparin, etc.).  
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Disequilibrium between these two systems leads to either 
hemorrhage or thrombosis. Sometimes, combination of both 
phenomena is occurred and syndrome of disseminated intravascular 
coagulation develops. All mentioned pathological states require the 
pharmacological correction. 
Drugs influencing blood coagulation are classified as follows.  
I. Drugs which are used to prevent and treat thrombosis.  
1. Drugs decreasing blood coagulation (anticoagulants): 
1.1. Directly acting anticoagulants. 
1.2. Indirectly acting anticoagulants.  
2. Drugs which activate fibrinolysis (fibrinolytics).  
3. Drugs decreasing platelets aggregation (antiaggregants). 
II. Drugs which promote blood coagulation (hemostatics).  
1. Drugs increasing blood clotting (procoagulants).  
2. Drugs inhibiting fibrinolysis (antifibrinolytics).  
3. Drugs promoting platelets adhesion and aggregation 
(proaggregants). 
 
Drugs Used to Prevent and Treat Thrombosis  
 
Drugs Decreasing Blood Coagulation (Anticoagulants)  
 
Blood clotting is regulated system of enzymatic reactions in 
which lot of coagulation factors are participating. Eventual result of 
this cascade is formation of thrombin converting soluble fibrinogen 
to insoluble fibrin. When insoluble fibers of fibrin are occurred, 
blood corpuscles fixed at them and thromb appears. 
According to mechanism of action, drugs decreasing blood 
coagulation are classified as follows. 
1. Directly acting anticoagulants (agents which inactivate 
clotting factors directly in blood): heparin, nadroparin 
(Fraxiparine), enoxaparin (Clexane), dalteparin 
(Fragmin), tinzaparin   (Logiparin),  hirudin, lepirudin and 
sodium hydrocitrate .  
2. Indirectly acting anticoagulants (agents which inhibit the 
synthesis of clotting factors in the liver): neodicumarinum (ethyl  
biscoumacetate, Pelentan), Syncumar (acenocoumarol) ,  
warfarin, and phenindione (Phenylinum).  
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Directly Acting Anticoagulants  
 
Heparin  is a natural anticoagulant synthesized by mast cells 
and basophilic leukocytes. Especially high concentration of heparin 
is contained in a liver and lungs. Heparin is an acidic 
mucopolysaccharide with molecular weight 15 000–20 000 daltons. 
Heparin molecules contain residues of sulfuric acid. Due to that, they 
are charged negatively and exert expressed acidity. Heparin is 
obtained from lungs and liver of cattle. Activity of obtained heparin 
is determinated by means of biological standardization, 1 mg  
of a drug should contain 130 units of heparin.   
Negatively charged sites of heparin interact with positively 
charged amino groups of antithrombin III and activate it. Activated 
molecules of antithrombin III interact with active centres of serine 
proteases IIa, IXa, Xa, XIa, XIIa, XIIIa and neutralize them. Besides, 
antithrombin III suppresses the conversion of prothrombin to 
thrombin. 
Moreover, heparin increases the activity of fibrinolytic system 
by means of binding with antiplasmin.  
Also, heparin inhibits the adhesion and aggregation of platelets 
because heparin molecules fix on the surface of endotheliocytes and 
blood cells that creates negative charge of endothelial surface and 
surface of platelets. Thus, heparin is an anticoagulant with 
antiaggregatory and fibrinolytic activity. Heparin is active both  
in vivo and in vitro.  
Besides, heparin exerts antiallergic effect. The drug suppresses 
cooperation of T- and B-lymphocytes and synthesis of 
immunoglobulins and activates histaminase.  
Heparin increases pulmonary ventilation and coronary blood 
circulation, inhibits complement system, reduces aldosterone 
synthesis, activates lipoprotein lipase and decreases blood level of 
cholesterol and β-lipoproteins.  
Heparin is administered intravenously, intramuscularly, 
subcutaneously, in inhalations, and by electrophoresis. Heparin is 
also used topically in ointments and gels (e. g., Lioton® 1 000). At 
intravenous administration, its effect develops immediately and lasts 
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4–6 hours. Effect of intramuscularly administered heparin starts in 
15–30 minutes and lasts 6–8 hours. At subcutaneous administration, 
heparin effect develops in 40–60 minutes and lasts up to 12 hours. 
Maximum effect of inhaled heparin appears in 18–20 hours and lasts 
up to 2 weeks.  
In urgent cases (e. g., acute myocardial infarction), an average 
therapeutic dose of intravenously administered heparin is  
15 000–20 000 units. In critical cases (e. g., pulmonary artery 
thromboembolism) heparin’s dose is increased up to 40 000– 
60 000 units with the following intramuscular or subcutaneous its 
administration (5 000–10 000 units) every 4 hours.  
Discontinuation of heparin administration should be gradual 
because a sudden cessation of therapy can provoke hypercoagulation. 
There are following therapeutic indications for heparin:  
– thrombosis of coronary vessels at myocardial infarction;  
– thromboembolism of pulmonary or cerebral vessels;  
– thrombophlebitis;  
– prevention of thromboembolism during surgery and in 
postsurgical period in patients with embolism in anamnesis; 
– large scale orthopedic surgery and sugery of heart and vessels;  
– prevention of blood clotting in an artificial blood-circulation 
apparatus;  
– thrombophlebitis of superficial veins of lower extremities 
(commonly in form of ointments and gels);  
– diseases with increased risk of thrombosis: atrial fibrillation, 
endarteritis, acute nephritis);  
– bronchial asthma and rheumatism.  
High-molecular-weight heparin does not cross through placenta 
and is not excreted in breast milk. Therefore, this heparin is the drug 
of choice if to need to prescribe a direct anticoagulant to pregnancy 
and breastfeeding mothers.   
Heparin therapy may be accompanied by the following 
complications.  
1. Common complication of heparin therapy is hemorrhage 
associated with overdose. This complication is treated by 
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administration of heparin antagonist – protamine sulfate. The drug is 
administered intravenously slowly considering that 1 mg protamine 
neutralizes 85–100 units of heparin. Duration of action of protamine 
sulfate is 2 hours.  
2. Thrombocytopenia which may be of two different types. On 
2–4 days after initiation of heparin therapy, moderate 
thrombocytopenia may develop that is transient and is disappeared 
during following treatment. 
Life-threatening thrombocytopenia develops on 6–12 days of 
treatment. Its mechanism is associated with synthesis of antibodies 
(immunoglobulins G and M) which cause platelets aggregation. 
Owing to this, heparin-induced thrombosis (white clot syndrome) 
develops that can cause embolia. 
3. Dyspeptic disorders.  
4. Allergic reactions.  
5. Osteoporosis and calcification of soft tissues. This 
complication develops in long-lasting heparin use and is associated 
with interaction of calcium with heparin and fatty acids, which are 
formed due to the increase of activity of lipoprotein lipase and 
parathormone.  
6. Alopecia.  
7. Sudden cessation of heparin therapy may provoke 
rethrombosis. For prevention of rethrombosis, discontinuation of 
heparin therapy should be gradual and with use of indirect 
anticoagulants.  
Recently, the new group of anticoagulants is introduced in 
medicine – low-molecular-weight heparins: nadroparin 
(Fraxiparine), enoxaparin (Clexane), dalteparin 
(Fragmin),  and tinzaparin   (Logiparin) . Molecular weight of 
these heparins is 2 500–8 000 daltons. These drugs are obtained by 
method of enzymatic depolymerization of heparin by bacterial 
heparinase. Low-molecular-weight heparins do not change the time 
of blood coagulation, because these drugs do not inhibit factor IIa 
(thrombin). Mechanism of action of low-molecular-weight heparins 
is associated with the increase of antithrombin III action upon 
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clotting factor Xa which is essential for transformation of 
prothrombin into thrombin. Main influence of low-molecular-weight 
heparins is directed to the decrease of adhesion and aggregation of 
thrombocytes. Bioavailability of these drugs is three times more than 
bioavailability of heparin. Duration of these drugs action is longer. 
Therefore, low-molecular-weight heparins are administered 
subcutaneously 1–2 times a day. Low-molecular-weight heparins 
seldom cause hemorrhages and thrombocytopenia. Antagonist of 
low-molecular weight heparins is protamine sulfate.  
Hirudin  is a direct anticoagulant, which is contained in salivary 
glands of leech. It is a polypeptide which consists of 65 amino acid 
residues. Hirudin inactivates thrombin. Lepirudin  is short-time 
acting recombinant analogue of hirudin which is used in medicine. 
Its half-life is 1.3 hours. The drug is administered intravenously. The 
agent can cause hemorrhages. There are no antagonists of lepirudin.  
Recently, some other derivatives of hirudin are approved in 
medicine: bivalirudin  and low-molecular-weight analogoues 
melagatran  and ximelagatran . Bivalirudin is administered 
intravenously for anticoagulant therapy during percutaneous 
transluminal coronary angioplasty. Melagatran is administered 
subcutaneously to prevent venous thromboembolism in patients 
undergoing hip or knee elective surgery. Ximelagatran is taken 
orally. Its indications are similar to melagatran.  
Sodium citrate  is also a directly acting anticoagulant. The 
agent interacts with calcium ions which participate in transformation 
of prothrombin into thrombin. To preserve donor blood, 4–5% 
sodium citrate solution is used.  
 
Indirectly Acting Anticoagulants  
 
Indirectly acting anticoagulants are synthetic agents inhibiting 
hepatic biosynthesis of vitamin K-dependent clotting factors. This 
group includes neodicumarinum (ethyl biscoumacetate,  
Pelentan),  Syncumar (acenocoumarol) ,  warfarin,  and 
phenindione (Phenylinum).  
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History of discovery of indirect anticoagulants is associated with 
severe disease of cattle that was at 1922–1924 in USA and Canada. 
This disease leaded to death of animals. Due to investigations, it was 
found that animals were feeded by sweet clover of poor quality. 
Professor Karl Paul Gerhard Link has separated from clover 
substance, the administration of which to experimental animals 
caused same disease. This substance was called dicoumarol. It 
appeared to be that clover is affected by sertain species of mycelial 
fungus which transfer coumarin of sweet clover to dicoumarol. On 
the base of this investigations, prof. Link has suggested to use 
dicoumarol in the treatment for diseases which are accompanied by 
increased blood coagulation. Presently, dicoumarol is not practically 
used owing to high its toxicity.     
Neodicumarinum  (ethyl biscoumacetate,  Pelentan ) is 
analogue of dicoumarol with less toxicity. Its chemical structure is 
similar to molecular structure of vitamin K that that is the base for 
structural antagonism between neodicumarinum and vitamin K. 
Mechanism of action of neodicumarinum is associated with 
inhibition of enzyme epoxide reductase catalyzing transformation of 
vitamin K epoxide form into the hydroquinone form. Hydroquinone 
form of vitamin K participates in the synthesis of factor II 
(prothrombin), factor VII (proconvertin), factor IX (antihemophilic 
globulin B or Christmas factor), and factor X (Stuart–Prower factor) 
which are essencial for blood coagulation. Because neodicumarinum 
inhibits hepatic synthesis of clotting factors, the agent is active only 
in vivo.  
Besides, neodicumarinum inhibits the activity of the factor 
supporting the elastisity of vascular wall. Therefore, long-lasting 
intake of neodicumarinum increases the fragility and permeability of 
capillaries.  
Neodicumarinum is taken orally 3–4 times a day. The drug is 
characterized by high degree of gastrointestinal absorption. 
Anticoagulant effect develops in 2–3 hours and reaches the 
maximum in 12–24 hours. Latent period of action of indirect 
anticoagulant is determined by the duration of existence of 
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previously synthesized clotting factors in the blood. After 
discontinuation of drug intake, anticoagulative effect lasts  
1.5–2 days. At long-lasting therapy, the drug accumulates in the 
body. It should be noticed that neodicumarinum penetrate through 
placenta easily. 
Therapeutic indications for neodicumarinum are the follows:  
1) prevention and treatment of venous thrombosis, 
thrombophlebitis, myocardial infarction, and ischemic stroke;  
2) prevention of thrombosis in postoperative period;  
3) prevention of thrombosis and thromboembolia in patients 
with rheumatic heart damages;  
4) prevention of thrombosis after angioplasty, prosthetic heart 
valves; 
5) Prevention of thrombosis after discontinuation of therapy by 
directly acting anticoagulants.  
There are following side effects of neodicumarinum therapy:  
1) hemorrhages due to excessive inhibition of blood clotting and 
increased vascular permeability. In this setting, it is necessary to 
discontinue neodicumarinum intake and immidiatly administre 
vitamin K or vicasolum (menadione), vitamins C and P. Blood 
transfusion is also possible; 
2) coumarin-induced necrosis of soft tissues (buttocks, breasts, 
cheeks, etc.) due to thrombosis of capillaries and small venules. This 
complication appears at 4–10 days after initiation of drug intake. 
Coumarin-induced thrombosis more frequently develops in women. 
Coumarin-induced necrosis is associated with low level of 
protein C – a serine protease with anticoagulant and fibrinolytic 
activity. After initiation of therapy by indirectly acting 
anticoagulants, the level of protein C is decreased more rapidly than 
the levels of clotting factors IX, X and II. Therefore, when indirect 
anticoagulant is given to a patient with low initial level of protein C, 
a transient hypercoagulable state develops that leads to local 
thrombosis;  
3) dyspepsia;  
4) allergic reactions;  
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5) toxic damage of the liver and kidneys;  
6) drug intake by pregnant woman can provoke malformations 
of the skeleton on the first part of pregnancy and hemorrhage in fetus 
on late pregnancy;  
7) sudden stop of neodicumarinum intake provokes thrombosis. 
 Mechanisms of action, effects, and indications for use of 
warfarin , Syncumar , and phenindione  are similar to 
neodicumarinum. Main difference of these drugs is a longer latent 
period (anticoagulant effect develops in 24–72 hours) and longer 
duration of action – up to 2–4 days.  
Antagonists of indirectly acting anticoagulants are vitamin K  
and its synthetic analogue – vicasolum .  
 
Drugs Activating Fibrinolysis (Fibrinolytic Drugs)  
 
Fibrinolytic system prevents intravascular coagulation, restricts 
clot propagation, and repairs vascular patency after cessation of 
hemorrhage. Treatment of patients with fibrinolytic drugs is not a 
substitute for the anticoagulant drugs. Because the purpose of 
thrombolytic therapy is a rapid lysis of already formed clots, while 
the aim of anticoagulant therapy is a prevention of the new clotting 
formation.  
Fibrinolysis is initiated due to the transformation of 
profibrinolysin (plasminogen) into fibrinolysin (plasmin) under 
influence of plasminogen activators (tissue plasminogen activator, 
urokinase). Plasmin is a proteolytic enzyme which normally does not 
exist in blood. Fibrinolysin catalyzes the degradation of fibrin.  
Fibrinolytic drugs are devided into 2 groups.  
1. Directly acting fibrinolytics: fibrinolysin (plasmin).  
2. Indirectly acting fibrinolytics: streptokinase, streptodecase, 
anistreplase, urokinase, and alteplase (Actilyse) .  
Fibrinolysin (plasmin)  is a proteolytic enzyme which is 
appiared due to activation of profibrinolysin by plasminogen 
activators. Fibrinolysin causes only superficial lysis of thrombus 
(predominantly in veins) because it is quickly neutralized by 
antiplasmin. Fibrinolysin is active both in vivo and in vitro. The drug 
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is administered intravenoulsy drop-by-drop. Prior administration, 
powder for injection is dissolved in sterile isotonic sodium chloride 
solution or sterile isotonic glucose solution at the ratio of 100–
160 units of fibrinolysin per 1 ml of solution. Also, heparin is added 
to this solution at the ratio 1 units of heparin per 2 units of 
fibrinolysin. Therapy with fibrinolysin lasts 10–14 days.  
There are the following therapeutic indications for fibrinolysin: 
thrombosis of peripheral arteries, myocardial infarction, ischemic 
stroke, and thrombosis of peripheral veins. It should be noticed, that 
in case of arterial trombosis, fibrinolysin is effective during the first 
day (especially initial 6 hours after thrombosis); while, in case of 
venous thrombosis, the drug is effective during 5–7 days. 
Hemorrhages is a common complication of fibrinolysin therapy. 
In this case, aminocaproic acid, plasma, or donated blood are 
administered. Because fibrinolysin is the drug of peptide origin, its 
administration may provoke allergic reactions.    
Streptokinase  is an enzymatic agent which is obtained from 
culture of β-hemolytic streptococcus. It is fibrinolytic drug with 
indirect action. Streptokinase interacts with plasminogen with 
formation of active complex which converts molecules of 
plasminogen into plasmin. Unlike fibrinolysin, streptokinase 
penetrates inside thrombus where it activates fibrinolysis. The drug is 
administered intravenously or intra-arterially drop-by-drop during 
16–18 hours. Onset of action occurs in 30–60 minutes. The course of 
treatment lasts 4–6 days. 
Therapeutic indications for streptokinase are follows:  
1) embolism of pulmonary artery and its branches;  
2) acute thrombosis and ambolism of peripheral arteries;  
3) acute thrombosis of superficial and deep veins; 
4) acute myocardial infarction (during initial 8 hours);  
5) acute thrombosis of retinal vessels.   
Its side effects include hemorrhages, hemolysis, nephrotoxicity, 
and allergic reactions. It should be noticed that allergic reactions can 
occur even at first administration of streptokinase because antibodies 
to streptococci are commonly present in human body.   
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Streptodecase  is a long-acting preparation containing 
streptokinase applied on water-soluble polysaccharide matrix. 
Duration of streptodecase action is 48–72 hours. Drug is 
administered intravenously.  
Recently, another drug containing strepkinase was approved – 
anistreplase (Eminase). It is complex of streptokinase with 
modified plasminogen. The drug is administered intravenously in 
coronary thrombosis. Elimination half-life of anistreplase is  
70–120 minutes. Its side effects are hemorrhages, allergic reactions, 
bradycardia, transient hypotension, etc.    
 Urokinase  is a plasminogen activator which obtained by 
means of gene engineering. Its fibrinolytic effect develops faster than 
those of streptokinase. Drug is administered intravenously in acute 
arterial and venous thrombosis of different localization. Urokinase 
does not exert marked antigenic properties; therefore, its repeated 
administration causes allergic reactions seldom. 
Alteplase  (Actilyse) is tissue-type plasminogen activator 
obtained by means of gene engineering. Alteplase exerts high affinity 
to fibrin of thromb. Therefore, alteplase causes fibrin-selective 
activation of plasminogen. The drug causes insignificant activation 
of plasminogen in plasma. Alteplase is administered intravenously or 
intra-arterialy. Its plasma half-life is 5 minutes. Fibrinolytic efficacy 
of alteplase is higher than the eficacy of streptokinase. Alteplase is 
administered intravenously or intra-arterially. Alteplase does not 
exert antigenic properties. Its possible side effect is hemorrhage. 
Recently, tenecteplase  (Metalyse) was approved in medical 
practice. The drug is a recombinant genetically modified activator of 
tissue plasminogen. Its plasma half-life is about 20–25 minutes. The 
drug is administered intravenously in the treatment for acute 
myocardial infarction. Its most common side effect is hemorrhage.  
 
 
 
 
 
230 
 
Drugs Inhibiting Thrombocyte Aggregation  
(Antiaggregants)  
 
In significant degree, platelet aggregation depends on ratio of 
thromboxane A2 (TXA2) and prostacyclin (PGI2). ADP released from 
the platelet granules activate phospholipase A2. In platelets, 
phospholipase A2, cyclooxygenase 1, and thromboxane synthetase 
consequentially convert arachidonic acid into cyclic endoperoxides 
and TXA2. Thromboxane A2 promotes adhesion and aggregation of 
thrombocytes. In endotheliocytes, prostacyclin synthetase converts 
cyclic endoperoxides into prostacyclin which decreases platelets 
aggregation and adhesion.  
There are other endogenous substances promoting platelet 
aggregation: serotonin, epinephrine, thrombin, collagen of vascular 
wall, prostaglandin Е2, etc. Endogenous substances with opposite 
function are prostaglandin E1, heparin, cAMP, adenosine, NO, etc. If 
the equilibrium TXA2 / PGI2 is broken for the benefit of TXA2, the 
platelet aggregation is increased that can provoke myocardial 
infarction, ischemic stroke, etc.  
Antiaggregants are drugs which decrease platelets aggregation 
and adhesion. Their clinical use is effective in regard to prevent 
thrombosis, because reversible aggregation of thrombocytes critically 
fastly turns out irreversible with formation of strong links between 
thrombocytes.       
According to mechanism of action, antiaggregants are classified 
as follows:  
1) agents inhibiting activity of thromboxane system: 
acetylsalicylic acid  (aspirin), dasoxiben, and ridogrel. 
2) drugs which increase the activity of prostacyclin system: 
epoprostenol  (prostacyclin); 
3) drugs inhibiting fibrin binding with thrombocyte receptors: 
ticlopidine (Ticlid), clopidogrel  (Plavix) , and abciximab 
(ReoPro); 
4) drugs with different mechanism of action: dipyridamole,  
pentoxifylline (Trental).   
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Drugs Inhibiting Activity of Thromboxane System 
 
Acetylsalicylic acid  (aspirin) exerts dose-dependent 
effects. To the extent that drug concentration in the blood is 
increased, the following effects appear: antiaggregant, antipyretic, 
analgesic, and anti-inflammatory.  
Acetylsalicylic acid irreversibly inhibits cyclooxygenase by 
acetylation of it. This process develops both in platelets, preventing 
the formation of TXA2, and in endothelial cells, inhibiting the 
synthesis of PGI2. But endothelial cells can synthesize a new 
cyclooxygenase while platelets can not, because platelets have not 
nucleus. Therefore, ratio TXA2 / PGI2 changes in favor of 
prostacyclin. The aim of therapy with acetylsalicylic acid is the 
selective inhibition of TXA2 synthesis in the platelets that leads to 
the decrease of platelet aggregation. It is achieved by drug intake  
in dose 50–125 mg per day. Activity of cyclooxygenace in 
endotheliocytes is resotered in several hours. Whereas activity of 
thrombocytar cyclooxygenase is restored only due to formation  
of new thrombocytes. It should be noticed that duration of 
thrombocyte life is 7–10 days. 
Nitro-aspirin  is aspirin derivative containing a nitro moiety. 
In the body, the drug releases nitric oxide (NO). Nitro-aspirin both 
decreases vascular tone and inhibits platelet aggregation.   
Dazoxiben  is a selective inhibitor of thromboxane synthase. As 
a rule, dasoxiben is used in combination with acetylsalicylic acid.   
 
Drugs Increasing the Activity  of Prostacyclin System 
 
Prostacyclin (epoprostenol ) dilates blood vessels and 
inhibits platelets aggregation. Because the drug has a very short 
duration of action, epoprostenol is administered intra-arterially  
drop-by-drop to treat vascular diseases of lower extremities. 
Epoprostenol improves blood circulation in skeletal muscules, 
decreases ischaemic pain, and promotes the healing of trophic ulcers. 
The drug is also used to prevent thrombocyte adhesion to dialysis 
membrane at hemodialysis and hemosorption, and in apparatus of 
extracorporeal circulation. 
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Drugs Inhibiting Fibrin Binding with Thrombocyte 
Receptors 
 
Abciximab (ReoPro) irreversibly blocks platelet glycoprotein 
receptors (GP IIb/IIIa) and prevents fibrinogen binding with them 
that leads to inhibition of platelet aggregation. Besides, the drug 
exerts anticoagulant activity. Abciximab is administered 
intravenously to treat myocardial infarction, severe angina pectoris, 
and to prevent blood coagulation during angioplasty. Its duration of 
action is about 24 hours. Most common side effect of abciximab is 
hemorrhages.  
Eptifibatide  and t irofiban  exerts identical mechanism of 
action to abciximab. Their duration of action is less (2–8 hours).  
Ticlopidine  (Ticlid) inhibits platelet aggregation by means of 
blockage of platelet P2-purinergic receptors activated by ADP. Due 
to this, the drug prevents ADP-induced binding of fibrinogen with 
glycoprotein receptors of thrombocytes. Its antiaggregative effect is 
higher than those of aspirin. Antiaggregative effect develops 
gradually within 3–5 days. Ticlopidine is taken orally 2 times a day 
while eating. Its therapeutic indications are myocardial infarction, 
unstable angina pectoris, ischemic stroke, and angioplasty. The drug 
is prescribed to patients who no tolerate aspirin. Side effects of 
ticlopidine are gastrointestinal disorders, leukopenia, 
agranulocytosis, elevation of level of atherogenic lipoproteins, and 
allergic reactions.  
Clopidogrel  (Plavix) exerts identical mechanism of action to 
ticlopidine. The drug is taken orally once a day. The drug produces 
fewer side effects than ticlopidine. Bone marrow toxicity is 
uncharacteristic of clopidogrel.  
 
Drugs with Different Mechanism of Action  
 
Dipyridamole  is a coronary vasodilator with antiaggregant 
activity. The drug inhibits phosphodiesterase that leads to elevation 
of cyclic adenosine monophosphate (cAMP) concentration in 
platelets. Besides, dipyridamole blocks adenosine deaminase and 
prevents destruction of adenosine which inhibits the platelets 
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aggregation and dilates vessels. Dipyridamole is also used with 
aspirin in co-formulated preparation Aggrenox . Side effects of 
dipyridamole include headache, dispepsy, hypotension, allergic 
reactions, and steal syndrome. 
Pentoxifylline  (Trental, Dartelin) is a xanthine derivative. 
The drug inhibits phosphodiesterase and promotes accumulation of 
cAMP in platelets that leads to the decrease of platelet aggregation. 
Besides, pentoxifylline blocks P2-purinergic receptors, decreases 
thromboxane A2 synthesis, and increases prostacyclin synthesis.  
The drug activates glycolysis in erythrocytes that leads to 
accumulation of ATP and diphosphoglycerate. Owing to this, the 
elasticity of erythrocytes increased that improves capillary 
circulation. Also, pentoxifylline increases the release of plasminogen 
activator, reduces the level of fibrinogen, and decreases blood 
viscosity. The drug exerts moderate vasodilative activity. Under the 
influence of pentoxifylline, blood rheology is improved. Marked 
therapeutic effect of pentoxifylline is observed in 2–4 weeks after 
initiation of therapy. Pentoxifylline is used to treat Raynaud’s 
disease, diabetic angiopathy, disorders of cerebral and coronary 
circulation, and shock. Its side effects are appetite loss, diarrhea, 
nausea, dizziness, hypotension, and facial flushing.  
Sulfinpyrazone (Anturan)  is antigout drug. But also, the 
drug inhibits adhesion and aggregation of thrombocytes. Its 
antiaggregant activity is low.    
 
Drugs Promoting Blood Coagulation  
(Hemostatics) 
 
Drugs, which promote hemostasis, are used to prevent and treat 
acute and chronic hemorrhages. Disorders of blood coagulation 
develop due to genetically determinated deficiency of clotting factors 
(haemophilia), sharp fibrinolysis activation, inhibition of adhesion 
and aggregation of thrombocytes, surgery (especially on the lungs 
and pelvic organs), hepatic diseases, protein starvation, shock, 
radiation sickness, intoxications, etc. To cessate hemorrhages, the 
following groups of drugs are used: drugs increasing blood clotting 
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(procoagulants), antifibrinolytics, and drugs promoting platelets 
agregation.     
 
Drugs Increasing Blood Clotting (Procoagulants)  
 
Procoagulants are classified as follows. 
1. Drugs for topical application: thrombin , hemostatic 
sponge , and beriplast . 
2. Drugs for systemic action: vicasolum , phytomenadione , 
fibrinogen , calcium chloride , calcium gluconate , gelatin , 
etamsylate,  VIII and IX clotting factors . 
Thrombin  is an active key factor of blood coagulation which 
converts fibrinogen to fibrin. The drug is obtained from donated 
blood. This drug is applied topically at surgery on parenchymatous 
organs (most commonly on the liver), at hemorrhages from osteal 
tissues, and gingiva. The parenteral introduction of thrombin is 
inadmissible, because the drug rapidly causes the generalized 
thrombosis. Sometimes, thrombin is taken orally at gastral 
hemorrhages or inhaled at lessions of respiratory tract.  
Hemostatic sponge  is obtained from plasma. The drug 
contains also calcium chloride and aminocaproic acid. Hemostatic 
spongle is used only topically to arrest capillary bleeding.  
Vitamin K  exists in two forms: K1 (phylloquinone) and  
K2 (menaquinone). Phylloquinone is contained in green parts of 
plants. Menaquinone is synthesized by intestinal bacterial flora and is 
contained in animal liver. Bile acids are essential for intestinal 
absorption of vitamin K; therefore, this process may significantly 
slow down at hepatic diseases.  
Vitamin K participates in hepatic synthesis of K-dependent 
factors of blood coagulation:  II (prothrombin), VII (proconvertin), 
IX (Christmas factor), and X (Stuart-Prower factor).  
Phytomenadione (phytonadione)  is synthetic preparation 
with identical activity to natural phylloquinone. The drug is taken 
orally 30 minutes before a meal or administered parenterally – 
subcutaneously, intramuscularly, or intravenously. 
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Vicasolum (menadione sodium bisulfi te)  is another 
synthetic analogue of vitamin K. Vicasolum is taken orally or 
administered intramuscularly 2–3 times a day. In the liver, vicasolum 
transforms into vitamin K1 and K2.  The response to vicasolum drugs 
is slow and requires about 24 hours.  
Besides procoagulant, vitamin K also exerts antihypoxic activity 
and participates in hydrogen transport in respiratory chain. 
Therefore, vitamin K is essential for mitochondrial ATP synthesis.  
Vitamin K deficiency is commonly observed against the 
background of the parenteral feeding, antibiotic therapy, and due to 
overdose of indirect anticoagulants. Also, vitamin K deficiency is 
observed in premature newborns.    
Clinical applications for preparations of vitamin K are the 
follows:  
– prevention and treatment of hemorrhages in pre- and 
aftersurgical periods;  
– hemorrhages at ulcer disease and radiation sickness;  
– uterine bleeding; 
– early and later forms of hemorrhagic disease of newborns 
(early hemorrhagic diseases developed during 1st day of life, later – 
in 1 month); 
– hypoprothrombinemia; 
– parenchymatous bleeding, etc.     
Fibrinogen is obtained from donated blood. The drug is 
administered intravenously drop-by-drop through the system with 
special filter during 2–4 hours 1 time a day under control of blood 
coagulation. The drug is used to cessate hemorrhages appeared due 
to hypofibrinogenemia: some hepatic diseases, overdosage of 
fibrinolitics or indirects anticoagulants, and in protein starvation, etc. 
Also, fibrinogen is preventively used before surgery on organs 
riching on tissue activators of fibrinolysis (lung, pancreas, prostates, 
and thyroid glands). Fibrinogen is used in obstetrics at placental 
abruption, cesarean section, and artificial delivery.  
Calcium-containing drugs (calcium chloride  and calcium 
gluconate) stimulate the formation of thromboplastin, conversion 
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of prothrombin to thrombin, and fibrin polimerization. Besides, 
calcium ions decrease vascular permeability. Calcium salts are used 
at internal bleeding appeared due to thrombocytopenia and increased 
vascular permeability. Also, calcium-containing drugs are 
administered to recipients at transfusion of citrated blood.  
 Gelatin  contains high quantity of calcium ions, and due to that, 
increases the blood coagulation. Also, gelatin increases blood 
viscosity and thromboplastin release. 10 % gelatin solution is 
administered intravenously.    
Etamsylate  stimulates the formation of thromboplastin. Also, 
the drug inhibits hyaluronidase that results in stabilization of vascular 
wall. Etamsylate is used to prevent and interrupt capillary bleeding at 
diabetic angiopathy and various surgery. The drug is taken orally or 
administered parenterally.   
VIII  and IX clotting factors  are obtained from donated blood 
and stored frozen. These drugs are used at hemorrhages due to 
deficiency of corresponding clotting factors. Deficiency of these 
factors is genetically determinated. Deficiency of VIII factor  
(anti-hemophilic factor) causes haemophilia A; while deficiency of 
IX factor leads to haemophilia B (Christmas disease). In both cases, 
blood loses completely the ability to coagulate. Hemorrhages 
appeared at these diseases require administration of corresponding 
clotting factors during 3–10 days. A cost of these drugs is very high. 
Pharmaceutical industry produces coformulated drugs (Autoplex,  
Feiba) which contain both mentioned active clotting factors and are 
effective even antibodies or inhibitors of these factors are present in 
blood of patient.    
 
Drugs Inhibiting Fibrinolysis (Antifibrinolytic Drugs)  
 
Increased fibrinolytic activity is due to overdose of fibrinolytic 
drugs, sepsis, severe traumas of internal organs, etc. Hemorrhages 
appeared owing to increased fibrinolytic activity are poorly treated 
by procoagulants and require an administration of antifibrinolytic 
drugs, fibrinogen, or plasma.    
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Antifibrinolytic drugs are Contrical, Trasylol , Gordox  
(aprotinin  is an active substance of these drugs), aminocaproic  
acid (Amicar),  aminomethylbenzoic acid  (Pamba),  
tranexamic acid (Cyklokapron).  
Aminocaproic acid  is a synthetic agent – lysine derivative. 
The drug interacts with profibrinolysin activator and inhibits it that 
prevents the transformation of profibrinolysin into fibrinolysin. 
Besides, aminocaproic acid interacts with active centres of 
profibrinolysin and fibrinolysin and inhibits their activity. The drug 
is taken orally or administered intravenously drop-by-drop. Its 
duration of action is 6 hours; therefore, the drug is taken 4 times a 
day. Side effects of aminocaproic acid are allergic reactions and 
dispeptic disorders. Intravenous administration of aminocaproic acid 
is accompanied by hypotension, thrombosis, embolism, disorders of 
color vision, etc.  
Aminomethylbenzoic acid (Pamba) is a synthetic drug 
with activity which is 3–7 times more than those of aminocaproic 
acid. The drug is taken orally and administered intravenously. Its 
duration of action is 3–8 hours.  
Tranexamic acid  (Cyklokapron) exerts higher 
antifibrinolytic activity than aminocaproic acid. The drug is taken 
orally or administered intravenously. At intravenous administration, 
its half-life is 2 hours.   
Aprotinin  is an active substance of such drugs as Contrical ,  
Trasylol ,  Gordox , etc. This protease inhibitor directly inhibits 
fibrinolysin, trypsin, chemotrypsin, kallikrein and other proteolytic 
enzymes. Inhibition of trypsin and chemotrypsin provides therapeutic 
effect of aprotinin at acute pancreatitis. Blockage of kallikrein and 
reduction of level of bradykinin and kallidin decrease bronchospastic 
and allergic reactions in the body.  
Gordox is obtained from animal pancreas, Contrical – from 
animal lungs, and Trasylol – from parotid glands. These drugs are 
administered intravenously slowly or drop-by-drop. The drugs are 
completely inactivated in the body in 2–4 hours after their 
administration.    
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There are the following therapeutic indications for antifibrinolytics: 
– overdose of fibrinolytics; 
– surgery and traumas of organs, which are rich by proteolytic 
enzymes (lungs, uterus, pancreas, prostate, etc.); 
– hemorrhagic insult; 
– placental abruption, intrauterine death of fetus; 
– acute pancreatitis; 
– renal ischemia; 
– staphylococcal pneumonia with phenomena of destruction; 
– pulmonary haemorrhages at tuberculosis; 
– gastric hemorrhages at ulcer disease, etc. 
 
Drugs Promoting Platelets Aggregation 
 
This group includes such drugs as serotonin, etamsylate 
(Dicynone), carbazochrome (Adroxon),  calcium 
gluconate, and calcium chloride .  
Serotonin  is an endogenous amine synthesized from 
tryptophan in body tissues.  It stimulates S1- and S2-serotonergic 
receptors on the platelet surface that promotes the platelet 
aggregation. Besides, serotonin causes vasospasm and increases 
vascular permeability. The drug is administered intravenously or 
intramuscularly at hemorrhages, hypo- and aplastic anemias. Adverse 
effects are bronchospasm, intestinal spasms, vascular spasm, etc. 
Adroxon (carbazochrome)   is epinephrine derivative unable 
to stimulate the adrenoceptors of smooth muscles and heart. Due to 
excitation of α-adrenoceptors of platelets, the drug activates 
phospholipase C that leads to release of substances stimulating 
platelet aggregation. Adroxon is taken orally, administered 
subcutaneously or intramuscularly, and applied topically.  
Calcium chloride  and calcium gluconate  increase platelet 
aggregation, activate thrombin formation, and decrease vascular 
permeability. Calcium gluconate is administered intramuscularly, 
intravenously or taken orally before a meal. Calcium chloride is 
intended for intravenous administration or taken orally after a meal. 
The frequency of administration for both drugs is 3–4 times a day.  
239 
 
These drugs are used to treat hypocalcemia, thrombocytopenia, 
angiasthenia, hemorrhages at gastroduodenal ulcers, pulmonary 
diseases, uterine hemorrhages, etc.  
Etamsylate (Dicynone) is one of the most effective 
proaggregants. The drug blocks prostacyclin effects that increases 
platelet aggregation. Besides, etamsylate promotes polymerization  
of hyaluronic acid that increases a density of basal membrane of 
capillary wall. Etamsylate is used in the treatment for 
parenchymatous and capillary hemorrhages and at thrombocytopenia. 
The drug is administered intravenously and intramuscularly or taken 
orally 3–4 times a day.  
It should be noticed that besides mentioned above drugs, 
glucocorticoids, ascorbic acid, and rutin also decrease vascular 
permeability. 
 
Table 9 – Drugs for prescription 
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product  
Acidum 
acetylsalicylicum 
Orally 0.075–0.325 g once  
a day  
Tablets 0.075 or 0.325 g 
Dipyridamolum  Orally 0.025–0.05 g 3 times 
a day  
Tablets 0.025 or 0.075 g 
Heparinum Intravenously 5 000–20 000 
IU 4 times a day  
Vials 5 ml (1 ml – 5 000, 
10 000, or 20 000 IU) 
Calcii chloridum Intravenously slowly  
0.5–1.0 g 1–2 times a day  
Ampoules 5 or 10 ml  
of 10% solution  
Neodicumarinum  Orally 0.05–0.1 g 3 times 
a day  
Tablets 0.05 or 0.1 g 
Syncumarum  Orally 0.001–0.006 g  
1–2 times a day  
Tablets 0.002 or 0.004 g 
Streptokinasum Intravenously drop-by-drop 
250 000–500 000 IU  
(250 000 IU is dissolved in  
50 ml sterile isotonic sodium 
chloride solution)  
Ampoules 250 000  
or 500 000 IU of powder 
for injection 
Acidum 
aminocapronicum  
Orally 2–3 g 4 times a day; 
intravenously drop-by-drop 
5.0 g once a day  
Powders for internal use; 
vials 100 ml of 5% 
solution 
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Continuation of the table 9  
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product  
Contricalum 
 
Intravenously drop-by-drop 
10 000–50 000 IU 4–6 times 
a day  
Vials containing 10 000, 
30 000 or 50 000 IU  
of powder for injection 
Fibrinogenum Intravenously drop-by-drop 
1.0–2.0 g (1g is dissoled  
in 250 ml of water  
for injections)  
Vials containing 1.0  
or 2.0 g of powder  
for injection 
Vikasolum Orally 0.015 g 2–3 times 
a day; 
intramuscularly 0.01 g 1 time 
a day  
Tablets 0.015 g; 
 
ampoules 1ml  
of 1% solution 
 
Step 1. Tasks for Self -Control  
Drugs Influencing Blood Coagulation  
 
1. A patient with thrombophlebitis is administered the complex 
therapy, which influences different stages of clot-forming. Which of 
the given substances contributes to the restoration of the vascular 
permeability? 
A. Acetylsalicylic acid. 
B. Fibrinolysin. 
C. Heparin. 
D. Neodicumarinum. 
E. Dipyridamole. 
2. Some drug had been prescribed to the patient with 
thromboembolism of lower extremities veins. In 2 days 
haemorrhages appeared on his skin. What drug was prescribed to the 
patient? 
A. Heparin. 
B. Dipyrodamole. 
C. Acetylsalicylic acid. 
D. Neodicumarinum. 
E. Phenylinum. 
3. An 8-year-old child is being prescribed for tonsillectomy. The 
analysis of blood has shown that the time of blood coagulation is 
241 
 
increased (up to 7 minutes). What drug should be included (5 days 
before the operation) into the complex of therapeutic agents of the 
preparatory period first of all? 
A. Etamsylate. 
B. Sodium chloride. 
C. Aminocaproic acid. 
D. Fibrinogen. 
E. Vicasolum.  
4. A doctor recommended to patient, who had an acute 
myocardial infarction, to take acetylsalicylic acid in the dose 0.25 g 
once per 2–3 days during 3–4 months. What effect did the doctor 
count on?  
A. Vasodilative. 
B. Antiaggregant.  
C. Antipyretic. 
D. Analgesic. 
E. Anti-inflammatory. 
5. Acetylsalicylic acid (75 mg, daily) is prescribed to the patient, 
who had myocardial infarction. What is the purpose of this 
prescription? 
A. Reduction of body temperature. 
B. Reduction of inflammation. 
C. Reduction of pain. 
D. Reduction of thrombocytes aggregation.  
E. Dilation of coronary vessels. 
6. Vicasolum is prescribed to patient during several days before 
planned surgery concerning an ulcer of stomach. What is the 
mechanism of vicasolum action? 
A. Drug binds the calcium ions.    
B. Drug decreases vessels permeability.  
C. Drug oppresses fibrinolysis. 
D. Drug oppresses aggregation of thrombocytes. 
E. Drug increases blood clotting in the result of increasing of 
prothrombin synthesis. 
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7. A patient with myocardial infarction is delivered to 
resuscitation unit. What drug should be administered to the patient 
for prevention of thrombus formation?  
A. Heparin. 
B. Chingaminum. 
C. Thyroxine. 
D. Biseptol 480. 
E. Dimedrol. 
8. Patient with angina pectoris is treated with acetylsalicylic acid 
in daily dose 100 mg daily. What is the aim of therapy with 
acetylsalicylic acid in this case? 
A. Decrease of cholesterol level. 
B. Inhibition of blood clotting. 
C. Dilation of coronary vessels. 
D. Decrease of prothrombin level. 
E. Inhibition of platelet aggregation. 
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DRUGS INFLUENCING METABOLISM 
 
VITAMINS 
 
This group includes drugs containing vitamins of natural and 
synthetic origin which are essencial for body metabolism.   
Vitamins are used to treat and prevent hypo- and avitaminosis 
and to treat certain pathological states by means of targeted 
metabolism regulation. 
Vitamin deficiency (hypo- and avitaminosis) develops due to 
their insufficient intake, disorders of their absorption in some 
gastrointestinal diseases, or in case of increased organism demand in 
vitamins (pregnancy, fever, thyrotoxicosis, etc.).  
Vitamins are classified as follows.  
1. Water-soluble vitamins: ascorbic acid (vitamin C), rutin 
(vitamin P), thiamine (vitamin B1), riboflavin (vitamin B2), 
panthotenic acid (vitamin B5), pyridoxine (vitamin B6), 
cyanocobalamin (vitamin B12), folic acid (vitamin Bc), and nicotinic 
acid (vitamin PP).  
2. Lipid-soloble vitamins: retinol (vitamin A), tocopherol 
(vitamin E), ergocalciferol (vitamin D), and naphthoquinones 
(phylloquinone – vitamin K1; menaquinone – vitamin K2).   
  
Drugs of Water-Soluble Vitamins  
 
Thiamine (Vitamin B 1) 
 
Thiamine  is found in the bran of cereal grain, rice, peas, yeast, 
and other products of plant and animal origin.   
Thiamine bromide  and thiamine chloride  are preparations 
of vitamin B1 which dosed orally or parenterally. In a body, thiamine 
undergoes phosphorylation with formation of thiamine 
monophosphate and thiamine diphosphate. Thiamine diphosphate is 
most effective and manufactured by pharmaceutical industry with 
name Cocarboxylase. Thiamine diphosphate participates in 
decarboxylation of pyruvic acid and α-ketoglutaric acid. Pyruvic acid 
is essential for formation of acetate which is used for synthesis of 
acetyl-CoA, acetylcholine, steroid hormones, and fatty acids.  
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α-Ketoglutaric acid is involved in citric acid cycle (Krebs cycle) and 
is essential for synthesis of ATP. 
Also, thiamine diphosphate is coenzyme of transketolase. It is 
key enzyme of pentose phosphate pathway, which is essential for 
synthesis of nicotinamide nucleotides, fatty acids, nucleic acids, 
proteins, etc.   
Thereby, vitamin B1 participates in regulation of carbohydrate, 
energy, peptide, and other types of body metabolism. Thiamine 
diphosphate eliminates metabolic acidosis.  
Thiamine dilates coronary vessels and improves blood supply of 
myocardium. The drug stimulates cardiac contraction and improves 
energy metabolism of myocardium due to activation of aerobic 
oxidation of carbohydrates and glucose catabolism in citric acid 
cycle.      
Owing to influence upon carbohydrate metabolism, thiamine 
exerts expressed influence upon peripheral nervous system. At 
inflammatory diseases of peripheral nervous system, carbohydrate 
metabolism is disturbed with accumulation of incompletely oxidized 
products and development of acidosis. It causes the painful syndrome 
in neuritis, lumbago, and neuralgia. Thiamine is effective in these 
pathological states due to its ability to normalize carbohydrate and 
energy metabolism and stimulate acetylcholine synthesis. Vitamin B1 
decreases the level of glucose and lactic acid in the blood and, 
therefore, is used in the treatment for diabetes mellitus.  
Thiamine stimulates the synthesis of GABA, serotonin, 
acetylcholine in central nervous system and therefore normalizes the 
processes of excitation and inhibition.  
Besides, vitamin B1 regulates the motility and secretion of 
gastrointestinal tract and activates epithelialization of skin and 
mucous membranes. 
Vitamin B1 deficiency is accompanied by development of 
neuritis, muscular weakness, and sensation disorders. In severe cases 
(disease beri-beri), the pareses and paralyses develop. Also, disorders 
of cardiovascular system, cardiac dystrophy, edemas, and dyspeptic 
disorders are observed.    
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Vitamin B1 is taken orally and administered intramuscularly or 
intravenously drop-by-drop. The drug is readily absorbed from the 
intestine and penetrates different tissues. Thiamine undergoes 
phosphorylation in the liver. 
Thiamine is used in the treatment for hypo- and avitaminosis 
(beri-beri), heart failure, tachyarrhythmias, ischemic heart disease, 
neuritis, lumbago, neuralgias, diabetes mellitus, dermatitis, eczema, 
and gastrointestinal diseases.  
Thiamine is the most toxic drug among water-soluble vitamins. 
There is a risk of synaptic plegia in case of its intravenous 
administration due to ability of thiamine to form the complexes with 
different mediators. Synaptic plegia is accompanied by drop of blood 
pressure, cardiac arrhythmias, relaxation of skeletal muscles 
(including respiratory muscles), and inhibition of central nervous 
system.  
Disorders of hepatic enzymes activity and development of 
allergic reactions up to anaphylactic shock are also possible due to 
therapy by thiamine.  
 
Riboflavin (Vitamin B2) 
 
Significant emount of riboflavin  is contained in liver, kidnays, 
eggs, dairy products, yeast, and cereals.  
Vitamin B2 is part of two coferments: FMN (flavin adenine 
mononucleotide) and FAD (flavin adenine dinucleotide). FMN and 
FAD are coenzynes of dehydrogenases and oxidases involved in 
redox processes. FMN and FAD are structural components of 
mitochondrial electron transport chain and thus involved in tissue 
respiration. Vitamin B2 participates in metabolism of amino acids and 
ensures the functioning of epithelial tissues, eye lens, and brain.  
Riboflavin is essential for synthesis and degradation of 
catecholamines both in central nervous system and in peripheral 
tissues. Vitamin B2 promotes the synthesis of erythropoietin 
(hormone regulating the erythropoiesis). Riboflavin participates in 
metabolism of pantothenic and folic acids. Riboflavin promotes 
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synthesis of pyridoxal phosphate due to activation of pyridoxal 
kinase.  
Riboflavin transforms short blue waves in longer green waves to 
which the retina is more sensitive. Therefore, riboflavin increases the 
visual acuity.  
Vitamin B2 also is necessary for vital activity of E. coli. 
Riboflavin deficiency is accompanied by angular stomatitis, 
glossitis, keratitis, conjunctivitis, lens clouding, optic athrophy, 
appearance of cracks in the corners of the mouth and on the lips, eye 
pain, and photophobia. Hysteria, hypochondria, depression, feeling 
of the heat in the body, and muscular weakness develop in the 
patient. The gastrointestinal secretion decreases.   
Riboflavin  is taken orally and applied topically. Riboflavin 
mononucleotide  is dosed parenterally. Riboflavin is readily 
absorbed from gastrointestinal tract and excreted by kidneys in 
unchanged form.  
Riboflavin is used in the treatment for hypo- and avitaminosis, 
depression, hypochondria, feet pain, convulsions, skin and mucosa 
lesions, hair loss, night blindness, cataract, and digestive disorders.  
Besides, vitamin B2 is used in hypotrophy, hypochromic and 
hyperchromic anaemias, acute hypoxia (at acute heart failure, 
pneumonia, etc.), dysbiosis, and hepatitis. 
Riboflavin can cause allergic reactions. Overdose of vitamin B2 
results in renal dysfunction owing to plugged renal tubules.   
 
Nicotinic Acid and Nicotinamide  
(Vitamin B3  or Vitamin PP)  
 
Nicotinic acid  is contained in cereals, yeast, buckwheat, liver, 
meat, milk, etc. Partly, vitamin PP is synthesized in intestine by 
saprophytic microorganisms.   
Nicotinic acid is a part of NAD (nicotinamide adenine 
dinucleotide) and NADP (nicotinamide adenine dinucleotide 
phosphate). NAD and NADP are primary components of 
mitochondrial and microsomal electron-transport chains. Thereby, 
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nicotinic acid is involved in all kinds of metabolism and 
detoxification of poisons.  
Vitamin PP influences interrelation of inhibition and excitation 
processes in central nervous system. In such diseases as neurosis and 
hysteria, nicotinic acid promotes inhibition processes in CNS. 
Nicotinic acid (but no nicotinamide) dilates vessels due to 
histamine release and activation of kinins system. 
Vitamin PP exerts antiatherogenic effect owing to the inhibition 
of synthesis of low-density lipoproteins and very low-density 
lipoproteins. Nicotinic acid improves carbohydrate and energetic 
metabolism in the heart due to reduction of contents of pyruvic and 
lactic acids and increases the coronary blood circulation. Besides, 
vitamin PP increases the contents of glycogen and ATP in 
myocardium. 
Nicotinic acid is essential for transformation of trans-retinol to 
cis-retinol which is involved in rhodopsin synthesis in eyes. 
Nicotinic acid decreases the platelet aggregation owing to 
reduction of tromboxane A2 synthesis and increases the activity  
of fibrinolytic system. Vitamin PP stimulates formation of 
normochromic erythrocytes and reticulocytes. 
Nicotinic acid increases the synthesis and secretion of bile in 
liver and imroves digestion. Besides, vitamin PP improves 
detoxification function of liver by means of activation of conjugation 
and methylation of toxins. 
Nicotinic acid deficiency results in pellagra. Main 
manifestations of pellagra include patological changes of mind 
(dementia – mental retardation, confusion, hallucinations, and 
cerebrospinal paralysis), digestive system (diarrhoea, stomatitis, and 
glossitis), and skin (dermatitis, pigmentation of exposed parts of the 
body).    
Nicotinic acid and nicotinamide are administered parenterally or 
traken orally. Preparations of vitamin PP are used in the treatment for 
hypo- and avitaminosis, atherosclerosis (in daily doses 3–9 g), 
arteritis obliterans, Raynaud’s disease, migraine, spasm of biliary or 
urinary tract, thrombosis, heart failure, ischemic heart disease, 
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hypoacid gastritis, gastroenteritis, hypochromic anemia, different 
intoxications, and for prevention of diabetus mellitus. 
At therapy with nicotinic acid, much of the complications 
develop due to histamine release and kinin system activation: 
hypotension, dizziness, redness and itching of the skin, 
gastrointestinal hypersecretion, burning sensation during urination, 
etc. Long-lasting administration of nicotinic acid may result in fatty 
liver. To prevent this complication, products rich by methionine are 
consumed.  
 
Pantothenic acid (Vitamin B5) 
 
Pantothenic acid  is found in yeast, liver, eggs, fish eggs, 
cereals, and cauliflower. Partly, vitamin B5 is synthesized by 
intestinal microflora.  
Pantothenic acid is a part of coenzyme A transporting acetate 
and other acyl groups. Vitamin B5 is essential for oxidation and 
synthesis of fatty acids, decarboxylation of ketoacids (pyruvic and  
α-ketoglutaric acids), synthesis of citric acid in Krebs’ cycle, 
corticosteroids, acetylcholine, etc. Vitamin B5 provides the normal 
structure of cell membranes and promotes the impulse transduction 
in cholinergic synapses.  
Pantothenic acid deficiency is almost not detectable in humans.   
Vitamin B5 is used as calcium pantothenate  to treat neuritis, 
neuralgia, allergy, respiratory diseases, postoperative intestinal 
atony, fatty liver, apathy, weakness, and disorders of neuromuscular 
transmission.  
The drug is administered intramuscularly and taken orally. 
Vitamin B5 is readily absorbed from gastrointestinal tract, does not 
undergo biotransformation in the body. The drug is excreted by 
kidneys (70 %) and liver (30 %). 
Sometimes, therapy with calcium pantothenate is accompanied 
by dispeptic disorders.           
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Pyridoxine (Vitamin B6) 
 
Pyridoxine  is found in yeast, cereals, legumes, bananas, meat, 
fish, liver, and kidneys. Also, this vitamin is synthesized by intestinal 
microflora.  
Pyridoxal phosphate is the main active form of vitamin B6. 
Pyridoxal phosphate participates in nitrogen metabolism. It promotes 
the absorption and distribution of amino acids, activates the 
processes of transamination, deamination, and decarboxylation of 
amino acids. For instance, decarboxylation of glutamic acid results in 
formation of γ-aminobutyric acid (GABA) – one of the main 
inhibitory mediators in central nervous system. Also, vitamin B6 
participates in transformation of tryptophan to serotonin and in 
conversion of tyrosine to dopamine and noradrenaline.  
Products of deamination of amino acids include such acids as 
pyruvic, α-ketoglutaric, and oxaloacetic ones. These acids together 
with coenzyme A form acetylcoenzyme A which participates in 
number important biochemical reactions. 
Pyridoxine exerts cardiotonic and hepatoprotective effects. 
Vitamin B6 increases the synthesis of proteins and carbohydrates and 
activates hepatic detoxification function. Besides, vitamin B6 
stimulates erythro- and leukopoiesis. 
Pyridoxine influences lipid metabolism. The vitamin promotes 
transformation of linoleic acid to nonsaturated arachidonic acid and 
decreases the level of cholesterol and lipids at atherosclerosis. 
Hypovitaminosis B6 is accompanied by stomatitis, convulsions, 
glossitis, seborrheic dermatitis on the face, etc.  
Pyridoxine is used in the treatment for myocardiodystrophy, 
myocardiosclerosis, hepatitis, toxic anemia, agranulocytosis, 
radiation sickness, chorea, parkinsonism, neuritis, intoxications, etc. 
Also, pyridoxine is used at therapy by antitubercular drugs 
(isonicotinic acid derivatives) to prevent central nervous system 
disorders.   
Pyridoxine and pyridoxal phosphate are administered 
subcutaneously, intramuscularly, intravenously and taken orally. At 
therapy by vitamin B6, numbness of extremities, allergic reactions, 
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and increased gastric juice acidity may occur. Overdose of 
pyridoxine leads to disorders of protein, carbohydrate, and lipid 
metabolism, degenerative changes of central nervous system and 
parenchymatous organs.   
 
Cyanocobalamin (Vitamin B12) 
 
Cyanocobalamin  is found in products of animal origin, 
especially in beef liver and kidneys. In human body, vitamin B12 is 
synthesized by intestinal bacteria. But this synthesis is not essential 
because vitamin B12 is mainly absorbed in small intestine. 
In a body, cyanocobalamin is converted to cobamamide which is 
coenzyme of number reductases. These enzymes reduce folic acid to 
tetrahydrofolic acid that activates synthesis of nucleic acids and 
proteins and stimulates cell division. Thus, cobamamide exerts an 
anabolic effect. Besides, cobamamide exhibits membrano-stabilizing 
effect because it contributes to maintain bonds in unsaturated fatty 
acids. Cobamamide promotes synthesis of methionine from 
homocysteine. It is the source of methyl groups which are used for 
synthesis of choline, acetylcholine, etc. Also, cobamamide transfers 
methylmalonic acid to succinic acid which is essential for myelin 
synthesis.  
Hypovitaminosis B12 leads to disorders of DNA synthesis. Most 
pronounced changes develop in rapidly proliferating tissues,  
e. g., cells of bone marrow (megaloblastic anemia develops). 
Digestive system is affected too: ahiliya and atrophy of mucous 
membrane of stomach develop. Paresthesia, pain along the nerves, 
and gait disturbance are pathological changes developed due to 
lesion of myelin synthesis in the nervous system. 
Gastrointestinal absorption of vitamin B12 requires biermerin 
(Castle’s intrinsic factor) which is synthesized by parietal cells of 
gastric mucosa. Also, biermerin prevents vitamin B12 absorption by 
intestinal bacteria. High concentration of vitamin B12 is accumulated 
in liver.  
Cyanocobalamin is administered parenterally (intramuscularly or 
intravenously), cobamamide is taken orally. In the blood, 
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cyanocobalamin binds with special proteins transporting it to tissues. 
Cobamide penetrates blood-brain barrier better than cyanocobalamin. 
Vitamin B12 is accumulated in the liver; its half-life in the liver is 
about 12 months. The drug is excreted from the body mainly by 
kidneys (about 93 %).  
Cyanocobalamin is used to treat pernicious anemia, 
hypochromic and hypoplastic anemias, radiculitis, degenerative 
changes in the central nervous system, fatty liver, radiation sickness, 
hypotrophy in children, etc.   
Side effects of cyanocobalamin are allergic reactions, 
tachycardia, heart pain, lipid infiltration of liver, and increased 
excitability.  
 
Folic acid (Vitamin Bc) 
 
Folic acid  is found in green peas, carrot, potatoes, egg yolk, 
liver, meat, fish, etc. Intestinal microflora also synthesizes folic acid.  
In human body, folic acid is reduced to tetrahydrofolic acid. 
Vitamins B12, C, and biotin are essential for synthesis of 
tetrahydrofolic acid. Tetrahydrofolic acid is cofactor of some 
enzymes participating in transport of one-carbon radicals (methyl 
group, methylene group, hydroxymethyl group, etc.). One-carbon 
groups are essential for synthesis of purine and pyrimidine bases, 
proteins, and amino acids. Therefore, tetrahydrofolic acid activates 
cellular division and growth and stimulates regenerative processes. 
Tetrahydrofolic acid participates in such processes as transformation 
of serin to glycine, synthesis of methionine from homocystein, etc.     
Folic acid deficiency is closely releated to deficiency of 
cyanocobalamin. Clinical manifestations of deficiency of both 
vitamins are very similar. A difference is that the neurological 
disturbances are more common at cyanocobalamin deficiency. 
Patological changes in peripheral blood and bone marrow are similar 
and include megaloblastic and macrocytic anemias. Besides, 
leukopenia and lesions of gastrointestinal tract are observed.    
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Folic acid is absorbed in small intestine and deposited in the 
liver. From the body, folic acid is excreted by kidneys and liver in 
unchanged form. 
Folic acid is used in the treatment for macrocytic, megaloblastic, 
hypochromic, and hypoplastic anemias, leukopenia, agranulocytosis, 
sprue, thrombocytopenia, enteritis, hypotrophy in children, wounds, 
burns, etc. 
Dispeptic disorders, insomnia, disorders of renal function, and 
neoplasm are side effects occuring at therapy by folic acid. 
Prescription of folic acid to elderly patients who have a propensity to 
cancer is especially dangerous. 
 
Ascorbic acid (Vitamin C)  
 
Significant amount of ascorbic acid  is found in vegetables, 
fruit, berries, pine needles, dog-rose, blackberry, etc.  
Main effects of ascorbic acid are associated with its role in redox 
processes. Transformation of ascorbic acid to dehydroascorbic acid is 
a reversible process which provides transport of hydrogen ions.  
Ascorbic acid catalyzes the following processes:  
– transformation of folic acid to tetrahydrofolic acid which 
participates in synthesis of nucleic acids and proteins;  
– synthesis of hyaluronic acid which decreases the permeability 
of the vessel wall; 
– synthesis of noradrenaline from tyrosine; 
– synthesis of steroid hormones from cholesterol;  
– synthesis of collagen, which is a structural component of the 
cartilage, bones, and other connective tissues;  
– synthesis of carnitine, which promotes utilization of fatty acids 
as the source of energy. 
 Besides, ascorbic acid promotes absorption of iron in the 
gastrointestinal tract due to reduction of Fe3+ to Fe2+. Vitamin C 
stimulates functional activity of the respiratory chain in hepatocytes 
and increases detoxificating and synthetic functions of the liver.  
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Ascorbic acid increases the synthesis of interferon and 
antibodies and activates phagocytosis and leukocyte chemotaxis. 
Thus, ascorbic acid activates non-specific immunity.  
High doses of ascorbic acid inhibit the synthesis and secretion of 
insulin. 
Vitamin C exerts antioxidative activity by means of reduction of 
free oxygen radicals in the presence of glutathione and α-tocopherol. 
Also, vitamin C exhibits antiatherosclerotic effect.  
Deficiency of ascorbic acid is accompanied by hypo- and 
avitaminosis (scurvy). Symptoms of scurvy include fatiguability, 
dryness of skin, hemorrhagic rash, gingivitis, bleeding from the 
gums, losing teeth, hemorrhages in the skeletal muscles, pain in the 
extremities, disturbances of internal organs functions (liver, heart, 
etc.), and decreasing of immunity. 
Ascorbic acid is taken orally and administered intramuscularly 
or intravenously. Absorption of ascorbic acid begins in oral cavity 
and continues in intestine with participation of glucose. Maximum 
concentration in the blood is observed in 4 hours. From the blood, 
ascorbic acid penetrates better into the leukocytes, platelets, pituitary, 
eye, adrenal glands, and liver.  
Biotransformation of ascorbic acid occurs in the liver. 
Metabolites are excreted mainly by kidneys. 
Ascorbic acid is used to prevent and treat scurvy and 
hypovitaminosis in winter-spring season, in complex treatment for 
viral and bacterial infections, at stress, hypoxia, metabolic and 
respiratory acidosis, hemorrhagic syndrome, inflammatory and 
allergic diseases, hypochromic anemia, atherosclerosis, acute 
hypotension, radiation sickness, etc. Ascorbic acid is prescribed to 
patients who are long-time treated by non-steroid anti-inflammatory 
drugs and antibiotics (tetracyclines, etc.) which eliminate vitamin C 
from the body.  
Therapeutic doses of ascorbic acid are well tolerated by patients. 
Long-time intake of high doses can cause damage of pancreas with 
hyperglycemia, damage of kidneys, and increase of blood pressure. 
Excess of ascorbic acid promotes the tendency to thrombosis, 
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hemolysis of errhythrocytes, formation of urinary stones, irritability, 
increased synthesis of estrogenes, and allergic reactions.   
 
Rutin (Vitamin P)  
 
Several substances – bioflavonoids belong to vitamin P. 
Bioflavonoids are found in citrus, blackberry, dog-rose, chokeberry, 
green tea, etc. 
Rutin  exerts antioxidant effect. Vitamin P promotes 
transformation of ascorbic acid to dehydroascorbic acid which easily 
penetrate the cells. Also, rutin prevents the transformation of 
dehydroascorbic acid to diketogulonic acid (it is inactive metabolite 
of ascorbic acid). Vitamin P promotes accumulation of ascorbic acid 
in the adrenal glands, liver, and other organs and slows down 
excretion of vitamin C from the body.  
Rutin is synergist of ascorbic acid in its influence upon vascular 
wall. Vitamin P decreases vascular permeability due to inhibition of 
hyaluronidase activity. Rutin prevents the oxidation of adrenaline 
and free fatty acids and increases the resistance of tissues to 
radiation. 
Rutin deficiency is accompanied by increased vascular 
permeability. 
Rutin is used in the treatment for angiasthenia, ischemic heart 
disease, cholestasis, and venous insufficiency of the lower limbs. 
Drug is taken orally.  
Therapy by rutin is not accompanied by side effects.  
 
Methylmethionine  (vitamin U) 
 
Methylmethionine  is found in tomatoes, asparagus beans, 
cabbage, celery, etc. Vitamin U is donator of methyl groups. Drug 
exerts anti-ulcer effect. Indications for use of methylmethionine are 
ulcer disease of stomach and duodenum, gastritis, and ulcerative 
colitis.  
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Drugs of Liposoluble Vitamins  
 
Retinol (Vitamin A)  
 
 Vitamin A brings together a number of compounds: retinol  
(vitamin A1), dehydroretinol  (vitamin A2), retinal , and retinoic 
acid . Vitamin A is found in animal products: cod-liver oil, liver, 
butter, yolk, etc. There are products of plant origin (carrots, parsley, 
buckthorn, black chokeberry, dog-rose, etc.) which contain 
provitamin A carotene. In human body, carotene is converted  
to vitamin A. Two molecules of vitamin A are synthesized due to 
hydrolysis of one carotene molecule. 
Cells of target organs contain specific receptors, which interact 
with retinol-binding protein. This complex penetrates the nucleus and 
activates genes responsible for synthesis of proteins and structural 
components of tissues. 
Each retinoid has its own value in a body. Thus, retinol provides 
growth, tissue differentiation, and normal function of reproductive 
system. Retinoic acid is essential for differentiation of epithelium 
and regulates activity of calcitriol receptors. Retinal provides normal 
function of retina, etc.  
Vitamin A is essential for activation of phospho-adenosine-
phosphosulfate which is the part of: 
– mucopolysaccharides: heparin, hyaluronic acid, chondroitin 
sulfate, and other components of connective tissue;  
– sulfate-contaning cerebrosides;  
– taurine, which is essential for synthesis of somatotropin and 
for providing synaptic transmission of impulses; 
– hepatic enzymes providing detoxification function.  
Retinol participates in the synthesis of somatomedins A, B, and 
C, which promote protein synthesis in muscles, inhibit lipolysis, and 
provide the incorporation of proline to collagen. Also, retinol is 
essential for incorporation of phosphates and thymidine in DNA 
molecules. 
Vitamin A stimulates the synthesis of steroid hormones and 
takes part in formation and functioning of thymus, spleen, and 
lymphoid tissue. This vitamin is essential for synthesis of 
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immunoglobulins, interferon, and lysozyme. Vitamin A supports the 
activity of phagocytes.  
Retinol stimulates the synthesis of enzymes in epithelial cells 
and prevents the excessive epidermidalization. 
Because retinol participates in rhodopsin synthesis, it is important 
for supporting visual acuity and for eye adaptation to the dusk. 
Rhodopsin is a photosensitive pigment contained in rods – cells which 
are sensitive to low intensity light. Under the influence of light, 
rhodopsin splits into retinal and opsin. This process causes impulse 
generation. Dehydrogenase transforms the retinal to retinol. 
Resynthesis of rhodopsin occurs in dark periods that increases the 
visual acuity in low light.   
Vitamin A deficiency is accompanied by development of 
nocturnal amblyopia (night blindness). Also, skin epithelium and 
mucous membranes are affected: different types of epithelium are 
transformed to stratified squamous epithelium and keratinization 
processes are increased. Skin becomes dry, there are rashes. The 
mucous membranes of eyes are affected: cornea becomes dry 
(xerophthalmia) and softened (keratomalacia). Severe cases of retinol 
deficiency may lead to total blindness.  
Vitamin A deficiency is also accompanied by lesions of 
respiratory, gastrointestinal, and urogenital system. Damages of skin 
and mucous membranes and immunosuppression promote infectious 
diseases. 
Retinol and carotenoids are readily absorbed from 
gastrointestinal tract. Fatty food and bile are essential for their 
absorption. In blood, vitamin A is binded with specific protein 
synthesized in liver. This complex interacts with special receptors of 
cellular membranes. Owing to this interaction, the free retinol 
penetrates the cells. Excess of vitamin A is deposited in a liver, there 
it undergoes biotransformation with formation of active and inactive 
metabolites. Metabolites of retinol are excreted by the kidneys and 
intestine. 
Vitamin A is used to treat and prevent hypo- and avitaminosis, 
in the treatment for infectious diseases (together with vitamin C), 
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rickets (together with vitamin D), night blindness, keratitis, 
xerophthalmia, psoriasis, dermatitis, acne, inflammatory diseases of 
respiratory and gastrointestinal tracts, burns, frostbite, trophic ulcers, 
etc. Retinol is also used in stomatology. 
Excessive intake of vitamin A leads to hypervitaminosis. Acute 
poisoning by retinol is manifested by convulsions and paralysis. 
Symptoms of chronic poisoning by vitamin A are worsen vision, 
photophobia, abdominal pain, dry skin, increased size of liver and 
spleen, increased intracranial pressure with headache, nausea, 
vomiting, etc. At appearance of such symptoms, therapy by vitamin 
A should be stopped. A patient is treated by osmotic diuretics  
(to reduce intracranial pressure), glucocorticoids, and tocopherol. 
 
Ergocalciferol (Vitamin D)  
 
Vitamin D includes ergocalciferol  (vitamin D2) and 
cholecalciferol  (vitamin D3). Ergocalciferol is substance of plant 
origin, while cholecalciferol is synthesized in skin under influence  
of ultraviolet. Significant amount of vitamin D is found in the liver of 
tuna, cod, halibut, and kit. Cow’s milk and egg yolks are also rich in 
vitamin D.  
Vitamins D2 and D3 are pharmacologically inactive. These 
vitamins are converted to active metabolites in kidneys. Metabolites 
of vitamin D (e. g., calcitriol) are hormone-like substances regulating 
metabolism of calcium and phosphorus.  
Calcitriol penetrates inside of the target cells and binds to 
cytoplasmic receptors. Complex calcitriol-receptor enters the nucleus 
and causes the derepression of genes responsible for synthesis of 
specific and non-specific proteins.  
Thus, in the intestinal mucosa, calcitriol activates the synthesis 
of specific protein binding calcium and non-specific proteins 
promoting absorption of calcium, magnesium, and phosphorus. 
Besides, vitamin D stimulates the synthesis of alkaline phosphatase 
in the intestinal mucosa. This enzyme participates in the intestinal 
absorption of calcium and synthesizes the calbindin binding 
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excessive amount of calcium and preventing its damaging influence 
upon the cells. 
In bones, vitamin D activates the synthesis of alkaline 
phosphatase which promotes calcium capture from the blood and its 
deposition in the growth zone of bones. In osteoclasts, vitamin D 
increases the synthesis of osteocalcin – protein which is matrix for 
ossification. Besides, vitamin D stimulates the synthesis of collagen 
in bones. It is necessary to note, that active metabolites of vitamin D 
also take part in resorption of calcium in diaphysis due to formation 
of water-soluble calcium citrate.  
In epithelial cells of renal tubules, vitamin D stimulates 
synthesis of calcium-binding protein. It provides calcium 
reabsorption in proximal convoluted tubules. Also, vitamin D 
increases the renal synthesis of alkaline phosphatase (participates in 
calcium capture form of the lumen of tubule) and some proteins 
providing reabsorption of sodium, amino acids, citrate, phosphates, 
and carnitine.  
Vitamin D stimulates secretion of thyroid-stimulating hormone 
and interleukin-1, and inhibits the formation of γ-globulin and 
interleukin-2. 
Vitamin D deficiency in children results in rickets. The 
manifestations of rickets include broken calcification of bones, 
deformation of spine and lower extremities, muscular hypotonia, and 
retardation of growth and development of child. Deficiency of 
vitamin D in adults, results to osteomalacia and osteoporosis. 
Absorption of vitamin D occurs in small intestine. In blood, 
vitamin D binds to α-globulin and this complex is transported to 
organs. Vitamin D is deposited in bones, fatty tissues, liver, mucous 
membranes of small intestine, and other organs. Vitamin D 
undergoes hepatic biotransformation with formation of both active 
and inactive metabolites. Inactive metabolites of vitamin D undergo 
mainly intestinal and, in small degree, – renal excretion.   
Elimination of vitamin D from organism is gradual, about 34 % 
administered dose is eliminated for 21 days. Therefore, there is 
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danger of accumulation of vitamin D in the body owing to its 
repeated intake.  
The following drugs of vitamin D are used in medicine: 
ergocalciferol , calcitriol , alfacalcidol ,  cholecalciferol  
(Vigantol), cod liver oil , etc. These drugs are used mainly to 
prevent and treat rickets. Preventive dose for chidren under 1 year is 
400–500 IU a day. To treat rickets, vitamin D is dosed individually 
starting from 5,000 IU a day. 
Besides, vitamin D is used in the treatment for osteomalacia, 
osteoporosis, bone fractures, tuberculoderma, psoriasis, and 
hypocalcemia (in patients with hypoparathyroidism, chronic renal 
failure, adminsitration of large volume of citrate blood).   
At pathologies when fast effect is necessary, drug of choice is 
calcitriol, which is administered together with calcium-containing 
drugs.   
Overdose of vitamin D results in acute or chronic 
hypervitaminosis which is accompanied by intensive calcium 
absorption in intestine and bone resorption. Due to these processes, 
following pathological changes are observed: hypercalcemia and 
calcification of soft tissues, vascular wall, lungs, intestine, kidneys, 
heart valves, etc. Increased formation of free oxygen radicals leads to 
lesions of cellular and subcellular membranes. It is accompanied by 
impairment of cardiac contractility, development of necrotic foci, 
and arrhythmias. Flaccidity, drowsiness, sudden anxiety, and 
convulsions are manifestations of damage of central nervous system.  
To treat vitamin D hypervitaminosis, glucocorticoids, vitamin E, 
magnesium- and potassium-containing drugs, ascorbic acid, retinol, 
and thiamine are used. Besides, symptomatic therapy is performed.   
 
Tocopherol  (Vitamin E) 
 
There are α-, β-, and γ-tocopherols . α-Tocopherol is the most 
active among them. Vitamin E is contained in cereals (oats, rice, rye, 
etc.), meat, fats, eggs, and milk. For humans, main sources of 
tocopherol are vegetative oils. 
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Tocopherol takes part is synthesis of lipids, 
mucopolysaccharides, and different proteins (collagen, contractile 
proteins of skeletal and smooth muscles, hepatic enzymes, 
vasopressin, coenzyme Q, heme, gonadotropins, etc.). 
Tocopherol is one of the most potent antioxidants. Vitamin E 
exerts marked protective effect on phospholipids of cellular, 
mitochondrial, and lysosomal membranes. Tocopherol protects 
chromosomes from mutagenic influence of free radicals. Free 
radicals play important role in pathogenesis of autoimmune and 
inflammatory diseases, hypoxia, hypertermia, shock, excessive 
stress, viral and bacterial infectious diseases, etc.  
Hypovitaminosis of vitamin E in humans is not registered. In 
animal models with complete deprivation of vitamin E, following 
pathological changes are observed: suppressing of spermatogenesis, 
suppressing of implantation, abortions, and degeneration of 
myocardium and skeletal muscles.    
Tocopherol  is administered intramuscularly or taken orally. 
Vitamin E is absorped in small intestine. Maximum concentrations of 
vitamin are observed in fat tissue, liver, muscles, and retina. 
Unconverted vitamin E is excreted mainly through intestine.  
At parenteral administration, about 1/3 administered dose of vitamin 
E is metabolized and excreted with the urine.  
Tocopherol is used in the treatment for reccurent abortions, 
violation of menses, juvenile bleeding, atherosclerosis, heart failure, 
coronary insufficiency, anemias, arthrosis, myocardiodystrophy, 
epilepsia, radiation sickness, etc.  
Long-lasting intake of vitamin E is accompanied by reduction of 
vitamin K activity, gastrointestinal bleeding, toxic influence upon the 
blood (affection of neutrophiles and thrombocytes), hepatotoxicity, 
and nephrotoxicity.  
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Naphthoquinone (Vitamin K)  
 
Group of naphthoquinones includes phylloquinone  (vitamin 
K1) and menaquinone  (vitamin K2). Vitamin K1 is substance of 
plant origin. Phylloquinone is contained in spinach, cabbage, 
pumpkin, etc. Menaquinone is synthesized by liver of animals and by 
intestinal microflora. Activity of vitamin K1 is higher than activity  
of vitamin K2. Vicasolum  (vitamin K3 or menadione) is synthetic 
water-soluble analogue of vitamin K.   
In liver, vitamin K stimulates a synthesis of prothrombin (factor 
II), proconvertin (factor VII, kappa factor), Christmas factor (factor 
IX), and Stuart-Prower factor (factor X, or prothrombinase). Besides, 
vitamin K promotes the synthesis of ATP, creatine phosphate, and 
some enzymes.    
Most commonly, vitamin K deficiency develops in result of 
intestinal or hepatic diseases and is accompanied by bleeding, 
hemorrhagic diathesis due to reduction of synthesis of K-dependent 
factors of blood clotting. 
Preparations of vitamin K are administered intramuscularly or 
taken orally. Bile acids are essential for intestinal absorption of 
vitamin K. 
Vitamin K is used in the treatment for bleeding, hemorrhagic 
diathesis, hepatitis, cirrhosis, diarrhoea, ulcer disease of stomach and 
duodenum, uterus bleeding. Also, vitamin K drugs are administered 
prior and after surgical operations to prevent hemorrhages. 
Therapeutic effects of vitamin K appear in several hours after drug 
administration.  
Ussually, side effects do not appear during therapy with vitamin 
K. But parenteral administration of vitamin K to newborns can cause 
hemolytic anemia and jaundice. 
 
Non-Vitamin Cofactors 
 
Non-vitamin cofactors are endogenous metabolites participating 
in regulation of body metabolism. Partly, these substances are taken 
with food so that have sertain similarity to vitamins (sometimes, 
symptoms of their deficiency are observed). There are the following 
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non-vitamin cofactors: lipoic acid and lipamide, carnitine  
(β-hydroxy-γ-N-trimethylaminobutyric acid),  pangamic 
acid (vitamin B1 5),  choline,  inosine (Riboxin),  adenosine 
monophosphate (AMP, Phosphaden),  and potassium 
orotate.  
Carnitine  is synthesized in the liver and kidneys by means of 
hydroxylase. Partly, carnitine is taken with ingredients of animal 
origin. Medical preparation carnitine chloride is obtained by 
synthetic way. In a body, carnitine catalyzes synthesis of acetyl-CoA 
which is essential for synthesis of pyruvate oxidase participating in 
gluconeogenesis.  
Carnitine deficiency is accompanied by disorders of amino acid 
metabolism and protein synthesis, slowdown of retardation of growth 
and development, hypoglycemia, disorders of synthesis of 
neurotransmitters (acetylcholine, etc.) and phosphatidyl choline 
(main component of surfactant). Mitochondrial long chain fatty acid 
β-oxidation is affected that leads to decrease of ATP synthesis. 
Carnitine deficiency leads to deposition of lipids in skeletal muscles 
and myocardium that affects their contractility.  
Besides, carnitine restricts lipid oxidation and formation  
of hydroperoxides of fatty acids and, therefore, keeps structure of 
cellular membranes.  
Carnitine is used in the treatment for immature infants who are 
on artificial nutrition, haemodialyzed patients (in this case, carnitine 
is excreted from the body and acyl ethers are accumulated), hypoxia, 
diphtheria, therapy with valproic acid, intractable diarrhea, 
cardiomyopathy, and infant respiratory distress syndrome. Besides, 
carnitine is used to treat organic acidemia (elevation of concentration 
of organic acids in the blood), cardiopulmonary failure, and chronic 
hypoxia. At mild and moderate thyrotoxicosis, carnitine improves 
patient status and promotes body weight gain.  
As a rule, 1 teaspoon of 20 % carnitine solution is taken orally 
2–3 times a day 30 minutes prior meal. Course of treatment lasts  
2–3 months. Carnitine is well tolerated by patients. Sometimes, 
stomach pain is possible that requires to decrease the drug dose. 
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Lipoic acid  is synthesized in a body and, partly, taken with 
meat products. It is cofactor of number of enzymes participating in 
carbohydrate and lipid metabolism. Lipoic acid activates citric acid 
cycle, decreases concentration of lactic acid, eliminates intracellular 
acidosis, and stimulates synthesis of CoA. Lipoic acid exerts 
hepatoprotective effect restricting lipid deposition in liver. Also, 
lipoic acid activates protein metabolism. Due to its ability to 
transform to dihydrolipoic acid, it takes part in mitochondrial 
transport of hydrogen. Lipoic acid contains thiol groups, thereby it 
normalizes lipid peroxidation and transformation of oxyhemoglobin 
to methemoglobin.  
Lipoic acid is manufactured in tablets containing 0.012  
or 0.025 g or in ampoules containing 2 ml of 0.5 % solution (for 
intramuscular administration).  
There are the following therapeutic indications for lipoic acid:  
– diabetes mellitus;  
– acute and chronic hepatites;  
– acute poisoning by hepatotoxic substances; 
– hypotrophia in children; 
– prevention of hypercholesterolemia. 
Side effects of lipoic acid include dyspepsia, allergic reactions, 
increased gastric secretion, etc.   
Inosine (Riboxin)  is purine derivative – precursor of ATP. 
The drug activates nucleic acid synthesis and tissue regeneration 
(especially, in myocardium and gastrointestinal tract), icreases stroke 
volume of heart, improves tissue microcirculation, and decreases 
platelet aggregation. Riboxin is dosed orally 0.2 g 3–4 times a day or 
intravenously slowly 10 ml of 2 % solution. The drug is used in the 
treatment for following diseases:  
– ischemic heart disease; 
– cardiac arrhythmias; 
– hepatitis and cirrhosis of liver; 
– ulcer disease of stomach and dupdenum; 
– poisoning by xanthines; 
– porphyria cutanea tarda. 
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Ribaxin is well tolerated by patients. Its possible side effects are 
gout exacerbation, itching, and skin hyperemia. 
Potassium orotate is pyrimidine precursor exerting anabolic 
effect. The drug is taken orally in dose 0.5 g 2–3 times a day. Course 
of treatment lasts 3–5 weeks. Therapeutic indications for otassium 
orotate are the follows: 
– hypothrophy in children; 
– chronic heart failure, myocardial infarction, cardiac 
arrhythmias; 
– toxic hepatitis; 
– leukopenia; 
– hypochromic anemia; 
– poorly healing ulcers and wounds; 
– progressing muscular dystrophy.   
Adenosine monophosphate (AMP, Phosphaden) is ATP 
precursor. The drug penetrates cells and activates synthesis of ATP. 
Phosphaden is part of enzymes activating redox processes. The drug 
is dosed orally 0.025–0.05 g 3–4 times a day or intramuscularly 1 ml 
of 2 % solution. Its clinical indications are the follows: 
– poisoning by lead with symptoms of polyneuritis; 
– acute intermittant porphyria; 
– chronic endarteritis and thrombophlebitis (Phosphaden dilates 
vessels and decreases platelet aggregation); 
– hepatic diseases; 
–ischemic heart disease and chronic heart failure. 
The drug is well tolerated by patients. Its possible side effects 
are dyspepsia, dizziness, tachycardia, and allergic reactions.   
 
Role of Zinc and Copper in Human Body  
 
Zinc is essential for synthesis more than 90 enzymes of human 
body. Zinc activates enzymes controling DNA synthesis, improves 
protein metabolism, activates tissue regeneration, and promotes body 
weight gain. This microelement is essential for function of insulin, 
sex hormones, pancreatic carboxypeptidase, angiotensin-converting 
enzyme, alcohol dehydrogenase in liver and eye retina, alkaline 
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phosphatase in bones, intestine and kidneys. Zinc maintains stability 
of cellular membranes, restricts histamine release from basophils and 
formation of free radicals. Zinc participates in regulation of functions 
of lymphoid tissue and immune system.  
In medicine, this microelement is used in form of zinc oxide  
and zinc sulfate (Zincteral)  for oral intake after meal. 
Indications for zinc-containing drugs are the follows: 
– prevention and treatment of hypodynamia;  
– pregnancy (especially last trimester); 
– premature infants; 
– renal and hepatic diseases, hypovitaminosis D, burns, enteritis, 
psoriasis, helmintoses and other pathological states which are 
accompanied by hypozincemia;  
– acute respiratory infections.   
Copper is cofactor of number enzymes. Copper is essential for 
gastrointestinal absorption of iron and its incorporation into heme, 
porphyrin synthesis, and maturation of reticulocytes. Copper 
activates superoxide dismutase – enzyme interfering free radical 
reactions and protecting cellular membranes from damage. 
Copper sulfate  is dosed orally to prevent and treat 
hypocupremia (commonly observed in premature infants) and to treat 
hypochromic anemias. Besides, copper-containing drugs are 
prescribed for children under parenteral nutrition and who feeding by 
cow milk.    
 
Antivitamins  
 
Antivitamins are substances which violate the use of vitamins by 
body with development of vitamin deficiency. Antivitamins are 
divided into two groups: 
1) antivitamins that disrupt vitamins or bind to vitamin 
molecules with formation of inactive forms: avidin  (protein of raw 
egg), thiaminase , ascorbinase , and lipoxidase;   
2) antivitamins which are structurally similar to vitamins and 
due to this can replace vitamins from bioactive compounds: 
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methotrexate , neodicumarin , quinacrine , quinine , 
isoniazid , and lead .  
Avidin is protein of raw eggs. Avidin can bind with vitamin H 
(biotin) with formation of water insoluble complex which lacks 
bioactivity. 
Thiaminase disrupts vitamin B1. Significant amount of 
thiaminase is contained in guts of fish and shellfish, in ferns, etc. It is 
proved, that mild forms of B1 hypovitaminosis which occured in 
Japanese is due to intestinal flora which produced thiaminase. 
Ascorbinase is contained in different plants. Ascorbinase 
metabolizes ascorbic acid to dehydroascorbic acid which is easily 
destroyed under influence of temperature and acid environment.  
Lipoxidase is contained in soybeans. It destroys carotine and 
promotes the development of vitamin A hypovitaminosis.  
Antivitamins of another group are structural vitamin analogues 
which significantly influence a body metabolism. Such substances 
have not own bioactivity but can restrict or eliminate effects of 
vitamins. Thus, there are both competitive and non-competitive 
antagonism between vitamin and antivitamin. 
Methotrexate is antagonist of folic acid. Methotrexate affects 
synthesis of active coenzyme form of folic acid – tetrahydrofolic acid 
which is essential for synthesis of purine bases. Due to this, DNA 
and RNA synthesis slows down that violates cells division. Because 
neoplastic cells rapidly proliferate, they are quite susceptible to 
methotrexate influence. Therefore, methotrexate is used in the 
treatment for leucosis (especially in children) and breast cancer. 
Antagonists of vitamin K (or indirect anticoagulants) are 
syncumar, neodicumarin, warfarin, and phenylin. These drugs affect 
synthesis of K-dependent factors of blood cloting: prothrombin (II 
factor), proconvertin (VII factor), Christmas factor (IX factor), and 
Stuart-Prower factor (X factor). Indirect anticoagulants are used to 
prevent thrombosis. There are the following indications for their use.  
1. Prevention and treatment of venous thrombosis, 
thrombophlebitis, myocardial infarction, and ischemic stroke.  
2. Prevention of thrombosis in postoperative period.  
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3. Prevention of thrombosis and thromboembolia in patients with 
rheumatic heart disease.  
4. Prevention of thrombosis after angioplasty, prosthetic heart 
valves.  
5. Prevention of thrombosis after discontinuation of therapy with 
directly acting anticoagulants. 
Isoniazid is derivative of isonicotinic acid which used in the 
treatment for tuberculosis. Isoniazid is antagonist of pyridoxine. It 
affects the formation of coenzyme form of vitamin B6 – pyridoxal 
phosphate which is essential for metabolism of amino acids and 
synthesis of certain neurotransmitters (GABA, serotonin, etc.). 
Reduced synthesis of pyridoxal phosphate is a cause of such side 
effects of isoniazid as peripheral neuropathy, seizures, hyperreflexia, 
increased frequency of seizures in patients with epilepsy, etc. To 
prevent these side effects, vitamin B6 is prescribed together with 
isoniazid. 
Antimalarial drugs quinene and mepacrine (quinacrine) suppress 
effects of riboflavin (vitamin B2). These drugs affect the flavin 
enzymes that facilitates its activity against malarial plasmodium, 
trichomonas, leishmania, and balantidium.      
Plumbum (lead) is noncompetitive antagonist of vitamin B12. 
Lead inhibits activity of intrinsic Castle’s factor and affects 
gastrointestinal absorption of cyanocobalamin.   
Antagonism between different vitamins is also known. Retinol is 
antagonist of calciferol. There are complex relationships between 
retinol and tocopherol. It is known, that tocopherol prevents 
oxidation of retinol. But on the other hand, significant amount of 
vitamin A reduces hepatic reserve of tocopherol.  
Pyridoxine is a thiamine antagonist. Excess of thiamine in food 
increases the symptoms of B6 hypovitaminosis. Neuronal toxicity of 
high doses of thiamine is eliminated by pyridoxine.  
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Table 10 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product 
Thiamini 
bromidum 
Orally 0.002 58–0.012 9 g;  
 
Intramuscularly 0.03–0.06 g 
Tablets 0.002 58  
or 0.012 9 g; 
ampoules 3 % or 6 % –  
1 ml 
Acidum 
nicotinicum 
Orally 0.02–0.05 g; 
intramuscularly 0.01 g;  
intravenously 0.05 g 
Tablets 0.05 g; 
ampoules 1 % – 1 ml 
Pyridoxini 
hydrochloridum 
Orally, subcutaneously, 
intramuscularly or 
intravenously 0.025–0.05 g 
Tablets 0.005 or 0.01 g; 
ampoules 1 % or 5 % –  
1 ml 
Acidum folicum Orally 0.005 g daily  Tablets 0.001 g 
Cyanocobalaminum Subcutaneously, 
intramuscularly or 
intravenously 0.000 1– 
0.000 5 g 1 time a day  
or 1 time per 2 days 
Ampoules 0.003 %, 
0.01 %, 0.02 % and 
0.05 % – 1ml 
Acidum 
ascorbinicum 
Orally 0.05–0.1 g; 
intramuscularly or 
intravenously 0.05–0.15 g 
Dragee 0.05 g; 
tablets 0.025; 0.05  
or 0.1 g; 
ampoules 5 % or 10 % – 
1 or 2 ml 
Retinoli acetas Orally or intramuscularly 
33 000–100 000 IU daily 
Coated tablets  
33 000 IU; 
ampoules with oil 
solution (25 000; 50 000 
or 100 000 IU in 1 ml) 
Ergocalciferolum Orally 10 000–100 000 IU 
daily 
Vials with 0.125 % or 
0.5 % oil solution 
(50 000 or 200 000 IU  
in 1 ml consequently) 
Tocopheroli acetas Orally or intramuscularly 
0.015–0.15 g daily 
Vials with 5 %, 10 %  
or 30 % oil solution – 
10; 20 or 50 ml; 
ampoules with 5 %, 
10 % or 30 % oil 
solution – 1 ml 
Vicasolum Orally 0.015 g; 
intramuscularly 0.01 g 
Tablets 0.015 g; 
ampoules 1 % – 1 ml 
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Step 1. Tasks for Self -Control  
Vitamins 
 
1. A 39-year-old man appealed to a hospital. Recently he noticed 
susceptibility to infectious diseases and impairment of twilight 
vision. During the examination a doctor diagnosed hyperkeratosis. 
What vitamin should be prescribed? 
A. Tocopherol acetate. 
B. Pyridoxine hydrochloride. 
C. Riboflavin. 
D. Ergocalciferol. 
E. Retinol acetate.  
2. A patient came to a doctor with complaints of twilight 
adaptation impairment (night blindness). What vitamin drug to be 
prescribed to the patient for the restoration of his sight? 
A. Tocopherol acetate. 
B. Vicasolum. 
C. Pyridoxine hydrochloride. 
D. Thiamine chloride. 
E. Retinol acetate. 
3. The deficiency of prothrombin in blood was detected during 
a preoperative examination of a patient. What drug is needed for the 
preliminary use for reducing blood loss during operation? 
A. Vicasolum. 
B. Thrombin. 
C. Aminocaproic acid.  
D. Phenylinum. 
E. Contrycal. 
4. A patient who was previously ill with mastectomy as a result 
of breast cancer was prescribed radiation therapy. What vitamin drug 
has marked radioprotective action caused by antioxidant activity? 
A. Folic acid.  
B. Ergocalciferol. 
C. Thiamine chloride. 
D. Tocopherol acetate.  
E. Riboflavin. 
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5. A patient suffers from hemeralopia. Which of the suggested 
substances will have curable effect? 
A. Carnitine. 
B. Keratin. 
C. Carotin. 
D. Carnosine. 
E. Creatine. 
6. A patient who has mastectomy because of the mammary gland 
cancer, is prescribed a course of radiotherapy. What vitamin drug has 
antiradiation effect caused by antioxidant activity? 
A. Follic acid.  
B. Ergocalciferol. 
C. Riboflavin. 
D. Cyanocobalamin. 
E. Tocopherol acetate.  
7. In experiment on fibrocytes culture it is established, that 
addition of cells of one of vitamins in an inhabitancy strengthens 
formation of fibrous fibers. This effect is oppressed with 
transcription inhibitors. What vitamin is used?   
A. Retinol. 
B. Tocopherol. 
C. Thiamine. 
D. Riboflavin. 
E. Rutin. 
8. A 28-year-old patient suffers from hemeralopia (night 
blindness). What vitamin should be prescribed to him? 
A. Ascorbic acid. 
B. Cyanocobalamin. 
C. Retinol. 
D. Tocopherol. 
E. Thiamine. 
9. On the ground of clinical presentations a patient was 
prescribed pyridoxal phosphate. This medication is recommended for 
correction of the following processes: 
A. Oxidative decarboxylation of ketonic acids. 
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B. Desamination of purine nucleotides. 
C. Protein synthesis. 
D. Synthesis of purine and pyrimidin bases. 
E. Transamination and decarboxylation of amino acids. 
10. A patient presents with twilight vision impairment. Which of 
the following vitamins should be administered? 
A. Ascorbic acid. 
B. Cyanocobalamin. 
C. Retinol acetate. 
D. Nicotinic acid. 
E. Pyridoxine hydrochloride. 
11. Before tooth extraction a patient was advised to take a certain 
drug for haemorrhage prevention. What drug was advised? 
A. Asparcam. 
B. Vicasolum. 
C. Heparin. 
D. Magnesium sulfate. 
E. Dimedrol. 
 
 
HORMONAL DRUGS 
 
Hormonal drugs include preparations of natural hormones 
obtained from endocrine glands of animals, its synthetic analogues 
and antagonists. 
Together with nervous system, endocrine system participates in 
regulation of organism homeostasis. In neuroendocrine complex, 
there are three levels of regulation: hypothalamus, pituitary, and 
peripheral endocrine glands.   
In response to chemical stimuli, hypothalamus secretes low-
molecular-weight peptides. Some of them (releasing-factors, or 
liberins) stimulate secretion of anterior pituitary hormones; other 
peptides (statins) inhibit it. Secretion of hypothalamic and pituitary 
hormones is regulated by means of negative feedback. Thus, 
reduction of secretion of certain pituitary hormone leads to increase 
of secretion of corresponding hypothalamic releasing-factor. And 
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vice versa, increase of certain pituitary hormone concentration results 
in reduction of corresponding liberin secretion. 
Second level regulating body neuroendocrine functions is 
anterior pituitary. It secretes several tropic hormones controling 
activity of peripheral endocrine glands. Some of them (somatotropin 
or growth hormone) directly influence tissues.  
Posterior pituitary deposits two hypothalamic hormones: 
vasopressin and oxytocin which directly influence the functions of 
target tissues.  
Third level of regulation of neuroendocrine complex includes 
peripheral endocrine glands: thyroid and parathyroid glands, adrenal 
cortex, testes, ovaries, and pancreas. Their hormones interact with 
specific receptors in target tissues. These receptors are located in cell 
membranes as well as intracellularly (in nucleus, in cytoplasm). Due 
to interaction with these receptors, hormones change enzymatic 
acitivity, ion transport, peptide synthesis, and other metabolic 
processes. Thus, hormones regulate growth, development, 
reproduction, protective properties, and other functions of organism. 
According to chemical structure, hormones are divided into  
3 groups.  
1. Peptide hormones: hormones of hypothalamus, pituitary, 
pancreas, parathyroid, and thyroid (calcitonin) glands.  
2. Steroid hormones: adrenocortical and sex hormones.  
3. Derivatives of amino acids: thyroid hormones (thyroxine, 
triiodothyronine) and hormones of adrenal medula (adrenaline, 
noradrenaline). 
In medicine, hormonal drugs are used for the following 
purposes:  
1) substitutive and stimulative therapy in cases of certain 
hormonal insufficiency. Thus, insulin is used for substitutive therapy 
at I type of diabetus melitus; glibenclamide is used for stimulative 
therapy at II type of diabetus melitus (it stimulates secretion of 
insulin by pancreas);   
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2) inhibitive therapy in cases of hyperactivity of certain gland 
(e. g., somatostatin is used to reduce somatotropin secretion by 
anterior pituitary);  
3) treatment of non-endocrinic diseases. In these cases, 
hormonal drugs are used as agents of pathogenetic therapy (e. g., 
glucocorticoids are used in the treatment for inflammatory diseases);  
4) diagnostic tests of functional state of endocrinic glands  
(e. g., practical use of hypothalamic hormones).  
Long-lasting use of hormonal drugs can reduce functional 
activity of an appropriate gland by the principle of negative 
feedback. In such case, sudden discontinuation of drug intake can 
lead to sharp aggravation of the disease or in development of 
insufficiency of appropriate gland. Therapy with peptide hormones 
can be accompanied by synthesis of appropriate antibodies. 
Hormonal drugs, which obtained from animal glands, undergo 
biological standardisation. Their activity is given in International 
Units. Some hormonal drugs are obtained by synthetic and 
semisynthetic ways; their activity is given in grams.                      
 
Drugs of Hypothalamic Hormones  
 
Hypothalamic hormones are devided into releasing factors or 
liberins (stimulating secretion of appropriate pituitary hormones) and 
statins (inhibiting secretion of appropriate pituitary hormones).  
The following drugs of hypothalamic hormones are used in 
medicine.  
Corticotropin releasing factor  (corticoliberin ) is 
obtained by synthetic way. The drug stimulates adrenocorticotropin 
secretion. Corticoliberin is used to make a diagnosis. 
Drug of somatotropin-releasing factor  is called 
sermorelin . The drug stimulates pituitary production of 
somatotripin. Sermorelin is used to diagnose and treat growth 
hormone deficiency in children.  
Somatostatin  is hypothalamic hormone which is also found in 
peripheral tissues. This hormone inhibits pituitary release of 
somatotropin, and suppresses the release of glucagone and other 
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gastrointestinal hormones. Pharmaceutical industry produces 
synthetic analogue of somatostatin – octreotide  (sandostatin).  
Indications for use of sandostatin are acromegaly and apudomas 
(tumors of APUD cells which are located in different tissues and 
organs, e. g., gastrointestinal tract, central nervous system). The drug 
is administered subcutaneously. 
Another synthetic analogue of somatostatin is called 
lanreotide . This drug is characterised by prolonged action and is 
administered 1 time in 10–14 days.  
Synthetic analogue of thyrotropin-releasing hormone  
(thyroliberin) is called rifothyroin . The drug stimulates the 
pituitary secretion of thyrotropin. Rifathyroin is used to diagnose 
thyroid gland pathology.  
Gonadorelin  is a synthetic analogue of gonadotropin-
releasing hormone . It stimulates the release of gonadotropins and 
is used to treat ovary dysfunction and delayed puberty. 
Leuprolide (leuprorelin) , buserelin , nafarelin , 
deslorelin , histrelin , and other drugs are also analogues of 
gonadotropin-releasing hormone . Effects of these drugs 
depend on the mode of their dosage. If drug is administered with 
pulsating character (which is similar to natural rhythm of hormone 
secretion), the stimulative effect develops. A stable long-time 
concentration of these drugs in the blood reduces pituitary secretion 
of gonadotropic hormones. Such stable concentrations are used to 
inhibit gonadotropin secretion (e. g., at treatment of prostate cancer).   
Danazol  is a synthetic inhibitor of gonadotropin synthesis. The 
drug causes atrophy of endometrium and inhibits function of ovaries 
in women and spermatogenesis in men. Danazol is used to treat 
endometriosis, gynecomastia, and uterine bleeding.  
  
Hormonal Drugs of Anterior Pituitary  
 
Anterior pituitary is a complex of glands, each of which consists 
of special type of cells. Their secretory activity is under control of 
appropriate hypothalamic hormones. Anterior pituitary produces the 
following hormones: adrenocorticotropic hormone (ACTH, 
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adrenocorticotropin), somatotropin (STH, growth hormone), thyroid-
stimulating hormone (TSH), prolactin, follicle-stimulating hormone 
(FSH), and luteinizing hormone (LH).   
 
Adrenocorticotropic Hormone  
 
Corticotropin  and tetracosactide  (synacthen depot,  
cosyntropin) are analogues of adrenocorticotropin which used in 
medicine. Corticotropin is obtained from animal pituitary (cattle, 
pigs, and sheep). Tetracosactide is a synthetic analogue with 
prolonged action. 
Corticotropin interacts with specific membrane receptors of 
adrenal cortex cells. Excitation of these receptors is accompanied by 
activation of adenylyl cyclase that leads to the increase of 
intracellular cAMP concentration. Due to this, cholesterol is 
converted into corticosteroids. Corticotropin mainly stimulates the 
synthesis of glucocorticoids.  
Unlike glucocorticoids, short-term use of corticotropin does not 
inhibit adrenal cortex function. But long-lasting corticotropin’s 
administration leads to exhaustion of adrenal cortex. 
Corticotropin stimulates lipolysis and protein catabolism and 
causes hyperglycemia. Corticotropin reduces the excretion of sodium 
and increases the excretion of potassium. The drug stimulates gastric 
secretion. Corticotropin exerts anti-inflammatory, antiallergic, 
immunosuppressive, and detoxification effects. The drug normalizes 
tone and permeability of the cerebral vessels, imroves memory, and 
normalizes the function of the extrapyramidal system. 
Corticotropin is administered intramuscularly or intravenously. 
At intramuscular administration, duration of its action is 6–8 hours. 
The drug is dosed 4–6 times a day. 
There are the following therapeutic indications for corticotropin: 
hypofunction of adrenal cortex, to diagnose functional ability of 
adrenal cortex, to prevent glucocorticoid withdrawal syndrome, 
rheumatism, bronchial asthma, disorders of cerebral circulation, 
Parkinson disease, and chorea.  
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Treatment with corticotropin is accompanied by such side 
effects as oedemas, increased blood pressure, delayed growth or 
wound healing, insomnia, etc. 
Natural corticotropin provokes synthesis of antibodies. 
Presently, a synthetic analogue with low immunogenic activity, 
tetracosactide (Synacthen Depot), is used in medicine.  
 
Somatotropin (Growth Hormone)  
 
Human growth hormone, somatotropin ,  nowardays is 
produced by genetic engineering. Somatrem  is a synthetic analogue 
of somatotropin. 
Somatotropin stimulates growth of bones and internal organs 
and increases the body weight. Growth hormone stimulates the 
synthesis of proteins and RNA; increases the transport of amino 
acids into the cells; retards in a body phosphorus, calcium, and 
sodium; causes hyperglycemia and lipolysis.   
Somatotropin is administered subcutaneously or intramuscularly. 
The period of its half-life is 4–5 minutes. About 90 % administered 
dose is metabolized in the liver. Course of treatment lasts from  
3 months to 2 years.  
Somatotropin is used to treat nanism in children and 
osteoporosis in adults.  
Side effects of somatotropin include allergic reactions, anorexia, 
headache, irritability, etc. The drug is contraindicated at neoplasma.   
Somatostatin  is hypothalamic hormone which has been 
synthesized. This hormone inhibits the release of somatotropin by 
pituitary. Synthetic somatostatin may be used to treat gigantism and 
acromegaly. But practically, the drug is unuseful due to very short 
duration of action (half-life period is 3–6 minutes).  
Sandostatin  is a synthetic octapeptide – analogue of 
somatostatin, with longer duration of action (half-life period is  
100 minutes). The drug is administered subcutaneously 2–3 times  
a  day. Octreotide (Sandostatin LAR) and lanreotide 
(Somatuline®  Depot Injection)  are drugs which act longer than 
sandostatin. Oсtreotide is dosed intramuscularly once per 4 weeks. 
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Lanreotide is administered subcutaneously or intramuscularly 1 time 
in 10–14 days. Therapeutic indications for these drugs are the 
follows: acromegaly, symptomatic treatment of endocrine tumors of 
gastrointestinal tract and pancreas, prevention of complications after 
surgery on the pancreas, acute pancreatitis, and persistent diarrhea in 
AIDS patients. 
Besides, dopaminomimetic bromocriptine  is used to treat 
acromegaly. 
 
Thyrotropin 
 
Thyrotropin  stimulates the secretion of thyroid hormones. 
Drug is obtained from bovine anterior pituitary. Thyrotropin interacts 
with specific receptors of the cells of thyroid gland and activates 
adenylyl cyclase. It results in the increase of intracellular 
concentration of cAMP. Thyrotropin activates the uptake of iodine 
by thyroid gland, iodination of tyrosine, synthesis of thyroid 
hormones, and their releasing into blood. Besides, thyrotropin 
activates the metabolism of carbohydrates, lipids, and proteins. 
Thyrotropin is administered subcutaneously and intramuscularly. 
The drug is used for differential diagnostics of myxoedema. 
Sometimes, drug is used in the treatment for thyroid malignant 
tumors. In this case, thyrotropin is administered together with 
radioactive iodine. 
 
Follicle-Stimulating Hormone 
 
Follicle-stimulating hormone does not exert sex specificity. The 
hormone stimulates the development of follicules and estrogen 
synthesis in women and the development of seminiferous tubules and 
spermatogenesis in men. 
Human menopausal gonadotropin  (HMG) is preparation 
of follicle-stimulating hormone which is obtained from the urine of 
postmenopausal women. The drug is used in the treatent for 
infertility in women for stimulation of ovarian follicle development 
and estrogen synthesis. HMG is also used in the treatment for sexual 
infantilism, cryptorchidism, and hypogonadism of hypothalamic-
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pituitary origin in men. Human menopausal gonadotropin is 
administered intramuscularly. Both in women and in men, the drug 
should be used in combination with luteinizing hormone. Side effects 
of HMG are allergic reactions, excessive increase in the ovary size, 
and abdominal pain.  
 
Luteinizing Hormone 
 
Luteinizing hormone does not exert sex specificity. In women, 
hormone stimulates ovulation, transformation of follicles into corpus 
luteum, and generation and release of progesterone and estrogens. In 
men, luteinizing hormone stimulates development of testicular 
Leydig cells and testosterone synthesis.  
Human chorionic gonadotropin  (HCG) is therapeutic 
preparation of luteinizing hormone. The drug is obtained from urine 
of pregnant women (HCG is produced by placenta). The drug is 
prescribed for woman with disorders of menstrual cycle and to treat 
infertility. In man, the drug is used to treat sexual infantilism and 
cryptorchism. Sometimes, HCG is used in the treatment for benign 
breast tumors, endometritis, gynecomastia, and uterine bleeding. 
Human chorionic gonadotropin is administered intramuscularly. Its 
side effects are allergic reactions and excessive increase of the ovary 
size or testicles. 
 
Prolactin 
 
Prolactin  stimulates mammary gland development and 
lactation. Therapeutic preparation of prolactin is obtained from 
pituitary of bovine. Prolactin is used to stimulate lactation in women 
in postpartum period. The drug is administered intramuscularly. 
Prolactin is contraindicated in women with a tendency to allergy. 
 Bromocriptine  is adrenomimetic agent inhibiting prolactin 
synthesis by anterior pituitary. The drug is used in the treatment for 
patients with symptomatic hyperprolactinemia. Besides, acromegaly 
and Parkinson’s disease are also therapeutic indications for 
bromocriptine. 
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Melanocyte-Stimulating Hormones  
 
Melanocyte-stimulating hormones are synthesized by 
intermediate lobe of pituitary. These hormones increase the 
sensitivity of retinal cells that results in improving visual acuity and 
dark adaptation. Intermedin  is a therapeutic preparation of 
melanocyte-stimulating hormones. The drug is obtained from bovine 
pituitary. Intermedin is used in the treatment for day blindness and 
retinal degenerative changes. The drug is instilled into the 
conjunctival cavity. Sometimes, intermedin is administered as 
subconjunctival injections and by means of electrophoresis.  
 
Hormonal Drugs of Posterior Pituitary  
 
Posterior pituitary (or neurohypophisis) consists of axons of 
cells extending from the supraoptic and paraventricular nuclei of 
hypothalamus. These axons release into blood hormones oxytocin 
and vasopressin. Both these hormones are polypeptides. 
Oxytocin  stimulates the uterine contraction and relaxes uterine 
neck. The uterus in the last period of pregnancy is especially 
sensitive to oxytocin. It is due to activity of estrogens preparing 
uterus to delivery. In uterus, estrogens promote accumulation of 
ATP, glycogen, potassium, calcium, magnesium, acetylcholine, etc. 
The high sensitivity of uterus to oxytocin persists during several days 
after delivery. Besides, oxytocin influences the alveoli cells of 
mammary gland and stimulates lactation.  
Oxytocin is used to stimulate delivery, to arrest uterine bleeding 
in postpartum or postabortion periods, and to stimulate lactation. 
Drug is administered intramuscularly, intravenously, and in the 
uterus neck. 
Desaminooxytocin (demoxytocin)  is a synthetic analogue 
of oxytocin with longer duration of action. The drug is manufactured 
in tablets for buccal use. Demoxytocin are used to accelerate uterine 
involution (reduction of the uterine body size) in the postpartum 
period and to stimulate lactation.  
Vasopressin  (antidiuretic hormone) promotes water retention 
in organism and stimulates smooth muscles of the internal organs. 
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The main function of the hormone is stimulation of water 
reabsorption in distal segment of nephron and in collecting ducts. 
Vasopressin influence upon smooth muscles is observed only if high 
doses of drug are used. In this case, the drug increases smooth 
muscle tone of arterioles, capillaries, intestine, and uterus. But 
vasopressin relaxes bronchi and facilitates lactation. Besides, 
vasopressin stimulates the platelet aggregation, increases 
concentration of VII factor of blood clotting, and promotes the 
secretion of adrenocorticotropin by anterior pituitary. 
The following vasopressin preparations are used in medicine: 
vasopressin,  pituitrin, adiuretin, desmopressin,  and 
felypressin . Vasopressin is administered subcutaneously or 
intramuscularly and acts 0.5–2 hours. Adiuretin and desmopressin 
exert more expressed antidiuretic effect. These drugs are applied 
intranasally by nasal drops (1–4 drops every 12 hours) or, 
sometimes, parenterally (subcutaneously, intramuscularly, or 
intravenously). The main therapeutic indication for vasopressin 
preparations is diabetes insipidus. Besides, these drugs are used in 
the treatment for acute arterial hypotension, intestinal atony, and 
bleeding from esophageal varices in patients with cirrhosis.  
 
Hormonal Drugs of Epiphysis  
 
Epiphysis synthesizes several peptide hormones, the main of 
which is melatonin (tryptophan derivative). This hormone regulates 
circadian rhythms of human body. Highest level of melatonin 
secretion is observed during night. Melatonin synthesis elevates 
when excitation of retina by light is decreased. Besides, hormone 
regulates seasonal sex activity. Melatonin exerts moderat hypnotic 
effect and decreases body temperature and secretion of luteinizing 
hormone. Also, melatonin exhibits immunostimulatory and 
antioxidative effects. 
Three types of melatonin receptors are found out in human body: 
Mel1A, Mel1B, and Mel1C. These receptors are located in 
suprachiasmatic nuclei of the hypothalamus, retina, some nuclei of 
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thalamus and anterior hypothalamic region, sex glands, and 
limphocytes. 
Melatonin preparation Melaxen  is used to treat insomnia and to 
regulate circadian rhythm for person adaptation at fast change of 
time zone. The drug is dosed 0.001–0.005 g orally or sublingually at 
evening. Melaxen is readily absorbed from gastrointestinal tract, 
easily penetrate central nervous system, and is quickly metabolized. 
Its side effects are drowsiness and mild oedemas.    
 
Thyroid and Antithyroid Drugs  
 
Thyroid gland synthesizes and releases iodine-containing 
hormones triiodothyronine (T3) and tetraiodothyronine (thyroxine, 
T4) and polypeptide hormone calcitonin. The last hormone 
participates in regulation of calcium metabolism. Circulated in blood 
iodine ions are absorbed by thyroid gland where they are oxidized to 
iodine. Molecular iodine interacts with tyrosine forming 
monoiodotyrosine (MIT) and diiodotyrosine (DIT). This process is 
called iodine organification. MIT and DIT produce triiodothyrosine 
and thyroxine. Thyroid hormones are accumulated in the follicles of 
the thyroid gland in form of thyroglobulin.  
Hypothalamic hormone thyroliberin regulates the secretion of 
thyrotropin by anterior pituitary. Thyrotropin stimulates the synthesis 
of thyroglobulin. In turn, there is negative feedback inhibition of the 
synthesis of appropriate hypothalamic and pituitary hormones by 
means of thyroid hormones circulating in blood. 
 
Thyroid Hormones  
 
Thyroid hormones influence the permeability of mitochondrial 
membranes and stimulate mitochondrial electron transport. It is 
accompanied by the increase of oxygen consumption, basal 
metabolism, and body temperature. Thyroid hormones stimulate 
catabolism of carbohydrates and lipids and decrease the level of 
cholesterol. Thyroid hormones regulate the synthesis of RNA, 
stimulate the activity of some cellular enzymes and growth and 
development of body.  
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The hormones increase intracellular concentration of cAMP due 
to stimulation of adenylyl cyclase. It is accompanied by the increase 
of heart rate, stroke volume, cardiac output, and blood pressure. 
Thyroid hormones potentiate the effects of catecholamines. 
Thyroid deficiency in children leads to cretinism (mental 
retardation and dwarfism). Hypofunction of thyroid gland in adults 
causes myxedema (slowdown of metabolism, reduced mental and 
physical performance, apathy, mucous oedema of tissues, weight 
gain, etc.). 
Thyroid hyperfunction results in hyperthyroidism or 
thyrotoxicosis (acceleration of metabolism, increased activity of 
sympathetic nervous system, tachycardia, cardiac arrhythmias, 
nervousness, etc.). 
Thyroid preparations include drugs of synthetic origin  
L-thyroxine  and triiodothyronine hydrochloride 
(liothyronine)  and the drug of animal origin – thyreoidine . 
There are coformulated drugs of thyroid hormones, e. g., 
Thyreocomb  (contains levothyroxine, liothyronine, and potassium 
iodide), Thyreotom  (contains levothyroxine sodium and 
liothyronine), etc.  
 Thyroidine  is obtained from desiccated and defatted thyroid 
gland of bovine. The drug contains a mix of thyroid hormones and is 
characterised by unstable activity. Thyroidine is taken orally in  
30 minutes before a meal. Onset of action develops in 2–3 days. 
Duration of its action is 3–4 weeks. 
L-thyroxine  is taken orally and, sometimes, administered 
intravenously. Its effect develops gradually. The maximum is 
observed in 8–10 days. Duration of its effect is several weeks. 
Maximal effect of triiodothyronine  is observed in  
24–48 hours after intake. Duration of its action is several days. In 
comparison to thyroxine, triiodothyronine exhibits 3–5 times higher 
influence upon metabolism. The drug is taken orally.  
The drugs of thyroid hormones are used for substitutive therapy 
in patients suffering from cretinism and myxedema. Besides these 
forms of hypothyroidism, the development of hypothyroid coma also 
283 
 
is possible. This patological state is characterized by the 
development of cardiovascular failure, dry and cold skin, oedemas of 
serosal and mucosal membranes. Treatment of hypothyroid coma is 
the following: immediate intravenous administration of 50 mg 
thyroxine, which should be repeated every 6–12 hours. Intravenous 
administration of a daily dose of thyroxine 100 mg is used for  
10 days. Subsequent treatment is based on oral intake of the 
hormone. 
In patients with hypothyroidism caused by iodine deficiency in 
the diet, the treatment is based on the enrichment of diet by iodine 
(iodinated salt, iodine rich foods). 
 
Antithyroid Drugs  
 
In comparison to hypothyroidism, hyperthyroidism is more 
common clinical pathology. The main manifestations of 
hyperthyroidism are the following: toxic goiter, tachycardia, 
nervousness, tremor, weight loss, low tolerance to heat, etc. At 
hyperthyroidism, level of basal metabolism increases by 20–60 %.  
The following groups of drugs are used to treat hyperthyroidism:  
1) drugs inhibiting the thyreotropin synthesis by anterior 
pituitary: potassium iodide , iodine solution;   
2) drugs which inhibit synthesis of thyroid hormones by thyroid 
gland: mercazoli l , propylthiouracil ;   
3) drugs affecting iodine uptake by thyroid gland: potassium 
perchlorate;  
4) drugs which destroy follicular cells of the thyroid gland: 
radioactive iodine . 
Iodine-containing drugs potassium iodide  and iodine 
solution  are prescribed in high doses (daily dose is more than 
6 mg). In this case, these drugs inhibit thyrotropin synthesis by 
anterior pituitary that results in reduction of thyroid hormone 
synthesis and their release in blood. Both size and vascularization of 
thyroid gland are decreased. Antithyroid effect of iodine-containing 
drugs is moderate and unstable. These agents are used only at mild 
form of thyrotoxicosis or to prepare patients for surgery. Side effects 
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of iodine-containing drugs are acne, hypersecretion of bronchial 
glands, metallic taste in the mouth, nausea, vomiting, etc.   
Mechanism of action of mercazoli l  and propylthiouracil  is 
associated with inhibition of synthesis of triiodothyronines and 
thyroxine. These drugs inhibit thyroid peroxidase – enzyme 
oxidizing iodine into active form and promoting iodination of 
tyrosine and synthesis of thyroid hormones. Besides, propylthiouracil 
inhibits transformation of thyroxine into triiodothyronine. Both drugs 
are taken orally. Therapy with these drugs results in reduction of 
thyrotoxicosis. But the size of the thyroid gland increases 
(goitrogenic effect). Goitrogenic effect is caused by the fact that the 
anterior pituitary increases the secretion of thyrotropin. Other side 
effects of mercazolil and propylthiouracil include leukopenia and 
agranulocytosis. Therefore, the constant monitoring of blood is 
required. 
Potassium perchlorate  reduces active uptake of iodine by 
thyroid gland. The drug is used mainly to treat mild and moderate 
forms of thyrotoxicosis in cases when other drugs are ineffective. 
Therapy with potassium perchlorate can provoke aplastic anemia. 
Sometimes, radioactive iodine  (131I and 132I) is used to treat 
hyperthyroidism. Half-life of 131I is 8 days, and half-life of 132I is  
2–3 hours. Destruction of thyroid gland cells develops due to the 
influence of β- and γ-rays. Drugs containing radioactive iodine are 
dosed orally. Their effect develops in 1–3 months after start of the 
drug intake. 
 
Calcitonin  
 
Calcitonin  is a polypeptide hormone secreted by parafollicular 
cells (C cells) of thyroid gland. Calcitonin regulates calcium-
phosphate metabolism. The hormone inhibits decalcification of 
bones and decreases calcium concentration in the blood. Calcitonin 
does not influence intestinal absorption of calcium and renal calcium 
excretion. There are synthetic analogues of calcitonin – 
Cibacalcin , Miacalcic , and Calcitrin. These drugs are used to 
treat osteoporosis and nephrocalcinosis.  
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Hormonal Drugs of Parathyroid Glands   
 
Parathyroid glands secrete parathyroidin . It is a polypeptide 
which consists of 84 amino acids. The main function of parathyroidin 
is to regulate calcium and phosphorus metabolism. The hormone 
stimulates decalcification of bones and increases calcium 
concentration in blood. Besides, parathyroidin promotes intestinal 
absorption of calcium and reabsorption of calcium in renal tubules. 
Simulateneously, parathyroidin inhibits renal reabsorption of 
phosphorus that results in the reduced concentration of phosphorus in 
blood. 
For therapeutic use, parathyroidin is obtained from the 
parathyroid glands of cattle. Its effect develops in 4 hours after 
administration. Duration of action is about 1 day. Parathyroidin is 
used in the treatment for chronic hypoparathyroidism and 
spasmophilia. The drug is administered subcutaneously and 
intramuscularly. It should be noticed that at acute 
hypoparathyroidism (tetany), calcium chloride or calcium gluconate 
are administered intravenously together with parathyroidin. At these 
states, the hormone is not administered alone due to the long latency 
period. 
Since 2002, a recombinant form of parathyroid hormone 
consisting of the 34 amino acids is used in medicine – teriparatide  
(Forteo). 
 
Hormonal Drugs of Pancreas  
 
Antidiabetic Drugs  
 
The endocrine part of pancreas (it is about 1 islets of Langerhans) 
consists mainly of β-cells (about 60–80 %) producing insulin. Besides  
β-cells, pancreas contains α-cells producing glucagon and σ-cells 
secreting somatostatin. There are also F-cells producing pancreatic 
polypeptide activating digestion. Main pancreatic hormones, insulin 
and glucagon, support the blood glucose concentration within normal 
physiological range. Disorders of these gormons secretion may 
provoke hyperglycemia or hypoglycemia.  
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Insulin is most valuable pancreatic hormone for practical 
medicine, because it is used to treat diabetes mellitus. Diabetes 
mellitus is metabolic disorders which characterized by high glucose 
blood level, glucosuria, accumulation of ketone bodies in the blood 
with following acidosis and intoxication; damage of capillaries in 
kidneys, retina, and nervous system; generalizing atherosclerosis, etc. 
Protein catabolism is increased, and amino acids is converted to 
glucose due to hepatic gluconeogenesis. Catabolism of lipids and 
fatty acids is also accelerated that leads to formation of ketone 
bodies. Renal excretion of glucose, nitrogenous substances, and 
ketone bodies promote osmotic diuresis that leads to dehydration and 
disorders of electrolyte and acid-base balance. According to WHO, 
this disease affects approximately from 0.8 % to 8 % of the 
population in different world countries and exerts tendency to 
increase. 
There are two types of diabetes mellitus: insulin-dependent 
diabetes mellitus (type I) and non-insulin-dependent diabetes 
mellitus (type II).  
Type I diabetes mellitus develops due to autoimmune 
destruction of pancreatic β-cells. About 10 % of diabetic patients are 
suffering from this type of disease. Type II of diabetes mellitus 
involves multiple factors for genetic predisposition to the disease. 
Frequency of type II diabetes is about 90 % diabetic patients. 
In severe cases of type I diabetes mellitus, diabetic ketoacidosis, 
serious complication of type I diabetes, occurs. Type II diabetes may 
be aggravated by hyperosmolar coma with hyperglycemia and 
dehydration. 
Antidiabetic drugs are classified as follows.  
1. Drugs for substitutive therapy: insulin prepartions.  
2. Synthetic antidiabetic drugs (oral hypoglycemic drugs).  
2.1. Sulfonylurea derivatives:  
– first-generation sulfonylureas: acetohexamide, 
chlorpropamide, tolazamide, and tolbutamide;  
– second-generation sulfonylureas: glibenclamide and 
glipizide;  
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– third-generation sulfonylureas: glimepiride.  
2.2. Biguanides: metformin  and buformin . 
2.3. Thiazolidinediones: rosiglitazone  and pioglitazone .  
2.4. α-Glucosidase inhibitors: acarbose  and miglitol .  
  
Insulin Preparations  
 
Insulin is most effective antidiabetic drug. It is a protein 
consisting of 51 amino acids, which are arranged in two polypeptide 
chains, an α-chain containing 21 amino acids and β-chain containing 
30 amino acids. Chains are linked by means of two disulfide bonds.  
Pancreatic secretion of insulin depends on glucose level. 
Glucose penetrates β-cells and undergoes metabolism that provides 
the increase of intracellular ATP. ATP blocks ATP-dependent 
potassium channels that leads to depolarization of cellular 
membranes. It increases calcium entrance into β-cells through 
potential-dependent calcium channels and following secretion of 
insulin. Besides glucose, amino acids, free fatty acids, glycogen, 
secretin, electrolytes, and parasympathetic nervous system are factors 
stimulating insulin secretion.  
Mechanism of insulin action is not clear enough. Insulin binds 
with specific receptors which are located in the cellular membranes 
of most tissues. A primary target tissues for insulin are liver, muscle, 
and adipose tissue. Insulin receptor consists of two parts, each of 
which consists of α-subunit (it is locolated extracellularly and is a 
recognition site) and β-subunit spanning cellular membrane. The  
β-subunit contains a tyrosine kinase. The binding of insulin with the 
α-subunits leads to conformational change which brings the catalytic 
loops of β-subunits into closer proximity. Tyrosine kinase is 
phosphorylated that leads to activation of some second intracellular 
messengers with development of multiple metabolic effects. 
Effects of insulin are complex and involve changes in 
carbohydrate, protein, and lipid metabolism. Insulin activates glucose 
transport through cellular membranes and its utilization by peripheral 
tissues.  
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Additionally to its role in stimulation of glucose uptake by 
tissues, insulin exerts the following effects:  
– reduction of glycogenolysis in liver and in skeletal muscles 
due to glycogen phosphorylase inhibition;  
– activation of glycogen synthesis owing to stimulation  
of glycogen synthetase;  
– inhibition of gluconeogenesis (transformation of 
noncarbohydrate substrates, like amino acids, into glucose);  
– reduction of lipolysis due to inhibition of lipase activity that 
leads to the decrease of concentration of free fatty acids and glycerol 
in plasma and elimination of ketoacidosis (blood concentration of 
acetone, acetoacetic and hydroxy-butyric acids is reduced);  
– activation of transport of amino acids into cells and stimulation 
of protein synthesis that results in positive nitrogen balance.  
Thus, blood concentration of glucose is reduced and glucosuria, 
polyuria, and thirst are disappeared. Normalization of protein 
metabolism is accompanied by activation of anabolic processes in the 
body and reduction of concentration of nitrogen compounds in urine. 
Body weight loss is terminated.  
Insulin preparations are dosed by International Units (IU). 
Preparations are tested on hungry rabbits. One International Unit of 
insulin is amount of hormone which reduces glucose in the rabbit’s 
blood in 45 mg %.    
Insulin preparations are classified on the base of their duration of 
action as follows.  
1. Rapid-acting insulin analogues: insulin l ispro 
(Humalog), insulin glulisine (Apidra),  and insulin Aspart  
(NovoLog). Their onset of action is within several minutes, 
duration of action is about 5 hours. 
2. Short-acting insulins: Actrapid, Humulin R, Novolin R . 
Their onset of action is in 30 minutes after administration, duration – 
6–8 hours.  
3. Intermediate-acting insulins. 
3.1. Monocomponent drugs: Monotard HM, Protaphane 
HM, Humulin L (Lente) , isophane insulin suspension . 
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Their onset of effect is in 1.5–2 hours, duration of action –  
16–24 hours. 
3.2. Premixed insulins (containing short-acting and intermediate-
acting insulins): Humulin M2, Humulin M3, Novolin 70/30  
(mixture of 70 % intermediate-acting insulin and 30 % short-acting 
insulin). 
4. Long-acting insulins: Ultralente Insulin (extended 
insulin Zinc suspension), Ultratard HM, insulin glargine  
(Lantus), insulin detemir (Levemir), and insulin degludec 
(Tresiba) . Their onset of action is about 4 hours, duration of action 
up to 36 hours and more (up to 42 hours – for Tresiba).  
Insulin is most commonly administered subcutaneously. 
Intramuscular injections of insulin are used less often because of 
more rapid absorption. Insulin is a polypeptide hormone; therefore, it 
is readily inactivated if administered orally. In emergencies, such as 
severe diabetic ketoacidosis, insulin is dosed intravenously. Plasma 
half-life of insulin is less than 10 minutes. A liver and kidneys are 
the main organs of hormone uptake and degradation. Hepatic 
insulinase inactivates about 50 % circulating insulin.  
Animal (beef and pork) insulins were the first insulin 
preparations which been introduced in clinical practice. Beef insulin 
differs from human insulin by three amino acids, whereas only one 
amino acid is different in human insulin and porcine. Therefore, beef 
insulin was slightly more antigenic than pork insulin.  
Presently, production of human insulin is carried out by means 
of recombinant DNA techniques. For this aim, human proinsulin 
gene is inserted into Escherichia coli or yeast. Extracted proinsulin 
undergoes further processing to obtain a molecule of human insulin.  
Rapid-acting insulins and short-acting insulins are clear 
solutions with neutral pH containing small amounts of zinc to 
improve their stability. Intermediate-acting and long-acting insulins 
are suspensions (except long-acting insulin analogues) containing 
either protamine or different zinc concentrations.  
Insulin analogues are obtained by means of chemical 
modification of human insulin molecules. Thus, insulin l ispro 
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(Humalog)  is produced by replacement of the positions of lysine-
proline residues in the β-chain of insulin molecule. Due to this 
chemical change, insulin lispro cannot form stable hexamers or 
dimers in subcutaneous tissue that promotes its rapid absorption and 
onset of action.  
Short-acting insulins (Humulin R, Novolin R, etc.) are also called 
regular insulins. Their onset of action is about 30 minutes. These 
drugs have a longer duration of action than rapid-acting insulin 
analogues. Regular insulins are administered in 30 minutes before a 
meal. Short-acting insulins are used to supplement intermediate- and 
long-acting insulin preparations. Also, these insulins are the drugs of 
choice for control of glucose concentration in blood during surgery, 
trauma, and shock. At hyperglycemic coma, short-acting insulin is 
administered intravenously.  
Intermediate-acting insulins are NPH insulin (isophane 
insulin suspension) , insulin Lente (insulin zinc 
suspension) , etc. These drugs have a slower onset of action  
(1–2 hours). Duration of their action is longer (about 13–24 hours) 
due to conjugation of insulin molecules with either zinc ions or 
protamine. These drugs are administered 1–2 times a day. 
Some preparations of intermediate-acting insulins are 
combinations with short-acting insulins in premixed ratio: 70 : 30, 
50 : 50, etc.  
Protamine zinc insulin  and insulin Ultralente  are 
representatives of long-acting insulin preparations. In contrast with 
intermediate-acting insulins, these drugs have more protamine and 
zinc in the mixture. Their onset of action 2–4 hours and duration of 
action about 36 hours. 
Insulin glargine  (Lantus),  insulin detemir (Levemir),  
and insulin degludec (Tresiba)  are long-acting insulin 
analogues. Glargine is soluble in manufactured acidic solution but 
precipitates in the more neutral body pH after subcutaneous 
injection. Glargine has a slow onset (1–2 hours) and long duration 
(up to 24 hours) of action. The drug is administered 1 time a day.   
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The main therapeutic indication for insulin is to treat type I 
diabetes mellites. Insulin is also used in the treatment for type II 
diabetes in patients which are refractory to oral hypoglycemic drugs. 
As a rule, insulin is administered as subcutaneous injection by means 
of needles and syringes. Portable pen injectors containing cartridges 
of insulin and replaceable needles are also widely used. Nowadays, 
insulin pumps are used in practice. Insulin pump contains an insulin 
reservoir, programme chip, keypad, and display screen. Insulin pump 
is usually placed on the abdomen. The insulin reservoir, tubing, and 
infusion set need to be changed every 2 or 3 days.  
The most common side effect of insulin is hypoglycemia which 
is manifested by tremors, lethargy, hunger, confusion, motor and 
sensory deficits, convulsions, anxiety, palpitations, tachycardia, and 
unconsciousness. In many cases, oral intake of carbohydrates  
(e. g., fruit juice, candys, or glucose tablets) can restore normal 
glucose blood level. At hypoglycemic coma, intravenous glucose, 
subcutaneous or intramuscular adrenaline, or intramuscular glucagon 
are administered. 
Another frequent side effect of insulin therapy is weight gain.  
Allergic reactions due to the use of recombinant DNA-derived 
human insulins are seldom. Local lipodystrophy (lipohypertrophy or 
lipoatrophy) due to repeated subcutaneous injections of human 
insulin is very seldom complication. Hypokalemia is possible due to 
the stimulation of Na+, K+-ATPase with redistribution of K+ ions 
intracellularly. This property of insulin is sometimes used in the 
emergency treatment of hyperkalemia. 
 
Oral Hypoglycemic Drugs  
 
Since 1955, synthetic oral hypoglycemic drugs are used to treat 
II type diabetes mellitus. These drugs are classified as follows.  
1. Sulfonylurea derivatives. 
1.1. First-generation sulfonylureas: acetohexamide, 
chlorpropamide, tolazamide, tolbutamide . 
1.2. Second-generation sulfonylureas: glibenclamide 
(Maninil) , glipizide . 
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1.3. Third-generation sulfonylureas: glimepiride.  
2. Biguanides: metformin  (Gliformin) . 
3. Thiazolidinediones: rosiglitazone  and pioglitazone .  
4. α-Glucosidase inhibitors: acarbose , and miglitol .  
 
Sulfonylurea Derivatives 
 
Sulfonylurea derivatives are the most widely used drugs to treat 
type II diabetes mellitus.  
Nowadays, the drugs of first-generation are not frequently used 
in the treatment of diabetes mellitus, because these drugs have 
relatively low specificity of action, slow onset of action, and many 
side effects.  
The second-generation and third-generation sulfonylurea 
derivatives are characterized by a higher specificity and affinity for 
the sulfonylurea receptor, more predictable pharmacokinetics, and 
relatively fewer side effects. These drugs may also exert mild 
diuretic effects.  
The mechanism of action of the sulfonylurea derivatives is 
associated with stimulation of insulin release due to interaction with 
sulfonylurea receptors of pancreatic β-cells. Sulfonylurea receptor is 
an ATP-sensitive potassium channel that is located on the β-cell 
membrane. A blockage of these channels by sulfonylurea derivatives 
leads to depolarization of β-cell membrane and opening of voltage-
dependent calcium channels. Calcium ions entrance in β-cell results 
in insulin release. Simultaneously, sensitivity of β-cells to glucose 
and amino acids is increased that also promotes insulin secretion. 
Therapy by sulfonylurea derivatives is accompanied by the increase 
of quantity of insulin receptors on the target cells.  
Besides, sulfonylurea derivatives decrease glucagon secretion by 
pancreatic α-cells. The higher doses of sulfonylurea derivatives also 
decrease hepatic production of glucose.  
Additionally, II- and III-generation drugs exert cholesterol 
lowering and antiaggregant effects and improve tissue 
microcirculation.  
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Sulfonylurea derivatives are taken orally. Drugs are 
characterized by high degree of binding with plasma proteins and 
undergo hepatic metabolism by microsomal enzymes.  
Sulfonylurea derivatives are used to treat mild and moderate 
diabetes mellitus of type II. These drugs are ineffective in patients 
with type I diabetes mellitus.   
Side effects of sulfonylurea derivatives are dispepsy, 
hypoglycemia, weight gain, fluid retention, oedemas, leukopenia, 
allergic reactions, cholestatic jaundice, and decreased alcohol 
tolerance (disulfiram-like effect). 
 Nateglinide (Starlix)  is D-phenylalanine derivative exerting 
similar mechanism of action with sulfonylurea derivatives. 
Nateglinide and sulfonylurea derivatives are commonly included into 
the group of so-called “insulin secretagogues”. Nateglinide is taken 
before a meal to regulate postprandial (postalimentary) glycemia. 
The drug has high gastrointestinal bioavailability, short duration of 
action (its half-life is 1.5 hours) and fast onset of effect. Nateglinide 
is well tolerated by patients. Hypoglycemia is observed seldom. 
It is known that at food intake, small bowel releases  
two hormones: glucose-dependent insulinotropic peptide 
(gastroinhibitory peptide, GIP) and glucagon-like peptide-1 (GLP-1). 
Exenatide  (Byetta)  is analogue of GLP-1 which is intended to 
treat II type diabetes mellitus. The drug amplifies insulin secretion 
stimulated by glucose. Exenatide is dosed subcutaneously 2 times a 
day. A main route of its excretion is kidneys. Side effects of 
exenatide are nausea, vomiting, diarrhea, and hypoglycemia.          
 
Biguanides  
 
Biguanides are hypoglycemic agents which are used for oral 
intake. The mechanism of action of biguanides is associated with 
their ability to stimulate glycolysis in tissues that leads to reduction 
of blood glucose level. Besides, biguanides suppress hepatic and 
renal gluconeogenesis. Also, the drugs reduce the gastrointestinal 
glucose absorption and decrease glucagon level in plasma. 
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The main representative of this group is metformin . The drug 
exerts antiatherosclerotic (decreases level of atherogenic 
lipoproteins) and antiaggregant effects and improve tissue 
microcirculation. Also, metformin inhibits appetite and promotes 
decrease of body weight.  
Metformin is used in the treatment of II type of diabetes 
mellitus, especially against the background of obesity. The drug is 
taken orally 2–3 times a day at mealtimes. Hypoglycemia is 
uncharacteristic of metformin therapy. Common side effects of 
metformin are nausea, vomiting, anorexia, metallic taste, and 
diarrhea. Also, the drug can cause lactic acidosis and decrases 
cyanocobalamin absorption. Metformin is contraindicated in patients 
with hepatic dysfunction. 
 
Thiazolidinediones  
 
Rosiglitazone  and pioglitazone  are thiazolidinedione 
derivatives which sensitize cells to insulin. Thiazolidinediones 
reduce insulin resistance and increase insulin action in target tissues 
due to activation of nuclear peroxisome proliferator-activated 
receptors (PPAR). These receptors are located in adipose tissue, 
muscle, and liver and modulate the expression of genes involving in 
insulin signal transduction and lipid and glucose metabolism. Thus, 
thiazolidinediones increase utilization of glucose and fatty acids by 
tissues and inhibit gluconeogenesis.    
Thiazolidinediones are used in the treatment for II type of 
diabetes mellitus. Their side effects are edema, weight gain, and mild 
anemia. Thiazolidinediones are contraindicated in severe heart 
failure.  
 
α-Glucosidase Inhibitors  
 
Representatives of α-glucosidase inhibitors are acarbose  and 
miglitol . α-Glucosidase inhibitors decrease postprandial 
hyperglycemia by slowing down of gastrointestinal carbohydrate 
absorbtion. These drugs competitively inhibit intestinal  
α-glucosidases (glucoamylase, sucrase, maltase, and dextranase).  
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α-Glucosidase inhibitors are taken before meal or at mealtimes to 
treat type II diabetes mellitus. As a rule, acarbose is not used alone. 
Commonly, this drug is prescribed together with insulin or 
sulfonylurea derivatives. Combination with metformin is 
unreasonable because acarbose reduces metformin absorption. Most 
common side effect of α-glucosidase inhibitors is flatulence 
(observed in 20–30 % patients).  
 
Glucagon 
 
Glucagon  is synthesized by pancreatic α-cells. It is a peptide 
consisting of 29 amino acids. Glucagon binds to specific receptors of 
hepatocytes which are coupled with Gs-proteins. This increases 
adenylyl cyclase activity and intracellular cAMP concentration. It 
results in the suppression of glycogen synthase and activation  
of glycogen phosphorylase with following intensification of 
glycogenolysis, gluconeogenesis and ketogenesis. Thus, glucose 
concentration in the blood is increased.  
Glucagon exerts positive inotropic, chronotropic, and 
dromotropic effects. These effects are associated with activation of 
calcium ions uptake by sarcoplasmic reticulum of cardiac histiocytes 
and accumulation of ATP in myocardium. Besides, glucagon 
promotes epinephrine release from adrenal medulla and stimulates 
secretion of somatotropin and calcitonin. 
Glucagon is dosed subcutaneously or intravenously in 
emergency treatment for hypoglycemic coma, heart failure, and 
cardiogenic shock. Also, glucagon may be used to reverse cardiac 
effects of β-adrenergic antagonists at their overdose. It should be 
noticed that glucagon increases oxygen demand of myocardium.   
Glucagon undergoes fast enzymatic inactivation in liver, 
kidneys, blood, and other tissues. Its half-life is about 3–6 minutes.  
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Table 11 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route  
of administration 
Drug product 
Corticotropinum Intramuscularly 10–20 IU  
3–4 times a day 
Vials containing 10; 20; 
30 or 40I A of powder  
for injection 
Oxytocinum Intravenously drop-by-drop 
5 IU in 500 ml of isotonic 
glucose solution; 
intramuscularly 0.2–2 IU 
Ampoules 1 or 2 ml (5 IU 
in 1 ml) 
Adiuretinum SD Into nose 1–4 drops 2–3 times 
a day  
Vials 5 ml of 0.01 % 
solution 
Triiodthyronini 
hydrochloridum 
Orally 0.000 02–0.000 05 g 
daily (in 1–3 intakes) 
Tablets 0.000 02  
or 0.000 05 g 
Mercazolilum Orally 0.005 g 3–4 times daily Tablets 0.005 g 
Actrapid HM Subcutaneously – dose is 
chosen individually, as a rule 
7–20 IU 3 times a day  
in 30 minutes before a meal 
Vials 10 ml (in 1 ml – 
100 IU of short-acting 
insulin) 
Susp. Protaphane 
HM  
Subcutaneously – dose is 
chosen individually, as a rule 
0.3–1.0 IU/kg/daily (daily 
dose is divided in 2 
administrations)   
Vials 10 ml (in 1 ml – 
100 IU of intermediate-
acting insulin) 
Insulin glargine Subcutaneously 1 time a day 
in individually chosen dose 
Cartridges 3 ml (in 1 ml – 
100 IU of insulin 
glargine); 
vials 10 ml (in 1 ml – 
100 IU) 
Glibenclamidum Orally 0.002 5–0.05 g 1 time 
a day (before breakfast) 
Tablets 0.005 g  
Metforminum Orally 0.5 g 2–3 times a day 
(at mealtimes) 
Tablets 0.5 g 
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Hormonal Drugs of Adrenal Cortex  
 
Hormones of adrenal cortex are devided into 3 groups:  
1) glucocorticoids: hydrocortisone and corticosterone; 
2) mineralocorticoids: aldosterone and desoxycorticosterone; 
3) sex hormones: androgens, estrogens and progestins. 
 
Glucocorticoids  
 
The main function of glucocorticoids is to provide body 
resistance to different extremal influences. Glucocorticoids provide 
“the second” line of body protection, while hormones of adrenal 
medulla (epinephrine and norepinephrine) participate in “the first” 
(immediate) line of protection. Maximal secretion of glucocorticoids 
is observed about 8 a.m. while minimal – in the middle of night. 
Glucocorticoids secretion increases up to the age of 30, then it 
reduces gradually. Glucocorticoid concentration is higher in males. 
Cortisone  and hydrocortisone  are natural glucocorticoids 
which preparations are used in medicine. Their synthetic analogues 
prednisolone  and prednisone  have more wide practical use. Due 
to double bond between C1 and C2 atoms of steroid ring in 
molecules, an anti-inflammatory activity of these synthetic agents is 
3–5 times higher than the activity of natural hormones.  
Glucocorticoid activity increases even more due to inclusion of 
fluorine atoms in molecular structure of a drug. Triamcinolone  
and dexamethasone  contein one fluorine atom in a molecule that 
increases their anti-inflammatory activity 5–30 times respectively in 
contrast to cortisone. Besides, these drugs have almost no 
mineralocorticoid activity. 
Sinaflan  and flumethasone  contain two fluorine atoms and 
have still higher anti-inflammatory activity. These drugs are not 
permeable through biomembranes and are used only topically as 
ointments and creams.  
Beclomethasone  and fluticasone  are glucocorticoids which 
do not exert systemic action; these drugs are used as inhalations. 
According to their duration of action, glucocorticoids are 
classified as follows.  
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1. Glucocorticoid preparations with short duration of action  
(5–12 hours): cortisone, hydrocortisone .  
2. Glucocorticoid preparations with intermediate duration of 
action (12–30 hours): prednisolone,methylprednisolone,  and 
prednisone.  
3. Glucocorticoid preparations with long duration of action (36–
72 hours): triamcinolone, dexamethasone, beclomethasone 
and fluticasone .  
Mechanism of action of glucocorticoids is the follows. 
Glucocorticoids bind with cytoplasmic receptors of target tissue 
cells. Complex steroid receptor penetrates nucleus and binds with 
DNA. It leads to activation of certain genes’ transcription with the 
following increase of activity of some enzymes (mainly catabolic) 
and decrease of activity of other enzymes (mainly anabolic). It 
results in changes of metabolism which are typical for glucocrticoids.  
Carbohydrate metabolism. Glucocorticoids stimulate hepatic 
gluconeogenesis, reduce glucose utilization by fat tissue, and increase 
glucose blood level. Simultaneously, hormones stimulate activity of 
hepatic glycogen synthase and increase glycogen synthesis. 
Lipid metabolism. Glucocorticoids redistribute fat. Prolonged 
drug intake results in accumulation of fat on the face, neck, and 
shoulders. 
Protein metabolism. Glucocorticoids inhibit synthesis and 
accelerate catabolism of proteins due to utilization of amino acids in 
gluconeogenesis. Most significant catabolic changes are observed in 
lymphoid, fat, connective tissues, and skeletal muscles that leads to 
hypotrophy. Prolonged use of glucocorticoids is accompanied by 
muscular weakness, growth retardation in children, delayed wound 
healing, demineralisation of bone tissues, and osteoporosis. At the 
same, glucocorticoids stimulate erythropoiesis, production of 
thrombocytes, and hepatic tissue regeneration. 
Influence of glucocorticoids upon water-salt balance is 
determinated their structure similarity to those of mineralocorticoids. 
Therefore, glucocorticoids promote the retention of water and salts in 
the body. 
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 Besides their metabolic effects, glucocorticoids also exert a lot 
of pharmacological effects: anti-inflammatory, antiallergic, 
antitumoral, antishock effect, etc. Glucocorticoids influence 
cardiovascular, respiratory, gastrointestinal systems and 
haemopoiesis.  
Anti-inflammatory effect. Glucocorticoids prevent or inhibit a 
development of inflammation due to inhibition of activity of 
macrophages and fibroblasts. Also, glucocorticoids stimulate the 
synthesis of lipocortins inhibiting phospholipase A2. Phospholipase 
A2 is an enzyme which frees arachidonic acid from phospholypids of 
cell membranes. Arachidonic acid is involved in inflammation as a 
substrate for the following synthesis of prostaglandins and 
leukotrienes. Due to inhibition of phospholipase A2, glucocorticoids 
decrease the synthesis of inflammatory mediators – prostaglandins 
and leukotrienes. 
Glucocorticoids stabilize the membranes of lysosomes and 
prevent the autolysis of cells. Besides, drugs stabilize the membranes 
of mast cells, decrease the permeability of capillaries and constrict 
small vessels. 
These changes slow down phases I and II of inflammation 
(alteration and exudation). Prolonged glucocorticoid therapy is 
accompanied by inhibition of phase III of inflammation 
(proliferation): capillary ingrowth, fibroblast proliferation, collagen 
and mucopolysaccharide synthesis are decelerated; scar formation of 
connective tissue is broken. 
Antiallergic effect. Glucocorticoids inhibit allergic reactions of 
immediate and delayed types. It is due to inhibition of T- and  
B-lymphocyte activity, reduction of interleukins 1 and 2 synthesis, 
decrease in number of circulating lymphocytes and macrophages. 
Glucocorticoids suppress factor inhibiting migration of macrophages, 
decrease an antibody titer, affect formation of complexes “antigen-
antibody”, prevent interaction of these complexes with target cells, 
and inhibit the synthesis of mediators of allergic reactions. 
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Antitumoral effect of glucocorticoids results from their catabolic 
influence upon peptide metabolism. Glucocorticoids are used in the 
treatment for leucosis and other tumors.  
Antishock effect of glucocorticoids is based on their ability to 
increase sensitivity of vascular wall to catecholamines, dopamine, 
and angiotensin II; elevate level of biogenic amines, and increase 
cardiac output. 
Glucocorticoids increase gastric production of pepsin and 
hydrochloric acid.   
In respiratory system, glucocorticoids stimulate surfactant 
release that increases pulmonary elasticity.   
Glucocorticoids reduce number of lymphocytes and eosinophils 
but increase the production of erythrocytes, reticulocytes, and 
neutrophiles. 
Glucocorticoids for systemic action are lipid-soluble 
compounds. In blood, glucocorticoids bind with plasma proteins; the 
degree of binding for synthetic agents is above 60–70 %, the binding 
of natural hormones is higher. In hypoproteinemia, therapeutic doses 
of glucocorticoids can transform to toxic doses. Drugs, which are 
taken orally, undergo fast and complete gastrointestinal absorption. 
Glucocorticoids are metabolized in the liver by ways of reduction 
and conjugation. Metabolits (sulfates and glucoronides) are excreted 
by kidneys. The metabolic rate of synthetic glucocorticoids is higher 
than those of natural hormones. 
All glucococrticoids for systemic use penetrate placenta. 
Significant concentrations of dexamethasone and beclomethasone are 
accumulated in fetal blood that can provoke hypofunction of adrenal 
cortex in fetus. At the same time, hydrocortisone and prednisolone 
are metabolized in fetus into less toxic substances.    
Inhalated glucocorticoids exert mainly local antiallergic and 
anti-inflammatory effects in respiratory tract. These agents are 
unsoluble in water.  
Hydrocortisone and its esters are approved for topical 
application and for parenteral administration. Ointment with 
hydrocortisone is used to treat allergic and contact dermatitis, 
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eczema, neurodermatitis, etc. Hydrocortisone acetate suspension is 
administered into a joint cavity or intramuscularly.  
Anti-inflammatory effect of prednisolone is 3–4 times higher 
expressed than those of hydrocortisone. Prednisolone exerts less 
influence upon water-salt balance. Prednisolone hemisuccinate 
sodium is administered intravenously. Methylprednisolone acetate is 
taken orally, administered parenterally, or applied topically as 
ointment. The drug exhibits marked anti-inflammatory and 
antiallergic effect. 
Anti-inflammatory activity of dexamethasone is 30 times more 
than those of hydrocortisone. The drug exerts minimal influence 
upon water-salt balance. The drug is taken orally and administered 
parenterally (intramuscularly, intravenously, or into a joint cavity).  
Triamcinolone exerts anti-inflammatory activity 5 times higher 
than activity of natural hormones. The drug is taken orally and 
administered intramuscularly or into a joint cavity. Triamcinolone 
does not influence water-salt balance. At the same time, 
triamcinolone can cause muscular atrophy, appetite loss,  
depression, etc.  
Glucocorticoids with two fluorine atoms in molecules (synaflan 
and flumethasone pivalate) exert high anti-inflammatory and 
antiallergic activity. These agents are used topically as ointments, 
creams, and suspensions. Due to ability to decrease skin resistance to 
infections, these drugs are commonly combined with antibacterial 
agents (Sinalar-H , Locacorten , etc.).  
Therapeutic indications for glucocorticoids are as follows:  
1) severe collagenosis. As a rule, large doses of oral 
glucocorticoids are prescribed to treat acute attacks of rheumatism. 
To treat rheumatoid arthritis, glucocorticoids are taken orally or 
administered into a joint cavity. Treatment of systemic lupus 
erythematosus, scleroderma, and other collagenosis is started with 
intravenous administration of glucocorticoids, after that therapy is 
continued by oral glucocorticoids;   
2) bronchial asthma. In case of severe asthma or status 
asthmaticus, glucocorticoids are administered intravenously during 
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first 1–2 days. After that, the high doses of drugs are taken orally 
with gradual dose decrease;   
3) anaphylactic shock. High doses of glucocorticoids are 
administered intravenously after epinephrine injection. Besides, 
glucocorticoids are used in the treatment for serum sickness, contact 
dermatitis, etc.;   
4) skin diseases (eczema, psoriasis, neurodermatitis, etc.). 
Topical application of drugs is preferable in these cases; 
5) treatment of acute and chronic inflammatory and allergic 
diseases of eyes. Glucocorticoids are used in the form of eye 
ointment or eye drops;  
6) severe intoxication in patients with infectious diseases, 
encephalitis, meningitis, etc. Glucocorticoids are used together with 
chemotherapy; 
7) blood diseases: autoimmune hemolytic anemia, acute allergic 
purpura, thrombocytopenia, agranulocytosis, aplastic anemia, 
lymphosarcoma, and leucosis;      
8) cranio-cerebral traumas and insults with risk of brain edema;  
9) acute and chronic glomerulonephritis; 
10) acute and chronic hepatitis and cirrhosis;  
11) traumatic, cardiogenic, and burn shock;     
12) to inhibit graft rejection in transplantation of tissues and 
organs; 
13) acute and chronic adrenal failure (for substitutive therapy).  
Glucocorticoids should be prescribed in individually tailored 
doses. A discontinuation of long-time therapy should be gradual with 
decrease of dose every 2–3 days. 
Typical side effects of glucocorticoids are as follows.  
1. Steroid drug withdrawal develops due to sudden 
discontinuation of drug intake. It is a result of atrophy or hypotrophy 
of adrenal cortex. Symptoms of steroid withdrawal include acute 
adrenal failure, aggravation of the disease treated by glucocorticoids, 
insomnia, nausea, vomiting, headache, myalgia, etc. Severe cases are 
accompanied by behavior disorders up to psychosis, generalization of 
inflammation with fever, pulmonary infiltrates, and other symptoms.  
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2. Steroid-induced diabetes mellitus. 
3. Decrease of immunity and aggravation of latent infections.   
4. Ulceration of stomach and intestine.  
5. Osteoporosis due to calcium loss.  
6. Hypertension and edemas due to sodium and water retention.  
7. Psychic disorders.  
8. Atrophy of skin and subcutaneous tissues.  
9. Increased intraocular pressure.  
10. Growth retardation in children. 
11. Body weight loss.  
12. Myopathy; 
13. Dysmenorrhea, etc. 
Presently, glucocorticoids antagonists are approved and used in 
medicine. Metyrapone (Metopirone) and mitotane 
(Lysodren) are block glucocorticoid synthesis. Mifepristone 
(Mifegyne) blocks glucocorticoid receptors. Glucocorticoid 
antagonists are used to treat adrenal cortex hyperthrophy (Cushing's 
syndrome) and to investigate corticotropin secretion. Mitotane is also 
used in the treatment for inoperable tumour of adrenal cortex.    
  
Mineralocorticoids  
 
Human adrenal cortex produces aldosterone and 
desoxycorticosterone. Activity of the last one is 10–20 times less 
than aldosterone activity. But stability of desoxycorticosterone is 
higher, and chemical synthesis of this hormone is possible. Thus, 
desoxycorticosterone preparations desoxycorticosterone 
acetate  and desoxycorticosterone trimethylacetate  are used 
in medicine. The drugs are administered intramuscularly, implanted 
subcutaneously, or taken sublingualy. 
Also, synthetic mineralocorticoid 9α-fluorohydrocortisone 
acetate (Fludrocortisone) is approved in medicine. The drug is 
3–4 times more active than aldosterone. Moreover, fludrocortisone 
exerts marked anti-inflammatory effect. The drug is taken orally. 
The main physiological stimulator of aldosterone secretion is 
angiotensin II. Aldosterone, by means of special receptors, penetrates 
304 
 
in nucleus of target tissue cells and stimulates the synthesis of protein 
– carrier of sodium. Thus, aldosterone stimulates the reabsorption of 
sodium and water and secretion of potassium.  
Mineralocorticoid preparations are used in the treatment for 
chronic adrenal failure (Addison’s disease). Besides, these drugs are 
used to treat myasthenia and adynamia because mineralocorticoids 
increase muscle tone and performance capability.  
Overdose of mineralocorticoids is accompanied by oedemas, 
increased circulatory volume, and hypertension. Antagonist of 
mineralocorticoids is spironolactone (Aldactone, 
Verospiron). It is a potassium-sparing diuretic which is used to 
treat hyperaldosteronism, congestive heart failure, hepatic cirrhosis, 
nephrotic syndrome, etc.    
 
 
Sex Hormones 
 
Sex hormones are mainly synthesized in sex glands; some 
amount of sex hormones is secreted by adrenal cortex. An important 
function of sex hormones is formation of secondary sex 
characteristics: body form, distribution of fat tissue, character of 
voice and psyche. Besides, sex hormones regulate peptide 
metabolism and exert mild mineralocorticoid activity. Sex hormones 
are classified into female (estrogens and progestins) and male 
(androgens) hormones. Synthesis of sex hormones is under control of 
gonadotropins (follicle-stimulating and luteinizing hormones). 
 
Preparations of Female Hormones  
 
Estrogens and progestins are the main female hormones. 
Estrogens are synthezied by the theca cells of the ovarian follicle. 
Progestines are synthezied by the granulosa cells of the corpus 
luteum. 
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Estrogens 
 
Classification of estrogen preparations: 
1) native estrogens: estron, estriol , and estradiol;   
2) semisynthetic estrogens: ethinylestradiol (Microfoll in)  
and methylestradiol ;   
3) synthetic estrogens: hexestrol  (Sinestrol),  sigetin , and 
diethylstilbestrol . 
A main site of estrogens synthesis is ovarian follicles. Besides, 
these hormones are also synthesized by adrenal cortex and placenta. 
In male body, small amount of estrogens is synthesized by testicles. 
Estrogens provide development of secondary sex characteristics in 
females, prepare uterus to ovule implantation, control endometrium 
proliferation, and myometrium hypertrophy, influence growth and 
functional activity of lacteal glands.  
A main target organ of estrogens is uterus, where they stimulate 
synthesis of contractile proteins. Estrogens improve energy 
metabolism and promote accumulation of glycogen, glucose, and 
ATP in myometrium. Estrogens increase myometrium excitability 
and its ability to spontaneous generation of action potentials. It is 
accompanied by increase of amplitude and frequency of uterine 
contractions. Estrogens increase myometrium sensitivity to oxytocin.  
It should be noticed that long-lasting increase of estrogens 
concentration with simultaneous reduction of progestins level may 
lead to pathologically excesive protein synthesis and carcinogenesis. 
Effects of estrogens is not limited by their influence on 
myometrium. Hormones promote accumulation of nitrogen, calcium, 
and phosphorus in a body. Estrogens improve glucose utilization due 
to increase of tissue sensitivity to insulin. Also, estrogens increase 
concentration of iron and copper in a body and activate renin-
angiotensin system. Estrogens stimulate synthesis of antibodies, 
formation of macrophages, function of phagocytes, increase 
resistance to infections.  
Therapeutic indications of estrogens are as follows. 
1. Stimulation of uterine contraction in labor.  
2. Osteoporosis in postmenopausal women. 
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3. Substitutive therapy in ovarian hypofunction. Estrogens are 
used to treat infantilism (retardation of sexual development), 
dysmenorrhea, amenorrhea, sterility, and menopause.  
4. Breast cancer after menopause (after 60 years of age).  
5. Disfunctional uterine bleeding.  
6. Prostate cancer. Estrogens are effective due to their ability to 
bind to androgen receptors.  
7. Peroral contraception (together with progestins).  
For substitutive therapy, estrogens are used in menopausal 
period and after ovariectomy. Progynova  (estradiol valerate), 
Climara  (transdermal estradiol), Climodien  (estradiol valerate and 
dienogest), and Klimonorm  (estradiol valerate with levonorgestrel), 
etc. are most commonly used with this end in view.  
Side effects of estrogens are oedemas, headache, hypertension, 
thrombophlebitis, uterine bleeding, renal and hepatic dysfunction. In 
males, estrogens cause feminization (development of female 
secondary sex characteristics) and decrease of potency. 
Due to their ability to stimulate tissue proliferation, estrogens are 
prescribed with caution in women with tumoral diseases, 
mastopathy, and after 40 years old. 
 
Antiestrogens  
 
Antiestrogens are analogues of synthetic estrogens: 
clomiphene (Clostilbegyt)  and tamoxifen (Nolvadex) .   
Clomiphene, taken in low doses, easily penetrates blood-brain 
barrier and blocks interaction of estrogens with specific receptors in 
hypothalamus and hypophysis. Due to negative feedback, it increases 
secretion of pituitary gonadotropins which promote ovulation. 
Clomiphene is used in the treatment for infertility in women and 
oligospermia.  
Tamoxifen does not penetrate central nervous system. Therefore, 
the drug blocks peripheral estrogen’s receptors in mammary glands 
and endometrium. Tamoxifen is used in the treatment for estrogen-
dependent tumors of mammary glands and endometrium. 
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Progestins  
 
Progestins are effective synthetic versions of progesterone. 
Progesterone is synthesized by the corpus luteum and adrenal cortex. 
During pregnancy, progesterone is synthesized by placenta. 
Progesterone prepares endometrium to implantation, promotes 
intensive proliferation of endometrial glands and placenta formation, 
and prevents ovulation due to inhibition of the production of pituitary 
hormones. Progesterone promotes synthesis of proteins in the uterus. 
Progesterone inhibits uterine excitability, increases membrane resting 
potential of smooth muscles of the uterus (hyperpolarization) that 
decreases spontaneous activity of myometrium. In other organs, 
progesterone exerts catabolic influence upon protein metabolism and 
causes negative nitrogen balance. 
Progestin preparations are classified as follows. 
1. Native hormone: progesterone .  
2. Synthetic preparations: oxyprogesterone capronate ,  
pregnin, allylestrenol  (Turinal), medroxyprogesterone 
acetate (Depo-Provera), norethisterone (Norcolut),  etc.  
Progestin preparations are characterized by different activity and 
duration of action. Progesterone exerts fast and short-time effect. The 
drug is administered intramuscularly everyday. Oxyprogesterone 
capronate acts during 7–14 days. Activity of pregnin is 5–15 times 
less than those of progesterone. Pregnin is taken sublingually. 
Allylestrenol is a synthetic progestin with highest activity. 
Norethisterone exerts progestin and androgen activity in ratio 1 : 1. 
Its duration of action is about 24 hours. Norethysterone is used to 
treat endometriosis, dismenorrhea, uterine myoma, glandular 
hyperplasia, and endometrial polyps. Depo-Provera is administered 
intramuscularly or taken orally. Its duration of action is about  
3 months.  
Therapeutic indications for progestins are as follows.  
1. Habitual abortion in early pregnancy.  
2. Dismenorrhea.  
3. Premenstrual syndrome.  
4. Contraception (in combination with estrogens or alone). 
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5. Disfunctional uterus bleeding due to corpus luteal 
insufficiency. 
6. Estrogen-dependent cancer of mammary glands, 
endometriosis, androgen-dependent adenoma and prostate cancer.  
7. Infertility.   
Side effects of progestins are hypertension, oedemas, headache, 
nausea, depression, feeling tired, dysfunctional uterine bleeding, etc.  
 
Anti-progestins  
 
Mifepristone (RU 486) is an agent with anti-progestin 
activity. The drug interacts with progestin receptors that prevents 
progesterone binding with those. Mifepristone stimulates uterine 
contraction and causes abortion. The drug is used in medicine to 
interrupt pregnancy. The drug significantly increases uterine 
sensitivity to prostaglandins; therefore, mifepristone is commonly 
combined with them. Besides, mifepristone is used to normalize 
menstrual cycle.  
 
Hormonal Contraceptives  
 
Contraceptives are used to birth control and to prevent unwanted 
pregnancies.  
Hormonal contraceptives are classified as follows.  
1. Co-formulated estrogen-progestin-containing drugs. 
2. Drugs containing microdoses of progestins. 
3. Prolonged progestin-containing drugs (depot-contraceptives). 
4. Postcoital contraceptives. 
5. Vaginal contraceptives.  
6. Male’s contraceptives. 
 
Combined Estrogen-Progestin Containing Drugs  
 
Co-formulation of estrogen with progesterone for oral 
contraception was proposed by Pincus in 1955. In Europe, 35–51 % 
women use this method of contraception. Ethinylestradiol  is most 
commonly used estrogen for such co-formulations. Testosterone 
derivatives (norethisterone, norgestrel , and levonorgestrel ) 
are progestins which most commonly included in these drugs.  
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Combined estrogen-progestin containing contraceptives prevent 
ovulation due to inhibition of gonadotropins secretion according to 
principle of negative feedback. Besides, these drugs prevent ovum 
fertilization by means of progestin which inhibits motility of 
Fallopian tubes and increases time of ovum moving in uterine cavity. 
Simultaneously, viscocity and acidity of cervical mucus is increased 
that prevents spermatosoids moving in uterine cavity and promotes 
their destruction. Combined contraceptives worsen conditions for 
implantation of fertilized ovum because progestin accelerates onset 
secretory phase in endometrium, violates its metabolism and 
stimulates degeneration. In such conditions, ovum implantation and 
development of pregnancy become impossible. 
There are monophasic, biphasic, and triphasic estrogen-
progestin-containing drugs. 
Monophasic and biphasic preparations are taken from 5th days 
of menstrual cycle, while triphasic drugs are taken from 1st day. 
Drugs are taken for 21 days, after that 7-days break is necessary 
when withdrawal bleeding occurs. Prolongation of break to 8–9 days 
is impossible because it increases risk of pregnancy due to 
spontaneous ovulation. 
Monophasic preparations include such drugs as Ovidon, 
Rigevidon, Diane-35, Non-Ovlon, Marvelon, Femoden,  
etc. These drugs contain constant concentrations of estrogen and 
progestin.  
In biphasic contraceptives, concentration of progestin in second 
phase of cycle is increased. These drugs include Neo-Eunomin,  
Anteovin,  etc. 
In triphasic drugs, progestin concentration is increased gradually 
in three steps, whereas estrogen concentration in first and third 
phases is constant. Representatives of triphasic contraceptives are 
Triquilar,  Trisiston, Tri -Regol,  Trinovum,  etc.  
Presently, monophasic drugs became preferable due to 
appearance of III-generation progestins (desogestrel, gestodene, 
norgestimate) exerting high affinity to progestin receptors and safety. 
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Estrogen-progestin containing contraceptives are readily 
absorbed from gastrointestinal tract. Their bioavailability is about 
70 %. These drugs are metabolized in liver by way of conjugation 
with glucuronic or sulfuric acid and excreted by kidneys.  
Estrogen-progestin containing drugs are taken orally in the same 
time of day. Long-lasting regular drug intake (more than 2 years) is 
accompanied by normalization of menstrual cycle, elimination of 
dysmenorrhea and premenstrual syndrome, reduced risk of 
inflammatory diseases of pelvic organs, decreased risk of cancer of 
endometrium and ovaries, fibromyoma, iron deficiency anemias, etc.  
Besides contraception, co-formulated estrogen-progestin drugs 
are used to treat endometriosis, dysmenorrhea, amenorrhea, and 
some form of infertility.  
It should be noticed that a probability of pregnancy is increased 
after discontinuation of drugs intake. 
Side effects of co-formulated drugs are observed most 
commonly during initial 1–2 monthes of therapy. After this time, 
their frequence is reduced to 5–10 %. Most common side effects are 
increased blood coagulation with risk of venous thrombosis and 
thromboembolism, hepatic dysfunction, headache, dizzinnes, nausea, 
body wheight gain, intermenstrual bleeding, etc.  
Estrogen-progestin containing drugs are contraindicated in 
pregnancy, hypertensive disease, ischemic heart disease, obesity, 
predisposition to thromboembolism, hepatic and oncological 
diseases, and for smoking women after 35 years old. 
 
Contraceptives Containing Microdoses of Progestins  
 
Contraceptives containing microdoses of progestins include such 
drugs as Exluton (lynestrenol),  Microlut  ( levonorgestrel) ,  
Continuin (ethynodiol diacetate), Ovral (norgestrel), etc.  
Progestin containing contraceptives are prescribed in cases when 
estrogen-progestin co-formulated drugs are contraindicated. 
Responsibility of these drugs is less.  
Mechanism of action of these drugs is not clear enough. It is 
supposed that progestins change amount and contents of cervical 
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mucus that interfere spermatosoids to penetrate through it. Besides, 
progestin-containing drugs slow down ovum moving in fallopian 
tubes and change characteristics of endometrium, therefore, these 
drugs that interfere ovum implantation. Inhibition of hypothalamic-
pituitary regulation is also possible.  
Maximal effect of these drugs develops in 3–4 hours after intake 
and lasts 16–19 hours. Disadvantages of progestin-containing 
contraceptives are their less efficacy in comparison with estrogen-
progestin co-formulations, necessity of more close dosage regimen, 
irregular menstrual cycle, intermenstrual bleeding, etc.  
 
Prolonged Progestin-Containing Contraceptives  
 
There are the following prolonged progestin-containing 
contraceptives. 
1. Drugs for injections: medroxyprogesterone acetate 
(Depo-Provera) . The drug is administered intramuscularly 1 time 
in 3–4 months.  
2. Subcutaneous implants: Norplant (levonorgestrel-
releasing implant ) . Five capsules of Norplant are implanted 
under the skin of forearm. Its duration of action is about 5 years.    
3. Intrauterine drugs: Mirena . It is intrauterine contraceptive 
device permanently releasing levonorgestrel for 5 years. Mirena 
exerts high contraceptive responsibility. The drug decreases 
frequency and volume of uterine bleeding and is aspecially intended 
for women suffering from menorrhagia and dysmenorrhea. 
Side effects of prolonged progestin-containing drugs are body 
weight gain, decreased libido, intermenstrual bleeding, hair loss, etc.  
 
Postcoital Contraceptives  
 
Postcoital contraceptives are represented by Postinor  and 
Escapel . Both drugs contain levonorgestrel. Poscoital 
contraceptives violate secretory phase of menstrual cycle and cause 
temporal atrophic changes in ovaries. These drugs are intended for 
contraception in women who do not use contraceptives regullary. 
Postcoital contraceptives are taken immidiatly after coitus but not 
oftener than 1 time per week (4 times per a month). 
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Vaginal Contraceptives  
 
Vaginal contraceptives are represented by benzalkonium 
chloride (Pharmatex)  and nonoxynol (Patentex oval,  
Conceptrol) . These drugs violet cellular membrane of 
spermatosoids that leads to their disruption.  
 
Male Contraceptives  
 
Male contraceptives are represented by gossypol  and inhibin . 
Their mechanism of action is associated with inhibition of 
spermatogenesis and semen maturation.  
Gossypol is obtained from cottonseed oil. At daily drug intake, 
its effect develops in 2 months. Spermatogenesis is restored in  
3 months after discontinuation of gossypol intake. Often side effect 
of gossypol is hypokalemia. The drug provokes infertility in about 
20 % of males who taken it.  
Inhibin affects hypothalamic-pituitary regulation of male sex 
glands. The drug selectively inhibits a follicle-stimulating hormone 
release that leads to violation of spermatogenesis without influence 
upon testosterone production. Inhibin is obtained from seminal fluid 
of males.       
           
Preparations of Male Hormones  
(Androgens)  
 
About 6 mg of androgens are synthesized in males mainly in 
interstitial Leydig’s cells and, partly, in cells of adrenal cortex. In 
females, certain quantity of androgens (nearly 0.3 mg/day) is 
synthesized by adrenal cortex and ovarian follicular cells. 
Biological effects of androgens are determined by testosterone 
and its metabolites – androstenediol, dihydrotestosterone, etc. 
Androgens influence formation of primary and secondary sex 
characteristics of males, promote normal development of prostate 
and reproductive organs. Androgens regulate spermatogenesis and 
potency. Besides, androgens stimulate protein synthesis (anabolic 
effect) and suppress protein catabolism. In females, small doses of 
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androgens stimulate synthesis of gonadotropins, while large doses 
block this process. 
Androgens increase renal reabsorption of sodium, calcium, 
chlorine, and equivalent volume of water. Also, hormones promote 
the deposition of calcium in bones, increase activity of some 
enzymes and somatotropin. It is accompanied by activation of tissue 
respiration, oxidative phosphorylation, and energy accumulation. 
Androgens stimulate synthesis of erythropoietins and increase the 
heart contractile function.   
The following synthetic analogues of androgens are used as 
medical preparations: testosterone propionate ,  
methyltestosterone, testosterone enanthate  (Testenate 
Depot), Sustanon-250 , etc.  
Testosterone and testosterone enanthate are manufactured as 
ampoules filled with oil solutions. Testosterone propionate is dosed 
intramuscularly 1 time in 2 days, testosterone enanthate – once in  
3–4 weeks. Methyltestosterone is taken sublingually 1–5 times a day. 
Sustanon-250 is a co-formulated androgen preparation containing 
several testosterone ethers with different duration of action. The 
effect of Sustanon-250 starts just after administration and lasts about 
3–4 weeks. Therefore, this drug is administered intramuscularly once 
in 3–4 weeks. Sustanon-250 is a drug of choice for prolonged 
hormone-replacement therapy. 
There are testosterone preparations for subcutaneous 
implantation in a fat of the abdominal wall. Implants are 
administered in dose 0.4–0.6 g every 4–6 months. Testosterone 
implants is the most appropriate form for maintenance of stable 
testosterone dose for 6 months. But in practice, the implants are not 
in wide use due to infections and implant extrusion.  
Recently, androgens are available for transdermal administration 
in forms of skin gel or special patch.  
There are the following therapeutic indicaiotns for androgens:  
– replacement therapy of sexual failure in males  
(e. g., infantilism, erectile dysfunction); 
– osteoporosis;  
– cancer of mammary glands, uterus, and ovaries in women 
younger than 60 years of age.  
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Side effects of androgens are increased sex arousal, 
masculinization in women, cholestatic jaundice, oedemas, nausea, 
hypercalcemia, etc.  
 
Antiandrogens  
 
Synthesis of testosterone can be suppressed by means of 
hypothalamic hormone gonadorelin  and its synthetic analogue 
leuprolide . The drugs are used to treat prostatic hyperplasia. But 
the following groups of antiandrogens are used more widely: 
– androgen receptor blocking drugs: cyproterone acetate,  
flutamide . 
– 5α-reductase inhibitors (enzyme catalyzing transformation of 
testosterone to dihydrotestosterone): finasteride (Proscar),  
dutasteride . 
Androgen receptor blocking drugs inhibit spermatogenesis due 
to blockage of androgen receptors. Their effect persists during  
4 months after removal of drug intake. besides, these drugs block 
androgen receptors in the central nervous system that leads to 
decrease of libido and impotence. Cyproterone and flutamide are 
used to treat prostate cancer, compulsive sexual behaviour, 
androgenization in women, etc.  
5α-reductase inhibitors suppress activity of enzyme catalyzing 
transformation of testosterone to dihydrotestosterone. Finasteride is 
used in the treatment for prostatic adenoma. The agent reduces the 
sizes of prostate and improves the urination in 1/3 of patients. As a 
rule, finasteride does not influence libido and potency.  
 
Anabolic Steroids 
 
A group of anabolic steroids includes such drugs as 
methandrostenolone, nandrolone decanoate (Retabolil) ,  
nandrolone phenylpropionate (Fenobolin), oxandrolone, 
stanozolol, silabolin , etc.  
Anabolic steroids activate iRNA synthesis that results in the 
increase of protein synthesis. Therapy by anabolic steroids is 
accompanied by accumulation of nitrogen, potassium, sulfur, 
phosphorus, and calcium in the body. Anabolic steroids stimulate 
315 
 
regenerative processes, increases muscular mass, improves appetite 
and general state of patients. 
Methandrostenolone is a drug with short duration of action. Its 
tablets are taken orally 1–2 times a day. Fenobolin and Retabolil are 
dosed intramuscularly. Duration of action of Fenobolin is 7–15 days. 
The effect of Retabolil lasts about 3 weeks.  
Therapeutic indications for anabolic steroids are as follows:  
– chronic infections (e. g., tuberculosis);        
– recovery period after serious exhausting diseases;  
– thyrotoxicosis;  
– dystrophy in children;  
– diseases of musculoskeletal system; 
– paralysis;  
– osteoporosis;  
– bone fractures;  
– chronic heart failure;  
– postinfarction period; 
– cirrhosis; 
– chronic renal diseases, etc. 
Side effects of anabolic steroids are oedemas, excessive 
accumulation of calcium in bones, hepatic dysfunction, and 
masculinization in females. Anabolic steroids are contraindicated in 
pregnancy, period of lactation, prostatic carcinoma, and some hepatic 
diseases.  
 
Table 12 – Drugs for prescription 
 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product 
Hydrocortisoni 
acetas 
Intrasinovially 0.005–0.025 g 
1 time in 3 days; 
intramuscularly 0.025 g  
2–6 times a day; 
in eye 0.5 % ointment  
Vials 5 ml  
of 2.5 % suspension; 
eye ointment 0.5 % – 
2.5 g 
Prednisolonum Orally 0.005–0.05 g 2 times 
a day; 
on injured part of skin 
0.5 % ointment 
Tablets 0.005 g; 
ointment 0.5 % – 10.0 g 
or 20.0 g 
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Continuation of the table 12 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product 
Prednisolini 
hemisuccinas 
Intravenously or 
intramuscularly 0.05–0.2 g 
2–6 times a day 
Ampoules 0.025 g  
of powder for injection  
Dexamethasonum Orally 0.000 5–0.001 g  
2–3 times a day 
Tablets 0.000 5 g 
Synaflanum On injured part of skin 
0.025 % ointment 
Ointment 0.025 % – 
10.0 or 15.0 g 
Beclomethasoni 
dipropionas 
2 inhalations 3–4 times 
a day 
Aerosol “Becotide” 
 or “Beclomet” 
Desoxycorticosteroni 
acetas 
Sublingually 0.005 g daily; 
intramuscularly 0.005 g  
1 time in 2 days – 0.01 g  
1–4 times a day 
Tablets 0.005 g; 
ampoules 1ml of 0.5 % 
oil solution 
Oestronum Intramuscularly 5 000–
10 000 IU 1 time a day 
Ampoules 1 ml of 0.05% 
or 0.1% solution  
(5 000 IU and 10 000 IU 
respectively) 
Synoestrolum Orally or intramuscularly 
0.001 g 1–2 times a day 
Tablets 0.001 g; 
ampoules 1 ml of 0.1% 
or 2% oil solution 
Progesteronum Intramuscularly 0.005–
0.015 g 1 time a day  
or 1 time per 2 days 
 
Ampoules 1 ml of 1%  
or 2.5% oil solution 
Turinalum Orally 0.005 g 2–3 times 
a day 
Tablets 0.005 g 
Testosteroni 
propionas 
Intramuscularly 0.01–0.025 g 
1 time per 2 days 
Ampoules 1 ml of 1%  
or 5% oil solution 
Phenobolinum Intramuscularly 0.025–0.05 g 
1 time per 7–10 days 
Ampoules 1 ml of 1%  
or 2.5% oil solution 
Retabolilum Intramuscularly 0.025– 
0.05 g 1 time per 2–3 weeks 
Ampoules 1 ml  
of 5% oil solution 
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Step 1. Tasks for Self -Control  
Hormonal Drugs 
 
1. A patient with diabetes mellitus experienced loss of 
consciousness and convulsions after an injection on insulin. What 
might be the result of biochemical blood analysis for concentration 
of sugar? 
A. 5.5 mmol/l. 
B. 10.0 mmol/l. 
C. 8.0 mmol/l. 
D. 1.5 mmol/l.  
E. 3.3 mmol/l. 
2. A patient with diabetes didn’t get insulin injection in time that 
caused hyperglycaemic coma (glucose in blood is 50 mmol/l). What 
mechanism is prevalent in the development of coma? 
A. Hyperosmia.  
B. Acidosis. 
C. Hypoxia. 
D. Hyponatremia. 
E. Hypokalaemia. 
3. A 56-year-old patient complaining of thirst and frequent 
urination was diagnosed with diabetes mellitus. Butamidum was 
prescribed. How does this drug act?  
A. It relieves transport of glucose through the cell membranes. 
B. It helps to absorb glucose by the cells of the organism tissues. 
C. It inhibits -cells of Langerhans islets. 
D. It inhibits absorption of glucose in the intestines. 
E. It stimulates -cells of Langerhans islets.  
4. Testosterone and its analogues increase the mass of skeletal 
muscles that allows to use them for treatment of dystrophy. Due to 
interaction of the hormone with what cell substance is this action 
caused? 
A. Chromatin. 
B. Proteins-activators transcription. 
C. Nuclear receptors.  
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D. Membrane receptors. 
E. Ribosomes. 
5. A patient had been taking glucocorticoids for a long time. 
When the drug was withdrawn, he developed the symptoms of 
disease aggravation, decreased blood pressure, and weakness. What 
is the reason of this condition? 
A. Cumulation. 
B. Hyperproduction of ACTH. 
C. Sensibilisation. 
D. Habituation. 
E. Appearance of adrenal insufficiency.  
6. A patient with infectious mononucleosis had been taking 
glucocorticoids for two weeks. He was brought into remission, but he 
fell ill with acute attack of chronic tonsillitis. What action of 
glucocorticoids caused this complication? 
A. Antitoxic. 
B. Anti-inflammatory. 
C. Immunosuppressive. 
D. Antiallergic. 
E. Antishock. 
7. A patient was on glucocorticoids for a long time, 
discontinuation of usage caused exacerbation of the illness, 
decreased BP, and weakness. How can you explain it? 
A. Cumulation. 
B. Insufficiency of adrenal glands.  
C. Adaptation to the drug. 
D. Sensitization. 
E. Hyperproduction of ACTH. 
8. Usage of oral contraceptives with sex hormones inhibits 
secretion of the hypophyseal hormones. Secretion of which of the 
indicated hormones is inhibited while using oral contraceptives with 
sex hormones? 
A. Vasopressin.  
B. Thyrotropic. 
C. Somatotropic. 
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D. Follicle-stimulating.  
E. Oxytocin. 
9. Because of a long-term drug application such complications 
as osteoporosis, erosive ulcers of the mucous coat of stomach, 
oedemas, increase of arterial pressure, and insomnia have developed. 
Laboratory tests detected hypernatremia, hypokalaemia, and 
hyperglycaemia. What drug has been applied? 
A. Reserpine. 
B. Hypothiazidum. 
C. Prednisolone.  
D. Indomethacin. 
E. Digoxin. 
10. Having a serious infection a patient needs an anabolic drug 
for the improvement of appetite. Which one? 
A. Retabolil.  
B. Thiamine chloride. 
C. Tinctura of wormwood (Tinctura Absinthii). 
D. Heparin. 
E. Folic acid. 
11. A medicine was prescribed for treatment of arthritis. It has 
the following pharmacological characteristics: it increases the 
production of lipomoduline, reduces phospholipase A2 activity, 
reduces the synthesis of arachidonic acid metabolism products 
(cyclic endoperoxides, prostaglandins). What drug is this? 
A. Glibenclamide. 
B. Adrenaline hydrochloride. 
C. Isadrinum 
D. Prednisolone.  
E. Butadione. 
12. A patient in soporous condition is delivered to 
endocrinologic unit. The increasing sweating and smell of acetone 
from the mouth are observed. The level of glucose in blood is 
22.43 mmol/l. The diagnosis is hyperglycemic coma. What 
hypoglycemic drug should be administered to the patient? 
A. Drug from sulfonylurea derivatives group. 
B. Insulin with intermediate duration of action. 
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C. Insulin with long duration of action. 
D. Drug from biguanides group. 
E. Insulin with short duration of action. 
13. The treatment of the first type of diabetes mellitus foresees 
the imitation of basiс and carbohydrate-induced secretion of insulin. 
What drug does imitate the carbohydrate-induced secretion of 
insulin?       
A. Suinsulin. 
B. Zinc-insulin. 
C. Glibenclamide. 
D. Metformin. 
E. Glibutidum. 
14. A patient with asthmatic status is delivered to urgent unit. 
The patient is suffering from bronchial asthma for 12 years. Earlier 
attacks were reduced by salbutamol but now this drug is ineffective.  
What drug should be administered to the patient first of all? 
A. Bisacodyl. 
B. Acyclovir. 
C. Oxytocin. 
D. Prednisolone. 
E. Famotidine. 
15. Deficiency of birth activity has developed in a woman during 
delivery. What drug should be administered to woman for restoration 
of contractive activity of myometrium? 
A. Dithylinum. 
B. Dimedrol. 
C. Unithiol. 
D. Aminazine. 
E. Oxytocin. 
16. A woman with acute glomerulonephritis is delivered to 
nephrology unit. What drug should be prescribed to her? 
A. Bisacodyl. 
B. Prazosin. 
C. Prednisolone. 
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D. Phenazepam. 
E. Spirituous solution of iodine. 
17. To prevent the transplant rejection after organ transplantation 
it is required to administer hormonotherapy for the purpose of 
immunosupression. What hormones are used for this purpose? 
A. Catecholamines. 
B. Mineralocorticoids. 
C. Glucocorticoids.  
D. Thyroid hormones. 
E. Sexual hormones. 
18. Continuous use of a certain drug may cause osteoporosis, 
erosions of stomach mucosa, hypokalaemia, retention of sodium and 
water in the organism, decreased concentration of corticotropin in the 
blood. What drug is it? 
A. Prednisolone.  
B. Hypothiazid. 
C. Reserpine. 
D. Digoxin. 
E. Indomethacin. 
19. An elderly female patient suffers from the type 2 diabetes 
mellitus accompanied by obesity, atherosclerosis, and coronary 
artery disease. Basal hyperinsulinemia is also present. What 
treatment would be the most appropriate? 
A. Amlodipine. 
B. Retabolil. 
C. Glibenclamide. 
D. Insulin. 
E. Lovastatin. 
20. A woman with bronchial asthma has been using 
prednisolone in tablets for two months. Owing to significant 
improving of condition, she suddenly stops drug intake. Which 
complication is possible in this case? 
A. Stomach bleeding.  
B. Cushing's syndrome. 
C. Obesity. 
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D. Hypotension. 
E. Withdrawal syndrome. 
21. A patient with rheumatoid arthritis has been using 
prednisolone for a long time. Why should he avoid the contacts with 
infectious patients? 
A. Owing to development of secondary immunodeficiency.  
B. Owing to blockage of interferon synthesis.  
C. Owing to ability of thrombosis. 
D. Owing to development of lymphopenia. 
E. Owing to possibility of arthritis aggravation. 
22. In experiment, hydrocortisone (intramuscularly, in dose  
1 g/kg) was administered to rats. The development of stomach ulcers 
was observed after 10 injections. What is the mechanism of 
ulceration? 
A. Hyperacidity. 
B. Decrease of gastrin secretion. 
C. Hypersecretion of mucus. 
D. Embolism of vessels. 
E. Ischemia of the stomach mucosa. 
23. Sugar in the urine was not found in examination of patient 
with diabetes mellitus. What is the tactic of physician for this 
patient?  
A. Without any remedial measures.   
B. Prescribe insulin. 
C. Prescribe insulin and glibenclamide. 
D. Prescribe glibenclamide. 
E. Don’t prescribe antidiabetic therapy and use carbohydrate 
diet. 
24. A patient suffers from insulin-dependent diabetes mellitus. 
Endocrinologist prescribes to him insulin and recommends to avoid 
stress because increase of adrenaline level in stress is accompanied 
by elevation of glucose level from glycogen in skeletal muscles. 
Which link of the regulation of glycogenolysis by adrenaline is 
affected by insulin? 
A. Activation of protein kinase.  
B. Synthesis of cAMP. 
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C. Stimulation of phosphodiesterase. 
D. Inhibition of protein phosphatase. 
E. Activation of adenylyl cyclase. 
25. A patient is unconscious with the smell of acetone from the 
mouth. A doctor has diagnosed diabetic coma. Which drug should be 
administered to the patient for interruption of coma?  
A. Acarbose.  
B. Chlorpropamide. 
C. Buformin. 
D. Insulin. 
E. Glipizide. 
26. A patient on the third day after thyroidectomy has seizures. 
Which drug should be prescribed to him?  
A. Phenobarbital.  
B. Potassium chloride. 
C. Calcium chloride.  
D. Potassium bromide. 
E. Neuroleptics. 
27. Excessive granulations have developed in a patient with 
chronic inflammatory processes of the skin. Specify the hormonal 
drug which should be used in treatment of this patient.  
A. Mineralocorticoids. 
B. Glucocorticoids. 
C. Thyroxine. 
D. Somatotropin. 
E. Insulin. 
28. Hormonal therapy is compulsory for suppression of 
autoimmune reactions after organ transplantation. Which hormones 
are used for this aim?  
A. Sex hormones.   
B. Mineralocorticoids. 
C. Adrenaline. 
D. Glucocorticoids. 
E. Somatotropin. 
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29. Glucocorticoids are widely used in modern clinical practice. 
Specify the effect which is achieved only with administration of high 
doses of glucocorticoids.  
A. Increase of sodium excretion. 
B. Suppression of inflammation. 
C. Support of normal vessels tone. 
D. Increase of water excretion. 
E. Inhibition of adrenocorticotropin secretion. 
30. A significant increase of diuresis is developed in a 50-year-
old woman after infective disease of brain. The glucose blood level is 
4.1 mmol/l. A doctor diagnosed the lack of endocrine function. What 
hormone deficiency is most likely? 
A. Cortisone.  
B. Vasopressin.  
C. Aldosterone. 
D. Glucagon.  
E. Insulin. 
31. Massive glucocorticoids therapy in patient with rheumatism 
results in hyperuricemia. Indicate metabolic process owing to change 
in which hyperuricemia is released.  
A. Intensive lipolysis.  
B. Activation of gluconeogenesis. 
C. Intensive catabolism of proteins. 
D. Intensive catabolism of pyrimidine nucleotides. 
E. Intensive degradation of purine nucleotides. 
32. A patient is admitted to the hospital with the diagnosis  
of lobar pneumonia. Doctor prescribes to him injections of 
benzylpenicillin. An injection of antibiotic results in development  
of anaphylactic shock in patient. Choose the hormonal drug which 
should be administered for rescue emergency care. 
A. Dimedrole. 
B. Adrenaline. 
C. Prednisolone hemisuccinate. 
D. Calcium chloride. 
E. Euphyllinum. 
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33. A doctor recommended iodine-containing drugs to 
liquidators, the victims of the Chernobyl nuclear power plant. What 
is the aim of this recommendation?  
A. Increase of iodine storage in organism. 
B. Compensation of iodine deficiency in organism. 
C. Compensation of iodine deficiency in thyroid gland. 
D. Preventive saturation of thyroid gland with nonradioactive 
iodine. 
E. Replacement of radioactive iodine by nonradioactive iodine. 
34. Long-term use of drug A. can cause osteoporosis, erosions of 
the gastric mucosa, hypokalemia, sodium and water retention in the 
body, reducing the content of corticotropin in the blood. Identify the 
product. 
A. Indomethacin. 
B. Reserpine. 
C. Hydrochlorthiazide. 
D. Prednisolone. 
E. Digoxin. 
35. A woman has been a habitual miscarriage. Identify the drug 
which should be prescribed to the woman for pregnancy saving.   
A. Hydrocortisone.  
B. Methandrostenolone. 
C. Progesterone. 
D. Estron. 
E. Testosterone. 
36. Explain why corticotropin is administered in the morning? 
A. Drug doesn’t influence upon sleep structure. 
B. For compensation of glucose level decrease after sleep. 
C. For maintenance of necessary daily hormone concentration. 
D. Drug doesn’t cause ulceration of stomach in the morning. 
E. According to natural rhythm of hormone synthesis. 
37. A 63-year-old woman suffers from diabetes mellitus. 
Endocrinologist prescribes to her butamide. What is the mechanism 
of butamide action? 
A. Drug stimulates the hypothalamus.  
B. Increase of glucose degradation.  
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C. Drug directly provides the transport of glucose into the cells. 
D. Drug increases the degradation of proteins. 
E. Activation of pancreatic islet beta-cells. 
38. A doctor prescribed to a 60-year-old woman after 
mastectomy synthetic drug which reduced simulative influence of 
estrogens upon tumor growth. Identify this drug. 
A. Cisplatin.  
B. Tamoxifen.  
C. Rubomycin. 
D. Diethystilbestrol. 
E. Fosfestrol. 
39. A doctor prescribed butadionum to patient with diabetes 
mellitus who was treated with butamide. After butadionum intake, 
hypoglycaemia developed in this patient. What is the cause of this 
complication? 
A. Butadionum replaces butamide from the binding with plasma 
proteins. 
B. Increase of butamide biotransformation. 
C. Increase of butamide excretion. 
D. Competition of drugs for connection with receptors. 
E. Pharmaceutical incompatibility of drugs. 
40. A 60-year-old patient with diabetes mellitus receives insulin 
semilente for correction of hyperglycemia. 10 days ago, he began 
treatment of hypertensive disease. In an hour after reception of 
hypotensive drug patient felt weakness, dizziness, decrease of blood 
pressure, and in few minutes later the patient lost consciousness. 
Identify pathological state which developed.  
A. All answers are incorrect. 
B. Acute disturbance of cerebral circulation. 
C. Cardiogenic shock. 
D. Hypoglycemic coma. 
E. Hyperglycemic coma. 
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41. Hyperglycemic coma develops in a patient with diabetes 
mellitus. Glucose concentration in the blood is 18.44 mmol/l. Which 
drug should be administered to the patient? 
A. Sulfonylurea derivative. 
B. Biguanide derivative. 
C. Insulin with short action.  
D. Insulin with long action. 
E. Insulin with intermediate duration of action. 
42. Mercazolil (thiamazole, methimazole) is prescribed to 
a patient with thyrotoxicosis. What is the mechanism of drug action? 
A. Mercazolil blocks the release of hormones by thyroid gland. 
B. Mercazolil suppresses the activity of thyrotropin.  
C. Mercazolil blocks the incorporation of iodine in hormones 
molecules. 
D. Mercazolil destroys the tissue of thyroid gland. 
E. Mercazolil decreases the synthesis of thyroxine in thyroid 
gland. 
43. Iodine-containing drug is prescribed to a patient with initial 
stage of hyperthyroidism. Which effect is the basis of antithyroid 
action of this drug? 
A. Destruction of tissue of thyroid gland.  
B. Inhibition of thyrotropin secretion by pituitary. 
C. Inhibition of enzymes synthesizing thyroid hormones. 
D. Blockage of iodine incorporation in the structure of 
hormones. 
E. Inhibition of thyrotropin-releasing hormone secretion by 
hypothalamus.  
44. Hypoglycemic drug A was prescribed to a patient with 
diabetes mellitus. In several weeks of treatment, the glucose level in 
blood is decreased. But lactic acidosis develops in patient. Identify 
the group of hypoglycemic drugs for which this complication is most 
typical.  
A. Sulfonylurea derivatives. 
B. Insulins with short action. 
C. Biguanides. 
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D. Insulins of long duration of action. 
E. Combined insulins. 
45. A patient with infectious mononucleosis took 
glucocorticoids for 2 weeks. Owing this treatment, the remission of 
infectious mononucleosis is developed in the patient. But aggravation 
of chronic tonsillitis also arises in him. What is the cause of this 
complication? 
A. Antioxidant effect of glucocorticoids. 
B. Anti-shock effect of glucocorticoids. 
C. Anti-inflammatory effect of glucocorticoids. 
D. Antiallergic effect of glucocorticoids. 
E. Immunosuppressive effect of glucocorticoids. 
46. The increased glucose blood concentration is revealed in a 
patient with neurodermatitis which is using dexamethasone for a long 
time. Identify the metabolic effect of glucocorticoids which results in 
this complication. 
A. Activation of gluconeogenesis.  
B. Increase of glucose absorption in intestine. 
C. Inhibition of glycogen synthesis. 
D. Increase of insulin degradation. 
E. Activation of glycogen synthesis. 
47. A patient uses prednisolone in tablets for treatment with 
bronchial asthma. Doctor recommends to replace prednisolone by 
dexamethasone. How many times should be less the dose of 
dexamethasone in comparison with prednisolone? 
A. 4 times. 
B. 20 times. 
C. 2 times. 
D. 7 times. 
E. 50 times. 
48. In a 43-year-old patient the glucose is determined in urine 
for the first time. Which drug should be prescribed to him? 
A. Saccharose. 
B. Butamide. 
C. Oxytocin. 
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D. Allopurinol. 
E. Vasopressin. 
49. A 38-year-old woman went to the Cancer Centre with tumor 
of the breast. After mastectomy doctor prescribes to woman 
antitumoral hormonal drug. Identify this drug.  
A. Testosterone. 
B. Myelosanum. 
C. Sarcolysin. 
D. Progesterone. 
E. Fosfestrol. 
50. A doctor administers prednisolone for increase of blood 
pressure in patient with acute vessels insufficiency. Why 
glucocorticoids increase blood presse? 
A. Glucocorticoids cause redistribution of blood in organism. 
B. Glucocorticoids cause retention of water in organism. 
C. Glucocorticoids directly stimulate alpha-adrenergic receptors 
of vessels. 
D. Glucocorticoids decrease the sensitivity of cholinoreceptors 
to acetylcholine. 
E. Glucocorticoids increase sensitivity of adrenergic receptors to 
catecholamines. 
51. A doctor prescribes finasteride (Proscar) to patient with 
benign hyperplasia of the prostate. What is the mechanism of 
antiandrogenic action of this drug? 
A. Blockage of androgenic receptors. 
B. Inhibition of androgens synthesis. 
C. Inhibition of androgens secretion. 
D. Inhibition of enzyme 5-alpha-reductase which promotes the 
transformation of testosterone into the dihydrotestosterone. 
E. Inhibition of gonadotropin synthesis. 
52. A 65-year-old woman has applied to orthopedic department 
with complaints of pain in the left leg. Medical examination has 
found the symptoms of osteoporosis and aseptic necrosis of femoral 
head. Which drug should be prescribed for treatment of this woman? 
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A. Cyanocobalamin. 
B. Calcitonin. 
C. Ergocalciferol. 
D. Calcium gluconate. 
E. Methionine. 
53. A 60-year-old patient is suffering from diabetes mellitus and 
receiving insulin semilente for correction of hyperglycemia. 10 days 
ago, he began treatment of hypertensive disease with certain drug. In 
an hour after drug intake, hypoglycemic coma is developed in the 
patient. Which of the following drug can cause this complication? 
A. Nifedipine. 
B. Anaprilinum. 
C. Verapamil. 
D. Captopril. 
E. Prazosin. 
54. A 60-year-old patient is suffering from diabetes mellitus and 
receiving insulin-semilente for correction of hyperglycemia. 10 days 
ago, he began treatment of hypertensive disease with anaprilinum. In 
an hour after drug intake, hypoglycemic coma is developed in the 
patient. What is the mechanism of this complication development? 
A. Increase of insulin-semilente bioavailability. 
B. Inhibition of glycogenolysis. 
C. Increase of insulin-semilente half-life. 
D. Decrease of glucose absorption. 
E. Decrease of glucagon release. 
55. A 60-year-old patient is suffering from diabetes mellitus and 
receiving insulin semilente for correction of hyperglycemia. 10 days 
ago, he began treatment of hypertensive disease with anaprilinum. In 
an hour after drug intake, the patient felt weakness, dizziness, drop of 
blood pressure. The patient lost consciousness in several minutes. 
Which pathological condition is developed in the patient? 
A. Acute vessels insufficiency.  
B. Hyperglycemic coma. 
C. Hypoglycemic coma. 
D. Acute disturbance of cerebral blood flow. 
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E. Cardiogenic shock. 
56. A 60-year-old patient is suffering from diabetes mellitus and 
receiving insulin-semilente for correction of hyperglycemia. 10 days 
ago, he began treatment of hypertensive disease with anaprilinum. In 
an hour after drug intake, the patient felt weakness, dizziness, drop of 
blood pressure. The patient lost consciousness in several minutes. 
Which drug should be administered to the patient for primary care? 
A. Bemegride. 
B. Glucose. 
C. Noradrenaline. 
D. Sodium bicarbonate. 
E. Insulin. 
57. A woman who for some time has been treated for chronic 
polyarthritis complains of blood pressure increase, redistribution of 
fat, and menstrual disturbances. Choose the drug which is taken by 
woman. 
A. Beclomethasone. 
B. Indomethacin. 
C. Butadione. 
D. Prednisolone.  
E. Synaflan. 
58. A patient with recurrent allergic dermatitis needs the 
appointment of glucocorticoid. Choose the drug which has local 
influence upon the skin without systemic side effects.  
A. Triamcinolone. 
B. Prednisolone. 
C. Hydrocortisone. 
D. Dexamethasone. 
E. Synaflan. 
59. Hypoglycemic coma is developed in patient owing to 
overdose of insulin. Which drug should be administered to its 
elimination?  
A. Glucose.  
B. Lente insulin. 
C. Prednisolone. 
D. Glucagon. 
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E. Tolbutamide. 
60. A 60-year-old woman during long time uses dexamethasone 
for treatment of arthritis. What is the mechanism of anti-
inflammatory effect of this drug?  
A. Blockage of folate reductase. 
B. Blockage of cyclooxygenase-1. 
C. Blockage of cyclooxygenase-2. 
D. Blockage of phospholipase A2. 
E. Blockage of folate synthetase. 
61. A 9-year-old child with multiple caries receives calcitonin. 
Which therapeutic effect of drug is used in this case? 
A. Increase of saliva pH. 
B. Inhibition of glycolysis.  
C. Activation of osteoblasts. 
D. Increase of fluor concentration in oral cavity. 
E. Decrease of glucose concentration on oral cavity. 
62. A patient with diabetes mellitus receives injections of 
thiamine for correction of metabolic acidosis. What is the mechanism 
of therapeutic action of vitamin B1 in this case? 
A. Increase of adrenaline synthesis. 
B. Activation of adenylyl cyclase. 
C. Blockage of phosphodiesterase. 
D. Increase of acetylcholine synthesis. 
E. Activation of the Krebs cycle dehydrogenases. 
63. Owing to sudden cessation of glucocorticoid intake, the 
following complications develop in patient: aggravation of 
rheumatoid arthritis, decrease of blood pressure, and weakness. What 
is the cause of these complications?  
A. Cumulation. 
B. Insufficiency of adrenal cortex.  
C. Sensibilisation. 
D. Hypersecretion of adrenocorticotropin. 
E. Development of tolerance. 
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64. A 25-year-old pregnant woman is admitted to the pregnancy 
pathology department with threatened abortion. Which drug should 
be prescribed to the woman?  
A. Synoestrol.  
B. Folliculin. 
C. Progesterone.  
D. Estradiol. 
E. Retabolil. 
65. A patient after subtotal resection of thyroid gland receives 
drug of substitute therapy. What is the name of this drug? 
A. Potassium perchlorate. 
B. Potassium iodide. 
C. Mercazolil. 
D. Thyroxine.  
E. Antistrumin. 
66. A 65-year-old patient with non-insulin-dependent diabetes 
mellitus receives glibenclamide perorally. What is the mechanism of 
glibenclamide action? 
A. Drug inhibits degradation of polysaccharides. 
B. Drug inhibits gluconeogenesis in liver. 
C. Drug increases the use of glucose by peripheral tissues. 
D. Drug suppresses absorption of glucose in intestine. 
E. Drug stimulates the release of insulin by beta-cells of 
pancreas. 
67. Pituitrin was administered to woman with weak labor. 
Indicate hormones which are contained in this drug? 
A. Vasopressin and progesterone.   
B. Oxytocin and vasopressin. 
C. Oxytocin and progesterone. 
D. Vasopressin and estradiol. 
E. Oxytocin and estradiol. 
68. A 47-year-old patient with thyrotoxicosis receives drug 
which inhibits the synthesis of thyroid hormones in thyroid gland. 
Choose this drug. 
A. Radioactive iodine. 
B. Diiodotyrosine. 
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C. Mercazolil. 
D. Thyroidin. 
E. Potassium iodide. 
69. A 45-year-old patient complains of constant thirst, marked 
polyuria. The glucose level in plasma is 5 mmol/L. There is no 
glucose in urine. Which drug should be prescribed for treatment of 
this patient? 
A. Prednisolone. 
B. Adiurecrinum. 
C. Desoxycorticosterone. 
D. Hydrocortisone. 
E. Insulin. 
 
 
ANTIALLERGIC DRUGS 
 
Allergy is an immunologic reaction caused by the action of the 
antigen, which is accompanied by different functional and structural 
disorders in body tissues. 
Both humoral and cell-mediated immunity participate in allergic 
reactions.  
Humoral immunity is directed against extracellular antigens. 
Five types of antibodies (immunoglobulins) participate in humoral 
immunity: IgG, IgM, IgA, IgD, and IgE. These immunoglobulins are 
synthesized by plasmocytes (B-lymphocytes transformed under 
antigen influence). 
Cell-mediated immunity is directed against intracellular and 
fungal infections, cancer cells, and intracellular parasites.  
Cell-mediated immunity is closely associated with T-lymphocytes. 
T-lymphocytes are devided into T-killers (kill cells which bind with 
antibodies), T-helpers (cells with cooperative function),  
T-producents of lymphokines, and T-suppressors (participate in 
formation of immune tolerance). 
Monocytes and macrophages also produce biologically active 
substances regulating and increasing immunity. These substances are 
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named cytokines. Cytokines influence inflammation and exert 
antibacterial, antitumoral, and antiproliferative effects. 
Allergic reactions are divided into allergic reactions of an 
immediate type and allergic reactions of a delayed type. 
There are 3 stages in pathogenesis of allergic reactions: 
immunological, pathochemical, and pathophysiological. 
Immunological stage develops during the initial penetration of 
an allergen in the body and its interaction with antibodies and  
T-lymphocytes (at repeated penetration in the body). During this 
stage, sensitization of the body occurs.  
Pathochemical stage is a period from an allergen interaction with 
immunity effectors to synthesis of biologically active substances – 
mediators of allergic reactions. 
Pathophysiological stage develops when mediators act on body 
cells and tissues that is accompanied by development of structural 
and functional disorders with corresponding clinical symptoms.  
To treat allergic reactions, it is necessary to determine allergen 
initially. Removal of the allergen gives the best result. If it is 
impossible, the specific hyposensitization is used. With this end in 
view, small doses of allergen are administered in the body that leads 
to decrease of body sensitivity to this allergen. 
Antiallergic drugs are used fot pathogenetic treatment of allergic 
reactions. These drugs are classified as follows.  
1. Drugs which are used to treat immediate-type allergy. 
1.1. Glucocorticoids: hydrocortisone, prednisolone, 
methylprednisolone, and dexamethasone . 
1.2. Antagonists of H1-histamine receptors: diprazinum, 
diphenhydramine   (Dimedrol), quifenadine (Phencarol),  
diazolinum, chloropyramine (Suprastin), and loratadine 
(Claritin) , etc.  
1.3. Stabilizers of membranes of tissue basophils: cromolyn 
sodium (Intal) and ketotifen (Zaditen) .  
1.4. Inhibitors of leukotriene receptors: zafirlukast  
(Accolate), montelukast  (Singulair), etc.  
1.5. 5-Lipoxygenase inhibitors: zileuton .  
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1.6. Inhibitors of fibrinolysis: aminocaproic acid , etc.    
1.7. Drugs decreasing the manifestations of allergic reactions:  
– adrenomimetics: adrenaline,  ephedrine,  mesatonum , 
etc.;  
– antagonists of M-cholinergic receptors: atropine, 
metacinium , etc;  
– myotropic spasmolytics: euphyll in , etc;  
– steroid and non-steroid anti-inflammatory drugs.  
2. Drugs used to treat delayed-type allergy.  
2.1. Immunosuppressive drugs: cytostatic agents, 
glucocorticoids, and “minor” immunosuppressants. 
2.2. Drugs reducing damage of tissues: steroid and non-steroid 
anti-inflammatory agents.   
 
Drugs Used to Treat Immediate-Type Allergy 
 
Glucocorticoids  
 
Glucocrticoids are hydrocortisone, prednisolone, 
dexamethasone, methylprednisolone, etc. These drugs inhibit 
protein synthesis in a body and, due to this, decrease synthesis of 
immunoglobulins that leads to decrease of formation of antigen-
antibody complex. 
Besides, glucocorticoids block Fc-receptors of basophils 
membranes that results in reduction of phospholipase A2 activity and 
decrease of calcium entrance in basophils. Due to this, the secretion 
of histamine, serotonin, SRS-A (slow-reacting substance of 
anaphylaxis) is reduced. Also, glucocorticoids sensibilize adrenergic 
receptors to catecholamines. 
Prednisolone, prednisone, and methylprednisolone are most 
commonly used glucocorticoids in clinical practice. Other drugs are 
used less often due to serious side effects. Even though triamcinolone 
has little influence upon water-salt balance, this agent causes weight 
loss, weakness, muscular atrophy, ulcer disease, and rush of blood to 
the head. Dexamethasone causes significant water retention and 
circulatory failure. 
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Most often, glucocorticoids are prescribed for oral intake. Its 
effect lasts 6–8 hours. At intramuscular or intravenous 
administration, drug effect lasts 2–3 hours. Presently, prolonged 
medicinal forms of betamethasone (Celestone) and triamcinolone are 
used for oral and parenteral administration. Also, inhaled forms of 
betamethasone are used treat moderate bronchial asthma. Herewith, 
the drug exerts mainly local influence upon bronchi with low 
frequency of side effects. 
Glucocorticoids are used to treat the following immediate-type 
allergic reactions:  
– status asthmaticus (prednisolone intravenously); 
– anaphylactic shock (prednisolone with adrenaline 
intravenously);  
– moderate bronchial asthma (drugs administered in inhalations).       
 
Histamine H1-Receptor Antagonists  
 
Nowadays, 4 types of histamine receptors are known. 
Stimulation of histamine H1-receptors leads to contraction of smooth 
muscles of internal organs, increased vascular permeability, tissue 
oedema, pain, and itch. Stimulation of histamine H2-receptors is 
accompanied by the increase of gastric secretion, vasorelaxation, and 
tachycardia. Stimulation of H3-receptors results in contraction of 
smooth muscles of gastrointestinal tract and bronchi, increased 
vascular permeability, and activation of T-lymphocytes, neutrophils, 
and eosinophils.  
Histamine H1-receptor antagonists block H1-receptors and 
reduce or eliminate the following effects of histamine: 
bronchoconstriction, intestinal spasms, uterine spasm, hypotension, 
increased vascular permeability, itch, tissue oedema, and erythema.  
Histamine H1-receptor antagonists are classified as follows.  
– I generation: diphenhydramine (Dimedrol), clemastine 
(Tavegyl), chloropyramine (Suprastin),  mebhydrolin 
(Diazolin),  promethazine (Diprazin, Pipolphen),  
quifenadine (Phencarol).  
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– II generation: terfenadine (Seldane),  astemizole  
(Hismanal),  loratadine (Claritin) .  
– III generation: levocetirizine, desloratadine, 
norastemizole .    
The drugs of II and III generations exert higher efficacy and 
selectivity, longer duration of action, and do not influence central 
nervous system. 
Histamine H1-receptor antagonists block only free histamine 
receptors. These drugs do not replace histamine binding with 
receptors. It is due to higher affinity of histamine to receptors in 
comparison with these drugs.  
Histamine H1-receptor antagonists are also characterized by 
some other pharmacological properties. Diprazin, Dimedrol, and 
Suprastin exhibit marked sedative and hypnotic influence on central 
nervous system. Besides, these drugs exert M-cholinoblocking 
activity. Also, Diprazin potentiates th effects of general anaesthetics, 
opioid analgesics, and local anaesthetics. Diprazin influences 
termoregulation and decreases the body temperature. Diprazin and 
Dimedrol exhibit local anaesthetic effect. Dimedrol blocks impulse 
transmission through vegetative ganglia that results to relaxation of 
smooth muscles of internal organs. Diprazin exerts α-adrenoblocking 
activity that decreases blood pressure, especially in case of 
intravenous administration. Diprazin, Dimedrol, and Suprastin exert 
direct moderate antispasmodic effect. 
Histamine H1-receptor antagonists are taken orally or 
administered intravenously and intramuscularly. In case of oral 
intake, the bioavailability of the I-generation drugs is about 40 %, 
because these drugs undergo metabolism at first pass through a liver. 
Bioavailability of II-generation drugs is above 90 %. A rate of 
binding with plasma proteins of histamine H1-receptor antagonists is 
about 90 %. In oral intake, onset of drug effect is 20–40 minutes. 
Duration of action of I-generation drugs is 4–6 hours. These drugs 
are taken 3–4 times a day (except Tavegyl which is taken 2 times 
a day). Therapeutic concentration of II-generation drugs remains in 
a body up to 20 hours. These drugs are taken once a day.  
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Most drugs of I generation (except Diazolin and Phencarol) 
easily penetrate through blood-brain barrier. II-generation drugs 
practically do not penetrate central nervous system. 
Histamine H1-receptor antagonists andergo hepatic metabolism 
by way of methylation. Main routes of drug excretion are kidneys 
and liver.  
Therapeutic indications for histamine H1-receptor antagonists 
are the following.  
1. Allergic reactions of immediate type: urticaria, allergic 
rhinitis, angioedema, itch, and neurodermatitis. 
2. Insomnia (Dimedrol and Diprazin are mainly used). 
3. Premedication (Diprazin and Dimedrol).  
4. Motion sickness (Dimedrol).  
5. Complex treatment of bronchial asthma, anaphylactic shock, 
and acute pulmonary oedema.  
6. Traumas of skin and soft tissues (to prevent histamine 
effects).   
7. Potentiation of analgesic effects of non-steroidal anti-
inflammatory drugs (Dimedrol). 
Most often side effects of histamine H1-receptors antagonists 
include dry mouth, constipation, tachycardia, accommodation 
disorders, drowsiness, and decreased attention span. These effects 
develop due to M-cholinoblocking and sedative activity of these 
drugs. Besides, Dimedrol exerts ganglion blocking activity and can 
lower blood pressure. Diprazin also lowers blood pressure due to 
blockage of α-adrenergic receptors. Some drugs (especially Diprazin 
and Diazolin) irritate mucous membrane of the stomach that results 
in dispepsia. Dimedrol increases seizure brain activity; therefore, the 
drug can provoke the convulsions in patients with epilepsy and 
encephalopathy. Drugs with sedative effect should be avoided in 
patients whose profession requires attention and fast psychomotor 
reactions.  
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Stabilizers of Membranes of Tissue Basophils  
 
This group is represented by cromolyn sodium (Intal)  and 
ketotifen (Zaditen). These drugs block calcium entering tissue 
basophils that results in histamine release inhibition. These drugs 
exert only preventive anti-allergic effect. 
Cromolyn sodium is administered by inhalation to treat 
bronchial asthma. For inhalation, a special capsule with finest 
powder of cromolyn sodium is placed in the Spinhaler™. 
Therapeutic effect develops gradually: in 2–4 weeks of everyday 
inhalations 4 times a day. Also, cromolyn sodium is used in the 
treatment for allergic rhinitis, conjunctivitis, and enteritis. 
Ketotifen also exhibits moderate ability to block histamine  
H1-receptors. The drug is taken orally 2 times a day. Ketotifen is 
readily absorbed from gastrointestinal tract. Therapeutic indications 
for ketotifen are bronchial asthma, allergic rhinitis, conjunctivitis, 
dermatitis, and alimentary allergy. Stable therapeutic effect develops 
in 10–12 weeks. Side effects develop seldom and include drowsiness 
and increased appetite. 
It should be noticed that phosphodiesterase inhibitors 
(euphyllin), glucocorticoids (prednisolone, beclomethasone, etc.),  
β2-adrenomimetics (salbutamol, fenoterol, etc.) are groups of drugs 
which also inhibit histamine release from basophils.  
 
Leukotriene Receptor Antagonists  
 
Zafirlukast  (Accolate), and montelukast  (Singulair) are 
drugs which block leukotriene C4, D4, and E4 CysLT1-receptors.  
Zafirlukast reduces bronchoconstriction, decreases the vascular 
permeability, and inhibits the bronchial secretion. The drug is taken 
orally in dose 0.02 g twice a day to prevent bronchial asthma attacks. 
Stable therapeutic effect develops in 1 week after initiation of 
therapy. 
Montelukast acts longer and is taken once a day.  
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5-Lipoxygenase Inhibitors  
 
Zileuton  blocks 5-lipoxygenase – enzyme catalyzing synthesis 
of leukotrienes from arachidonic acid. The drug is used to treat 
bronchial asthma. Zileuton is especially effective in aspirin-induced 
asthma, which is a complication of non-steroid anti-inflammatory 
drugs.  
 
Drugs Reducing Manifestations of Allergic Reactions  
 
Variety of chemical messengers of allergy and deficiency of 
their antagonists require to use functional antagonists of allergy 
mediators in the treatment of allergic reactions. A choice of 
antagonists is determinated by character of allergic reaction. Usually, 
functional antagonists of allergy mediatirs, antihistaminergic drugs, 
and drugs of basic therapy inhibiting release of mediators are used 
simultaneously.    
At muscle spasms of the gastrointestinal tract (allergic enteritis, 
colitis, etc.), antagonists of M-cholinergic receptors (atropine , etc.) 
and myotropic antispasmodic drugs (No-spa , etc.) are drugs of 
choice. Loperamide (Imodium) and bismuth  subsalicylate  
(Pepto-Bismol) are used to cessate diarrhea. Also, H1-histamine 
blockers (dimedrolum , etc.) are used in the treatment for allergic 
enteritis and colitis.  
At bronchial asthma, β-adrenomimetics (isadrinum, 
salbutamol , etc.), antagonists of M-cholinergic receptors 
(ipratropium bromide (Atrovent), traventol , metacinium , 
etc.), myotropic antispasmodic drugs (euphyllinum , etc.), 
glucocorticoids (prednisolone, beclomethasone , etc.), and 
stabilizers of the basophile cell membranes (cromolyn sodium, 
ketotifen , etc.) are used. 
At cutaneous manifestations of allergy, histamine H1-receptor 
antagonists are drugs of choice. Glucocrticoids are used in the 
treatment for generalized severe cutaneous manifestations. Besides, 
non-steroid anti-inflammatory drugs are applied topically. 
Antibacterial and antifungal drugs are prescribed if allergy is 
aggraveted by bacterial or fungal infection. 
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Local α-adrenomimetics (naphthyzinum , etc.) and histamine  
H1-receptor antagonists are used in the treatment for allergic rhinitis. 
To prevent allergic rhinitis, stabilizers of the basophile cell 
membranes are used. 
Nowadays, co-formulated drugs containing H1-histamine 
receptor antagonists and pseudoephedrine are approved in the 
treatment for allergic rhinitis, laryngitis, and other allergic diseases 
of respiratory tract. Clarinase  is a representative of such drugs. 
Pseudoephedrine is an indirect adrenomimetic. The drug causes 
vascular spasm due to stimulation of α-adrenergic receptors. It is 
accompanied by reduced swelling of respiratory mucous membrane. 
Pseudoephedrine has insignificant influence upon heart rate, blood 
pressure, and central nervous system.  
Anaphylactic shock is a most dangerous immediate-type allergic 
reaction. Therapy of anaphylactic shock is directed to immediate 
elimination of cardiovascular collapse, respiratory disorders, 
hypovolemia, and convulsions. Adrenaline  is a drug of choice to 
treat anaphylactic shock. About 0.3–0.5 ml 0.1 % adrenaline solution 
is administered subcutaneously or intramuscularly with intervals of 
5–15 minutes under blood pressure control. Maximum dose of 
adrenaline is 2 ml. Adrenaline is an antagonist of different chemical 
messengers of anaphylaxis influencing smooth muscles. Besides, 
intravenous drop-by-drop administration of dopamine  or 
noradrenaline  with isotonic sodium chloride (glucose) solution is 
performed. Large-dose glucocorticoid (prednisolone , up to 
100 mg), calcium chloride , and histamine H1-receptor antagonist 
(dimedrolum) are also administered. If necessary, diazepam, 
strophanthin , and furosemide  are prescribed. Mortality due to 
anaphylactic shock is within 10–60 %. Anaphylactic shock recurs in  
12–15 % patients due to retaining of antigen in the body. Therefore, 
close monitoring of patient condition is necessary for several days. 
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Drugs Used to Treat Delayed-Type Allergy  
 
Immunosuppressive Drugs  
 
Immunosuppressive drugs are divided info the following groups.  
1. Cytostatics: cyclosporine, azathioprine, methotrexate,  
mercaptopurine , etc. 
2. Glucocrticoids: prednisolone, methylprednisolone, 
dexamethazone, beclomethazone, etc.  
3. “Minor” immunosuppressants: chloroquine, gold-
containing drugs (auranofin, aurotioprol , sodium 
aurothiomalate  (Myokrisin, Tauredon), penisillamine.  
Immunosuppressive drugs are used for pathogenetic therapy of 
severe manifestations of delayed hypersensitivity reactions. Mainly, 
these drugs are used to treat rheumatic diseases (rheumatoid arthritis, 
systemic lupus erythematosus, periarteritis nodosa, scleroderma, 
etc.), immune destruction of central nervous system, kidneys, and 
other autoimmune diseases. Immunosuppressive drugs are also used 
to inhibit graft rejection. 
Lymphocytes play a major role in delayed hypersensitivity. Due 
to many receptors, lymphocytes recognize antigens and provide the 
specific reaction of the immune system. In this process, of great 
importance is interleukin-1 which is produced by monocytes-
macrophages (cells which perform phagocytosis and antigen 
processing). Interleukin-1 activates T-helpers. Activated T-helpers 
produce specific cytokines – lymphokines, such as interleukin-2 
(main mediator of the immune system regulating all phases of 
immune response), γ-interferon, etc. Interleukin-2 controls 
proliferation of T-killers, T-suppressors, and T-helpers. Besides, 
interleukin-2 promotes proliferation of B-lymphocytes producing 
different types of antibodies (immunoglobulins М, G, A, D, E). 
Further interaction of immunoglobulins with antigens results in 
autoimmune diseases. 
The basis of immunosuppressants’ efficacy is their ability to 
influence the key stages of the immune response.   
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Cytostatics  
 
This group is represented by such drugs as cyclosporine, 
tacrolimus, azathioprine, methotrexate, mercaptopurine, 
cyclophosphamide , etc. Cytostatics are used in the treatment for 
severe forms of rheumatoid arthritis, systemic lupus erythematosus, 
and other autoimmune diseases in cases when other drugs are 
ineffective.  Also, these drugs are used to inhibit graft rejection. 
Cyclosporine  is an antibiotic consisting of 11 amino acids. 
Cyclosporine inhibits peptide synthesis and proliferation of T- and  
B-lymphocytes. Peculiarity of the drug is its ability to reversible 
selective inhibition of early stages of cellular immune response. 
Cyclosporine inhibits ability of T-helpers to produce interleukin-2 
and γ-interferon. It results in a reduction of killer T-cell formation. In 
contrast with other cytostatics, cyclosporine does not inhibit 
hemopoiesis and proliferation of gastrointestinal mucosa. 
Cyclosporine is mainly used to inhibit graft rejection (after 
transplantation of bone marrow, kidneys, liver, heart, etc.). Besides, 
the drug is used in the treatment for autoimmune diseases. It should 
be noticed that cyclosporine exerts marked nephrotoxicity and can 
inhibit hepatic function. Besides, cyclosporine can cause infertility, 
hair loss, nausea, and vomiting. 
Tacrolimus (Prograf)  is an antibiotic of macrolide group. 
The drug inhibits activation of T-lymphocytes and reduces 
interleukin-2 production. Immunodepressive activity of tacrolimus is 
100 times more than those of cyclosporine. The drug is used to 
inhibit graft rejection. Side effects of tacrolimus are nephrotoxicity, 
neurotoxicity, hypertension, dyspeptic disorders, etc. 
The properties of azathioprine  are similar to mercaptopurine, 
but this drug is less toxic. In a body, azathioprine is converted into  
6-mercaptopurine. This metabolite inhibits the proliferation of  
T-lymphocytes. Therapeutic indications for azathioprine are 
autoimmune diseases (rheumatoid arthritis, systemic lupus 
erythematosus, etc.) and inhibition of graft rejection. Azathioprine 
inhibits the function of bone marrow that results in leukopenia, 
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anemia, and thrombocytopenia. Dyspeptic disorders and toxic 
damage of liver are also possible.        
Cyclophosphamide, methotrexate , and mercaptopurine  
are also used as immunosuppressive drugs. These agents block 
cellular proliferation of cells, including B- and T-lymphocytes, and 
slow down the protein synthesis. The drugs exert different 
mechanisms of action. Thus, cyclophosphamide crosslinks DNA 
helices and affects the normal DNA structure that results in disorders 
of replication and cell division. Methotrexate is folic acid antagonist 
and affects synthesis of purines and pyrimidines. Mercaptopurine is a 
competitor of natural purine nucleotides.                                                                                                                                                                                
Serious disadvantages of cytostatics are:  
– cytotoxic effect concerning tissues with high rate of 
physiological regeneration (inhibition of hemopoiesis with anemia, 
leukopenia, and thrombocytopenia; slowdown of regeneration of 
gastrointestinal mucosa, etc.); 
– reduction of body resistance to viruses, bacteria, and fungi;  
– nephro- and hepatotoxicity. 
It is advisable to combine cytostatic therapy with intake of 
nonsteroid and steroid anti-inflammatory drugs.  
 
Glucocorticoids  
 
Glucocorticoids (prednisolone, dexamethazone, 
triamcinolone , etc.) exert marked immunosuppressive effect. 
These drugs inhibit proliferation of T- and B-lymphocytes. 
Glucocrticoids influence macrophages and violate antigen 
recognition. Also, glucocorticoids inhibit production of interleukin-2, 
γ-interferon, and factor inhibiting migration of macrophages. 
Glucocorticoids suppress cytotoxicity of T-killers. High doses of 
glucocorticoids inhibit immunoglobulins synthesis by plasma cells. 
Besides, glucocorticoids exert fast and marked anti-inflammatory 
effect. 
Combination of immunosuppressive and anti-inflammatory 
effects promotes the high efficacy of glucocorticoids in therapy of 
different autoimmune diseases. Glucocrticoids are used in the 
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treatment for rheumatoid diseases, other autoimmune processes, and 
to inhibit graft rejection. 
After kidney transplantation, muromonab-CD3 (Orthoclone 
OKT3)  is used to prevent graft rejection. This drug is preparation of 
monoclonal antibodies which selectively inhibit T-lymphocytes.  
 
“Minor” Immunosuppressants  
 
This group includes such drugs as chloroquine , gold 
preparations (auranofin, aurotioprol,  sodium 
aurothiomalate  (Myokrisin, Tauredon),  etc.), and 
penicil lamine . “Minor” immunodeppressants are drugs for 
baseline therapy of collagenosis. Most commonly, these drugs are 
used in treatment of such diseases as rheumatoid arthritis, systemic 
lupus erythematosus, etc. The drugs inhibit cellular and humoral 
immunity and suppress inflamation (mainly in proliferation phase). 
Chloroquine  stabilizes lysosomal and cellular membranes, 
inhibits phagocytosis, decreases synthesis of interleukines 1 and 2, 
inhibits proliferation of T-lymphocytes and cells of connective 
tissues in rheumatoid lesions, and destroys collagen synthesis.  
Anti-inflammatory activity of chloroquine is less than the those of 
penicillamine and gold preparations. But chloroquine exerts low 
toxicity. Drug effect develops in 10–12 weeks after the initiation of 
therapy. 
Auranofin, aurotioprol, sodium aurothiomalate  
(Myokrisin,  Tauredon),  etc. are gold-containing preparations. 
These drugs are accumulated in rheumatoid lesions of joints, inhibit 
macrophagal function, and reduce blood concentrations of 
immunoglobulins and rheumatoid factor that results in the decrease 
of joint damage. Aurotioprol is administered intramuscularly 1 time 
in 2–5 days. Its effect develops in 6 months after therapy initiation. 
Gold preparations are characterized by high nephro- and 
hematotoxicity.      
Penicillamine  interacts with rheumatoid factor and destroys it. 
Besides, the drug affects collagen maturation and suppresses 
proliferation of T-lymphocytes. Penicillamine forms the complexes 
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with bivalent metals. Thus, complexation with copper is 
accompanied by neutralization of active oxygen radicals which 
support the autoimmune processes and inflammation. Penicillamine 
is taken orally according to scheme. The drug efficacy may be 
estimated within 9–15 months after initiation of therapy. 
Penicillamine is toxic drug which can cause nausea, vomiting, 
diarrhea, hypertermia, renal dysfunction, skin redness, etc.  
 
 
IMMUNOMODULATORS 
 
Immunomodulators are drugs which normalize cellular and 
humoral immunity. Drugs are used in the treatment for diseases 
developing due to immune dysfunction: immunodeficiency states, 
chronic infections, and oncological diseases. 
Immunomodulators are classified as follows. 
1. Preparations of thymus: thymalin,  thymoptin,  
tactivinum, vilosenum .  
2. Synthetic drugs: levamisole,  dibazolum  (bendazole),  
pentoxyl , methyluracil, bemethyl . 
3. Agents of microbial origin: Ribomunyl , bronchomunal ,  
pyrogenalum, prodigiozan, BCG vaccine, poludanum, 
licopid,  Ismigen, IRS-19 .    
4. Cytokines (preparations of lymphokines that are produced by 
lymphocytes): interferon α, interferon α-2a, interferon  
α-2b ,  interferon β , interferon β-1b ,  interferon γ ,  
interleukin-1 (betaleukin),  interleukin-2 (proleukin),  
reaferon, roncoleukin . 
5. Drugs of plant origin: preparations of echinacea, 
ginseng, eleutherococcus , etc.  
Thymus produces about 8–10 hormones promoting maturation 
of lymphocytes and regulation of different stages of immune 
response. Thymalin, thymoptin,  tactivinum, vilosenum , etc. 
are extracted from thymus and contain several thymus hormones. 
Thymus preparations restore the activity of the immune system at its 
inhibition or disfunction. These drugs activate both humoral and 
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cellular immunity, phagocytosis, tissue regeneration, and 
hemopoiesis. 
Thymalin and tactivinum are used in the treatment for indolent 
viral, bacterial, and fungal infections; burn disease; sores; bedsores; 
radiation damage, etc. Thymalin is administered intramuscularly 
during 5–20 days, tactivinum – subcutaneously. Vilosenum is 
applied intranasally to treat rhinitis and sinusitis. 
Synthetic drugs influence membrane receptors of lymphocytes 
which are sensitive to neurohumoral regulation including influence 
of thymus hormones.      
Levamisole  increases the cell sensitivity to thymus hormones 
and stimulates cellular and humoral immunity and phagocytosis. Also, 
levamisole stimulates the proliferation of T-lymphocytes and 
production of interleukins and interferons. The drug is taken 1–2 times  
per week. The course of treatment lasts from 2–3 weeks up to 1 year. 
Toxicity of levamisole is high. Levamisole therapy is accompanied by 
gastrointestinal dysfunction, agranulocytosis, insomnia, etc.  
Dibazolum  (bendazole) activates nonspecific body resistance 
and phagocytosis, increases synthesis of antibodies, interferons, and 
other mediators of immunity. Its immunomodulating effect develops 
gradually. The drug is used to prevent infectious diseases. 
Bemethyl  activates protein synthesis and energy production in 
tissues including cells of immune system. The drug increases 
synthesis of antibodies and stimulates T-lymphocytes activity and 
macrophagal function. Bemethyl is used in the treatment for viral 
hepatitis, recurrent respiratory infections, recurrent erysipelas, 
pyoderma, etc.  
Pentoxyl  and methyluracil  are widely used to accelerate 
wound healing, to stimulate cellular or humoral immunity and 
leukopoiesis.   
Licopid  is a synthetic immunomodulator. Molecules of licopid 
contains glucosaminyl-muramyl-dipeptide (GMDP). GMDP is the 
component of almost all bacterial cell walls. Therefore, licopid 
stimulates phagocytosis, activates T- and B-lymphocytes, increases the 
synthesis of interferons, interleukins, the tumor necrosis factor, 
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antibodies, and other mediators of immunity. Licopid is intended for 
treatment of chronic infectious diseases.   
Prodigiozan  is the lipopolysaccharide complex obtained from 
bacteria. Ribomunyl  contains fragments of bacterial membranes. 
Both drugs stimulate cellular and humoral immunity, increase 
synthesis of interferons and nonspecific organism resistanse. Drugs 
are used to treat infectious diseases (sinusitis, dysentery, hepatitis B, 
sepsis, pneumonia, bronchitis, rhinitis, osteomyelitis, etc.) in patients 
with immunodeficiency. Prodigiozan is administered intramuscularly 
1 time for 3–5 days. Ribomunyl is taken orally according to a dosing 
regimen.    
BCG vaccine  is used to prevent tuberculosis. Besides, it is 
used in the complex treatment for malignant tumours. BCG vaccine 
stimulates macrophages and T-lymphocytes. Therapeutic effect of 
BCG vaccine is observed in myeloid leukemia, some lymphoma, 
cancer of intestine and mammary gland, bladder, etc. 
Bronchomunal  is a hydrolysate of 8 microbial species most 
common causative agents of respiratory infections. Bronchomunal 
stimulates the activity of macrophages, and T-helpers. Besides, the 
drug increases concentration of immunoglobulin A and synthesis of 
interleukin-2 and γ-interferon. Bronchomunal is used to prevent and 
treat respiratory infectious.  
Interferons  are used as antiviral drugs. γ-Interferon exerts less 
influence upon viral infections, but higher influence upon deep 
regulation of immune response. γ-Interferon inhibits phagocytosis, 
stimulates activity of T-killers, and modulates the antibodies’ 
synthesis. γ-Interferon is used in the treatment for tumoral diseases, 
chronic viral and fungal infections, rheumatoid arthritis, and other 
collagenosis. 
Betaleukin (interleukin-1β) is intended to treat leukopenia, 
thrombocytopenia, and lymphopenia in oncological patients after 
intensive chemo- and radiation therapy.   
Roncoleukin  is recombinant interleukin-2. The drug is used in 
the treatment for chlamidiasis, malignant tumors, pyoinflammatory 
diseases, bacterial, viral and fungal infections.  
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Immunomodulators of plant origin stimulate cellular immunity 
and phagocytosis, promote release of interferons, and increase 
nonspecific body resistance. These drugs are used to prevent and 
treat respiratory infections, influenza, etc.     
     
Table 13 – Drugs for prescription 
  
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product  
Acidum 
acetylsalicylicum 
Orally 0.25–1.0 g 3–4 times 
a day 
Tablets 0.1; 0.25 or 0.5 g 
Analginum Orally 0.25–0.5 g 2–3 times 
a day; 
intramuscularly and 
intravenously 0.25–0.5 g  
2–3 times a day 
Tablets 0.5 g; 
 
ampoules 1 ml or 2 ml  
of 25 % or 50 % solution 
Butadionum Orally 0.1–0.15 g 2–4 times 
a day; 
externally 5 % ointment 
Tablets 0.15 g; 
 
ointment 5 % – 20 g 
Celecoxibum Orally 0.1–0.2 g 1–2 times 
daily 
Capsules 0.1 or 0.2 g  
Ibuprofenum Orally 0.2 g 3–4 times daily Coated tablets 0.2 g 
Diclofenac-
natrium 
Orally 0.025–0.05 g  
1–3 times a day; 
intramuscularly 0.075 g 1 time 
a day 
Coated tablets 0.025 g;  
 
ampoules 3 ml  
of 2.5 % solution 
Prednisolonum Orally 0.005–0.01 g; 
externally 0.5 % ointment 
Tablets 0.005 g; 
ointment 0.5 % – 10.0  
or 20.0 g 
Prednisoloni 
hemisuccinas 
Intravenously  
or intramuscularly 0.05–0.2 g 
2–6 times a day 
Ampoules 0.025 g  
of powder for injection  
Dexamethasonum Orally 0.000 5–0.001 g  
2–3 times a day 
Tablets 0.000 5 g 
Cromolinum-
natrium 
For inhalation 1 capsule  
4 times a day 
Capsules 0.02 g 
Dimedrolum Orally 0.03–0.05 g 1–3 times 
a day; 
intramuscularly  
or intravenously 0.01–0.05 g 
Tablets 0.03 or 0.05 g; 
  
ampoules 1 ml  
of 1 % solution  
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Continuation of the table 13 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product  
Diprazinum Orally 0.025 g 2–3 times 
a day; 
intramuscularly  
or intravenously 0.05–0.25 g 
Coated tablets 0.025 g; 
 
ampoules 2 ml of 2.5 % 
solution  
Suprastinum Orally 0.025 g 2–3 times 
a day; 
intramuscularly  
or intravenously 0.02–0.04 g  
Tablets 0.025 g; 
 
ampoules 1 ml  
of 2 % solution  
Thymalinum Intramuscularly 0.005–0.03 g  
1 time a day 
Vials 0.01 g of powder  
for injection 
Euphyllinum Orally 0.25 g 2–3 times a day; 
intramuscularly 0.24–0.36 g 
1–3 times a day; 
intravenously slowly or 
intravenously drop-by-drop 
0.12–0.24 g  
Tablets 0.25 g; 
ampoules 5 ml  
of 2 % solution 
Adrenalini 
hydrochloridum 
Subcutaneously, 
intramuscularly  
or intravenously 0.0005 g 
Ampoules 1 ml  
of 0.1 % solution 
 
 
Step 1.  Tasks for Self -Control  
Antiallergic and Immunotropic Drugs  
 
1. A patient has urticaria, which is treated with dimedrol. Which 
element of allergy pathogenesis is the therapeutic effect of dimedrol 
connected with? 
A. Activation of -lymphocytes. 
B. Interaction of histamine with receptors in organs.  
C. Formation of the antigen-antibody complex. 
D. Synthesis of immunoglobulins. 
E. Histamine secration. 
2. For treatment of joints arthritis a physician prescribed a drug 
which belongs to nonsteroid anti-inflammatory medicines. It mainly 
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influences cyclooxygenase-2. It has no irritative influence on the 
mucous coat of the digestive system. What drug is it? 
A. Ibuprofen. 
B. Indomethacin. 
C. Diclofenac sodium. 
D. Acetylsalicylic acid. 
E. Celecoxib.  
3. Second generation antihistaminic drug is a derivative of 
piperidine, taken once a day. It has no M-anticholinergic and 
adrenergic blocking effects. It shows antiallergenic, antiexudative, 
antipruritic action. What drug is this? 
A. Retinol acetate. 
B. Dimedrol. 
C. Loratadine. 
D. Suprastin. 
E. Diazolin. 
4. A 45-year-old woman suffers from allergic seasonal coryza 
caused by the ambrosia blossoming. What adipose cells group 
stabilizer medicine can be used for prevention of this disease? 
A. Diazolin. 
B. Dimedrol. 
C. Phencarol. 
D. Ketotifen. 
E. Tavegyl. 
5. A patient with continuous bronchopneumonia was admitted to 
the therapeutic department. Antibiotic therapy didn’t give much 
effect. What drug for improvement of immune state should be added 
to the complex treatment of this patient? 
A. Analginum. 
B. Benadryl. 
C. Sulfocamphocaine. 
D. Timaline.  
E. Paracetamol. 
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6. Signs of gastropathy develop in patient with rheumatoid 
arthritis who was treated with indomethacin. What activity of the 
drug does cause this complication? 
A. Antihistamine. 
B. Anti-cyclooxygenase.  
C. Local irritating. 
D. Antikinine. 
E. Antiserotonin. 
7. Aspirin has anti-inflammatory effect due to inhibition of the 
cyclooxygenase activity. Level of what biological active compounds 
will decrease? 
A. Biogenic amines. 
B. Catecholamines. 
C. Prostaglandins.  
D. Iodinethyronyns. 
E. Leukotrienes. 
8. A 52-year-old patient with bronchial asthma was treated with 
glucocorticoids. Fever reaction appeared as a result of postinjective 
abscess. The patient had subfebrile temperature, which didn’t 
correspond to latitude and severity of inflammatory process. Why did 
the patient have low fever reaction? 
A. Violation of heat-producing mechanisms.  
B. Thermoregulation centre inhibition. 
C. Violation of heat loss through lungs. 
D. Inflammatory barrier formation in injection place. 
E. Inhibited endogen pyrogens production. 
9. A 40-year-old woman appealed to a doctor with a complaint 
of pain in the knee joints. During examination the doctor revealed 
swelling, reddening, hyperthermia in these joints area. Laboratory 
tests showed positive acute phase reactions. What drugs have to be 
used for treatment of the patient? 
A. Anti-inflammatory agents of nonsteroid structure.  
B. Opioid analgesics. 
C. Antidepressants. 
D. Antibiotics. 
E. Sulfamides. 
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10. A 62-year-old man has been suffering from coxitis for a long 
time. A doctor prescribed him a new nonsteroid anti-inflammatory 
agent celecoxib. It improved the patient’s state. What is the 
advantage of this drug? 
A. Activation of phosphodiesterase. 
B. Depression of phosphodiesterase. 
C. Activation of adenylate cyclase. 
D. Depression of cholineesterase. 
E. Selective blockade of cyclooxygenase-2.  
11. A patient with rheumatoid arthritis had been taking 
glucocorticosteroid during several weeks. Then he suddenly stopped 
taking this drug. What complication can occur in this case? 
A. Formation of ulcers on the mucous coat of the stomach and 
duodenum.  
B. Hypertension. 
C. Withdrawal syndrome.  
D. Exacerbation of chronic infection processes. 
E. Hyperglycemia. 
12. Allergic dermatitis produces itching, hypostasis, reddening, 
and insomnia. What drug is expedient for prescribing to the patient? 
A. Natrii oxybutiras 
B. Phenobarbital. 
C. Nitrazepam. 
D. Chloral hydrate. 
E. Dimedrol. 
13. A 30-year-old male, who works as a driver, suffers from 
allergic rhinitis which is aggravated during spring. The doctor has 
prescribed to him antihistamine drug with long duration of action 
(about 24 hours) and with insignificant sedative action. What drug 
was prescribed? 
A. Loratadine. 
B. Dimedrol. 
C. Heparin. 
D. Vicasolum. 
E. Oxytocin. 
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14. Urticaria has developed in a 40-year-old female after the use 
of washing-up liquid. Simultaneously with local treatment, the 
dermatologist has recommended the antihistamine drug loratidine. 
What should be the frequency of loratidine administration? 
A. 1 time per a week.   
B. 2 times daily. 
C. 4 times daily. 
D. 1 time daily. 
E. 1 time per 2 days. 
15. A female has appealed to a doctor with complaints of nasal 
stuffiness, dacryagogue, weakness, and dizziness which arise in the 
period of ambrosia flowering. What antihistamine agent should be 
prescribed? 
A. Bisacodyl. 
B. Penicillin. 
C. Loratadine. 
D. Metoprolol. 
E. Analginum. 
16. The marked drowsiness has developed in female suffering 
from allergic dermatitis that uses certain antiallergic drug during 
a week. Indicate this drug.  
A. Cromolyn sodium. 
B. Essenciale. 
C. Dimedrol. 
D. Adrenaline hydrochloride. 
E. Aminazine. 
17. After penicillin administration, Quincke’s oedema has 
developed in a patient. What drug should be administered to the 
patient immediately? 
A. Rifampicin. 
B. Ascorbic acid. 
C. No-spa. 
D. Sulfacylum-natrium. 
E. Prednisolone. 
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18. Antihistamine drug of the second generation was prescribed 
to the female suffering from allergic dermatitis. This drug does not 
render inhibitory influence upon the CNS. Identify this drug. 
A. Loratadine. 
B. Diazolin. 
C. Tavegyl. 
D. Dimedrol. 
E. Ketotifen. 
19. A student came to see a doctor and asked to administer him 
a drug for treatment of allergic rhinitis that occurs in the period of 
linden flowering. What drug may be used? 
A. Propranolol. 
B. Loratadine.  
C. Losartan. 
D. Noradrenaline hydrotartrate. 
E. Ambroxol. 
20. The quantity of phagocytes and antibody level decrease in 
patient during long-time treatment of pneumonia with 
aminoglycosides and sulfonamides. Which drug should be given to 
patient? 
A. Mercazolil. 
B. Coamidum. 
C. Ferrum Lek. 
D. Methyluracil. 
E. Prednisolone. 
21. The decrease of T-lymphocytes level is observed in a patient 
after ionizing radiation. Which drug should be prescribed to the 
patient? 
A. Methyluracil. 
B. Azathioprine. 
C. Sodium nucleinate. 
D. Ascorbic acid. 
E. Thymalin. 
22. A patient with aggravation of rheumatoid arthritis entered to 
hospital. Chronic hyperacidic gastritis is present in his anamnesis. 
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Choose drug, the administration of which is most appropriate in this 
case.  
A. Butadione.  
B. Indomethacin. 
C. Ortofen (diclofenac-sodium). 
D. Prednisolone. 
E. Acetylsalicylic acid. 
23. A patient suffers from seasonal allergic rhinitis owing to 
flowering poplar. Which drug should be prescribed to him for 
prevention of seasonal agravation of allergy? 
A. Ranitidine. 
B. Cromolyn sodium. 
C. Ephedrine. 
D. Prednisolone. 
E. Diazolin. 
24. A patient with acute rheumatism is treated with salicylates. 
After some time, he had insomnia. Doctor prescribes phenobarbital 
for treatment of insomnia. After several days of phenobarbital using, 
the anti-inflammatory effect of salicylates decreased. What is the 
cause of anti-iflammatory effect weakening? 
A. Increase of salicylates elimination.  
B. Chemical antagonism. 
C. Pharmaceutical antagonism. 
D. Inhibition of hepatic enzymes by phenobarbital. 
E. Induction of hepatic enzymes by phenobarbital. 
25. The cell-mediated immunity decreased in oncologic patient 
after radiation therapy. Choose immunomodulator for treatment of 
this patient. 
A. Interferon. 
B. Tactivinum. 
C. Interferon-beta. 
D. Reaferon. 
E. Prodigiosanum. 
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26. Gastric bleeding developed in a 55-year-old patient on the  
4-th day after the start of indomethacin intake. What is the cause of 
this complication? 
A. Decrease of thromboxane synthesis.  
B. Decrease of leukotriene synthesis. 
C. Decrease of prostaglandin E1 synthesis. 
D. Decrease of cyclic endoperoxides synthesis. 
E. Decrease of prostagladin E2 synthesis. 
27. The following symptoms developed in a patient after long-
time treatment with acetylsalicylic acid: headache, dizziness, sonitus, 
nausea, and epigastric pain. Which drug can cause these side effects? 
A. Midantanum. 
B. Acetylsalicylic acid. 
C. Naphthyzinum. 
D. Bromhexinum. 
E. Vitamin C. 
28. A 40-year-old woman has appealed to a doctor with 
complains of pain in joints. Laboratory exfmsnation has shown 
positive rheumatic test. Which group of drugs should be prescribed 
first of all?  
A. Immunomodulators. 
B. Opioid analgesics. 
C. H1-histamine receptor blockers. 
D. Glucocorticoids. 
E. Nonsteroid anti-inflammatory drugs. 
29. Indomethacin has been prescribed to a patient with 
rheumatism. But owing to aggravation of accompanied disease, the 
doctor has canceled this agent. Which disease is contraindication for 
indomethacin?  
A. Hypertensive disease. 
B. Angina pectoris. 
C. Ulcer disease of stomach.  
D. Diabetes mellitus. 
E. Bronchitis. 
359 
 
30. A patient with rheumatoid arthritis suddenly stops the 
glucocorticoids intake after several weeks of treatment. Which 
complication can develop in this patient?  
A. Acute adrenal insufficiency.  
B. Hypertension. 
C. Hyperglycaemia. 
D. Aggravation of chronic infections. 
E. Ulceration of stomach mucous membrane. 
 
 
ANTI-ATHEROSCLEROTIC DRUGS  
 
Anti-atherosclerotic (hypolipidemic) drugs are drugs of different 
chemical structure which reduce amount of cholesterol and 
triglycerides and their atherogenic carries in the blood. Due to this, 
hypolipidemic drugs slow down atherosclerosis progress and 
promote its regression. Majority of serious cardiovascular diseases 
are associated with atherosclerosis: ischemic heart diseases, 
myocardial infarction, ischemic stroke, encephalopathy, etc.  
A basis of atherosclerosis progress is disorders of lipid 
metabolism leading to increase of cholesterol and triglycerides 
concentration on the blood. In plasma, lipids bind to proteins and 
form lipoproteins. There are the following groups of lipoproteins: 
– chylomicrons; 
– very-low-density lipoproteins (VLDL); 
– intermediate-density lipoproteins (IDL); 
– low-density lipoproteins (LDL); 
– high-density lipoproteins (HDL).  
VLDL, IDL, and LDL contain high concentrations of 
triglycerides and cholesterol and exert atherogenic properties.   
Hyperlipoproteinemias are classified as follows. 
1. Type I is characterized by increased blood concentration  
of chylomicrons.  
2. Type II is characterized by increased blood concentrations  
of cholesterol, LDL, and VLDL.  
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3. Type III is characterized by increased blood concentrations  
of IDL and VLDL. 
4. Type IV is characterized by increased blood concentration  
of VLDL. 
5. Type V is characterized by increased blood concentration  
of chylomicrons and VLDL.  
Hyperlipoproteinemias of I and V types are observed very 
seldom and occur in childhood. Risk of atherosclerosis at these types 
is insignificant.  
Majority of hyperlipoproteinemias are primary, that is develops 
due to nutritive disturbances and sedentary lifestyle. Secondary 
hyperlipoproteinemias develop against the background of some 
diseases (diabetes melites, hypothyreosis, renal and hepatic diseases) 
or result from therapy by some drugs (β-adrenergic antagonists, 
diuretics, etc.).  
Treatment of hyperlipoproteinemias is initiated with diet. If diet 
is ineffective, hypolipidemic drugs are prescribed to patient.  
According to mechanism of action, hypolipidemic drugs are 
classified as follows. 
1. Drugs decreasing blood concentration of cholesterol (LDL). 
1.1. Inhibitors of cholesterol synthesis (statins): lovastatin 
(Mevacor),  fluvastatin (Lescol), mevastatin,  simvastatin  
(Zocor),  pravastatin (Lipostat),  atorvastatin .   
1.2. Drugs increasing elimination of bile acids from the body 
(bile acid sequestrants): cholestyramine  and colestipol .   
1.3. Antioxidants: probucol, vitamin E (tocopherol),  
vitamin C (ascorbic acid), vitamin B 6  (pyridoxine),   
β-carotin,  microdoses of selenium .  
2. Drugs decreasing blood concentration of triglycerides 
(VLDL) – fibric acid derivatives (fibrates): clofibrate, 
bezafibrate, gemfibrozil ,  fenofibrate .   
3. Drugs decreasing blood concentrations of both cholesterol 
(LDL) and triglycerides (VLDL). 
3.1. Preparations of nicotinic acid: nicotinic acid  and 
acipimox .  
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3.2. Drugs containing non-saturated fatty acids: Moristerol ,  
lipostabil , Essentiale , cod liver oil . 
3.3. Anticoagulants: heparin .  
4. Direct vasoprotectors.   
4.1. Endotheliotropic drugs: parmidine, etamsylate ,  
quercetin . 
4.2. Calcium antagonists: verapamil , nifedipine .   
4.3. Antioxidants: tocopherol, ascorbic acid,  rutin ,  
cysteine, methionine, glutamic acid .   
 
Drugs Decreasing Blood Concentration  
of Cholesterol  
 
Cholesterol Synthesis Inhibitors (Statins)  
 
Presently, this group is estimated as most effective for treatment 
of different types of hyperlipidemias including most severe forms. 
Mechanism of action of statins is associated with inhibition of  
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. It 
leads to slowdown of cholesterol synthesis at the stage of formation 
of mevalonic acid. Due to this, liver lacks about 60 % cholesterol 
which is essential for synthesis of bile acids. Deficiency of hepatic 
cholesterol is compensated by increased use of cholesterol and its 
ethers contained in food and increased utilization of cholesterol 
contained in vascular wall. Accumulation of cholesterol in vessels is 
cessated and atherosclerotic changes undergo regress. Amount of 
HDL, participating in cholesterol transport to the liver, is increased. 
Due to decrease of cholesterol synthesis, a density of LDL-receptors 
is increased. These receptors bind to LDL, VLDL, and IDL 
circulating in blood. It is importance, that statins do not block 
cholesterol synthesis in adrenal cortex and sex glands and do not 
inhibit synthesis of corticosteroids and sex hormones. Also, these 
drugs do not affect cholesterol synthesis in central nervous system. 
Lovastatin,  simvastatin, and pravastatin are natural 
substances produced by some species of fungi. Other drugs are 
synthetic agents. 
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Because cholesterol synthesis occurs mainly at night, statins are 
taken at evening while eating (absorption of drugs on an empty 
stomach is less). Maximum concentration in the blood is observed in 
1.5 hours after drugs intake. A degree of binding with plasma 
proteins for statins is about 95 %. Statins andergo partial hepatic 
metabolism. Unchanged drugs and their metabolites are excreted by 
kidneys and liver. These drugs are well tolerated by patients. 
Therapeutic effect reach maximum in 4–6 weeks after initiation of 
treatment. 
Side effects of statins are impaired hepatic function with 
elevation of blood level of transaminases, myopathy, dyspepsia, skin 
rash, photosensitization, anemia, and thrombocytopenia. 
Statins are used to treat ischemic heart disease, II–IV types of 
hyperlipidemia, atherosclerosis of aorta, cerebral vessels, vessels  
of lower extremities, etc. Statins exert high efficacy at hereditary 
heterozygous form of hypercholesterinemia and non-hereditary 
(polygenic) hypercholesterinemia.  Statins are not used to treat 
homozygous familial hyperlipoproteinemia because LDL-receptors 
are completely absent in these patients.  
Therapy with statins is long-lasting and intake of minimal 
effective doses is preferable. A correction of initial dose is fulfilled 
in a month of therapy initiation with control of general cholesterol 
level (lower than 3.6 mmol/l).  
 
Drugs Increasing Elimination of Bile Acids from the 
Body (Bile Acid Sequestrants)  
 
This group is represented by enterosorbents and anion-exchange 
resins (cholestyramine  and colestipol ).  
Molecules of these drugs contain many quaternary ammonium 
radicals and, therefore, bind anionic groups of bile acids with 
formation of non dissociable complexes excreted with feces. Due to 
their action, increased utilization of atherogenic lipoproteins (LDL 
and VLDL) is occurred in the liver and their synthesis is reduced. 
Simultaneously, hepatic synthesis of cholesterol, which is eccential 
for synthesis of bile acids, is increased. 
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Therapeutic effect is observed in 30–40 days after initiation of 
the drugs intake. Sequestrants of bile acids are mainly used to treat  
II type of hyperlipidemia. These drugs may be combined with other 
drugs in case of high hypercholesterolemia. Their effect develops in 
1 month after initiation of therapy. Due to high safety, these drugs 
are used in pediatric practice.  
Cholestyramine  is taken orally as powder. Its dose is 
increased gradually from 3 g to 16–24 g daily for 1 month. The drug 
has very off-flavor taste and odour, therefore many patients swear off 
its intake. Side effects of cholestyramine are constipation, nausea, 
vomiting, diarrhea, and pancreatitis. Long-time drug intake can lead 
to deficiency of lipid-soluble vitamins.     
Colestipol is better tolerated by patients. Its initial daily dose is  
5–10 g. For 2–3 months, this dose is gradually increased up to 30 g. 
When therapeutic effect is reached, dose is gradually decreased to 
minimum. Colestipol is contraindicated for children under 6 years 
old. The drug violates intestinal absorption of medications and lipid 
soluble vitamins; therefore, their simultaneous intake is not 
recommended.  
β-Sitosterol  is natural steroid of plant origin which violate 
intestinal cholesterol absorption. The drug is used to treat II type 
hyperlipoproteinemia. The drug is well tolerated by patients, but its 
efficacy is low.  
Presently, nonspecific sorbents of bile acids and cholesterol are 
widely used in medicine: vegetable fibres, pectins, cellulose, 
vegetable slimes and gums, some semisynthetic substances – sulfated 
derivatives of chitosan, polymannoses (long chain polysaccharides), 
Guar gum (guaran), activated lignin, etc. These drugs bind bile acids, 
cholesterol, bacterial toxins, and microelements. Their daily doses 
are about 20–50 g. Despite of these drugs are tolerated by patients 
well they have not self-sufficient value in the treatment  
of hyperlipoproteinemias.  
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Antioxidants  
 
Peroxidation plays an importance role in pathogenesis of 
atherosclerosis. Before accumulation of vascular wall, ethers  
of cholesterol and triglycerides undergo oxidation by aggressive free 
oxygen radicals. Oxidation is occurred in case of deficiency of 
physiological antioxidants – vitamins E, A, and β-carotin. 
Peroxidation is also decelerated by vitamins C, B6, microdoses of 
selenium, and vegetable flavonoids. 
Antioxidants are divided into antioxidants of direct action and 
drugs of indirect action.  
Antioxidants of direct action are tocopherol, polyphenols, 
ascorbic acid, “Aevit”, ceruloplasmin, and superoxide dismutase. 
These drugs directly inhibit formation of free radicals. 
Vasoprotective action of these drugs is associated with their 
influence upon peroxidative, lipidemic, and thrombogenic 
mechanisms of atherogenesis. Due to deceleration of peroxidation of 
plasma lipoproteins, lipids, and phospholipids of vascular 
endothelium, these drugs protect vessels from damage. Besides, 
direct antioxidants decrease synthesis and increase catabolism of 
cholesterol and inhibit formation f thromboxane A2. Thus, these 
drugs prevent destructive changes in vessels, their infiltration by 
lipids, fibrosis, and calcinosis.  
Indirect antioxidants include such drugs as glutamic acid, 
methionine, cysteine, Preductal, sodium selenite, emoxypine, dibunol 
(butylated hydroxytoluene), etc. These drugs promote accumulation 
of glutathione which restore oxidized forms of tissue antioxidants 
and activity of peroxidases inactivating peroxides and 
hydroperoxides. Therapeutic effect of these drugs is mediated by 
their participation in phospholipid biosynthesis and hepatic oxidation 
of fatty acids.  
Therapy with antioxidants is intended for 2–3 months in winter-
spring period when intake of antioxidants with food is restricted. 
Probucol (Lorelco)  is synthetic antioxidant playing an 
importance role in therapy of atherosclerosis. The drug slows down 
lipid peroxidation, decreases uptake of LDL by cells of vascular 
365 
 
intima, and promote reduction of vascular accumulation of 
cholesterol. Probucol reduces plasma concentration of LDL. It 
should be noticed that the drug is effective in marked hereditary 
disorders of lipid metabolism, when statins are ineffective. Probucol 
is well tolerated by patients. The drug is taken orally in dose 0.5 g 
two times a day at mealtime. At II type hyperlipoproteinemia, 
therapeutic effect is observed in 1–3 months. Side effects of probucol 
are nausea, appetite loss, abdominal pain, and diarrhea. Cardiac 
arrhythmias due to disorders of impulse conduction is rare 
complication of probucol therapy. The drug is commonly combined 
with other hypolipidemic drugs.  
 
Drugs Decreasing Blood Concentration of 
Triglycerides  
 
Fibric Acid Derivatives  
 
Fibric acid derivatives (fibrates) include such drugs as 
clofibrate, bezafibrate,  gemfibrozil , and fenofibrate . 
Clofibrate was approved in medicine more than 30 years ago. In 
a body, clofibrate is metabolized into parachlorophenol 
hydroxyisobutyric acid exerting antiatherosclerotic activity. Effect of 
clofibrate develops in 2–5 days after therapy intitiation and reachs 
maximum in several weeks or months.  
Mechanism of action of fibric acid derivatives is associated with 
the increase of activity of lipoproteinlipase in capillaries. In result, 
catabolism of triglycerides and VLDL is increased. Blood level of 
triglycerides is reduced on 40–50 %. Simultaneously, blood level of 
antiatherogenic HDL is increased. Due to increased hepatic 
catabolism of VLDL, concentration of cholesterol and triglycerides 
in hepatocytes is increased that enchances cholesterol utilization for 
synthesis of bile acids and their release with bile. But this effect 
increases risk of formation of bile stones.   
Clofibrate is rather toxic drug. Its side effects include dyspepsia, 
drowsiness, skin rash, leukopenia, cardiac arrhthymias, vascular 
disorders, muscular pain, reduced libido, rhabdomyolysis, muscular 
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weekness, hepatothoxicity, risk of cholelithiasis, alopecia, and 
cancerogenesis (tumors of large intestine and neck of bile blader). 
To decrease side effects, new derivatives of fibric acid was 
synthesized and approved in practice: bezafibrate (II generation), 
fenofibrate, and gemfibrozil (III generation). These drugs exert same 
or higher antiatherosclerotic activity as clofibrate and longer duration 
of action (fenofibrate acts about 24 hours).  
Fibrates are used to treat II and III types hyperlipidemias, 
especially in patients with excesive body weight and diabetes 
mellites. Also, these drugs are used in the treatment for IV and  
V types hyperlipidemias (more common prescribed for patients with 
risk of pancreatitis) and to decrease risk of ischemic heart disease. 
Fibrates exert low efficacy or are ineffective at hereditary 
hyperlipidemias.    
It should be noted that if level of triglycerides is not decreased 
for 3 months of treatment, therapy with fibrates should be 
discontinued. 
 
Drugs Decreasing Blood Concentration of Cholesterol 
(LDL) and Triglycerides (VLDL)  
 
Preparations of Nicotinic Acid  
 
Nicotinic acid  and its derivatives are effective to treat all 
types of hyperlipidemias, because decrease blood concentration of 
VLDL, LDL, and IDL. Total amount of triglycerides in blood is 
decreased on 20–30 %. Many clinicians consider intake of nicotinic 
acid in combination with diet as most optimal mode of initial 
monotherapy of atherosclerosis.  
Nicotinic acid inhibits lipolysis in fat tissue, decreases hepatic 
synthesis of VLDL, LDL, triglycerides, and cholesterol, and 
increases activity of lipoprotein lipase.  
Long-lasting intake of nicotinic acid is accompanied by an 
increase of HDL concentration. Transport of cholesterol from tissues 
to a liver and its utilization for synthesis of bile acids are increased.  
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Nicotinic acid is effective to treat II–V types hyperlipidemias. 
To treat hyperlipidemias, doses of nicotinic acid are about 100 times 
more than those which are used in hypovitaminosis.  
Nicotinic acid is readily absorbed from gastrointestinal tract, 
partly metabolized and excreted with urine. Its typical side effects are 
skin hyperemia, itching, skin rash, and hot feeling. These effects are 
due to release of prostanoids from walls of small vessels and may be 
prevented by low doses of aspirin (about 0.125–0.25 g). Besides, 
dyspepsia, hepatic dysfunction, gastric ulcer, hyperglycemia are 
possible complications of nicotinic acid therapy. Nicotinic acid slows 
down thrombocytes aggregation and activates fibrinolysis. 
Acypimox (Olbetam)  is derivative of nicotinic acid which is better 
tolerated by patients. But this drug is used seldom. 
 
Unsatureted fatty acids  
 
Clinical use of unsaturated fatty acids is based on the 
observations upon human populations of high north which 
traditionally use fats of sea fish and animals. Among these 
populations, atherosclerosis, ischemic heart disease, and myocardial 
infarction are practically not observed. Unsaturated fatty acids are 
represented by oleic, linoleic, linolenic, and arachidonic acids. These 
acids are easily integrated in body metabolism as source of energy, 
as well as source for synthesis of membrane phospholipids and 
prostanoids. Preparations of unsaturated fatty acids (Omacor, 
Natalben Supra, cod liver oil ,  etc.) are used as dietary 
additives for patients with atherosclerosis and for its prevention. Cod 
liver oil  and its preparations are used in the treatment for II and  
V types of hyperlipidemias. These drugs are contraindicated in  
IV type hypelipidemia.  
Moristerol  is drug of plant origin with high content  
of polyunsaturated fatty acids. Moristerol reduces plasma level of 
atherogenic lipoproteins, decreases platelets aggregation, 
consolidates structure of capillaries, increases cholesterol excretion 
with bile and decreases its intestinal absorption. The drug is taken in 
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capsules or in granules at mealtime. Moristerol is used in the 
treatment for all types of hyperlipidemias.  
Lipostabil  in capsules contains complex of unsaturated fatty 
acids and derivative of theophylline. Lipostabil for injections 
contains same components together with vitamins PP and B6 and 
adenosine 5-monophosphate. The drug is used in the treatment for 
atherosclerosis and disorders of coronary, cerebral, and peripheral 
circulation. Lipostabil is taken orally 1–2 capsules 3 times a day or 
administered intravenously slowly 10–20 ml. Lipostabil is well 
tolerated by patients.    
Essentiale  is co-formulated drug containing essential 
phospholipids – diglycidyl ethers of choline-phosphoric acid and 
unsaturated fatty acids together with vitamins: pyridoxine, 
cyanocobalamin, nicotinamide, pantothenic acid, riboflavin, and 
tocopherol. The drug activates cholesterol catabolism by means of 
formation of its ethers with unsaturated fatty acids, improves stability 
of protein-lipid complexes, increases cholesterol acceptor and 
cholesterol-transporting properties of blood and hepatic function. 
Essentiale is used as antiatherosclerotic and hepatoprotective drug: to 
treat ischemic heart disease, hepatitis, hepatic dystrophy and 
cirrhosis, toxic liver damage, alcoholism, etc.   
These drugs are not used for monotherapy of atherosclerosis 
because under the background of unsaturated fatty acids intake, body 
level of cholesterol and triglycerides is decreased insignificantly. 
 
Anticoagulants  
 
Heparin exerts moderate ability to decrease blood level of 
cholesterol and triglycerides due to activation of lipoprotein lipase. 
Thus, heparin decreases blood level of atherogenic lipoproteins. 
Besides, heparin increases negative charge of endothelial cells of 
vascular wall, that prevents lipoproteins absorption and their 
interaction with mucopolysaccharides of vascular intima.        
 
 
 
369 
 
Angioprotectors  
 
Endotheliotropic drugs (vasoprotectors or angioprotectors) are 
used in the complex therapy of atherosclerosis. These drugs decrease 
vascular permeability.  
Parmidine (pyridinol  carbamate)  is representative of such 
drugs. The drug exerts antibradykinin effect, decreases oedema, and 
reduces permeability of vascular wall. Besides, parmidine improves 
microcirculation, reduces thrombocytes aggregation, promotes 
restoration of elastic and muscular fibers in sytes of cholesterol 
accumulation, and inhibits blood coagulation. Parmidine is taken 
oraly for several months. The drug is well tolerated by patients. Its 
side effects are nausea and allergic reactions.  
Etamsylate (Dicynone) inhibits hyaluronidase activity that 
reduces destruction of mucopolysaccharides of vascular wall. The 
drug increases stability of capillaries and normalizes their 
permeability. Besides, etamsylate decreases bleeding and increases 
number of thrombocytes.  
Quercetin  is preparation of vitamin P. The drug decreases 
vascular permeability and angiasthenia. Together with ascorbic acid, 
quercetin participates in redox processes and inhibits hyaluronidase.    
 
 
DRUGS WHICH USED TO TREAT OBESITY 
 
Obesity is widely spreaded metabolic disorder which is 
manifested by excessive accumulation of fat. The coses of obesity 
are low physical activity and excessive intake of calorigenic foods: 
animal fats, starchy and confectionery products, etc., and insufficient 
intake of proteins, plant oils, fresh vegetables and fruits. Aberrations 
of food regimen promotes obesity: dry food, fast food, and 
overnutrition at evening. Besides, there is genetic disposition to 
obesity. A risk of obesity increases with age, at psychical and 
endocrine disorders.   
In turn, obesity is a risk factor of diabetes melites, 
atherosclerosis, hypertension, ischemic heart disease, arthritis, etc. At 
obesity, a lowering of body wheight is accompanied by decrease of 
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risk of myocardial infarction, cerebral stroke, and other 
complications which lead to disability and death.  
Traditionally, treatment of obesity is based on diet and physical 
activity, surgical resection of fat tissue, body fat suction, and drug 
therapy.     
Drugs which are used to treat obesity are classified as follows.  
1. Drugs decreasing appetite (anorexigenic drugs). 
1.1. Drugs influencing catecholaminergic system: mazindol 
(Sanorex), chlorphentermine  (Desopimon), amfepramone 
(Phepranon).    
1.2. Drugs influencing catecholaminergic and serotoninergic 
systems: fenfluramine  and sibutramine .  
2. Drugs stimulating lipolysis and thermogenesis (β3-adrenergic 
agonists): mirabegron. 
3. Drugs violating intestinal fats absorption: orlistat.  
4. Drugs substituting fats: olestra. 
5. Drugs substituting carbohydrates: aspartame and saccharin.  
Besides mentioned drugs, phytotherapy with dietary additives is 
widely used to correct metabolism and to decrease appetite. Such 
dietary additives are reach by vitamins, minerals, polyunsaturated 
fatty acids, amino acids, and dietary fibers. These preparations 
promote elimination of cholesterol and other metabolic products 
from the body. An advisability of the dietary additives use is 
obvious, but their efficacy should not be overstated.   
 
Drugs Decreasing Appetite  
 
Drugs Influencing Catecholaminergic System  
 
Phenamine  was one of the first anorexigenic drugs. Phenamine 
exerts central and peripheral indirect adrenomimetic action. The drug 
increases release of norepinephrine and dopamine from adrenergic 
nervous terminals and inhibits their neuronal reuptake. Phenamine 
stimulates brain's satiation center that leads to reduction of hunger 
center activity. Besides, the drug is potent psychostimulant. 
Therefore, its use to treat obesity is accompanied by insomnia, 
tachycardia, hypertension, anxiety, etc. Also, phenamine can cause 
psychical and physical dependence.    
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In medicine, such drugs as amfepramone (Phepranon)and 
chlorphentermine  (Desopimon)  are used to treat obesity. These 
drugs exert same mechanism of action as phenamine. But 
anorexigenic effect of these drugs is less. Besides, these drugs 
stimulate central nervous system in less degree, and their peripheral 
side effects are less expressed. The drugs are taken orally in  
30 minutes before a meal at first part of day. Their possible side 
effects are tachycarida, cardiac arrhythmias, hypertension, anxiety, 
insomnia, etc. Besides, these drugs can cause tolerance and drug 
dependence.   
Mazindol  (Sanorex)  exhibits 5–10 times higher anorexigenic 
activity than phenamine. Its mechanism of action is similar to 
mechanism of action of phenamine. Besides, the drug inhibits 
intestinal absorption and body synthesis of triglycerides and 
decreases cholesterol level. The drug is taken orally at first part of 
day. Mazindol intake is accompanied by low risk of drug 
dependence. Its side effects are insomnia, dry mouth, dyspepsia, and 
allergic reactions. 
 
Drugs Influencing Catecholaminergic  
and Serotoninergic Systems  
 
Fenfluramine  and sibutramine  exert sedative influence upon 
central nervous system. Their mechanism of action is associated with 
stimulation of neuronal release of catecholamines and serotonin. 
Besides, these drugs inhibit neuronal reuptake of these mediators and 
increase metabolism of serotonin in the brain. The drugs inhibit 
intestinal absorption of lipids and body synthesis of triglycerides. 
Their possible side effects are hypertension, tachycardia, dyspepsia, 
insomnia, and depression. 
During last years, anorexigens inhibiting cannabinoid (CB-1) 
receptors was approved in medicine. These group is represented by 
rimonabant  (Acomplia).  The drug is taken orally. Its 
anorexigenic efficacy is similar to efficacy of sibutramine. 
Rimonabant is well tolerated by patients. Its possible side effects are 
dyspepsia, depression, and dizinness.  
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Drugs Stimulating Lipolysis and Thermogenesis  
(β3-Adrenergic Agonists)  
 
It is known that stimulation of β3-adrenergic receptors leads to 
activation of lipolysis and thermogenesis. This fact was a base for 
creation of new group of drugs to treat obesity. The therapy with   
β3-adrenomimetic mirabegron is accompanied by decrease of body 
wheight in all patients; but this drug is not broadly used nowadays. 
 
Drugs inhibiting intestinal absorption of fats  
 
This group is represented by orlistat  (Xenical). The drug 
violates fat absorption due to inhibition of intestinal lipase. Violation 
of hydrolysis of triglycerides reduces their intestinal absorption and 
absorption of cholesterol about 30 %. Taken orally orlistat is 
excreted in unchanged form by intestine during 3–5 days. Its side 
effects are abdominal pain, diarrhea, nausea, vomiting, steatorrhea.    
 
Drugs Substituting Fats 
 
Different low-calorie or poorly absorbed substitutes of fats are 
used to treat obesity. Their tast is similar to tast of fats. Olestra  is 
representative of these drugs. The drug consists of esters of sucrose 
with various long chain fatty acids. Olestra is not absorbed from 
gastrointestinal tract and reduces absorption of fat-soluble vitamins, 
cholesterol, and bile acids. The drug can cause abdominal pain and 
diarrhea.    
 
Drugs Substituting Carbohydrates  
 
Aspartame and saccharin are carbogydrate substitutors which 
used to reduce caloric content of food. Their tast is similar to tast of 
sugar, but these drugs are poorly absorbed from gastrointestinal tract 
and their calorific value is low.  
Research of new drugs to treat obesity continue. Findings of 
leptin (hormone of fat tissue) and melanocortin show that these 
hormones are able to decrease appetite. A creation of corresponding 
drugs of these hormones allows to treat obesity with higher efficacy. 
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At the same time, it is finding that some peptides (neuropeptide Y, 
orexin) stimulate appetite. Nowadays, active search of their 
antagonists is in progress. Cholecystokinin, produced by cells of 
digestive system, stimulates satiety and creation of drugs on its base 
is also perspective. 
 
 
DRUGS TO TREAT OSTEOPOROSIS  
 
Osteoporosis is a group of metabolic diseases of bones which 
characterized by reduction of density of bone mineralization, due to 
that bones became porous and fine. A resistance of bones to 
mechanical influences reduced that leads to increased risk of bone 
fractures and is a common cause of disability and mortality. These 
problems are widely spread between young people and, especially, 
between people of moderate and old age. 
It is known that bone tissue is permanently restored. Osteoclasts 
perform resorption of bone and osteoblasts are responsible for 
growth of bone tissue. Weight of bones reach maximum about  
30 years old, after that it is gradually decreased. To 75 years old, 
bone mass is reduced on 30–50 %. Osteoporosis develops due to 
violation of dynamic equilibrium between bone resorption and their 
formation. These processes are regulated by estrogens, androgens, 
growth hormone, parathyroid hormone, corticosteroids, calcitonin, 
vitamin D and its metabolits, special proteins regulating activity of 
osteoclasts, cytokines, calcium ions, etc. Physical exercises and 
genetic factors play an important role in maintenance of bone 
mineralization. 
Drugs which are used to treat osteoporosis are classified as 
follows.  
1. Hormonal drugs and their analogues. 
1.1. Sex hormones: estrogens ,  androgens ,  and anabolic 
steroids.  
1.2. Calcitonin.   
2. Active metabolites of vitamin D: alfacalcidol  and 
calcitriol.  
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3. Combined drugs of animal origin: ossein-hydroxyapatite.  
4. Synthetic drugs. 
4.1. Bisphosphonates: etidronate, pamidronate,  and 
alendronate.  
4.2. Fluorides: sodium monofluorophosphate and sodium 
fluoride. 
4.3. Calcium preparations: calcium carbonate  and calcium 
citrate. 
4.4. Strontium salts: strontium ranelate. 
As a rule, osteoporosis is observed in old patient and is 
associated with reduction of sex hormones production. Especially, 
osteoporosis is common in women after 50–55 years and is 
associated with reduced amount of estrogens in menopause. In this 
case, estrogens  are prescribed to prevent osteoporosis. A course of 
treatment lasts 5–10 years. Estrogens inhibit function of osteoclasts 
that decreases bone resorption. But such therapy increases the risk of 
breast and uterine cancer. Therefore, estrogens are combined with 
progestins to decrease risk of cancer.  
Calcitonin  is produced by thyroid gland. It reduces bone 
resorption by means of direct inhibition of osteoclasts activity. 
Besides, the hormone exerts analgesic activity owing to influence 
central nervous system. In medicine, a lot of different preparations of 
calcitonin is used: synthetic human calcitonin, natural pork 
calcitonin, Miacalcic  (synthetic salmon’s calcitonin), 
Elcatonin  (eel’s calcitonin), etc. 
Chemical structure and activity of Miacalcic  is similar to those 
of human calcitonin. Miacalcic is dosed in international units and 
administered subcutaneously, intramuscularly, and intranasaly (as 
spray). The drug regulates calcium metabolism, decreases increased 
blood concentration of calcium due to inhibition of bone resorption 
and inhibition of renal reabsorption of calcium. Miacalcic is used to 
treat menopausal, senile, and corticosteroid-induced osteoporosis. 
Especially, therapy with Miacalcic is reasonable at osteoporosis 
which is accompanied by pain. Side effects of Miacalcic include 
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dyspepsia, hyperemia of face, inflammation at the sites of drug 
administration.      
Active metabolites of vitamin D (calcitriol  and alfacalcidol) 
promote intestinal absorption of calcium and phsophates, increase 
calcium renal reabsorption, stimulate removal of calcium and 
phosphates from the bones in the blood. Owing to these effects, 
metabolites of vitamin D maintain necessary blood concentration of 
calcium and phosphates, that provides favorable conditions for bone 
mineralization.  
Calcitriol  is active metabolite of vitamin D, activity of which 
is increased under influence of parathyroid hormone. It is considered 
that calcitriol deficiency is a cause of osteoporosis and 
hyperparathyreosis at renal failure. Calcitriol is taken orally or 
administered intravenously. At oral intake, calcitriol acts during  
3–5 days. The drug is metabolized in the liver and excreted with bile 
in the intestine. Effects of alfacalcidol  are softer. The drug causes 
hypercalcemia seldom. Alfacalcidol is taken orally in capsules. 
Overdose of active metabolites of vitamin D leads to increase of 
calcium concentration in blood, anorexia, vomiting, nausea, 
constipation, and stupor. In such cases, high doses of calcitonin, loop 
diuretics, and large amount of fluids are prescribed to patient. At 
acute overdose of calcitriol, gastric lavage is also recommended. 
Ossein-hydroxyapatite (Osteogenon) is obtained from 
animal bones. It is supposed that the drug activates osteoblasts and 
inactivates osteoclasts; but its mechanism of action is unknown 
completely. Its side effects are observed seldom and include nausea, 
hypercalcemia, and allergic reactions. Osteogenon is used to treat 
osteoporosis in combination with other drugs.  
Bisphosphonates (etidronate, pamidronate, alendronate ,  
etc.) bind with crystals of hydroxyapatite of bones and are kept in 
bone tissue during several months or years. At bone resorption, 
bisphosphonates are locally released from the tissue and inhibit 
activity of osteoclasts that leads to a decrease of bone resorption. 
Bisphosphonates are poorly absorbed from gastrointestinal tract 
(about 10 %). These drugs decrease blood concentration of calcium 
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and phosphates and may be used to eliminate hypercalcemia. 
Bisphosphonates are tolerated by patients well and used to treat and 
prevent osteoporosis by courses lasting from several months to a year 
and more. These drugs are classified in 3 generations. II-Generation 
(alendronate and pamidronate) and III-generation (risedronate and 
bondronat) drugs are preferable than I-generation drugs  
(e. g., etidronate) because these drugs do not inhibit bone 
calcification and do not cause osteomalacia. Bisphosphonates are 
used to treat osteoporosis, hypercalcemia, hyperparathyroidism, bone 
tumors, and Paget’s disease. Their side effects are dyspepsia, 
myalgia, lymphocytopenia, hypocalcemia, etc. 
There is no consensus about usefulness of fluorides in the 
treatment for osteoporosis. But some clinicians prescribe these drugs 
noting their positive effect. Fluorides stimulate osteoblasts and 
promote their proliferation. These drugs are taken orally; their 
bioavailability is about 100 %. Significant part of absorbed sodium 
fluoride enters bones, rest is excreted with urine. Course of treatment 
lasts 4–6 months. Fluorides have a narrow therapeutic window. Their 
intake is accompanied by dyspepsia, osteomalacia, etc.   
There is evidence that teriparatide (active residue of human 
parathyroid hormone) stimulates osteoblasts and increases density of 
bone trabecules. For this aim, the small doses of drug are prescribed 
by intermittent courses. But these data need additional investigations.  
To prevent osteoporosis, calcium preparations (carbonate, 
phosphate, lactate, etc.) are commonly used in combination with 
other minerals. Osteomag and Osteomag forte contain calcium 
carbonate, cholecalciferol, magnesium, copper, zinc, manganese, and 
boron. These drugs are taken orally. Preparations eliminate 
deficiency of micro- and macroelements in a body.  
Anabolic steroids (Retabolil, Phenobolin, etc.) increase bone 
mass and decrease osteoporosis. But their use is restricted by sucg 
side effects as masculinization, increase of blood concentration of 
atherogenic lipoproteins, and dyspepsia.  
Strontium ranelate stimulates grouth of bone tissue and inhibits 
its resorption. The drug is taken orally and readily absorbed from 
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gastrointestinal tract. Strontium ranelate is tolerated by patients well. 
Its side effects include headache and dyspepsia.  
 
 
DRUGS TO TREAT DYSTROPHIC CHANGES  
OF CARTILAGINOUS TISSUE 
(OSTEOCHONDROSIS AND OSTEOARTHROSIS)  
 
Diseases of cartilaginous tissue are quite spread. At least  
1/3 peoples after 50 years are suffering from these diseases. But 
dystrophic changes of cartilaginous tissue continue to spread 
between under 50-years old humans.    
Cartilaginous capping of joints and synovial fluid provide 
mobility of joints. Cartilaginous tissue has not vessels; therefore, its 
supporting by necessary compounds is provided due to diffusion of 
substances from bone’s epiphysis. Disorders of blood circulation in 
epiphysis lead to dystrophic damage of cartilaginous tissue. This 
process is accompanied by inflammation, pain, and disorders of 
mobility in joints. As a rule, non-steroid anti-inflammatory drugs are 
used to treat acute inflammatory processes in joints. Glucocorticoids 
are prescribed in cases of severe inflammation. These drugs decrease 
pain and improve joint mobility, but their effects are temporal and 
need additional use of drugs stimulating regeneration and functions 
of cartilaginous tissue.   
Rumalon  is extract of cartilages and bone marrow of calves. 
The drug is administered intramuscularly. Commonly, Rumalon is 
called as chondroprotector. Rumalon stimulates synthesis of 
components of synovial fluid and extracellular matrix. Besides, 
Rumalon accelerates cartilages regeneration and inhibits activity of 
enzymes which decrease density of tissues. Rumalon is prescribed 
several times for year by courses lasting 20–25 days. The drug slows 
down progress of osteochondrosis and promotes regeneration  
of cartilageous tissue. Side effects of Rumalon are allergic reactions. 
Structum  is polysaccharide which participates in formation of 
ground substance of bone and cartilaginous tissue and slows down 
substitution of its cells by components of connective tissue. Structum 
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is taken orally in capsules. Course of treatment lasts 3 months and 
more. Side effects of Structum are allergic reactions.  
Ascorbic acid  and tocopherol  are essential for regeneration 
of cartilaginous tissue. Ascorbic acid (vitamin C) provides includion 
of sulfur in mucopolysaccharides in process of formation of 
cartilaginous tissue and hyaluronic acid (main ground substance  
of connective tissue and synovia). Besides, vitamin C is essential for 
synthesis of hydroxyproline and collagen, participates in formation 
of cartilage skeleton and bone osein, and promotes wound healing. 
Also, antioxidative properties of ascorbic acid are important.   
Tocopherol (vitamin E) is one of the most potent antioxidants. 
Therefore, it considered as one of the essential components in 
osteochondrosis treatment, because aggressive influence of free 
radicals plays an important role in pathogenesis of this disease. 
Tocopherol is prescribed orally or intramuscularly in high doses by 
long-lasting courses.  
Also, vasodilators, irritative and anti-inflammatory drugs are 
used in osteochondrosis treatment. These drugs increase blood 
supply of joints that improves tissue trophicity.       
 
 
DRUGS USED TO TREAT GOUT  
 
Gout is a chronic disease which develops due to disorders of 
purine (adenine and guanine) metabolisim that leads to 
hyperuricemia and formation of microcristalls of sodium salt of uric 
acid in cartilages, stratum synoviale, joint oil, kidneys, and soft 
tissues.   
There are primary (idiopatic) and secondary gout. Idiopathic 
gout is associated with gereditary abnormality of enzymes 
participating in purine metabolism: reduced activity of hypoxanthine-
guanine phosphoribosyltransferase and adenine-phosphoribosyl 
pyrophosphate synthase leads to increase of uric acid synthesis.  
Most commom causes of secondary gout are renal diseases with 
violation of their ability to excrete nitrous compaunds, polycitemia, 
chronic intoxication by lead, and leukemia in period of cytostatic 
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therapy (massive degradation of blood cells is accompanied by 
release of nuclear purine bases.  
Consumption of alcohol, tea, coffee, and food with increased 
amount of purines (meat, fish, mushrooms, etc.) promotes gout 
development. 
It is known that uric acid is final product of purine metabolism. 
In extracellular fluid, where sodium is a main cation, uric acid is 
transformed from ionized state to sodium salt. This salt is poorly 
soluble in water, therefore insignificant increase of its concentration 
in extracellular fluid leads to formation of crystals of sodium urate. 
Formation of such crystals in the hoints causes gout and acute 
inflammatory arthritis, in renal intesrsticium – gouty nephropathy 
and nephrolithiasis, in the soft tissues – formation of tophaceous 
gout.  
Inflammation of joints is associated with uptake by neutrophils 
of sodium urate crystals. Crystals affect lysosomal membranes, cause 
destruction of cells, and, therefore, induce free-radical processes 
(superoxide radicals are formed) and release of bioactive substances 
(prostaglandin E2, leukotriene B4, interleukin-1, etc.) from damaged 
polymorphonuclear leukocytes and monocytes. 
From a body, uric acid is excreted kidneys. It is filtered in 
glomeruli and reabsorbed practicly completely in proximal 
convoluted tubules. Distally in proximal tubules, uric acid is secreted 
secondary and andergoes repeated reabsorption. Normal, clearance of 
uric acid is about 10 % of volume of its filtrate. 
Excretion of large amount of urates may lead to formation of 
crystals. This process is increased due to acidic reaction of urine and 
inflammatory processes in kidneys.   
Drugs to treat gout are classified as follows.  
1. Anti-inflammatory drugs (used to treat acute gout, do not 
influence hyperuricemia): colchicine, steroid anti-inflammatory 
drugs (prednisolone, dexamethazone), and nonsteroid  
anti-inflammatory drugs (indomethacin , diclofenac sodium, 
phenylbutazone).  
2. Drugs decreasing blood concentration of uric acid. 
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2.1. Drugs reducing uric acid synthesis: allopurinol and 
febuxostat .   
2.2. Drugs increasing uric acid excretion by kidneys (uricosuric 
drugs): sulf inpyrazone, etabenecid, probenecid,  urodanum, 
solimok. 
2.3. Drugs inhibiting synthesis and excretion of uric acid: 
benzbromarone  and Allomaron  (containing allopurinol and 
benzbromarone).  
Drugs of 2.2 and 2.3 groups are used to prevent gout attacks.  
Solimok , Uralyt-U , and Blemaren  are used to treat 
nephrolithiasis with domination of stones of urates. 
Allopurinol (Milurit )  is the inhibitor of xanthine oxidase 
(enzyme which catalizes the transformation of hypoxanthine and 
xanthine into the uric acid). The drug suppresses the synthesis of uric 
acid, decreases blood concentration of uric acid and its excretion 
with urine. Excretion of hypoxanthine and xanthine with urine is 
increased, but water solubility of these substances is higher than 
solubility of uric acid. In a body, allopurinol is metabolized into 
alloxanthine which also exerts ability to inhibit xanthine oxidase 
activity, but in less degree than allopuriniol. Thus, allopurinol 
decreases synthesis of uric acid and xanthine and hypoxanthine 
become the main final products of purine metabolism.    
Allopurinol is used to treat chronic gout, renal pathology or renal 
stones against background of hyperuricemia, tophaceous gout, and in 
patient showing significant and constant high plasma concentration 
of urates. 
Acute gout attack may arise during initial period of treatment by 
allopurinol. To prevent such complication, the drug is prescribed in 
minimal doses for first days of treatment. It is necessary to maintain 
diuresis on level at least two litres per day; pH of urine should be 
neutral or weakly-basic. Allopurinol is not used at gout attacks and 
during 3–4 week after it. Besides, it is reasonable to combine 
allopurinol with colchicine which is able prevent gout exacerbation. 
Allopurinol can cause such side effects as nausea, vomiting, diarrhea, 
peripheral neuritis, necrotizing vasculitis, inhibition of hemopoiesis 
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(even aplastic anemia), hepatic and renal damages, allergic reactions, 
etc. Allopurinol is deposited in lens with following development of 
cataract. The drug is contraindicated in pregnancy, lactation, to 
persons suffering from idiopathic hemochromatosis, etc. 
Febuxostat  (Adenuric) is new selective inhibitor of xanthine 
oxidase which decreases uric acid level in plasma of patients with 
chronic gout and violated renal function. In comparison with 
allopurinol, febuxostat has some advantages. Its therapeutic action is 
associated with reduction of blood concentration of uric acid by 
means of marked inhibition of different form of xanthine oxidase 
which are able transform one to another due to exchange of 
molybdenum ions. Febuxostat inhibits enzyme due to simultaneous 
binding by strong bonds with both oxidated and reduced forms  
of xanthine oxidase. Allopurinol binds mainly with reduced form of 
xanthine oxidase by weak bond. It should be noticed that structure  
of allopurinol allows it to participate in purine reactions that reduces 
its therapeutic effect. Molecules of febuxostat block permeability  
of narrow molybdenum channels that leads to stable inhibition of 
xanthine oxidase activity. Even first taken dose of febuxostat leads to 
long-lasting inhibition of enzyme. Therefore, therapeutic effect of the 
drug develops due to intake of less doses and less blood 
concentration of febuxostat.  
Unlike allopurinol, therapeutic doses of febuxostat do not affect 
other enzymes participating in purine and pyrimidine metabolism 
(guanine deaminase, orotidine 5’-phosphate decarboxylase, and 
purine nucleoside phosphorylase).   
Febuxostat is rapidly absorbed after oral intake. Its degree of 
binding with plasma proteins is about 100 %. The drug is 
metabolized only in liver by means of cytochrome P-450 system and 
conjugation by UDP-glucuronosyltransferase. Its half-life is  
5–8 hours. Renal excretion of febuxostat and its metabolites is less 
than 10 %; therefore, the drug is used in the treatment for gout in 
patients with chronic renal failure. It should be noticed that 
allopurinol, renal excretion of which is about 80 %, is 
contraindicated at chronic renal failure. 
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In initial period of therapy, febuxostat can increase plasma 
concentration of uric acid, thereby initiation of therapy with this drug 
should not congruent with period of gout exacerbation. Therapy is 
initiated in the absence of exacerbation with simultaneous intake of 
non-specific anti-inflammatory drugs or colchicine. Febuxostat may 
be combined with indomethacin or naproxen because it does not 
influence pharmacokinetics of these drugs. 
Сonsidering that febuxostat inhibits xanthine oxidase, its use 
with azathioprine and mercaptopurine is not recommended, because 
such combination can lead to elevation of blood concentration of 
these drugs. Azathioprine and mercaptopurine are structural 
analogues (antimetabolites) of adenine, guanine, and hypoxanthine; 
these drugs are metabolized in a liver by means of xanthine oxidase 
with formation of 6-thiourea. The same may be said about febuxostat 
use together with theophylline, caffeine, and other drugs which 
metabolized with formation of uric acid as final product.  
Besides, febuxostat is not recommended at secondary 
hyperuricemia arising due to cancer chemotherapy.  
Sulfinpyrazone  (Anturan) is pyrazolone derivative. The 
drug exerts uricosuric and antiagregative effects. Sulfinpyrazone 
increase renal excretion of uric acid owing to reduction of its 
reabsorption in proximal convoluted tubules. Besides, the drug 
decreases renal excretion of benzylpenicillin. After several weeks of 
treatment, Anturan promotes significant reduction of intensity and 
frequency of gout attacks, decreases joint pain and improves their 
mobility. Later, elimination of tophus and periartricular depositions 
of uric acid are observed. Also, the drug prevents formation of new 
lesions of gout. Therapy with sulfinpyrazone should be started at 
least in 2–3 weeks after the end of acute gout attack.  
It should be noticed that sulfinpyrazone decreases adhesion and 
aggregation of thrombocytes, inhibits synthesis of thromboxane A2, 
and protects vascular endothelium. In this regard, the drug may be 
used as alternative of acetylsalicylic acid. Because sulfinpyrazone 
irritates gastrointestinal tract it is taken at mealtime. 
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Side effects of sulfinpyrazone are gout exacerbation for firsts 
days of treatment, gastrointestinal disorders (even bleeding), skin 
rashes, and blood dyscrasias (aplastic anemia, leukopenia, 
thrombocytopenia, granulocytopenia, etc.). The drug intake should 
be discontinued if thrombocytopenia, leukopenia, or allergic 
reactions occurred. Sulfinpyrazone is contraindicated during 
exacerbation of erosive-ulcer lesions of gastrointestinal tract, 
functional disorders of liver and kidneys, etc. 
Etabenecid (Aethamidum) and probenecid  are derivatives 
of benzoic acid. Their mechanism of action is same with those  
of sulfinpyrazone. These drugs inhibit the reabsorbtion of uric acid in 
proximal convoluted tubules. Besides, both drugs decrease renal 
secretion of benzylpenicillin.  
Etebenecid is used to treat chronic gout, polyarthritis with 
disorders of purine metabolism, nephrolithiasis and urolithiasis of 
urate origin.  
Probenecid is used to treat symptomatic hyperuricemia and 
gouty arthritis in patients for which other drugs to treat 
hyperuricemia are contraindicated. Under probenecid action, 
an increase of uric acid excretion leads to elevation of its release 
from tissue depositions into blood that, in turn, can cause acute gout 
attack. Probenecid is contraindicated in acute gout attack and 
urolithiasis (especially at presence of urate concrements). Probenecid 
is no used in secondary hyperuricemia associated with cancer or 
therapy by chemotherapeutic drugs because this drug only increases 
secretion of uric acid and does not decrease its synthesis. 
Hyperuricemia, arising in this case, increases risk of nephropathy. 
The drug should be taken carefully by patients having ulcer disease 
in anamnesis. Probenecid may be ineffective in patients with chronic 
renal failure, especially if level of glomerular filtration is less than  
30 ml / min.  
Urodanum  is co-formulation containing piperazine phosphate, 
hexamethylentetramine, lithium benzoate, and some other salts 
which increase urine pH. Besides, lithium salts and piperazine form 
easily soluble salts with uric acid that increases its excretion from 
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a body. The drug is used to treat gout, nephrolithiasis, 
spondyloarthritis, and chronic polyarthritis. 
Benzbromarone  (Hipurik, Minurik)  exerts hypouricemic 
and uricosuric effects. Hypouricemic effect is associated with 
inhibition of enzymes participating in purine synthesis, and 
uricosuric action is due to inhibition of uric acid reabsorption in 
proximal convoluted tubules and increased its excretion by kidneys. 
The main indications for use of benzbromarone are gout, 
hyperuricemia, psoriasis, and hematological diseases.    
Allomaron  is co-formulated drug containing allopurinol and 
benzbromarone. The drug exerts hypouricemic and uricosuric effects.  
Colchicine  is alkaloid obtained from Colchicum autumnale. 
The drug exerts marked anti-inflammatory effect at acute gout 
attacks. Colchicine inhibits proliferation of granulocytes and their 
migration into inflammatory regions. Besides, colchicine reduces 
phagocytosis of crystals of uric acid salts and slows down their 
deposition in tissues. The drug prevents mytosis and degranulation  
of neutrophils, stabilizes lysosomal membranes, decreases release of 
lysosomal enzymes, and inhibits synthesis of prostaglandins and 
leukotriene B4 which are mediators of acute gouty inflammation. 
Also, colchicine decreases formation of lactic acid and prevents 
tissue acidosis and, due to this, restricts crystallization of urates.  
It must be understood that between these mechanisms there are no 
reduction of uric acid concentration in blood and elevation of its 
body excretion.  
Colchicine is readily absorbed in gastrointestinal tract. Its 
maximum concentration in plasma is observed about 1–2 hours after 
oral intake. the drug is excreted from a body by kidneys and 
intestine.  
Anti-gout efficacy of colchicine is reduced by cytostatics and 
drugs which acidifying urine. And vice versa, drugs, enhancing pH 
of urine, increase colchicine efficacy.  
Colchicine is used to treat gout, to facilitate patient state at acute 
gout, and to prevent gout exacerbation (especially during first several 
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months of therapy with allopurinol and drugs promoting uric acid 
excretion).  
Blemaren allows maintain urine pH within interval 6,6–6,8 
that creates optimal conditions to increase dissolution of uric acid 
salts.  
Long-lasting intake of blemaren leads to dissolution of urate stones 
and prevents their formation. Blemaren is used to treat urolithiasis 
with domination of urates and to prevent formation of urate stones.     
Solimok  is co-formulation containing potassium citrate, sodium 
citrate, and citric acid. The drug increases urine pH and promotes 
dissolution of urate stones, decrease of their size, and their 
spontaneous discharge. Solimok is used to treat gout, and in cases of 
occurrence of urate stones in kidneys, ureters, or bladder. 
Like Solimok, Uralyt-U  contains potassium citrate, sodium 
citrate, and citric acid. The drug maintains urine pH within range 
6,2–7,5 when uric acid salts are soluble and do not form 
concrements. The drug is used to dissolve urate concrements and to 
prevent their following formation. Besides, Uralyt-U is used during 
ttherapy with cytostatics and in the treatment for porphyria cutanea 
tarda.     
 
Tablte 14 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route 
of administration 
Drug product  
Aethamidum  Orally 0.35 g 4 times a day  Tablets 0.35 g 
Allopurinolum  Orally 0.1–0.2 g once a day  Tablets 0.1 g 
Febuxostatum Orally 0.08–0.12 g 1 time  
a day 
Coated tablets 0.08  
or 0.12 g 
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Step 1. Tasks for Self -Control  
Drugs to Treat Goat 
 
1. A 42-year-old man suffering from gout has increased level of 
urinary acid in the blood. Allopurinol was prescribed to decrease the 
level of urinary acid. Competitive inhibitor of what enzyme is 
allopurinol? 
A. Adenine phosphoribosyltransferase. 
B. Xanthine oxidase.  
C. Guanine deaminase.  
D. Adenosine deaminase. 
E. Hypoxantine phosphoribosyltransferase. 
2. A doctor administered allopurinol to a 26-year-old man with 
symptoms of gout. What pharmacological action of allopurinol 
ensures therapeutic effect? 
A. General analgesic effect. 
B. General anti-inflammatory effect. 
C. Inhibiting leucocyte migration into the joint. 
D. Increasing uric acid excretion. 
E. Inhibiting uric acid synthesis.  
3. Acute uric acid nephropathy, which is characterized by the 
acute overproduction of uric acid and by extreme hyperuricemia, can 
best be prevented with which of the following? 
A. Sodium chloride. 
B. Aethamidum. 
C. Allopurinol.  
D. Amiloride. 
E. Antidiuretic hormone. 
4. The most widely used agent for the treatment of acute gouty 
arthritis is: 
A. Phenylbutazone. 
B. Allopurinol. 
C. Probenecid. 
D. Colchicine.  
E. Indomethacin. 
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5. The mechanism by which probenecid lowers plasma levels of 
uric acid is by: 
A. Promoting tubular reabsorption of uric acid. 
B. Inhibiting production of uric acid in the liver. 
C. Promoting tubular secretion of uric acid. 
D. Inhibiting breakdown of purines to uric acid. 
E. Inhibiting proximal tubular reabsorption of uric acid. 
6. Allopurinol reduces serum urate levels by: 
A. Promoting tubular reabsorption of uric acid. 
B. Inhibiting uric acid synthesis.  
C. Impairing renal urate reabsorption. 
D. Decreasing metabolism of uric acid. 
E. Promoting the active secretion of uric acid in kidneys. 
 
 
PLASMA SUBSTITUTES  
SOLUTIONS FOR MAINTAIN OF WATER-SALT 
AND ACID-BASIC BALANCE  
DRUGS FOR PARENTERAL NUTRITION 
 
Plasma Substitutes  
 
Plasma substitutes are drugs which are used to restore normal 
circulating blood volume. These drugs should have sufficient 
molecular weight to prevent penetration of drug molecules from 
bloodstream into tissues and to maintain stable osmotic pressure. 
Plasma substitutes should be nontoxic and easily excreted from 
a body.  
Donor blood plasma  contains all components of the fluid part 
of human blood. Fresh frozen plasma is stored up to 6 months; dried 
plasma is kept during several years. Plasma is used to eliminate 
circulating blood volume deficit in severe bleeding, plasma loss, or 
dehydration, to improve rheological blood properties, and to decrease 
the risk of thrombosis. 
Hypotonic, hypertonic, and isotonic blood plasma are used. 
Plasma is administered intravenously drop-by-drop or as intravenous 
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push. Administered plasma should be identical with the blood group 
of the recipient. Volume of administered plasma is 0.5–2 l. Plasma 
administration may provoke allergic reactions.  
Ceruloplasmin freeze-dried for injections is  
a copper-containing glycoprotein relating to α-globulin fraction of 
the blood serum. The drug stabilizes cellular membranes, normalizes 
lipid peroxidation, stimulates erythropoiesis, exerts detoxifying 
action, etc. Therapeutic indications for ceruloplasmin are blood loss, 
intoxication, anemia, sepsis, oncological diseases, etc.   
Dextrans are polysaccharides dissolved in isotonic solution of 
sodium chloride or glucose. Dextrans are obtained from culture of 
some microorganisms. Dextran preparations are polyglucin  
(molecular weight about 60 000) and rheopolyglucin  (molecular 
weight about 35 000). Due to less molecular weight, rheopolyglucin 
influences rheological properties of the blood positively and reduces 
platelet aggregation. Rheopolyglucin is used to treat ischemic stroke, 
myocardial infarction, acute pancreatitis, significant blood loss, etc. 
The drug is administered in postoperative period to decrease 
thrombosis risk. Administered volume varies from  
400–1 200 ml up to 2 500 ml. In a body, dextrans undergo partial 
hydrolysis and are excreted by kidneys. Dextrans are contraindicated 
in craniocerebral injury with increased intracranial pressure and in 
hemorrhagic stroke. 
Rheogluman  is co-formulation containing 10 % dextran 
solution, 5 % mannitol solution, and isotonic sodium chloride 
solution. Its properties are similar to the properties of rheopolyglucin. 
Besides, the drug stimulates diuresis. 
Gelatinol  is a hydrolyzate of gelatin with molecular weight 
20 000. The drug increases circulating blood volume, decreases 
platelet aggregation, and eliminates metabolic acidosis. Therapeutic 
indications for gelatinol are blood loss, intoxications, acute 
pancreatitis, hepatatis, peritonitis, etc.  Gelatinol is administered as 
intravenous push or drop-by-drop. 
Hemodez (polyvidone) is a solution of low-molecular-weight 
polyvinylpyrrolidone (molecular weight about 15 000) dissolved in 
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polyelectrolyte solution which contains cations of sodium, calcium, 
magnesium, and potassium, chlorine anions, and bicarbonate. 
Hemodez increases circulating blood volume, improves rheological 
properties of blood, collects interstitial fluid into bloodstream, and 
stimulates diuresis. Hemodez sorbs different toxins circulating in 
blood and eliminates them through the kidneys. Hemodez is used in 
the treatment for burn disease, severe dysentery, enterocolitis, sepsis, 
peritonitis, post-traumatic and postoperative intoxications, 
craniocerebral injuries with brain oedema, etc. About 80 % 
administered Hemodez is excreted from a body for 4 hours. Side 
effects of the drug are hypotension, tachycardia, and difficulty 
breathing. Contraindications for Hemodez are bronchial asthma, 
acute nephritis, and cerebral hemorrhage.   
Neohemodez  is a 6 % solution of low-molecular-weight 
polyvinylpyrrolidone with molecular weight 6 000–10 000 D. It is 
a complexing agent which binds toxins and excretes them with urine. 
The drug improves microcirculation and tissue oxygenation. 
Neohemodez improves renal circulation and stimulates diuresis. 
Neohemodez is administered intravenously drop-by-drop in the 
treatment for different intoxications. Its side effects are hypotension 
and allergic reactions. 
Polydez  is 3 % solution of low-molecular wheight polyvinyl 
alcohol in isotonic sodium chloride solution. The drug increases 
circulating blood volume, improves tissue oxygenation, exerts 
desintoxicated effect. Polydez is used in the treatment for blood loss, 
surgical shock, intoxications, sepsis, etc. The drug is administered 
intravenously drop-by-drop.  
There are hypertonic and isotonic solutions of starch: Refortan, 
Stabisol,  HAES-steril,  and Infukoll HES . These drugs increase 
circulating blood volume, improve rheological properties of blood 
and microcirculation. The drugs are used in the treatment for sepsis 
and shocks.  
Sorbitol  is the hexatomic alcohol which is administered 
intravenously streamly or drop-by-drop. Sorbitol undergoes 
biotransfor-mation in liver with further formation of fructose which 
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provides dietery energy. Simultaneously, the concentrations of 
choline and glycogen are increased in a body. Therapeutic 
indications for sorbitol are blood loss, intoxications, hepatic diseases, 
renal failure, increased intracranial pressure, brain oedema, and 
pulmonary oedema. 
Different solutions of electrolytes are used for intravenous 
administration to eliminate dehydration. Dehydration can result from 
vomiting or diarrhea, after surgery, in burns, severe blood loss, etc. 
Electrolyte solutions improve rheological properties of blood and 
restore circulating blood volume. The following electrolyte solutions 
are used in medicine: isotonic sodium chloride solution , 
Ringer solution, Locke-Ringer solution ,  “Acesol”, 
“Lactosol”,  polarizing mixture (contains potassium chloride, 
glucose, and insulin),  etc. If parenteral administration is impossible 
and contraindications are absence (unconsciousness, vomiting, 
penetrating wounds of abdomen, etc.), peroral administration  
of 1–1.5 l of electrolyte solution is used.  
General contraindications for administration of electrolyte 
solutions are heart failure, risk of brain or lung oedema, cerebral 
hemorrhage, and acute renal failure.  
Solutions without potassium are contraindicated in hyponatremia 
and hypokalemia; potassium-containing solutions are contraindicated 
in hyperkalemia and renal failure. Presence of bicarbonate or lactate 
sodium in some solutions (e. g., “Lactosol”) allows to decrease 
severe damages and intoxications but do not eliminate disorders  
of acid-base balance.  
Asparcamum (Panangin)  is used to correct deficiency of 
potassium ions in a heart and intestinal wall. Asparcam is used to 
treat tachyarrhythmias (in myocardial infarction, overdose of cardiac 
glycosides), postoperative paresis of intestine, and paralytic ileus. 
Polarizing mixture is also used with same end in view.    
Disorders of acid-base balance requires intensive therapy. 
Metabolic acidosis is the most common disturbance. Normal blood 
pH is 7.34–7.4. A decrease of pH to 7.3–7.25 is accompanied by 
metabolic and functional disorders. The following pathological 
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processes are developed in a body: multiple microthrombosis, 
hypoxia, increased vascular permeability, disorders of energy 
metabolism, and functional disorders of central nervous system, 
heart, kidneys, liver, and lungs. Compatible with life values of pH 
vary between 6,8–7,8. Buffered solutions, binding hydrogen ions and 
eliminating them through kidneys, are used to compensate acidosis. 
Preparations of buffered solutions are trisamine, tromethamol ,  
sodium hydrocarbonate, sodium lactate,  etc. These drugs are 
administered intravenously drop-by-drop. 
Treatment of metabolic alkalosis is a significantly more difficult 
task. Alkalosis results in hypokalemia with disorders of heart rhythm 
and myocardial contractility, convulsions, disorders of 
neuromuscular transmission. Ammonium chloride  solution  and 
diacarb  (acetazolamide) are used to correct alkalosis. In severe 
alkalosis, careful administration of hydrochloric acid  in 5 % 
glucose solution is used under control of blood pH. 
Drugs for parenteral nutrition  are solutions of 
carbohydrates, lipids, and amino acids. These drugs are used when 
enteral nutrition is impossible: intestinal obstruction, severe diarrhea 
or vomiting, disorders of digestion and absorption, etc. 
Isotonic (5 %) and hypertonic (10–40 %) solutions of  
glucose  are administered intravenously. Isotonic glucose solution is 
used as plasma substituting agent to restore blood volume. 
Simultaneously, glucose is a nutrient. Hypertonic glucose solutions 
are administered to treat brain or pulmonary oedema. Administration 
of hypertonic solutions improves the detoxifying function of a liver 
and increases myocardial contractility and diuresis. Glucose 
solutions are used in the treatment for hypoglycemia, liver dystrophy, 
brain and lung oedema, cardiac decompensation, shock, and collapse. 
Glucose solution with methylene blue is used to treat poisoning by 
hydrocyanic acid. 
Fat emulsions (lipofundin, intralipid , etc.) are used for 
intravenous administration. They are 10 % and 20 % emulsions of 
purified soybean and cottonseed oils, in which soybean 
phospholipids or egg yolk are used as an emulsifier. Energy value of 
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1 l of 20 % lipofundin is within the daily needs of a healthy person 
(about 2 000 kcal). Besides, fat emulsions provide the need of 
essential unsaturated fatty acids. 
Amino acid solutions (vamin, intrafusin , aminosol , 
aminosteril  N-Hepa, hydrolysin, aminosol, aminoped , etc.) 
are also used for parenteral nutrition. About 1–2 l of such solutions 
are administered in a body for providing daily amino acid 
requirements. Amino acid solutions are contraindicated in shock, 
acute hemodynamic disturbances, acute renal and hepatic failure, 
uremia, acidosis, and hypokalemia.  
 
Acids and Alkalis.  Salts of  Alkali   
and Alkaline Earth Metals  
 
Acids 
 
Acids are required for maintenance of acid-base balance. Also, 
acids exhibit antimicrobial, local, reflex, and resorptive effects. 
Antimicrobial effect of the acids is the result of the influence of 
hydrogen ion upon proteins of bacterial cells with the following their 
dehydration and denaturation. 
Local effect of the acids occurs due to formation of albumins. 
Depending on concentration of hydrogen ions, the acid interacts with 
albumins that results in astringent, irritating, or cauterizing effects. 
Weak acids (most of organic acids) and strong acids (inorganic 
acids) in low concentrations exert astringent effect due to protein 
denaturation in superficial layers of skin and mucous membranes. 
Denaturation of proteins in deeper layers results in cauterizing effect.  
Resorptive action of acids occurs due to interaction of hydrogen 
ions with buffer system of blood. It results in compensated and 
uncompensated acidosis.  
Boric, salicylic , and benzoic acids  are used topically. 
Boric acid exhibits astringent, anti-inflammatory, and antimicrobial 
(including antifungal) effects. In case of resorptive action, boric acid 
is accumulated in a body that leads to damages of kidney 
parenchyma. 
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Salicylic acid exerts keratoplastic (1–2 % solutions) and 
keratolytic (3–10 % solutions) effects. Besides, salicylic acid exhibits 
irritative, anti-inflammatory, antibacterial, and antifungal effects.   
Benzoic acid is used as an antibacterial agent. In case of oral 
intake, benzoic acid stimulates bronchial secretion and may be used 
as an expectorant agent.  
Diluted hydrochloric acid  (3–8 % solutions) is taken orally 
to treat hypoacidic gastritis, dyspepsia, and hypochromic anemia. 
Also, hydrochloric acid exerts antimicrobial effect. 
Poisoning by acids is accompanied by acidosis and symptoms of 
their influence upon mucous membranes (burns of gastrointestinal 
mucosa, gastric pain, vomiting, diarrhea, and painful shock). 
Uncompensated acidosis can cause loss of consciousness, dyspnea, 
sudden increase in blood pressure, and convulsions. Death develops 
due to respiratory paralysis. Treatment of poisoning includes the 
following measures: neutralisation of acids, gastric lavage with water 
or suspension of magnesium oxide, and intake of covering agents 
(e. g., milk, egg white). To prevent shock, opioid analgesics (e. g., 
morphine, promedol) are administered. To reduce acidosis, sodium 
hydrocarbonate is administered orally, rectally, or intravenously. 
Simptomatic therapy is also used. 
The following amino acids which are used in medicine 
glutamic acid , methionine, glycine, cysteine,  histidine,  
taurine , etc. Glutamic acid is used in the treatment for central 
nervous system diseases: epilepsy and psychosis. Methionine is used 
to treat liver diseases and dystrophy. Therapeutic indications for 
histidine are hepatitis and ulcer disease of stomach or duodenum. 
Glycine is used in the treatment for depression and alcoholism. 
Cysteine and taurine are used in ophthalmology.  
 
Alkalis  
 
Sodium hydrocarbonate  is used as cleansing agent in the 
treatment for inflammatory diseases of mucosa. The drug exerts 
antibacterial, antimicotic, and irritative effects. Also, sodium 
hydrocarbonate improves microcirculation. In case of oral intake, 
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sodium hydrocarbonate exhibits antacid and expectorant effects. 
Solution of sodium hydrocarbonate is administered intravenously to 
reduce acidosis. 
Magnesium oxide  is an antacid with laxative effect.  
Suspension of aluminium hydroxide  is taken orally as an 
antacid and covering agent for treatment of hyperacidic gastritis and 
ulcer disease. 
Ammonium solution  is used as an antiseptic. Besides, this 
agent irritates the mucosa and reflexively stimulates respiratory 
centre. Therefore, it is used as a respiratory stimulant. 
 
Drugs of Alkali and Alkaline Earth Metals  
 
The main function of these drugs is to maintain ionic 
composition and osmotic pressure in the organism.  
Sodium chloride . In medicine, sodium chloride is used in 
solutions of the following concentrations: isotonic (about 0.9 %), 
hypotonic (0.45–0.6 %), and hypertonic (2–10 %).  
Isotonic sodium chloride solution is used for restoration of blood 
volume in collaps, shock, hemorrhage, diarhea, or vomiting. It is 
used for washing eyes and mucosa.  
Hypertonic solutions are used for treatment of purulent wounds, 
for constipation, and for gastric lavage in poisoning with silver 
compounds. 
Hypotonic solutions are used for preparation of local anaesthetic 
solutions (hypotonic solution prevents the absorption of the 
anaesthetic into the blood). Besides, 0.45 % solution is administered 
intravenously for treatment of hyperosmolar diabetic coma.   
Potassium-contaning drugs are: potassium chloride,  
Asparcamum, Panangin,  and polarizing mixture . These 
drugs are used for treatment of hypokalemia, tachyarrhythmias, 
ischaemic heart disease, and hypotrophy.  
Calcium-containing drugs are: calcium chloride , calcium 
gluconate, calcium glycerophosphate ,  and calcium 
lactate . These drugs exhibit antiallergic and anti-inflammatory 
effects. The agents reduce the permeability of vessel walls. Calcium-
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containing drugs are used for treatment of allergic diseases, bleeding, 
hypofunction of parathyroid glands, poisoning with magnesium salts 
and oxalic acid, osteoporosis, bone fractures, rickets, etc. 
Magnesium-contaning drugs are magnesium oxide  and 
magnesium sulfate . Magnesium sulfate exhibits the 
antispasmodic, anticonvulsive, sedative, curare-like, and ganglion 
blocking effects. In case of parenteral administration, magnesium 
sulfate lowers blood pressure and exhibits antiarrhythmic effect. 
Therapeutic indications for magnesium sulfate are hypertensive 
crisis, convulsions, eclampsia, tachyarrhythmias due to cardiac 
glycoside poisoning and hypokalemia.  
Magnesium oxide is used as an antacid in the treatment for ulcer 
disease and hyperacid gastritis. 
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ANTIMICROBIAL AND ANTIPARASITIC 
DRUGS 
  
ANTISEPTICS AND DISINFECTANT DRUGS 
 
 
According to statistics, about 40–50 % of all human diseases are 
caused by different parasites (bacteria, spirochetes, rickettsia, 
chlamydia, fungi, viruses, and protozoa which account about  
1 000 species). Besides, diseases may be caused by helminths and 
arthropods. Drugs, which are used to combat human pathogens, are 
divided into 2 groups: 
– antiseptics and disinfectant drugs; 
– chemotherapeutic drugs.  
Antiseptics are used to combat human pathogens on the body 
surface (skin and mucosa). Sometimes, antiseptics are used to 
combat human pathogens in gastrointestinal and urinary tracts. 
Disinfectant drugs are used to destruct pathogens in the 
environment: disinfection of medical instruments, medical supplies 
for nurses, dishes, clothes, rooms, and patient care equipment.  
Antiseptics and disinfectants should have marked antibacterial 
and antiparasital effect. Simultaneously, these agents should be safe 
for human, don’t irritate tissues, and don’t damage instruments.  
Division of drugs into antiseptics and disinfectants is somewhat 
relative, because some antiseptics in high concentrations are used for 
disinfection of the environment.  
Chemotherapeutic agents are used to combat human pathogens 
into the organism. These drugs have high selective action upon 
certain species of microorganisms. Chemotherapeutic drugs should 
not affect the main functions of human organism. These drugs are 
used to prevent and treat infections.  
It should be noted that some chemotherapeutic drugs may be 
used as antiseptics (e. g., furacilinum).  
According to chemical structure, antiseptics and disinfectants are 
classified into the following groups:  
1. Detergents: cerigelum, aethonium, chlorhexidine, 
benzalconium chloride, etc.  
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2. Nitrofuran derivatives: furacilinum  (nitrofural).  
3. Phenol group: phenol, resorcin, ichthyol, wood-tar, 
and lysol .  
4. Stains: brilliant green, ethacridine lactate  (Rivanol), 
and methylene blue.  
5. Halogens:  
– chlorine compounds: bleaching powder, chloramine B, 
and pantocide ;  
– iodine compounds: alcohol solution of iodine ,  Lugol’s 
solution, iodinol , and  iodovidonum .  
6. Oxidisers: hydrogen peroxide and potassium 
permanganate .  
7. Heavy metal compounds:   
– silver-containing drugs: silver nitrate,  Protargolum, and 
Collargolum ; 
– zinc-containing drugs: zinc sulfate and zinc oxide; 
– copper-containing drugs: copper sulfate ; 
– mercury-containing drugs: yellow mercury oxide,  
mercuric chloride (mercury (II) chloride), and  mercury 
ammonium chloride ; 
– bismuth-containing drugs: bismuth nitrate , xeroform, and 
dermatol .  
8. Alcohols: ethanol .  
9. Aldehydes: formaldehyde and hexamethylenetetramine  
(urotropine).   
10. Acids and alkalies: boric acid, salicylic acid , aqueous 
ammonium solution, and  sodium hydrocarbonate solution .   
 
Detergents  
 
Detergents are synthetic compounds with high surface activity 
which exhibit the marked antiseptic and detergent (washing) 
properties. Detergent drugs include organic substances containing 
two positively charged nitrogen atoms (cationic detergents) and some 
negatively charged compounds (anionic detergents). Detergent 
molecules are accumulated on the surface of the phase separation. 
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Antibacterial activity of detergents is due to their ability to decrease 
the surface tension that leads to disruption of cell membrane 
permeability of microorganisms. The ensuing disturbances of 
osmotic balance lead to death of microorganisms. 
Anionic detergents include such agents as green soap  and 
laundry soap . These agents are sodium or potassium salts of fatty 
acids with long hydrocarbon chain. Anionic detergents are less active 
than cationic detergents. Anionic detergents are used for laundry, wet 
cleaning, handwashing, disinfection, etc. Green soap is a component 
of Wilkinson’s ointment. 
Cationic detergents exhibit bactericidal effect against bacteria, 
fungi, viruses, and some protozoa. Cationic detergents include such 
agents as cerigelum, miramistin, chlorhexidine , etc. These 
agents are used for surgical hand preparation; disinfection of 
operative field and instruments; washing bladder, wounds, infected 
cavities, etc. Cationic detergents cannot be combined with anionic 
ones, because the antimicrobial activity reduces due to such 
combination. It should be noted that activity of cationic detergents is 
decreased in protein environment (e. g., presence of pus). 
 
Nitrofuran Derivatives  
 
Nitrofuran derivatives exhibit high antimicrobial activity and 
low toxicity. Thereby, these agents are used as both antiseptics and 
chemotherapeutic drugs. Drugs exhibit bacteriostatic or bactericidal 
effects depending on the doses used. Mechanism of nitrofuran’s 
action is based on ability of their nitro groups to reduce into amino 
groups. Nitrofurans compete with natural hydrogen acceptors of 
microbial cells. Due to this ability, the agents slow down the cellular 
respiration and destroy energetic balance of microorganisms. 
Spectrum of antimicrobial action of nitrofurans includes  
Gram-positive and Gram-negative bacteria, fungi, and protozoa 
(chlamydia, giardia, and trichomonas).  
Furacilinum  (nitrofural) and furazolidone  are derivatives 
of nitrofuran used as antiseptics. Water solution of furacilinum is 
used to treat wounds, burns, otitis; for nasal and pleural lavage. Eye 
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drops with furacilinum are used to treat conjunctivitis and 
blepharitis. Sometimes, furacilinum is used in dysentery treatment. 
Furacilinum is a component of such drugs as Furaplastum  and 
Lifusolum . Furaplastum is used to treat wounds and minor skin 
injuries (bruises, scratches, cracks, etc.). The agent forms protective 
layer on the damaged surface and improves healing. Lifusolum, the 
drug aerosol, is used to treat wounds.  
Antibacterial activity of furazolidone  against gram-negative 
bacteria, giardia, and trichomonas is significantly higher than activity 
of furacilinum. Furazolidone is used mainly as chemotherapeutic 
agent. 
Side effects of nitrofurans are dyspepsia, headache, disiness, and 
allergic reactions.  
 
Phenol Group 
 
Phenol  is the oldest antiseptic agent. It is used as a standard to 
estimate activity of other antiseptics and disinfectants. Phenol in low 
concentrations exhibits bacteriostatic effect. Phenol in high (1–5 %) 
concentrations has bactericidal effect. Phenol destroys the 
permeability of the cell membrane and blocks the activity of 
dehydrogenase. The agent has a wide spectrum of action. Proteins do 
not reduce the activity of phenol.  
Phenol easily penetrates through skin and mucous membranes. 
Poisoning by phenol is manifested by dizziness, weakness, dyspnea, 
tachycardia, sweating, and sonitus. Collapse and significant 
disturbances of respiration develop in severe cases. If phenol was 
taken perorally, a poisoned patient needs gastric lavage with 
vegetable oil. Affected regions of skin should be washed by 50 % 
ethyl alcohol or vegetable oil. In case of central nervous system 
depression, stimulating agents should be administered. 
Phenol in form of 2–5 % carbolic soap mixture is used to 
disinfect rooms, supplies for nurses, clothes, and places contaminated 
with feces. With the same end in view, lysol and tricresol are used in 
medicine. 
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Vagothyl  is a 36 % water solution of polyethylene-metacresol-
sulfonic acid. The drug exhibits bactericidal effect and high activity 
against trichomonads. Vagothyl is used to treat cervical erosion, 
bladder diseases, and ulcers of lower extrimities. 
Phenyl salicylate  is a phenyl ester of salicylic acid. In 
intestine, this agent is cleft with formation of phenol and salicylic 
acid. The drug is used to treat infective diseases of bowels, bile 
ducts, and urinary tract. 
Resorcin  is a derivative of phenol. Resorcin exhibits both 
keratoplastic (in concentrations about 2 %) and keratolytic (in 
concentrations about 20 %) effects. The drug is used to treat 
seborrhea, eczema, herpes, ringworm, etc.  
Wood tar  and ichthyol  are agents which are also containing 
phenol and its derivatives. These drugs are widely used to treat 
bacterial and parasitic skin diseases. Ointments and liniments with 
wood tar are used to treat eczema, psoriasis, furunculosis, etc. Wood 
tar is included in Vishnevsky ointment  (tretment of wounds, 
burns, ulcers, and bedsores) and Wilkinson ointment  (treatment 
for scab and fungal diseases).  
Thymol  is a phenol derivative which is included in aerosol 
Hexaspray  and in pastilles Septolete  and Hexadreps . These 
drugs are used to treat the diseases of throat and pharynx.  
      
Dyes 
 
Soluble dyes include such colouring agents as brilliant green, 
ethacridine lactate , and methylene blue  (Rivanol). Dyes 
occupy the intermediate position between antiseptics and 
chemotherapeutic drugs. Dyes have certain selectivity against 
microorganisms and are sometimes used for resorptive action. All 
agents are effective in treatment for coccal infections. The dyes are 
characterised by low toxicity. They affect the permeability of 
bacterial cell membranes which causes osmotic disbalance and lysis 
of microorganisms. Besides, dyes inhibit the activity of catalase, 
galactosidases, and other enzymes. 
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Brilliant green  is active against staphylococci, 
corynebacterium diphtheriae, and other Gram-positive bacteria. This 
agent is used as 1–2 % alcoholic (or water) solution for 
the lubrication of wounds, pustular skin lesions, blepharitis, etc.  
Methylene blue  is characterised by less antibacterial activity 
than brilliant green. But the agent exhibits antimycotic activity. 
Ability of methylene blue to attach and release hydrogen atoms is 
used in the treatment of poisoning by cyanides. In this case,  
50–100 ml of a 1 % solution of the drug is administered 
intravenously. Methylene blue transforms hemoglobin into 
methemoglobin. The latter substance interacts with cyanides to form 
non-toxic cyanmethemoglobin. Also, methylene blue is used to treat 
burns, cystitis, urethritis, to wash body cavities, etc.  
Ethacridine lactate (Rivanol)  is a bacteriostatic agent with 
slowly developing effect. Rivanol is used in ointments, pastes, and 
solutions for external application. Therapeutic indications for 
Rivanol are purulent wounds, burns, washing body cavities, etc. 
Ethacridine lactate is a non-toxic agent.  
 
Halogen-Containing Drugs:  
 
Chlorine-Containing Drugs  
 
Chlorine-releasing agents are chloramine B, chlorhexidine , 
and household  bleach . These agents have high antimicrobial 
activity and broad spectrum of action. Chlorine-containing drugs are 
active against bacteria, viruses, and amoeba. Acid-fast bacilli  
(e. g., Mycobacterium tuberculosis) are less sensitive to chlorine-
containing drugs. In an aqueous environment, chlorine-containing 
compounds decompose with the release of atomic chlorine which 
interacts with cytoplasmatic proteins of microorganisms. In proteins, 
chlorine ions replace the hydrogen ions that makes hydrogen bond 
formation between polypeptide chains impossible. Due to this fact, 
secondary structure of proteins is disrupted. Chlorine-releasing 
agents also have deodorizing properties. Household bleach is used as 
disinfectant.  
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Chloramine B  is used as an antiseptic. Its effect develops 
slowly and lasts for a long time. Chloramine B has also antimycotic 
activity. The agent is used to wash infected wounds, operative field, 
and hands. Chloramine B is also used in disinfection of instruments 
and rooms. 
Chlorhexidine  is one of the most effective antiseptics. Water 
and alcoholic solutions of chlorhexidine are used to sterilize 
instruments, wash wounds, burns, bladder, and hands. The agent is 
also used in room disinfection.   
 
Iodine-Containing Drugs  
 
Action mechanism of iodine-containing drugs is associated with 
interaction of N-groups of proteins with iodine. This interaction leads 
to coagulation of microorganism proteins. Antibacterial spectrum of 
iodine-containing drugs is very broad. Iodine-containing drugs are 
used as both antiseptics and agents for resorptive action. Thus, 
radioactive iodine is used in diagnostics and treatment of thyroid 
gland diseases. Radioactive iodine compounds are used to diagnose 
liver, kidney, bronchi, uterus, and vessels diseases. 
Alcoholic iodine  solution is used in disinfection of 
a surgeon’s hands and an operative area, in the fungal disease 
treatment, and in lubrication of wounds. Besides, distracting effect  
of this agent is used in treatment for myositis and neuralgia. 
Lugol’s solution  contains iodine in water solution  
of potassium iodide. The drug is used in mucous membranes of 
pharynx and larynx treatment. 
Today, complex compounds of iodine with macromolecular 
surfactants are introduced in medicine: Iodinol, Iodovidonum, 
Iodonatum , etc. These compounds are called iodophors. Their 
advantage over alcoholic iodine solution is that these agents are 
water-soluble and have high bactericidal and absorptive activity, 
don't irritate skin and don't provoke the allergic reactions. Iodophores 
are used to cleanse mucous membranes of mouth and nasopharynx, 
to disinfect an operative area, treat wounds, burns, ulcers, etc.  
403 
 
Ioddicerinum  is a mixture of iodine, dimexidum, and 
glycerine. The drug has a broad spectrum of antimicrobial actions. 
Ioddicerinum is used in the treatment of infections of skin, mucous 
membranes, wounds, etc., caused by Staphylococcus, meningococci, 
Neisseria gonorrhoeae, Klebsiella, Shigella, Proteus, virus of herpes 
and varicella zoster, Chlamydia, etc. 
 
Oxidizers  
 
Group of oxidizers contains hydrogen peroxide  and 
potassium permanganate . Oxidizers change redox potential and 
therefore violate the normal physiological redox processes in 
microorganisms.  
Under the influence of catalase, hydrogen peroxide  
decomposes with the release of molecular oxygen which exhibits low 
antimicrobial activity. Also, the process of decomposition is 
accompanied by formation of significant amount of foam. This foam 
washes away pus, blood clots, and dead tissue from the wounds. 
Therefore, hydrogen peroxide cleans the wounds. A 3% hydrogen 
peroxide solution is used to rins the mouth and throat, in treatment of 
purulent otitis media, and to stop nasal bleeding (release of oxygen 
accelerates the transformation of fibrinogen into fibrin). 
Potassium permanganate  exhibits higher antiseptic activity 
because it releases atomic oxigen which oxidizes biological 
substances. Also, potassium permanganate causes astringent, 
irritative, deodorant, and cauterizing effects. Potassium 
permanganate is used in gastric lavage in treatment of poisoning 
(0.02–0.1 % solutions) caused by poisons which are oxidized by 
potassium permanganate (e. g., morphine); in cleaning wounds, 
washing urethra and vagina (0.01–0.5 % water solutions); in 
treatment of burns (2–5 % water solutions).  
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Heavy Metal Compounds 
 
Heavy metals (silver, mercury, copper, bismuth, etc.) interact 
with proteins of microbial cells with the formation of albuminates. 
Heavy metals preparations exhibit the fast and marked bactericidal 
effect. Some drugs have atypical for other antiseptics activity against 
certain microorganisms. Thus, mercury and bismuth preparations are 
active against Treponema pallidum, silver preparations – against 
cocci. 
Mechanism of action of heavy metal preparations is the 
following: ions of metal interact with SH2-groups of proteins. 
Inactivation of SH-containing enzymes needs significantly less metal 
concentrations in cells than necessary for protein coagulation. This 
inactivation results in disruption of bacterial cell metabolism and 
growth inhibition of microorganisms. Besides, heavy metal salts 
influence proteins of skin and mucous membranes. Depending on 
concentration and the type of metal, the following effects can 
develop on the place of drug application: astringent, irritative, or 
cauterizing. These effects are based on the ability of salts to interact 
with tissue proteins with the formation of albiminates. The interation 
with only superficial layers of skin and mucosa is accompanied by 
formation of dense albuminates preventing the penetration of ions 
into the deep layers of tissues. In this case, the astringent effect 
develops. In case of loose albuminate formation, metal ions penetrate 
into the deep layers of tissues that results in cauterizing effect on the 
tissue, accompanied by tissue damage (necrosis). Professor 
Schmiedeberg made up a list of metals based on albuminate density:    
Pb, Al, ... Fe, Cu, Zn, ... Ag, Hg. 
Metals which are located in the left part of this list have mainly 
astringent and irritative actions. Metals which are located in the right 
part of Schmiedeberg’s list have cauterizing action. Metals which are 
located in the middle part of the list can exhibit all these actions in 
dependence on their concentration. 
In the human organism, salts of heavy metals are distributed 
irregularly: most of the drug is accumulated in bones, liver, kidneys, 
and bone marrow. Slow ellimination of heavy metal salts is carried 
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out by kidneys, sweat and salivary glands, and gastrointestinal 
mucosa. 
Silver-containing drugs are silver nitrate,  protargolum 
(silver proteinate), and collargolum (colloidal silver ). 
These drugs have antibacterial, astringent, and anti-inflammatory 
actions.  
Silver nitrate 1–2 % solution is used in the treatment for 
conjunctivitis. Silver nitrate 5–10 % solution or sticks are used in 
the treatment of trachoma, skin ulcers, erosion, and hypersarcosis. 
Protargolum and colargolum are used to treat conjunctivitis, rhinitis, 
urethritis, and chronic cystitis.  
Zinc and copper salts have astringent, iritative, cauterizing, and 
antibacterial actions. Copper sulfate  is used to treat conjunctivitis, 
urethritis, and vaginitis. Ophthalmic pencils with copper sulfate are 
used in the treatment of trachoma. Eye drops with zinc sulfate  and 
copper sulfate  are used in the treatment of conjunctivitis. Also, 
zinc sulfate solutions are used in the treatment for laryngitis, 
vaginitis, and urethritis. Zinc sulfate is the part of the dusting 
powders, ointments, and pastes.  
Water-soluble aluminum preparations have an astringent,  
anti-inflammatory, and antibacterial actions. Insoluble aluminum 
salts have an absorptive capacity. 
The preparations of lead are used as astringent and antibacterial 
agents in the treatment for pyderma, furunculosis, and carbuncles. 
Mercuric chloride (mercury (II) chloride )  and yellow 
mercury oxide  are used as antiseptics. Mercuric chloride is easily 
soluble in water and has high antibacterial activity. The agent is used 
to disinfect dishes, premises, etc. Mercuric chloride isn’t used to 
disinfect metal surfaces because it causes metal corrosion. For skin 
disinfection, mercuric chloride is used seldom due to high irritant 
effect. Eye ointment with yellow mercury oxide is used to treat 
conjunctivitis and keratitis. 
Bismuth preparations have no astringent and cauterizing effects. 
Antibacterial effect of bismuth salts is manifested due to blockage  
of HS-groups of bacterial enzymes. Besides, bismuth exerts 
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an antidiarrheal effect due to its ability to bind hydrogen sulfide in 
the intestine. Bismuth-containing drugs (dermatol  and xeroform) 
are used for treatment of the skin diseases (ulcers, eczema, and 
dermatitis). Also, bismuth-containing drugs are used to treat stomach 
ulcer and syphilis.  
At present, heavy metal salts are used seldom.  
High concentrations of heavy metal salts can cause acute 
poisoning with the initial excitation replaced by inhibition in the 
central nervous system. Simultaneously, the cardiac depression and 
paralytic dilation of capillaries are observed (especially caused in 
abdominal cavity). 
Chronic poisoning may be caused due to constant intake of 
heavy metal salts. 
The constant contact with lead or its salts can cause the chronic 
poisoning (saturnism) due to the accumulation of lead, mainly in 
bone tissue. Interaction between lead and hydrogen sulfide in the oral 
cavity causes formation of lead sulfide which forms the gray film on 
the gums. Later, blood disorders (anemia), abdominal pain attacks 
(lead colic), and damage to the peripheral nervous system (lead 
polyneuropathy) are observed. Lead polyneuropathy is characterized 
by a primary lesion of the motor fibers of peripheral nerves with the 
development of lead paralysis. The antidote – metal-complexing 
agent tetacinum-calcium – is used to treat lead poisoning. The drug is 
administered intravenously drop-by-drop. Besides, the drug is taken 
orally in dose 0.5 g 4 times a day. The treatment of acute lead 
poisoning includes subcutaneous administration of atropine sulfate 
solution 0.1 %, subcutaneous omnoponum, intravenous sodium 
bromide, and rectal delivery of magnesium sulfate.  
Acute poisoning by mercuric chloride is accompanied by 
abdominal pain, vomiting, diarrhea, excitation of central nervous 
system with the following depression, and acute cardiovascular 
failure. In 2–4 days, the renal failure and lesions of gastrointestinal 
tract are observed. Unithiol is an antidote to the toxicity of mercuric 
chloride. The drug is administered intramuscularly or 
subcutaneously. Saline laxatives, activated carbon, astringent agents, 
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milk, and egg white are taken orally. The treatment also includes 
gastric lavage, forced diuresis, and hemodialysis. 
Chronic poisoning by mercury salts is called mercurialism. The 
following are symptoms of mercurialism: disorders of central 
nervous system (dementia, tremor), stomatitis, anemia, etc. The 
treatment of chronic poisoning includes the administration of 
antidotes (unithiol, tetacinum-calcium, or sodium thiosulfate), the 
actions to remove the mercury salt from the organism, and 
symptomatic therapy.  
 
Alcohols  
 
Ethyl alcohol  is used in medicine as an antiseptic and 
disinfectant agent. Ethanol antibacterial activity is defined due to its 
ability to cause dehydration and denaturation of proteins. Ethyl 
alcohol is used to disinfect hands of the surgeon, surgical field, and 
medical instruments. Disinfection of the skin is more effective if 
70 % ethanol is used. Higher concentrations of ethanol have less 
antibacterial activity in this case because concentrated ethanol seals 
the epidermis that prevents its diffusion into the ducts of sweat and 
sebaceous glands. 20–40 % ethanol solutions significantly irritate the 
skin and, therefore, they are used in compresses and grinding.  
A 90–95 % ethanol is used to sterilize medical instruments.  
 
Aldehydes 
 
Formaldehyde  is a water-soluble gas with a pungent irritating 
odor. The agent has high antibacterial activity against vegetative and 
spore forms of bacteria. Formaldehyde interacts with aminogroups of 
bacterial proteins that results in their dehydration. Formaldehyde (gas 
and solutions) is used to disinfect rooms, clothes, etc. Dehydrating 
effects of formaldehyde cause epithelial cell irritation. Mucous 
membranes are especially sensitive to formaldehyde. Formaldehyde 
affects the sweat glands and causes dry skin.  
Formalin  and hexamethylenetetramine  (methenamine, 
urotropin)  are drugs which contain formaldehyde.  
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Formalin is a 36.5–37.5 % water solution of formaldehyde. 
The drug is used to dry the skin of hands, in increased sweating  
of legs (0.5–1 % solutions), to sterilize instruments (0.5 %), and to 
preserve cadaveric material. 
Urotropine  converts into formaldehyde in an acidic 
environment. The drug is taken orally (0.05–1.0 g 5 times a day after 
a meal) or administered intravenously (5–10 ml of 40 % solution) for 
treatment of urinary tract infections. The activity of urotropin against 
Gram-negative bacteria is restricted. Also, hexamethylenetetramine 
is a part of tablets Calcex .  
Inhalation of concentrated formaldehyde vapors can cause  
the acute poisoning with lacrimation, sharp cough, and the feeling  
of chest tightness. Oral intake of formaldehyde results in drooling, 
epigastric burning, gastric pain, nausea, vomiting, diarrhea, 
inflammation of the kidneys, loss of consciousness, and convulsions 
with the following inhibition of nerve centres. The treatment of 
poisoning includes the gastric lavage with weak ammonia 
solution  and intake of covering agents (milk or egg white). 
 
Acids and Alkalis  
 
Antibacterial effect of acids and alkalis manifests itself due to 
their ability to penetrate (in the form of undissociated molecules) into 
bacterial cells. In bacterial cells, molecules of acids and alkalis 
dissociate and cause the denaturation of bacterial proteins. Boric 
acid  and salicylic acid  are used as anticeptics in medicine.  
Boric acid is used to treat conjunctivitis, otitis, eczema, 
dermatitis, colpitis, pyoderma, etc. The following medicinal forms of 
boric acid are used in medicine: water, alcohol, and glycerol 
solutions, eye drops, ointments, pastes, and antiseptic powders for 
external use.  
 Preparations of salicylic acid have antiseptic, irritating, 
keratoplastic (in concentrations up to 5 %) or keratolytic (in 
concentrations 5–10 %) effects. Water and alcohol solutions, 
ointments and pastes with salicylic acid are used in the treatment of 
different inflammatory and infectious skin diseases. Indications for 
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its use include burns, blisters, warts, hyperkeratosis, excessive 
sweating of the feet, hair loss, psoriasis, acne vulgaris, seborrheic 
dermatitis, eczema, ichthyosis vulgaris, otitis media, etc. 
Ammonia solution  (contains 10 % ammonia) and sodium 
hydrocarbonate  are alkalis that act as antiseptics. Ammonia 
solution is used in surgical hand antisepsis. The irritating activity of 
ammonia solution and ability reflexively stimulate the respiratory 
centre give grounds for use in syncope. Sodium hydrocarbonate 
solution has an expressed detergency. The drug is used to rinse 
mouth and throat in tonsilitis, to wash eyes, and sterilize instruments.   
 
Table 15 – Drugs for prescription 
 
 
Drug name 
(Latin) 
Single dose and mode of 
administration 
Drug product 
Chlorhexidini 
bigluconas  
For disinfection of skin  
or mucous membranes 0.05, 
0.2, or 0.5 % solution;  
for disinfection of surgical 
field 0.5 % aqueous-
alcoholic solution;  
for disinfection of wounds 
and burns 0.5 % water 
solution;  
for hand disinfection 0.5 % 
alcoholic or 1 % water 
solution 
0.05 % water solution  
in bottles 100 ml;  
20 % water solution  
in bottles 100 or 500 ml 
Aethonium For treatment of wounds and 
ulcers: 0.02–1 % solution  
or 0.5–2 % ointment; 
for treatment of keratitis, 
corneal ulcers, and other eye 
lesions: 0.1 % eye drops;  
for treatment of stomatitis: 
0.5 % solution;  
for treatment of dermatitis 
and burns: 0.5–2 % ointment    
Pouder for solution 
preparation; 
ointment 0.5 % or 1 % – 
25 g 
 
Sol. Iodi  
spirituosae 
For external use 5 % solution in bottles 10, 
15 or 25 ml  
Ioddicerinum For external use Bottles 15 ml 
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Continuation of table 15 
Drug name 
(Latin) 
Single dose and mode of 
administration 
Drug product 
Spiritus aethylicus For skin preparation 70 % 
solution;  
for processing surgical 
instruments 90 % solution 
Bottles 100 ml  
Acidum boricum Solution or ointment  
for external use 
2–4 % solution; 
5–10 % ointment 
Zinci sulfas 1–2 drops in eyes 3–4 times 
daily 
0.25 % or 0.5 % solution 
of eye drops 
Sol. Viridis nitentis 
spirituosae 
For external use 1 % or 2 % spirituous 
solutions 
Furacilinum Orally 0.1 g 4 times a day; 
ointment for external use; 
solutions for washing 
infected cavities and mucous 
membranes  
Tablets 0.1 g (for oral 
intake); 
tablets 0.02 g  
(for preparation  
of solutions); 
ointment 0.2 % – 25 g; 
water solution 1:5 000  
(1 part of furacilinum  
to 5 000 parts of water);  
alcoholic solution 1:1 500 
Sol. Hydrogenii 
peroxydi diluta 
For external use 3 % solution in bottles  
50 ml 
Kalii 
permanganas 
0.1–0.5 % solution  
for processing of wounds; 
2–5 % solution  
for processing of burns; 
0.02–0.05 % solution  
for gastric lavage 
Solutions with different 
concentrations 
Aethacridini 
lactas 
Solutions, ointment and 
aspersion for external use 
0.1 % or 0.2 % solutions; 
3 % ointment; 
3 % aspersion; 
5–10 % paste  
Unithiolum Intramuscularly 0.25–0.5 g 
2–4 times daily 
Ampoules 5 ml  
of 5 % solution  
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Step 1. Tasks for Self -Control  
Antiseptics and Disinfectants  
 
1. To prepare an operative field a doctor used dichlorinated 
biguanid derivative. It is the most active local antiseptic, that shows 
fast and strong bactericidal action on Gram-negative and  
Gram-positive bacteria. What drug is this? 
A. Unithiol. 
B. Brilliant green. 
C. Furacilinum (nitrofural). 
D. Chloramine.  
E. Phenasalum. 
2. For the processing of the burn surface of the patient’s skin a 
specific drug was used. Its antiseptic properties are provided by free 
oxygen that reacts with organic substances. What drug is this? 
A. Potassium permanganate.  
B. Furacilinum. 
C. Chlorhexidine bigluconate. 
D. Boric acid. 
E. Sodium hydrocarbonate. 
3. Profuse foam appeared when dentist put hydrogen peroxide 
on the mucous membrane of the oral cavity. What enzyme caused 
such activity? 
A. Cholinesterase. 
B. Catalase.  
C. Glucose-6-phosphate dehydrogenase. 
D. Acetyltransferase. 
E. Methemoglobin reductase. 
4. A patient with mercury poisoning was admitted to the 
toxicological department from the chemical industry. What drug 
should be used? 
A. Naloxone. 
B. Enterosorbent. 
C. Isonitrosine. 
D. Unithiol.  
E. Activated carbon. 
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5. A patient with abscess of the cat wound applied to the 
traumatological department. The wound was washed with 3 % 
hydrogen peroxide to be cleaned from the pus. Foam was not 
observed. What caused inefficiency of the drug? 
A. Pus in the wound. 
B. Shallow wound. 
C. Low concentration of H2O2. 
D. Inherited insufficiency of erythrocyte phosphate dehydrogenase. 
E. Inherited insufficiency of catalase.  
6. A patient working at a chemical plant was admitted to the 
toxicological department with mercury poisoning. What medicine 
should be used? 
A. Unithiol.  
B. Enterosorbent. 
C. Activated carbon. 
D. Naloxone. 
E. Isonitrosine. 
7. A 38-year-old man who poisoned himself with mercuric 
chloride was taken to the admission room in grave condition. What 
antidote should be immediately introduced? 
A. Atropine. 
B. Nalorphine. 
C. Unithiol.  
D. Isonitrosine. 
E. Dipiroxime. 
8. A patient has applied to doctor with complaints of multiple 
purulent rashes on the skin of extremities. What antiseptic should be 
prescribed to him?  
A. Alcoholic solution of iodine.  
B. Insulin. 
C. Prednisolone. 
D. Sibazon. 
E. Heparin. 
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CHEMOTHERAPEUTIC DRUGS 
 
ANTIBIOTICS 
 
Paul Ehrlich is the founder of the modern chemotherapy.  In 
1907, he suggested the first effective agent for syphilis treatment – 
salvarsan. In 1932, Gerhard Domagk discovered the antibacterial 
properties of red streptocid.  
The first antibiotic penicillin was discovered by Sir Alexander 
Fleming in 1929. In 1940, Sir Howard Walter Florey and Ernst Boris 
Chain produced a pure form of penicillin. In the USSR, the pure 
penicillin was produced by Z. V. Yermolyeva and T. I. Balyazina in 
1942. The significant amount of natural and synthetic antibacterial 
drugs has been created in succeeding years. The synthesis of new 
antibacterial drugs is presently going on. 
Chemotherapeutic drugs are characterized by definite spectrum 
of antibacterial action. One of the requirements for drugs is their low 
toxicity for humans and animals. 
There are the following main principles of chemotherapy.  
1. It is necessary to make the precise diagnosis and identify the 
pathogen and its antibiotic sensitivity.  
2. It is necessary to start treatment as early as possible, yet the 
number of causative agent is low and the serious lesions of internal 
organs do not develop. 
3. The route of drug administration should be optimal that 
provides the best drug – pathogen interaction.  
4. The drug concentration in human organism should be 
effective and stable throughout the whole therapy. Sometimes, the 
knockout dose is prescribed in early treatment to create a necessary 
effective concentration of the antibacterial agent. 
5. The duration of antibacterial therapy should be optimal  
(the therapy lasts 3–5 days after clinical recovery. 
6. The measures to support the body's defences should be 
provided together with chemotherapy (vitamins, immunomodulators, 
drugs that support the hepatic and renal functions, etc.).  
 
414 
 
Chemotherapeutic drugs include the following drug groups:  
1) antibiotics; 
2) sulfonamides; 
3) synthetic antibacterial drugs with different chemical structure 
(quinolones, fluoroquinolones, hydroxyquinolines, nitroimidazole 
derivatives, and nitrofurane derivatives);  
4) antifungal drugs; 
5) antiviral drugs; 
6) antiprotozoal drugs;  
7) antisyphylitic drugs; 
8) antituberculosis drugs; 
9) anthelmintic drugs.  
Antibiotics are drugs of bacterial origin and their semi-synthetic 
analogues which selectively damage or kill certain microbial species. 
Antibiotics are classified according to their origin, chemical 
structure, mechanism of action, and character of the influence upon 
bacteria.  
Antibiotic classification according to chemical structure is  
the following:  
1) β-lactam antibiotics: penicillins, cephalosporins, carbapenems, 
and monobactams;  
2) antibiotics containing the macrocyclic lactone rings in 
molecules: macrolides and azalides;  
3) tetracyclines (antibiotics containing four condensed  
six-membered rings in molecules);  
4) chloramphenicol drug group; 
5) aminoglycosides (antibiotics containing the aminosugars in 
molecules);  
6) polypeptides (polymyxins and gramicidin C); 
7) polyenes (amphotericin B, nystatin, and levorin); 
8) glycopeptides (vancomycin and ristomycin); 
9) lincosamides (lincomycin and clindamycin); 
10) ansamycins (rifampicin and rifamycin); 
11) antibiotics with steroidal structure (sodium fusidate); 
12) different antibiotics (fusafungine).  
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According to mechanism of action, antibiotics are classified into 
the following groups:  
1) antibiotics affecting the synthesis of bacterial cell wall:  
β-lactams and glycopeptides; 
2) antibiotics affecting the function of bacterial cytoplasmic 
membrane: polypeptides and polyenes;  
3) antibiotics affecting the synthesis of bacterial proteins: 
aminoglycosides, tetracyclines, chloramphenicols, macrolides, and 
lincosamides;  
4) antibiotics affecting the synthesis of nucleic acids: 
ansamycins. 
There are two types of antibacterial action of antibiotics: 
bactericidal and bacteriostatic. Bactericidal antibiotics affect the 
synthesis of bacterial cell wall or the function of cytoplasmic 
membrane; these agents kill the bacteria. Bactericidal antibiotics 
include β-lactams, glycopeptides, polypeptides, and polyenes. 
Besides, high doses of aminoglycosides, chloramphenicol, and 
rifampicin are cases of bactericidal action. Tetracyclines, macrolides, 
ansamycins, lincosamides, etc. have the bacteriostatic effect. 
Bacteriostatic antibiotics affect the growth and division  
of bacteria. 
Depending on the number of bacteria species affected by a drug, 
antibiotics are divided into the drugs of broad spectrum and the 
agents of narrow spectrum. The antibiotics of broad spectrum of 
antibacterial activity include tetracyclines, chloramphenicol, 
aminoglycosides, cephalosporins, and semisynthetic penicillins, 
azalides, and macrolides. Narrow spectrum is typical for biosynthetic 
penicillins, macrolides, lincosamides (these groups are active against 
Gram-positive bacteria), and polymyxines (active against  
Gram-negative flora).         
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β-Lactam Antibiotics  
 
It is the dominant group of modern antibiotics which includes 
penicillins, cephalosporins, carbapenems, and monobactams.  
β-lactams are bactericidal antibiotics. Their mechanism of action is 
associated with inhibiting cell wall synthesis due to the blockage of 
transpeptidase (an enzyme that cross-links the peptidoglycan chains 
to form rigid cell walls). It results in lysis of bacterial cells.  
 
Penicillins  
 
Penicillins are a type of antibiotics that contain  
the 6-aminopenicillanic acid in the molecules. Natural penicillins  
are produced by Penicillium molds. The semisynthetic penicillins are 
synthezied due to chemical modification of 6-aminopenicillanic acid.  
Penicillins are classified as follows.  
1. Biosynthetic penicillins.  
1.1. Drugs for parenteral administration: 
– short-acting penicillins: benzylpenicillin  sodium  and 
benzylpenicillin  potassium ;  
– long-acting penicillins: benzylpenicillin novocaine 
salt,  bicillin-1,and bicillin-5.  
1.2. Drugs for enteral administration: phenoxymethylpenicillin.  
2. Semisynthetic penicillins.  
2.1. Drugs for both parenteral and enteral administration:  
– drugs stable to penicillinase: oxacillin  and nafcillin ; 
– drugs of broad spectrum (aminopenicillins): ampicillin  
and amoxicillin . 
2.2. Drugs of broad spectrum for parenteral administration: 
– carboxypenicillins: carbenicillin disodium and ticarcillin; 
– ureidopenicillins: azlocillin, piperacillin, and mezlocillin.  
2.3. Drugs for enteral administration of broad spectrum:  
– carboxypenicillins: carbenicillin indanyl sodium and 
carfecillin . 
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Biosynthetic Penicill ins  
 
Biosynthetic penicillins are drugs of narrow antibacterial 
spectrum which include mainly Gram-positive bacteria. The 
following bacteria are sensitive to biosynthetic penicillins: 
staphylococci, streptococci, pneumococci, gonococci, meningococci, 
Clostridia (the causative agents of gas gangrene and tetanus), 
Corynebacterium diphtheriae, Bacillus anthracis, spirochetes (the 
causative agents of syphilis, relapsing fever, and leptospirosis), and 
actinomycetes.  
Benzylpenicillin  sodium  and benzylpenicillin  potassium  
are the water-soluble salts of monobasic acid. In case of oral intake, 
these drugs are dystroyed by hydrochloric acid, therefore they are 
administered parenterally, mainly intramuscularly. Duration of 
benzylpenicillin action is 3–4 hours, therefore drugs are administered 
6 times a day. In special cases, benzylpenicillin is administered 
intravenously, intra-arterially, into the spinal canal (only sodium 
salt), joint capsules, and serous cavities, or it is used in inhalations. 
Nearly 60–70 % of administered benzylpenicillin is excreted through 
kidneys in non-modified form. Insignificant part of the drug is 
secreted into biliary ducts and excreted through intestine. The rate of 
drug elimination depends on renal and hepatic functions. The 
elimination of benzylpenicillin in patients with simultaneous damage 
of renal and hepatic functions can be slowed down 10 times.  
There are benzylpenicillin preparations of prolonged action: 
benzylpenicillin novocaine , bicillin-1 , and bicillin-5 . Water 
suspensions of these drugs are administered intramuscularly. 
Benzylpenicillin novocaine is administered twice a day, bicillin-1 – 
once in 1–2 weaks, and bicillin-5 – once a month. Long-acting drugs 
are prescribed only if it is known that a patient has no allergy to 
penicillins and causative agent has high sensitivity to a prescribed 
drug. Therapeutic indications for the long-acting biosynthetic 
penicillins are rheumatism and syphilis.  
Phenoxymethylpenicillin  is an acid-stable penicillin because 
its molecules contain the phenoxymethyl groups. Antibacterial 
spectrum of phenoxymethylpenicillin is identical to antibacterial 
418 
 
spectrum of benzylpenicillin. The drug is easily absorbed in 
gastrointestinal tract but its blood concentration is not high. 
Therefore, phenoxymethylpenicillin is not used in treatment of 
severe infections. The drug is prescribed for oral intake 4–6 times a 
day for the teatment of mild to moderate infections, such as 
pharyngitis, tonsillitis, sinusitis, otitis, bronchitis, pneumonia, 
erysipelas, erysipeloid, erythema migrans, lymphadenitis, 
lymphangitis, scarlet fever, etc.  
 
Semisynthetic Penicillins  
 
Semisynthetic penicillins are synthesized by the acylation of  
6-aminopenicillanic acid.  
Oxacillin  and nafcil lin  are known as antistaphylococcal 
penicillins. The antibacterial spectrum of these drugs is similar to the 
spectrum of benzylpenicillin. But these drugs are stable to 
penicillinase action, therefore they are highly active against different 
strains of Staphylococci, including penicillinase producing strains.  
Oxacillin is taken orally or administered parenterally 4–6 times 
a day. The degree of drug binding to plasma proteins is 90–95%. 
Oxacillin does not penetrate through the blood-brain barrier. The 
main route of the drug excretion is kidneys.  
Nafcillin has high antibacterial activity. Nafcillin is administered 
both orally and parenterally. The drug easily penetrates through the 
blood-brain barrier. The drug is mainly excreted with bile. 
Ampicil lin  and amoxicillin  are aminopenicillins. The drugs 
have the broad spectrum of antibacterial action but are broken by 
penicillinase. The spectrum of antibacterial action of 
aminopenicillins includes Gram-positive and Gram-negative 
bacteria. Aminopenicillins are active against Enterococcus, 
Salmonella, Shigella, Escherichia coli, some strains of Proteus, etc. 
It is significant that activity of aminopenicillins against  
Gram-positive bacteria is 3–4 times less than the activity of 
biosynthetic penicillins. But their activity against Gram-negative 
bacteria is higher than the activity of tetracyclines and 
419 
 
chloramphenicol. Aminopenicillins are not active against 
Pseudomonas aureginosa.  
Ampicillin is an acid-stable antibiotic which is easily absorbed in 
gastro-intestinal tract. The degree of binding to plasma proteins is 
low. The drug is excreted from the body through the kidneys and liver 
and creates the high concentration in urine and bile. This allows its 
use in the treatment for infections of urinary and biliary tracts. 
Ampicillin badly penetrates through the blood-brain barrier. The drug 
is taken orally 3–4 times a day or administered intramuscularly  
4–6 times a day. Toxicity of ampicillin is low.  
Amoxicillin is similar to ampicillin. But the drug is better 
absorbed in gastrointestinal tract with high concentrations in plasma 
and tissues. 
There are co-formulated penicillin preparations such as Ampiox  
(combination of ampicillin with oxacillin in ratio 2:1). 
Carbenicillin  is a broad-spectrum semisynthetic penicillin of 
carboxypenicillin group. The drug is active against many  
Gram-positive and Gram-negative bacteria including Pseudomonas 
aureginosa, Proteus, and some bacteroides. Beta-lactamase breaks 
up carbenicillin, therefore it does not influence staphylococci 
producing penicillinase. Carbenicillin is used mainly as a reserve 
antibiotic in treatment of infectious diseases caused by  
P. aureginosa.            
Carbenicillin is an acid-labile antibiotic, therefore it is 
administered intramuscularly or intravenously. The drug 
permeability through the blood-brain barrier is low. The main route 
of excretion is through the kidneys. Duration of carbenicillin action 
is 4–6 hours. Carbenicillin indanyl sodium is an acid-stable form  
of carbenicillin which is administered orally mainly in treatment of 
urinary tract infections.  
Ticarcill in  is carboxypenicillin with high activity against  
Pseudomonas aureginosa. The drug is administered parenterally. 
Such carboxypenicillins as carfecillin and carindacillin are to be 
given orally. Their bioavailability in oral intake is above 40 %.  
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A group of ureidopenicillins includes such medications as 
azlocillin,  mezlocillin , and piperacillin . Ureidopenicillins are 
characterized by high activity against P. aureginosa and fast 
development of bacterial resistance. These drugs are administered 
only parenterally 3 times a day. 
There are inhibitors of β-lactamases that prevent the destruction 
of penicillins by penicillinase: clavulanic acid , sulbactam , and 
tazobactam . These agents are used in combination with penicillins. 
For example, Augmentin  consists of amoxicillin and clavulanic 
acid. The drug is administered once a day for treatment of infectious 
diseases of respiratory and urinary tracts, joints, bones, sepsis, etc. 
Another group of  combination drugs includes Unazinum  
(ampicillin with sulbactam), Co-amoxiclav  (amoxicillin with 
clavulanic acid), and Tazocin  (piperacillin with tazobactam). 
Despite low toxicity and inability to accumulate in the organism, 
penicillins have many side effects.  
Allergic reactions (skin rash, bronchospasm, and anaphylactic 
shock) are the most common side effect of penicillins. To prevent 
allergy, the test for sensitivity to penicillins shoud be performed 
before the drug administration. In the case of anaphylactic shock, 
intramuscular adrenaline, intravenous glucocorticoids and calcium 
chloride must be administered very quickly.  
Other side effects of penicillins are painful injections, infiltrates, 
and aseptic necrosis in the injection site. Oral drug intake can cause 
nausea, diarrhea, stomatitis, and glossitis. Intravenous administration 
can cause phlebitis and trombophlebitis. Large doses of penicillins or 
their use in patients with renal failure can result in development  
of neurotoxic effects. Sometimes, penicillins cause disturbances of 
cardiac activity and inhibition of hepatic enzymes. Semisynthetic 
broad-spectrum penicillins can cause disbiosis and superinfection.  
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Cephalosporins  
 
Cephalosporins are semisynthetic antibiotics with β-lactam ring 
in molecules. Mechanism of cephalosporins’ action is associated 
with affection of bacterial cell wall synthesis due to inhibition of 
transpeptidase. Cephalosporins have the bactericidal effect and are 
broad-spectrum antibiotics. The drugs are stable to staphyloccocal  
β-lactamase, but β-lactamases of Gram-negative bacteria can affect 
some cephalosporins.  
Cephalosporins are grouped into four generations.  
1.   Cephalosporins, 1st generation.  
1.1. Drugs for parenteral administration: cephaloridine,  
cefalotin,  cefazolin, cefradine, and cefapirine.  
1.2. Drugs for enteral use: cephalexin,  cephradine,  and 
cefadroxil.  
2.   Cephalosporins, 2nd generation. 
2.1. Drugs for parenteral administration: cefamandole,  
cefuroxime, cefoxitin , cefmetazole, and ceforanide. 
2.2. Drugs for enteral use: loracarbef , cefaclor, and 
cefuroxime. 
3.   Cephalosporins, 3rd generation.  
3.1. Drugs for parenteral administration: cefoperazone, 
cefotaxime, ceftriaxone, ceftazidime,cefmenoxime,  
and moxalactam. 
3.2. Drugs for enteral use: cefixime, ceftibuten, and 
cefpodoxime.  
4.   The 4th generation cephalosporins are the drugs for 
parenteral administration: cefepime, cefpirome, 
cefclidine,  and cefozopran.  
 
First  Generation Cephalosporins  
 
First generation cephalosporins are antibiotics with high activity 
against Gram-positive bacteria. Also, some Gram-negative bacteria 
are sensitive to these drugs. Antibacterial spectrum of 1st generation 
cephalosporins includes staphylococci, streptococci, pneumococci, 
meningococci, gonococci, Proteus mirabilis, Escherichia coli, 
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Corynebacterium diphtheriae, Clostridium, Klebsiella pneumoniae, 
Salmonella, Shigella, and actinomycetes. First-generation 
cephalosporins have no activity against methicillin-resistant 
staphylococci, Pseudomonas, indole-positive Proteus, Bacteroides, 
Enterococcus, Enterobacter, etc. 
Therapeutic indications for 1st generation drugs are infectious 
diseases of respiratory tract, pneumonia, peritonitis, osteomyelitis, 
otitis, furunculosis, infected wounds, infections of urinary tract, 
prevention of surgical infections, etc. 
Cefazolin  is 1st generation cephalosporin for parenteral 
administration. The drug is administered intramuscularly or 
intravenously 3–4 times a day. Cefazolin has high antibacterial 
activity and penetrates in the tissues better than other 1st generation 
drugs. The high drug concentration is created in bile and urine. The 
nephrotoxicity of cefazolin is low. There are the following side 
effects of the drug: superinfection caused by Candida or 
Pseudomonas aeruginosa, allergic reactions, leukopenia, pain and 
infiltrations in the injection site.   
Cephalexin  is easily absorbable in the gastrointestinal tract. 
The drug is taken orally 4 times a day. Cephalexin is available in the 
following medical forms: capsules, tablets and suspension for oral 
intake. The drug is used to treat infectious diseases of moderate 
severity. Side effects of cephalexin are as follows: dysbiosis and 
leukopenia.   
 
Second Generation Cephalosporins  
 
The antibacterial spectrum of 2nd generation cephalosporins is 
similar to the 1st-generation cephalosporins. But 2nd-generation has 
higher activity against Gram-negative bacteria and it is less active 
against Gram-positive flora. These drugs are not active against 
Pseudomonas aeruginosa. Second generation cephalosporins are 
used to treat infectious diseases of respiratory tract, abdominal and 
gynecological infections, septicemia, endocarditis, urinary tract 
infections, infections of bones, joints, skin and soft tissues, to prevent 
postoperative infections.  
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Cefoxitin  is active against bacteroids. It is highly active against 
other Gram-negative bacteria (Escherichia coli, Haemophilus 
influenzae, Salmonella, Shigella, Proteus mirabilis, gonococci). 
Cefoxitin is also active against Gram-positive bacteria 
(Staphylococcus, Streptococcus) and against some anaerobic 
bacteria. The drug is resistant to β-lactamase. Pseudomonas 
aeruginosa, Listeria, many strains of enterococci and methicillin-
resistant staphylococci, and others are insensitive to cefoxitin.  
The drug is administered intramuscularly or intravenously 2–3 times 
a day.  
Cefaclor  is the 2nd generation cephalosporin for peroral use. 
The drug is taken orally 3 times a day. The drug is highly active 
against Gram-negative bacteria (Escherichia coli, Haemophilus 
influenzae, Salmonella, Shigella, Proteus mirabilis, Klebsiella, 
Neisseria gonorrhoeae, Citrobacter). Besides, cefaclor is active 
against Gram-positive bacteria. The drug has no activity against 
anaerobic microorganisms (Bacteroides, etc.), Pseudomonas, 
Enterococcus, Listeria, Serratia, etc.  
Cefuroxime  is available both for peroral and parenteral 
administration. The drug has a higher ability to penetrate through the 
blood-brain barrier than other drugs of the 2nd generation, and it is 
used to treat meningitis. The drug is administered parenterally or 
taken orally 2–3 times a day.    
 
Third Generation Cephalosporins  
 
Antibacterial spectrum of these drugs is wider, and their activity 
against Gram-negative bacteria is higher compared to preceding 
drugs. Third generation cephalosporins are stable to Gram-negative 
β-lactamases. Ceftazidime , cefotaxime , and cefoperazone  are 
active agaisnt Pseudomonas aeruginosa.  
All third generation cephalosporins (except cefoperazone) easily 
penetrate into tissues, including central nervous system. Most of the 
drugs are excreted through the kidneys in unchanged form. Only 
ceftriaxone and cefoperazone are excreted mainly with bile. 
Therapeutic indications for the third generation cephalosporins are 
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infections of respiratory tract, bones, soft tissues, abdominal cavity, 
and urinary tract, sepsis, meningitis, endocarditis, etc. The drugs 
should be taken 2–3 times a day, but ceftriaxone and cefoperazone – 
1–2 times a day.  
 
Fourth Generation Cephalosporins  
 
All forth-generation cephalosporins are administered only 
parenterally. These drugs have the extended antibacterial spectrum 
and high activity against both Gram-positive and Gram-negative 
bacteria. These drugs have a greater resistance to β-lactamases than 
the 3rd generation cephalosporins. Fourth generation cephalosporins 
affect bacteria insensitive to other antibiotics (including 
carbapenems). It is due to drug ability to penetrate through cell 
membranes and to bind to bacterial penicillin-binding proteins. 
Besides, the 4th generation cephalosporins create high concentrations 
in periplasmic space. But these drugs are inactive against 
bacteroides, therefore, for expansion of antibacterial spectrum, they 
are combined with metronidazole, carboxypenicillins, and 
ureidopenicillins. Secondary resistance of bacteria to these drugs 
develops slowly. The therapeutic indications for the 4th generation 
cephalosporins are infections of respiratory and urinary tracts, sepsis, 
surgical infections, meningitis, etc. Cefepime and cefpirome are 
administered twice a day.  
Therapy with cephalosporins may be accompanied by allergic 
reactions. Cephalosporins are contraindicated to patients with allergy 
to penicillins in anamnesis. Nephrotoxicity is typical mainly for the  
1st-generation cephalosporins. Neurotoxicity (hallucinations, 
convulsions, nystagmus) is due to antagonism between 
cephalosporins and γ-aminobutyric acid. Hematotoxicity 
(leukopenia, thrombocytopenia, neutropeniza) can develop in 
patients with renal failure or in the case of parenteral administration 
of high doses of cephalosporins. Therapy by cephalosporins can be 
accompanied by elevated liver enzymes in blood. Enteral 
cephalosporin intake can cause disbiosis. Patients treated with 
cephalosporins should avoid alcohol consumption because the drugs 
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have Antabuse-like effect. In this case, alcohol intake can result in 
nausea, vomiting, diarrhea, tachycardia, etc.   
 
Monobactams 
 
Monobactams are β-lactam antibiotics which are active only 
against aerobic Gram-negative bacteria (e. g., Escherichia coli, 
Enterobacter, Neisseria, Pseudomonas, Proteus, Serratia, 
Morganella, Salmonella, Shigella, Klebsiella, etc.).  
The representative of monobactams is aztreonam . The drug 
has high stability to β-lactamases of Gram-negative bacteria, but it is 
destroyed by β-lacatamases of Gram-positive microorganisms. Thus, 
aztreonam has no activity against Gram-positive bacteria, 
bacteroides, and other anaerobes. The therapeutic indications of 
aztreonam are severe infections of urinary and respiratiry tracts, 
abdominal cavity, soft tissues, meningitis, sepsis, etc. The drug is 
administered intramuscularly or intravenously 2–3 times a day. The 
side effects of aztreonam are allergic reactions, dysbiosis, dyspepsia, 
and phlebitis. 
 
Carbapenems 
 
It is a modern group of β-lactam antibiotics with high stability to 
β-lactamases and broad antibacterial spectrum. Carbapenems are 
active against both Gram-positive and Gram-negative aerobic and 
anaerobic bacteria, including Pseudomonas aeruginosa. The 
mechanism of carbapenems’ action is identical to other β-lactam 
antibiotics. These drugs are divided into two generations:  
– 1st generation: imipenem, tienam, primaxin ; 
– 2nd generation: meropenem .    
Imipenem  is a semisynthetic antibiotic with broad spectrum of 
action. The drug is stable to β-lactamases but is destroyed by 
dehydropeptidase-I (enzyme of proximal tubules of nephron). 
Tienam  and primaxin  are co-formulated drugs which contain 
imipenem and cilastatin in ration 1:1. Cilastatin is inhibitor of 
dehydropeptidase-I. 
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Meropenem  is stable to dehydropeptidase-I, therefore it does 
not require the combination with cilastatin. Also, antibiotic is stable 
to β-lactamase action. Antistaphylococcal activity of meropenem is 
2–4 times less than the activity of tienam. On the other hand, the 
drug activity against Gram-negative enterobacteria and Pseudomonas 
is higher 2–8 times. 
There are microorganisms with natural resistance to 
carbapenems. They are Chlamydia, Mycoplasma, Corynebacterium, 
Mycobacterium, Flavobacterium, methicillin-resistant staphylococci, 
fungi, and protozoa.    
Carabapenems are administered only parenterally. Tienam is 
administered intravenously 4 times a day or intramascularly 2 times a 
day. Meropenem is administered intravenously 3 times a day. 
Carbapenems are reserve antibiotics which are used in treatment of 
severe infections in case of ineffectiveness of other antibiotics. There 
are the following therapeutic indications for carbapenems:  
– intraperitoneal surgical infections;  
– gynecological infections after labor, cesarean section, and 
surgery;  
– intensive therapy for newborns;  
– complicated infections of urinary tract;  
– complicated infections of bones, joints, skin, and soft tissues;  
– sepsis;  
– pulmonary infections;  
– infectious diseases in patients with neutropenia;  
– meningitis (meropenem is a drug of choice due to higher 
permeability through the blood-brain barrier and less neurotoxicity).  
Side effects of carbapenems are as follows:  
– pain, thrombophlebitis, and sealing the injection site;  
– allergic reactions;  
– superinfections;  
– nephrotoxicity (more common for imipenem);  
– neurotoxicity: tremor, muscular hypertone, paresthesia, 
encephalopathy, convulsions (in the case of intravenous 
administration of tienam or primaxin, but not meropenem).  
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Macrolides and Azalides  
 
Macrolides are antibiotics containing macrocyclic lactone rings 
in molecules. 
There are three generations of macrolides:  
– 1st generation: erythromycin and oleandomycin;  
– 2nd generation: clarithromycin, roxithromycin, spiramycin, 
and  midecamycin.  
– 3rd generation (azalides): azithromycin.  
Mechanism of macrolide action is as follows. Drugs bind to  
50S ribosomal subunit that results in violation of ribosome 
translocation along mRNA and inhibition of protein synthesis. The 
macrolides are bacteriostatic antibiotics.  
First-generation macrolides are drugs with narrow antibacterial 
spectrum. These drugs are active mainly against Gram-positive 
bacteria (streptococci, staphylococci, pneumococci, 
Corynebacterium diphtheriae, etc.). Besides, gonococci, 
Mycoplasma, Chlamydia, Legionella, spirochetes, certain strains of 
Brucella and Mycobacteria are sensitive to 1st-generation 
macrolides. But most Gram-negative microorganisms have high 
resistance to these drugs. 
The second- and third-generation macrolides have the broad 
antibacterial spectrum. These drugs are active against enterococci, 
Escherichia coli, Haemophilus influenzae, Shigella, Salmonella, 
Bacteroides, Helicobacter pylori, etc. Azithromycin has high activity 
against bacteria – causative agents of genital infections (Neisseria 
gonorrhoeae, Chlamydia, spirochetes, and Trichomonas vaginalis). 
Macrolide resistance of bacteria develops readily, therefore 
a course of treatment should not exceed 7 days.  
Erythromycin  is a low toxic antibiotic for oral intake. The 
drug is slowly absorbed in gastrointestinal tract. Erythromycin is 
partly degraded by gastric juice, therefore the drug is used in 
capsules or specially-coated tablets. The bioavailability of 
erythromycin is higher if taken before a meal. The drug esealy 
penetrates into tissues and body fluids (except central nervous 
system). High concentrations of the drug are created in lungs, liver, 
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prostate, and urinary tract. About 60–70 % of the administered dose 
undergo hepatic metabolism. Erythromycin is taken 4–6 times a day 
before a a meal or used locally in ointments. Erythromycin phosphate 
is used in intravenous administration 2–3 times a day in a dose  
of 0.2 g.  
Oleandomycin  has lower antibacterial activity than 
erythromycin, but irritative ability of oleandomycin is higher. The 
drug is taken orally 4 times a day. Presently, oleandomycin is not 
used in monotherapy. It is most commonly combined with 
tetracyclines (oletetrin, tetraolean, etc.).  
Clarithromycin  is 2–4 times more active against 
staphylococci and streptococci than erythromycin. The drug is used 
in treatment of infectious diseases caused by Mycoplasma, 
Chlamydia, Toxoplasma, and Helicobacter pylori. Clarithromycin is 
easily absorbed in gastrointestinal tract. The drug undergoes hepatic 
metabolism and is excreted through the kidneys. Clarithromycin is 
taken 2 times a day. Course of treatment is 5–14 days. Side effects 
are abdominal pain, diarrhea, and nausea.  
In comparison with the 1st and 2nd generations, molecules of the  
3rd-generation macrolides have aromatic group in the structure of 
macrocyclic lactone ring, and due to this they have new properties. In 
contrast with erythromycin, azithromycin  is 2–4 times less active 
against Gram-positive cocci. But drug activity against Gram-negative 
bacteria is higher. The bioavailability of azithromycin in 
gastrointestinal tract is low. The drug can accumulate in the cells 
(intracellular concentration may be higher than plasma concentration 
10–100 times). Azithromycin does not penetrate through the blood-
brain barrier. The drug is excreted through the kidneys in unchanged 
form. Azithromycin is taken orally once a day. The first dose is twice 
higher than subsequent doses. Therapeutic indications for 
azithromycin are bronchitis, otitis, sinusitis, erysipelas, mastitis, 
whooping cough, diphtheria, chlamydial conjunctivitis, chlamydial 
pneumonia of newborns, pneumonia caused by Mycoplasma 
pneumoniae, lobar pneumonia caused by Legionella pneumophila 
and Moraxella catarrhalis, primary syphilis, gonorrhea, 
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cholecystitis, enteritis, colitis, toxoplasmosis, urogenital infections, 
and ulcer diseases of stomach and duodenum.  
New macrolide antibiotic josamycin  is approved in medicine. 
The drug has broad antibacterial spectrum and causes bacteriostatic 
or bactericidal (in high doses) effect. The resistance of bacteria to 
josamycin develops seldom. 
 
Tetracyclines  
 
Tetracyclines are antibiotics with four condensed 6-member 
cycles in molecules. A classification of tetracyclines is as follows:  
1) biosynthetic tetracyclines: oxytetracycline , tetracycline,  
and demeclocycline;   
2) semisynthetic tetracyclines: metacycline (rondomycine),  
doxycycline (vibramycin), and minocycline . 
The antibacterial spectrum of tetracyclines is broad and includes 
such microorganisms as Gram-positive and Gram-negative cocci, 
Escherichia coli, Chlamydia, Rickettsia, Mycoplasma, Ameba, 
Plasmodium, Helicobacter pylori, Klebsiella, Enterobacter, 
Spirochaetales, Vibrio cholerae, Yersinia pestis, Francisella 
tularensis, Brucella, Shigella, Salmonella, etc. Tetracyclines have no 
activity against Proteus, Pseudomonas aeruginosa, viruses, and 
fungi. Bacterial resistance to tetracyclines develops slowly and can 
be characterized by cross-resistance.  
Tetracyclines block protein synthesis in bacterial cells. The 
drugs bind to 30S ribosomal subunits and affect the binding of tRNA 
to them, that stops protein synthesis. Besides, tetracyclines form the 
compounds with biologically active two valence metals (iron, 
calcium, zink, etc.). Tetracyclines have the bacteriostatic effect. 
Tetracyclines are liposoluble agents, therefore they are easily 
absorbed in gastrointestinal tract. Also, tetracyclines easily penetrate 
through tissue barriers and accumulated in the tissues. It is necessary 
to notice that the drug permeability into mother's milk and amniotic 
fluid is better than into the skin, cerebrospinal fluid, and saliva. The 
degree of binding to proteins for biosynthetic tetracyclines is  
20–40 % and for semisynthetic drugs – 60–95 %. Tetracyclines 
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undergo partial biotransformation in the liver and are excreted with 
urine and bile. The drugs are taken orally. Their absorption is higher 
if the drug is taken 1–1.5 hours before a meal or 3 hours after a meal. 
It is necessary to notice that milk significantly reduces the absorption 
of tetracyclines due to formation of complexes between the drug and 
two valence metals. Semisynthetic tetracyclines are less capable to 
form such compounds, therefore their bioavailability at oral intake is 
closer to 100 %. Oxytetracycline and tetracycline are also used in 
ointments. Tetracycline is administered intramuscularly, and 
doxycycline – intravenously. Oxytetracycline and tetracycline are 
prescribed to take 4 times a day, methacycline – 2–3 times, 
doxycycline and minocycline – 1–2 times, and demeclocycline – 
once a day. 
Therapeutic indications for tetracyclines are as follows: putrid 
fever, Q fever, trachoma, psittacosis, ornithosis, urogenital 
chlamydiosis, dysentery, leptospirosis, plague, brucellosis, tularemia, 
anthrax, cholera, bronchitis, pneumonia, tonsilitis, otitis, sinusitis, 
infections of urinary and biliary tracts, osteomyelitis, syphilis, 
gonorrhea, ulcer diseases of stomach and duodenum (doxycycline), 
intestinal amebiasis, etc.  
Presently, tigecycline , a new tetracycline derivative, is 
approved in medicine. The drug has high activity against Gram-
positive and Gram-negative bacteria. Tigecycline is used as a reserve 
antibiotic when other antibiotics are ineffective. The drug is 
administered intravenously, drop-by-drop, twice a day.  
It is necessary to notice that tetracyclines affect cell division 
both in microorganisms and in a human organism. Due to this, drugs 
affect the epithelization of the intestine (dyspesia, erosions, ulcers, 
glossitis) and the skin (dermatitis, photosensitization) and suppress 
the hemopoiesis (leukopenia, anemia, thrombocytopenia). Catabolic 
effect of tetracyclines results in inhibition of protein synthesis and 
immunity.  
Tetracyclines are hepatotoxic and teratogenic drugs. 
Tetracyclines form the chelates with calcium phosphate in teeth 
and bones that results in the delay of skeletal growth in children, 
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yellow coloration of teeth, violation of tooth enamel formation, and 
caries. Due to this, tetracyclines are contraindicated in children aged 
under 12 years, pregnant woman, and nursing mothers. 
Expired tetracyclines form toxic substances. In this case, the 
following intake of expired tetracyclines causes an acute kidney 
injury (Fanconi’s syndrome). 
Tetracycline in young children can cause the increase of 
intracranial pressure along with development of meningeal 
symptoms (headache, vomiting, etc.). 
Tetracyclines can cause dysbiosis, hypovitaminosis B, 
candidiasis, and enterocolitis. Fast intravenous administration of 
doxycycline can cause the development of acute heart failure. 
Minocycline causes vestibular disturbances. Tetracycline therapy can 
cause allergic reactions.   
 
Chloramphenicol Group 
 
Levomycetin  (chloramphenicol ) is the main representative 
of this group. Such drugs as levomycetin, levomycetin stearate, 
levomycetin palmitate, and levomycetin succinate are the most 
commonly used in medicine. 
Levomycetin inhibits the protein synthesis in bacterial cells due 
to binding to 50S subunit of ribosomes. Also, the drug inhibits 
peptidyl transferase activity that impedes prolongation of 
polypeptides. Chloramphenicol has a bacteriostatic effect.  
Levomycetin is a broad-spectrum antibiotic. Unfortunately, 
practical realization of the drug potential in medicine is impossible 
due to high drug toxicity. Therefore, levomycetin is used as a reserve 
antibiotic. Levomycetin inhibits the growth of the most strains of 
staphylococci, pneumococci, streptococci, meningococci, 
Haemophilus influenzae, Brucella, Rickettsia, Chlamydia, 
Mycoplasma, Vibrio cholerae, Escherichia coli, Shigella, 
Salmonella, and Enterobacter. It is important that chloramphenicol 
inhibits the growth of such anaerobes as bacteroides, anaerobic cocci, 
and fusobacteriales. The resistance of bacteria to chloramphenicol 
develops slowly. 
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Levomycetin is prescribed mainly for oral intake. Levomycetin 
succinate is administered intravenously (seldom – intramuscularly or 
in the form of an aerosol in lungs). Sometimes levomycetin is 
administered rectally. 
The drug bioavailability in gastrointestinal tract is more than 
90 %. Parenteral administration of levomycetin is used in treatment 
of meningitis. The degree of drug binding to plasma proteins is  
50–60 %. Chloramphenicol easily penetrates into different tissues 
and fluids of the body. Nearly 90 % of administered chloramphenicol 
dose are metabolized in the liver. Unchanged 10 % of the drug is 
excreted through the kidneys that provides the antibacterial effect in 
the urinary tract.  
Levomycetin is used only in treatment for severe infections 
caused by sensitive to levomycetin bacteria. Therapeutic indications 
for levomycetin are brain abscess, systemic salmonolesis, dysentery, 
richettsiosis, intrzoccular infections (eye burns, trachoma), 
brucellosis, tularemia, reactive arthritis, meningitis caused by 
Haemophilus influenzae, meningococci, and pneumococci. Aerosol 
thiamphenicol glycinate asetylcysteinate (co-formulated levomycetin 
preparation) is used in treatment of respiratory tract infections. 
Chloramphenicol for oral intake is prescribed at 0.25–0.5 g dose 
given 4 times a day. A 20 % solution of levomycetin succinate is 
administered parenterally 2–3 times a day. Levomycetin liniment 
10 %, or synthomycin liniment 10 %, is used in treatment of skin 
infections, burns, fissures, etc. Levomycetin is a component of 
different ointments (“Levomekol”, “Levosin”) and aerosols 
(“Levovinisol”, “Olasol”).  
An accurate calculation of the dosage is based on the body 
weight of the patient in cases of enteral and parenteral administration 
of chloramphenicol. Course of treatment should not exceed  
10–14 days. Control of the blood and liver function is required.  
Levomycetin is a toxic antibiotic with narrow therapeutic action. 
The drug inhibits haematopoiesis that results in anemia, leukopenia, 
and thrombocytopenia. Chloramphenicol can cause acute drug-
induced hemolysis in patients with genetically determined deficiency 
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of glucose-6-phosphate dehydrogenase. Non-hemolytic anemia can 
develop in patients with genetically determined deficiency of 
uridine-diphosphoglucuronic transferase. Levomycetin blocks 
mitochondrial ferrochelatase (enzyme which provides the iron 
inclusion in the structure of heme) that results in iron deficiency 
anemia, myodystrophy, and hypotrophy.  
Gray baby syndrome is one of the possible complications caused 
by levomycetin in newborn infants and badies under 3 months. The 
gray baby syndrome is manifested by respiratory disturbances, severe 
metabolic acidosis, and vascular collapse. This complication is 
caused by insufficiency of mitochondrial respiratory enzymes in 
myocardium, slow excretion of drug with urine, and insufficiency of 
hepatic enzymes.  
Sometimes the complications caused by chemotherapeutic effect 
of levomycetin are possible: aggravation of disease due to massive 
degradation of bacterial cells and release of endotoxins, dysbiosis, 
candidiasis, superinfection caused by Pseudomonas aeruginosa, 
resistant strains of staphylococci, and Proteus. 
 
Aminoglycosides  
 
Aminoglycosides are antibiotics containing aminosugars in 
molecules. These antibiotics are grouped into 4 generations: 
– 1st generation: streptomycin, neomycin, kanamycin,  
monomycin .  
– 2nd generation: gentamicin .  
– 3rd generation: tobramycin, sisomicin,  amikacin,  
netilmicin .  
– 4th generation: isepamicin .  
Aminoglycosides irreversibly inhibit 30S subunits of ribosomes 
that results in incorrect reading of mRNA and incorporation of 
mistaken amino acids in the protein structure. Also, aminoglycosides 
affect the structure and function of bacterial cytoplasmic membrane. 
Aminoglycosides are bactericidal antibiotics. 
Aminoglycosides are broad-spectrum antibiotics. These drugs 
are active against Gram-negative aerobic (Escherichia coli, 
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Pseudomonas aeruginosa, Klebsiella, Shigella, Proteus, and 
enterobacteria) and Gram-positive coccal flora (staphylococci, 
streptococci, and pneumococci). Besides, gentamycin is active 
against Francisella tularensis; streptomycin, amikacin, and 
kanamycin – against Mycobacterium tuberculosis; monomycin – 
against Entamoeba histolytica, Leishmania, and Trichomonas. 
Isepamicin, besides the above mentioned flora, is active against 
Citrobacter, Acinetobacter, Morganella, Listeria, and Nocardia.  
The bacterial resistance to aminoglycosides develops quickly 
due to the ability of bacteria to synthesize the enzymes which  
destroy aminoglycosides. There are 15 known enzymes that destroy 
aminoglycosides of the 1st generation, 10 enzymes destroying 
2nd generation drugs, and only 3 enzymes that destroy 
aminoglycosides of the 3rd and 4th generations.  
The main routes for aminoglycoside administration are 
intramuscular and intravenous (bolus or drop-by-drop). 
Aminoglycosides have poor solubility in lipids and their degree  
of absorption in gastrointestinal tract is low. The degree of 
aminoglycoside binding to plasma proteins is 10–30 %. These drugs 
have low ability to penetrate inside of the cells. But aminoglycosides 
easily penetrate through placenta, accumulate in the inner ear and 
adrenal cortex. Aminoglycosides do not undergo metabolism in the 
body and are excreted unchanged. 
Presently, clinical use of the 1st generation aminoglycosides is 
restricted due to bacterial resistance and high drug toxocity. Thus, 
streptomycin is used only in treatment of tuberculosis, tularemia, and 
plaque. Widely used in the past combination of streptomycin and 
benzylpenicillin, nowadays, is used only in treatment of enterococcal 
endocarditis, due to high toxicity. Monomycin is used only in 
treatment of skin leishmaniasis. Tablets of kanamycin and neomycin 
are used in treatment of gastrointestinal infections (enterocolitis and 
dysentery) and for sanitation of intestine before surgery. Also, both 
agents are used externaly in treatment of dermatitis and infectious 
inflammatory diseases of skin. Kanamycin sulfate for parenteral 
administration is used in treatment of tuberculosis. 
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Gentamicin is a broad-spectrum aminoglycoside antibiotic of the 
2nd generation. The most important is its activity against 
Pseudomonas aeruginosa, Proteus, Escherichia coli, Enterobacter, 
Klebsiella, and number of other bacteria, including staphylococci, 
resistant to the 1st generation aminoglycosides and benzylpenicillin. 
Bacterial resistance to gentamicin develops slowly. Normally, 
gentamicin does not penetrate through the blood-brain barrier, but in 
patients with meningitis the permeability of the blood-brain barrier is 
increased. The therapeutic indications for gentamicin are sepsis, 
urogenital infections, pneumonia, bronchitis, infections of central 
nervous system (including meningitis), osteomyelitis, peritonitis, 
postsurgical infections, infected wounds and burns, etc. The drug is 
administered intramuscularly or intravenously 2–3 times a day. Also, 
gentamicin is used topically in treatment of skin and eye infections 
caused by sensitive flora.  
Third generation aminoglycosides are characterizied by higher 
activity against Pseudomonas aeruginosa, different strains of 
Proteus, Klebsiella, and Enterobacter. Amikacin also is active 
against Mycobacterium tuberculosis. Secondary resistance of 
bacteria to gentamicin develops significantly slowly than to 
gentamicin. 
Fourth generation aminoglycoside isepamicin has longer 
duration of action than previous drugs. Isepamicin is administered 
intramuscularly or intravenously once a day. Toxicity of isepamicin 
is low. 
Aminoglycoside therapy may be accompannied by development 
of serious side effects and complications.  
Ototoxicity. Aminoglycosides accumulate in the outer and inner 
hair cells within the organ of Corti that results in degenerative 
changes of hair cells. Sensitive nerve fibers of the inner ear also 
degenerate. In case of streptomycin and gentamicin therapy 
vestibular disfunction develops initially. Other aminoglycosides may 
cause the initial hearing loss. 
Nephrotoxicity occurs due to aminoglycoside accumulation in 
proximal convoluted tubules and functional disturbances of many 
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enzymes that cause the development of interstitial nephritis, impaired 
concentration of urine, proteinuria, and leukocyturia. 
Blockage of neuromuscular synapses is accompanied by 
weakness of diaphragm and other respiratory muscles that can cause 
respiratory paralysis. 
Aminoglycosides inhibit the absorption of nutrients in 
gastrointestinal tract. Other possible side effects of aminoglycosides 
include allergic reactions, polyneuritis, and phlebitis in case of 
intravenous administration. 
 
Polymyxins (Cyclic Polypeptides)  
 
The group is represented by such drugs as polymyxin M, 
polymyxin B, and polymyxin E .  
Polymyxins affect the functions of cytoplasmatic membranes of 
bacteria. Antibiotics interact with phospholipids of membranes that 
results in the increase of membrane permeability. Polymyxins have a 
bactericidal action.  
Antibacterial spectrum of polymyxins is narrow and includes 
Gram-negative bacteria: Escherichia coli, Shigella, Salmonella, 
Klebsiella, Enterobacter, Vibrio cholerae, and most strains of 
Pseudomonas aeruginosa.  
Polymyxin M is taken orally or used topically. The degree of the 
drug absorption in the gastrointestinal tract is about 1–2 %, but in 
patients with intestinal infections drug absorption increases up to  
10–15 %. This fact should be considered because polymyxins are 
drugs with narrow therapeutic margin.  
Polymyxin B and polymyxin E are administered intramuscularly, 
intravenously, into body cavities, and in aerosols for inhalation. The 
drugs have low degree of binding to plasma proteins. Polymyxins 
penetrate through cell membranes and into pleural and peritoneal 
fluids poorly. Therefore, in relevant cases these drugs are 
administered directly into the foci of the infection or intrathecally. 
Only 2–4 % of administered dose undergoes biotransformation. 
About 90 % of the dose is excreted unchanged through the kidneys. 
Polymyxins are active in the urinary tract only in the acidic urine. 
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The drugs are prescribed to be taken 3–4 times a day. For newborn 
infants, polymyxins should be taken only once a day.  
Therapeutic indications for polymyxins are infections of 
intestine and urinary tract, pneumonia, endocarditis, and sepsis 
caused by sensitive flora. Also, polymyxins are used in treatment of 
purulent wounds, burns, purulent otitis and conjunctivitis, etc. 
Polymyxins have the marked neurotoxicity and nephrotoxicity. 
These drugs can affect neuromuscular transmission (muscular 
weakness, and respiratory disturbances), vision, speech, and hearing. 
Therapy with polymyxins may be accompanied by drowsiness and 
irritability. Proteins, cylinders, and erythrocytes in the urine are 
manifestations of polymyxin nephrotoxicity. 
Daptomycin  is a new antibiotic with chemical structure similar 
to polymyxins. Daptomycin is a semisynthetic antibiotic active 
against Gram-positive and Gram-negative bacteria. Therapeutic 
indications for daptomycin include complicated infections of the skin 
and soft tissues and bacteremia caused by Staphylococcus aureus 
(including endocarditis). The drug is used only in the treatment of 
adults. The drug is administered intravenously once daily. Side 
effects are nausea, vomiting, muscular pain, etc. 
 
Rifamycins 
 
 Rifamycin group includes such drugs as rifamycin  (natural 
antibiotic) and rifampicin  (semisynthetic antibiotic).  
Rifamycins block the synthesis of RNA due to inhibition  
of DNA-dependent RNA-polymerase. Antibacterial effect of 
rifamycins is bacteriostatic. Spectrum of activity includes mainly 
Gram-positive bacteria: Mycobacterium tuberculosis, staphylococci, 
streptococci, pneumococci, meningococci, enterococci, gonococci, 
Haemophilus influenzae, Mycobacterium leprae, Bacillus anthrax, 
etc. Large doses of rifamycins affect also Gram-negative bacteria: 
Escherichia coli, Shigella, Salmonella, Rickettsia, Klebsiella, 
Chlamydia, Brucella, some strains of Pseudomonas aeruginosa and 
Proteus, etc. The bacterial resistance to rifamycins develops readily 
(in few days after the start of treatment). 
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Rifampicin  is taken orally or administered intramuscularly or 
intravenously. The drug is easily absorbed in gastrointestinal tract. 
Rifampicin penetrates through tissue barrier, creates high 
concentrations in lungs, pleural cavity, peritoneal exudate, liquor, 
and bones. About 70 % of administered dose is metabolized in the 
liver. A part of rifampicin dose is excreted with bile into intestine 
where it is absorbed in the blood. About 30 % of the dose is excreted 
with the urine unchanged.  
Rifampicin is mainly used to treat tuberculosis. Besides, the drug 
is prescribed to treat leprae, pneumonia, osteomielitis, urinary and 
biliary tract infections, acute gonorrhea, etc. The drug is also used to 
prevent rabies encephalitis in humans and meningitis in the carriers 
of meningococcal infection. 
Rifampicin is a low-toxic antibiotic. Side effects of rifampicin 
include hepatotoxicity, leukopenia, thrombocytopenia, allergic 
reactions, and dispepsia. It is necessary to notice, that rifampicin 
turns the saliva, urine, sweat, feces, and tears an orange-red color. 
Rifampicin is not recommended for intake during first three months 
of pregnancy. 
 
Lincosamides  
 
The group includes such antibiotics as lincomycin  and 
clindamycin . 
Lincosamides inhibit the protein synthesis on the level of 50S 
subunit of bacterial ribosome. Lincosamides exhibit the bacteriostatic 
effect. 
Antibacterial spectrum of lincosamides is broad, but preferably 
directed against Gram-positive bacteria: staphylococci, streptococci, 
pneumococci, Corynebacterium diphtheriae, and anaerobes 
(bacteroides, Clostridium, Fusobacterium). The activity of 
lincosamides against Gram-negative bacteria is less expressed. The 
following Gram-negative bacteria are sensitive to lincosamides: 
meningococci, gonococci, some strains of Haemophilus influenzae, 
and Mycoplasma. Clindamycin is also active against Toxoplasma 
439 
 
gondii, Plasmodium, and some strains of Pneumocystis. Clindamycin 
is 50 times more active against bacteroides than lincomycin.  
Secondary bacterial resistance to lincosamides develops slowly. 
Lincosamides are taken orally or administered intramuscularly 
and intravenously. Bioavailability of the drugs is 50 %. The degree 
of binding to plasma proteins is about 50 %. Lincosamides easily 
penetrate into different tissues and fluids of the body, except 
cerebrospinal fluid. Also, lincosamides are known to accumulate in 
bones. Nearly 80–90 % of administered dose is excreted  
in inactivated form with bile. Only 10–20 % of dose is excreted in 
unchanged form through the kidneys. Lincosamides exhibit the 
highest activity in alkaline environment. The drugs are prescribed to 
be taken 3–4 times a day. 
Lincosamides are reserve antibiotics. The therapeutic indications 
for lincosamides are sepsis, endocariditis, artritis, osteomyelitis, 
lower respiratory tract infections, otitis, infected wounds, diabetic 
foot, toxoplasmosis, and tropical malaria. These drugs are also used 
to prevent infections after surgery in abdomynal cavity and on the 
pelvic organs.  
Side effects of lincosamides are nausea, vomiting, abdominal 
pain, allergic reactions, leukopenia, and thrombocytopenia. Fast 
intravenous administration of the drugs can cause a decrease in blood 
pressure, dizziness, and a decrease in skeletal muscle tone. 
Lincosamides are contraindicated during pregnancy and in patients 
with severe hepatic and renal diseases. 
 
Glycopeptides  
 
The main representatives of this group are vancomycin  and 
teicoplanin (Targocid).  
Glycopetides inhibit the synthesis of bacterial cell wall and 
simultaneously affect the function of bacterial cytoplasmatic 
membrane. Glycopeptides are antibiotics with bactericidal activity. 
Antibacterial spectrum includes Staphylococcus (including 
strains with resistance to other antibiotics), Streptococcus, 
Enterococcus, Clostridium difficile, and some other microorganisms.  
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Vancomycin  is used in treatment of infections caused by  
Gram-positive bacteria: sepsis, endocarditis, meningitis, 
osteomyelitis, pneumonia, and enterocolitis (including 
pseudomembranous colitis). The drug is administered intravenously 
drop-by-drop 3–4 times a day.  
Vancomycin is an antibiotic with high nephro- and ototoxicity. 
The fast drug administration can cause a massive release of 
histamine from basophils that results in low blood pressure and skin 
rashes. Vancomycin can cause phlebitis, neutropenia, and 
thrombocytopenia.  
Teicoplanin  has similar antibacterial spectrum with 
vancomycin. The drug is used in treatment of serious infections 
caused by sensitive bacterial flora (severe infections of respiratory 
and urinary systems, sepsis, peritonitis, etc.). Teicoplanin is 
administered intramuscularly or intravenously once a day.  
 
Table 16 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product 
Benzylpenicillinum
-natrium 
Intramuscularly 250 000–
1 000 000 IU 4–6 times a day; 
intravenously slowly 
1 000 000–2 000 000 IU; 
intravenously drop-by-drop 
2 000 000–5 000 000 IU 
Vials 250 000; 500 000 
or 1 000 000 IU, powder 
for injection 
Benzylpenicillinum
-kalium 
Intramuscularly 250 000–
500 000 IU 4–6 times a day 
Vials 250 000; 500 000 
or 1 000 000 IU, powder 
for injection 
Benzylpenicillinum
-novocainum 
Intramuscularly 300 000–
600 000IU 2–3 times a day 
Vials 300,000 or 600,000 
IU, powder for injection 
Bicillinum-5 Intramuscularly 1 500 000 IU 
once a month 
Vials 1 500 000 IU, 
powder for injection 
Oxacillinum-
natrium  
Orally, intramuscularly  
or intravenously 0.25–0.5 g  
4–6 times a day 
Tablets 0.25 or 0.5 g; 
capsules 0.25 g; 
vials 0.25 or 0.5 g  
of powder for parenteral 
administration 
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Continuation of the table 16 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product 
Ampicillinum  Orally 0.5 g 3–6 times a day Capsules and tablets  
0.25 g 
Amoxicillinum Orally 0.25–1.0 g 3 times 
a day; 
intramuscularly  
or intravenously 1.0 g  
2 times a day 
Coated tablets 1.0 g; 
capsules 0.25 or 0.5 g; 
vials 1.0 g of powder  
for injection 
Cefalexinum  Orally 0.25–0.5 g 4 times 
a day 
Capsules 0.25 g; 
tablets 0.5 g 
Cefotaximum  Intramuscularly  
or intravenously 0.5–1.0 g  
2–3 times a day 
Vials 0.5, 1.0 or 2.0 g  
of powder for injection 
Cefoxitinum  Intramuscularly  
or intravenously 1–2 g  
2–4 times a day 
Vials 1.0 or 2.0 g  
of powder for injection 
Ceftriaxone Intramuscularly  
or intravenously 1–2 g once 
a day or 0.5–1.0 g twice a day 
Vials 0.5, 1.0 or 2.0 g  
of powder for injection 
Erythromycinum  
 
Orally 0.1–0.25 g 4–6 times 
a day; 
into the lower eyelid pocket 
1 % ointment up to 6 times 
a day 
Tablets 0.1 or 0.25 g; 
 
1 % ophthalmic ointment 
7 g  
Azithromycinum Orally 0.25–1.0 g once a day Capsules 0.125 or 0.25 g; 
tablets 0.5 g 
Tetracyclinum Orally 0.2–0.25 g 4 times 
a day; 
into the lower eyelid pocket 
1 % ointment ointment  
2–6 times daily 
Coated tablets 0.05, 0.1 
or 0.25 g; 
1 % ophthalmic ointment 
3.0 or 10.0 g 
Methacyclini 
hydrochloridum 
Orally 0.3 g 2 times a day Capsules 0.15 or 0.3 g  
Doxycyclinum  Orally 0.1 g 1–2 times a day 
or 0.2 g once a day 
Capsules 0.1 g 
Streptomycini 
sulfas 
Intramuscularly 0.5 g  
2 times a day 
Vials 0.25, 0.5 or 1.0 g 
of powder for injection 
Synthomycinum 
 
1–10 % topically 1 %, 5 % or 10 % 
liniment 
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Continuation of the table 16 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product 
Laevomycetinum Orally 0.25–0.5 g 3–4 times 
a day; 
1–2 drops of 0.25 % solution 
into the eye 
Tablets 0.25 or 0.5 g; 
capsules 0.1, 0.25 or  
0.5 g; 
vials 10 ml  
of 0.25 % solution  
Gentamycini 
sulfas 
Intramuscularly  
or intravenously  
0.0004–0.001 g/kg  
2–3 times daily; 
 
 
 
1–2 drops of 0.3 % solution 
into the affected eye(s) 
Ampoules 1 or 2 ml  
of 4 % solution;  
vials 0.08 g of powder 
for injection  
(for parenteral 
administration, it should 
be dissolved before 
using); 
ophthalmic solution: 
0.3 % – 10 ml 
Amikacini sulfas Intramuscularly  
or intravenously (slowly  
or drop-by-drop) 0.007 5 g/kg 
twice a day or 0.005 g/kg  
3 times a day 
Vials 0.25, 0.5 or 1 g  
of powder for injection; 
ampoules 2 ml of 5 %  
or 25 % solution 
Polymyxini M 
sulfas 
Orally 500 000 IU 3–4 times 
daily; 
topically, in liniment 
(10 000 IU/1 g) or in solution 
(10 000–20 000 IU/ml) to treat 
wounds  
Tablets 500 000 IU; 
 
vials 500 000  
or 1 000 000 IU  
of powder (to prepare 
solution for external 
use); 
liniment 30,0 g (10 000 IU 
in 1 g) 
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Step 1. Tasks for Self -Control  
Antibiotics  
 
1. A 19-year-old patient has primary syphilis. He gets a complex 
therapy. Benzylpenicillin sodium is a part of this therapy. What is the 
mechanism of this drug action? 
A. Blockade of DNA synthesis. 
B. Blockade of cytoplasm proteins synthesis. 
C. Blockade of microbe membrane peptidoglycan synthesis.  
D. Blockade of RNA synthesis. 
E. Blockade of thiol enzyme groups. 
2. A 27-year-old woman has dropped penicillin containing eye 
drops. In few minutes there appeared feeling of itching, burning of 
skin, lips and eyelids edema, whistling cough, decreasing of blood 
pressure. What antibodies take part in the development of this 
allergic reaction? 
A. IgE and IgG.  
B. IgG and IgD. 
C. IgM and IgD. 
D. IgM and IgG. 
E. IgA and IgM. 
3. A patient was admitted to the infection unit with diagnosis of 
bacterial dysentery. On laboratory examinations it was revealed that 
causative element is sensitive to many antimicrobial medicines, but 
patient has anaemia. What drug is contraindicated to the patient? 
A. Furazolidone.  
B. Enteroseptol. 
C. Ampicillin. 
D. Levomycetin.  
E. Phthalazolum. 
4. A patient was admitted to the infection unit with diagnosis of 
bacterial dysentery. On laboratory studies it was revealed that 
causative element is sensitive to many antimicrobial medicines, but 
patient had anaemia. What medicine was contraindicated to the 
patient? 
A. Phthalazolum. 
B. Enteroseptol. 
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C. Furazolidone. 
D. Ampicillin. 
E. Levomycetinum (chloramphenicol).  
5. A patient with pneumonia was treated with antibiotics for 
a long period. After treatment patient complains of frequent and 
watery stool, abdominal pain. What is the reason of intestine function 
disorder? 
A. Bacteria toxins influence. 
B. Antibiotic toxic influence on the GIT. 
C. Intestinal disbacteriosis development.  
D. Autoimmune reaction development. 
E. Hereditary enzyme defect. 
6. A 60-year-old patient was admitted to the surgical department 
because of infection caused by blue pus bacillus (Pseudomonas 
aeruginosa) which is sensitive to penicillin antibiotics. Indicate 
which of the given penicillins has marked activity to the 
Pseudomonas aeruginoca? 
A. Methacillin. 
B. Benzylpenicillin. 
C. Phenoxymethylpenicillin. 
D. Oxacillin. 
E. Carbenicillin disodium.  
7. A 50-year-old patient with typhoid fever was treated with 
levomycetin. The next day his condition became worse, temperature 
raised to 39.6 0 C. What caused the worsening? 
A. Allergic reaction. 
B. The effect of endotoxin agent.  
C. Irresponsiveness of an agent to the levomycetin. 
D. Reinfection. 
E. Secondary infection addition. 
8. Penicillin-induced epilepsy has developed in a 28-year-old 
patient in the result of antibiotic therapy. What drug can cause this 
complication? 
A. Isoniazid. 
B. Doxycycline. 
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C. Rifampicin. 
D. Benzylpenicillin sodium. 
E. Amoxicillin. 
9. Serious generalized septic infection menacing to life has 
developed in patient. What of the listed groups of chemotherapeutic 
agents should be used in this case?   
A. Macrolides. 
B. Tetracyclines. 
C. Cephalosporins. 
D. Laevomycetin. 
E. Sulfonamides. 
10. Treatment course of bacterial pneumonia included 
benzylpenicillin sodium salt. What is the mechanism of its 
antimicrobial action? 
A. Inhibition of the cholinesterase activity. 
B. Antagonism with the para-aminobenzoic acid. 
C. Inhibition of the intracellular protein synthesis. 
D. Inhibition of the microorganisms enzymes SH groups. 
E. Inhibition of cell wall synthesis of the microorganism. 
11. A patient suffering from stomach ulcer has been treated with 
antacid drug almagel. For acute bronchitis treatment he was 
prescribed antibiotic methacicline. However, within the next 5 days 
the fever didn’t fall, cough and sputum nature remained unchanged. 
A physician came to the conclusion that the drugs were incompatible. 
What type of drug incompatibility is the case? 
A. Direct antagonism. 
B. Pharmaceutic. 
C. Pharmacokinetic, biotransformation stage. 
D. Pharmacokinetic, absorption stage. 
E. Pharmacodynamic. 
12. As a result of durative antibiotic therapy a 37-year-old patient 
developed intestinal dysbacteriosis. What type of drugs should be 
used in order to normalize intestinal microflora? 
A. Vitamins.  
B. Sulfanilamides. 
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C. Bacteriophages. 
D. Eubiotics. 
E. Autovaccines. 
13. A doctor prescribed cephalosporin antibiotic to the patient 
after appendectomy for infection prevention. Antimicrobial activity 
of this group of antibiotics is based upon the disturbance of the 
following process:  
A. Cholinesterase block. 
B. Ribosome protein synthesis. 
C. Energy metabolism. 
D. Nucleic acid synthesis. 
E. Microbial wall formation. 
 
 
SULFONAMIDES  
 
Sulfonamides are synthetic chemotherapeutic drugs – derivatives 
of sulfanilic acid.  
Sulfonamides are classified as follows.  
1. Resorptive sulfonamides.  
1.1. Short-acting drugs: streptocid, norsulfazol ,  etazol,  
sulfadiazine, and sulfadimezine .  
1.2. Intermediate-acting drugs: sulfamethoxazole and sulfazine.  
1.3. Long-acting drugs: sulfapyridazine and sulfadimethoxine.  
1.4. Ultra-long-acting drugs: sulfalen and sulfadoxine . 
2. Sulfonamides acting in the intestinal lumen:  
–  phthalazolum (phthalylsulfathiazole),  phthazinum   
(phthalylsulfapyridazine), and sulginum (sulfaguanidine); 
–  co-formulated drugs of sulfonamides and 5-aminosalicylic 
acid: salazodimethoxine and salazopyridazine  
(mesalazine).   
3. Sulfonamides for topical application: sulfacyl sodium and 
silver sulfadiazine .  
Chemical structure of sulfonamides is similar to the structure  
of para-aminobenzoic acid (PABA). PABA is a component of folic 
acid. Folic acid participates in synthesis of nucleic acids and proteins 
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(transfers the one-carbon radicals). A significant number of bacteria 
synthesize folic acid. Due to structural resemblance, sulfonamides 
are competitive antagonists of PABA. When concentration of 
sulfonamides in environment is higher than PABA concentration, 
bacterial cells absorb molecules of sulfonamides instead of 
molecules of PABA. Also, sulfonamides are competitive inhibitors 
of dihydropteroate synthase – a bacterial enzyme involved in folate 
synthesis. As a result, the synthesis of folic acid is violated with the 
following inhibition of protein and nucleic acid synthesis. 
Sulfonamides are bacteriostatic agents.  
It is necessary to notice that human cells do not synthesize folic 
acid but require its dietary intake in the form of vitamin Bc, therefore, 
sulfonamides are not antimetabolites for human organism. 
Sulfonamides have the broad spectrum of antibacterial action. 
These drugs are active against both Gram-positive and  
Gram-negative cocci (staphylococci, streptococci, pneumococci, 
meningococci, gonococci), as well as against Haemophilus influenza, 
Bacillus anthracis, Yersinia pestis, Brucella, Vibrio cholerae, 
Corinebacterium diphtheriae, Shigella, Chlamidya, Toxoplasma, 
Plasmodium, Pneumocystis, Actinomycetes, etc. 
Resorptive sulfonamides are readily absorbed in gastrointestinal 
tract. The degree of plasma protein binding ranges from 20 % up to 
90 %. The main step of drug metabolism, acetylation, take place in 
the liver. Acetylated forms have a higher ability to bind to plasma 
proteins and a low ability to penetrate into tissues. Acetylated 
sulfonamides do not have antibacterial properties. These metabolites 
are excreted through the kidneys without the following reabsorption.  
Acetylated forms are badly dissolved in water and can form 
precipitate in the acid urine with the obstruction of renal tubules. 
This complication may be prevented by intake of sodium 
hydrocarbonate or alkaline mineral water (alkalinization of urine). 
Sulfonamides easily penetrate through the blood-brain barrier. 
Significant drug concentrations are observed in kidneys, lungs, liver, 
skin, peritoneal and pleural fluids, milk, saliva, bile, urine, etc. 
Sulfonamides do not accumulate in the bones.  
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Long-acting and ultra-long-acting sulfonamides are slowly 
inactivated in organism. These drugs undergo a significant 
reabsorption in distal convoluted tubules. Therefore, these drugs 
have long duration of action. 
Short-acting sulfonamides are prescribed to be taken 4–6 times a 
day in a daily dose 4–6 g. Intermediate-acting drugs are prescribed 
for 2 times a day intake in a daily dose 1–3 g. Short-acting and 
intermediate-acting sulfonamides are used to treat acute infections. 
Long-acting sulfonamides are prescribed to take once a day for 
treatment of chronic infections. Ultra-long-acting drugs are 
prescribed to be taken by the scheme (as a rule once a week). 
Therapeutic indications for sulfonamides are infections of 
urinary, respiratory or biliary tracts, intestinal infections, infections 
of skin and soft tissues, etc.   
Sulfonamides acting in intestinal lumen are prescribed for  
4 times a day intake in a daily dose 4–6 g.  
Co-formulated sulfonamides with 5-aminosalicylic acid are 
called salazosulfonamides. Salazopyridazine  (mesalazine) is the 
most commonly used among them. Under the influence of bacterial 
enzymes in large intestine, salazosulfonamides are decomposed to 
sulfonamide and 5-aminosalicylic acid that provides the  
anti-inflammatory effect. Salazosulfonamides are used to treat 
nonspecific ulcerative colitis and Crohn’s disease. 
Sulfonamides for topical application are used in solutions, eye 
drops, ointments, pastes, antiseptic powders, or aerosols. Before drug 
application, skin breaks, wounds, or burns should be cleaned from 
the pus because it reduces sulfonamide activity owing to presence  
of PABA. Eye drops of sodium sulfacyl are used in treatment of 
blepharitis, corneal ulcers, and blennophthalmia. 
Sulfonamides seldom cause the development of side effects. As 
a rule, undesirable phenomena develop due to overdose and include 
the following symptoms: central nervous system intoxication 
(dizziness, headache, depression of consciousness, nausea, and 
vomiting), hemolytic or aplastic anemia, granulocytopenia, 
thrombocytopenia, allergic reactions (dermatitis and skin rashes), and 
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nephrotoxicity (proteinuria, erythrocytes and drug microcrystals in 
urine, and low back pain). The formation of microcrystals may be 
prevented by intake of alkaline liquids, because in alkaline 
environment the ability of sulfonamides and their acetylated 
metabolites to precipitate is low. Sulfonamides should be prescribed 
with caution for patients with diseases of liver and kidney.  
 
Sulfonamide and Trimethoprim C o-Formulations 
 
There is a number of drug co-formulations comprising 
sulfonamides and trimethoprim: Co-trimoxazole (Biseptol ,  
Bactrim, Groseptol),  Sulfaton, Lidaprim, Potesepti l , etc. 
The optimal ratio of trimethoprim to sulfonamide is 1:5. Thus, the 
most commonly used drug Biseptol contains 400 mg  
of sulfamethoxazole  and 80 mg of trimethoprim .  
A combination of sulfonamides with trimethoprim provides the 
possibility to block the synthesis of tetrahydrofolic acid in two steps:  
– sulfonamide compete with PABA;  
– trimethoprim blocks the enzyme, providing transformation of 
dihydrofolic acid into tetrahydrofolic acid – dihydrofolate reductase. 
Due to this mechanism, co-formulated drugs have bactericidal 
effect. The bacterial resistance to combination drugs develops 
slowly.  
It is necessary to notice that human dihydrofolate reductase is 
50 000 times less sensitive to trimethoprim than bacterial enzyme. 
Trimethoprim is readily absorbed in gastrointestinal tract and 
easily penetrates into tissues and fluids of the body. Nearly 50–60 % 
of the administered dose is exscreted from the body with urine. The 
rest is excreted with bile, sputum, etc.  
Biseptol is used to treat infections of moderate severity. Children 
older than 12 eyars and adult patients should take 2 tablets of 
Biseptol twice a day. There are Bactrim or Septrin solutions in 
ampoules for intravenous infusion. The content of the ampule should 
be diluted with 5 % dextrose in water and administered intravenously 
drop-by-drop.  
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Therapeutic indications for Biseptol are as follows: respiratory 
tract infections (acute bronchitis, pneumonia, icluding pneumonia 
caused by Pneumocystes), urinary tract infections, enteritis, colitis, 
otitis, meningitis, sepsis, toxoplasmosis, and tropical malaria. 
Side effects of co-formulated drugs are allergic reactions, 
nephrotoxicity, hepatotoxicity, methemoglobinemia, hemolytic 
anemia, neuritis, teratogenicity, porphyria (in patients with hereditary 
metabolic disorders), superinfection, deficiency of folic acid that 
results in anemia, hypotrophy, dyspepsia, and disturbances in 
spermatogenesis. 
Co-formulated drugs are contraindicated to children under  
6 years of age, pregnant women, patients with disturbances in 
haematopoiesis, and in diseases of liver and kidneys.  
 
SYNTHETIC ANTIBACTERIAL DRUGS  
WITH DIFFERENT CHEMICAL STRUCTURE 
 
This group includes antimicrobial drugs with different chemical 
structure which are classified into different groups.  
1. Quinolone derivatives. 
2. Nitrofuran derivatives. 
3. Quinoxaline derivatives.  
4. Oxazolidinones. 
 
Quinolones 
 
There are three generations of quinolones which differ by their 
antibacterial spectrum, activity, and toxicity. 
 
First  Generation Quinolones  
 
First generation quinolones are nitroxolinum, intestopan, 
chiniofonum, enteroseptol , and chlorchinaldolum . There are 
combination drugs containing enteroseptol: Mexaform  (contains 
enteroseptol,  entobex , and oxyphenonium bromide) and 
Mexasa  (enteroseptol, entobex, bile acids,  pancreatin , and 
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bromelain) . Oxyphenonium bromide is a drug with antispasmodic 
activity. Bromelain is a proteolytic enzyme contained in a pineapple. 
First generation quinolones affect the activity of metal-
containing bacterial enzymes and inhibit the synthesis of bacterial 
DNA. Besides, molecules of these drugs contain the atoms of I, Cl, 
or Br and cause the denaturation of bacterial proteins. 
Pharmacological effect of the 1st generation quinolones is 
bactericidal. 
Antibacterial spectrum of the 1st generation drugs is broad and 
includes Gram-positive and Gram-negative bacteria, protozoa 
(amoeba, lamblia), and Candida. One should have in view that 
microorganisms become resistant to the 1st generation quinolones 
very quickly. 
All drugs (except nitroxoline) are almost not absorbed from 
gastrointestinal tract, therefore they act only on microflora of the 
gastrointestinal tract. Most 1st generation drugs are taken orally  
4 times a day. 
About 50 % of orally taken nitroxoline  is absorbed in the 
blood. Nitroxoline binds to plasma proteins, poorly penetrates into 
fluids and tissues of the body (except renal tissue and prostate), and 
is excreted through the kidneys unchanged. Nitroxoline is used in 
treatment for urinary tract infections. The toxicity of nitroxoline is 
low. Side effects are allergic reactions and dispeptic disorders. The 
drug turns the urine violent yellow. 
Chiniofonum  is used mainly to treat amoebic dysentery. 
Intestopan , enteroseptol , and chlorchinaldolum  are used to 
treat intestinal infections (dysentery, salmonellosis, intestinal 
disorders caused by staphylococci, Proteus, enterobacteria, etc.). 
Mexaform  is a drug of choice in case a patient is concerned about 
painful spasms of intestinal smooth muscles. In case of meteorism, 
Mexasa  is preferable. Iodine-containing drugs are contraindicated to 
patients with hyperthyreosis. 
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Second Generation Quinolones  
 
Second generation quinolones are nalidixic acid , oxolinic 
acid (gramurin), and pipemidic acid (palin) . These drugs 
inhibit metal-containing enzymes of bacterial cells. Depending on 
concentration, the 2nd generation quinolones cause bacteriostatic or 
bactericidal effect.  
Antibacterial spectrum of the 2nd generation quinolones directs 
upon Gram-negative bacteria (Escherichia, Shigella, Salmonella, 
Klebsiella, and Proteus). Pseudomonas aeruginosa is resistant to the 
2nd generation drugs. Bacteria quickly develop secondary resistance 
to these drugs.  
The 2nd generation quinolones are prodrugs, which after 
hydroxylation in liver, are transformed into pharmacologically active 
substances. 
The drugs are taken orally because they have high bioavailability 
in the gastrointestinal tract. The 2nd generation drugs poorly 
penetrate into tissues and fluids of the body, being excreted through 
the kidneys. These drugs are prescribed to be taken 4 times a day. 
Therapeutic indications for the 2nd generation quinolones are acute 
and chronic infections of urinary tract. It is necessary to acidify the 
urine during treatment with these drugs.  
Side effects of the 2nd generation quinolones are allergic 
reactions, dyspetic disorders, headache, photodermatosis, and 
isomnia. The drugs are contraindicated to patients with severe 
violations of hepatic and renal functions, for pregnant women in first 
3 months of pregnancy, and for children under 2 years of age. 
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Third Generation Quinolones  
(Fluoroquinolones or Systemic Quinolones)  
 
Molecules of these drugs contain fluorine and piperidine radicals 
that significantly influence upon their antibacterial spectrum and 
pharmacological properties. Fluoroquinolones are classified into the 
following groups:  
– monofluoroquinolones: norfloxacin (floxacin), 
pefloxacin (abactal),  enoxacin,  ofloxacin (tarivid),  
ciprofloxacin (ciprobay),  pufloxacin ; 
– difluoroquinolones: sparfloxacin  (zagam), lomefloxacin  
(maxacvin);  
– trifluoroquinolones: tosufloxacin, fleroxacin (Quinodis).  
Fluoroquinolones inhibit DNA gyrase (also known as 
topoisomerase II) activity – an enzyme essential for bacteria 
viability. DNA gyrase paticipates in the process of DNA replication. 
DNA gyrase provides the formation of negative supercoiling in the 
relaxed circular prokaryotic DNA molecules. Interaction between 
gyrase and DNA leads to DNA winding around the enzyme. There is 
a positive supercoiling in places of DNA which is associated with 
gyrase. Thereafter, the enzyme makes a double-stranded break in 
DNA, moves a double strand from inside to outside, and stitches 
segments back together. Thus, positive supercoiling of DNA 
transformes into negative supercoiling that promotes the movement 
of DNA polymerase along DNA. 
Bacterial DNA gyrase essentially differs from human DNA 
gyrase. This provides the high selectivity of fluoroquinolones against 
microorganisms and their low toxicity for humans. 
Some fluoroquinolones (ofloxacin, ciprofloxacin, and 
lomefloxacin) have an ability to inhibit the enzyme that provides the 
synthesis of the SOS-system proteins. These proteins protect the 
bacterial cell from unfavorable external factors and are responsible 
for changes of the rod-shaped bacteria (filamentous forms) before 
cell division. Fluoroquinolones are bactericidal agents.  
Fluoroquinolones are ultra-broad-spectrum antibacterial agents. 
Gram-negative microflora is more sensitive than Gram-positive 
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bacteria to these drugs. Fluoroquinolones are active against 
gonococci, Escherichia coli, Shigella, Salmonella, Klebsiella, 
Enterobacter, Haemophilus influenzae, Pseudomonas aeruginosa, 
Mycoplasma, Chlamidia, etc. There are resistant bacteria to 
fluoroquinolones: Spirochaetales, fecal enterococci, and anaerobes. It 
is necessary to notice that sparfloxacin has the highest activity 
against Gram-positive cocci, Chlamidia, Mycoplasma,  
M. tuberculosis and M. leprae. 
Moxifloxacin (Avelox, Avalox)  exhibits the high activity 
against streptococci, staphylococci, Chlamydia, Mycoplasma, 
Ureaplasma, and anaerobes. In activity against anaerobes, 
moxifloxacin is similar to metronidazole and imipenem. 
Bacteria slowly develop the secondary resistance to 
fluoroquinolones. As soon as bacterial resistance is developed, it 
spreads to the 1st and the 2nd generation quinolones and a significant 
amount of antibiotics (tetracyclines, chloramphenicol, and β-lactam 
antibiotics). Therefore, fluoroquinolones should be used only as 
reserve drugs. 
There are known such new fluoroquinolones as gatifloxacin, 
gemifloxacin, and levofloxacin . The drugs have high activity 
against Gram-positive and Gram-negative bacteria, especially against 
pathogens causing respiratory tract infection and tuberculosis. These 
new agents are taken orally. 
Fluoroquinolones are taken orally, administered intravenously, 
or used externally. For intravenous administration, the drug  
(e. g. ciprofloxacin, pefloxacin) is diluted ex tempore. Solutions 
should be protected from light. 
Fluoroquinolones are readily absorbed in the gastrointestinal 
tract. Simultaneous intake of fluoroquinolones with antacids and 
iron-containing drugs should be avoided, because the bioavailability 
of fluoroquinolones is reduced. The degree of fluoroquinolone 
binding to plasma proteins is about 40 %. Fluoroquinolones readily 
penetrate into main tissues and fluids of the body, but only some 
drugs (ofloxacin, pefloxacin, and ciprofloxacin) can penetrate 
through the blood-brain barrier. The main route of drug elimination 
455 
 
is kidneys. Fluoroquinolones are prescribed to be taken 1–2 times 
a day. 
Fluoroquinolones should be prescribed only in cases when 
broad-spectrum antibiotics are ineffective. The therapeutic 
indications for fluoroquinolones are infections of urinary tract 
(foremost caused by Pseudomonas aeruginosa), respiratory system, 
gastrointestinal tract, severe purulent surgical infections caused by 
multiresistant microflora or Staphylococcus aureus, treatment and 
prevention of infections in patients with neutropenia, oncological 
diseases, and immunodeficiency.  
Fluoroquinolones are low-toxic drugs. Their side effects are 
dyspepsia, skin rash and other allergic reactions, headache, dizziness, 
insomnia, photosensitization, temporal arthralgia, disbiosis, and 
disturbances of renal and hepatic functions.  
 
Nitrofurans 
 
Nitrofurans include such drugs as furacilinum (nitrofural, 
nitrofurazone), furazolidone, furaginum (furazidin), 
furadoninum (nitrofurantoin), and furazolinum.  
Nitrofurans form the complex compound with bacterial DNA, 
affect the transport of electrons in respiratory chain, violate the redox 
processes in citric acid cycle. It results in the disturbances of 
cytoplasmic membrane function and destruction of bacterial cell 
wall. Depending on a dose, nitrofurans exhibit bacteriostatic or 
bactericidal effect. Unlike other antibacterial drugs which inhibit 
immunity, nitrofurans slightly increase the resistance of 
macroorganisms to infection (nitrofurans stimulate phagocytosis, 
etc.). Under the nitrofuran influence, the production of toxins by 
bacteria is reduced. Nitrofurans keep their activity in precence of pus 
and other products of tissue disintegration.  
Nitrofuran antibacterial spectrum is broad and includes such 
microorganisms as Gram-positive and Gram-negative bacteria 
(staphylococci, pneumococci, streptococci, Klebsiella, Proteus, 
Enterobacter, meningococci, gonococci, etc.) and protozoa 
(Trichomonas and Giardia lamblia).  
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The bacterial resistance to nitrofurans develops slowly and is not 
cross-reactive with sulfonamides and antibiotics. 
Nitrofurans are taken orally after a meal. Furaginum is also used 
for intravenous administration. Furacilinum and furaginum are used 
topically. The degree of nitrofuran absorption in gastrointestinal tract 
is about 50 % (for furazolidone – only 30 %). The degree of binding 
with plasma proteins is very low. Nitrofurans readily penetrate into 
lymph and accumulate in the bile duct. Only 10 % of administered 
nitrofuran dose undergoes biotransformation. Nitrofurans are 
excreted from the body through the kidneys. The intensity of 
excretion is higher in alkaline urine. In acid urine, nitrofurans 
undergo reabsorption that provides for their accumulation. 
Nitrofurans are prescribed to be taken 4 times a day.  
Furadoninum (nitrofurantoin)  is mainly used in treatment 
of urinary tract infections (pyelonephritis, cystitis, and uretritis). 
Also, furadoninum is used to prevent infection in cystoscopy and 
prolonged catheterization. 
Furazolidone  is poorly absorbed in the gastrointestinal tract 
that allows it to be used in enterocolitis treatment. The drug is also 
used to treat lambliasis and colpitis caused by Trichomonas. 
Furazolidone is taken orally and applied intravaginally or rectally. 
Furacilinum (nitrofural)  is known as antiseptic for external 
use. The drug is used for antiseptic rinsing, washing of wounds, 
burns, and bedsores. Also, furacilin is used in form of eye and ear 
drops. 
Side effects of nitrofurans are expressed by loss of appetite, 
nausea, epigastric pain, allergic reactions (skin rash, bronchospasm, 
fever, etc.), disturbances of renal function, neuritis, and 
methemoglobinemia. Drinking plenty of fluids and taking in  
H2-receptor antagonists and vitamins of group B are prescribed when 
treating by nitrofurans to prevent or diminish their side effects. 
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Quinoxaline Derivatives  
 
Quinoxaline derivatives are quinoxidine  and dioxidine . 
Quinoxalines are synthetic agents with bactericidal effect. The 
mechanism of their action is poorly understood. Antibacterial 
spectrum includes Proteus, Pseudomonas aeruginosa, Klebsiella, 
Escherichia coli, Shigella, Salmonella, staphylococci, streptococci, 
Clostridium, and Bacteroides. Bacteria slowly develop secondary 
resistance to quinoxalines.  
Quinoxidine is taken orally 3–4 times a day after a meal. The 
drug is readily absorbed in the gastrointestinal tract. Dioxidine is 
administered intravenously drop-by-drop (0.1–0.2 % sterile 
solutions) or administered in body cavities. Also, solutions or 
ointments with dioxidine are used topically. Quinoxaline derivatives 
are excreted through the kidneys unchanged. 
Quinoxaline derivatives are used as reserve drugs in treatment of 
purulent inflammatory processes of different localization: purulent 
pleuritis, lung abscess, peritonitis, pyelonephritis, cholecystitis, and 
severe sepsis.  
Quinoxalines are quite toxic drugs. Their side effects are 
expressed by dispepsia, dizziness, headache, allergic reactions, 
candidiasis, muscle twitching, carcinogenesis, teratogenicity, etc. 
 
Oxazolidinones  
 
The representative of this new antibacterial group is linezolid  
(Zyvox) . Linezolid affects the syntheisis of nucleic acids and protein 
synthesis on ribosomes. As a rule, linezolid exhibits bacteriostatic 
effect, but against Gram-positive cocci the drug can produce the 
bactericidal effect. 
Antibacterial spectrum of linezolid is broad and includes such 
microorganisms as aerobic Gram-positive bacteria and cocci, some 
Gram-negative bacteria, Mycobacterium tuberculosis, and many 
anaerobes.  
Linezolid is administered intravenously or taken orally  
1–2 times a day. The drug is readily absorbed in the gastrointestinal 
tract. Its bioavailability is about 100 %. The degree of binding to 
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plasma proteins is about 30 %. Inactivated linezolid is excreted 
through the kidneys (30 %) and liver (70 %). 
The therapeutic indications for linezolid are sepsis, endocarditis, 
pneumonia, infections of skin and soft tissues, and other severe 
infections caused by Gram-positive cocci. 
The side effects of linezolid are dysbiosis, candidiasis, nausea, 
vomiting, headache, and changes in gustatory perception. The 
prolonged drug use can cause thrombocytopenia, peripheral 
neuropathy (including optic nerve), allergic reactions, pancreatitis, 
and liver damage.  
 
Table 17 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product  
Sulfadimezinum Orally 1st administration – 
2.0 g; all subsequent 
administrations 1.0 g 
4–6 times daily 
Tablets 0.25 or 0.5 g 
Aethazolum Orally 1.0 g 4–6 times daily Tablets 0.25 or 0.5 g 
Sulfacylum-natrium Intravenously slowly 3–5 ml 
of 30 % solution twice  
a day; 
1–2 drops into eyes  
2–6 times daily 
Ampoules 5 ml  
of 30 % solution;  
 
eye drops: bottles 10 ml 
of 20 % or 30 % solution   
Sulfadimethoxinum Orally 1st administration – 
1.0–2.0 g; all subsequent 
administrations 0.5–1.0 g  
1–2 times a day 
Tablets 0.2 or 0.5 g 
Phthalazolum Orally 1.0 g 4–6 times daily  Tablets 0.5 g 
Biseptol-480 
 
Orally 2 tablets 2 times 
daily; 
 
intravenously drop-by-drop 
10 ml deluted in 250 ml  
of isotonic solution of NaCl 
twice a day 
Tablets containing 0.4 g  
of sulfamethoxazole and 
0.08 g of trimethoprim; 
ampoules 5 ml 
Nitroxolinum Orally 0.1 g 4 times a day Coated tablets 0.05 g 
Acidum 
nalidixicum 
Orally 0.5–1.0 g 4 times 
daily 
Tablets or capsules 0.5 g 
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Continuation of the table 17 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product  
Furazolidonum Orally 0.1 g 4 times daily Tablets 0.05 g 
Ciprofloxacinum Orally 0.25–0.75 g 2 times 
daily; 
intravenously drop-by-drop 
0.2–0.4 g with 50 ml  
of isotonic sodium chloride 
solu-tion 2 times a day 
Tablets 0.25; 0.5 or 0.75 
g; 
 
ampoules 10 ml  
of 1 % solution 
  
 
Step 1. Tasks for Self -Control  
Sulfonamides.  Synthetic Antimicrobial Drugs 
 
1. Gonorrhoea was revealed in the patient on bacterioscopy of 
the smear from urethra. Taking into account that medicines for 
gonorrhea are fluorquinolones, patient should be prescribed: 
A. Fluorouracil. 
B. Ciprofloxacin.  
C. Furasolidone. 
D. Cefazolin. 
E. Urosulfanum. 
2. A patient with pneumonia has intolerance to antibiotics. 
Which of the combined sulfanilamide drug should be prescribed to 
this patient? 
A. Biseptol. 
B. Streptocid. 
C. Aethazol. 
D. Sulfadimethoxine. 
E. Sulfacylum natrium. 
3. Relative granulocytopenia is observed in patient after course 
of treatment with sulfonamides. It is known that patient has tendency 
to allergies. Point out an immunologic process which is the cause  
of granulocytopenia? 
A. Increased activity of macrophages. 
B. Decrease of immunologic tolerance. 
C. Formation of immunologic complexes in blood. 
460 
 
D. Increased activity of killer lymphocytes. 
E. The lysis of leucocytes which are acquired from antigenic 
properties. 
4. Combined sulfonamide drug with bactericidal effect was 
prescribed to patient with pneumonia. Which drug was prescribed?  
A. Phthalazolum (phthalylsulfathiazole). 
B. Aethazolum (sulfaethidole). 
C. Norsulfazol (sulfathiazole). 
D. Bactrim. 
E. Sulfalen. 
5. A doctor prescribes biseptol to patient with tonsillitis. What is 
the priority of biseptol in comparison with other sulfonamides? 
A. Biseptol has less degree of binding with plasma proteins. 
B. Trimethoprim increases the imitation of PABA by 
sulfonamides. 
C. Biseptol better penetrates into the microorganisms. 
D. Trimethoprim decreases the sulfonamide biotransformation. 
E. Trimethoprim blocks the next stage of folic acid metabolism. 
6. A doctor prescribes sulfonamide to patient with pneumonia. 
What is the mechanism of sulfonamides action? 
A. Increase of bacterial cell membrane permeability. 
B. Competitive antagonism with para-aminobenzoic acid 
(PABA). 
C. Regulation of vessels tone. 
D. Influence upon bacterial cell wall. 
E. Blockage of SH groups of bacterial enzymes. 
7. A patient with bacterial dysentery receives phthalazolum. 
Why is this drug used only for treatment of intestinal infections? 
A. Drug is easily eliminated from the body. 
B. Drug has high degree of reabsorption in the kidneys. 
C. Drug undergoes enterohepatic circulation. 
D. Drug is easily absorbed in the blood. 
E. Drug acts only on the intestine because it isn’t absorbed into 
the blood. 
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8. A patient received sulfalen for treatment of chronic infection. 
Haemolysis of erythrocytes develops in the patient in several days 
after initiation of treatment. Deficiency of which enzyme is the cause 
of this complication? 
A. N-acetyltransferase. 
B. Cholinesterase. 
C. Acetaldehyde dehydrogenase. 
D. Glucose-6-phosphate dehydrogenase. 
E. MAO. 
9. A 7-years-old child receives phthalazolum for treatment of 
enterocilitis. What is the mechanism of drug action? 
A. Blockage of peptidyl transferase. 
B. Inhibition of dihydropteroate synthase.  
C. Inhibition of RNA-polymerase. 
D. Inhibition of DNA-transcriptase. 
E. Inhibition of DNA-polymerase. 
10. A doctor prescribed sulfonamide for treatment of patient 
with infection of urinary tract. Which drug was prescribed by the 
doctor? 
A. Sulfadimethoxine. 
B. Phthalazolum. 
C. Urosulfanum. 
D. Sulfacylum-natrium. 
E. Sulginum. 
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ANTISYPHYLITIC DRUGS 
 
Antisyphylitic drugs are used to treat syphilis. The infectious 
agent causing syphilis is Treponema pallidum. The antisyphylitic 
therapy is complex and requires pill-dosing regimen. 
Presently, three groups of drugs are most commonly used to treat 
syphilis: antibiotics, fluoroquinolones, and bismuth preparations. 
Classification of antisyphylitic drugs is as follows. 
1. Antibiotics:  
– penicillins: benzylpenicil lin sodium, benzylpenicillin 
potassium, benzylpenicil lin novocaine salt ,  bicill in-1,  
bicil lin-5,  ampicillin , oxacillin ; 
– macrolides and azalides: erythromycin, oleandomycin,  
azithromycin ;  
– cephalosporins: cefazolin,  ceftriaxone , etc; 
– tetracyclines: doxycycline, tetracycline . 
2. Fluoroquiniolones: ofloxacin , etc.  
3. Bismuth-containing drugs: biiochinol, bismoverol . 
Both short-acting and long-acting penicillins are used to treat 
syphilis. Penicillins are the most efficient drugs for syphilis therapy 
and are active against Treponema pallidum in all stages of the 
disease. Penicillins are especially effective if used in combination 
with bismuth preparations.  
In case of individual intolerance to penicillins, other effective 
antibiotics (macrolides, tetracyclines, and cephalosporins) are 
prescribed for syphilis treatment. But all of them are less active 
against Treponema pallidum. 
Bismuth-containing drugs are biiochinolum and bismoverolum. 
Both drugs are the suspensions of bismuth-containing substances in 
peach kernel oil. These drugs are active only against Treponema 
pallidum. Bismuth blocks the thiol enzymes of Treponema. The 
activity of bismuth-containing drugs is less than penicillin activity, 
and their effect develops slower. Bismuth-containing drugs are 
especially effective in neurosyphilis. Both drugs are non-absorbable 
in gastrointestinal tract, therefore they are administered 
intramuscularly. Bismuth-containing drugs accumulate in the body 
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with a significant accumulation in the bones, kidneys, liver, and 
nervous tissue. The routes of drug excretion are kidneys and 
intestine. Bismuth-containing drugs are used in treatment of all forms 
of syphilis. 
The common complication of bismuth therapy is so-called 
“bismuth flu”: generalized weakness, fever, and fatigue. These 
symptoms appear right after drug administration: gray colored border 
around the edge of the gums, dermatitis, gingivitis, colitis, stomatitis, 
and dark spots on the cheeks appear subsequently. Sometimes, 
leukopenia and disturbances of hepatic and renal functions are 
observed. 
Iodine preparations are used in resorption of intracranial 
gummas in the tertiary stage of syphilis. 
 
Table 18 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product 
Benzylpenicillinum
-natrium  
 
Intramuscularly 250 000–
1 000 000 IU 4–6 times daily 
Vials 250 000; 500 000 
or 1 000 000 IU  
of powder for injection 
Bicillinum-5 Intramuscularly 1 500 000 IU  
1 time per month  
Vials 1 500 000 IU  
of powder for injection 
Biiochinolum Intramuscularly 2–3 ml 1 time 
per 3 days  
Vials 100 ml 
Bismoverolum Intramuscularly 1.5 ml 2 times 
per week 
Vials 100 ml 
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ANTITUBERCULOSIS DRUGS 
 
Tuberculosis is an infective disease caused by three species of 
Mycobacterium: M. tuberculosis, M. bolis and M. avium.  
M. tuberculosis is a so-called “human” specie which is transmitted 
only from human to human. M. bolis and M. avium (bovine and avian 
species) can infect both humans and animals. 
Modern tuberculosis is characterized by mainly 
bronchopulmonary localization (about 80 % of cases). According to 
WHO, there are about 20 million sick people with active tuberculosis 
around the world. Annually, from 50 to 100 million people are 
infected and more than 3 million people die. The risk of falling ill is 
significantly increased in people with immunodeficiency: AIDS/HIV 
patients, smokers, patients with chronic bronchopulmonary diseases, 
and in malnutrition. The stress is not the least among health risk 
factors. Thus, the incidence of tuberculosis is sharply increased in 
times of crises and wars. 
Antituberculosis drugs include both antibiotics and synthetic 
agents. Synthetic drugs are active only against species of 
Mycobacterium causing tuberculosis. Some of them are also active 
against Mycobacterium leprae. Antibiotics which are used to treat 
tuberculosis are broad spectrum antibiotics mainly of rifamycin and 
aminoglycoside groups. 
According to reccomendations of the International Union 
Against Tuberculosis and Lung Disease (1997), antituberculosis 
drugs are classified into the following groups based on their activity. 
1. Most effective antituberculosis drugs.  
1.1. Isonicotinic acid derivatives: isoniazid, ftivazide,  
saluzidum .  
1.2. Rifamicins: rifampicin, rifabutin,  rifaximin .  
2. Drugs with high antituberculosis activity:  
2.1. Aminoglycosides: streptomycin, kanamycin, amikacin .   
2.2. Derivatives of isonicotinic acid: pyrazinamide, 
ethionamide, prothionamide.  
2.3. Aminobutanol derivatives: ethambutol .  
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2.4. Fluoroquinolones: ofloxacin, sparfloxacin, lomefloxacin, 
ciprofloxacin. 
2.5. Antibiotics of different groups: florimycin, cycloserine, 
capreomycin.  
3. Drugs with moderate antituberculosis activity:  
3.1. Para-aminobenzoic acid derivatives: sodium para-
aminosalicylate (PAS) and  calcium para-petrolyl - 
aminosalicylate (Bepascum) .  
3.2. Thiosemicarbazone derivatives: thioacetazone . 
According to the degree and reliability of action upon 
M. tuberculosis, antituberculosis drugs are divided into two groups.  
 1. First-line drugs: isoniazid, ri fampicin,  ethambutol ,  
pyrazinamide, and streptomycin .  
 2. Second-line drugs: ethionamide, prothionamide, 
cycloserine, florimycin, capreomycin, amikacin,  
kanamycin, lomefloxacin, ofloxacin, ciprofloxacin,  
and PAS .  
There are several populations of M. tuberculosis. First 
population mycobacteria are located outside the cells, have intensive 
metabolism and rapidly grow in the acidic environment. This 
population is predominant in acute phase of disease. Dispite of high 
sensitivity of these bacteria to antituberculosis drugs, the resistant 
strains are often found between them. Therefore, the treatment of 
tuberculosis starts with the use of 3–5 drugs.  
Second population mycobacteria are located inside the cells 
(mainly within macrophages) and characterized by low metabolic 
rate and slow growth in the acidic environment. This population is 
typical for chronic forms of tuberculosis. Second population 
mycobacteria are sensitive to pyrazinamide, isoniazid, and 
rifampicin. Aminoglycosides do not penetrate into the cells, 
therefore, they do not significantly affect this population. 
Third-population mycobacteria are characterized by slow growth 
and location in caseous foci. This population is sensitive only to 
pyrazinamide and rifampicin. Second- and third population 
mycobacterium can transform into latent forms. In unfavourable 
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conditions (reduction of immunity, deterioration of the living 
conditions of the patient), these latent forms cause the disease 
recurrence. The latent forms of mycobacteria are sensitive to 
rifampicin and pyrazinamide. 
There are some peculiarities of tuberculosis treatment. It is 
necessary to choose the drugs to which mycobacteria are sensitive. 
The course of treatment can take from several months to several 
years. Pharmacotherapy includes simultaneous intake of several 
drugs. A prolonged antituberculosis therapy is accompanied by the 
development of bacterial resistance and toxic effects in the human 
body. The combined pharmacotherapy with 3–5 antituberculosis 
drugs prevents the bacterial resistance. The efficacy of tuberculosis 
therapy increases if antituberculosis drugs are used together with 
immunomodulators. Also, ambenum is used because this drug 
prevents the lungs’ fibrosis. In prolonged antituberculosis therapy, 
such agents as insulin (8 units a day), glucocorticoids, folic acid, and 
stimulator of phagocytosis flurenizid are used. Hepatoprotectors are 
prescribed to prevent liver damage (Essentiale, Solcoseryl,  
LIV 52, etc.). 
From the clinical point of view, all tuberculosis patients are 
divided into 4 groups. The first group includes the patients who 
release mycobacteria into the external environment. The short-term 
therapeutic regimen (during 6 months) is used to treat such patients. 
The treatment is performed in two phases. A combination of four 
drugs is prescribed in the initial phase of treatment. This combination 
includes isoniazid, rifampicin, pyrazinamide, and ethambutol or 
streptomycin. The duration of this phase is 2 months. The second 
phase lasts four months. Two drugs – isoniazid and rifampicin – are 
prescribed in this phase. As a result of therapy, the release of 
mycobacteria is terminated in 100 % of patients and closing of 
caverns is observed in 89 %.  
The second group includes tuberculosis patients who do not 
release mycobacteria. These patients are treated by 4-drug 
combination (isoniazid, rifampicin, pyrazinamide, and ethambutol or 
streptomycin) during four months.  
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The third group includes elderly patients. A so-called “mild” 
regimen of intermittent therapy is used in their treatment. According 
to this regimen, three drugs are prescribed to be taken two times a 
week during the first half-year.  
The fourth group includes healthy people at high risk for 
tuberculosis: persons who contact sick people releasing 
mycobacteria, patients with hyperergic tuberculin reaction (more 
than 6 mm), healthcare workers of TB dispensary, etc. They take 
isoniazid once a day after a meal during 2–3 moonths or three times a 
week (intermittent method). 
 
Most Effective Antituberculosis Drugs:  
 
Isonicotinic  Acid Derivatives  
 
Hydrazides of isonicotinic acid include such drugs as isoniazid, 
ftivazide, saluzidum, prothionamide, and ethionamide .  
Isoniazid  is most commonly used among them. The drug 
exerts high activity against Mycobacterium tuberculosis. Isoniazid 
acts upon both extracellular and intracellular mycobacteria.  
A mechanism of isoniazid action is not clear enough. The drug 
affects synthesis of mycolic acids which are essential for the cell wall 
of mycobacteria, because mycolic acids are structural components of 
the cell wall only for mycobacteria, therefore isoniazid action is 
highly specific, and it is active only against mycobacteria. Besides, 
there is a viewpoint that isoniazid also inhibits the nucleic acid 
synthesis. Effect of isoniazid is bactericidal. 
Isoniazid is taken orally or administered intramuscularly, 
intravenoulsly, by inhalation, and into cavernas. Orally, isoniazid is 
taken 1–3 times a day after a meal. The drug is readily absorbed in 
the gastrointestinal tract. Isoniazid easily penetrates through tissue 
barriers including the blood-brain barrier.  
The rate of isoniazid inactivation (hepatic acetylation) 
significantly differs in different patients. This fact should be taken 
into account for drug dosing. The speed of hepatic acetylation is 
genetically determined, and about 50 % of European population has a 
low speed of this reaction. In these patients (so-called “slow 
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acetylators”), plasma drug concentration reduces 2–2.5 times slower 
than in “fast acetylators”. The main route of isoniazid excretion is 
kidneys.  
Intramuscular or intravenous routes of isoniazid administration 
are used in severe forms of tuberculosis. After intravenous drug 
administration, a patient should lie at least during 1–1.5 hours. 
Usually, intravenous administration of isoniazid improves the 
pulmonary blood circulation. 
Therapy with isoniazid is accompanied by significant side 
effects and complications. Neurotoxic effects are the first among 
them: neuritis, damage of ocular nerve, insomnia, psychic 
disturbances, dizziness, and memory loss. Nausea, vomiting, 
constipation, dry mouth, and allergic skin rash are possible due to the 
drug intake. Isoniazid affects the synthesis of vitamin B6 active  
form – pyridoxal phosphate. The last one is the essential co-enzyme 
for deamination and transamination of amino acids and participates 
in protein synthesis. Therefore, isoniazid can cause disturbances of 
protein synthesis with the following muscular atrophy and anemia. 
Also, gynecomastia in males and menorrhagia in females are 
possible side effects of isoniazid. Pyridoxine, glutamic acid, 
thiamine, and ATP-Long are used for reduction of isoniazid toxicity. 
Isoniazid contraindications are epilepsy and other convulsive 
diseases, disturbances of hepatic and renal functions, marked 
atherosclerosis, and phlebitis.  
Other derivatives of isonicotinic acid (ftivazide, saluzid, 
ethionamide, prothionamide) are less active in comparison with 
isoniazid. These drugs are used in case of isoniazid intolerance. 
 
Rifamicins  
 
The main representative of this antibiotic group is rifampicin. 
This broad-spectrum antibiotic is active against Mycobacteria,  
Gram-positive and Gram-negative bacteria, including some strains  
of Pseudomonas aeruginosa, Proteus, and capsular bacteria. 
Rifampicin inhibits the RNA synthesis due to blockage  
of DNA-dependent RNA-polymerase. Depending on the used dose, 
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antibacterial effect of rifampicin is either bacteriostatic or 
bactericidal. Bacterial resistance to rifampicin develops quickly. 
Rifampicin is taken orally 1–2 times a day 0.5–1 hour before 
a meal. The drug is easily absorbed from gastrointestinal tract. 
Maximum blood concentration is achieved in 2–2.5 hours. Also, 
rifampicin is administered intravenously drop-by-drop (only for 
adults). Duration of the drug action is 8–12 hours. Rifampicin readily 
penetrates through the histohematic barrier and is excreted with bile, 
urine, and bronchial secret. The drug can turn urine, tears, saliva, and 
other body fluids red.  
As a rule, rifampicin is prescribed together with other 
antituberculosis agents. Also, rifampicin is used as a reserve drug for 
treatment of other infectious diseases. Sometimes, rifampicin is used 
to treat lepra and rabies (in incubation period, because the drug 
inhibits the development of rabies encephalitis).  
Rifampicin is hepatotoxic and immunosupressive agent.  
To prevent immunodeficiency, immunocorrectors (levamisole, 
Tactivin, etc.) are used during therapy with rifampicin.  
Rifampicin therapy may be complicated by leukopenia, 
dyspepsia, and allergic reactions. The drug is contraindicated to 
pregnant women, infants, and in severe hepatic and renal diseases.    
 
Drugs with High Antituberculosis Activity : 
 
Aminoglycosides  
 
Streptomycin  is an antibiotic of broad antibacterial spectrum. 
The drug is active against mycobacteria and most Gram-positive and  
Gram-negative bacteria. Anaerobes, spirochetes, rickettsia, viruses, 
fungi, and protozoa are not sensitive to streptomycin.  
Streptomycin inhibits the protein synthesis and affects the 
permeability of the bacterial cell membrane. Streptomycin is 
a bactericidal medication. 
Streptomycin is badly absorbed in the gastrointestinal tract and 
therefore it is administered intramuscularly. Maximum blood 
concentration of streptomycin is achieved in 1–2 hours after 
administration. For tuberculosis treatment, the drug is administered 
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1–2 times a day. For treatment of other infections, streptomycin may 
be administered 3–4 times a day. Sometimes, streptomycin is 
administered intratrachealy (aerosol) or into cavernas (10 % solution, 
once a day, only in hospital). Streptomycin is excreted unchanged 
through the kidneys.  
Ototoxic effect of streptomycin arises due to the damage to the 
vestibular branch of the 8th cranial nerve (vestibulocochlear nerve). 
The auditory branch is affected less frequently. The disturbances 
start from noise in ears. At that moment, the drug use should be 
stopped. 
Streptomycin is a nephrotoxic agent. Also, the drug inhibits 
neuromyscular transmission that can result in respiratory depression. 
Streptomycin is contraindicated in renal failure, severe forms of 
cardiovascular failure, disorders of cerebrovascular circulation, 
myasthenia gravis, and diseases of vestibulocochlear nerve.  
Vitamins of A, B group, and C are prescribed for prevention or 
reduction of streptomycin neurotoxicity. Also, streptomycin 
pantothenate or streptomycin ascorbate are used with the same 
purpose. Streptomycin is prescribed only for inpatients.  
Kanamycin  is another representative of aminoglycosides. 
The drug has broad antibacterial spectrum of action. Kanamycin is 
used in tuberculosis treatment in the case when other antituberculous 
drugs are ineffective.  
 
Other Antibiotics  
 
Cycloserine  is an antibiotic with broad antibacterial spectrum, 
including Gram-positive and Gram-negative bacteria. The most 
valuable property of cycloserine is its activity against mycobacteria. 
The drug is active against both extracellular and intracellular 
mycobacteria. Cycloserine is used to treat tuberculosis as a reserve 
agent when other antituberculosis drugs become ineffective. 
Cycloserine is the drug with high neurotoxicity. Side effects of the 
drug are headache, dizziness, insomnia, irritability, memory loss, 
paresthesia, peripheral neuritis, anxiety, psychasthenic state 
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(a condition characterized by rapid mood changes, suicidality, 
depression, etc.), epileptiform seizures, loss of consciousness, etc.  
Florimycin (viomycin) is a polypeptide antibiotic. The drug 
affects protein synthesis that results in bacteriostatic effect. The drug 
is characterized by low absorbability in the gastrointestinal tract, 
therefore it is administered intramuscularly. Florimycin easily 
penetrates through the tissue barriers. Viomycin is used to treat 
different forms of tuberculosis when other drugs are ineffective. The 
side effects of florimycin are the damage to VIII (vestibulocochlear) 
cranial nerve, disturbances of renal function, allergic reactions, and 
electrolyte disturbances.  
 
Synthetic Drugs  
 
Ethambutol  is a synthetic agent with high antituberculosis 
activity. The drug affects only mycobacteria and is active in cases of 
bacterial resistance to isoniazid, streptomycin, and other drugs. 
Mechanism of action is based on ethambutol ability to inhibit the 
synthesis of RNA and proteins and the ability to interact with 
divalent metal ions. Also, ethambutol affects the ribosome structure. 
Ethambutol is bacteriostatic antitubercular agent. The drug is taken 
orally once a day after a meal. Ethambutol is easily absorbed from 
the gastrointestinal tract and excreted unchanged through the 
kidneys. Insignificant amount of the drug is excreted unchanged in 
feces. 
Ethambutol is used in combination with other antituberculosis 
agents in treatment of different forms of tuberculosis. Side effects of 
ethambutol are dispepsia, dizziness, depression, allergic reactions, 
and visual field loss. Drug intake during 2–6 months may be 
accompanied by disturbances of color vision (especially perception 
of red and green colors). The vision is restored after drug removal. 
Pyrazinamide  is a derivative of pyrazincarbonic acid. The 
value of the drug is its ability to affect mycobacteria with resistance 
to other antituberculosis drugs. Antituberculosis activity of 
pyrazinamide is lower than the activity of isoniazid, rifampicin and 
aminoglycosides. Mechanism of pyrazinamide action is not 
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completely known. It is apparent that the drug inhibits mycobacteria 
development on the stage of intracellular division.  
Pyrazinamide is easily absorbed in the gastrointestinal tract, 
penetrates into tuberculous foci and exhibits high activity in the 
acidic environment of caseous masses. Pyrazinamide is excreted 
through the kidneys. The drug is taken orally 3–4 times a day after 
a meal. Bacterial resistance to pyrazinamide develops readily. The 
drug is used to treat tuberculosis in combination with other 
antituberculosis drugs. Side effects are dispepsia, disturbances of 
liver functions, allergic reactions, artralgia, gout exacerbation, and 
photosensitization. Cyanocobalamin, methionine, and glucose are 
used to diminish pyrazinamide toxicity.  
Ethionamide  and prothionamide  are isonicotinic acid 
derivatives. The mechanism of action of these drugs is the same as 
that with isoniazid. Their properties are close to the properties of 
isoniazid, but antituberculosis activity is low. Ethionamide and 
prothionamide are bacteriostatic agents, they are active against both 
extracellular and intracellular mycobacteria. Both drugs stimulate 
phagocytosis in the inflammatory foci. The value of these drugs is 
their ability to affect mycobacteria which are isoniazid-resistant. The 
drugs are taken orally or administered rectally 3–4 times a day, but in 
case of poor tolerance – 2 times a day. It is necessary to notice that 
patients tolerate prothionamide better. The side effects of 
ethionamide and prothionamide are nausea, vomiting, diarrhea, liver 
function disturbances, allergic reactions, insomnia, and orthostatic 
hypotension. For prevention or reduction of these side effects, 
pyridoxine and nicotinamide are used. Ethionamide and 
prothionamide are contraindicated in pregnancy.  
 
Drugs with Moderate Antituberculosis Activity : 
 
Para-Aminosalycilic Acid Derivatives  
 
Sodium para-aminosalicylate (PAS)  and calcium para-
petrolyl-aminosalicylate (Bepascum)  exhibit bacteriostatic 
effect against mycobacteria. The molecular structure of these drugs is 
similar to the structure of para-aminobenzoic acid (PABA). 
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Therefore, para-aminosalycilic acid derivatives are competitive 
antagonists of PABA. It is known that PABA is used by 
Mycobacteria for protein synthesis. Inhibition of protein synthesis by 
PAS and Bepascum slows down the growth and division of bacteria.  
PAS is taken orally after meal (with milk or alkaline mineral 
water). The drug is easily absorbed from the gastrointestinal tract. 
After absorption, the drug quickly penetrates into tissues of the 
internal organs. About 90 % of the taken dose is excreted through the 
kidneys, 10 % – with bile in an inactive form. The main route of PAS 
inactivation is acetylation. Sometimes PAS is administered 
intravenously drop-by-drop.  
Bepascum is a drug with prolonged action which releases para-
aminosalycilic acid. The drug is taken orally.  
Both drugs can cause such side effects as dispepsia (nausea, 
vomiting, diarrhea, and abdominal pain), allergic reactions (skin 
rash), hepatotoxicity, crystalluria, agranulocytosis, increased growth 
of the thyroid gland, and hypothyroidism.   
 
Thiosemicarbazone Derivatives  
 
Thiacetazone  is a synthetic agent which is active against 
M. tuberculosis and M. leprae. The drug exerts bacteriostatic 
activity. Thiacetazone is taken orally after a meal. The clinical use  
of thiacetazone is restricted by its high toxicity. The drug is used 
only in combination with other antituberculosis agents in the 
treatment for extrapulmonary tuberculosis: tuberculosis of mucous 
and serous membranes, lymphadenitis, specific fistulas, etc.  
Side effects of thiacetazone are headache, nausea, dermatitis, 
blood dyscrasias (anemia, thrombocytopenia, leukopenia, and 
agranulocytosis), and disturbances of liver and renal functions.  
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Table 19 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product  
Isoniazidum 
 
Orally 0.3 g 2–3 times daily; 
intramuscularly 0.3–0.9 g  
or intravenously  
drop-by-drop 0.01 g/kg  
(as 0.2 % solution)  daily 
Tablets 0.1 or 0.3 g; 
ampoules 5 ml  
of 10 % solution  
Rifampicinum  
 
Orally 0.45 g daily; 
intravenously drop-by-drop 
0.45 g daily 
Capsules 0.15 g; 
ampoules 0.15 g  
of powder for injections 
Natrii  
para-aminosalicylas  
 
Orally 3–4 g 3–4 times daily 
(1–2 teaspoons of granules); 
intravenously drop-by-drop 
7.5–15 g daily (as 3 % 
solution) 
Tablets 0.5 g; 
granules 100 g; 
vials 250 or 500 ml  
of 3 % solution  
Ethambutolum  Orally 0.025 g/kg daily Tablets 0.1 or 0.4 g 
 
Streptomycini 
sulfas  
Intramuscularly 0.5 g 2 times 
daily 
Vials 0.5 g of powder  
for injections 
Pirazinamidum Orally 0.015–0.025 g/kg 
once a day or 0.05–0.07 g/kg 
2–3 times per week   
Tablets 0.5 or 0.75 g 
 
 
Step 1. Tasks for Self -Control  
Antisyphilitic Drugs. Antituberculosis  Drugs 
 
1. A 35-year-old man received antitubercular drug has acute pain 
onset of right big toe, swelling, and low-grade fever. Gouty arthritis 
was diagnosed and high serum uric acid level was found. Which  
of the following antituberculosis drugs are known for causing high 
uric acid levels? 
A. Pyrazinamide. 
B. Aminosalycylic acid. 
C. Rifampicin. 
D. Thioacetazone. 
E. Cycloserine. 
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2. A patient has appealed to the doctor with complaints of red 
colour of urine and tears. It is known, that he is treated for pulmonary 
tuberculosis. What drug can cause this adverse effect? 
A. Doxycycline. 
B. Rifampicin. 
C. Metronidazole. 
D. Streptomycin sulfate. 
E. Isoniazid. 
3. The first-line drug for treatment of tuberculosis is prescribed to  
38-year-old patient. It is known that drug causes several adverse 
effects, which are connected with oppressing of pyridoxalphosphate 
formation. Call this drug. 
A. Isoniazid.  
B. Rifampicin. 
C. Doxycycline. 
D. Metronidazole. 
E. Chingaminum. 
4. Neuritis of optic nerve occurred in the patient in result  
of treating with certain antituberculosis drug. Identify this drug. 
A. Streptomycin. 
B. Ethambutol. 
C. Kanamycin. 
D. Isoniazid. 
E. Rifampicin. 
5. It is known, that patient A. with pulmonary tuberculosis has 
hereditary insufficiency of N-acetyltransferase. Indicate the 
antituberculosis agent which can promote the development  
of marked toxic effects in this patient. 
A. Sodium salt of PAS. 
B. Streptomycin. 
C. Ethambutol. 
D. Isoniazid. 
E. Rifampicin. 
6. In clinical practice tuberculosis is treated with izoniazid – that 
is an antivitamin able to penetrate into the tuberculosis bacillus. 
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Tuberculostatic effect is induced by the interference with replication 
processes and oxidation-reduction reactions due to the buildup  
of pseudo-coenzyme: 
A. NAD. 
B. TDP. 
C. FMN. 
D. CoQ. 
E. FAD. 
7. A patient suffering from syphilis has been treated with bismuth 
preparations. As a result of it some grey spots turned up on the 
mucous membrane of the oral cavity; nephropathy symptoms were 
also present. What drug should be used for treatment of bismuth 
intoxication? 
A. Methylene blue. 
B. Naloxone. 
C. Bemegride. 
D. Unithiol. 
E. Nalorphine. 
 
ANTILEPROSY DRUGS 
 
Leprosy is an infectious disease caused by Mycobacterium 
leprae (Hansen’s bacillus). Drugs for leprosy treatment (antileprosy 
drugs) are classified into the following groups. 
1. Derivatives of aromatic sulfones: DDS – diaminodiphenyl  
sulfone (dapsone, avlosulfon), solusulfonum 
(sulphedrone, cimedone), dimociphone, diuciphone.  
2. Antibiotics:  
– rifamycins: rifampicin; 
– macrolides: clarithromycin; 
– tetracyclines: minocycline.  
3. Fluoroquinolones: ofloxacin (Tarivid).  
4. Synthetic antituberculosis drugs: ethionamide, 
prothionamide, thioacetazone.  
5. Phenazine derivatives: clofazimine (lamprene).  
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Diaphenylsulfone (dapsone)  is one of the main drugs for 
leprosy treatment. Dapsone is a competitive antagonist of para-
aminobenzoic acid and due to this fact it influences the synthesis of 
folic acid by Mycobacterium leprae. Also, the drug activates 
lysosomes of macrophages. The drug is taken 0.05–0.1 g once a day 
six days a week. The drug is rapidly and almost completely absorbed 
from the gastrointestinal tract. The half-live for dapsone in the body 
is 24 hours. Side effects of dapsone are weakness, headache, 
dyspepsia, toxic hepatitis, precordialgia, hemolysis, and 
agranulocytosis. The toxicity of the drug is limited due to reduction 
of the dose and intake of B group vitamins and iron-preparations.  
Diuciphone  is a diphenyl sulfone derivative containing two 
residues of methyluracil. The drug has antileprosy and 
immunomodulating effects.  
As a rule, antibiotics, ofloxacin, and synthetic antituberculosis 
agents in combination with sulfones are used to treat leprosy. The 
rapid effect is typical for rifampicin. Rifampicin is taken every day 
or twice a week (in combination with other antileprosy agents). 
Being located in the skin, Mycobacterium leprae lose their viability 
in 5 days. Synthetic antituberculosis drugs are less effective in 
leprosy treatment, but more toxic.   
Clofazimine  is a lipid-soluble phenazine derivative. The drug 
accumulates in the skin, gastrointestinal tract, and in the cells of 
monocyte macrophage sprout. Side effects are ichthyosis, skin 
dyschromia (red-brown skin), diarrhea, intestinal colic, etc. 
Clofazimine is contraindicated in pregnancy.  
The chemotherapy of leprosy is a long-term cure. 
Mycobacterium leprae resistance and disease relaspse are common 
problems. A relapse in leprosy occurs due to persistent 
Mycobacterium leprae in bone marrow, nervous and muscular 
tissues. The combined antileprosy chemotherapy by means  
of 2–3 drugs with different chemical structure is used to prevent 
leprosy prolapse and antileprosy drug resistance. The most common 
drug combination includes diphenyl sulfone, rifampicin, and 
clofazimine. Besides, the use of immunomodulators and vitamins in 
treatment of leprosy is advisable.  
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ANTIVIRAL DRUGS 
 
Antiviral drugs are agents of different chemical structure which 
interfere with viral penetration into the cells, synthesis of viral 
nucleic acids and proteins, and viral replication. 
The following mechanisms of action are typical for different 
antiviral drugs:  
1) inhibition of viral absorption and penetration into the host 
cell: γ-globulin, enfuvirtide ;  
2) impairment of the efficient release of the viral genome: 
amantadine (midantanum), rimantadine ;  
3) violation of viral protein synthesis: guanidine,  
saquinavir ;  
4) violation of nucleic acid synthesis: zidovudine, acyclovir ,  
vidarabine, idoxuridine ;  
5) violation of the virion assembly: metisazon .  
Nowadays, about 30 antiviral drugs are used in medicine. Except 
interferons, all of them are synthetic agents.  
There are the following groups of antiviral drugs:  
– drugs for influenza treatment;  
– drugs active against cytomegalovirus and herpes simplex 
virus;  
– drugs active against human immunodeficiency virus (HIV);  
– drugs active against retrovirus and picornavirus;  
– drugs affecting variola virus; 
– drugs active against Hepatitis B and Hepatitis C viruses.    
 
Drugs for Influenza Treatment  
 
This group is reffered by the following drugs.  
1. Drugs which block viral M2 proton channel: rimantadine, 
amantadine, and adapromine.  
2. Drugs which inhibit viral enzyme neuraminidase: zanamivir, 
oseltamivir.  
3. Drugs which inhibit viral RNA-polymerase: ribavirin.  
4. Other drugs: arbidol, oxoline.  
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The Matrix-2 (M2) protein is a specific protein of influenza 
virus. This protein is located in viral membrane and functions as 
an ionic channel. Drugs blocking this protein affect the 
disassembling of the virus and prevent the release of the viral 
genome in the host cells. Due to this, viral replication is abolished. 
Amantadine (midantanum)  is used to prevent influenza  
type A. However, the drug has low efficiancy to use it with that end 
in view. The drug is taken in dose 100 mg twice a day (every  
12 hours). Amantadine is readily absorbed in the gastrointestinal 
tract and excreted from the body with urine. 
Adapromine  and rimantadine  are more effective agents. 
Rimantadine is active against influenza type A virus (especially  
type A2). Adapromine is active against influenza A and B type 
viruses. Also, rimantadine affects the tick-borne encephalitis virus. 
For prevention of influenza, rimantadine is taken orally in dose  
0.05 g, adapromine – in dose 0.1 g once a day during 10–20 days. 
Timely drug intake reduces the frequency of the disease incidence by 
50 % and more. In case of taking influenza, it is mild. It is necessary 
to notice that intake of the drugs in 2–3 days after the disease onset 
has low efficiency. The drug intake in 5 days after the start of the 
disease is completly ineffective. For prevention of tick-borne 
encephalitis, rimantadine is taken twice a day in dose 0.1 g during  
3–5 days. Preventive drug intake starts immediately after a tick bite. 
Rimantadine is readily absorbed in the gastrointestinal tract, 
metabolized in the liver, and excreted through the kidneys. As a rule, 
the drug is well tolerated by patients. Side effects include dyspepsia, 
headache, insomnia, dizziness, and irritability. Rimantadine has 
teratogenic and embryotoxic effects. Adapromine is a less toxic 
agent. Both drugs are contraindicated in acute hepatic and renal 
diseases and during pregnancy.  
Influenza viruses quickly develop resistance to the drugs of this 
group. 
Neuraminidase is a glycoprotein which is located on the surface 
of the influenza viruse types A and B. The enzyme promotes 
penetration of the virus into the target cells in the respiratory tract. 
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The drugs, blocking neuraminidase, violate the virus propagation and 
affect the viral replication. Zanamivir  and oseltamivir  are drugs 
with such mechanism of action.  
Zanamivir  is used for intranasal application or for inhalations. 
About 15 % of administered dose of zanamivir penetrates into the 
systemic blood circulation. The drug is excreted through the kidneys.  
Oseltamivir (Tamiflu) is taken orally. The drug is active 
against influenza viruses types A and B, including virus АН4N2. 
Oseltamivir is readily absorbed in the gastrointestinal tract. The drug 
undergoes fast hydrolysis in the intestine, liver, and blood. 
Bioavailability of its active metabolites is about 80 %. The main 
route of excretion is the kidneys. The half-life period is 6–10 hours. 
Side effects of oseltamivir are nausea, vomiting, and nephrotoxicity.  
Ribavirin  is a derivative of guanosine. The drug is 
phosphorylated in the body into ribavirin monophosphate and 
ribavirin triphosphate. Ribavirin monophosphate inhibits the 
synthesis of guanine nucleotides. Ribavirin triphosphate inhibits viral 
RNA-polymerase and affects the formation of iRNA. Ribavirin is 
active against influenza viruses A and B. Also, the drug is used in 
treatment of severe infections caused by respiratory syncytial virus 
and hemorrhagic fever with renal syndrome. Side effects of ribavirin 
are skin rash and conjunctivitis. Ribavirin has mutagenic, 
teratogenic, and cancerogenic properties.  
Arbidol  is used to prevent and treat influenza type A and B, 
acute respiratory viral infections, and herpes recurrent infection. 
Arbidol exhibits interferonogenic activity, stimulates cellular and 
humoral immunity. The drug is taken orally and tolerated by patients 
well.  
Oxoline  is used to prevent influenza and to treat viral rhinitis, 
adenoviral keratoconjunctivitis, herpetic keratitis, and some viral 
skin diseases (shingles, etc.). Oxolinic ointment is used to lubricate 
nasal mucosa, to apply over the lower eyelid, or on the skin.  
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Antiherpethetic Drugs and Drugs for Cytomegalovirus 
Infection Treatment  
 
The following drugs are used to treat herpes. 
1. Drugs for resorbtive action: acyclovir, valacyclovir ,  
famcyclovir, vidarabine .  
2. Drugs for topical use: trifluridine,  idoxuridine,  
megosin, gossypol .  
Acyclovir (Zovirax)  is a drug of high activity. It is a synthetic 
purine nucleoside analogue. In a human body, acyclovir is 
phosphorylated with active metabolite formation. Phosphorylated 
acyclovir inhibits DNA-polymerase. It results in violation of nucleic 
acid synthesis and inhibition of viral replication. It should be noticed 
that viral DNA-polymerase is 100 times more sensitive to acyclovir 
action than human DNA-polymerase. The oral bioavailability  
of acyclovir is about 20 %. Acyclovir has satisfactory permeability 
through the blood-brain barrier. The therapeutic indications for 
acyclovir are herpes simplex, herpetic lesions of eyes and genitalia, 
and cytomegalovirus infection. The drug is taken orally, 
administered intravenously, or applied topically (5 % skin cream, or 
3 % ophthalmic ointment which are used 5 times a day). In case  
of significant skin damage, acyclovir is taken orally 5 times a day in 
dose 0.2–0.4 g. Intravenous acyclovir is used to treat herpetic 
infections in patients with immunodeficiency or to treat severe 
herpetic lesions of genitalia. Side effects develop seldom. During 
acyclovir therapy the following side effects are observed: nausea, 
vomiting, diarrhea, headache, and allergic reactions. Intravenous 
acyclovir administration can cause the reversible neurological 
complications (hallucination, excitement, and confusion), renal 
dysfunction, phlebitis, and skin rash. External acyclovir application 
can cause dry and peeling skin.  
Valacyclovir  is a new agent for treatment of herpetic 
infection. Oral bioavailability of valacyclovir is about 54 %. It is 
necessary to notice that valacyclovir has no antiviral activity. 
Valacyclovir is converted to acyclovir in the intestine and liver.  
Famcyclovir  and ganciclovir  are similar to acyclovir. 
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Vidarabine  is phosphorylated by kinases into the active 
metabolite. Phosphorylated metabolite inhibits viral DNA-
polymerase and suppresses the virus replication. Vidarabine is used 
to treat herpetic encephalitis. The drug decreases the mortality from 
this disease by 30–70 %. Sometimes, vidarabine is used to treat 
shingles and herpetic keratoconjunctivitis. Also, vidarabine is used to 
treat patients suffering from allergic reactions to idoxuridine. Side 
effects of vidarabine are dyspepsia, tremor, psychosis, allergic 
reactions, blood clots on the injection site.  
Idoxuridine  and trifluridine  are antiherpetic drugs which are 
used topically. Therapeutic indications for their use are herpetic 
keratitis and keratoconjunctivitis. Side effects are irritation of 
mucous membranes and eyelid oedema.  
Ganciclovir, valganciclovir, foscarnet , and Vitravene 
(fomivirsen)  are drugs for treatment of cytomegalovirus infection.  
Mechanism of action of ganciclovir is similar to acyclovir. The 
drug is used to treat cytomegalovirus retinitis, colitis, esophagitis, 
pneumonia, etc. Ganciclovir is administered intravenously or used 
topically in conjunctival cavity. The side effects of ganciclovir are 
headache, psychosis, convulsions, liver damage, granulocytopenia, 
thrombocytopenia, and skin rash. Ganciclovir is a drug with 
teratogenic activity.  
Valganciclovir is metabolized to gancyclovir in the intestine and 
liver. The bioavailability of valganciclovir is about 60 % (in 10– 
12 times higher than ganciclovir).   
Foscarnet is a drug with the same mechanism of action. The 
drug is used to treat cytomegalovirus retinitis in patients with AIDS. 
Also, foscarnet may be used as an alternative to acyclovir to treat 
herpes simplex and shingles. Foscarnet is administered intravenously 
or applied topically in ointment. The toxicity of foscarnet is higher 
than gancyclovir toxicity. But foscarnet inhibits the leukopoiesis to 
a lesser degree than gancyclovir. Side effects of foscarnet are fever, 
headache, convulsions, nephrotoxicity, cardiac arrhythmias, 
encephalopathy, disturbances of mineral and electrolyte balance, etc.  
Vitravene is used to treat cytomegalovirus rhinitis and retinitis. 
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Drugs Active Against Human Immunodeficiency Virus  
(Antiretroviral Drugs) 
 
The following drugs are used to treat HIV-infection: 
1. Reverse transcriptase inhibitors. 
1.1. Nucleosides: zidovudine, didanosine, stavudine, and 
zalcitabine.  
1.2. Non-nucleoside compounds: nevirapine, delavirdine, 
and efavirenz.  
2. HIV protease inhibitors: indinavir, ritonavir, saquinavir, 
and nelfinavir. 
The synthesis of viral DNA on the matrix (viral RNA) occurs 
after penetration of AIDS virus into lymphocytes. This synthesis is 
controlled by reverse transcriptase. After phosphorylation, zidovudine 
blocks reverse transcriptase and inhibits DNA synthesis. This results 
in inhibition of iRNA and viral protein synthesis. Zidovudine  is 
effective mainly against virus carriers (before the appearance of AIDS 
symptoms). In sick patients, zidovudine slows down the disease 
progression, prolongs the duration of life, and reduces the frequency 
and severity of infectious complications. But recovery does not 
complete. Zidovudine is taken orally 0.1 g 5–6 times a day or 0.2 g  
3 times a day. The drug is readily absorbed in the gastrointestinal tract. 
Zidovudine readily penetrates through the blood-brain barrier. About 
75 % of administered dose is metabolized in the liver. The main route 
of zidovudine excretion is through the kidneys. The prolonged therapy 
with zidovudine (more than 6 months) results in development of 
antiviral drug resistance. Side effects of zidovudine are anemia, 
neutropenia, thrombocytopenia, pancytopenia, headache, diarrhea, 
fever, and renal dysfunction. After prolonged use of zidovudine, the 
following drugs may be prescribed to a patient: didanosine, 
zalcitabine, stavudine, lamivudine, or abacavir. These drugs have an 
identical mechanism of action with zidovudine. All drugs are taken 
orally and undergo hepatic metabolism with the subsequent renal 
excretion. Hematotoxicity (thrombocytopenia, leukopenia, and 
anemia), neurotoxicity (headache and insomnia), and renal, pancreatic 
and hepatic dysfunctions are typical side effects of these drugs.  
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The non-nucleoside agents for AIDS treatment are nevirapine,  
delavirdine,  and efavirenz . These drugs also block reverse 
transcriptase, but bind to enzyme in another site than nucleosides. 
There is an evidence that these drugs also simultaneously inhibit 
DNA-polymerase. Non-nucleoside drugs are taken orally and used 
only in HIV-1 infection.  
HIV protease inhibitors (indinavir, ritonavir,  saquinavir ,  
nelfinavir) block enzymes regulating formation of structural 
proteins and enzymes which are necessary for virus replication. The 
deficit of these proteins results in formation of virus immature 
precursors and slows down the development of infection. Saquinavir is 
the most commonly used HIV protease inhibitor. The drug is effective 
against both HIV-1 and HIV-2 infections. Saquinavir is taken orally. 
The bioavailability of the drug is very low (about 4 %), but blood 
concentration of the drug is enough to inhibit retroviral replication. 
The side effects of saquinavir are dyspepsia, disturbances of lipid and 
carbohydrate metabolism, anemia, and dysuria. The prolonged drug 
intake causes the development of antiviral drug resistance.  
Co-formulated drug use is the most effective in HIV therapy: 
zidovudine + zalcitabine + saquinavir, zidovudine + saquinavir, etc.  
 
Drugs Active Against Variola Virus 
 
Metisazon  is used to prevent smallpox and to decrease the 
risk of vaccine complication. Metisazon may act by inhibiting viral 
structural protein synthesis or blocking late stages of virus assembly. 
The drug is taken orally. Side effects include dyspeptic disorders and 
dizziness.  
Broad Spectrum Antiviral Drugs  
(Including Hepatitis B and C Viruses)  
 
Interferons are recovered from the cultures of human leukocytes  
(α-interferon), fibroblasts (β-interferon), or lymphocytes  
(γ-interferon). Recombinant interferons are derived by means  
of implantation of correspondent human genes to Escherichia coli.  
Interferons are species-specific low molecular weight 
glycoproteins. Interferons are not themselves antiviral active. 
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Interferon interacts with a specific receptor located on the cellular 
surface that results in activation of protein kinase and formation  
of low-molecular inhibitor of protein synthesis. This inhibitor acts 
due to stimulation of enzymes which destroy RNA of viruses and 
host cells.  
Besides antiviral and antibacterial effects, interferons also 
activate the immunity (phagocytic activity of macrophages and 
toxicity of killers increase), exhibit antitumor and radioprotective 
activity, and influence functions of different systems of the body, 
including CNS.  
There is the following classification of interferon preparations:  
– α-2A-interferons: Reaferon, Roferon-A, Laferon; 
– α-2B-inteferons: Intron-A, Viferon; 
– α-2C-interferons: Berofor, Wellferon;  
– β-interferons: Betaseron (Betaferon), Feron; 
– γ-interferons: Gammaferon, Imunoferon.  
Alfa-interferons (-2А, -2В) are used mainly as antiviral 
drugs. These drugs are effective in treatment of herpetic keratitis, 
herpetic lessions of the skin and sex organs, acute respiratory viral 
infection, shingles, viral hepatitis B and C, and AIDS.  
Laferon  and Reaferon  are used topically as nasal or eye drops 
(to prevent a disease – 2–3 drops in nose or in conjunctival cavity  
1–2 times a day; to treat the disease – 4–6 times a day). The drugs 
are also used topically to treat shingles.  
There are high-purified interferons (1 mg – 5 000 000 IU) for oral 
intake or for parenteral administration (intravenously, intramuscularly, 
intraosseously, endolymphatically, and endolumbarly). Interferons are 
quickly inactivated, therefore they are administered 4–6 times a day. 
High-purified interferons are used in treatment for systemic viral 
infections or malignant neoplasms. Recombinant interferons 
(Reaferon, Roferon, Intron-A, Viferon, and Wellferon) are 
administered 2–3 times a day. Moreover, the drugs may be 
administered rectally. Side effects are possible in case of parenteral 
interferon administration and include fever, headache, muscular pain, 
reduction of blood pressure, cardiac arrhythmias, paresis and 
paralisis, blood dyscrasias, and dyspepsia.  
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A disadvantage of interferon therapy is the development of drug 
resistance after 1–2 injections. The combined use of several 
inductors of interferons is recommended to prevent it. 
Interferon inductors  are drugs which stimulate the formation 
of interferons. There are natural (bacteria, viruses, rickettsia, fungi, 
etc.) and synthetic (vitamins, synthetic polynucleotides, polyanions, 
and some low-molecular-wheight and high-molecular-wheigh 
compounds). The representatives of synthetic low-molecular-wheight 
interferon inductors are Amixin (tilorone) , mefenamic acid , 
megosin,  etc. The representative of high-molecular-wheight 
interferon inductors is poludanum . Poludanum is used in eye drops 
for treatment of viral lesions of mucous membranes of the eyes. 
Also, poludanum is administered subcutaneously once a week in 
treatment for chronic hepatitis C. Mefenamic acid is used to treat 
influenza. Megosin is applied topically to treat viral skin diseases. 
Tilorone is used to treat influenza, acute respiratory viral diseases, 
hepatitis B and C, herpes, cytomegalovirus infections, neurotropic 
viral infections, tuberculosis, and chlamydiosis. This drug is 
contraindicated to pregnant women.  
Some drugs of other pharmacological groups also exhibit the 
property to induce interferon formation. They are levamisole, 
isoprinosine, dipyridamole, theophylline, bendazol 
(dibazol), Trental (pentoxifylline), etc.  
Beta-interferon  is used in treatment of multiple sclerosis. It is 
a disease caused by demyelination of nervous fibers in the central 
nervous system. Multiple sclerosis occurs to young people, 
progressively worses, and results in disability. Recently, Betaseron  
was established by means of gene engineering. The drug 
significantly reduces the frequency and severity of the exacerbations 
and slows down the disease progressing. Betaseron is administered 
subcutaneously once every 48 hours. Side effects of betaseron are 
pain and redness on the injection site, fever, weakness, muscle pain, 
anemia, thrombocytopenia, neutropenia, lymphopenia, and menstrual 
irregularities. 
 
 
487 
 
Table 20 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product 
Oxolinum Topically to apply to the nasal 
mucosa 2 times daily; 
1–2 drops in each eye 5–6 times 
daily 
Ointment 0.25 %  
or 0.5 % 10.0 or 15.0 g; 
eye drops: 0.1 % solution 
10 ml 
Remantadinum Orally 0.1 g 1–3 times daily Tablets 0.05 g 
Azidothimidinum 
(Zidovudine) 
Orally 0.1 g 5–6 times a day  
or 0.2 g 3 times a day 
Capsules 0.1 or 0.25 g 
Aciclovir Orally 0.2–0.8 g 4–5 times 
a day; 
intravenously slowly 0.000 5– 
0.001 g/kg 3 times daily; 
topically to treat skin infections; 
for instillation into a lower 
conjunctival sac 5 times a day 
Tablets 0.2; 0.4  
or 0.8 g; 
vials 0.25 g of powder 
for injections; 
ointment 5 % 5 g; 
eye ointment 3 % 4.5 g 
or 5 g 
Laferon For instillation into the nose (3–
6 drops) or eyes (1–2 drops) 
(before using, the powder of the 
ampoule is dissolved in 2 ml  
of sterile water) 3–6 times daily; 
intramuscularly, subcutaneously 
or intravenously 1 000 000–
5 000 000 IU 1–2 times daily  
Ampoules or vials with 
powder 1 000 000; 
3 000 000  
or 5 000 000 IU 
(dissolved before 
administration) 
 
ANTIPROTOZOAL DRUGS 
 
It is known that more than 1 000 species of protozoa are 
pathogenic for humans. Antiprotozoal drugs are selectively active 
against protozoa – causative agents of malaria, amoebiasis, 
giardiasis, toxoplasmosis, leishmaniasis, trichomoniasis, and 
balantidiasis. Antiprotozoal drugs include synthetic agents and some 
antibiotics, and they are classified into the following groups. 
1. Antimalarial drugs. 
2. Drugs for giardiasis treatment.  
3. Drugs for toxoplasmosis treatment.  
4. Drugs for balantidiasis treatment.  
5. Drugs for trichomoniasis treatment.  
6. Drugs for leishmaniasis treatment.  
488 
 
Antimalarial Drugs 
 
In the past, malaria was one of the most common diseases in  
the world. About one million peple were dying every year. In 50–60s 
of the 20th century, malaria morbidity was significantly reduced due 
to the broadest antimalarial actions under UN auspices. 
Unfortunatelly, last years the formation of drug resistant strains  
of Plasmodium results in the increase of malaria morbidity.  
A source of malaria infection is the sick person or a gamete 
carrier. A person can get infection through the bite of infected 
mosquitoes (seldom – due to blood transfusion from the sick person). 
Thus malaria parasites enter the blood.  
There are 4 species of malaria parasites: 
– Plasmodium vivax, and Plasmodium ovale – the causative 
agents of vivax (three-day malaria); 
– Plasmodium malaria – the causative agent of quartan  
(four-day malaria);  
– Plasmodium falciparum – the causative agent of tropical 
malaria.  
 Plasmodium ovale is found only in the tropics. 
The Plasmodium parasite undergoes two cycles of replication: 
asexual cycle (schizogony) takes place in the human body, and 
sexual cycle (sporogony) occurs in the mosquito. Due to infected 
mosquito bite, the sporozoites enter the blood of the person, then 
quickly enter hepatocytes. Inside hepatocites, multiplication occurs: 
pre-erythrocytic or exo-erythrocytic schizogony stage. Tens of 
thousands of merozoites are formed due to multiple division of one 
sporozoit. Pre-erythrocytic schizogony is asymptomatic. After 
completion of pre-erythrocytic schizogony, merozoites penetrate into 
erythrocytes and undergo the stage of erythrocytic schizogony. This 
stage is accompanied by erythrocyte rupture and fever attacks. 
Erythrocytic merozoites again penetrate into erythrocytes and repeat 
the erythrocytic cycle. In infection with Pl. vivax and Pl. ovale, these 
cyclical fevers occur every 48 hours, in infection with Pl. malarie – 
every 72 hours, and in infection with Pl. falciparum – every 6 hours. 
Along with asexual division, the sexual forms of Plasmodium are 
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formed in the human blood. These sexual forms are called 
gametocytes (gamonts). Their presence in the blood is not 
accompanied by the disease symptoms, but gamonts are dangerous in 
the context of epidemiology. Such patients are the source of 
mosquito infection.  
In the tropical and four-day malaria, after the completion  
of pre-erythrocytic schizogony, merozoites enter the blood and their 
following development occurs only in the erythrocytes. In the three-
day malaria, the infection by genetically heterogeneous set  
of parasites occurs. A part of them (tachysporozoites or primary 
forms) pass the stage of tissue schizogony after penetration into 
hepatocytes and are released from the liver after completion of this 
stage. Another part of sporozoites (bradysporozoites or secondary 
forms) are capable to be in liver in dormant form from 8–9 months 
up to 2 years. After completion of the latent period, these dormant 
sporozoites undergo exoerythrocytic schizogony which finishes 
when parasites enter the blood and develop primary malaria or its 
relapse.  
The duration of sporogony, exo- and erythrocytic schizogony, 
the ability of drug-resistant Plasmodium to appear are different for 
different species of Plasmodium. 
Presently, the following chemical groups of drugs are used to 
treat malaria.  
1. Quinoline derivatives: quinine, chloroquine 
(chingaminum), mefloquine, primaquine, and quinocide.  
2. Biguanides: bigumal. 
3. Pyrimidine derivatives: chloridinum (pyrimethamine). 
4. 9-aminoacridine derivatives: quinacrine. 
5. Sulfonamides. 
6. Sulfones. 
7. Tetracyclines.  
Pharmaceutical industry produces a lot of co-formulated drugs: 
Metakelfin  (contains pyrimethamine  and sulfalen), Fansidar  
(contains pyrimethamine  and sulfadoxine), Fansimef  (contains 
mefloquine, sulfadoxine, and pyrimethamine), etc.  
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According to antimalarial action, the drugs are divided into the 
following groups.  
1. Blood schizonticides  are the drugs active against 
erythrocytic forms of Plasmodium: chingaminum (chloroquine), 
mefloquine, quinine. Also, the following agents are used in co-
formulated drugs: hydroxychloroquine, chloridinum, bigumal, 
sulfadoxine, and doxycycline.  
These drugs eliminate schizonts from the peripheral blood after  
3–5 days treatment. These drugs prevent and interrupt malaria 
attacks in the acute phase of the disease.  
2. Tissue schizonticides  are the drugs which affect tissue 
forms of Plasmodium. These drugs are divided into two groups:  
– drugs active against tachysporozoites are tissue schizonticides 
which are active against pre-erythrocytic forms: bigumal and 
chloridinum ; these drugs are used to prevent malaria; 
– drugs active against  bradysporozoites are tissue schizonticides 
which are active against para-erythrocytic forms of Plasmodium: 
primaquine  and quinocide; these drugs are used to prevent 
malaria relapses.  
3. Gametocides are the drugs which are active against sexual 
forms of Plasmodium. These drugs are divided into two groups: 
– gametocides acting upon sexual forms of Plasmodium in 
human erythrocytes: primaquine  and quinocide ; 
– drugs inhibiting the sporogony in the body of mosquito: 
bigumal  and chloridinum .  
These drugs are used for collective protection against malaria – 
prevention of disease transmission from the sick to healthy person 
through a mosquito bite. Due to the use of these agents, sporozoites 
are not formed in the mosquito body.  
 
Blood Schizonticides  
 
Quinine  is an alkaloid found in the bark of the cinchona tree. 
Different species of cinchona tree are native to South America.  
In the 17th century, the bark of the cinchona tree was brought to 
Europe and since then it was used to treat malaria as well as fever.  
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In 1816 quinine was isolated from the bark by Jeff Giese. Other 
antimalarial drugs were synthezied later on. 
Quinine affects erythrocytic schizonts of Plasmodium, gamonts, 
pre-erythrocytic forms of P. falciparum, and the causative agent of 
toxoplasmosis. The drug is readily absorbed from the gastrointestinal 
tract and quickly excreted from the body. Quinine inhibits the centre 
of thermoregulation and decreases the body temperature in fever. 
Also, quinine inhibits the excitability of myocardium, exhibits 
negative chronotropic effect, stimulates uterine contractions in 
pregnant women, and stimulates the spleen to contract. Mechanism 
of action of quinine is identical with chingaminum, primaquine, 
quinocide, and mefloquine. This mechanism is associated with 
violation of DNA synthesis both in Plasmodium cells and in host 
cells. Besides, quinine seals the lysosomal membranes, resulting in 
impaired assimilation of hemoglobin by Plasmodium.  
Therapy with quinine is commonly accompanied by side effects: 
dizziness, vomiting, headache, collapse, tinnitus, etc. Presently, 
quinine is once again being used to treat tropical malaria, because 
Plasmodium infections became resistant to other drugs. 
Chingaminum (chloroquine)  hes been suggested for malaria 
treatment in 1943. The drug is one of the best blood schizonticides. 
Chloroquine interrupts the acute malarial fever within 24–48 hours. 
Plasmodium infections disappear from the peripheral blood in  
2–3 weeks after the start of therapy with chingaminum. The drug is 
used to prevent and treat all types of malaria.   
Along with antimalarial effect, chloroquine exerts  
anti-inflammatory activity and is widely used to treat polyarthritis, 
systemic lupus erythematosus, scleroderma, and other collagen-
vascular diseases. Also, chingaminum is used to treat amebiasis.  
Chingaminum is taken orally and administered intramuscularly 
or intravenously. The drug is readily absorbed from the 
gastrointestinal tract. About 50 % of the drug bind to plasma 
proteins. The elimination rate for the drug is low. Kidneys are the 
main route of chingaminum excretion. Chloroquine side effects are 
headache, nausea, dermatitis, and loss of appetite. Its overdose can 
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cause dystrophy of myocardium and liver, tinnitus, disturbances of 
accommodation, and leukopenia.  
Mefloquine  is an active antimalarial agent. In tropical malaria, 
the single use of the drug interrupts malarial fever and kills 
chloroquine-resistant strains of Plasmodium. Mefloquine is also 
effective in three-day malaria but does not prevent relapse. The 
toxicity of mefloquine is low. Sometimes, therapy with mefloquine 
can result in nausea, vomiting, abdominal pain, and drowsiness. 
Central nervous system disorders are seldom possible (depression, 
halucinations, convulsions, and disorientation).  
Chloridinum  (pyrimethamine)  is a synthetic agent – 
derivative of pyrimidine. The drug violates the synthesis of 
dihydrofolic acid due to the inhibition of dihydrofolate reductase. 
Pyrimethamine is active against erythrocytic and pre-erythrocytic 
forms of Plasmodium, and also inhibits the sporogony in the body  
of mosquito. Pyrimethamine is taken orally and easily absorbed from 
the gastrointestinal tract. The drug is able to accumulate in tissues 
and, therefore, has the prolonged effect. The therapeutic indications 
for chloridinum are treatment of malaria, toxoplasmosis, and 
leishmaniasis. Also, the drug is used for personal protection against 
malaria. The side effects include headache, dizziness, discomfort in 
the heart area, hepatic disfunction, megaloblastic anemia, leukopenia, 
and teratogenic effect.  
Sulfonamides and sulfones are also blood schizonticides. These 
drugs affect utilization of benzoic acid by Plasmodium. The activity 
of these agents are relatively low and their antimalarial effect 
develops slowly. Sulfonamides and sulfones in combination with 
other drugs are used to treat malaria.  
 
Tissue Schizonticides  
 
Chloridinum  (pyrimethamine)  and bigumal  are active 
against pre-erythrocytic forms (tachysporozoites). Both drugs inhibit 
dihydrofolic acid reductase that results in violation of terahydrofolic 
acid and nucleic acid synthesis.  
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Bigumal  is a biguanide derivative. The drug is active against  
pre-erythrocytic forms and gamonts of Plasmodium. The activity of 
bigumal is lower than the activity of chloridinum. Bigumal is taken 
orally, readily absorbed from the gastrointestinal tract, and is readily 
excreted from the body. The therapeutic effect of bigumal develops 
slowly. The side effects are leukocytosis and erythrocyturia. It is 
necessary to notice that Plasmodium quickly develops the tolerance 
to bigumal.  
Primaquine  and quinocide  are tissue schizonticides which 
are active against para-erythrocytic forms of Plasmodium 
(bradysporozoites). Primaquine affects bradysporozoites of Pl. vivax 
and Pl. ovale which cause the relapse. Also, primaquine affects the 
sexual forms of Pl. vivax, Pl. ovale, and Pl. falciparum in human 
erythrocytes. Primaquine is taken orally and well absorbed from the 
gastrointestinal tract. Maximal concentration in the blood is observed 
in 2 hours after drug intake. The drug is metabolized in the body and 
excreted through the kidneys. Therapeutic indications for primaquine 
are prevention of relapses of three-day malaria and prevention of 
malaria spreading through the carrier. Primaquine is commonly 
combined with other antimalarial drugs. Side effects of primaquine 
are dyspepsia, methemoglobinemia, leukocytosis or leukopenia.  
Quinocide is more toxic than primaquine. Other antimalarial 
agents increase its toxicity, therefore, combined use of quinocide 
with them is impossible. Quinocide is taken orally 1–2 times a day 
after a meal. Side effects of quinocide are nausea, cyanosis, fever, 
irritation of bladder, leukopenia or leukocytosis. These complications 
disappear after giving up the drug.   
 
Gametocides  
 
Gametocides are drugs which are active against sexual forms  
of Plasmodium. Gametocides which inhibit the sexual forms of 
Plasmodium in human erythrocytes are primaquine  and 
quinocide . Gametocides inhibiting the sporogony in the body  
of mosquito are bigumal and chloridinum. Pharmacology of these 
drugs is described above.  
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Selection Criteria for Antimalarial  Drugs 
 
Antimalarial drugs are used to treat and prevent malaria. In acute 
period (malarial fever, malarial coma), blood schizonticides are used 
(chingaminum (chloroquine), mefloquine, quinine, etc.). These drugs 
readily penetrate human erythrocytes and facilitate the fast 
improvement in clinical findings. The resistance of Plasmodium to 
these drugs develops relatively slow. In malarial coma, chloroquine 
and quinine are administered parenterally.  
The reserve group (used in case of Plasmodium resistance to the 
main drugs) includes such drugs as pyrimethamine, bigumal, 
primaquine, quinocide, sulfonamides, sulfones, and tetracyclines. 
These drugs are less effective in comparison with main drugs. Their 
effect develops slowly, while resistance of Plasmodium develops 
quickly. Therefore, drug combinations with different mechanism of 
action are commonly used.  
Primaquine is used to prevent relapse of three-day and four-day 
malaria.  
The drugs influencing upon pre-erythrocytic forms of 
Plasmodium (for instance, pyrimethamine) are used for individual 
preventive chemotherapy in people who live in or travel to malaria 
risk areas. Blood schizonticides (chloroquine, mefloquine, etc.) are 
also sometimes used with this end in view.  
The total preventive chemotherapy of malaria suggests the 
prevention of malaria transmission from the sick person to healthy 
people through mosquito bite. Gametocides (primaquine, 
pyrimethamine, and quinocide) are used for this purpose – to prevent 
formation of sporozoites in mosquito.  
 
Drugs for Amebiasis Treatment  
 
The causative agent of amebiasis is Entamoeba histolytica, 
which exists in two forms: vegetative and cystic. The transformation 
of vegetative form into cystic occurs in the presence of anaerobic 
bacterial flora (clostridium). Cystic forms, in turn, transform into 
vegetative amoeba, living in the intestinal lumen (without symptoms) 
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and feeding on the organic wastes of bacterial origin. Under the 
influence of aerobic bacteria (E. coli), amoeba takes on pathogenic 
properties. Vegetative forms of amoeba secrete proteolytic enzyme 
which dissolves tissues. It provides the formation of invasive forms 
of amoeba – hematophagous amoebas. A significant amount of 
erythrocytes is observed in the endoplasma of invasive forms of 
amoeba. At this stage, the invasive amoebiasis develops when 
amoeba is present both in the intestinal lumen and in the intestinal 
wall. By hematogenic way, amoeba can penetrate into the liver, 
lungs, and other organs.  
Treatment of amebiasis differs depending on amoeba 
localization. 
The drugs which are used to treat amoebiasis are classified as 
follows.  
1. Drugs which are effective in any localization of amoeba: 
metronidazole .  
2. Drugs of dirrect action which are effective against amoeba 
localized in the intestinal lumen: chiniofonum and intetrix .  
3. Drugs of indirect action which are effective against amoeba 
localized in the both intestinal lumen and intestinal wall: 
tetracyclines .  
4. Drugs acting upon amoeba which is mainly located in the 
intestinal wall and liver: emetine hydrochloride .  
5. Drugs which are mainly effective against amoeba localized in 
the liver: chloroquine .  
Metronidazole  is a drug which is effective in any localization 
of amoeba. The drug was introduced in the medical practice in 1951 
as an agent for the treatment of trichomoniasis. Metronidazole is also 
active against amoeba, giardia, balantidium, and Helicobacter pylori. 
Metronidazole is not active against cystic forms of amoeba. The drug 
is taken orally 0.25–0.5 g three times a day after a meal. 
Metronidazole is readily absorbed from the gastrointestinal tract and 
is well metabolized. The main route for drug excretion is via kidneys. 
Insignificant amount of metronidazole is excreted by salivary glands, 
intestine, and mammary glands. Metronidazole is manufactured in 
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tablets, solution for intravenous administration, and vaginal 
suppositories. Side effects of metronidazole are nausea, diarrhea, 
metallic taste in mouth, appetite loss, tremor, and disturbances of 
accommodation. Sometime, lesions of skin and mucous membranes 
are possible. Efficacy of metronidazole is low in localization  
of amoeba in the intestinal lumen. In this case, metronidazole is 
combined with chiniofonum. It is necessary to notice that 
metronidazole inhibits the activity of acetaldehyde dehydrogenase 
and causes accumulation of acetaldehyde that results in alcohol 
intolerance.  
Chiniofonum (yatren)  affects the vegetative and cystic forms 
of amoeba located in the intestinal lumen. The drug is taken orally. 
Gastrointestinal absorption of chiniofonum is low (about 10–15 %), 
therefore, high drug concentration is created in the intestinal lumen. 
Toxicity of yatren is low. Chiniofonum also exhibits significant 
antibacterial and antifungal activity. The drug is used to treat amebic 
dysentery, colitis, and uretritis. Ointments and solutions  
of chiniofonum are used externally in treatment for purulent wound, 
burns, ulcers, etc.  
Intetrix  is active against amoeba, Candida, Gram-positive and  
Gram-negative bacteria. The drug is used in treatment of intestinal 
amoebiasis and diarrhea. Toxicity of intetrix is low.  
Tetracycline  is an antibiotic which has indirect influence upon 
amoeba. Tetracycline affects the bacterial intestinal microflora which 
utilizes oxygen. Since species of amoeba are anaerobic, they can not 
live in the presense of oxigen. Therefore, tetracycline is an indirect 
amoebicide. Efficacy of tetracycline is lower than the efficacy of 
direct amoebicides. Aminoglycoside monomicine  is also used to 
treat acute intestinal amoebiasis.  
Emetine hydrochloride  is an alkaloid of ipecacuanha. In 
therapeutic doses, emetine inhibits vegetative forms of amoeba but 
practically does not influence upon its cystic forms. The drug quickly 
eliminates the symptoms of amoebic dysentery, but does not prevent 
the relapses. Emetine is administered intramuscularly because oral 
intake of emetine significantly irritates the gastrointestinal mucosa. 
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Emetine is eliminated very slowly (more than a month), therefore, 
the drug is able to acummulate in the body. The main sites of 
emetine accumulation are the liver, lungs, and intestinal wall. 
Emetine does not penetrate the blood-brain barrier. Emetine is used 
in treatment for hepatic, pulmonary, and intestinal amoebiasis. The 
drug does not influence upon amoeba which is located in the 
intestinal lumen or in the brain. The side effects of emetine are 
nausea, vomiting, diarrhea, tachycardia, hypotension, precordialgia, 
polyneuritis, abnormal hepatic and renal functions, etc. 
Chingaminum  (chloroquine) is active against amoeba 
which is located in the liver, bacause the liver can accumulate a high 
concentration of the drug. The characteristics of chingaminum are 
given in subsection “Antimalarial drugs”.  
 
Drugs for Lambliasis Treatment  
 
Lambliasis (giardiasis) is caused by Lamblia intestinalis. 
Parasites can damage the intestine with the following development of 
duodenitis and enteritis. Also, Lamblia can penetrate into the bile and 
pancreatic ducts. The following drugs are used to treat lambliasis: 
metronidazole, albendazole (Vormil), furazolidone, and 
aminoquinol .  
Aminoquinol  is a derivative of quinoline. The drug is used in 
treatment of lambliosis, toxoplasmosis, skin leishmaniasis, and 
systemic collagenosis. In lambliasis, aminoquinol is taken orally  
20–30 minutes after a meal. After absorption, the drug is excreted 
with bile into the intestine. Simple drug intake results in excretion  
of the agent with bile during one month. The side effects of 
aminoquinol are dyspepsia, weakness, headache, tinnitus, insomnia, 
leukopenia, liver and kidney failure. 
Pharmacology of albendazole is given in “Anthelmintic drugs”.  
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Drugs for Trichomoniasis Treatment  
 
 A causative agent of trichomoniasis is Trichomonas vaginalis. 
The disease occurs in the form of colpitis or vulvovaginitis (in 
women), cystitis, stomatitis, colitis, and urethritis. The following 
drugs are used for trichomoniasis treatment:  
– nitroimidazole derivatives: metronidazole ,  tinidazole , 
ornidazole ; 
– aminoquinoline derivatives: trichomonacide ; 
– imidazole derivatives: econazole, nitazole, miconazole, 
clotrimazole; 
– nitrofuran derivatives: furazolidone.  
Tinidazole (Fasigyn) exhibits high activity against 
Trichomonas vaginalis. Besides, the drug is active against obligate 
anaerobes. Tinidazole is readily absorbed from the gastrointestinal 
tract. The blood concentration of tinidazole is higher than the 
concentration of metronidazole. The duration of tinidazole action is 
much longer.  
Trichomonacide  has high activity against Trichomonas 
vaginalis. The drug is readily absorbed from the gastrointestinal 
tract. Trichomonacide is mainly used in treatment of urogenital 
trichomoniasis. The drug is taken orally or used topically in the form 
of suppositories or globules. Trichomonacide irritates the mucous 
membranes.  
The pharmacological characteristics of imidazole derivatives 
(ornidazole, miconazole, econazole, clotrimazole) is given in 
“Antifungal drugs”. Pharmacology of furazolidone is described in 
“Nitrofuranes”.  
 
Drugs for Toxoplasmosis Treatment  
 
A causative agent of toxoplasmosis is Toxoplasma gondii. There 
are several forms of the disease which are accompanied by lessions 
of lymph nodes, intestine, lungs, eyes, central nervous system, and 
other organs. Toxoplasmosis can result in premature labor, abortion, 
congenital malformations, and stillbirth. To prevent congenital 
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toxoplasmosis, chloridinum  and aminoquinol  in combination 
with sulfonamides  are prescribed to pregnant women. Preventive 
use of chloridinum and aminoquinol is contraindicated during the 
first 9 weeks of pregnancy due to their toxic influence upon the fetus. 
During this period, sulfonamides are used for prevention of fetal 
infection. Chingaminum  and pentamidine  are also used to treat 
toxoplasmosis.  
 
Drugs for Balantidiasis Treatment  
 
A causative agent of balantidiasis is infusorium Balantidium coli 
parasitizing the large intestine. Tetracyclines  and chiniofonum  
are used to treat balantidiasis. Pharmacological characteristics of 
these agents are given in the corresponding sections.  
 
Drugs for Leishmaniasis Treatment  
 
Leishmaniasis is a protozoal disease which is caused by 
Leishmania donovani (the causative agent of visceral leishmaniasis – 
kala-azar) and Leishmania tropica (the causative agent of skin 
leishmaniasis). Visceral leishmaniasis is accompanied by high 
temperature, anemia, leukopenia, and splenomegaly. Initialy, 
leishmania parasites cause skin sores or ulcers at the site of the bite. 
If the disease progressies, it attacks the immune system. 
Solusurminum  is the most commonly used agent to treat 
visceral leishmaniasis. It is a preparation of pentavalent antimony. 
The drug is administered intravenously. Solusurminum blocks thiol 
groups of Leishmania enzymes that affects their growth and division. 
Side effects of solusurminum are nausea, headache, skin rash, and 
agranulocytosis. After an overdose of solusurminum, unithiol is 
administered as an antidote.  
Sodium stibogluconate  is also a preparation of pentavalent 
antimony. The drug is administered intramuscularly or intravenously. 
Its side effects are dyspepsia, vomiting, appetite loss, arterial 
hypotension, and chest pain. 
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Glukantim, pentakarinat  (pentamidine), neostibazine, 
and pentostim  are also preparations of pentavalent antimony for 
visceral leishmaniasis treatment.  
Pentacarinat (pentamidine) is administered intramuscularly 
and in inhalations. Mechanism of drug action is associated with 
blocking thymidylate synthetase that inhibits of DNA synthesis. 
Pentakarinat is used to treat visceral and skin leishmaniasis, to 
prevent pneumonia in AIDS patients, and to treat trypanosomiasis, 
also known as African sleeping sickness. Side effects of pentakarinat 
are cough, dyspnea, bronchospasm, skin rash, metallic taste in the 
mouth, dizziness, arterial hypotension, acute pancreatitis, anemia, 
leukopenia, thrombocytopenia, increased blood urea nitrogen level 
and creatinine. 
All above preparations of pentavalent antimony may be used to 
treat skin leishmaniasis. Also, the following agents are used to treat 
skin leishmaniasis: quinacrine, monomycin, metronidazole , 
neomycin, and aminoquinol .     
  
Drugs for Trypanosomiasis Treatment  
 
Causative agents of trypanosomosis are Trypanosoma 
gambiense and Trypanosoma brucei rhodesiense (sleeping sickness) 
and Trypanosoma cruzi (Chagas disease).  
Melarsoprol  is used as a primery agent for treatment of 
sleeping sickness. It is arsenicum derivative which easily penetrates 
through blood-brain barrier. Besides, pentacarinat  
(pentamidine)  and suramin  are used to treat African 
trypanosomosis. But these drugs do not penetrate into the central 
nervous system and, therefore, are effective only at early stages of 
the disease (when the brain is not affected by Trypanosoma). All 
these drugs are toxic and cause a large number of side effects.  
To treat Chagas disease (spread in South America), 
primaquine  and antibiotic puromycin  are used.  
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Drugs for Chlamydiosis Treatment  
 
Chlamydia are intracellular parasites of humans and animals. 
There are three species of Chlamydia which are causative agents for 
humans: Chlamydia trachomatis, Chlamydia psittaci and Chlamydia 
pneumonia. Chlamydia trachomatis is the most common sexually 
transmitted infection. Chlamydia pneumonia causes pneumonia. 
Chlamydia psittici mainly affects birds.  
Chlamydia trachomatis can cause a recurrent ocular infection – 
trachoma. Other serological forms of Chlamydia cause 
lymphogranuloma venereum, conjunctivitis, child pneumonia, 
urethritis, endometritis, salpingitis, cervicitis, and epididymitis 
(inflammation of the epididymis). During pregnancy, Chlamydia can 
commonly cause premature labor and endometritis. Moreover, 
chlamydial infection may be associated with septic arthritis.  
To treat chlamydiosis, tetracycline  and erythromycin  are 
aminly used. Penicillin is ineffective in that disease. Also, 
rifampicin,  chloramphenicol,  and sulfonamides  are used. 
Doxycycline  and azithromycin  are drugs of choice for the 
treatment of urogenital chlamydiosis.    
 
Table 21 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product  
Chingaminum Orally 0.25–0.5 g 1–2 times 
daily; 
intramuscularly  
or intravenously 0.5 g  
Tablets 0.25 g; 
ampoules 5 ml  
of 5 % solution  
Chloridinum 0.01 g 3 times daily  
0.02 (for malaria treatment); 
0.025 g 2–3 times daily  
(for toxoplasmosis 
treatment) 
Tablets 0.01 or 0.025 g 
Chinini 
hydrochloridum 
Orally 0.5 g 2 times daily; 
subcutaneously 1.0 g 2 times 
daily; 
intravenously 1 ml in 20 ml 
of 40 % glucose solution  
Tablets 0.25 or 0.5 g; 
ampoules 1 ml  
of 50 % solution  
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Continuation of the table 21 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product 
Primachinum Orally 0.009 g 3 times daily Tablets 0.009 g 
 
Metronidazolum Orally 0.25–0.5 g 2–3 times 
daily; 
intravenously drop-by-drop 
0.5 g 3 times daily 
Tablets 0.25 g; 
 
bottles 100 ml  
of 0.5 % solution  
Emethini 
hydrochloridum 
Intramuscularly  
or subcutaneously 0.015 g 
twice a day 
Ampoules 1 ml  
of 1 % solution  
Furazolidonum Orally 0.1 g 4 times daily Tablets 0.05 g 
Solusurminum Intravenously slowly, 
intramuscularly  
or subcutaneously  
0.1–0.12 g/kg once a day 
Ampoules 10 ml  
of 20 % solution  
 
 
ANTIFUNGAL DRUGS 
 
Fungal infections (mycoses) are very common. Sick people, 
animals, and environment (plants, soil, etc.) can be the source of 
infection. Infection occurs through the injured skin, gastrointestinal 
tract, respiratory tract. Besides, potential pathogens, especially of the 
genus Candida, are located on the skin, in the upper respiratory 
system, on the mucous membranes of sex organs, and in the 
gastrointestinal tract. The cause of saprophytic flora transformation 
into pathogens is the reduction of the human body resistance due to 
immunodeficiency (at severe diseases, hormonal therapy, and the use 
of cytostatic drugs or some antibiotics). 
Antifungal drugs are classified into the following groups.  
1. Drugs for treatment of systemic or deep mycoses: 
 – antibiotics: amphotericin B, amphoglucaminum, and 
mycoheptin ; 
 – azole derivatives: miconazole, ketoconazole (nizoral),  
clotrimazole,  itraconazole, and  fluconazole. 
2. Drugs for treatment of dermatomycoses:  
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 – antibiotics: griseofulvin ; 
 – azole derivatives: ketoconazole (nizoral), itraconazole ,  
miconazole,  fluconazole , and  clotrimazole ; 
– N-methylnaphthaline derivatives: terbinafine (Lamisil ); 
 – nitrophenol derivatives: nitrofungin ;  
 – thiocarbamate derivatives: chinofungin ; 
 – undecylenic acid derivatives: ointments “Zincundanum”  
and “Undecinum” ;   
 – iodine preparations: alcohol solution of  iodine  and 
potassium iodide .  
3. Drugs for treatment of mycoses caused by fungi Candida:  
 – antibiotics: nystatin , levorin,  amphotericin B, and 
natamycin (Pimafucin); 
 – azole derivatives: itraconazole,  clotrimazole,  
ketoconazole,  and  miconazole ; 
 – bis-quaternary ammonium salts: decaminum ; 
 – halogens, non-organic acids, and alkalis.  
 
Drugs for Systemic or Deep Mycosis Treatment  
 
Systemic or deep mycoses affect the liver, bones and joints, 
gastrointestinal tract, brain and meninges, lymph nodes, etc. 
Sometimes, systemic mycoses develop in septic form. The deep 
mycoses are rare and difficult to treat. More than half of them are 
caused by saprophytic Candida activity. Less often, deep mycoses 
are caused by the causative agents of cryptococcosis, 
coccidioidomycosis, paracoccidioidomycosis, histoplasmosis, 
blastomycosis, etc.  
Amphotericin B  is one of the main drugs for treatment of deep 
mycoses. It is a polyen antibiotic which is produced by Streptomyces 
nodosum. Amphotericin B does not affect bacteria, rickettsia, and 
viruses. Mechanism of action is associated with violation of transport 
function and permeability of fungi cell membrane. Selectivity of 
antifungal action occurs due to the fact that amphotericin B interacts 
with the main lipid of fungal cell wall – ergosterol. The main lipid of 
human and bacterial cells is cholesterol. Antifungal effect of 
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amphotericin B is characterized as fungistatic. This antibiotic is 
practically not absorbed in the gastrointestinal tract. Amphotericin B 
is administered intravenously and into body cavities, applied 
topically, and used in inhalations. The drug does not penetrate 
through the blood-brain barrier. About 95 % of the drug, circulating 
in the blood, bind to plasma proteins. The main organ of 
amphotericin B biotransformation is the liver. The drug elimination 
from the body is slow (about 20–40 % of administered dose during 
a week). The therapeutic indications for amphotericin B are 
hystomycosis, coccidioidomycosis, visceral candidomycosis, 
blastomycosis, and deep generalized trichophytosis. 
Amphotericin B is a very toxic drug. Therefore, the drug is 
administered intravenously only in cases of life-threatening mycosis. 
Amphotericin B is dissolved by 5 % glucose solution and 
administered intravenously drop-by-drop during 3–6 hours. The drug 
is administered once in two days or twice a week. Side effects are 
headache, fever, dyspepsia, hypotension, nephrotoxicity, anemia, 
hypokalemia, disturbances of hepatic function, nephrotoxicity, 
thrombophlebitis, and allergic reactions. Amphotericin B is 
contraindicated in hepatic and renal diseases. 
Despite identical mechanism of action, amphoglucaminum  is 
a less toxic drug than amphotericin B. Amphoglucaminum is used to 
treat mycoses of the urinary, gastrointestinal, and respiratory tracts. 
The drug is administered during 10–14 days. To treat chronic 
(granulomatous) candidiasis and deep mycoses, amphoglucaminum 
is used during 3–4 weeks. Amphoglucaminum is taken orally. The 
drug is gradually absorbed from the gastrointestinal tract with 
maximum blood concentration in 2–3 days. Amphoglucaminum is 
excreted with urine during 10 days. Side effects are identical with 
amphotericin B but less expressed.  
Mycoheptin  has similar properties with amphotericin B. 
Mycoheptin is taken orally during 10–14 days or applied topically. 
The drug is partially absorbed in the gastrointestinal tract and 
excreted with urine. The therapeutic indications for mycoheptin are 
visceral mycoses, sepsis caused by Candida, aspergilosis, and 
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geotrichosis. Side effects are gastrointestinal distress, renal 
disfunction, and allergic reactions.  
Miconazole  is a derivative of imidazole. The drug is taken 
orally and administered intravenously or subarachnoidally to treat 
deep mycoses. Also, miconazole is applied topically to treat vaginal 
mucosa damage caused by Candida and for the treatment of 
dermatomycoses. The side effects of miconazole are 
thrombophlebitis, nausea, anemia, hyperlipidemia, hyponatremia, 
leukopenia, and allergic reactions.  
Ketoconazole (Nizoral)  is readily absorbed from the 
gastrointestinal tract. About 90 % of the absorbed drug bind to 
plasma proteins. The permeability of the drug through the blood-
brain barrier is low. Ketoconazole is metabolized in the liver and 
excreted with urine and bile. The drug is used to treat deep mycoses 
and lesions of mucous membranes by Candida. Mechanism of action 
is associated with inhibition of ergosterol, triglyceride, and 
phospholipid biosynthesis that violates the structure of the fungal cell 
membrane. Side effects of ketoconazole are dyspepsia and hepatic 
dysfunction.  
Itraconazole  is a triazole derivative. The drug is taken orally. 
The drug absorption from the gastrointestinal tract is high, but 
permeability through the blood-brain barrier is low. Itraconazole is 
extensively metabolized by the liver. A large number of metabolites 
and unchanged itraconazole are excreted through the kidneys. Side 
effects are dyspepsia, headache, hepatic dysfunction, and allergic 
reactions. 
Fluconazole  is also a derivative of triazole. Fluconazole is one 
the most effective antifungal drugs. The drug is taken orally. 
Fluconazole easily penetrates through the blood-brain barrier. 
Unchanged fluconazole is excreted from the body through the 
kidneys. The therapeutic indications for fluconazole are fungal 
meningitis, coccidioidomycosis, candidomycosis, etc. Side effects of 
fluconazole are dyspepsia, hepatotoxicity, and skin allergy.  
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Drugs for Dermatomycosis Treatment  
 
In dermatomycoses, the skin, nails, and hair are affected. The 
causative agents of dermatomycoses are Trichophyton violaceum, 
Microsporum lanosum, Achorion schonlein, different species of 
Epidermophyton, etc. Onichomycoses (fungal lesions of nails) are 
widely spreaded. Onichomycoses are caused by dermatophytes (most 
commonly by Trichophyton rubrum), Candida, and mild fungi 
(Scopulariopsis brevicaulis, Aspergillus spp., etc.). The fungi of the 
genus Candida and sometimes molds (causative agents of 
aspergillosis) are the most common pathogens among saprophytic 
fungi.  
The most effective drugs for dermatomycoses treatment are 
terbinafine (Lamisil ), itraconazole, ketoconazole (Nizoral), 
and griseofulvin . Micospor, cyclopirox, amorolfine, and 
tioconazole  are used topically. 
Griseofulvin  is an antibiotic which is produced by mold-
forming fungi Penicillium nigricans. The drug has narrow antifungal 
spectrum and is active against such causative agents of 
dermatomycoses as Trichophyton, Epidermophyton, Mikrosporum, 
and favus. Griseofulvin is ineffective against Candida and causative 
agents of deep mycoses. Mechanism of action is associated with 
violation of nucleic acid synthesis due to griseofulvin interaction 
with guanidine bases of RNA. The fungal resistance to griseofulvin 
does not develop in general. Griseofulvin is taken orally. The drug is 
readily absorbed from the gastrointestinal tract. Griseofulvin 
accumulates in the tissues, synthesizing keratin. Therefore, stratum 
corneum, nails, and hair become resistant to dermatomycetes. But in 
the upper epidermal layers, griseofulvin is determined only in  
1–2 months after the start of therapy. Moreover, griseofulvin does 
not penetrate into the nail plates. Therefore, nail avulsion involves 
application of keratolytic agents. The daily dose of griseofulvin is 
divided into 4 intakes to provide the stable high drug concentration in 
the blood. Although a single drug intake of the daily dose is also 
possible. The duration of treatment with griseofulvin is 1–8 months. 
Also, liniment with griseofulvin is used topically.  
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The main routes of griseofulvin excretion from the body are 
kidneys and an intestine. A main part of the antibiotic dose 
undergoes the drug biotransformation in the liver. 
The side effects of griseofulvin are headache, nausea, insomnia, 
disorientation, photodermatosis, fear, leukopenia, eosinophilia, etc. It 
is necessary to notice that nowadays the clinical use of griseofulvin is 
significantly restricted due to its cancerogenic property. 
Terbinafine (Lamisil ) is a derivative of N-methylnaphthalene. 
The drug affects ergosterol synthesis and formation of fungal 
membranes due to the influence upon the early steps of synthesis and 
violation of squalene accumulation. Lamisil exhibits the fungicidal 
effect. The spectrum of antifungal action includes dermatophytes and 
Candida. Terbinafine is taken orally. The drug is readily absorbed 
from the gastrointestinal tract and accumulates in the skin, 
subcutaneous fat, nail plates, hair follicles, and sebaceous glands. 
Terbinafine is metabolized in the liver and excreted through the 
kidneys. Lamisil cream is used topically twice a day.  
The therapeutic indications for terbinafine are dermatomycosis 
of different localization and candidiasis. Most commonly the drug is 
used to treat onychomycosis and candidiasis of mucous membranes. 
The course of treatment lasts from 2 to 6 months. Lamisil is not 
recommended for pregnant women and for nursing mothers. The side 
effects of terbinafine are dyspepsia and allergic reactions. External 
drug use can cause itching and red skin. 
Nitrofungin  is a nitrophenol derivative. The drug is used 
topically as an alcoholic solution. Antifungal activity of nitrofungin 
is low.  
The following drugs are also used topically for treatment of 
mycoses: miconazole, clotrimazole, preparations of undecylenic 
acid (ointments “Zincundanum”, “Mycoseptin”, “Undecinum”), 
and iodine preparations (alcoholic iodine solution, and potassium 
iodide).  
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Drugs for Candidiasis Treatment 
 
Candidiasis most commonly affects mucous membranes  
of gastrointestinal tract, bronchi, sex organs, and skin. The main 
causative agent of candidiasis is Candida albicans.  
Antibiotics nystatin  and levorin  exhibit fungiostatic and 
fungicidal effects. These drugs violate permeability of the fungal cell 
membrane. These drugs are characterized by low intestinal 
absorption. Nystatin and levorin are used orally to treat 
gastrointestinal candidiasis or to prevent candidiasis in patients 
treated by antibacterial drugs of broad spectrum. To treat candidiasis 
of oral cavity of sex organs, nystatin and levorin are used in solutions 
for syringing or in suppositories.  
Toxicity of nystatin is very low. Its side effects are dyspepsia 
and allergic reactions. Levorin has a higher toxicity. But resistance of 
Candida to levorin develops more slowly. Levorin is also used in 
treatment of trichomoniasis and in therapy of patients with prostate 
adenoma.  
Natamycin (pimafucin)  is a polyene antibiotic with broad 
spectrum of antifungal action. Candida is especially highly sensitive 
to natamycin. Dermatophytes are less sensitive to natamycin. 
Pimafucin is used topically in treatment for candidiasis of the skin 
and mucous membranes. Suppositories with natamycin are used in 
treatment for vaginal candidiasis, and tablets – in treatment for 
intestinal candidiasis (drug is taken orally 4 times a day). To treat 
dermatomycoses, pimafucin is used in combination with 
griseofulvin. Toxicity of pimafucin is low. The side effects are 
dyspepsia and irritation and burning in case of local use. 
Clotrimazole  is imidazole derivative. It is a highly toxic agent 
which is used topically to treat candidiasis, resistant to polyene 
antibiotics.  
Decaminum  is bis-quaternary ammonium salt. It is a detergent 
with high surface activity. Decaminum violates permeability of 
fungal cytoplasmic membrane and due to this exhibits bactericidal, 
fungistatic, and fungicidal effects. The ointment with decaminum is 
used to treat fungal lesions of skin 1–2 times a day during  
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2–3 weeks. Decaminum is also effective in inflammatory lesions of 
the oral cavity, throat, and vagina.  
 
Table 22 – Drugs for prescription 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product  
Nystatinum Orally 500 000 IU 3–4 times 
daily; 
for rectal or vaginal 
introduction 1 suppository  
2 times daily; 
ointment for applying  
on the skin 
Tablets 250 000  
or 500 000 IU; 
suppositories 250 000  
or 500 000 IU; 
 
ointment 1 % – 15.0 g  
Amphotericinum 
B 
Intravenously drop-by-drop 
100–1 000 IU/kg (in 450 ml 
of 5 % glucose solution)  
2–3 times per week; 
ointment for applying  
on injured parts of the skin 
Vials with 50 000 IU  
of powder for injection; 
 
 
ointment 15.0 or 30.0 g 
(1 g contains 30 000 IU  
of amphotericinum B) 
Ketoconazole Orally 0.2–0.4 g once a day Tablets 0.2 g 
Itraconazole Orally 0.1–0.2 g once a day Capsules 0.1 g 
Griseofulvinum Orally 1 tablet 4 times daily; 
liniment for applying  
on injured parts of the skin 
Tablets 0.125 g; 
liniment 2.5 % – 30.0 g 
Fluconazole Orally or intravenously  
drop-by-drop 0.05–0.4 g  
once a day 
Capsules 0.05; 0.1; 0.2 g; 
vials 50; 100 or 200 ml   
of 0.2 % solution 
 
Step 1.  Tasks for Self -Control  
Antiviral,  Antiprotosoal , and Antifungal Drugs 
 
1. A child was delivered to the hospital with punctated 
incrustation (white and yellowish spots) on the mucous tunics  
of cheeks, palate, and tongue caused by Candida albicans fungus. 
Which of the following drugs is used for treatment of the child? 
A. Itraconazole.  
B. Gentamicin sulfate. 
C. Tetracycline hydrochloride. 
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D. Cefalexin. 
E. Benzylpenicillin sodium.  
2. A stomatologist diagnosed herpetic stomatitis. What is it 
necessary to prescribe for treatment in this case? 
A. Sulfacylum-natrium. 
B. Tetracycline. 
C. Clotrimazole. 
D. Acyclovir.  
E. Itraconazole. 
3. A patient suffers from candidiasis of mucous membranes  
of oral cavity. Choose the antibiotics group which is used for 
treatment of this patient. 
A. Tetracyclines. 
B. Polyene antibiotics.  
C. Macrolides. 
D. Aminoglycosides. 
E. Penicillines. 
4. Prescribe antiviral drug for patient suffering from surrounding 
herpes. 
A. Lamivudine. 
B. Ganciclovir. 
C. Zidovudine. 
D. Rimantadine. 
E. Acyclovir. 
5. A patient with amebic dysentery was prescribed a drug, which 
also inhibits the development of the erythrocyte forms of malaria 
plasmodium. What is it? 
A. Quinine. 
B. Emethine hydrochloride. 
C. Chingaminum.  
D. Erythromycin. 
E. Tetracycline. 
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6. Systemic amebiasis with involvement of intestines, liver, and 
lungs was diagnosed in a 52-year-old patient. What drug should be 
prescribed? 
A. Enteroseptol. 
B. Metronidasole. 
C. Quiniofone. 
D. Chloroquine. 
E. Tetracycline. 
7. In order to prevent long-term effects of 4-day malaria  
a 42-year-old man was prescribed prymaquine. On the 3rd day from 
the begining of the treatment there appeared stomach and heart pains, 
dyspepsia, general cyanosis, hemoglobinuria. What could cause such 
side effects? 
A. Potential activity with other preparations. 
B. Delay preparation excretion with urine. 
C. Reduced activity of microsomal liver enzymes. 
D. Accumulation of the medication. 
E. Genetic insufficiency of glucose-6-phosphate dehydrogenase.  
8. Systemic amebiasis with involvement of intestines, liver, and 
lungs was diagnosed in a 52-year-old patient.  What drug should be 
prescribed? 
A. Enteroseptol. 
B. Metronidasole.  
C. Chloroquine. 
D. Tetracycline. 
E. Quiniofone. 
9. Undergoing a metronidazole cure a patient drank a small 
amount of alcohol due to which a severe poisoning developed. What 
is the cause of the poisoning? 
A. Disorder of kidney function. 
B. Allergic reaction. 
C. Acetaldehyde accumulation.  
D. Cardiovascular collapse. 
E. Neural disorders. 
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10. A female with dysentery is delivered to infectious unit. By 
means of laboratory investigations it is established that the causative 
agent of disease is Entamoeba histolytica. What drug should be 
prescribed to female? 
A. Benzylpenicillin sodium salt.   
B. Chingaminum.   
C. Rifampicin.    
D. Metronidazole.    
E. Isoniazid.    
11. Drug A. is prescribed to patient with ulcer disease  
of stomach. It is known that drug A. suppresses the growth and 
reproduction of H. pylori. Indicate this drug.  
A. Metronidazole. 
B. Glauvent. 
C. Prazosin. 
D. Corglycon. 
E. Furosemide. 
12. Indicate the drug which should not be used with ethyl 
alcohol, because this drug inhibits ethanol metabolism.  
A. Aminazine. 
B. Metronidazole. 
C. Clophelinum. 
D. Diazepam. 
E. Reserpine. 
13. A 30-year-old patient complains of having abdominal pain 
and diarrhoea for five days; body temperature rises up to 37.5 0C 
along with chills. The day before a patient had been in a forest and 
drunk from an open water reservoir. Labotatory analyses enabled to 
make the following diagnosis: amebic dysentery. What is the drug of 
choice for its treatment? 
A. Levomycetin. 
B. Phthalazolum. 
C. Metronidazole. 
D. Emetine hydrochloride. 
E. Furazolidone. 
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ANTHELMINTIC DRUGS 
 
More than 250 species of worms can parasitize in a human body. 
The worms cause an enormous damage for the host organism due to 
the release of toxins and mechanical damage of the internal organs. 
Helminthiases can cause anemia, allergic reactions, disordes of the 
central nervous system activity, gastrointestinal distress, functional 
disturbances of the liver, lungs, eyes, blood and lymphatic  
vessels, etc. The incidence of worm infections is quite high.  
Depending on localization of worms in the human organism, 
there are intestinal and extraintestinal helminthiases. Depending on 
the types of worms, which cause the disease, helminthiases are 
divided into nematodiasis (causative agents are roundworms or 
nematodes), cestodiasis (causative agents are flatworms or cestodes), 
and trematodiasis (causative agents are flukes or trematodes).  
 
Drugs for Intestinal Helminthiasis Treatment  
 
Drugs for Intestinal Nematodiasis Treatment  
 
The following drugs are used to treat intestinal nematodiasis: 
mebendazole, albendazole, levamisole, medamin, naftamon, 
piperazine, pervinium pamoate, and pyrantel pamoate .  
Mebendazole (Vermox) is a benzimidazole derivative.  
The drug has a broad spectrum of anthelmintic action which includes 
main types of roundworms: Ascaris lumbricoides (causative agent of 
ascariasis), Enterobius vermicularis (enterobiasis), Trichocephalus 
trichiurus (trichocephaliasis), Ancylostoma duodenale 
(ancylostomiasis), and Strongyloides stercoralis (strongyloidiasis). 
Mebendazole is active against infections, caused by cestodes 
Taeniarhynchus saginatus (bovine tapeworm), Hymenolepis nana 
(dwarf tapeworm), and Taenia solium (pork tapeworm). Vermox 
affects both worms and their eggs.  
The mechanism of mebendazole action is associated with 
violation of glucose absorption by worms that results in disturbances 
of energy metabolism. At the same time, the violation of glucose 
absorption by mammalian cells is not observed. The inhibition of 
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motor activity and death of helminths develop gradually. The 
excretion of dead parasites with feces is observed during several 
days. 
Mebendazole is taken orally during or after a meal. 
Gastrointestinal absorption of mebendazole is low (not more than 
10 %). The absorbed part of the drug undergoes hepatic metabolism 
and is excreted by the kidneys within 1–2 days. For better absorption, 
an intake of mebendazole suspension in sunflower oil is 
recommended. The treatment with mebendazole does not require 
a special diet. The single mebendazole intake is used in case of 
invasion by Ascaris lumbricoides or Enterobius vermicularis. 
Repeated intake of the drug is recommended in two weeks. To treat 
other helminthiases, the course of treatment with mebendazole varies 
depending on the type of helminth.  
The therapeutic indications for mebendazole are intestinal 
nematodiasis (ascariasis, enterobiasis, ankylostomiasis, 
trichocephaliasis, and strongyloidiasis), intestinal cestodiasis 
(teniasis, teniarinchiasis, and hymenolepiasis), extraintestinal 
nematodiasis (filariasis and trichinelliasis), and extraintestinal 
cestodiasis (cysticercosis and echinococcosis). 
Albendazole (Vormil)  is effective in intestinal nematodiasis, 
cysticercosis, and echinococcosis. Vormil also affects the eggs of 
Ascaris lumbricoides, Ancylostoma duodenale, and Trichocephalus 
trichiurus (whipworm). The drug violates glucose utilization by 
helminths. Taken orally, albendazole is easily absorbed from the 
gastrointestinal tract and metabolized in the liver. The drug 
metabolites are excreted mainly by the kidneys. The side effects  
of albendazole are headache, diarrhea, dizziness, and insomnia. 
Prolonged intake of albendazole can cause leukopenia, vomiting, 
skin rash, abdominal pain, and alopecia.  
Pyrantel pamoate  is a pyrimidine derivative. The drug is 
used at invasion by roundworms. Pyrantel violates neuro-muscular 
transmission due to cholinesterase inhibition. It results in spastic 
paralysis of helminths. Pyrantel is taken orally. The degree of 
intestinal drug absorption is about 50 %. The main route of excretion 
515 
 
is the intestine. The therapeutic indications for pyrantel are 
ascariasis, enterobiasis, ancylostomiasis, and trichostrongyliasis. Side 
effects of pyrantel are dyspepsia, loss of appetite, and headache. 
Levamisole (decaris )  is commonly used in ascariasis 
treatment. The drug causes depolarization of helminth muscular 
membranes that results in muscular paralysis. Besides, levamisole 
inhibits the activity of fumaratereductase and violates metabolism  
of the helminths. Simple drug intake provides the full 
dehelminthization in 90–100 % of patients with ascariasis. 
Levamisole activity is lower in ancylostomiasis and strongyloidiasis. 
Levamisole effects positively in patients with extraintestinal 
helmintiasis, for instance with filariasis. 
The side effects of levamisole are abdominal pain, nausea, 
vomiting, and headache.  
Levamisole also has immunomodulatory effect. The drug 
normalizes function of macrophages and T-lymphocytes in patients 
with immunodeficiency. The course of treatment with levamisole 
lasts from 2–3 weeks up to a year. Prolonged therapy with 
levamisole can be aggreveted by a lot of serious side effects: 
insomnia, disorders of taste and smell, skin rash, and 
agranulocytosis.   
Piperazine adipate  is widely used to treat ascariasis and 
enterobiasis. Pyperazine paralyzes the neuromuscular systems of 
helminths that prevents their movement through the intestine and 
penetration into the bile ducts. Also, pyperazine stimulates the 
intestinal peristalsis that provides favorable conditions for evacuation 
of helminths from the intestine. The drug is readily absorbed from 
the intestine, its metabolites are excreted with the urine. The 
treatment with pyperasine does not require a special diet and intake 
of laxative drugs. An efficacy of pyperazine in ascariasis is  
90–100 %. Pyperazine is a low toxic drug. Its side effects are 
dyspepsia and headache.  
Naftamon  is a monoquaternary ammonium compound. The 
drug is highly effective in ascariasis, enterobiasis, ankylostomiasis, 
and trichostrongyliasis. Mechanism of action is associated with 
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inhibition of neuromuscular transmission of helminths. Naftamon is 
characterized by low ability to absorb from gastrointestinal tract and 
laxative activity. A very bitter taste of naftamon is the cause of 
nausea and vomiting. Naftamon is prescribed for oral intake for  
1–2 hours before a meal.  
Pyrvinium pamoate  is mainly used to treat enterobiasis and 
strongyloidiasis. The drug inhibits aerobic respiration of helminths 
and violates the utilization of exogenic glucose. The absorption from 
gastrointestinal tract is low. Pervinium seldom causes the side 
effects.  
 
Drugs for Intestinal Cestodiasis Treatment  
 
The drugs to treat intestinal cestodiasis are praziquantel , 
niclosamide (phenasalum), extract of male fern, pumpkin 
seeds, etc.  
Niclosamide (phenasalum)  is active against Taenia solium, 
Taeniarincus saginatus, Diphyllobothrium latum, etc. The drug 
inhibits phosphorylation in mitochondria of cestodes, utilization of 
oxigen and glucose by helminths, and paralyzes their neuromuscular 
system. Besides, niclosamide decreases the resistance of helminths to 
proteolytic enzymes of the gastrointestinal tract that provokes 
degradation of the coating tissues of helminths. The treatment with 
niclosamide requires a specific patient preparation – carbohydrate 
diet because proteins bind to drug and inactivate it. Overnight, the 
patient drinks only tea and fruit juice and gets an enema. 
Niclosamide is taken in the morning on an empty stomach. Laxative 
drugs are given only in case of teniasis (to prevent cysticercosis). 
Niclosamide is readily absorbed from the gastrointestinal tract. 
About 25–30 % of the drug is excreted from the body in urine, 
another part – in feces. Side effects of niclosamide are nausea, 
vomiting, and abdominal pain.  
Praziquantel (biltricide)  is highly effective drug to treat 
intestinal cestodiasis (teniasis, diphyllobothriasis, teniarinchiasis, and 
hymenolepiasis), extraintestinal trematodiasis, and cysticercosis. 
Praziquantel increases permeability of calcium in helminthic cell 
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membranes. Calcium entrance causes a short-time increase of 
muscular activity which is replaced by spastic paralysis of helminths. 
Praziquantel is readily absorbed from the gastrointestinal tract, 
undergoes fast hepatic metabolism, and is being excreted by the 
kidneys. Side effects of praziquantel are dyspepsia, headache, and 
skin rash. The drug is contraindicated in first trimester of pregnancy 
and for nursing mothers.  
The extract of the male fern  is obtained from the rhizome 
of this plant. The extract contains dezaspidin, dezaspidiol, and other 
derivatives of phloroglucinol. The taken orally drug is practically not 
absorbed from the gastrointestinal tract. However, the presence of 
fats can increase the gastrointestinal absorption of the extract that 
results in poisoning. The extract of the male fern causes the muscular 
paralysis in helminths, therefore, parasites can not attach to the 
intestinal wall. The extract of the male fern is used to treat teniasis, 
diphyllobothriasis, teniarinchiasis, and hymenolepiasis. Due to high 
toxicity, the treatment by the extract of the male fern is carried out 
according to certain regimen and only in the hospital. Two days 
before treatment, a special diet with easily digestible meatless 
products is prescribed to a patient. In the evening before the drug 
intake, a patient drinks a cup of tea with rusk. The laxative drug is 
prescribed for the night. In the morning, the patient receives the 
cleansing enema and takes the drug (required number of capsules 
within 30 minutes). The capsules are washed down by a solution of 
sodium hydrocarbonate. It is necessary for pyloric relaxation and 
increase of drug evacuation rate from the stomach into the intestine. 
After 1–1.5 hours, the patient receives the laxative drug. If laxative 
effect does not develop in 3 hours, the patient receives the cleansing 
enema. Side effects of the extract of the male fern are headache, 
vomiting, diarrhea, convulsions, paralysis, respiratory depression, 
atrophy of the optic nerve, heart disorders, and collapse. Due to high 
toxicity, the extract of the male fern is used seldom.  
Mebendazole  may be used to treat some cases of cysticercosis. 
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Drugs for Intestinal Trematodiasis Treatment  
 
Ethylene tetrachloride  and praziquantel  are used to treat 
metagonimosis (caused by Metagonimus yokogawai).  
Ethylene tetrachloride  is taken orally. The drug absorption 
from the gastrointestinal tract is low. The special fat-free and 
carbohydrate-rich diet should bt used during 1–2 days to prepare 
a patient to treatment. Also, alcohol is contraindicated during this 
time. In 15–20 minutes after ethylene tetrachloride intake, the patient 
receives saline laxative drug. Ethylene tetrachloride is also effective 
in ancylostomiasis.  
 
Drugs for Extraintestinal Helminthiasis Treatment  
 
Drugs for Extraintestinal  Nematodiasis Treatment  
 
Filariasis is the most common extraintestinal nematodiasis. 
There are several causative agents of filariasis: Wunchereria 
Bancrofti and Brugia malayi affect the lymphatic system; Loa Loa 
parasitizes in the subcutaneous fat; Onchocerca volvulus parasitizes 
in the subcutaneous fat and in the eyes. Other widely spread 
extraintestinal nematodiasis is trichinelliasis at which Trichinella 
spiralis affects the skeletal muscles (larval stage) and the intestine 
(mature stage).  
To treat extraintestinal nematodiasis, diethylcarbamazine  
(ditrazinum)  and ivermectin  are used.  
Diethylcarbamazine  is an effective drug for filariasis 
treatment (the highest activity against microfilariae). The drug is 
easily absorbed from the gastrointestinal tract, it undergoes partial 
biotransformation and is excreted in the urine within 2 days. 
Ditrazinum inhibits the ability of microfilariae to resist phagocytosis. 
Ditrazinum exhibits a nematicidal effect. However, 
diethylcarbamazine provides the marked therapeutic effect only at 
early stages of the disease. The side effects of diethylcarbamazine are 
headache, weakness, nausea, and vomiting. These complications are 
caused by toxic influence of decomposition products of microfilariae 
and rapidly disappear.  
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Ivermectin  is highly active againt microfilariae and 
Strongyloides stercolaris, but not active against macrofilariae. 
Ivermectin is semisynthetic macrocyclic lactone compound. The 
drug is taken orally. Therapeutic effect develops after a single intake. 
Ivermectin causes the flaccid paralysis of helminths due to inhibition 
of GABA. The highest drug activity develops when treating 
onchocercosis (blinding filarial disease or river blindness). The side 
effects of ivermectin are fever, drowsiness, dizziness, headache, 
bronchospasm, etc.  
There are no effective drugs for trichinelliasis treatment. Certain 
positive effect in this case is possible for mebendazole .  
 
Drugs for Extraintestinal  Trematodiasis Treatm ent 
 
Schistosomiasis is the most common extraintestinal 
trematodiasis. The causative agents of schistosomiasis are 
Schistosoma mansoni, Schistosoma haematobium, and Schistosoma 
japonicum. These parazites affect the blood vessels that results in 
disorders of internal organs (intestine, liver, lungs, spleen, urogenital 
system, etc.).  
The most effective drug for schistosomiasis treatment is 
praziquantel  (Biltricide) . The drug is also effective in other 
extraintestinal trematodoses:  
– opisthorchiasis (causative agent is Opisthorchis felineus which 
affects the liver and pancreas); 
– clonorchiosis (Clonorchis sinensis parasitizes also in the liver 
and pancreas); 
– paragonimiasis (Paragonimus Westermani affects the brain, 
lungs, and lymphatic system); 
– fascioliasis (Fasciola hepatica parasitizes in the liver and 
gallbladder).  
Besides, praziquantel is used to treat metagonimiasis. The 
pharmacological characteristics of praziquantel is given above. 
Antimony sodium tartrate  is a drug containing antimony. 
The drug is administered intravenously, slowly, daily during 20 days. 
Antimony sodium destroys helminth larvae which are located in 
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eggs. Also, the drug interacts with thiol groups of enzymes, and due 
to this, inhibits the vital functions of helminths. Antimony sodium 
tartrate is a toxic agent and commonly causes side effects. The drug 
may cause phlebitis. Accidental subcutaneous administration of its 
solution causes sharp pain and tissue oedema. Weakness, headache, 
extrasystoles, metallic taste, nausea, muscular and joint pain, 
hypotension, insomnia, skin rash, cough, chest pain, and anaphylaxis 
are also possible side effects of antimony sodium tartrate. The drug is 
contraindicated in patients with diseases of heart, liver, and kidneys, 
in pregnant women, and during menses. In case of drug overdose, 
unithiol is used as an antidote. 
Chloxilum  is an effective agent in treatment for opisthorchiasis 
and fascioliasis in which helminths affect the liver, bile ducts, and 
pancreas. Chloxilum reduces the helminth resistance to the action of 
helminth proteolytic enzymes that results in death of helminths. The 
drug is taken orally. Patient preparation to treatment lasts 1–2 days, 
and duration of therapy with chloxilum is 2 days. Within this time, 
a patient adheres to the fat-free diet and excludes alcohol. 
Therapeutic efficacy of chloxilum is 35–40 %. In significant number 
of patients, only reduction in invasion severity is observed. The 
helminth eggs can be released from the body during 3 months after 
treatment. Taken orally chloxilum is slowly and incompletely 
absorbed from the intestine. A main part of the taken dose is excreted 
from the intestine in feces during the first day. Another part of the 
drug, which has reached the systemic blood circulation, is 
accumulated in the body and excreted within 6–28 days. The side 
effects of chloxilum are headache, light inebriation, drowsiness, pain 
in the liver and heart, and allergic reactions. Chloxilum is 
contraindicated in patients with diseases of heart, liver, and in 
pregnant women.  
Bithionol  and emetine hydrochloride are used for treatment of 
fascioliasis. 
Bithionol is a drug of choice for paragonimiasis treatment. 
Typical side effect of this drug is diarrhea.  
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Drugs for Extraintestinal  Cestodiasis Treatment  
 
In extraintestinal cestodiasis treatment, some success has been 
recently achieved. Thus, therapy with mebendazole  and 
albendazole  exhibits positive results in treatment for 
echinococcosis and cysticercosis. Praziquantel  is used to treat 
cysticercosis, but the drug is ineffective when helminths depoint in 
the spinal cord and into the cerebral ventricles.  
 
Table 23 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product 
Mebendazolum Orally 0.1 g once (only  
for treatment of enterobiasis) 
or 0.1–0.4 g 2–3 times a day 
Tablets 0.1 g  
Piperazini 
adipinas 
Orally 1.5–2.0 g 2 times a day Tablets 0.2 or 0.5 g  
Phenasalum Orally 2.0 g Tablets 0.25 g 
Ditrazini citras Orally 0.002 g/kg 3 times  
a day 
Tablets 0.05 or 0.1 g 
Praziquantel Orally 0.025–0.04 g/kg 
 
Tablets 0.6 g 
Chloxilum Orally 0.06 g/kg Powder  
 
 
ANTITUMORAL DRUGS 
 
Antitumoral drugs are agents with different chemical structure 
which are able to inhibit the division of malignant cells in various 
stages of cell cycle. These drugs are used in chemotherapy for 
different oncological diseases. According to medical statistics, 
malignant solid tumors and blood diseases rank second among the 
causes of human death.  
Nowadays, about 200 antitumoral drugs are used in oncology. 
But drugs which are fatally toxic for malignant cells and 
simultaneously safe for normal body cells are still not developed. 
Therefore, one of the most important principles for modern 
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chemotherapy is a simultaneous use of several drugs with different 
chemical structures and mechanisms of action. This enables to 
increase antitumoral activity and to reduce the toxicity of the drugs.   
Classification of antitumoral drugs is as follows.  
1.    Cytotoxic drugs.  
1.1. Alkylating agents: 
– chloroethylamines: embichin (chlormethine), sarcolysin 
(melphalan), dopanum (chlorethylaminouracil, 
uramustine), prospidine, chlorbutinum (chlorambucil), 
and  cyclophosphan (cyclophosphamide); 
– ethylenimines: thiodipine and thiophosphamide 
(ThioTEPA), ; 
– methanesulphonic acid derivatives: myelobromol and  
myelosanum (busulfan);  
– nitrosourea derivatives: nitrosomethylurea, carmustine, 
and  lomustine. 
1.2. Antimetabolites:  
– folic acid antagonists: methotrexate; 
– purine antagonists: mercaptopurine; 
– pyrimidine antagonists: phthoruracilum (fluorouracil),  
cytarabine, and  ftorafur (tegafur).  
1.3. Cytotoxic antibiotics: dactinomycin, rubomycin,  
carminomycin, olivomycin, bruneomycin, bleomycin,  
epirubicin, and  mitomycin.  
1.4. Cytotoxic drugs of plant origin:  
– Vinca rosea alkaloids: vinblastine and vincristine;  
– taxanes (alkaloids of yew-free): paclitaxel (taxol),  
docetaxel, and  taxotere; 
– podophyllotoxin (obteined from Podophyllum peltatum): 
etoposide, teniposide, and podophylline;  
– alkaloids of Colchicum autumnale: colchamine and 
colchicine.  
1.5. Other synthetic cytotoxic drugs: cisplatin, carboplatin, 
dacarbazine, and  procarbazine.   
2.    Hormones and their antagonists:  
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– androgens: testosterone propionate, tetrasterone, 
testenate, and  medrotestrone propionate;  
– antiandrogens: flutamide and cyproterone (androcur);  
– estrogens: fosfestrol, diethylstilbestrol, and ethinyl 
estradiol;  
– antiestrogens: tamoxifen and toremifene; 
– progestins: oxyprogesterone capronate and medroxy-
progesterone acetate; 
– analogues of gonadotropin-releasing hormone: goserelin 
and leuprorelin; 
– inhibitors of aromatase: aminoglutethimide and letrozole.  
– glucocorticoids: prednisolone and dexamethasone .  
3.    Enzymes: L-asparaginase .  
4.    Cytokins: 
– interferons: α-interferon ; 
– interleukins: aldesleukin .  
5.   Monoclonal antibodies: herceptin . 
6.   Tyrosine kinase inhibitors: imatinib,  gefitinib,  and 
erlotinib .  
Most antitumoral drugs cause multiple side effects which restrict 
their clinical use. To prevent or reduce these side effects, the 
following drugs are used.  
1.    Drugs stimulating hemopoiesis (colony-stimulating factors). 
1.1. Drugs stimulating leucopoiesis: molgramostim 
(Leucomax) and  filgrastim.  
1.2. Drugs stimulating erythropoiesis: erythropoietins (epoetin 
alfa and epoetin beta ). 
2.    Antiemetic drugs: ondansetron, tropisetron, and 
metoclopramide.  
3.    Immunomodulators: interferons, interleukins , thymus 
preparations, and  levamisole.  
4.    Drugs which inhibit manifestations of carcinoid syndrome 
associated with malignant neuroendocrine tumors: 
octreotide.  
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5.    Drugs which prevent osteoporosis associated with tumor 
metastasis spread to bones: bisphosphonates 
(pamidronate,  clodronate, and  zoledronate).   
 
Alkylating Drugs 
 
Alkylating drugs include cytotoxic agents of different chemical 
strucrure with identical mechanism of action. It is believed that 
radicals of alkylating drugs form covalent bonds with different 
molecules of the cell. The bonds with guanine of DNA are the most 
important. As a result, the cross-linking of DNA strands occurs. 
DNA double helix loses its ability to diverge, gene mutations occur, 
and replication is violated.  
Embichin (chlormethine) is the first drug of subgroup  
of chloroethylamine. Like most drugs of this group, embochin is 
used to treat hemoblastoses (chronic leukemia, lymphosarcoma, 
lymphogranulomatosis, reticulosarcoma, etc.).  
Sarcolysin (melphalan)  is chloroethylamine derivative. The 
drug is used in lymphosarcoma, reticulosarcoma, multiple myeloma, 
and some solid tumors (testicular seminoma, and Ewing sarcoma). In 
testicular seminoma, sarcolysin is effective even in the presence of 
metastases. Sarcolysin is administered parenterally or taken orally.  
Cyclophosphan (cyclophosphamide)  is the most effective 
drug within chloroethylamine derivatives. It is a prodrug which is 
transformed in the human body into the metabolites with antitumoral 
activity. Cyclophosphan is used to treat hemoblastoses, multiple 
myeloma, testicular cancer, breast cancer, and small-cell lung cancer 
(small-cell carcinoma). Cyclophosphan causes a long-term remission 
in patients with lymphoid leukemia. The drug is administered 
parenterally and taken orally.  
Dopanum (uramustine) and chlorbutinum (chlorambucil) 
are also used to treat hemoblastoses. Both drugs are taken orally. 
Prospidine  is chlorethylamine derivative which is used in 
laryngeal cancer treatment.  
Thiophosphamide (ThioTEPA) is ethylenimine derivative 
which is used in treatment for hemoblastoses (chronic leukemia, 
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lymphogranulomatosis, lymphosarcoma, reticulosarcoma) and solid 
tumors (testicular cancer and breast cancer).  
Methanesulphonic acid derivatives myelosanum (busulfan)  
and myelobromol  are used in exacerbation of chronic myeloid 
leukemia. Both drugs are taken orally.   
Drugs – nitrosourea derivatives are nitrosomethylurea , 
lomustine , and carmustine . Nitrosomethylurea is effective at 
small-cell carcinoma and lymphogranulomatosis. Other drugs are 
used in treatment for brain cancer, colon and rectal carcer, Hodgkin's 
disease, and other lymphomas. Another representative of nitrosourea 
derivatives is fotemustine . The drug is used to treat malignant 
melanoma and primary brain tumors.  
Dacarbazine  and procarbazine  are cytotoxic agents – 
derivatives of triazenes which are used in melanoma treatment.  
Cisplatin  is platinum compound which is used to treat 
testicular tumors, ovary cancer, bladder cancer, squamous head and 
neck cancer, endometrial cancer, lymphomas, and non-small cell 
lung cancer. Like alkylating drugs, cisplatin chemically interact with 
DNA that results in violation of DNA function.  
All alkylating drugs are characterized by high toxicity. Therapy 
by these drugs is accompanied by nausea, vomiting, hemopoiesis 
depression (anemia, thrombocytopenia, and neutropenia), ulceration 
of gastrointestinal tract and bladder, etc. Intravenous administration 
of alkylating drugs can cause thromoflebitis. Amenorea, impotention, 
and hair loss are also possible. At present, cytokins (filgrastim and 
molgramostim), erythropoietin, and some interleukins are used to 
stimulate hemopoiesis. Antibiotics are used to prevent and treat 
various infections.   
 
Antimetabolites  
 
Antimetabolites are structural analogues of natural metabolites: 
folic acid, purines, and pyrimidines. The mechanism of their action is 
based on the drug ability to compete with natural metabolites and 
replace them in the body compounds. Since antimetabolites cannot 
fulfil the normal physiological functions, their incorporation in 
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molecules of nucleic acid blocks its normal synthesis. 
Antimetabolites are active only against dividing malignant cells. 
These drugs do not influence dormant stem cells of tumors. 
Folic acid antagonist methotrexate  and purine antagonist 
mercaptopurine  are mainly used in acute lymphoblastic leukemia 
treatment. Methotrexate has higher activity in children, but 
mercaptopurine – in adult patients. Besides, both drugs are used in 
uterine horionepithelioma. Methotrexate is also used in 
chemotherapy for such solid tumors as breast cancer. Both drugs are 
taken orally, and methotrexate is administered parenterally.  
Phthoruracilum (f luorouracil)  is a pyrimidine antagonist. 
The drug is used in therapy of solid tumors: cancer of stomach, 
pancreas, breast, and colon. Fluorouracil causes temporal tumor 
regression in some patients. Fluorouracil is administered 
intravenously. For peroral intake, capecitabine was created. It is 
a prodrug which, under the influence of thymidine phosphorylase, is 
transformed into fluorouracil.  
Ftorafur (tegafur)  is a less toxic drug than fluorouracil. The 
drug is used in breast cancer, cancer of stomach, colon, and rectum.  
Cytarabine  and thioguanine  are used in chemotherapy for 
acute myeloid and lymphoid leukemia.  
Antimetabolites are highly toxic drugs. Their side effects are 
nausea, vomiting, inhibition of hemopoiesis, lesions of 
gastrointestinal tract, hair loss, etc. Only mercaptopurine and 
thioguanine are relatively well tolerated by patients.  
 
Cytotoxic Antibiotics  
 
Cytotoxic antibiotics are produced by different species of 
Streptomyces and Actinomycetes. These drugs have different 
chemical structure. Mechanism of action is associated with inhibition 
of synthesis and function of nucleic acids that results in suppression 
of cell division.  
Dactinomycin  is produced by actinomycetes. The drug is used 
in chemotherapy for horionepitelioma, Wilms’ tumor 
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(nephroblastoma) of children, and lymphogranulomatosis. 
Dactinomycin is administered intravenously or into the body cavities.  
Olivomycin  is a derivative of aureolic acid which is produced 
by actinomycetes. Olivomycin is used in the treatment for seminoma, 
teratoblastoma, embryonal carcinoma, lymphoepithelioma, 
reticulosarcoma, and melanoma. The drug is administered 
intravenously or applied topically in ointments. 
Rubomycin, doxorubicin (Adriamycin), carminomycin  
are anthracycline antitumor antibiotics. These drugs are used in the 
treatment for sarcomas of mesenchymal origin. Also, doxorubicin is 
used in bone sarcoma, breast, lungs, bladder, thyroid, and ovarian 
cancer, etc. Rubomycin is used in treatment for acute leukemia, 
reticulosarcoma, and uterine horionepithelioma.  
Bleomycin  is cytotoxic glycopeptide antibiotic produced by 
Streptomyces verticillus. The drug is used in treatment for squamous 
cell carcinoma of the oral mucosa, tongue, tonsil, skin, and uterus. 
Also, bleomycin is used in lymphogranulomatosis and penile cancer.  
Bruneomycin  is used in treatment for lymphogranulomatosis, 
reticulo- and lymphosarcoma, and chronic lymphocytic leukemia.  
Cytotoxic antibiotics may be combined with other antitumoral 
drugs, except alkylating drugs and antimetabolites.   
It is necessary to notice that all cytotoxic antibiotics have also 
antibacterial activity, but it has no practical value. 
Cytotoxic antibiotics are drugs with high toxicity. Chemotherapy 
with them is accompanied by numerous side effects: appetite loss, 
nausea, vomiting, diarrhea, candidiasis, inhibition of hemopoiesis, 
hair loss, fever, hypotension, cardiotoxicity, allergic reactions, and 
anaphylactic shock.  
 
Antitumoral Drugs of Plant Origin  
 
Vinblastine  and vincristine  are alkaloids of Vinca rosea. 
Their mechanism of action is associated with metaphase-blockage 
mitosis due to disruption in formation and function of the 
microtubule spindle. It results in violation of DNA divergence to the 
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poles of the cell, the following degradation of DNA strands, and cell 
death.  
Both drugs are used in the treatment for hemoblastoses (acute 
leukemia, reticulo- and lymphosarcoma), lymphogranulomatosis, 
breast cancer, neuroblastoma, etc. Vinca rosea alkaloids are 
commonly combined with other antitumoral drugs. Both drugs are 
administered intravenously. Their side effects are inhibition of 
hemopoiesis, nephrotoxicity, neurological disturbances (ataxia, 
violation of neuro-muscular transmission), alopecia, jaundice, etc.  
Yew-tree (Taxus) preparations are paclitaxel  (taxol) and 
docetaxel  (Taxotere). These drugs exhibit antimitotic activity due 
to interaction with tubulin. Taxones are used in the treatment for 
breast and ovarian cancer, small cell lung cancer, and epithelial 
tumors of the head and neck. The side effects of taxones are nausea, 
vomiting, diarrhea, neutropenia, thrombocytopenia, hypotension, etc.  
Podophyllum peltatum (mayapple) preparations are etoposide, 
teniposide, and podophylline. These drugs are used in the 
treatment for laryngeal and bladder papillomatosis, small cell lung 
cancer, Ewing’s sarcoma, etc. 
Colchamine  and colchicine  are alkaloids of Colchicum 
autumnale and Colchicum speciosum. Colchamine is used topically 
in ointment in the treatment for skin cancer, esophagus, and stomach 
cancer (in the combination with sarcolysin). Colchamine kills 
malignant cells practically without damage of normal epithelial cells. 
Colchamine can cause skin rashes. After removing necrotic tissue, 
wounds may be healed with good cosmetic result.  
Besides, some plant preparations are used as antitumoral agents: 
befungin, drugs of celandine, calendula, wild poppy, plantain, etc.  
 
Enzymes 
 
L-asparaginase  is enzyme which is used in the treatment for 
acute lymphoblastic leukemia and lymphosarcoma. This enzyme 
distroys L-asparagine. L-asparagine is amino acid which is required 
for the synthesis of proteins, RNA, and DNA. Side effects  
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of L-asparaginase are neuro-, nephro- and hepatotoxicity, and 
affection of pancreas.  
 
Hormonal Drugs and Their Analogues  
 
This group includes male and female sex hormones and their 
antagonists, and also glucocorticoids which play complementary 
role. Sex hormones are used in the treatment for malignant 
neoplasms of ovaries, uterus, prostate, and breast. There are 
evidences that under the influence of sex hormones, malignant cells 
do not die because hormonal drugs only slow down their division and 
metastasis.  
As a rule, chemotherapy with sex hormones is combined with 
surgical and radiation treatments.  
Androgens (testosterone propionate ,  testenate,  
tetrasterone, medrotestrone propionate ) are used to treat 
breast cancer in women with menstrual cycle and in the first 5 years 
after menopause. In these cases, androgens inhibit production  
of estrogens. The use of high androgen doses is accompanied by 
virilization (excess facial and body hair, baldness, acne, deepening  
of the voice, increased muscularity), dizziness, nausea, etc.  
Antiandrogens include such drugs as flutamide  and 
cyproterone (androcur) . Their mechanism of action is associated 
with the inhibition of transport and binding of dihydrotestosterone 
with receptors in the prostatic cells. It results in slowing down 
tumoral cell growth in the prostate. Both drugs are taken orally. 
Antiandrogens exhibit high efficacy in prostate cancer and cause 
prolonged remission in the majority of patients. The drugs are well 
tolerated by patients. Prolonged anti-androgen therapy may be 
accompanied by the development of gynecomastia, but it does not 
affect sexual function.  
Estrogens (fosfestrol , diethylstilbestrol , ethinylestradiol) 
are used to treat breast cancer in women with menopause which lasts 
more than 5 years. In these patients, estrogens inhibit the production 
of pituitary gonadotropins which indirectly stimulate the growth  
of tumoral cells.  
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Besides, estrogens are used in the treatment for prostate cancer. 
In this case, estrogens inhibit the function of natural androgens. One 
of the drugs for prostate cancer treatment is fosfestrol (sodium salt  
of diphosphoric ether of diethylstilbestrol). Under the influence of 
acid phosphatase of tumoral cells, fosfestrol is transformed into 
diethylstilbestrol. Fosfestrol is taken orally or administered 
intravenously. Fosfestrol is characterized by fast efficacy 
development and low toxicity in contrast to diethylstilbestrol. The 
use of estrogens in males can cause feminization, dyspepsia, itchy 
skin, and hemorrhagic rash. In 1–2 years of estrogen use, malignant 
cells lose the sensitivity to these agents.  
Antiestrogens (tamoxifen, toremifene) bind to estrogen 
receptors of neoplastic cells of the breast and prevent  
estrogen-induced tumor growth. Antiestrogens are used to treat 
estrogen-induced breast cancer, especially in postmenopausal 
women. The side effects of these drugs are vaginal hemorrhage, 
redness of the skin, vomiting, dermatitis, etc.    
At present, drugs inhibiting the synthesis of androgens are 
introduced in the medical practice. These drugs are aromatase 
inhibitors. In postmenopausal period, estrogens are synthesized from 
androgens which are produced by adrenal cortex. This process is 
regulated by enzyme aromatase. Inhibition of aromatase results in 
violation of estrogen synthesis.  
Aromatase inhibitors are such drugs as letrozole (Femara), 
aminoglutethimide (Cytadren), anastrozole (Arimidex), etc. 
Aromatase inhibitors are used to treat breast cancer and ovarian 
cancer in postmenopausal women and gynecomastia in men.  
Their side effects are headache, dyspepsia, skin rash, weakness, 
vaginal bleeding, etc.  
Progestins (oxyprogesterone caproate, medroxy-
progesterone acetate) are used to treat uterine cancer. Progestins 
cause the cancer regression in significant number of patients. 
Analogues of gonadotropin-releasing hormone (goserelin,  
leuprorelin) also exhibit the antitumoral activity. In case of 
continuous use, these drugs reduce the secretion of gonadotropins by 
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the anterior pituitary and exhibit therapeutic effect in patients with 
prostate cancer.  
Glucocorticoids  and preparations of adrenocorticotropin  
are commonly used to treat acute leukemia in children, chronic 
lymphocytic leukemia, lymphogranulomatosis, and lymphosarcoma.  
 
Cytokines 
 
Cytokines include interferons and interleukins. 
Recombinan t  human interferon α  is interferon which is 
used in the complex treatment for some tumors. The drug activates 
macrophages, T-lymphocytes, and T-killer cells. Recombinant 
human interferon α is effective in multiple myeloma, Kaposi’s 
sarcoma, renal cell carcinoma, etc. The drug is administered 
parenterally. Side effects of this drug are headache, fever, myalgia, 
arthralgia, dyspepsia, blood dyscrasias, thyroid dysfunction, etc. 
Interleukin-2 (proleukin)  stimulates proliferation and 
differentiation of T-helpers and cytotoxic T-lymphocytes, activates 
macrophages, stimulates proliferation of B-lymphocytes. Proleukin is 
derived by genetic engineering. The drug is administered 
parenterally. Side effects are hypotension, pulmonary oedema, 
inhibition of hematopoiesis, nephrotoxicity, lesions of the central 
nervous system, and allergic reactions. 
 
Monoclonal Antibodies  
 
Monoclonal antibodies include trastuzumab (Herceptin)  
and rituximab (Mabthera). These drugs are produced by genetic 
engineering. Both drugs are administered intravenously. Monoclonal 
antibodies are used in complex chemotherapy for some oncological 
diseases. 
Herceptin  is an antibody against antigenic HER2 (human 
epidermal growth factor receptor 2) of the breast malignant cells that 
results in cytotoxic effect. Overexpression of these receptors leads to 
proliferation and malignant transformation of the cells. 
Overexpression of HER2 protein is observed in 20–30 % of patients 
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with breast cancer. Therapeutic indication for trastuzumab is 
metastatic breast cancer with HER2 protein overexpression.  
Rituximab  interacts with protein CD20 which is an antigen 
located on the membranes of B-cells of non-Hodgkin's lymphomas.  
Bevacizumab (Avastin) is a monoclonal antibody preparation 
which blocks the vascular endothelial growth factor. The drug 
inhibits the growth of tumor vessels that violates its blood supply and 
slows down the tumoral growth. Avastin is administered 
intravenously. Bevacizumab is used in complex chemotherapy for 
colorectal cancer.  
The side effects of monoclonal antibodies are fever, nausea, 
vomiting, skin rash, headache, hypo- or hypertension, nephrotoxicity, 
oedemas, bronchospasms, a cough, lymphopenia, leukopenia, etc. 
 
Tyrosine Kinase Inhibitors  
 
Tyrosine kinase inhibitors include imatinib, gefitinib, and 
erlotinib . It is a new group of antitumoral drugs. Tyrosine kinase is 
an important functional element of membrane receptors – growth 
factors of thrombocytes, epithelium, stem cells, vascular 
endothelium, nerves, etc. Besides, there are tyrosine kinases of the 
cytoplasmic and nuclear localization. Tyrosine kinase regulates the 
growth and differentiation of cells and their apoptosis.  
The first representative of this group is imatinib . The drug 
blocks tyrosine kinase of the receptors for platelet-derived growth 
factor, stem cell factor, and cytoplasmic tyrosine kinase. Imatinib is 
used to treat chronic myelogenous leukemia and gastrointestinal 
stromal tumors. The drug is taken orally. Side effects of imatinib are 
nausea, vomiting, neutropenia, skin rash, etc.  
Gefitinib  blocks tyrosine kinase of the receptor for epidermal 
growth factor. The drug is used to treat non-small cell lung cancer 
and head cancer.  
Erlotinib  blocks several receptor tyrosine kinases, and it is 
used to treat non-small cell lung cancer.  
Sunitinib  is used to treat gastrointestinal stromal tumors and 
a clear-cell subtype of renal cell carcinoma.  
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Table 24 – Drugs for prescription 
 
Drug name 
(Latin) 
Single dose and route of 
administration 
Drug product 
Cyclophosphanum Orally, intramuscularly  
or intravenously 0.2 g once 
a day; 0.4 g once every  
2 days 
Coated tablets 0.05 g; 
ampoules 0.1 or 0.2 g  
of powder for solution 
Chlorbutinum Orally 0.002–0.01 g once 
a day 
Tablets 0.002 or 0.005 g 
Myelosanum Orally 0.002–0.01 g once 
a day 
Tablets 0.002 g 
Mercaptopurinum Orally 0.001–0.001 25 g/kg 
once a day  
Tablets 0.05 g 
Methotrexatum Orally, intramuscularly  
or intravenously 0.03 g  
2 times in a week, or 0.05 g 
once in five days 
Coated tablets 0.002 5 g; 
ampoules 0.005, 0.05  
or 0.1 g of powder  
for solution 
Phthoruracilum Intravenously slowly  
or drop-by-drop  
0.01–0.015 g/kg once a day  
or once every 2 days 
Ampoules 5 ml  
of 5 % solution  
Vinblastinum 
(Rosevinum) 
Intravenously 0.000 15–
0.000 3 g/kg once per week 
Ampoules 0.005 or 0.01 g 
of powder for solution 
Vincristinum  Intravenously 0.000 01–
0.000 03 g/kg once per week 
Ampoules 1 or 5 ml  
of 0.1 % solution;  
vials 0.0005 or 0.001 g  
of powder for solution 
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RADIOPROTECTORS  
RADIONUCLIDE DECORPORATION DRUGS  
 
Radioprotectors are drugs which are used in case of radiation 
threat, during radiotherapy of cancer patients, and in work with 
radionuclides. Radioprotectors reduce or prevent the destructive 
action of ionizing radiation.  
Radioprotectors are classified as follows.  
1. Sulfur-containing drugs.  
1.1. Sulfur-containing amino acids and their derivatives: 
cysteine, methionine, cysteamine hydrochloride ,  
taurine, acetylcysteine. 
1.2. Other groups of sulfur-containing drugs: unithiol ,   
β-mercaptoethylamide, isothiuronyl , cystophos,  
gamaphos,  β-aminoethyl.  
2. Biogenic amines: serotonin adipate ,  mexamine, 
adrenaline.  
3. Amino acids and their derivatives: glutamic acid ,  
asparaginic acid , Asparcamum, Panangin . 
4. Derivatives of nucleotides and nucleosides: sodium 
nucleinate, methyluracil , phosphadenum, ATP, 
riboxinum.  
5. Alcohols: butyl alcohol.  
6. Vitamins: rutin, ascorbic acid, pyridoxine, tocopherol , 
nicotinamide, methylmethionine sulfonium .  
7. Antioxidants.  
7.1. Antioxidants of direct action: tocopherol,  ubiquinone .  
7.2. Antioxidants of indirect action: selenium-containing 
drugs, zinc-containing drugs,  copper -containing 
drugs, amino acids,  caffeine.  
8. Biopolymers: zymosan.  
9. Estrogens: estradiol.  
10. Polysacharides: prodigiozan.  
11. Complexones: pentacinum, tetacinum-calcium.  
12. Sorbents: enterosorbent CKN, silica gel , activated 
carbon, carbolong, carbalose.  
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13. Herbal preparations: liquid extract and tincture of  
Ginseng, tinctures of Aralia, Chinese schizandra, 
Eleutherococcus, polyphenolic compounds.  
14. Methemoglobin-forming drugs: sodium nitri te ,  
methylene blue. 
According to duration of action, there are short-acting and long-
acting radioprotectors. Short-acting radioprotectors develop effect in 
0.5–4 hours after administration. These drugs protect from single 
radiation or short-term high-level radiation. Short-acting 
radioprotectors are administered in maximal doses. This group 
includes sulfur-containing compounds, biogenic amines, and 
methemoglobin-forming drugs which disrupt tissue oxygenation.   
Long-acting radioprotectors are used to protect human body 
from long-term effects of low-level radiation. These drugs are 
divided into drugs with hypoxic mechanism of action and drugs with 
non-hypoxic mechanism of action. Drugs with hypoxic mechanism 
of action are biogenic amines and methemoglobin-forming drugs. 
Drugs with non-hypoxic mechanism of action include sulfur-
contaning compounds and drugs of other groups. 
Mexamine  and cysteamine hydrochloride  are drugs which 
are most commonly used to prevent and treat radiation sickness.  
The damaging effect of ionizing radiation is lower in hypoxia. 
The drugs causing vasoconstriction and reducing oxygen blood 
concentration cause hypoxia and inhibit lipid peroxidation. These 
properties are typical for biogenic amines. These drugs are used to 
treat and prevent radiation sickness.  
Mexamine is a biogenic amine which has a similar chemical 
structure to serotonin. Mexamine causes contraction of smooth 
muscles and provides sedating effect on the central nervous system. 
The drug is taken orally 30–40 minutes prior to radiation therapy. 
Mexamine is well tolerated by patients.  
Sulfur-containing drugs contain SH2-groups and are the most 
active radioprotectors. Sulfur-containing drugs inhibit free radicals in 
cell bodies, form compounds of heavy metals, normalize protein 
metabolism on the DNA level, and increase cAMP concentration.   
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Cysteamine hydrochloride is taken orally 1 hour prior to 
radiation therapy. The duration of the effect is 5 hours. The drug is 
used to prevent and treat chronic radiation sickness. Cysteamine 
hydrochloride is ineffective in cases of acute radiation sickness.  
Cyanides also exhibit radioprotective effect due to blockage  
of respiratory enzyme cytochrome oxidase which provides transport 
of the electrons from cytochrome to oxygen.  
Estrogens increase human body resistance to ionizing radiation. 
These drugs protect the bone marrow, thyroid gland, decrease 
catabolic action of ionizing radiation, and activate the immunity 
(phagocytosis).  
Some macromolecular substances also have radioprotective 
activity (polysaccharides, nucleic acids, alcohols, and synthetic 
polymers). Their radioprotective effect arises 0.5–2 hours after intake 
and lasts up to 3 days. Mechanism of their action is based on 
stimulation of nucleic acid synthesis and bone marrow cell 
regeneration. Among glycans, zymosan  is characterised by the 
highest radioprotective activity. Zymosan protects hematopoiesis 
from negative influence of antitumoral drugs and ionizing radiation. 
The drug is administered intramuscularly in dose 1–2 ml on alternate 
days. The treatment course is 5–10 injections. 
Batilol  protects leukocyte and erythrocyte sprouts from 
ionixing radiation within 4–6 weeks. The drug is taken orally 
together with butter or vegetable oil which improve batilol 
absorption.  
Thesanum  is used in skin protection from ionizing radiation. 
Liniment of thesanum is applied on the skin prior to radiation 
session.  
Direct antioxidants are drugs with radiprotective properties: 
tocopherol, ascorbic acid, nicotinamide, riboflavin,  
pyridoxine , preparations of Ginseng, Chinese magnolia,  
Manchurian Aralia, Eleutherococcus , etc.  
Selenium  preparations are drugs with indirect antioxidant 
activity. Selenium stimulates enzymes of the antioxidant cellular 
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system (activates glutathione peroxidase and promotes synthesis  
of cytochrome C and ubiquinone).  
Besides, antioxidant properties are typical for compounds of zinc 
and copper, glutathione precursors, linoleic acid, and caffeine. 
Stimulators of leukopoiesis (sodium nucleinate and 
methyluracil ) also provide radioprotective effect. Some 
radioprotective activity is typical for vasopressin, prostaglandins, and 
acetylcholine.  
Chelators (pentacinum, tetacinum-calcium,  and 
alginates), sorbents (activated carbon, enterosorbent SKN, 
carbolong, silica gel , etc.), pectins, vegetable fibers, and 
carboxymethyl cellulose bind radionuclides and provide their 
elimination from the body.  
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Step 1. Correct Answers to Tasks for Self-Control  
 
Drugs Influencing Respiratory System  
 
1. C.  
2. A.  
3. D.  
4. E. 
5. B.  
6. E.  
7. B.  
8. E. 
9. B.  
10. C.  
11. D.  
12. E. 
13. A.  
14. D.  
15. B.  
16. A. 
 
Cardiotonic Drugs 
 
1. C.  
2. A.  
3. E.  
4. C.  
5. E.  
 
6. E.  
7. B.  
8. A.   
9. D.  
10. E.  
11. B.  
12. E.  
13. A.  
14. C.  
15. E. 
16. A. 
17. C. 
18. B. 
Antihypertensive and Hypertensive Drugs  
 
1. B.  
2. D.  
3. E.  
4. A.  
5. A.  
6. B.  
 
7. E.  
8. D.   
9. B.  
10. A.  
11. C.  
12. E. 
13. A.  
14. E.  
15. B.  
16. C. 
17. E.  
18. B. 
 
19. C. 
20. E. 
21. A. 
22. E. 
Drugs to Treat Ischaemic Heart Disease  
(Antianginal Drugs)  
 
1. E.  
2. B.  
3. E.  
4. D.  
5. C.  
6. C.  
7. E.  
8. B.   
9. D.  
10. A.  
11. C.  
12. E.  
13. D.  
14. B. 
15. C.  
16. E. 
17. A.  
18. A. 
19. C. 
20. D. 
21. C. 
 
22. B. 
23. D. 
24. E. 
25. D. 
26. B. 
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Antiarrhythmic Drugs  
 
1. B.  
2. D.  
3. E.  
4. A.  
5. B.  
6. C. 
7. E.  
8. B.   
9. B.  
10. C.  
11. B.  
12. D.  
13. A.  
14. E.  
15. C.  
16. D. 
17. A.  
18. D. 
 
19. C. 
20. E. 
21. B. 
Drugs Influencing Digestive System  
 
1. B.  
2. C.  
3. A.  
4. E.  
5. E.  
6. B.  
7. D.  
8. E.   
9. A.  
 
10. C.  
11. A.  
12. D.  
13. E.  
14. B.  
15. A.  
16. B. 
17. E.  
18. C. 
 
19. B. 
20. D. 
21. E. 
22. E. 
23. C. 
24. E. 
25. A. 
26. D. 
27. A. 
 
28. E. 
29. A. 
30. E. 
31. B. 
32.E. 
33. C. 
Diuretic Drugs. Drugs Influencing Myometrium  
 
 
1. B.  
2. A.  
3. E.  
4. A.  
5. D.  
6. B. 
 
7. E.  
8. C.   
9. D.  
10. E.  
11. C.  
12. C. 
 
 13. A.  
14. B.  
15. D.  
16. A. 
17. D.  
18. E. 
 
19. C. 
20. D. 
21. D. 
 
Drugs Influencing Erythro- and Leucopoesis  
 
1. C.  
2. A.  
3. D.  
4. E.  
5. B.  
6. E. 
7. B.  
8. D.   
9. D.  
 
10. B.  
11. A.  
12. A. 
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Drugs Influencing Blood Coagulation  
 
1. B.  
2. A.  
 
3. E.  
4. B.  
 
 5. D.  
6. E. 
7. A.  
8. E.   
Vitamins 
 
1. E.  
2. B.  
3. A.  
4. D.  
5. C.  
6. E. 
7. A.  
8. C.   
9. E.  
 
10. C.  
11. E.  
 
Hormonal Drugs 
 
1. D.  
2. A.  
3. E.  
4. C.  
5. E.  
6. C.  
7. B.  
8. D.   
9. C.  
10. A.  
11. D.  
12. E.  
13. A.  
14. D.  
15. E.  
16. C. 
17. C.  
18. A. 
19. C. 
20. E. 
21. A. 
22. E. 
23. E. 
24. E. 
25. D. 
26. C. 
27. B. 
28. D. 
29. E. 
30. B. 
31. E. 
32. C. 
33. E. 
34. D. 
35. C. 
36. E. 
37. E. 
38. B. 
39. A. 
40. D. 
41. C. 
42. E. 
43. E. 
44. C. 
45. E. 
46. A. 
47. D. 
48. B.  
49. A. 
50. E. 
51. D. 
52. B. 
53. B.  
54. B. 
55. C. 
56. B. 
57.D. 
58. E. 
59. A. 
60. D. 
61. C. 
62. E. 
63. B. 
64. C.  
65. D. 
66. E.  
67. B. 
68. C. 
69. B. 
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Antiallergic and Immunotropic Drugs  
 
1. B.  
2. E.  
3. C.  
4. D.  
5. D.  
6. B.  
7. C.  
8. E. 
9. A.  
10. E.  
11. C.  
12. E.  
13. A.  
14. D.  
15. C.  
16. C. 
17. E.  
18. A. 
19. B. 
20. D. 
21. E. 
22. C. 
23. B. 
24. E. 
25. B. 
26. E. 
27. B. 
28. E. 
29. C. 
30. A. 
 
Drugs to Treat Goat 
 
1. B.  
2. E. 
 
3. C.  
4. D.  
5. E.  
6. B.   
 
 
Antiseptics and Disinfectants  
 
1. D.  
2. A.  
 
3. B.  
4. D.  
 
5. E.  
6. A. 
7. C.  
8. A.   
Antibiotics  
 
1. C.  
2. A.  
3. D.  
4. E. 
5. C.  
6. E.  
7. B.  
8. D. 
9. C.  
10. E.  
11. D.  
12. D.  
13. E. 
 
Sulfonamides.  Synthetic Antimicrobial Drugs 
 
1. B.  
2. A.  
3. E.  
4. D.  
5. E.  
6. B. 
7. E.  
8. D.   
9. B.  
10. C.  
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Antisyphilitic Drugs. Antituberculosis  Drugs 
 
1. A.  
2. B.  
 
3. A.  
4. D.  
 
5. D.  
6. A. 
7. D.  
 
Antiviral,  Antiprotosoal , and Antifungal Drugs  
 
1. A.  
2. D.  
3. B.  
4. E. 
5. C.  
6. B.  
7. E.  
8. B. 
9. C.  
10. D.  
11. A.  
12. B.  
13. C. 
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INDEX  
 
Abactal q.v. pefloxacin 
Abciximab 230, 232 
Abomin 143 
Acarbose 287, 292, 294 
Acebutalol 97 
Aceclidine 141, 168 
Acesol 390 
Acetazolamide 186, 191, 391 
Acetohexamide 286, 291 
Acetylcysteine 20, 22, 23, 534 
Acetylsalicylic acid 230, 231, 382 
Acidin-pepsin 143 
Acomplia q.v. rimonabant 
Activated carbon 159, 171, 406, 534, 
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Actrapid 288 
Acyclovir 478, 481, 482 
Acypimox 367 
Adapromine 478, 479 
Ademetionine 163, 164 
Adenosine 114, 123, 124 
Adenuric q.v. febuxostat 
Adrenaline 6–8, 114, 125, 291, 336, 
342, 420, 534 
Adriamycin q.v. doxorubicin 
Adroxon 238 
Aeron 167 
Aethamidum q.v. etabenecid 
Aetmozinum 114, 118 
Aethonium 396 
Ajmaline 114, 116 
Accolate 19, 335, 340 
Actilyse q.v. alteplase 
Albendazole 497, 513, 514, 521 
Alcohol solution of iodine 397, 503 
Aldactone q.v. spironolactone 
Aldesleukin 523 
Alendronate 374, 376 
Alfacalcidol 259, 373, 375 
Alinidine 89, 99, 114 
Allochol 159 
Allomaron 380, 384 
Allopurinol 380–385 
Allylestrenol 307 
Almagel 154–156 
Alteplase 103, 237, 229 
Aluminium hydroxide 154–156, 394 
Amantadine 478, 479 
Ambroxol 20–23 
Amfepramone 139, 140, 370 
Amicar q.v. aminocaproic acid 
Amikacin 433–435, 464, 465 
Amiloride 64, 186, 191, 195 
Aminazine 29, 79, 139, 167 
Aminocaproic acid, 158, 228, 234, 
237, 336 
Aminoglutethimide 523, 530 
Aminoped 392 
Aminoquinol 497–500 
Aminosol 392 
Aminosteril N-Hepa 392 
Amiodarone 89, 95, 103, 114, 121 
Amixin 486 
Amlodipine 57, 59, 89, 93, 94 
Ammonia solution 408, 409 
Ammonium chloride 391, 394, 397 
Amoxicillin 416, 418–420 
Amphetamine 139, 140 
Amphoglucaminum 502, 504 
Amphotericin B 414, 502–504 
Ampicillin 416, 418–420, 462 
Amrinone 41, 45, 46 
Anaprilinum 54, 55, 89, 97, 114, 
119, 196, 199 
Androcur q.v. cyproterone 
Angiotensinamide 79–81 
Anistreplase 227, 229 
Antimonyl sodium tartrate 519 
Anturan q.v. sulfinpyrazone 
Apomorphine 165, 166 
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Apressinum 74 
Aprotinin 158, 237 
Arbidol 478, 480 
Arfonad 70, 71 
Artificial gastric juice 143 
Ascofer 211 
Ascorbic acid 136, 162, 171, 199, 
200, 209–211, 214, 219, 239, 
243, 252–254  
Ascorbinase 265 
Asparaginase 209, 523, 528 
Asparaginic acid 534 
Asparcamum 114, 123, 124, 394 
Aspartame 370, 372 
Aspirin q.v. acetylsalicylic acid 
Astemizole 338 
Atenolol 54–56, 77, 97, 98, 114, 
119, 120, 195 
Atorvastatin 360 
Atropine 6, 11, 45, 114, 125, 141, 
145, 158, 162, 165, 197, 202, 
336, 341, 406 
Atrovent 6, 11, 341 
Auranofin 343, 346 
Avalox q.v. moxifloxacin 
Avastin q.v. bevacizumab 
Avidin 265 
Avlosulfon q.v. diaphenylsulfone 
Axid q.v. nizatidine 
Azamethonium q.v. pentaminum 
Azathioprine 343, 344, 382, 
Azithromycin 427, 428, 462, 501 
Azlocillin 416, 420 
Aztreonam 425 
Bactrim q.v. Co-trimoxazole 
Bearberry leaves 186, 194 
Beclomethasone 15, 297, 300, 340 
Bekarbon 146 
Bellalgin 146 
Bellastezin 146 
Benazepril 60, 62 
Bendazol q.v. dibazolum 
Benzalconium chloride 396 
Benzbromarone 380, 384 
Benzohexonium 29, 70, 134, 165, 
169 
Benzylpenicillin novocaine salt 416, 
417, 462  
Benzylpenicillin-novocainum q.v. 
benzylpenicillin novocaine salt  
Benzylpenicillin potassium 416, 417, 
462 
Benzylpenicillin sodium, 416, 417, 
462 
Bepascum q.v. para-benzoil 
aminosalicylate calcium 
Berberine sulfate 159, 160 
Beriplast 234 
Berofor 485 
Berotec q.v. fenoterol 
Betaferon q.v. Betaseron 
Betaleukin 347, 349 
Betaseron 485, 486 
Betaxolol 54 
Bevacizumab 532 
Bezafibrate 360, 365, 366 
Bicillin-1 416, 417, 462 
Bicillin-5, 416, 417, 462 
Bigumal, 489, 490, 492–494 
Biiochinolum 462 
Biltricide q.v. praziquantel 
Birch buds 186, 194 
Bisacodyl 172, 174 
Biseptol q.v. Co-trimoxazole 
Bismoverol 462 
Bismuth citrate 148 
Bismuth nitrate 397 
Bismuth subsalicylate 341 
Bithionol 520 
Black currant 213 
Bleaching powder 397 
Blemaren 380, 385 
Bleomycin 522, 527 
Blueberry fruits 170 
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Boric acid 392, 397, 408  
Brilliant green 397, 400, 401 
Bromelain 451 
Bromhexinum 20, 23 
Bromocriptine 277, 278 
Bronchomunal 347, 349 
Bruneomycin 522, 527 
Bufenox q.v. bumethanide 
Buformin 287 
Bumetanide 186–188 
Buscopan 165 
Buserelin 274 
Busulfan q.v. myelosanum 
Butyl alcohol 534 
Caffeine 25–27, 79, 124, 134, 382, 
534, 537 
Calcitonin 272, 281, 284, 295, 373–
375 
Calcitrin 284 
Calcitriol 255, 257, 259, 373, 375, 
342 
Calcium carbonate 154, 374, 376 
Calcium chloride 74, 196, 199, 234, 
238, 285, 342 
Calcium citrate 258, 374 
Calcium gluconate 234, 238, 285, 
394 
Calcium glycerophosphate 394 
Calcium lactate 394 
Calcium pantothenate 248 
Camphor 25–28, 79 
Candesartan 63 
Capreomycin 465 
Captopril 60–62, 77, 78, 134 
Carbacholine 141 
Carbenicillin 416  
Carbenicillin indanyl sodium 416 
Carbenicillin disodium 416 
Carbenoxolone 151, 153 
Carbocromen 89 
Carbolong 534, 537 
Carboplatin 522 
Carfecillin 416, 419 
Carminomycin 522, 527 
Carmustine 522, 525 
Carsil 162 
Castor oil 172, 173, 196, 199, 200 
Cefaclor 421, 423 
Cefadroxil 421 
Cefalotin 421 
Cefamandole 421 
Cefapirine 421 
Cefazolin 421, 422, 462 
Cefclidine 421 
Cefepime 421 
Cefixime 421 
Cefmenoxime 421 
Cefmetazole 421 
Cefoperazone 421, 423 
Ceforanide 421 
Cefotaxime 421, 423 
Cefoxitin 421, 423 
Cefozopran 421 
Cefpirome 421, 424 
Cefpodoxime 421 
Cefradine 421 
Ceftazidime 421, 423 
Ceftriaxone 421, 423, 462 
Cefuroxime 421, 423 
Celanidum 37, 41, 42 
Cephalexin 421, 422 
Cephaloridine 421 
Cephradine 421 
Cerigelum 396, 398 
Charcoal 44 
Chenodeoxycholic acid 159, 164 
Chingaminum q.v. chloroquine 
Chiniofonum 450, 451, 495, 496, 
499 
Chinodis q.v. flefloxacin 
Chinofungin 503 
Chlorambucil q.v. chlorbutinum 
Chloramine B 397, 401, 402 
Chloramphenicol q.v. levomycetin 
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Chlorbutinum 522, 524 
Chlorchinaldolum 450, 451 
Chlorethylamino-uracil q.v. 
dopanum 
Chlorhexidine 396, 398, 401 
Chloridinum 489–493, 499 
Chlormethine q.v. embichin 
Chloropyramine 335, 337 
Chloroquine 343, 346, 489–495, 497  
Chlorphentermine 139, 370, 371 
Chlorpromazine q.v. aminazine 
Chlorpropamide 286, 291  
Chloxilum 520 
Cholaflux 159 
Cholecalciferol 257, 259, 376 
Cholecystokinin 161 
Cholenzymum 159, 160 
Cholestyramine 44, 360–363 
Chymotrypsin 22 
Cilica gel 534 
Cimedone q.v. solusulfonum 
Cimetidine 145, 147, 148 
Ciprobay q.v. ciprofloxacin 
Ciprofloxacin 453, 454, 465 
Cisapride 165, 168 
Cisplatin 522, 525 
Clarithromycin 427, 428, 476 
Claritin 335, 338 
Clemastine 337 
Clentiazem 57, 93 
Clindamycin 414, 438, 439 
Clodronate 524 
Clofazimine 476, 477 
Clofibrate 360, 365, 366 
Clomiphene 306 
Clonidine 68, 69, 134, 139 
Clopamide 64, 65, 186, 187, 189, 
195 
Clophelinum q.v. clonidine 
Clopidogrel 103, 230, 232 
Clotrimazole 498, 502, 503, 507, 
508 
Coamidum 209, 211 
Cod liver oil 259, 361, 367 
Codeine 24 
Colchamine 522, 528 
Colchicine 379, 380, 382, 384, 522, 
528 
Colestipol 360, 362, 363 
Contrical 237 
Copper sulfate, 265, 397, 405 
Cordiaminum 79 
Corglycon 30, 37, 41, 42 
Corticoliberin 273 
Corticotropin 60, 273, 275, 276 
Cortisone 297, 298 
Cosyntropin 275 
Cotarnine 196, 201 
Co-trimoxazole 449 
Cromoglycate sodium 17, 18 
Cromolyn sodium 11, 335, 340, 341 
Crystepin 195 
Cyanocobalamin, 209–213, 243, 
250, 368, 472 
Cyclokapron q.v. Tranexamic acid 
Cyclomethiazide 186, 187, 190 
Cyclophosphamide q.v. 
cyclophosphan 
Cyclophosphan 209, 522, 524 
Cycloserine 465, 470 
Cyclosporine 343, 344 
Cycvalonum 159, 160 
Cyproterone 314, 523, 529 
Cysteamine hydrochloride 534–536 
Cystophos 534 
Cytarabine 522, 526 
Dacarbazine 522, 525 
Dactinomycin 522, 526 
Dalteparin 220, 223 
Danazol 274 
Dapsone q.v. diaphenylsulfone 
Daptomycin 437 
Dasoxiben 230, 231 
Decaminum 503, 508 
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Decaris q.v. levamisole 
Delavirdine 483, 484 
Demeclocycline 429, 430 
De-nol 151, 152 
Depo-Provera 307, 311 
Dermatol 397, 406 
Desaminooxytocin 196, 197, 279 
Desloratadine 338 
Deslorelin 274 
Desopimon q.v. chlorphentermine 
Desoxycorticosterone acetate 303 
Desoxycorticosterone 
trimethylacetate 303 
Desoxyribonuclease 20, 22 
Dexamethasone 30, 209, 297, 298, 
300, 335, 336, 523 
Dexfenfluramine 139 
Diakarb 186, 187, 191 
Diaphenylsulfone 477 
Diazepam 78, 102, 148, 342 
Diazolinum 335 
Diazoxide 72, 73, 78 
Dibazolum 74, 347, 348 
Dichlothiazidum 64, 65, 186–190 
Diclofenac sodium 379 
Dicynone q.v. etamsylate 
Didanosine 483 
Diethylcarbamazine 518 
Diethylstilbestrol 305, 523, 529 
Digestal 157 
Digitoxin 37–43 
Digoxin 37–44, 114, 124 
Diltiazem 57, 59, 89, 93, 114, 123 
Diluted hydrochloric acid 143, 393 
Dimedrolum 167, 341, 342 
Dimociphone 476 
Dinoprost 196–198, 202 
Dinoprostone 196–198, 202 
Dioxidine 457 
Dipheninum 45, 114, 117, 118, 213 
Diprazinum 167, 335 
Dipyridamole 89, 99, 100, 105, 230, 
232, 486 
Disopyramide 114–116 
Distigmine 168 
Ditrazinum q.v. diethylcarbamazine 
Diuciphone 476, 477 
Dobutamine 41, 44–46, 79, 103 
Docetaxel 522, 528 
Domperidone 165 
Dopamine 41, 44, 45, 79, 81, 103, 
342 
Dopanum 522, 524 
Doxazosin 66, 67, 134 
Doxorubicin 527 
Doxycycline 429–431, 462, 490, 501 
Droperidol 29, 79, 102 
Drotaverine q.v. No-spa 
Dutasteride 314 
Echinacea 347 
Econazole 498 
Efavirenz 483, 484 
Elcatonin 374 
Eleutherococcus 79, 347, 535, 536 
Embichin 522, 524 
Emetine hydrochloride 495–497, 
520 
Emopamil 57, 58, 93 
Enalapril 60–62, 77, 134, 195 
Enap-H 77, 195 
Enfuvirtide 478 
Enoxacin 453 
Enoxaparin 220, 223 
Enteroseptol 450, 451 
Enterosorbent CKN 534, 537 
Entobex 450 
Enzystal 157 
Ephedrine 6, 8, 30, 79, 114, 125, 
336, 342 
Epirubicin 522 
Epoetin alfa, 209, 212, 523 
Epoetin beta, 209, 212, 523 
Epoprostenol 230, 231 
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Ergocalciferol 257, 259 
Ergometrine 196, 201 
Ergot extract 196, 201 
Ergotal 196, 201 
Ergotamine 196, 201 
Erlotinib 523, 532 
Erynitum 88 
Erythromycin 8, 169, 427, 428, 462, 
501 
Esomeprazole 145 
Essentiale 163, 361, 368, 466 
Estradiol 196, 199, 305, 306, 523, 
529, 534 
Estriol 305 
Estron 196, 199, 305 
Etabenecid 380, 383 
Etamsylate 234, 236, 238, 239, 361, 
369 
Etazol 446 
Ethacizine 114, 119 
Ethacridine lactate 397, 400, 401 
Etacrynic acid, 29, 64, 186, 187, 
190, 195 
Ethambutol 464–466, 471 
Ethanol 397, 407 
Ethinylestradiol 305, 308, 529 
Ethionamide 464–468, 472, 476 
Ethylene tetrachloride 518 
Ethylmorphine 24 
Etidronate 374–376 
Etoposide 522, 528 
Euphyllinum, 6, 12, 186, 187, 193, 
341 
Extract of buckthorn (Rhamnus) 
cortex 172 
Extract of male fern 516, 517 
Extract of Rhodiola 79 
Falipamil 57, 89, 99, 114 
Famcyclovir 481 
Famotidine 145, 147, 148 
Fansidar 489 
Fansimef 489 
Fasigyn q.v. Tinidazole 
Febuxostat 380–382 
Felodipine 57, 59, 77, 93 
Fenobolin 314, 315 
Fenofibrate 360, 365, 366 
Fenoterol 6, 9, 12, 196, 200, 340 
Fercoven 209 
Feron 485 
Ferramid 209 
Ferrogradumet 211 
Ferroplex 209, 211 
Ferrous lactate 209 
Ferrous sulfate 309 
Ferrum Lek 209 
Festal 157 
Fibrinogen 234, 235 
Fibrinolysin 227, 228 
Filgrastim 209, 214, 215, 523 
Finasteride 314 
Flamіnum 159, 160 
Flecainide 114 
Florimycin 465, 471 
Floxacin q.v. norfloxacin 
Fluconazole 502, 503, 505 
Flumethasone 297, 301 
Flunisolid 15 
Fluorouracil q.v. phthoruracilum 
Flutamide 314, 523, 529 
Fluticasone 11, 297, 298 
Fluvastatin 360 
Folic acid 209–213, 243, 251 
Fomiversen q.v. vitravene 
Formaldehyde 397, 407, 408 
Formalin 407 
Formoterol 6, 9, 10 
Fosfestrol 523, 529 
Fosinopril 60 
Fraxiparine 103, 220, 223 
Ftivazide 464, 467, 468 
Ftorafur 522, 526 
Furacilinum 369, 370, 398, 399, 455 
Furadoninum 455, 456 
549 
 
Furaginum 455, 456 
Furaplastum 399 
Furazidin q.v. furaginum 
Furazolidone 398, 399, 455, 456, 
497, 498 
Furazolinum 455 
Furosemide 29, 64, 78, 134, 186–
190, 195, 342 
Gallopamil 57, 89, 93 
Gamaphos 534 
Gammaferon 485 
Ganciclovir 481, 482 
Gastal 154, 155 
Gastrin 142 
Gatifloxacin 454 
Gefitinib 523, 532 
Gelatin 234, 236 
Gelatinol 388 
Gemfibrozil 360, 365, 366 
Gemifloxacin 454 
Gentamicin 195, 433, 435 
Ginseng 79, 347, 535, 536 
Glaucine 24 
Glibenclamide 272, 286, 291 
Glimepiride 287, 292 
Glipizide 286, 291 
Globiron 211 
Glucagon 114, 126, 295 
Glucose 45, 103, 391 
Glukantim 500 
Glutamic acid 361, 364, 393, 534 
Glycine 393 
Gonadorelin 274, 314 
Gonadotropin-releasing hormone 
274, 523 
Gordox 158, 237 
Goserelin 523, 530 
Gossypol 312, 481 
Granisetron 167, 168 
Grass of Labrador tea 20 
Grass of Thermopsis 20 
Green soap 398 
Griseofulvin 503, 506–508 
Guanidine 478 
Guttalax 172, 174 
Haemostimulinum 209 
Hemostatic sponge 234 
Hepabene 162 
Heparin 103, 219, 220–224, 361, 
368 
Hepatofalk Planta 162 
Heptral q.v. Ademethionine 
Herb of thermopsis 20, 165, 166 
Herceptin. q.v. trastuzumab 
Hexamethonium q.v. 
benzohexonium 
Hexamethylenetetramine 397, 407, 
408 
Hipurik Q. v. benzbromarone 
Hirudin 220, 224 
Histidine 393 
Histrelin 274 
Holagol 159, 160 
Holosas 159, 160 
Horsetail herb 186, 194 
Humalog 288, 290 
Human chorionic gonadotropin 278 
Human menopausal gonadotropin 
277 
Humulin M2 289 
Humulin M3 289 
Humulin R 288, 290 
Hydralazine 74 
Hydrochloric acid 143, 144, 391, 
393 
Hydrochlorthiazide q.v. 
dichlothiazidum  
Hydrocortisone 297–300, 335, 336 
Hydrogen peroxide 397, 403 
Hydroxychloroquine 490 
Hygronium 29, 30 
Hypericum grass 170 
Ichthyol 397, 400 
Idoxuridine 478, 481, 482 
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Imatinib 523, 532 
Imipenem 425, 426, 454 
Imodium q.v. Loperamide 
Imunoferon 485 
Indapamide 64, 65, 186, 189 
Indinavir 483, 484 
Indomethacin 379, 382 
Infusion of adonis herb 38, 43 
Insulin 45, 286–291, 466 
Insulin Aspart 288 
Insulin Glargine 289, 290 
Insulin lispro 288 
Insulin Ultralente 289, 290 
Interferon α 210 374, 484 
Interferon α-2a 347 
Interferon α-2b 347 
Interferon β 347, 484 
Interferon β-1b 347 
Interferon γ 347, 349, 484 
Intermedin 279 
Intestopan 450, 451 
Intetrix 495, 496 
Intrafusin 392 
Intralipid 391 
Intron-A 485 
Iodine solution 283, 402, 507 
Iodinol 397, 402 
Iodonatum 402 
Iodovidonum 397, 402 
Ipecacuanha root q.v. root of 
Ipecacuanha 
Ipratropium bromide 6, 11, 341 
Irbesartan 63 
IRS-19 347 
Isadrinum 6, 8, 114, 125, 341 
Isaphenine 172, 174 
Isepamicin 433–435 
Ismigen 347 
Isoniazid 266, 434–468, 471 
Isophane Insulin Suspension 288, 
290 
Isoprenaline 6 ,8, 114, 125 
Isoprinozin 486 
Isosorbide dinitrate 88, 92, 103, 134 
Isosorbide mononitrate 88, 92, 134 
Isothiuronyl 534 
Isotonic sodium chloride solution 
390, 394 
Itraconazole 502–506 
Ivermectin 518, 519 
Josamycin 429 
Kanamycin 433, 434. 464, 465, 470 
Ketoconazole 502–506 
Ketotifen 17, 18, 335, 340, 341 
Kreon 157 
Labetalol 68, 78, 134 
Lactosol 390 
Laferon 485 
Lamisil q.v. terbinafine 
Lamprene q.v. clofazimine 
Lanreotide 274, 276, 277 
Lansoprazole 145, 149 
Lantus 289, 290 
L-asparaginase 209, 523, 528 
Laundry soap 398 
Leaves of plantain 20, 528 
Legalon 162, 163 
Lenograstim 209, 214, 215 
Leptin 141 
Lescol q.v. fluvastatin 
Lespeflan 194 
Letrozole 523, 530 
Leucomax q.v. molgramostim 
Leukogen 214, 215 
Leuprolide 274, 314 
Leuprorelin 274, 523, 530 
Levamisole 347, 348, 469, 486, 513, 
515, 523 
Levocetirizine 338 
Levofloxacin 454 
Levomekol 432 
Levomycetin 431–433 
Levorin 414, 503, 508 
Levosimendan 45, 46 
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Levosin 432 
Levovinisol 432 
Libexin 24 
Licopid 347–349 
Licrease 157 
Lidaprim q.v. Co-trimoxazole 
Lidocaine 45, 103, 114, 117, 122 
Lincomycin 414, 438 
Linezolid 457, 458 
Liobilum 160 
Lipofundin 391 
Lipoic acid 164, 262, 263 
Lipostabil 361, 368 
Lipostat q.v. pravastatin 
Lipoxidase 265, 266 
Lisinopril 60, 61, 134 
LIV-52 165 
Logiparin 220, 223 
Lomefloxacin 453, 465 
Lomustine 522, 525 
Loperamide 171, 341 
Loracarbef 421 
Loratadine 335, 338 
Lorelco q.v. probucol 
Losartan 63, 77, 134 
Lovastatin 360, 361 
L-thyroxine 272, 282 
Lugol’s solution 397, 402 
Lysol 397, 399 
Lіobіlum 160 
Maalox 154, 155 
Mabthera q.v. rituximab 
Magnesium oxide 154–156, 393–
395 
Magnesium sulfate, 45, 74, 78, 124, 
161, 172, 196, 201, 395, 406 
Mannitol 186, 187, 192, 388 
Maxacvin q.v. lomefloxacin 
Mazindol 139, 370, 371 
Mebendazole 513, 517, 519, 521 
Mebhydrolin 337 
Medamin 513 
Medrotestrone propionate 523, 529 
Medroxyprogesterone acetate 307, 
311 
Mefenamic acid 486 
Mefloquine 489–494 
Megosin 481, 486 
Melanocortin 141 
Melphalan q.v. sarcolysin 
Menaquinone 234, 243, 261 
Mercaptopurine 209, 343–345, 382, 
522, 526 
Mercazolil 283, 284 
Mercury ammonium chloride 397 
Meropenem 425, 426 
Mesalazine q.v. salazopyridazine 
Mesatonum 79, 81, 336 
Metacinium 6, 11, 145, 165, 169, 
336, 341 
Metakelfin 489 
Metalyse q.v. Tenecteplase 
Metformin 287, 292, 294, 295 
Methandrostenolone 314 
Methionine 361, 393, 472, 534 
Methotrexate 266, 345, 526 
Methyldinoprost 196, 198 
Methyldopa 68, 70 
Methylene blue 397, 400, 401, 535 
Methylergometrine 196, 201 
Methylestradiol 305 
Methylmethionine 254 
Methylmethionine sulfonium 534 
Methylprednisolone 298, 301, 335, 
343 
Methyltestosterone 313 
Methyluracil 137, 209, 214, 347, 
348, 534, 537 
Metisazon 478, 484 
Metoclopramide 165, 167, 168, 523 
Metoprolol 54, 77, 89, 97, 98, 103, 
114, 119, 120 
Metronidazole 424, 454, 495, 497 
Mevacor q.v. lovastatin 
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Mevastatin 360 
Mexaform 450, 451 
Mexamine 534, 535 
Mexasa 450, 451 
Mezlocillin 416, 420 
Mezym Forte 157 
Miacalcic 284, 374 
Miconazole 498, 502, 503, 505 
Midantanum q.v. amantadine 
Midecamycin 427 
Mifepristone 303, 308 
Miglitol 287, 292, 294 
Milrinone 45, 46, 134 
Milurit q.v. allopurinol 
Minocycline 429, 430, 431, 476 
Minoxidil 72, 77 
Mirabegron 370, 372 
Miramistin 398 
Misoprostol 145, 151, 153 
Mitomycin 522 
Moduretic 195 
Molgramostim 209, 214, 215, 523 
Molsidomine 89, 95, 96, 134 
Monomycin 433, 434, 500 
Monotard HM 288 
Montelukast 20, 335, 340 
Moracizine 114, 118 
Moristerol 361, 367, 368 
Morphine 29, 102, 393, 403 
Motilium q.v. domperidone 
Moxalactam 421 
Moxifloxacin 454 
Mucaltin 20, 21 
Myelobromol 522, 525 
Myelosanum 209, 522, 525 
Nadolol 54, 89, 97, 120 
Nadroparin 220, 223 
Nafarelin 274 
Nafcillin 416, 418 
Naftamon 513, 515, 516 
Naftopidil 57, 58, 93 
Nalidixic acid 452 
Naphthyzinum 342 
Natalben Supra 367 
Natamycin 503, 508 
Nateglinide 293 
Natural gastric juice 143 
Nebivolol 54, 55, 89, 97 
Nedocromil sodium 17, 18 
Nelfinavir 483, 484 
Neodicumarinum 220, 224–227, 266 
Neohaemodes 79 
Neomycin 433, 434, 500, 522, 527 
Neostibazine 500 
Netilmicin 433 
Nevirapine 483, 484 
Nicardipine 57, 89, 93 
Niclosamide 516 
Nicorandil 79, 85 
Nicotinamide 209, 244, 246, 534, 
536 
Nicotinic acid 75, 243, 246, 360, 366 
Nifedipine 6, 15, 57, 59, 78, 89, 94, 
201, 361 
Nitazole 498 
Nitrofungin 503, 507 
Nitrofural q.v. furacilinum 
Nitrofurantoin q.v. furadoninum 
Nitrofurazone q.v. furacilin 
Nitroglycerin 29, 73, 78, 88, 91, 92, 
101, 103, 134 
Nitrong 88 
Nitrosomethylurea 522, 525 
Nitrosorbidum 88, 92, 134 
Nitroxolinum 450 
Nizatidine 145, 147, 148 
Nizoral q.v. ketoconazole 
Noradrenaline 79, 342 
Norastemizole 338 
Norethisterone 307, 308 
Norfloxacin 453 
Norsulfazol 446 
No-spa 75, 89, 162, 165, 169, 202, 
341 
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Novocainamidum 114, 116 
Novolin 70/30 289 
Novolin R 288, 290 
Novolog 288 
Nystatin 414, 503, 508 
Nіkodinum 161 
Oak bark 170 
Oats seeds 159 
Octadine 71, 72, 77 
Octreotide 274, 276, 523  
Odeston 159, 160 
Ofloxacin 453, 454, 462, 465, 476, 
477 
Olbetam q.v. acypimox 
Oleandomycin 168, 169, 427, 428, 
462 
Olestra 370, 372 
Olivomycin 522, 527 
Omacor 367 
Omeprazole 145, 149 
Ondansetron 167, 168, 523 
Orciprenaline 6 
Orlistat 139, 140, 370, 372 
Ornidazole 498 
Ornidum 114, 121 
Oseltamivir 478, 480 
Ossein-hydroxyapatite 374, 375 
Osteogenon q.v. ossein 
hydroxyapatite 
Oxacillin 416–419, 462 
Oxandrolone 314 
Oxeladine 24, 25 
Oxodolinum 64, 186, 190 
Oxoline 478, 480 
Oxolinic acid 452 
Oxprenolol 54, 55, 89, 97, 119, 120 
Oxyphenonium bromide 450 
Oxyprogesterone capronate 307, 
523, 530 
Oxytetracycline 429, 430 
Oxytocin 196, 197, 202, 279 
Pachycarpine 196, 199, 200 
Paclitaxel 522, 528 
Pamidronate 374, 375, 524 
Panangin 45, 65, 114, 123, 124, 390, 
394, 584 
Pancreatin 157, 450 
Pantocide 397 
Pantocrinum 79 
Pantoprazole 145, 149 
Pantothenic acid 248, 368 
Panzinorm 157 
Papaverine 74, 75, 89, 99, 100, 162, 
165, 169 
Para-aminosalicylate sodium 465, 
472 
PAS q.v. para-aminosalicylate 
sodium 
Parathyroidin 285 
Parmidine 361, 369 
Partusisten q.v. Fenoterol  
Pefloxacin 453, 454 
Penicillamine 346, 347 
Pentacinum 534, 537 
Pentagastrin 142 
Pentakarinat 500 
Pentamidine q.v. Pentakarinat  
Pentaminum 29, 134 
Pentostim 500 
Pentoxifylline 75, 137, 230, 233, 486 
Pentoxyl 209, 214, 347, 348 
Pepsin 143 
Perindopril 60, 62 
Pertussinum 20 
Pervinium pamoate 513, 516 
Phenamine 370 
Phenaminum q.v. amphetamine 
Phenasalum q.v. niclosamide 
Phencarol 335, 339 
Phenindione 220, 224, 227 
Phenol 397, 399, 400 
Phenolphthalein 172, 174 
Phenoxymethylpenicillin 416, 417 
Phentanyl 102 
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Phentolamine 6, 14, 29, 66, 78, 134 
Phenylbutazone 379 
Phenytoin 114, 117 
Phepranon q.v. amfepramone 
Phepranone 139, 140 
Phosphadenum 534 
Phosphalugel 154, 156 
Phthalazolum 446 
Phthalylsulfapyridazine q.v. 
phthazinum 
Phthazinum 446 
Phthoruracilum 522, 526 
Phylloquinone 234, 243, 261 
Phytomenadione 234 
Phytonadione q.v. Vitamin K 
Pilocarpine 141 
Pilorid q.v. bismuth citrate 
Pimafucin q.v. natamycin 
Pinacidil 89, 95 
Pindolol 54, 56, 97, 98, 114, 119 
Pioglitazone 287, 292, 294 
Pipemidic acid 452 
Piperacillin 416, 420 
Pirenzepine 145, 146, 147 
Pirilenum 70, 169 
Pituitrinum 196, 197 
Plasma 387 
Platyphyllin 6, 11, 145, 146, 162, 
165, 169 
Podophylline 522, 528 
Polarising mixture 124, 390, 394 
Poludanum 347, 486 
Polyglucinum 79, 388 
Polymyxin B 436 
Polymyxin E 436 
Polymyxin M 436 
Polythiazide 186, 190 
Polyvidone 388 
Potassium chloride 45, 114, 123, 
124, 390, 394 
Potassium iodide 20, 282, 283, 402, 
503, 507 
Potassium perchlorate 283, 284 
Potassium permanganate 397, 403 
Poteseptil q.v. Co-trimoxazole 
Pravastatin 360, 361 
Praziquantel 516–519, 521 
Prazosin 6, 14, 66, 67, 78, 134 
Prednisolone 30, 209, 297, 300, 301, 
335–337, 340–345 
Prednisone 297, 298 
Preductal 89, 101, 364 
Pregnin 307 
Primaquine 489–494, 500 
Primaxin 425, 426 
Probenecid 80, 383 
Probucol 360, 364, 365 
Procainamide 114, 116 
Procarbazine 522, 525 
Prodigiozan 347, 349, 534 
Progesterone 196, 201, 307, 308 
Proglumide 145, 151 
Prograf 344 
Prolactin 278 
Proleukin 531 
Promedol 102, 393 
Promethazine 337 
Propafenone 114, 119 
Propranolol q.v. anaprilinum 
Propylthiouracil 283, 284 
Proscar 314 
Proserinum 141, 168, 169, 196, 199, 
200 
Prospidine 522, 524 
Prostacyclin 219, 230–233, 239 
Prostaglandin E2 q.v. dinoproston  
Prostaglandin F2α q.v. dinoprost 
Protaphane HM 288 
Protargolum 397, 405 
Prothionamide 464–468, 472, 476 
Pufloxacin 453 
Pumpkin seeds 516 
Pyrantel pamoate 513–515 
Pyrazinamide 464–466, 471, 472 
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Pyridinolcarbamate q.v. parmidine 
Pyridostigmine 168 
Pyridoxine q.v. vitamin B6 
Pyrimethamine q.v. chloridinum 
Pyrogenalum 347 
Pyrroxane 6, 14, 66, 78 
Quamatel q.v. famotidine 
Quercetin 361, 369 
Quifenadine 335, 337 
Quinacrine 266, 267, 489, 500 
Quinidine sulfate 114–116 
Quinine 196, 199, 200, 266, 489, 
490, 494 
Quinocide 493 
Quinoxidine 457 
Rabeprozole 145, 149 
Radioactive iodine 277, 283, 284, 
402 
Ramipril 60, 62 
Ranitidine 145, 147–149 
Reaferon 442, 443 
Recombinant human interferon α 
531 
Reserpine 71, 72, 195 
Resorcin 397, 400 
Retabolil 314, 315, 376 
Retinol 243, 255–259, 267 
Rheopolyglucin 79, 137, 388 
Rhubarb (Rheum) root 172, 173 
Ribavirin 478, 480 
Riboflavin 243, 245, 267, 368, 536 
Riboflavin mononucleotide 246 
Ribomunyl 347, 349 
Riboxinum 534 
Rifabutin 464 
Rifampicin 13, 415, 437, 464–469, 
471, 476, 501 
Rifamycin 378, 399, 424 
Rifaximin 464 
Rimantadine 478, 479 
Rimonabant 371 
Ringer solution 390 
Ringer-Lokk solution 390 
Ritonavir 483, 484 
Rituximab 531, 532 
Rivanol q.v. ethacridine lactate 
Roferon-A 485 
Roncoleukin 347, 349 
Rondomycine q.v. methacycline 
Root of ipecacuanha 165 
Root of milkwort 20 
Rosiglitazone 287, 292, 294 
Rowan fruits 213 
Roxane q.v. roxatidine 
Roxithromycin 427 
Rubomycin 209, 522, 527 
Rumalon 377 
Rutin 135, 136, 214, 239, 243, 254, 
361, 534 
Saccharin 370, 372 
Salazodimethoxine 446 
Salazopyridazine 446, 448 
Salbutamol 6, 9–11, 196, 200, 340, 
341 
Salicylic acid 393, 397, 400, 408 
Salmeterol 6, 9, 10 
Saluzidum 464, 467 
Sandostatin 274, 276 
Sandostatin LAR 276 
Sanorex q.v. mazindol 
Saquinavir 478, 483, 484 
Sarcolysin 522, 524, 528 
Scopolamine 141, 167 
Selenium 360, 364, 534, 537 
Senna leaves 172, 173 
Sermorelin 273 
Serotonin 199, 200, 238, 534 
Serotonin adipate 534 
Sibutramine 139, 140, 370, 371 
Sigetin 305 
Silabolin 314 
Silver nitrate 397, 405 
Simvastatin 360, 361 
Sinaflan 297 
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Sinestrol 196, 305,  
Sisomicin 433 
Sodium benzoate 20, 21 
Sodium chloride 390, 394 
Sodium fluoride 374, 376 
Sodium hydrocarbonate 20, 21, 150, 
154, 391, 393, 397, 409, 447, 517 
Sodium hydrocitrate 220 
Sodium lactate 394 
Sodium monofluorophosphate 374 
Sodium nitrite 535 
Sodium nitroprusside 29, 73, 78, 134 
Sodium nucleinate 209, 214, 534, 
537 
Sodium phosphate with radioactive 
isotope 32P 209, 214 
Sodium stibogluconate 499 
Sodium sulfate 172 
Solimok 380, 385 
Solusulfonum 499 
Solusurminum 499 
Somatostatin 153, 273–276 
Somatotropin 276, 277 
Somatotropin-releasing factor 273 
Sorbifer 211 
Sorbitol 156, 161, 174, 389 
Sotalol 54, 97, 114, 122 
Sparfloxacin 453, 454, 465 
Spiramycin 427 
Spironolactone 64, 186, 187, 192, 
195, 304 
Stanozolol 314 
Starch slime 170 
Stavudine 483 
Stigmatum maydis 159 
Strawberry fruit 213 
Streptocid 446 
Streptodecase 227, 229 
Streptokinase 103, 227–229 
Streptomycin 433, 435, 464–466, 
469–471 
Strontium ranelate 374, 376 
Strophanthin 30, 37, 41–43, 342 
Structum 377, 378 
Sucralfate 151, 152 
Sulfacyl sodium 446 
Sulfadiazine 446 
Sulfadiazine silver 446 
Sulfadimethoxine 446 
Sulfadimezine 446 
Sulfadoxine 446, 489 
Sulfaguanidine q.v. sulginum 
Sulfalen 446, 489 
Sulfamethoxazole 446, 449 
Sulfapyridazine 446 
Sulfazine 446 
Sulfinpyrazone 233, 380, 382, 383 
Sulfocamphocaine 25, 26, 28, 79 
Sulginum 446 
Sulmazol 45, 46 
Sulphedrone q.v. solusulfonum 
Sunitinib 534 
Suprastin 335, 337, 338 
Sustac forte 88, 92 
Sustac mite 88, 92 
Sustanon-250 313 
Syncumar 220, 224, 227, 266 
Tacrolimus 344 
Tactivinum 317, 348 
Talinolol 54, 89, 97, 103, 114, 119, 
120 
Tamiflu q.v. oseltamivir 
Tamoxifen 306, 523, 530 
Tannin 44, 170 
Tardyferon 209 
Targocid q.v. teicoplanin 
Tarivid q.v. ofloxacin 
Tauredon 343, 346 
Taurine 393, 534 
Tavegyl 337, 338 
Taxol q.v. paclitaxel 
Taxotere 522, 528 
Tegafur q.v. ftorafur 
Teicoplanin 439, 440 
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Telenzepine 145–147 
Telmisartan 63 
Tenecteplase 229 
Teniposide 522, 528 
Tenoric 56, 77, 195 
Terazosin 66 
Terbinafine 503, 506, 507 
Terbutaline 6, 9, 10, 196, 200 
Terfenadine 338 
Testenate 313, 523, 529 
Testosterone enanthate 313 
Testosterone propionate 313, 523, 
529 
Tetacinum-calcium 406, 407, 534, 
537 
Tetracosactide 275 
Tetracycline 253, 418, 428–431, 
454, 462, 476, 489, 494–496 
Tetrasterone 523, 529 
Theophylline 12, 14, 19, 124, 148, 
193, 368, 382, 486 
Thermopsis herb q.v. herb of 
thermopsis 
Thiamine q.v. vitamin B1 
Thiaminase 265, 66 
Thiethylperazine 167, 168 
Thioacetazone 465, 476 
Thiodipine 522 
Thiophosphamide 209, 522, 524 
Thiotepa q.v. thiophosphamide 
Thiotriazoline 163, 164 
Thrombin 234 
Thymalin 347, 348 
Thymol 400 
Thymoptin 347 
Thymus preparations 347, 523 
Thyreoidine 282 
Thyroidine 282 
Thyroliberin 274 
Thyrotropin 138, 274, 277 
Thyrotropin-releasing hormone 274 
Ticarcillin 416, 419 
Ticlopidine 103, 230, 232 
Tienam 425, 426 
Tilorone q.v. amixin 
Tincture of Ginseng 79, 347, 535, 
536 
Tinidazole 498 
Tobramycin 433 
Tocopherol 103, 163, 201, 214, 243, 
253, 257, 259, 260, 267, 360, 
361, 364, 368, 378, 534, 536 
Tolazamide 286, 291 
Tolbutamide 286, 291 
Torasemide 64, 78, 186–188 
Toremifene 523, 530 
Torsemide q.v. torasemide 
Tosufloxacin 453 
Trandolapril 60, 62 
Tranexamic acid 237 
Trastuzumab 531, 532 
Trasylol 158, 237 
Traventol 341 
Trental 75, 230, 233, 486 
Triamcinolone 297, 298, 301, 336, 
345 
Triampur Compositum 195 
Triamterene 64, 186, 187, 191, 195 
Trichomonacide 498 
Trifluridine 481, 482 
Triftazinum 167, 168 
Triiodothyronine 272, 281, 282, 284 
Trilon B 45 
Trimetazidine 89, 101 
Trinitrolong 88, 92 
Trisamine 391 
Tromethamol 391 
Tropaphenum 66 
Tropisetron 167, 168, 523 
Trypsin 20, 22, 156, 237 
Turinal 201, 307 
Ubiquinone 102, 534, 537 
Ultratard HM 289 
Undecinum 503, 507 
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Unithiol 44, 45, 406, 407, 499, 520, 
534 
Uralyt-U 380, 385 
Urodanum 380, 383 
Urokinase 103, 227, 229 
Urotropine q.v. 
hexamethylenetetramine 
Ursodeoxycholic acid 164 
Ursofalk q.v. ursodeoxycholic acid 
Vagothyl 400 
Valacyclovir 481 
Validolum 89, 101 
Vamin 392 
Vancomycin 414, 439, 440 
Vasopressin 60, 79, 133, 169, 185, 
189, 197, 279, 280, 537 
Vasotec 61 
Vastarel 101 
Venter q.v. sucralfate  
Ventolin q.v. salbutamol 
Verapamil 57, 59, 78, 89, 93, 114, 
123, 361 
Vermox q.v. mebendazole 
Verospiron q.v. spironolactone 
Vesnarinone 45 
Vibramycin q.v. doxycycline 
Vicasolum 226, 227, 234, 235, 261 
Vidarabine 478, 481, 482 
Viferon 485 
Vilosenum 347, 348 
Vinblastine 210, 522, 527 
Vincristine 210, 522, 527 
Viomycin q.v. florimycin 
Vishnevsky ointment 400 
Vitamin B1 199, 243–245, 266 
Vitamin B12 212, 243, 250, 251, 267  
Vitamin B6 243, 249, 267, 360, 368 
Vitamin C 136, 160, 200, 243, 252–
256, 360, 378 
Vitamin E 162, 201, 243, 259, 260, 
360 
Vitamin K 225–227, 234, 243, 260, 
266 
Vitravene 482 
Vormil q.v. albendazole 
Warfarin 220, 224, 227, 266 
Wellferon 485 
Wilkinson ointment 398, 400 
Wood-tar 397 
Xenical q.v. orlistat 
Xeroform 397, 406 
Yellow mercury oxide 397, 405 
Zafirlukast 19, 20, 335, 340 
Zagam q.v. sparfloxacin 
Zalcitabine 483, 484 
Zanamivir 478, 480 
Zantac q.v. ranitidine 
Zidovudine 478, 483, 484 
Zileuton 19, 335, 341 
Zinc oxide 265, 397 
Zinc sulfate 165, 166, 265, 397, 405 
Zincundanum 503, 507 
Zocor q.v. simvastatin 
Zofran q.v. ondansetron 
Zoledronate 524 
Zovirax q.v. acyclovir 
Zymosan 534, 536 
Zyvox q.v. linezolid 
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